Compounds > serine
Page last updated: 2024-11-04

serine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID5951
CHEMBL ID11298
CHEBI ID17115
SCHEMBL ID1775
MeSH IDM0019675

Synonyms (160)

Synonym
AC-1190
serine (van)
einecs 200-274-3
serina [spanish]
brn 1721404
propanoic acid, 2-amino-3-hydroxy-, (s)-
ser (iupac abbrev)
serinum [latin]
nsc 118365
serine [usan:inn]
gtpl726
beta-hydroxyalanine
(s)-2-amino-3-hydroxypropanoic acid
serin
l-3-hydroxy-2-aminopropionic acid
(s)-(-)-serine
beta-hydroxy-l-alanine
CHEBI:17115 ,
(s)-serine
(s)-alpha-amino-beta-hydroxypropionic acid
l-serin
(2s)-2-amino-3-hydroxypropanoic acid
D00016
l-serine (jp17)
serine (usp)
NCGC00024507-01
tocris-0227
NCGC00024507-02
lopac-s-4250
NCGC00015952-01
tocris-0226
serine, l-
.beta.-hydroxyalanine
l-(-)-serine
56-45-1
serine
nsc118365
nsc-118365
l-serine ,
hsdb 680
l-alanine, 3-hydroxy-
alpha-amino-beta-hydroxypropionic acid
(-)-serine
2-amino-3-hydroxypropanoic acid, (s)-
propanoic acid, 2-amino-3-hydroxy-, (s)
3-hydroxyalanine
2-amino-3-hydroxypropionic acid
l-2-amino-3-hydroxypropionic acid
SER ,
l-3-hydroxy-alanine
C00065
l-ser
l-serine, reagentplus(r), >=99% (hplc)
l-serine, from non-animal source, meets ep, usp testing specifications, suitable for cell culture, 98.5-101.0%
DB00133
l-serine, bioultra, >=99.5% (nt)
3AB40D3A-043A-488F-8361-D1BF309F842C
BMSE000048
CHEMBL11298
h-ser-oh
S0035
6898-95-9
A20660
(s)-2-amino-3-hydroxypropanoicacid;2-amion-3-hydroxypropionicacid
BMSE000885
BMSE000867
serene
4-04-00-03118 (beilstein handbook reference)
serina
452vly9402 ,
unii-452vly9402
ec 200-274-3
serinum
BMSE000809
(s)-2-amino-3-hydroxypropionic acid
nsc760115
pharmakon1600-01301010
nsc-760115
b-hydroxy-l-alanine
(s)-a-amino-b-hydroxypropionic acid
bdbm50357212
(l)-serine
BP-13282
AM20100375
EPITOPE ID:150900
AKOS015854115
serine [hsdb]
serine [vandf]
serine [mart.]
serine [usp monograph]
serine [usan]
serine [inci]
l-serine [usp-rs]
(2s)-2-amino-3-hydroxy-propanoic acid
serine [ii]
serine [inn]
serine [ep monograph]
serine [who-dd]
l-serine [fcc]
l-serine [jan]
serine [mi]
SCHEMBL1775
2-amino-3-hydroxypropanoic acid-, (s)-
.alpha.-amino-.beta.-hydroxypropionic acid-, (s)-
l-2-amino-3-hydroxy-propanoic acid
h-ser
(s)-2-amino-3-hydroxy-propanoic acid
rac-serine
racemic serine
3h-l-serine
?-hydroxyalanine
(s)-(+)-2-amino-3-hydroxypropionic acid
l-serine;
l-serine, cell culture reagent (h-l-ser-oh)
mfcd00064224
F1905-7047
l-serine, tested according to ph.eur.
l-serine, >=99.0% (nt)
SR-01000597708-1
sr-01000597708
l-serine, certified reference material, tracecert(r)
l-serine, united states pharmacopeia (usp) reference standard
l-serine, vetec(tm) reagent grade, >=99%
l-serine, pharmaceutical secondary standard; certified reference material
l-serine, vetec(tm), 98.5%
serine, european pharmacopoeia (ep) reference standard
serine (l-serine)
(s)-2-amino-3-hydroxy-propanoate
(s)-b-amino-3-hydroxypropionate
l-3-hydroxy-2-aminopropionate
(s)-b-amino-3-hydroxypropionic acid
(s)-2-amino-3-hydroxypropanoate
(s)-beta-amino-3-hydroxypropionic acid
(s)-alpha-amino-beta-hydroxypropionate
3-hydroxy-l-alanine
(s)-a-amino-b-hydroxypropionate
(s)-beta-amino-3-hydroxypropionate
HY-N0650
SY002847
CS-W020136
l-serine - cas 56-45-1
fmoc-(2-aminomethylphenyl)aceticacid
l-serine,(s)
Q183290
STR02557
CCG-266038
(2s)-2-amino-3-hydroxypropanoic acid.
DTXSID60883230 ,
S9353
l serine
EN300-52635
DTXSID301031857
serine (mart.)
serine (usp monograph)
serine (ii)
dtxcid501022779
serine (ep monograph)
l-serine (usp-rs)
serinum (latin)
Z756440058

Research Excerpts

Toxicity

L-serine appears to be generally safe for patients with ALS. An adverse effect of high-dose serine therapy on head growth and on the transport of neutral amino acids should be considered.

ExcerptReferenceRelevance
"2-Methoxyethanol (2-ME) is an industrial solvent which is toxic to both male and female reproductive systems of laboratory animals."( Attenuation of 2-methoxyethanol-induced testicular toxicity in the rat by simple physiological compounds.
Mebus, CA; Welsch, F; Working, PK, 1989)		0.28
"Rats were fed toxic levels of methionine with or without simultaneous dietary supplements of glycine and serine."( Methionine toxicity in the rat in relation to hepatic accumulation of S-adenosylmethionine: prevention by dietary stimulation of the hepatic transsulfuration pathway.
Alakuijala, L; Eloranta, TO; Korhonen, VP; Regina, M; Smith, TK, 1993)		0.29
" Cyclophosphamide was not directly toxic to SEC, but in coculture of SEC and hepatocytes, cyclophosphamide was significantly more toxic to SEC."( Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation.
DeLeve, LD, 1996)		0.29
"Phosphorus oxychloride (POCl(3)) is an intermediate in the synthesis of many organophosphorus insecticides and chemical warfare nerve gases that are toxic to insects and mammals by inhibition of acetylcholinesterase (AChE) activity."( Phosphoacetylcholinesterase: toxicity of phosphorus oxychloride to mammals and insects that can be attributed to selective phosphorylation of acetylcholinesterase by phosphorodichloridic acid.
Casida, JE; Quistad, GB; Sparks, SE; Zhang, N, 2000)		0.31
" It can be postulated that sodium activation of the Gcn2p pathway has toxic effects on growth under NaCl stress and that this novel mechanism of sodium toxicity may be of general significance in eukaryotes."( The protein kinase Gcn2p mediates sodium toxicity in yeast.
Dever, TE; Goossens, A; Pascual-Ahuir, A; Serrano, R, 2001)		0.31
" An adverse effect of high-dose serine therapy on head growth and on the transport of neutral amino acids across the blood-brain barrier should be considered and requires adjustment of treatment."( Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings.
Häusler, MG; Jaeken, J; Mönch, E; Ramaekers, VT, 2001)		0.31
" We propose that T-kininogen may be required to counteract apoptosis in proximal tubular cells in order to minimize tissue damage following a toxic insult."( A correlation between a proteomic evaluation and conventional measurements in the assessment of renal proximal tubular toxicity.
Bandara, LR; Kelly, MD; Kennedy, S; Lock, EA, 2003)		0.32
" These data predict that the ability of cdk5 phosphorylation to protect against htt cleavage, aggregation, and toxicity is compromised in cells expressing toxic fragments of htt."( Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity.
Davies, JE; Luo, S; Rubinsztein, DC; Vacher, C, 2005)		0.33
"Although many animal studies have reported that dietary excess of methionine causes toxic changes including growth suppression and hemolytic anemia, the biochemical mechanism and biomarkers for methionine toxicity have not been well elucidated."( Screening of toxicity biomarkers for methionine excess in rats.
Amao, M; Kawamata, Y; Kimura, T; Kodama, R; Sakai, R; Toue, S, 2006)		0.33
"Bacillus thuringiensis Cry1Ac toxin is 100 times less toxic than Cry1C to Mamestra brassicae."( The mutation R(423)S in the Bacillus thuringiensis hybrid toxin CryAAC slightly increases toxicity for Mamestra brassicae L.
Ayra-Pardo, C; Davis, P; Ellar, DJ, 2007)		0.34
" Together, these data suggest that phosphorylation of Ser(357) mediates at least in part the adverse effects of PKC-delta activation on insulin action."( Phosphorylation of Ser357 of rat insulin receptor substrate-1 mediates adverse effects of protein kinase C-delta on insulin action in skeletal muscle cells.
Häring, HU; Hennige, AM; Kalbacher, H; Lehmann, R; Lutz, SZ; Schleicher, ED; Voelter, W; Waraich, RS; Weigert, C, 2008)		0.35
" The response of the receptors to inhibitors of polyglutamine toxicity is altered by the amino acid exchanges suggesting that careful consideration is needed in the choice of potential therapies of disorders involving toxic polyQ species."( Specific N-terminal mutations in the human androgen receptor induce cytotoxicity.
Cato, AC; Funderburk, SF; Mink, S; Shatkina, L; Weg-Remers, S; Weis, Q, 2009)		0.35
" There were no treatment-related adverse effects on urinalysis, hematology, serum biochemistry, organ weights, gross and histopathological examination."( A 13-week subchronic oral toxicity study of L-serine in rats.
Han, L; Hayamizu, K; Kaneko, I; Li, C; Li, J; Liang, A; Liu, T; Yi, Y; Zhao, Y, 2009)		0.35
" Our findings suggest that alpha-synuclein neurotoxicity in Parkinson disease and related synucleinopathies may result from an imbalance between the detrimental, oligomer-promoting effect of serine 129 phosphorylation and a neuroprotective action of tyrosine 125 phosphorylation that inhibits toxic oligomer formation."( Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.
Chen, L; Feany, MB; Hyman, BT; McLean, PJ; Negro, A; Periquet, M; Wang, X, 2009)		0.35
" We investigated the basis for these other phenotypes and found that they are dependent on the toxic biosynthetic intermediate homoserine."( Homoserine toxicity in Saccharomyces cerevisiae and Candida albicans homoserine kinase (thr1Delta) mutants.
Kingsbury, JM; McCusker, JH, 2010)		0.36
" Close collaboration with cardiology colleagues for early indicators of serious cardiac adverse events will likely minimize toxicity while optimizing the therapeutic potential of VDAs and ultimately enhancing patient outcomes."( Cardiovascular toxicity profiles of vascular-disrupting agents.
Lenihan, DJ; Subbiah, IM; Tsimberidou, AM, 2011)		0.37
" Strikingly, overexpression of the phosphomimic mutant S87E did not show any toxic effect on dopaminergic neurons and resulted in significantly less α-syn aggregates, dystrophic fibers, and motor impairment."( Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease.
Aebischer, P; Lashuel, HA; Oueslati, A; Paleologou, KE; Schneider, BL, 2012)		0.38
" Conversely, known activators of autophagy, such as lithium and rapamycin, displayed neuroprotection against this toxic compound."( Role of autophagy inhibitors and inducers in modulating the toxicity of trimethyltin in neuronal cell cultures.
Biagioni, F; Fabrizi, C; Fornai, F; Fumagalli, L; Lenzi, P; Pompili, E; Somma, F, 2012)		0.38
" The role of p66shc in adverse effects of OA was determined using knockdown, p66shc serine36 phosphorylation and cytochrome c binding-deficient cells."( Role of p66shc in renal toxicity of oleic acid.
Arany, I; Clark, JS; Dixit, M; Juncos, LA; Reed, DK, 2013)		0.39
" The most frequent related adverse events in this group were diarrhea, nausea, and hypertension."( An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)		0.4
" We determined the specific base requirements for recombination by these enzymes and demonstrate their potential for genome engineering by selecting for variants capable of specifically recombining target sites present in the human CCR5 gene and the AAVS1 safe harbor locus."( Redesigning Recombinase Specificity for Safe Harbor Sites in the Human Genome.
Barbas, CF; Gaj, T; Wallen, MC, 2015)		0.42
" The most toxic compound analyzed showed about 50 times less cytotoxicity than the cisplatin reference compound in HT-29 cells."( Cytotoxicity studies of water soluble coordination compounds with a [Mo2O2S2](2+) core.
Bobersky, S; Gretarsdóttir, JM; Metzler-Nolte, N; Suman, SG, 2016)		0.43
" We found that S421 phosphorylation mitigates neurodegeneration by increasing proteasome-dependent turnover of mHTT and reducing the presence of a toxic mHTT conformer."( Serine 421 regulates mutant huntingtin toxicity and clearance in mice.
Daub, AC; Finkbeiner, S; Gu, X; Humbert, S; Kratter, IH; Lau, A; Masliah, E; Osmand, A; Saudou, F; Steffan, JS; Tsvetkov, AS; Weiberth, KF; Yang, XW; Zahed, H, 2016)		0.43
" Based on this small study, L-serine appears to be generally safe for patients with ALS."( Phase I clinical trial of safety of L-serine for ALS patients.
Banack, SA; Bradley, WG; Cox, PA; Flynn, LE; Forshew, DA; Katz, JS; Levine, TD; Metcalf, JS; Miller, RG; Moore, DH; Saperstein, DS, 2017)		0.46
"A major dose-limiting side effect of docetaxel chemotherapy is peripheral neuropathy."( Role of 1-Deoxysphingolipids in docetaxel neurotoxicity.
Becker, KA; Bieberich, E; Bielawski, J; Doolen, S; Goins, L; Gulbins, E; McQuerry, KJ; Spassieva, SD; Sure, U; Taylor, BK; Uerschels, AK, 2020)		0.56
" Thymidine promotes microbial conversion of the prodrug FUdR into toxic 5-fluorouridine-5'-monophosphate (FUMP), leading to enhanced host death associated with mitochondrial RNA and DNA depletion, and lethal activation of autophagy."( Dietary serine-microbiota interaction enhances chemotherapeutic toxicity without altering drug conversion.
Benjamin, SB; Drangowska-Way, A; Hilzendeger, MA; Joshi, C; Ke, W; Lewis, N; Locasale, J; Mony, VK; O'Rourke, EJ; Patti, GJ; Saba, JA; Yao, CH; Zhang, S, 2020)		0.56
" Phosphomimetic mHTT aggravates and the phosphoresistant mutation ameliorates mHTT-induced toxicity in the context of both FL- and exon1- mHTT in Drosophila although in all cases FL appears less toxic than exon1."( Serine residues 13 and 16 are key modulators of mutant huntingtin induced toxicity in Drosophila.
Agrawal, N; Chatterjee, M; Lukacsovich, T; Marsh, JL; Steffan, JS, 2021)		0.62
" No subjects experienced serious adverse events or discontinued treatment due to adverse events."( Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment.
Dowell, JA; Henkel, T; Marbury, TC; Smith, WB, 2022)		0.72
" Hyperphosphorylated TDP-43 was found within the inclusion bodies in disease lesions; however, the role of hyperphosphorylation and the toxic species are still ambiguous."( Hyperphosphorylation-Mimetic TDP-43 Drives Amyloid Formation and Possesses Neuronal Toxicity at the Oligomeric Stage.
Chang, LY; Chen, YR; Chiang, WC; Chou, SC; Fang, YS; Ganesan, K; Huang, SH; Lye, YS; Weng, TY, 2022)		0.72
" All adverse events were investigated and recorded."( Pharmacokinetics and Safety of Sodium Benzoate, a d-Amino Acid Oxidase (DAAO) Inhibitor, in Healthy Subjects: A Phase I, Open-label Study.
Lin, YS; Mao, WC; Tsai, GE; Yao, NT, 2022)		0.72
"Acrolein (ACR) and formaldehyde (FA) are toxic aldehydes co-produced in foods."( Cytotoxicity of a Novel Compound Produced in Foods via the Reaction of Amino Acids with Acrolein along with Formaldehyde.
Hu, J; Ou, J; Ou, S, 2022)		0.72
" ASPNJ can cause significant toxic effects on Jurkat cells and enhance the effects of VCR."( Cytotoxicity of alkaline serine protease (ASPNJ) on Jurkat cells and its correlation with changes in the expression of membrane-associated proteins.
Cui, J; Hong, M; Li, C; Liu, J; Ren, K; Zhang, J, 2023)		0.91

Pharmacokinetics

ExcerptReferenceRelevance
" As TACC3 localization to mitotic spindles depends on Aurora A-mediated phosphorylation, quantifying TACC3 mislocalization represents a novel pharmacodynamic approach for measuring Aurora A activity in cancer patients treated with inhibitors of Aurora A kinase."( Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
Bowman, D; Burke, KE; Ecsedy, JA; Galvin, K; Hoar, KM; Hunter, JJ; LeRoy, PJ; Ruan, J; Shinde, V, 2007)		0.34
" In the present study, the time- and dose-dependent distributions of administered glycine were investigated from a pharmacokinetic viewpoint."( Pharmacokinetics and cerebral distribution of glycine administered to rats.
Bannai, M; Kawai, N; Koizumi, T; Matsuzawa, D; Nagao, K; Seki, S; Shimizu, E; Shinkai, K; Takahashi, M, 2012)		0.38
" Thus, a potent DAAO inhibitor with a longer half-life should be capable of maintaining high plasma D-serine levels over a sustained period of time and might have therapeutic implications for the treatment of schizophrenia."( Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
Brandon, NJ; Engle, SJ; Jaaro-Peled, H; Rais, R; Rojas, C; Sawa, A; Slusher, BS; Strick, CA; Thomas, AG; Tsukamoto, T; Wozniak, K; Wu, Y, 2012)		0.38
" Safety, tumor response, pharmacokinetics, and pharmacodynamic biomarkers were evaluated."( Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Bahleda, R; Braghetti, A; Cohen, P; Delmonte, A; Farace, F; Hospitel, M; Lassau, N; Lorusso, P; Sessa, C; Soria, JC; Tolcher, A; Veyrat-Follet, C, 2013)		0.39
"To determine ombrabulin's maximum tolerated dose and dose recommended for Japanese patients with advanced solid tumors and to assess its antitumor activity and overall safety and pharmacokinetic profiles."( An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)		0.4
" Pharmacokinetic parameters were comparable to those in non-Japanese patients."( An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)		0.4
" The safety and pharmacokinetic profiles were comparable between Japanese and Caucasian patients (funded by Sanofi; ClinicalTrials."( An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N, 2014)		0.4
" Pharmacokinetic analyses did not show any relevant drug interactions."( A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.
Dieras, V; Eskens, FA; Fontaine, H; Hospitel, M; Oprea, C; Tosi, D; Tresca, P; Van der Gaast, A; Van Doorn, L; Veyrat-Follet, C, 2014)		0.4
" Ombrabulin clearance was high with a short terminal half-life and a medium volume of distribution."( Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A, 2014)		0.4
"Bckground: One of the major challenges of biopharmaceuticals having short plasma half-life is that daily high dose injections are needed which can lead to economic burden, patient inconvenience and undesirable side effects."( PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
Ahmadpour, S; Hosseinimehr, SJ, 2018)		0.48
"In this review, we focus on PASylation technology as a novel method to enhance the pharmacokinetic (PK) properties of biopharmaceuticals."( PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
Ahmadpour, S; Hosseinimehr, SJ, 2018)		0.48
"We explain the general concept of PASylation, its development; advantages compared to other PK modifying technologies and describe furthermore the pharmacodynamic (PD) and PK properties of several PAS-fusion proteins in preclinical studies."( PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
Ahmadpour, S; Hosseinimehr, SJ, 2018)		0.48
"The biodegradable PAS sequence was already used for prolonging plasma half-life of clinical important agents such as antibody fragments, cytokines, enzymes and receptor-binding peptides."( PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
Ahmadpour, S; Hosseinimehr, SJ, 2018)		0.48
" coli-expressed recombinant fused and unfused proteins were compared in terms of bioactivity, physicochemical, and pharmacokinetic properties using standard methods."( Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology.
Aghaabdollahian, S; Ahangari Cohan, R; Asadi Karam, MR; Davami, F; Latif Dizaji, S; Moazzami, R; Norouzian, D; Torkashvand, F; Vaseghi, G, 2019)		0.51
"Therapeutic fragmented antibodies show a poor pharmacokinetic profile that leads to frequent high-dose administration."( New Proline, Alanine, Serine Repeat Sequence for Pharmacokinetic Enhancement of Anti-VEGF Single-Domain Antibody.
Cohan, RA; Karami, E; Khodabakhsh, F; Khosravy, MS; Mehdizadeh, A; Salimian, M; Vafabakhsh, A, 2020)		0.56
" The aim of this study was to evaluate whether the addition of avibactam could reduce or close the mutant selection window (MSW) of aztreonam in Escherichia coli and Klebsiella pneumoniae harbouring MBLs; MSW is a pharmacodynamic (PD) parameter for the selection of emergent resistant mutants."( Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases.
Dong, D; Feng, K; Gong, H; Jia, N; Liu, Y; Lv, Z; Martins, FS; Sy, S; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S; Zhu, Y, 2021)		0.62
" For therapeutic application of sodium benzoate in CNS disorders, we conducted a Phase I study to evaluate its safety, tolerability, and pharmacokinetic profile after single-dose oral administration in healthy volunteers."( Pharmacokinetics and Safety of Sodium Benzoate, a d-Amino Acid Oxidase (DAAO) Inhibitor, in Healthy Subjects: A Phase I, Open-label Study.
Lin, YS; Mao, WC; Tsai, GE; Yao, NT, 2022)		0.72
" The pharmacokinetic parameters of sodium benzoate were assessed after exposure to 250, 500, 1000, and 2000 mg of sodium benzoate."( Pharmacokinetics and Safety of Sodium Benzoate, a d-Amino Acid Oxidase (DAAO) Inhibitor, in Healthy Subjects: A Phase I, Open-label Study.
Lin, YS; Mao, WC; Tsai, GE; Yao, NT, 2022)		0.72
"The nonlinear pharmacokinetic response was observed within the dose range up to 2000 mg."( Pharmacokinetics and Safety of Sodium Benzoate, a d-Amino Acid Oxidase (DAAO) Inhibitor, in Healthy Subjects: A Phase I, Open-label Study.
Lin, YS; Mao, WC; Tsai, GE; Yao, NT, 2022)		0.72

Compound-Compound Interactions

Biapenem is being developed in combination with RPX7009, a new inhibitor of serine β-lactamases. The aim of study was to investigate the effects of pyrroloquinoline quinone (PQQ) combined with d-serine on the modulation of glycine sites in the brain of rats.

ExcerptReferenceRelevance
" subtilis when the azasteroid was combined with vancomycin or chloramphenicol."( Antibacterial activity of 15-azasteroids alone and in combination with antibiotics.
Berlin, KD; Brown, RA; Chesnut, RW; Durham, NN; Mawdsley, EA, 1976)		0.26
" We conclude that SNPs in PPARD modify the conversion from IGT to type 2 diabetes, particularly in combination with the SNPs of PGC-1A and PPARG2."( Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
Andrulionyte, L; Chiasson, JL; Laakso, M; Peltola, P, 2006)		0.33
") administration of D-serine, a selective agonist for the glycine site of the NMDA receptors, alone or in combination with morphine using the tail-flick test."( Activation of supraspinal NMDA receptors by both D-serine alone or in combination with morphine leads to the potentiation of antinociception in tail-flick test of rats.
Akahori, K; Hashimoto, A; Ito, K; Jin, XL; Kobayashi, H; Maeda, M; Matsuda, M; Oka, T; Suzuki, T; Takahashi, S; Yoshikawa, M, 2007)		0.34
" Treatment of 1 nM letrozole in combination with 1 μM or 10 μM ZA resulted in an additive drug interaction on inhibition of cell viability, as measured by MTT assay."( Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
Brodie, AH; Nemieboka, BE; Schech, AJ, 2012)		0.38
"Biapenem is a carbapenem being developed in combination with RPX7009, a new inhibitor of serine β-lactamases."( In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
Citron, DM; Goldstein, EJ; Merriam, CV; Tyrrell, KL, 2013)		0.39
" Ombrabulin was combined with two standard taxane/platinum doublets in a phase I study to determine the recommended combination doses."( Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A, 2014)		0.4
"Ionizing radiation exposure combined with wound injury increases animal mortalities than ionizing radiation exposure alone."( Ciprofloxacin Therapy Results in Mitigation of ATP Loss after Irradiation Combined with Wound Trauma: Preservation of Pyruvate Dehydrogenase and Inhibition of Pyruvate Dehydrogenase Kinase 1.
Kiang, JG; Smith, JT; Swift, JM, 2015)		0.42
"The aim of study was to investigate the effects of pyrroloquinoline quinone (PQQ) combined with d-serine on the modulation of glycine sites in the brain of rats using social recognition test."( Modulation of glycine sites enhances social memory in rats using PQQ combined with d-serine.
Liu, D; Mao, S; Peng, Y; Qin, X; Zhang, R; Zhou, X, 2016)		0.43
"5-35 mg/m2) in combination with docetaxel (60 or 75 mg/m2) and cisplatin (75 mg/m2), agents were administered 24 h apart every 3 weeks to Japanese patients with advanced solid tumors."( Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors.
Ecstein-Fraisse, E; Hida, T; Horiike, A; Horio, Y; Nishio, M; Satouchi, M; Sunaga, Y, 2018)		0.48
" Finally, by overexpressing the novel exporter SerE, combined with L-serine synthetic pathway key enzyme serAΔ197, serC, and serB, the resulting strain presented an L-serine titer of 43."( High-yield production of L-serine through a novel identified exporter combined with synthetic pathway in Corynebacterium glutamicum.
Chen, Z; Gao, Y; Koffas, MAG; Li, H; Shi, J; Xu, G; Xu, Z; Zhang, X, 2020)		0.56
" A cefepime human-simulated regimen (HSR) equivalent to a clinical dose of 2 g q8h as a 2 h infusion was given in combination with taniborbactam for 24 h."( In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.
Abdelraouf, K; Almarzoky Abuhussain, S; Nicolau, DP, 2020)		0.56

Bioavailability

This compound proved to have limited bioavailability (1% in rats) due to cleavage of the serine ester bond and rapid hepatic extraction. The effect was also present when the vehicle (Trappsol(®) was tested with D-serine, suggesting that the reduction in locomotor activity was not related to DAAO inhibition.

ExcerptReferenceRelevance
" This compound proved to have limited bioavailability (1% in rats) due to cleavage of the serine ester bond and rapid hepatic extraction."( Highly potent, orally active diester macrocyclic human renin inhibitors.
Ball, RG; Colletti, AE; Doyle, JJ; Halgren, TA; Krieter, PA; Schorn, TW; Stearns, RA; Steiner, MG; Tata, JR; Weber, AE, 1992)		0.28
" These data suggest that despite their brain bioavailability and marked potency at the glycine receptor in vitro, ACC and ACBC are rapidly inactivated and thus have limited in vivo utility."( Neuropharmacological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate-associated glycine receptor.
Cler, JA; Compton, RP; Emmett, MR; Iyengar, S; Mick, S; Rao, TS; Sun, ET; Wood, PL, 1990)		0.28
" Unlike tetracosactrin depot, however, it is well absorbed when given intranasally and does not produce painful reactions at the site of injection."( Prolonged corticotrophic action of a synthetic substituted 1-18 ACTH.
Besser, GM; Chamberlain, MA; Keenan, J; Thompson, JB, 1971)		0.25
" It appears likely that there is a gap in the bioavailability of oligomethionine between the octamer and nonamer when added to a low-protein diet, probably due to the rigidity of the structure increasing with the polymerization degree by alpha-helix formation."( Polymerization degree of oligomethionine to determine its bioavailability when added to a low-protein diets.
Kasai, T; Kiriyama, S; Tanaka, T, 1996)		0.29
" The central bioavailability of peripherally administered glycine has not been adequately characterized in humans."( IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans.
Abi-Saab, D; Bennett, A; Cassello, K; Charney, DS; D'Souza, DC; Gil, R; Karper, LP; Krystal, JH; Morrissey, K; Sturwold, R; White, J; Zuzarte, E, 2000)		0.31
" Therefore, we investigated whether endothelial dysfunction and/or vascular NO bioavailability is reflected by decreased vessel wall P-VASP and whether improvement of endothelial dysfunction restores this P-VASP."( Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction.
Bodenschatz, M; Hoffmann, N; Meinertz, T; Mollnau, H; Münzel, T; Oelze, M; Skatchkov, M; Smolenski, A; Walter, U; Warnholtz, A, 2000)		0.31
" A reduction of NO bioavailability leads to endothelial dysfunction that has been shown to be improved by alpha-tocopherol in certain conditions."( Alpha-Tocopherol and endothelial nitric oxide synthesis.
Heller, R; Werner, ER; Werner-Felmayer, G, 2004)		0.32
" First, we evaluated the response of human cells to microwave exposure at a specific absorption rate (SAR) of 80 mW/kg, which corresponds to the limit of the average whole-body SAR for general public exposure defined as a basic restriction by the International Commission on Non-Ionizing Radiation Protection (ICNIRP) guidelines."( Phosphorylation and gene expression of p53 are not affected in human cells exposed to 2.1425 GHz band CW or W-CDMA modulated radiation allocated to mobile radio base stations.
Hirose, H; Kaji, N; Miyakoshi, J; Nojima, T; Sakuma, N; Sekijima, M; Suhara, T, 2006)		0.33
" Perfusion studies in the rat establish that the mesenteric permeability to 4 is more than 20-fold greater than to 1, and the bioavailability of 4 is increased 6-fold relative to 1 in an in vivo murine model."( Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity.
Borysko, KZ; Breitenbach, JM; Drach, JC; Eriksson, U; Hilfinger, JM; Kashemirov, BA; Kijek, P; Kim, JS; McKenna, CE; Mitchell, S; Peterson, LW, )		0.13
"ATP-binding cassette transporter ABCG2 [breast cancer resistance protein (BCRP)] is a member of the ABC transporter superfamily that actively extrudes xenotoxins from cells and is a major determinant of the bioavailability of many compounds."( Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors.
Alvarez, AI; Baro, MF; Gonzalez-Lobato, L; Marques, MM; Merino, G; Prieto, JG; Real, R, 2009)		0.35
" Our results indicate that AMPK phosphorylation of eNOS Ser633 is a functional signaling event for NO bioavailability in ECs."( AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633.
Chen, Z; DeFea, K; Fu, Y; Hsu, PH; Pan, S; Peng, IC; Shyy, JY; Su, MI; Sun, W; Tsai, MD; Zhu, Y, 2009)		0.35
"Obesity and type 2 diabetes mellitus are characterized by insulin resistance, reduced bioavailability of the antiatherosclerotic signaling molecule nitric oxide (NO), and accelerated atherosclerosis."( Vascular insulin-like growth factor-I resistance and diet-induced obesity.
Abbas, A; Ajjan, R; Cubbon, RM; Duncan, ER; Ezzat, VA; Gage, M; Grant, PJ; Imrie, H; Kahn, M; Kearney, MT; Rajwani, A; Viswambharan, H; Wheatcroft, SB, 2009)		0.35
"Hyperglycaemia is known to reduce nitric oxide (NO) bioavailability by modulating endothelial NO synthase (eNOS) activity, and polyphenols are believed to have cardiovascular benefit."( Beneficial effect of the oligomerized polyphenol oligonol on high glucose-induced changes in eNOS phosphorylation and dephosphorylation in endothelial cells.
Fujii, H; Hattori, Y; Hayashi, T; Matsuda, N; Nishioka, H; Yokoo, H; Zhang, XH, 2010)		0.36
"Phosphorylation enhances IGFBP-1 binding to IGF-I, thereby limiting the bioavailability of IGF-I that may be important in fetal growth."( Site-specific IGFBP-1 hyper-phosphorylation in fetal growth restriction: clinical and functional relevance.
Abu Shehab, M; Gupta, MB; Han, VK; Khosravi, J; Shilton, BH, 2010)		0.36
" The results indicate that the previously observed enhanced oral bioavailability of 2a relative to the parent drug is unlikely to be due to active transport by hPEPT1."( Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1.
Kashemirov, BA; Krylov, IS; McKenna, CE; Peterson, LW; Sala-Rabanal, M; Serpi, M, 2010)		0.36
"Red blood cells (RBC) play an important role in the balance between generation and scavenging of nitric oxide (NO) and hence its local bioavailability and influence on vasomotor control."( Shear stress activation of nitric oxide synthase and increased nitric oxide levels in human red blood cells.
Baskurt, OK; Celik-Ozenci, C; Johnson, PC; Meiselman, HJ; Ulker, P; Yalcin, O; Yaras, N, 2011)		0.37
" Alterations of its protein turnover can influence drug metabolism, drug-drug interactions, and the bioavailability of chemotherapeutic drugs."( Multisite phosphorylation of human liver cytochrome P450 3A4 enhances Its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction.
Acharya, P; Brandman, R; Burlingame, AL; Correia, MA; Guan, S; Liu, Y; Schuetz, EG; Thirumaran, RK; Wang, Y, 2012)		0.38
"We exposed human umbilical vein endothelial cells to low glucose conditions in a clinically relevant range (40-70 mg/dL) and found rapid and marked reductions in nitric oxide (NO) bioavailability (P<0."( Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase.
Alexanian, A; Dharmashankar, K; Gutterman, DD; Kizhakekuttu, TJ; Vasquez-Vivar, J; Wang, J; Widlansky, ME; Ying, R, 2012)		0.38
"Our data suggest that moderate low glucose exposure rapidly impairs NO bioavailability and endothelial function in the human endothelium and that pharmacological AMP kinase activation inhibit this effect in an NO-dependent manner."( Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase.
Alexanian, A; Dharmashankar, K; Gutterman, DD; Kizhakekuttu, TJ; Vasquez-Vivar, J; Wang, J; Widlansky, ME; Ying, R, 2012)		0.38
" Treatment with PPARδ ligand GW501516 (2 mg/kg/day) for 14 days significantly increased BH(4) bioavailability and improved endothelium-dependent relaxations in Tg2576 mice aortas."( Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein.
d'Uscio, LV; Das, P; He, T; Katusic, ZS; Santhanam, AV; Younkin, SG, 2012)		0.38
" One way is to improve the bioavailability and efficacy by synthesizing derivatives that reversibly bind to carbonic anhydrase II (CAII) in red blood cells followed by a slow release into the blood circulation system."( In vitro evaluation of ESE-15-ol, an estradiol analogue with nanomolar antimitotic and carbonic anhydrase inhibitory activity.
Joubert, AM; Joubert, F; McKenna, R; Sippel, KH; Stander, BA; Tu, C, 2012)		0.38
" Angiotensin II-induced ROS decreased the bioavailability of eNOS under the FC-enriched condition."( Angiotensin II impairs endothelial nitric-oxide synthase bioavailability under free cholesterol-enriched conditions via intracellular free cholesterol-rich membrane microdomains.
Amiya, E; Hosoya, Y; Imai, Y; Komuro, I; Maemura, K; Manabe, I; Nagai, R; Nakao, T; Saito, T; Shiga, T; Takeda, N; Watanabe, M, 2013)		0.39
" However, the effect was also present when the vehicle (Trappsol(®)) was tested with D-serine, suggesting that the reduction in locomotor activity was not related to DAAO inhibition, but possibly reflected enhanced bioavailability of D-serine across the blood brain barrier related to the vehicle."( Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.
Cooper, TB; Dunlop, DS; Hashim, A; Javitt, DC; Sershen, H; Suckow, RF, 2016)		0.43
" It is well established that reduced vascular endothelial nitric oxide (NO) bioavailability promotes arterial inflammation; however, the role of NO in modulating inflammation in AT remains disputed."( Ablation of eNOS does not promote adipose tissue inflammation.
Gastecki, ML; Jurrissen, TJ; Padilla, J; Rector, RS; Sheldon, RD; Vieira-Potter, VJ; Woodford, ML; Zidon, TM, 2016)		0.43
" Impaired bioavailability of endothelial nitric oxide synthase (eNOS) is one of the main reasons of endothelial dysfunction."( mZD7349 peptide-conjugated PLGA nanoparticles directed against VCAM-1 for targeted delivery of simvastatin to restore dysfunctional HUVECs.
Amani, A; Deiham, B; Doosti, M; Faramarzi, MA; Imanparast, F; Kobarfard, F; Paknejad, M; Vatannejad, A, 2017)		0.46
" Additionally, anti-miR-93 and anti-miR-484 restore KLF2 and eNOS expression and NO bioavailability in ECs under OS."( Shear stress regulation of miR-93 and miR-484 maturation through nucleolin.
Chen, L; Chen, S; Chien, S; Gongol, B; Han, Y; He, M; Huang, PH; Johnson, DA; Kang, J; Li, J; Li, YS; Liu, JH; Lytle, C; Marin, T; Martin, M; Shyy, JY; Sun, W; Wang, SC; Zhang, J, 2019)		0.51

Dosage Studied

Dose-response effects of glutamate and serine were studied on the population spikes evoked in the granular cell layer. In the dose-response experiment, the expression of PHGDH enzyme in L02 cells gradually decreased with the incr. Dosing of animals with L-serine and human clinical trials investigating the therapeutic effects of L- Serine support the FDA's determination that L-Serine is generally regarded as safe.

ExcerptRelevanceReference
" The effects on the amino acids are not due to a change in the food intake caused by dosing with arsenate."( The effects of sodium arsenate on the free amino acid levels in erythrocytes and plasma in rats.
Kilroe-Smith, TA; McLoughlin, JL, 1979)		0.26
" The icb dose-response data indicated a unimolecular interaction for these compounds."( Glycine, glycinamide and D-serine act as positive modulators of signal transduction at the N-methyl-D-aspartate (NMDA) receptor in vivo: differential effects on mouse cerebellar cyclic guanosine monophosphate levels.
Cler, JA; Emmett, MR; Iyengar, S; Mick, SJ; Rao, TS; Wood, PL, 1990)		0.28
" Biologically, sea turtle PRL was active in pigeon crop-sac assay but the dose-response characteristics were nonparallel when compared to ovine PRL."( Isolation and properties of sea turtle (Chelonia mydas) pituitary prolactin.
Chang, YS; Papkoff, H, 1985)		0.27
" Consistent with the loss of Ser190 and/or Ser191 mutant receptor affinity for agonists was a corresponding shift to the right in the dose-response curve for isoproterenol-induced increases in intracellular cyclic AMP concentrations in cells expressing the mutant receptors."( Site-directed mutagenesis of beta-adrenergic receptors. Identification of conserved cysteine residues that independently affect ligand binding and receptor activation.
Fraser, CM, 1989)		0.28
" L-Serine borate complex, 45 mM, used as an inhibitor of the degradation of LTC4 to LTD4 by the enzyme gamma-glutamyl transpeptidase, in paired airway segments (adjacent segments from the same branch), produced a small degree (about 3-fold) of shift to the right of the dose-response curve and reduction of the maximum response to LTC4."( Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4.
Bernstein, PR; Buckner, CK; Coursin, DB; Krell, RD; Laravuso, RB; Will, JA, 1986)		0.27
"Cumulative dose-response curves to leukotriene C4 (LTC4) and leukotriene D4 (LTD)4 were obtained on indomethacin (5 microM) treated isolated guinea pig tracheal spiral strips."( Pharmacological comparison of L-serine borate and glutathione as inhibitors of metabolism of LTC4 to LTD4 by the isolated guinea pig trachea.
Hand, JM; Schwalm, SF, 1987)		0.27
" Time-course and dose-response evaluations of the 1,25-(OH)2D3 effect revealed that the decrease in [14C]choline incorporation was seen within 12 h of incubation and occurred with as little as 10(-9) M, respectively."( Effect of 1,25-dihydroxyvitamin D3 on phospholipid metabolism in cultured bovine parathyroid cells.
Morrissey, J; Ritter, C; Slatopolsky, E; Sugimoto, T, 1988)		0.27
" With the exception of gamma-amino butyric acid and L-alanine benzyl ester all analogues which had appreciable activity gave dose-response curves parallel to L-alanine."( Isolation and identification of pharmacologically active amino acids in skin and their structure-activity relationship on the guinea-pig ileum.
Lewis, GP; McMartin, C; Rosenthal, SR; Yates, C, 1972)		0.25
" 33P-O-phosphothreonine was also identified in experiments using a dosage of 10 mCi per embryo."( Radioautographic visualization and biochemical identification of O-phosphoserine- and O-phosphothreonine-containing phosphoproteins in mineralizing embryonic chick bone.
Brickley-Parsons, D; Glimcher, MJ; Landis, WJ; Sanzone, CF, 1984)		0.27
"A dosage series of the X chromosome site for serine-4 transfer RNA consisting of one of three copies in females and one to two in males was constructed to test whether transfer RNA expression is governed by dosage compensation."( Dosage compensation of serine-4 transfer RNA in Drosophila melanogaster.
Birchler, JA; Jacobson, KB; Owenby, RK, 1982)		0.26
" GABA dose-response characteristics of wild type and mutant receptors were very similar."( A unique amino acid of the Drosophila GABA receptor with influence on drug sensitivity by two mechanisms.
ffrench-Constant, RH; Jackson, MB; Zhang, HG, 1994)		0.29
" Pretreatment with glycine, an agonist to the glycine/NMDA receptors, shifted the dose-response effect of felbamate to the right (ED50 = 56."( Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice.
Aguglia, U; Bertorelli, R; De Sarro, A; De Sarro, G; Ongini, E, 1994)		0.29
" 25-Hydroxycholesterol dose-response curves for activation of sphingomyelin synthesis, suppression of sterol-regulated transcription, and activation of cholesteryl ester synthesis were also similar."( 25-Hydroxycholesterol stimulates sphingomyelin synthesis in Chinese hamster ovary cells.
Ridgway, ND, 1995)		0.29
" The dose-response curve of PS action showed significant potentiation above 250 nM and a half-maximal effect at approximately 29 microM."( Pregnenolone sulfate potentiation of N-methyl-D-aspartate receptor channels in hippocampal neurons.
Bowlby, MR, 1993)		0.29
" Membrane-associated wild-type and C3S G(o)1 alpha appeared to interact with guanine nucleotides with similar affinity, as no alteration in the dose-response curves for guanine-nucleotide-induced maintenance of a stable 37 kDa tryptic fragment was noted for the two forms of G(o)1 alpha."( The palmitoylation status of the G-protein G(o)1 alpha regulates its activity of interaction with the plasma membrane.
Grassie, MA; Guzzi, F; Magee, AI; McCallum, JF; Milligan, G; Parenti, M, 1994)		0.29
" The dose-response effects of glutamate and serine were studied on the population spikes evoked in the granular cell layer."( Serine released from hippocampal slices during deprivation of oxygen and glucose enhances the effects of glutamate on neuronal function.
Hirai, H; Okada, Y, 1993)		0.29
" The rapid degradation and inactivation of the peptides makes it difficult to assess dose-response relationships precisely or to conduct long term incubations with cells in the presence of plasma or serum."( Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation.
Ceruso, M; Coller, BS; Kutok, JL; Prestwich, GD; Scudder, LE; Springer, KT, 1993)		0.29
" The serum levels of SHBG and CBG increased during treatment and a weak association between progesterone dosage and CBG was observed."( Liver metabolism during treatment with estradiol and natural progesterone.
Axelsson, O; Carlström, K; Darj, E; Nilsson, S; von Schoultz, B, 1993)		0.29
" Dose-response curves were generated using six 4 x 4 Latin squares."( Dietary crude protein increases slightly the requirement for threonine in kittens.
Hammer, VA; Morris, JG; Rogers, QR, 1996)		0.29
" Finally, glucagon-stimulated insulin secretion by RIN cells expressing the mutant receptor was decreased such that the dose-response curve was shifted to the right in comparison to that obtained with cells expressing the wild type receptor."( The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon.
Abrahamsen, N; Froguel, P; Hager, J; Hansen, LH; Jelinek, L; Kindsvogel, W; Nishimura, E, 1996)		0.29
" This could be suppressed by increasing the gene dosage of the mutant alleles."( A yeast phosphofructokinase insensitive to the allosteric activator fructose 2,6-bisphosphate. Glycolysis/metabolic regulation/allosteric control.
Boles, E; Heinisch, JJ; Timpel, C, 1996)		0.29
" The T88A and T88S mutant receptor fully stimulated adenylyl cyclase, with the dose-response curves to CGS 21680 highly shifted to the right."( Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
Jacobson, KA; Jiang, Q; Kim, J; Van Rhee, AM; Wess, J; Yehle, S, 1996)		0.29
"A comparative study of the variations of amino acid concentration with age in Down's syndrome subjects aged 0 to 60 years and in control subjects aged 0 to 94 years was made in order to determine whether these impairments could be explained by generalized premature aging, or by a specific gene dosage effect."( [Variation of amino acids in relation to age in Down syndrome subjects].
Kamoun, P; Lejeune, J; Mircher, C; Parvy, P; Peeters, MA; Rabier, D; Salabelle, A, 1997)		0.3
"001) were found in Down's syndrome: a decrease in plasma concentration of serine at any age, which could be due to a dosage effect of cytathionine-beta-synthase, and an increase in plasma lysine concentration in patients above 10 year's old, probably due to premature aging."( [Variation of amino acids in relation to age in Down syndrome subjects].
Kamoun, P; Lejeune, J; Mircher, C; Parvy, P; Peeters, MA; Rabier, D; Salabelle, A, 1997)		0.3
" Neither Ag dosage effect nor absence of B cell-mediated Ag presentation could fully account for these effects."( C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation.
Hosoi, S; Korematsu, S; Koyanagi, S; Mikami, B; Minato, N; Tanaka, Y; Yokota, T, 2000)		0.31
" Some of the point mutations caused shifts in the GABA dose-response curve, indicating that the mutations changed the apparent affinity of the receptor for GABA."( Volatile anesthetic actions on the GABAA receptors: contrasting effects of alpha 1(S270) and beta 2(N265) point mutations.
Harrison, NL; Jenkins, A; Nishikawa, K; Paraskevakis, I, 2002)		0.31
" A progress of psychomotor development was only observed in one patient, diagnosed early and treated with a high dosage of L-serine."( Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids.
De Koning, TJ; Dorland, L; Duran, M; Gooskens, R; Jaeken, J; Pineda, M; Poll-The, BT; Van Maldergem, L, 2002)		0.31
" This combination effect was found over wide dosage ranges of AC-7700 (20-80 mg/kg) and CDDP (2."( Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo.
Ehara, S; Harada, K; Morinaga, Y; Nihei, Y; Suga, Y; Suzuki, M, 2003)		0.32
" The procedure was applied successfully to resolve commercial ampoules of ketoprofen dosage formulation."( Enantiomeric resolution of some 2-arylpropionic acids using L-(-)-serine-impregnated silica as stationary phase by thin layer chromatography.
Aboul-Enein, HY; El-Awady, MI; Heard, CM, 2003)		0.32
" Reduced dosage of CTK1 rescued the growth defect of ess1(ts) mutants, while overexpression of CTK1 enhanced the growth defects of ess1(ts) mutants."( Genetic interactions with C-terminal domain (CTD) kinases and the CTD of RNA Pol II suggest a role for ESS1 in transcription initiation and elongation in Saccharomyces cerevisiae.
Hanes, SD; Rossettini, A; Wilcox, CB, 2004)		0.32
" FAK phosphorylation at Ser-910 could be distinguished from that at Tyr-397 in terms of dose-response relationships and kinetics."( PDGF and FGF induce focal adhesion kinase (FAK) phosphorylation at Ser-910: dissociation from Tyr-397 phosphorylation and requirement for ERK activation.
Fan, RS; Hunger-Glaser, I; Perez-Salazar, E; Rozengurt, E, 2004)		0.32
" More relevant, nocodazole inhibited, in a dose-response manner, mTOR phosphorylation at Ser2448."( Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt.
Asnaghi, L; Bevilacqua, A; Calastretti, A; Canti, G; Capaccioli, S; D'Agnano, I; Delia, D; Gatti, G; Nicolin, A, 2004)		0.32
"25 mumol/L UCN-01, glucose transport is inhibited 66, 29, and 26% at insulin concentrations of 10, 50, and 100,000 (100K) microunits/mL respectively, thus shifting the dose-response curve to the right."( 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport.
Cushman, SW; Kondapaka, SB; Sausville, EA; Yver, DR; Zarnowski, M, 2004)		0.32
" D-AAO activity in the kidney was decreased by 50% 1 h after dosing with SB suggesting that inhibition of this enzyme may be responsible for the observed protection."( Sodium benzoate attenuates D-serine induced nephrotoxicity in the rat.
Lock, EA; Williams, RE, 2005)		0.33
" Alderely Park (Wistar-derived) rats were dosed with either D-serine (250 mg/kg ip) or vehicle (deionised water) and urine was collected at 0-12, 12-24, 24-36 and 36-48 h post-dosing."( D-Serine-induced nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach.
Lenz, EM; Lock, EA; Major, H; Williams, RE; Wilson, ID, 2005)		0.33
" OPCs from hemizygous mice also undergo precocious differentiation, indicating a role for PDGFRalpha gene dosage in timing OPC maturation."( PDGF alpha-receptor signal strength controls an RTK rheostat that integrates phosphoinositol 3'-kinase and phospholipase Cgamma pathways during oligodendrocyte maturation.
Kiel, ME; McKinnon, RD; Waldron, S, 2005)		0.33
" The dose-response functions for 5-HT and (+/-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane (DOI) to elicit phosphoinositide hydrolysis did not differ in either HEK293 or NIH-3T3 fibroblasts expressing the receptor variants."( Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms.
Backstrom, JR; Fentress, HM; Grinde, E; Herrick-Davis, K; Mazurkiewicz, JE; Sanders-Bush, E, 2005)		0.33
" Therefore, genotyping of patients scheduled for ovarian stimulation could be an attractive tool to individualize FSH dosing according to genetic differences in ovarian sensitivity."( Pharmacogenetics in ovarian stimulation - current concepts and future options.
Behre, HM; Greb, RR; Simoni, M, 2005)		0.33
"Parkinson disease related to LRRK2 is characterized by typical clinical features, and the similarities between patients with homozygous and heterozygous mutations do not support a gene dosage effect."( Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
Amouri, R; Brice, A; Dürr, A; Farrer, MJ; Foroud, TM; Gibson, R; Griffith, A; Hattori, N; Hentati, F; Ishihara, L; Leppert, D; Lesage, S; Middleton, L; Nichols, WC; Tazir, M; Uitti, RJ; Warren, L; Watts, R; Wszolek, ZK; Zabetian, CP, 2006)		0.33
" Comparisons between individuals with heterozygous and homozygous LRRK2 mutations suggested that gene dosage was not correlated with phenotypic differences; however, the estimated penetrance was greater in homozygotes across all age groups."( Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.
Akkari, PA; Amouri, R; Ben Sassi, S; Ben Yahmed, S; Burn, DJ; El Euch-Fayeche, G; Elango, R; Freeman, A; Gibson, RA; Gouider-Khouja, N; Hattori, N; Hentati, F; Hunter, C; Ishihara, L; Jankovic, J; Kefi, M; Leppert, D; Lyons, K; Middleton, L; Nance, M; Pahwa, R; Ragone, L; Reeves, KH; Surh, L; Swartz, JE; Thomas, S; Warren, L; Watts, RL; Wielinski, C; Zouari, M, 2007)		0.34
" Altering CKIdelta dosage modulates the S662 phenotype demonstrating that CKIdelta can regulate period through PER2 in vivo."( Modeling of a human circadian mutation yields insights into clock regulation by PER2.
Fu, YH; Jones, CR; Ptácek, LJ; Shin, JY; Toh, KL; Xu, Y, 2007)		0.34
" In this PD model, insoluble deposits of Ser129-phosphorylated alpha-synuclein(A53T) are negatively correlated with the dosage of Sept4."( Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity.
Hagiwara, A; Hattori, N; Hikawa, R; Ihara, M; Kinoshita, M; Kitano, A; Miyakawa, T; Mori, H; Noda, M; Takanashi, M; Tanigaki, A; Tomimoto, H; Yamasaki, N, 2007)		0.34
" The mutation to alanine was accompanied by significantly altered dose-response and desensitization properties."( Kinetics and functional characterization of the glycine receptor alpha2 and alpha3 subunit.
Brune, K; Heindl, C; Renner, B, 2007)		0.34
" We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats."( The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors.
Abeywickrema, P; Almond, S; Brandon, N; Byrne, N; Campbell, A; Hutson, PH; Jacobson, M; Jones, B; Munshi, S; Pascarella, D; Pike, A; Prasad, GS; Sachs, N; Sakatis, M; Sardana, V; Sparey, T; Venkatraman, S; Young, MB, 2008)		0.35
" The increased dosage of Dyrk1A in DS brain due to trisomy of chromosome 21 correlates to an increase in 3R-tau level, which on abnormal hyperphosphorylation and aggregation of tau results in neurofibrillary degeneration."( Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome.
Chohan, MO; Gong, CX; Grundke-Iqbal, I; Gu, X; Hwang, YW; Iqbal, K; Liu, F; Shi, J; Wegiel, J; Zhang, T; Zhou, C; Zhou, J, 2008)		0.35
" Increased dosage of MeCP2 also leads to clinically similar neurological disorders and mental retardation."( Genetic modifiers of MeCP2 function in Drosophila.
Botas, J; Collins, AL; Cukier, HN; Perez, AM; Zhou, Z; Zoghbi, HY, 2008)		0.35
" The dose-response pattern of the down-regulated cluster showed nearly a perfect mirror image of that of the up-regulated one."( D-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats.
Chan, VT; Davidson, ME; Kerepesi, LA; Soto, A, 2009)		0.35
" Clinical factors such as gender, age, duration of illness, education level, diagnostic subtype and medication dosage were recorded."( Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
Chen, CH; Chen, SF; Shen, YC, 2009)		0.35
" The right medial superior frontal gyrus volume was significantly correlated with daily dosage of antipsychotic medication in Ser homozygote schizophrenia patients."( The Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain morphology in schizophrenia.
Hagino, H; Kawasaki, Y; Kobayashi, S; Kurachi, M; Maeno, N; Niu, L; Ozaki, N; Sasaoka, T; Seto, H; Suzuki, M; Takahashi, T; Tsuneki, H; Tsunoda, M; Zhou, SY, 2009)		0.35
" The thermal dose-response curve for the fluorescence intensity of gammaH2AX appearance in DNA-PKcs-/- cells during the heating period was similar to that observed in DNA-PKcs+/+ cells."( ATM is the predominant kinase involved in the phosphorylation of histone H2AX after heating.
Chen, DJ; Ejima, Y; Kondo, N; Mori, E; Nakagawa, Y; Noda, T; Ohnishi, K; Ohnishi, T; Okamoto, N; Su, X; Takahashi, A; Toki, A; Uemura, H, 2010)		0.36
" Transport studies in a rat model have shown enhanced levels of total cidofovir species in the plasma after oral dosing with L-Val-L-Ser-OMe cHPMPC, 2a."( Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1.
Kashemirov, BA; Krylov, IS; McKenna, CE; Peterson, LW; Sala-Rabanal, M; Serpi, M, 2010)		0.36
" Likewise, a similar dosing regimen of sarcosine or D-serine did not cause evident activity-impairing effect."( D-cycloserine, sarcosine and D-serine diminish the expression of cocaine-induced conditioned place preference.
Chang, WT; Cheng, LY; Cherng, CG; Chuang, JY; Kao, GS; Lee, YS; Yang, FY; Yu, L, 2013)		0.39
" Ethanol dose-response (1-5 g/kg body weight) and time-course (1-4 h) experiments were conducted, and various parameters were monitored."( Histone H3 phosphorylation (Ser10, Ser28) and phosphoacetylation (K9S10) are differentially associated with gene expression in liver of rats treated in vivo with acute ethanol.
Aroor, AR; James, TT; Lim, RW; Shukla, SD, 2012)		0.38
" Reduced cholesterol did not change the MC4R dose-response curve to α-MSH, but it decreased the amount of cAMP generated per receptor number indicating that a population of MC4R at the cell surface becomes nonfunctional."( Constitutive cholesterol-dependent endocytosis of melanocortin-4 receptor (MC4R) is essential to maintain receptor responsiveness to α-melanocyte-stimulating hormone (α-MSH).
Baldini, G; Granell, S; McDaniel, FK; McPike, L; Mohammad, S; Molden, BM; Narducci, P, 2012)		0.38
" Estradiol was able to partially rescue the effect of 1 μM and 10 μM ZA on cell viability following treatment for 72 h, as shown by a shift to the right in the estradiol dose-response curve."( Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
Brodie, AH; Nemieboka, BE; Schech, AJ, 2012)		0.38
" Non-diabetic mice were administered increasing doses of insulin to define a dose-response relationship between insulin and Akt activation in the dorsal root ganglion (DRG) and sciatic nerve."( In vivo peripheral nervous system insulin signaling.
Grote, CW; Ryals, JM; Wright, DE, 2013)		0.39
" Dependent on its kinase activity and correlated with the dosage of overexpression, DYRK1A blocked proliferation of SH-SY5Y neuroblastoma cells within 24 h and arrested the cells in G₁ phase."( The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
Becker, W; Florencio Ortiz, V; Pasqualon, T; Schumacher, J; Soppa, U; Tejedor, FJ, 2014)		0.4
" Patients in the homozygous SS group demonstrated higher basal FSH levels, required more dosage of exogenous gonadotropin for ovarian stimulation, and had fewer numbers of oocytes retrieved compared with patients in the homozygous NN and heterozygous groups."( The Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation.
Du, J; Hong, L; Huang, X; Li, L; Shi, H; Sun, X; Zhang, H; Zhang, Z; Zhou, W, 2015)		0.42
" The plasma levels of QLT0267 were determined by LC-MS/MS methods following oral dosing of QLT0267 (200 mg/kg)."( Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo Model of Ca
Bally, MB; Dragowska, WH; Kalra, J, 2015)		0.42
" In a couple related to patient's 2 family, dosage of serine was performed on fetal cord blood when the fetus presented severe microcephaly, showing reduced serine levels at 30 weeks of pregnancy."( Two new cases of serine deficiency disorders treated with l-serine.
Bahi-Buisson, N; Boddaert, N; Brassier, A; de Lonlay, P; Desguerre, I; Habarou, F; Hubert, L; Kaminska, A; Ottolenghi, C; Valayannopoulos, V; Van Schaftingen, E; Wiame, E, 2016)		0.43
" We report here that MSL1, a central component of the dosage compensation complex in Drosophila melanogaster and Drosophila virilis, displays evolutionarily conserved sex-independent binding to promoters."( Functional interplay between MSL1 and CDK7 controls RNA polymerase II Ser5 phosphorylation.
Akhtar, A; Cadete, FT; Chelmicki, T; Chlamydas, S; Conrad, T; Dasmeh, P; Dündar, F; Georgiev, P; Holz, H; Luscombe, NM; Manke, T; Mittler, G; Pelechano, V; Raja, S; Ramírez, F; Samata, M; Steinmetz, LM; Wei, W, 2016)		0.43
" Cerebellar D-serine levels were increased by both agents with a delay of approximately 6 h after dosing before the peak effect was achieved."( Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756.
Barnes, M; Bestwick, M; Canning, H; Carlton, M; Ellery, J; Farnaby, W; Fieldhouse, C; Fradley, R; Harrison, H; Hazel, K; Hoffman, I; Howley, E; Kerr, C; Kinsella, N; Leveridge, M; Livermore, DG; Merchant, K; Miller, DJ; Mitchell, P; Okada, K; Patel, T; Sykes, AP; Walsh, L, 2017)		0.46
" Dosing of animals with L-serine and human clinical trials investigating the therapeutic effects of L-serine support the FDA's determination that L-serine is generally regarded as safe (GRAS); it also appears to be neuroprotective."( L-Serine: a Naturally-Occurring Amino Acid with Therapeutic Potential.
Banack, SA; Cox, PA; Dunlop, RA; Metcalf, JS; Powell, JT, 2018)		0.48
" UHPLC-MS/MS was used to confirm BMAA exposures in dosed vervets."( l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND.
Banack, SA; Beierschmitt, A; Bradley, WG; Cox, PA; Davis, DA; Garamszegi, SP; Hagan, MJ; Lecusay, PD; Mash, DC; Metcalf, JS; Palmour, RM; Powell, JT, 2020)		0.56
" The study period consisted of 8-wk dosing and 4-wk posttreatment observation."( l-Serine and EPA Relieve Chronic Low-Back and Knee Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.
Hashimoto, M; Kobuna, Y; Mine, T; Nagao, K; Nishikata, N; Sasahara, I; Suga, Y; Suzuki, K; Takada, M; Takeshita, M; Yamamoto, A, 2020)		0.56
"Dose-fractionation studies revealed that dosing frequency had no impact on taniborbactam potentiation of cefepime activity."( In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.
Abdelraouf, K; Almarzoky Abuhussain, S; Nicolau, DP, 2020)		0.56
" Seed bioassay and whole-plant dose-response experiments were conducted using commercial IMI herbicides."( Ser-653-Asn substitution in the acetohydroxyacid synthase gene confers resistance in weedy rice to imidazolinone herbicides in Malaysia.
Ahmad-Hamdani, MS; Mazlan, N; Ruzmi, R, 2020)		0.56
" Cefepime and tazobactam dosing regimens produced plasma profiles of fAUC, fT>MIC and fCmax similar to human exposure after WCK 4282 2/2 g every 8 h (1."( In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
Abdelraouf, K; Gill, CM; Nicolau, DP, 2021)		0.62
" Genome-scale metabolic modeling identified phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase (PSAT1) as the synthetic dosage lethal (SDL) partners of IDH2."( Serine Biosynthesis Is a Metabolic Vulnerability in IDH2-Driven Breast Cancer Progression.
Barnabas, GD; Beck, L; Erez, N; Geiger, T; Harel, M; Jerby-Arnon, L; Lee, JS; Ruppin, E; Selitrennik, M; Shami, T, 2021)		0.62
" These results support the lack of evidence for widespread dosage compensation or dysregulation of chromosomal domains in human autosomes."( Consequences of aneuploidy in human fibroblasts with trisomy 21.
Cavaliere, P; Dephoure, N; Hwang, S; Li, R; Torres, EM; Zhu, LJ, 2021)		0.62
") was administered following the 7-day CPF dosing period, little to no differences in lung immune responses (cytokines and immunophenotyping) were noted between the CPF and vehicle groups."( Effects of Chlorpyrifos on Serine Hydrolase Activities, Lipid Mediators, and Immune Responses in Lungs of Neonatal and Adult Mice.
Borazjani, A; Carr, RL; Kaplan, BLF; Lehner, R; Ross, MK; Seay, CN; Szafran, BN, 2021)		0.62
"Smoking was linked to the risk of HCC with an increased dose-response effect."( p53 Mutation at Serine 249 and Its Gain of Function Are Highly Related to Hepatocellular Carcinoma after Smoking Exposure.
Chen, L; Wang, H; Zeng, C; Zhang, Z; Zhou, T, 2021)		0.62
" For aztreonam/avibactam dosing regimens evaluated in clinical trials, fT>MPC values were >90% and >80%, whereas fTMSW measures were <10% and <20% in plasma and ELF, respectively."( Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases.
Dong, D; Feng, K; Gong, H; Jia, N; Liu, Y; Lv, Z; Martins, FS; Sy, S; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S; Zhu, Y, 2021)		0.62
"To observe the effect of exogenous serine or glycine on the synthesis of selenoprotein and endogenous serine and the expression of metabolic enzymes in hepatocytes cultured with high-selenium in vitro and its dose-response relationship."( [Intervention study to inhibit the glucose metabolic remodeling in hepatocytes induced by high-selenium in vitro].
Han, F; Huang, Z; Liu, Y; Wang, J; Wang, Q; Xiang, X; Zhang, X, 2023)		0.91
"The experiment was divided into two parts, namely a inhibition experiment and a dose-response experiment, using L02 cells as the intervention target."( [Intervention study to inhibit the glucose metabolic remodeling in hepatocytes induced by high-selenium in vitro].
Han, F; Huang, Z; Liu, Y; Wang, J; Wang, Q; Xiang, X; Zhang, X, 2023)		0.91
" (2) In the dose-response experiment, the expression of PHGDH enzyme in L02 cells gradually decreased with the increase of the concentration of exogenous serine or glycine, showing an obvious dose-dependent effect."( [Intervention study to inhibit the glucose metabolic remodeling in hepatocytes induced by high-selenium in vitro].
Han, F; Huang, Z; Liu, Y; Wang, J; Wang, Q; Xiang, X; Zhang, X, 2023)		0.91
" However, currently, there are no recommendations set by national health agencies for tolerable upper intake levels (UL) for amino acids because of a lack of well-conducted human dose-response trials."( Tolerable Upper Intake Level for Individual Amino Acids in Humans: A Narrative Review of Recent Clinical Studies.
Elango, R, 2023)		0.91
"N-methyl-D-aspartate (NMDA) receptor hypofunctionality is a well-studied hypothesis for schizophrenia pathophysiology, and daily dosing of the NMDA receptor co-agonist, D-serine, in clinical trials has shown positive effects in patients."( Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.
Almond, S; Burley, R; Carlton, M; Davies, CH; Delgado García, JM; Fradley, R; Gaskin, P; Goetghebeur, P; Gray, I; Grayson, B; Gruart I Massó, A; Howley, E; Miller, D; Neill, JC; Serrats, J; Zhu, B, 2023)		0.91
" Dose-response validation of the top candidate, quizartinib, was conducted in two cell lines of HT-22 and MEFs."( Quizartinib inhibits necroptosis by targeting receptor-interacting serine/threonine protein kinase 1.
Fu, S; Gu, T; He, X; Hu, X; Li, M; Mou, Y; Wang, J; Wei, J; Xiao, X; Ye, Z; You, X; Yu, Y; Zha, Y; Zhu, G, 2023)		0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
serine zwitterionAn amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of serine.
L-alpha-amino acidAny alpha-amino acid having L-configuration at the alpha-carbon.
serineAn alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
serine family amino acidAn L-alpha-amino acid which is biosynthesised from 3-phosphoglycerate (i.e. serine, glycine, cysteine and homocysteine). A closed class.
proteinogenic amino acidAny of the 23 alpha-amino acids that are precursors to proteins, and are incorporated into proteins during translation. The group includes the 20 amino acids encoded by the nuclear genes of eukaryotes together with selenocysteine, pyrrolysine, and N-formylmethionine. Apart from glycine, which is non-chiral, all have L configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2,796)

PathwayProteinsCompounds
Selenoamino Acid Metabolism1226
Glycine and Serine Metabolism2452
Ammonia Recycling1227
Methionine Metabolism1637
Homocysteine Degradation27
Sphingolipid Metabolism2335
Cystathionine beta-Synthase Deficiency1637
Hypermethioninemia1637
S-Adenosylhomocysteine (SAH) Hydrolase Deficiency1637
Glycine N-Methyltransferase Deficiency1637
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)1637
Methionine Adenosyltransferase Deficiency1637
Dimethylglycine Dehydrogenase Deficiency2452
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)2452
Sarcosinemia2452
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Non-Ketotic Hyperglycinemia2452
Hyperglycinemia, Non-Ketotic2452
gamma-Cystathionase Deficiency (CTH)27
Homocystinuria, Cystathionine beta-Synthase Deficiency27
Fabry Disease2335
Krabbe Disease2335
Homocystinuria-Megaloblastic Anemia Due to Defect in Cobalamin Metabolism, cblG Complementation Type1637
3-Phosphoglycerate Dehydrogenase Deficiency2452
Biosynthesis of Siderophore Group Nonribosomal Peptides1821
Inner Membrane Transport7862
tRNA Charging5227
Cysteine Biosynthesis1329
tRNA Charging 22225
Glycine Biosynthesis47
Serine Biosynthesis and Metabolism1020
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/19:0cycv8c/17:0cycw7c))814
Secondary Metabolites: Cysteine Biosynthesis from Serine720
phospholipid biosynthesis I (CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)) )1324
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/19:0cycv8c))1321
phospholipid biosynthesis (CL(18:1/18:1/18:1/18:1))1222
phospholipid biosynthesis CL(14:0/15:0cyclo/14:0/17:0cycw7c)1118
phospholipid biosynthesis (CL(14:0/15:0cyclo/17:0cycw7c/14:0)1318
phospholipid biosynthesis CL(14:0/16:0/14:0/14:0)1320
phospholipid biosynthesis CL(14:0/16:0/14:0/16:0)1120
Phospholipid Biosynthesis CL(14:0/16:0/14:0/18:1(9Z))1220
phospholipid biosynthesis CL(14:0/16:0/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(14:0/16:0/16:1(9Z)/14:0)1320
phospholipid biosynthesis CL(14:0/16:0/18:1(9Z)/14:0)1321
phospholipid biosynthesis CL(14:0/16:0/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(14:0/16:1(9Z)/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(14:0/16:1(9Z)/14:0/18:1(9Z))1321
phospholipid biosynthesis CL(14:0/16:1(9Z)/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(14:0/16:1(9Z)/18:1(9Z)/14:0)1321
phospholipid biosynthesis CL(14:0/16:1(9Z)/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(14:0/18:1(9Z)/14:0/14:0)1321
phospholipid biosynthesis CL(14:0/18:1(9Z)/14:0/17:0cycw7c)1118
phospholipid biosynthesis CL(14:0/18:1(9Z)/14:0/18:1(9Z))1321
phospholipid biosynthesis CL(14:0/18:1(9Z)/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(14:0/18:1(9Z)/17:0cycw7c/14:0)1319
phospholipid biosynthesis CL(14:0/18:1(9Z)/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(14:0/19:0cycv8c/14:0/17:0cycw7c)1319
phospholipid biosynthesis CL(14:0/19:0cycv8c/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(14:0/19:0cycv8c/17:0cycw7c/14:0)1319
phospholipid biosynthesis CL(15:0cyclo/14:0/14:0/17:0cycw7c)1319
phospholipid biosynthesis CL(15:0cyclo/14:0/16:1(9Z)/16:1(9Z))1321
phospholipid biosynthesis CL(15:0cyclo/14:0/17:0cycw7c/14:0)1117
phospholipid biosynthesis CL(15:0cyclo/14:0/17:0cycw7c/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/14:0/18:1(9Z)/18:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/14:0/19:0cycv8c/19:0cycv8c)1318
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/14:0/16:0)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/14:0/16:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/14:0/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/14:0/19:0cycv8c)1117
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:0/16:1(9Z))1322
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/15:0cyclo/18:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/15:0cyclo/19:0cycv8c)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:0/14:0)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:0/17:0cycw7c)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:0/18:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:0/19:0cycv8c)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:1(9Z)/14:0)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:1(9Z)/16:0)1121
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:1(9Z)/18:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:1(9Z)/19:0cycv8c)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/17:0cycw7c/16:0)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/17:0cycw7c/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/17:0cycw7c/18:1(9Z))1118
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/17:0cycw7c/19:0cycv8c)1117
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/18:1(9Z)/14:0)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/18:1(9Z)/15:0cyclo)1120
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/18:1(9Z)/16:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/18:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/18:1(9Z)/18:1(9Z))1123
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/18:1(9Z)/19:0cycv8c)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/19:0cycv8c/14:0)1117
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/19:0cycv8c/15:0cyclo)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/19:0cycv8c/16:0)1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/19:0cycv8c/16:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/19:0cycv8c/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/19:0cycv8c/18:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/19:0cycv8c/19:0cycv8c)1118
phospholipid biosynthesis CL(15:0cyclo/16:0/14:0/15:0cyclo)1118
phospholipid biosynthesis CL(15:0cyclo/16:0/15:0cyclo/14:0)1118
phospholipid biosynthesis CL(15:0cyclo/16:0/15:0cyclo/16:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/16:0/15:0cyclo/17:0cycw7c)1118
phospholipid biosynthesis CL(15:0cyclo/16:0/15:0cyclo/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/16:0/15:0cyclo/19:0cycv8c)1118
phospholipid biosynthesis CL(15:0cyclo/16:0/16:0/16:0)1121
phospholipid biosynthesis CL(15:0cyclo/16:0/17:0cycw7c/15:0cyclo)1118
phospholipid biosynthesis CL(15:0cyclo/16:0/16:0/16:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/16:0/16:0/17:0cycw7c)1119
phospholipid biosynthesis CL(15:0cyclo/16:0/16:0/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/16:0/16:0/19:0cycv8c)1119
phospholipid biosynthesis CL(15:0cyclo/16:0/16:1(9Z)/16:0)1121
phospholipid biosynthesis CL(15:0cyclo/16:0/16:1(9Z)/15:0cyclo)1120
phospholipid biosynthesis CL(15:0cyclo/16:0/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/16:0/17:0cycw7c/16:0)1119
phospholipid biosynthesis CL(15:0cyclo/16:0/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(15:0cyclo/16:0/18:1(9Z)/15:0cyclo)1120
phospholipid biosynthesis CL(15:0cyclo/16:0/18:1(9Z)/16:0)1123
phospholipid biosynthesis CL(15:0cyclo/16:0/18:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis (CL(15:0cyclo/16:0/19:0cycv8c/15:0cyclo))1118
phospholipid biosynthesis CL(15:0cyclo/16:0/19:0cycv8c/16:0)1119
phospholipid biosynthesis CL(15:0cyclo/16:0/19:0cycv8c/19:0cycv8c)1018
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/14:0/15:0cyclo)1118
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/15:0cyclo/14:0)1118
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/15:0cyclo/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/15:0cyclo/17:0cycw7c)1118
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/15:0cyclo/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/15:0cyclo/19:0cycv8c)1118
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:0/16:0)1121
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:0/16:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/14:0)1321
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/15:0cyclo)1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/16:0)1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/18:1(9Z))1322
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/17:0cycw7c/15:0cyclo)1118
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/18:1(9Z)/15:0cyclo)1120
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/18:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/18:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/19:0cycv8c/15:0cyclo)1118
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/19:0cycv8c/19:0cycv8c)1018
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/14:0/14:0)1319
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/14:0/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/15:0cyclo/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/16:0/16:0)1119
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/16:0/17:0cycw7c)1118
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/16:1(9Z)/16:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/16:1(9Z)/17:0cycw7c)1118
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/17:0cycw7c/14:0)1117
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/17:0cycw7c/15:0cyclo)1117
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/17:0cycw7c)/16:0)1118
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/17:0cycw7c/16:1(9Z))1118
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/17:0cycw7c/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/17:0cycw7c/18:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/17:0cycw7c/19:0cycv8c)1117
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/18:1(9Z)/17:0cycw7c)1120
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/18:1(9Z)/18:1(9Z))1118
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/19:0cycv8c/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/14:0/15:0cyclo)1119
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/14:0/18:1(9Z))1118
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/15:0cyclo/14:0)1119
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/15:0cyclo/17:0cycw7c)1118
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/15:0cyclo/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/15:0cyclo/19:0cycv8c)1119
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/16:0/16:0)1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/16:0/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/16:1(9Z)/16:1(9Z))1322
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/16:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/17:0cycw7c/15:0cyclo)1118
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/17:0cycw7c/17:0cycw7c)1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/17:0cycw7c/18:1(9Z))1118
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/14:0)1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/15:0cyclo)1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/16:0)1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/16:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/17:0cycw7c)1118
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/18:1(9Z))1119
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/19:0cycv8c)1320
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/19:0cycv8c/15:0cyclo)1119
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/19:0cycv8c/18:1(9Z))1320
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/19:0cycv8c/19:0cycv8c)815
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/14:0/15:0cyclo)1117
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/14:0/19:0cycv8c)1320
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/15:0cyclo/14:0)1117
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/19:0cycv8c/15:0cyclo))1118
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/15:0cyclo/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/15:0cyclo/19:0cycv8c)1118
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/16:0/16:0)1119
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/16:0/19:0cycv8c)1018
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/16:1(9Z)/16:1(9Z))1321
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/16:1(9Z)/19:0cycv8c)1018
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/17:0cycw7c/15:0cyclo)1117
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/19:0cycv8c/16:0))1118
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/17:0cycw7c/17:0cycw7c)1117
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/18:1(9Z)/18:1(9Z))1320
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/18:1(9Z)/19:0cycv8c)1120
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/19:0cycv8c/14:0)1117
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/19:0cycv8c/15:0cyclo)1118
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/19:0cycv8c/16:0)1018
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/19:0cycv8c/16:1(9Z))1018
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/19:0cycv8c/18:1(9Z))1118
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/19:0cycv8c/19:0cycv8c)1018
phospholipid biosynthesis CL(16:0/14:0/14:0/14:0)1320
phospholipid biosynthesis CL(16:0/14:0/14:0/16:0)1321
phospholipid biosynthesis CL(16:0/14:0/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(16:0/14:0/14:0/18:1(9Z))1321
phospholipid biosynthesis CL(16:0/14:0/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(16:0/14:0/16:0/14:0)1322
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/19:0cycv8c/17:0cycw7c))1118
phospholipid biosynthesis (CL(18:1(9Z)/19:0cycv8c/14:0/14:0))1118
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/19:0cycv8c/16:1(9Z))1118
phospholipid biosynthesis CL(16:0/14:0/16:1(9Z)/14:0)1320
phospholipid biosynthesis CL(16:0/14:0/16:1(9Z)/16:1(9Z))1120
phospholipid biosynthesis CL(16:0/14:0/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(16:0/14:0/18:1(9Z)/14:0)1120
phospholipid biosynthesis CL(16:0/14:0/18:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis CL(16:0/14:0/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(16:0/14:0/19:0cycv8c/19:0cycv8c)1018
phospholipid biosynthesis CL(16:0/15:0cyclo/14:0/15:0cyclo)1118
phospholipid biosynthesis CL(16:0/15:0cyclo/15:0cyclo/14:0)1118
phospholipid biosynthesis CL(16:0/15:0cyclo/15:0cyclo/16:1(9Z))1120
phospholipid biosynthesis CL(16:0/15:0cyclo/15:0cyclo/17:0cycw7c)1118
phospholipid biosynthesis CL(16:0/15:0cyclo/15:0cyclo/18:1(9Z))1121
phospholipid biosynthesis CL(16:0/15:0cyclo/15:0cyclo/19:0cycv8c)1118
phospholipid biosynthesis CL(16:0/15:0cyclo/16:0/16:0)1121
phospholipid biosynthesis CL(16:0/15:0cyclo/16:0/16:1(9Z))1121
phospholipid biosynthesis CL(16:0/15:0cyclo/16:0/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/15:0cyclo/16:0/18:1(9Z))1120
phospholipid biosynthesis CL(16:0/15:0cyclo/16:0/19:0cycv8c)1119
phospholipid biosynthesis CL(16:0/15:0cyclo/16:1(9Z)/15:0cyclo)1121
phospholipid biosynthesis CL(16:0/15:0cyclo/16:1(9Z)/16:0)1121
phospholipid biosynthesis (CL(18:1(9Z)/19:0cycv8c/14:0/18:1(9Z)))1119
phospholipid biosynthesis (CL(18:1(9Z)/19:0cycv8c/14:0/19:0cycv8c))1117
phospholipid biosynthesis CL(16:0/15:0cyclo/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(16:0/15:0cyclo/17:0cycw7c/15:0cyclo)1118
phospholipid biosynthesis CL(16:0/15:0cyclo/17:0cycw7c/16:0)1119
phospholipid biosynthesis CL(16:0/15:0cyclo/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(16:0/15:0cyclo/18:1(9Z)/15:0cyclo)1120
phospholipid biosynthesis (CL(18:1(9Z)/19:0cycv8c/17:0cycw7c/17:0cycw7c))1116
phospholipid biosynthesis (CL(18:1(9Z)/19:0cycv8c/17:0cycw7c/18:1(9Z)))1118
phospholipid biosynthesis CL(16:0/15:0cyclo/18:1(9Z)/16:0)1121
phospholipid biosynthesis CL(16:0/15:0cyclo/18:1(9Z)/18:1(9Z))1121
phospholipid biosynthesis (CL(18:1(9Z)/19:0cycv8c/18:1(9Z)/14:0))1117
phospholipid biosynthesis CL(16:0/15:0cyclo/19:0cycv8c/15:0cyclo)1118
phospholipid biosynthesis CL(16:0/15:0cyclo/19:0cycv8c/16:0)1119
phospholipid biosynthesis CL(16:0/15:0cyclo/19:0cycv8c/19:0cycv8c)1018
phospholipid biosynthesis (CL(18:1(9Z)/19:0cycv8c/18:1(9Z)/17:0cycw7c))1118
phospholipid biosynthesis (CL(18:1(9Z)/19:0cycv8c/19:0cycv8c/14:0))1117
phospholipid biosynthesis CL(16:0/16:0/14:0/14:0)1121
phospholipid biosynthesis (CL(19:0cycv8c/14:0/14:0/17:0cycw7c))915
phospholipid biosynthesis CL(16:0/16:0/14:0/16:1(9Z))1121
phospholipid biosynthesis (CL(19:0cycv8c/14:0/14:0/19:0cycv8c))915
phospholipid biosynthesis CL(16:0/16:0/14:0/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/16:0/14:0/18:1(9Z))1121
phospholipid biosynthesis CL(16:0/16:0/14:0/19:0cycv8c)1119
phospholipid biosynthesis CL(16:0/16:0/16:0/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/16:0/16:0/18:1(9Z))1122
phospholipid biosynthesis CL(16:0/16:0/16:0/19:0cycv8c)1119
phospholipid biosynthesis CL(16:0/16:0/16:1(9Z)/14:0)1121
phospholipid biosynthesis CL(16:0/16:0/16:1(9Z)/15:0cyclo)1121
phospholipid biosynthesis (CL(19:0cycv8c/14:0/17:0cycw7c/14:0))915
phospholipid biosynthesis (CL(19:0cycv8c/14:0/17:0cycw7c/17:0cycw7c))814
phospholipid biosynthesis CL(16:0/16:0/16:1(9Z)/16:0)1122
phospholipid biosynthesis CL(16:0/16:0/16:1(9Z)/16:1(9Z))1122
phospholipid biosynthesis CL(16:0/16:0/18:1(9Z)/14:0)1121
phospholipid biosynthesis CL(16:0/16:0/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/16:0/16:1(9Z)/18:1(9Z))1122
phospholipid biosynthesis CL(16:0/16:0/16:1(9Z)/19:0cycv8c)1119
phospholipid biosynthesis CL(16:0/16:0/17:0cycw7c/14:0)1119
phospholipid biosynthesis CL(16:0/16:0/17:0cycw7c/15:0cyclo)1119
phospholipid biosynthesis CL(16:0/16:0/17:0cycw7c/16:0)1119
phospholipid biosynthesis CL(16:0/16:0/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(16:0/16:0/17:0cycw7c/17:0cycw7c)1119
phospholipid biosynthesis (CL(19:0cycv8c/14:0/19:0cycv8c/14:0))915
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/14:0/15:0cyclo))1117
phospholipid biosynthesis CL(16:0/16:0/17:0cycw7c/18:1(9Z))1120
phospholipid biosynthesis CL(16:0/16:0/17:0cycw7c/19:0cycv8c)1019
phospholipid biosynthesis CL(16:0/16:0/18:1(9Z)/15:0cyclo)1121
phospholipid biosynthesis CL(16:0/16:0/18:1(9Z)/16:0)1122
phospholipid biosynthesis CL(16:0/16:0/18:1(9Z)/16:1(9Z))1122
phospholipid biosynthesis CL(16:0/16:0/18:1(9Z)/17:0cycw7c)1120
phospholipid biosynthesis CL(16:0/16:0/18:1(9Z)/18:1(9Z))1122
phospholipid biosynthesis CL(16:0/16:0/18:1(9Z)/19:0cycv8c)1119
phospholipid biosynthesis CL(16:0/16:0/19:0cycv8c/14:0)1119
phospholipid biosynthesis CL(16:0/16:0/19:0cycv8c/15:0cyclo)1119
phospholipid biosynthesis CL(16:0/16:0/19:0cycv8c/16:0)1119
phospholipid biosynthesis CL(16:0/16:0/19:0cycv8c/16:1(9Z))1119
phospholipid biosynthesis CL(16:0/16:0/19:0cycv8c/17:0cycw7c)1019
phospholipid biosynthesis CL(16:0/16:0/19:0cycv8c/18:1(9Z))1119
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/14:0/19:0cycv8c))1117
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/15:0cyclo/14:0))915
phospholipid biosynthesis CL(16:0/16:1(9Z)/14:0/14:0)1120
phospholipid biosynthesis CL(16:0/16:1(9Z)/14:0/16:0)1121
phospholipid biosynthesis CL(16:0/16:1(9Z)/14:0/16:1(9Z))1121
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:0/14:0)1122
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:0/16:1(9Z))1123
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/15:0cyclo/17:0cycw7c))915
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/16:0/19:0cycv8c))915
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/16:1(9Z)/19:0cycv8c))915
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/17:0cycw7c/15:0cyclo))814
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/17:0cycw7c/17:0cycw7c))1116
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:0/17:0cycw7c)1119
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/18:1(9Z)/19:0cycv8c))915
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:0/18:1(9Z))1122
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:0/19:0cycv8c)1119
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/14:0)1121
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/16:0)1122
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/19:0cycv8c/14:0))1116
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/19:0cycv8c/15:0cyclo))915
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/16:1(9Z))1122
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/18:1(9Z))1324
phospholipid biosynthesisCL(16:0/16:1(9Z)/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:0/16:1(9Z)/17:0cycw7c/16:0)1119
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/19:0cycv8c/16:0))1116
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/19:0cycv8c/16:1(9Z)))815
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/19:0cycv8c/18:1(9Z)))915
phospholipid biosynthesis (CL(19:0cycv8c/15:0cyclo/19:0cycv8c/19:0cycv8c))815
phospholipid biosynthesis (CL(19:0cycv8c/16:0/14:0/14:0))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:0/14:0/16:0))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:0/14:0/19:0cycv8c))915
phospholipid biosynthesis (CL(19:0cycv8c/16:0/16:0/14:0))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:0/16:0/17:0cycw7c))1119
phospholipid biosynthesis CL(16:0/16:1(9Z)/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:0/16:1(9Z)/19:0cycv8c))1119
phospholipid biosynthesis CL(16:0/16:1(9Z)/17:0cycw7c/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/16:0)1122
phospholipid biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/18:1(9Z))1122
phospholipid biosynthesis (CL(19:0cycv8c/16:0/17:0cycw7c/16:0))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:0/17:0cycw7c/17:0cycw7c))814
phospholipid biosynthesis (CL(19:0cycv8c/16:0/17:0cycw7c/19:0cycv8c))1116
phospholipid biosynthesis (CL(19:0cycv8c/16:0/18:1(9Z)/19:0cycv8c))1119
phospholipid biosynthesis CL(16:0/16:1(9Z)/19:0cycv8c/16:0)1119
phospholipid biosynthesis CL(16:0/16:1(9Z)/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:0/16:1(9Z)/19:0cycv8c/19:0cycv8c)920
phospholipid biosynthesis CL(16:0/17:0cycw7c/14:0/16:0)1119
phospholipid biosynthesis CL(16:0/17:0cycw7c/14:0/17:0cycw7c)1117
phospholipid biosynthesis (CL(19:0cycv8c/16:0/19:0cycv8c/14:0))915
phospholipid biosynthesis (CL(19:0cycv8c/16:0/19:0cycv8c/16:1(9Z)))1116
phospholipid biosynthesis CL(16:0/17:0cycw7c/16:0/14:0)1119
phospholipid biosynthesis CL(16:0/17:0cycw7c/16:0/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/17:0cycw7c/16:1(9Z)/16:1(9Z))1119
phospholipid biosynthesis CL(16:0/17:0cycw7c/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/17:0cycw7c/17:0cycw7c/14:0)1118
phospholipid biosynthesis CL(16:0/17:0cycw7c/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(16:0/17:0cycw7c/17:0cycw7c/18:1(9Z))1119
phospholipid biosynthesis CL(16:0/17:0cycw7c/17:0cycw7c/19:0cycv8c)1118
phospholipid biosynthesis CL(16:0/17:0cycw7c/18:1(9Z)/17:0cycw7c)1120
phospholipid biosynthesis CL(16:0/17:0cycw7c/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(16:0/17:0cycw7c/18:1(9Z)/18:1(9Z))1118
phospholipid biosynthesis CL(16:0/17:0cycw7c/19:0cycv8c/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/17:0cycw7c/19:0cycv8c/19:0cycv8c)816
phospholipid biosynthesis CL(16:0/18:1(9Z)/14:0/14:0)1120
phospholipid biosynthesis CL(16:0/18:1(9Z)/14:0/16:0)1121
phospholipid biosynthesis CL(16:0/18:1(9Z)/14:0/18:1(9Z))1120
phospholipid biosynthesis CL(16:0/18:1(9Z)/16:0/14:0)1121
phospholipid biosynthesis CL(16:0/18:1(9Z)/16:0/17:0cycw7c)1120
phospholipid biosynthesis CL(16:0/18:1(9Z)/16:0/18:1(9Z))1124
phospholipid biosynthesis CL(16:0/18:1(9Z)/16:0/19:0cycv8c)1119
phospholipid biosynthesis CL(16:0/18:1(9Z)/16:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:0/18:1(9Z)/16:1(9Z)/18:1(9Z))1121
phospholipid biosynthesis CL(16:0/18:1(9Z)/17:0cycw7c/16:0)1120
phospholipid biosynthesis CL(16:0/18:1(9Z)/17:0cycw7c/17:0cycw7c)1119
phospholipid biosynthesis CL(16:0/18:1(9Z)/17:0cycw7c/18:1(9Z))1118
phospholipid biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/14:0)1120
phospholipid biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/16:0)1122
phospholipid biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/16:1(9Z))1122
phospholipid biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/17:0cycw7c)1118
phospholipid biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/18:1(9Z))1121
phospholipid biosynthesis (CL(19:0cycv8c/16:0/19:0cycv8c/17:0cycw7c))1116
phospholipid biosynthesis (CL(19:0cycv8c/16:0/19:0cycv8c/18:1(9Z)))1117
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/14:0/14:0))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/14:0/16:1(9Z)))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/14:0/19:0cycv8c))915
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/16:1(9Z)/14:0))1119
phospholipid biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/19:0cycv8c)1120
phospholipid biosynthesis CL(16:0/18:1(9Z)/19:0cycv8c/16:0)1119
phospholipid biosynthesis CL(16:0/18:1(9Z)/19:0cycv8c/18:1(9Z))1120
phospholipid biosynthesis CL(16:0/18:1(9Z)/19:0cycv8c/19:0cycv8c)1121
phospholipid biosynthesis CL(16:0/19:0cycv8c/14:0/14:0)1319
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/16:1(9Z)/17:0cycw7c))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/17:0cycw7c/16:1(9Z)))1116
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/17:0cycw7c/17:0cycw7c))1016
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/17:0cycw7c/19:0cycv8c))1116
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/18:1(9Z)/19:0cycv8c))1119
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/19:0cycv8c/14:0))915
phospholipid biosynthesis CL(16:0/19:0cycv8c/14:0/16:0)1119
phospholipid biosynthesis CL(16:0/19:0cycv8c/14:0/19:0cycv8c)1018
phospholipid biosynthesis CL(16:0/19:0cycv8c/16:0/14:0)1119
phospholipid biosynthesis CL(16:0/19:0cycv8c/16:0/17:0cycw7c)1019
phospholipid biosynthesis CL(16:0/19:0cycv8c/16:1(9Z)/16:1(9Z))1321
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/19:0cycv8c/16:1(9Z)))915
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/19:0cycv8c/17:0cycw7c))915
phospholipid biosynthesis (CL(19:0cycv8c/16:1(9Z)/19:0cycv8c/18:1(9Z)))915
phospholipid biosynthesis (CL(19:0cycv8c/17:0cycw7c/14:0/14:0))1118
phospholipid biosynthesis CL(16:0/19:0cycv8c/16:1(9Z)/19:0cycv8c)920
phospholipid biosynthesis CL(16:0/19:0cycv8c/17:0cycw7c/16:0)1119
phospholipid biosynthesis CL(16:0/19:0cycv8c/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(16:0/19:0cycv8c/17:0cycw7c/19:0cycv8c)1019
phospholipid biosynthesis CL(16:0/19:0cycv8c/18:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis (CL(19:0cycv8c/17:0cycw7c/14:0/17:0cycw7c))1116
phospholipid biosynthesis (CL(19:0cycv8c/17:0cycw7c/14:0/19:0cycv8c))815
phospholipid biosynthesis (CL(19:0cycv8c/17:0cycw7c/17:0cycw7c/14:0))915
phospholipid biosynthesis (CL(19:0cycv8c/17:0cycw7c/17:0cycw7c/19:0cycv8c))1017
phospholipid biosynthesis (CL(19:0cycv8c/17:0cycw7c/19:0cycv8c/17:0cycw7c))915
phospholipid biosynthesis CL(16:0/19:0cycv8c/18:1(9Z)/19:0cycv8c)1121
phospholipid biosynthesis CL(16:0/19:0cycv8c/19:0cycv8c/14:0)1118
phospholipid biosynthesis CL(16:0/19:0cycv8c/19:0cycv8c/16:1(9Z))920
phospholipid biosynthesis CL(16:0/19:0cycv8c/19:0cycv8c/17:0cycw7c)1019
phospholipid biosynthesis CL(16:0/19:0cycv8c/19:0cycv8c/18:1(9Z))1121
phospholipid biosynthesis (CL(19:0cycv8c/18:1(9Z)/14:0/14:0))917
phospholipid biosynthesis (CL(19:0cycv8c/18:1(9Z)/14:0/18:1(9Z)))1119
phospholipid biosynthesis CL(16:1(9Z)/14:0/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/14:0/14:0/18:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/14:0/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(16:1(9Z)/14:0/16:1(9Z)/14:0)1322
phospholipid biosynthesis (CL(19:0cycv8c/18:1(9Z)/14:0/19:0cycv8c))915
phospholipid biosynthesis CL(16:1(9Z)/14:0/17:0cycw7c/17:0cycw7c)1117
phospholipid biosynthesis (CL(19:0cycv8c/18:1(9Z)/17:0cycw7c/17:0cycw7c))1116
phospholipid biosynthesis (CL(19:0cycv8c/18:1(9Z)/17:0cycw7c/18:1(9Z)))1118
phospholipid biosynthesis (CL(19:0cycv8c/18:1(9Z)/18:1(9Z)/14:0))1118
phospholipid biosynthesis CL(16:1(9Z)/14:0/18:1(9Z)/14:0)1321
phospholipid biosynthesis (CL(19:0cycv8c/18:1(9Z)/18:1(9Z)/17:0cycw7c))1118
phospholipid biosynthesis CL(16:1(9Z)/14:0/18:1(9Z)/18:1(9Z))1119
phospholipid biosynthesis (CL(19:0cycv8c/18:1(9Z)/19:0cycv8c/14:0))915
phospholipid biosynthesis CL(16:1(9Z)/14:0/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(16:1(9Z)/14:0/19:0cycv8c/19:0cycv8c)1016
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/14:0/15:0cyclo)1119
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/14:0/14:0))1018
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/14:0/15:0cyclo))815
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/14:0/16:0))1118
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/14:0/16:1(9Z)))815
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/14:0/17:0cycw7c))915
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/14:0/16:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/15:0cyclo/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/15:0cyclo/18:1(9Z))1121
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/15:0cyclo/19:0cycv8c)1118
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/14:0/19:0cycv8c))915
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/17:0cycw7c/14:0))915
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/17:0cycw7c/16:0))815
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/17:0cycw7c/16:1(9Z)))815
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/17:0cycw7c/17:0cycw7c))915
phospholipid biosynthesis (CL(19:0cycv8c/19:0cycv8c/19:0cycv8c/14:0))915
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:0/16:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/14:0)1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/15:0cyclo)1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/16:0)1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesisCL(16:1(9Z)/15:0cyclo/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/18:1(9Z))1322
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/17:0cycw7c/15:0cyclo)1118
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/18:1(9Z)/15:0cyclo)1121
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/18:1(9Z)/16:1(9Z))1322
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/18:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/19:0cycv8c/15:0cyclo)1118
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/17:0cycw7c/14:0))814
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/17:0cycw7c/17:0cycw7c))1016
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/17:0cycw7c/18:1(9Z)))1017
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/17:0cycw7c/19:0cycv8c))814
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/19:0cycv8c/19:0cycv8c)1018
phospholipid biosynthesis CL(16:1(9Z)/16:0/14:0/14:0)1121
phospholipid biosynthesis CL(16:1(9Z)/16:0/14:0/16:0)1121
phospholipid biosynthesis CL(16:1(9Z)/16:0/14:0/16:1(9Z))1122
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/18:1(9Z)/14:0))1016
phospholipid biosynthesis (CL(17:0cycw7c/19:0cycv8c/14:0/14:0))1118
phospholipid biosynthesis (CL(17:0cycw7c/19:0cycv8c/14:0/17:0cycw7c))1117
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:0/14:0)1121
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:0/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:0/18:1(9Z))1121
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:0/19:0cycv8c)1119
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/14:0)1122
phospholipid biosynthesis (CL(17:0cycw7c/19:0cycv8c/14:0/19:0cycv8c))815
phospholipid biosynthesis (CL(17:0cycw7c/19:0cycv8c/17:0cycw7c/14:0))915
phospholipid biosynthesis (CL(17:0cycw7c/19:0cycv8c/17:0cycw7c/19:0cycv8c))815
phospholipid biosynthesis (CL(17:0cycw7c/19:0cycv8c/19:0cycv8c/14:0))1116
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/16:0)1123
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/16:1(9Z))1122
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/18:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/16:0/17:0cycw7c/16:0)1119
phospholipid biosynthesis (CL(18:1(9Z)/14:0/14:0/17:0cycw7c))915
phospholipid biosynthesis (CL(18:1(9Z)/14:0/14:0/14:0))1120
phospholipid biosynthesis (CL(18:1(9Z)/14:0/14:0/18:1(9Z)))1120
phospholipid biosynthesis (CL(18:1(9Z)/14:0/14:0/19:0cycv8c))915
phospholipid biosynthesis CL(16:1(9Z)/16:0/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(16:1(9Z)/16:0/17:0cycw7c/17:0cycw7c)1119
phospholipid biosynthesis (CL(18:1(9Z)/14:0/17:0cycw7c/14:0))1118
phospholipid biosynthesis (CL(18:1(9Z)/14:0/17:0cycw7c/17:0cycw7c))915
phospholipid biosynthesis (CL(18:1(9Z)/14:0/18:1(9Z)/14:0))1120
phospholipid biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/16:0)1122
phospholipid biosynthesis (CL(18:1(9Z)/14:0/19:0cycv8c/14:0))1118
phospholipid biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/18:1(9Z))1121
phospholipid biosynthesis CL(16:1(9Z)/16:0/19:0cycv8c/16:0)1119
phospholipid biosynthesis (CL(18:1(9Z)/14:0/19:0cycv8c/19:0cycv8c))915
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/14:0/15:0cyclo))815
phospholipid biosynthesis CL(16:1(9Z)/16:0/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/16:0/19:0cycv8c/19:0cycv8c)1020
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/15:0cyclo)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/16:0)1121
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/16:1(9Z))1120
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/14:0/18:1(9Z)))1117
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/15:0cyclo/14:0))815
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/15:0cyclo/17:0cycw7c))815
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/15:0cyclo/19:0cycv8c))815
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/16:0/18:1(9Z)))1019
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/16:1(9Z)/18:1(9Z)))1019
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/18:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/14:0)1120
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/18:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/17:0cycw7c/15:0cyclo))1017
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/17:0cycw7c/17:0cycw7c))815
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/17:0cycw7c/18:1(9Z)))917
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/18:1(9Z)/14:0))815
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/18:1(9Z)/16:0))1018
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/18:1(9Z)/16:1(9Z)))1018
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/18:1(9Z)/17:0cycw7c))917
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7c/14:0)1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7c/15:0cyclo)1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7c/16:0)1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7c/17:0cycw7c)1119
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/18:1(9Z)/18:1(9Z)))1018
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/18:1(9Z)/19:0cycv8c))815
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7c/18:1(9Z))1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7c/19:0cycv8c)1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/14:0)1323
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/15:0cyclo)1323
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/16:0)1324
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/18:1(9Z))1325
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/15:0cyclo)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/16:0)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/17:0cycw7c)1118
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/18:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/19:0cycv8c)1221
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/14:0/16:1(9Z))1119
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/14:0/17:0cycw7c)1117
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/16:1(9Z)/14:0)1119
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/17:0cycw7c/14:0)1117
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/17:0cycw7c/18:1(9Z))1120
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/17:0cycw7c/19:0cycv8c)1117
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/18:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/18:1(9Z)/18:1(9Z))1118
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/19:0cycv8c/17:0cycw7c)1118
phospholipid biosynthesis CL(16:1(9Z)/17:0cycw7c/19:0cycv8c/19:0cycv8c)1119
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/16:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/18:1(9Z))1119
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/14:0)1323
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/18:1(9Z))1324
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/19:0cycv8c/15:0cyclo))815
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/19:0cycv8c/18:1(9Z)))815
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/19:0cycv8c/19:0cycv8c))1017
phospholipid biosynthesis (CL(18:1(9Z)/16:0/14:0/14:0))1121
phospholipid biosynthesis (CL(18:1(9Z)/16:0/14:0/16:0))1121
phospholipid biosynthesis (CL(18:1(9Z)/16:0/14:0/18:1(9Z)))1121
phospholipid biosynthesis (CL(18:1(9Z)/16:0/16:0/19:0cycv8c))1119
phospholipid biosynthesis (CL(18:1(9Z)/16:0/17:0cycw7c/16:0))917
phospholipid biosynthesis (CL(18:1(9Z)/16:0/17:0cycw7c/17:0cycw7c))1018
phospholipid biosynthesis (CL(18:1(9Z)/16:0/17:0cycw7c/18:1(9Z)))1017
phospholipid biosynthesis (CL(18:1(9Z)/16:0/18:1(9Z)/14:0))1121
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7c/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7c/18:1(9Z))1118
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/14:0)1120
phospholipid biosynthesis (CL(18:1(9Z)/16:0/18:1(9Z)/16:1(9Z)))1122
phospholipid biosynthesis (CL(18:1(9Z)/16:0/18:1(9Z)/17:0cycw7c))1017
phospholipid biosynthesis (CL(18:1(9Z)/16:0/18:1(9Z)/18:1(9Z)))1122
phospholipid biosynthesis (CL(18:1(9Z)/16:0/18:1(9Z)/19:0cycv8c))1118
phospholipid biosynthesis (CL(18:1(9Z)/16:0/19:0cycv8c/16:0))1119
phospholipid biosynthesis (CL(18:1(9Z)/16:0/19:0cycv8c/18:1(9Z)))1118
phospholipid biosynthesis (CL(18:1(9Z)/16:0/19:0cycv8c/19:0cycv8c))1119
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/14:0/14:0))1121
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/17:0cycw7c)1118
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/18:1(9Z))1121
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/19:0cycv8c)1120
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/14:0/16:1(9Z)))1121
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/14:0/18:1(9Z)))1121
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/14:0))1121
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/17:0cycw7c))1119
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycv8c/18:1(9Z))1120
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/19:0cycv8c))1119
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/17:0cycw7c/16:1(9Z)))1018
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycv8c/19:0cycv8c)1020
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/14:0/14:0)1319
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/14:0/19:0cycv8c)1016
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/17:0cycw7c/17:0cycw7c))1018
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/17:0cycw7c/18:1(9Z)))1118
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/14:0))1121
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/19:0cycv8c))1119
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/16:1(9Z)/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/16:1(9Z)/19:0cycv8c)1221
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/17:0cycw7c/16:1(9Z))1118
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/19:0cycv8c/16:1(9Z)))1119
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/19:0cycv8c/18:1(9Z)))1119
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/17:0cycw7c/19:0cycv8c)1119
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/19:0cycv8c/19:0cycv8c))1119
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/14:0/14:0))814
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/14:0/17:0cycw7c))814
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/14:0/18:1(9Z)))1118
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/18:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/18:1(9Z)/19:0cycv8c)1020
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/17:0cycw7c/14:0))814
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/19:0cycv8c/14:0)1016
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/17:0cycw7c/17:0cycw7c))814
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/19:0cycv8c/16:1(9Z))1221
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/19:0cycv8c/17:0cycw7c)1119
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/19:0cycv8c/18:1(9Z))1020
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/17:0cycw7c/18:1(9Z)))1017
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/17:0cycw7c/19:0cycv8c))814
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/18:1(9Z)/14:0))1018
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/18:1(9Z)/17:0cycw7c))1017
phospholipid biosynthesis (CL(18:1(9Z)/17:0cycw7c/19:0cycv8c/17:0cycw7c))814
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/14:0/14:0))1120
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/14:0/14:0)1319
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/14:0/17:0cycw7c)915
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/16:0/17:0cycw7c)1118
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/16:1(9Z)/17:0cycw7c)1118
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/17:0cycw7c/14:0)1117
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/17:0cycw7c/15:0cyclo)1117
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/17:0cycw7c/16:0)1118
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/17:0cycw7c/16:1(9Z))1118
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/17:0cycw7c/17:0cycw7c)1117
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/17:0cycw7c/18:1(9Z))1120
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/17:0cycw7c/19:0cycv8c)1117
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/18:1(9Z)/17:0cycw7c)1120
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/19:0cycv8c/17:0cycw7c)1117
phospholipid biosynthesis CL(17:0cycw7c/16:0/14:0/16:0)1119
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/14:0/15:0cyclo))1018
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/14:0/16:0))1120
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/14:0/16:1(9Z)))1120
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/14:0/17:0cycw7c))1118
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/14:0/18:1(9Z)))1120
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/14:0/19:0cycv8c))1118
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/17:0cycw7c/14:0))1118
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/17:0cycw7c/15:0cyclo))917
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/17:0cycw7c/16:0))1118
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/17:0cycw7c/16:1(9Z)))1118
phospholipid biosynthesis CL(17:0cycw7c/16:0/14:0/17:0cycw7c)1118
phospholipid biosynthesis CL(17:0cycw7c/16:0/16:0/14:0)1119
phospholipid biosynthesis CL(17:0cycw7c/16:0/16:0/17:0cycw7c)1119
phospholipid biosynthesis CL(17:0cycw7c/16:0/16:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(17:0cycw7c/16:0/17:0cycw7c/14:0)1118
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/17:0cycw7c/17:0cycw7c))1121
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/17:0cycw7c/18:1(9Z)))1017
phospholipid biosynthesis CL(17:0cycw7c/16:0/17:0cycw7c/16:0)1119
phospholipid biosynthesis CL(17:0cycw7c/16:0/17:0cycw7c/16:1(9Z))1119
phospholipid biosynthesis CL(17:0cycw7c/16:0/17:0cycw7c/17:0cycw7c)1118
phospholipid biosynthesis CL(17:0cycw7c/16:0/17:0cycw7c/18:1(9Z))1119
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/17:0cycw7c/19:0cycv8c))1118
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/14:0))1120
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/17:0cycw7c))1017
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/19:0cycv8c/14:0))1118
phospholipid biosynthesis CL(17:0cycw7c/16:0/17:0cycw7c/19:0cycv8c)1118
phospholipid biosynthesis CL(17:0cycw7c/16:0/18:1(9Z)/17:0cycw7c)1119
phospholipid biosynthesis CL(17:0cycw7c/16:0/19:0cycv8c/17:0cycw7c)1118
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/14:0/17:0cycw7c))814
phospholipid biosynthesis CL(17:0cycw7c/16:1(9Z)/14:0/16:1(9Z))1119
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/16:1(9Z)/14:0))1119
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/17:0cycw7c/14:0))814
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/17:0cycw7c/16:1(9Z)))1018
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/17:0cycw7c/17:0cycw7c))1016
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/17:0cycw7c/18:1(9Z)))1018
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/17:0cycw7c/19:0cycv8c))814
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/18:1(9Z)/17:0cycw7c))1018
phospholipid biosynthesis (CL(17:0cycw7c/16:1(9Z)/19:0cycv8c/17:0cycw7c))814
phospholipid biosynthesis (CL(17:0cycw7c/17:0cycw7c/14:0/15:0cyclo))1016
phospholipid biosynthesis (CL(17:0cycw7c/17:0cycw7c/14:0/16:0))815
phospholipid biosynthesis (CL(17:0cycw7c/17:0cycw7c/14:0/16:1(9Z)))814
phospholipid biosynthesis (CL(17:0cycw7c/17:0cycw7c/14:0/17:0cycw7c))1016
phospholipid biosynthesis (CL(17:0cycw7c/17:0cycw7c/14:0/18:1(9Z)))814
phospholipid biosynthesis (CL(17:0cycw7c/17:0cycw7c/14:0/19:0cycv8c))1016
phospholipid biosynthesis (CL(17:0cycw7c/17:0cycw7c/17:0cycw7c/14:0))915
phospholipid biosynthesis (CL(17:0cycw7c/17:0cycw7c/17:0cycw7c/17:0cycw7c))915
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/14:0/14:0))915
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/14:0/17:0cycw7c))814
phospholipid biosynthesis (CL(17:0cycw7c/18:1(9Z)/14:0/18:1(9Z)))1118
phospholipid biosynthesis (CL(15:0cyclo/15:0cyclo/18:1(9Z)/16:0))916
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/15:0cyclo/14:0) )1119
One Carbon Pool by Folate1227
phospholipid biosynthesis (PE(16:0/10:0(3-OH)))714
phospholipid biosynthesis CDP-DG(10:0/10:0) I713
phospholipid biosynthesis (PE(16:0/12:0(3-OH)))714
phospholipid biosynthesis CDP-DG(10:0/12:0)714
phospholipid biosynthesis CDP-DG(10:0/14:0)714
phospholipid biosynthesis (PE(16:0/18:0))717
phospholipid biosynthesis CDP-DG(10:0/15:0)714
phospholipid biosynthesis CDP-DG(10:0/16:0)714
phospholipid biosynthesis (PE(16:0/19:iso))713
phospholipid biosynthesis CDP-DG(10:0/16:1(9Z))713
phospholipid biosynthesis (PE(16:1(9Z)/10:0(3-OH)))713
phospholipid biosynthesis CDP-DG(10:0/18:0)714
phospholipid biosynthesis (PE(16:1(9Z)/12:0(3-OH)))713
phospholipid biosynthesis CDP-DG(10:0/18:1(9Z))713
phospholipid biosynthesis (PE(16:1(9Z)/18:0))716
phospholipid biosynthesis (CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/14:0))1022
phospholipid biosynthesis (PE(16:1(9Z)/19:iso))713
phospholipid biosynthesis CDP-DG(10:0/19:1(9Z))713
phospholipid biosynthesis CDP-DG(12:0/10:0)714
phospholipid biosynthesis (PE(18:0/14:0))716
phospholipid biosynthesis (PE(18:0/16:0))717
phospholipid biosynthesis CDP-DG(12:0/14:0)714
phospholipid biosynthesis CDP-DG(12:0/15:0)714
phospholipid biosynthesis (PE(18:0/16:1(9Z)))716
phospholipid biosynthesis CDP-DG(12:0/16:0)713
phospholipid biosynthesis (PE(18:0/18:0))717
phospholipid biosynthesis CDP-DG(12:0/16:1(9Z))713
phospholipid biosynthesis (PE(18:0/18:1(9Z)))717
phospholipid biosynthesis CDP-DG(12:0/18:0)714
phospholipid biosynthesis CDP-DG(12:0/18:1(9Z))713
phospholipid biosynthesis CDP-DG(12:0/19:1(9Z))713
phospholipid biosynthesis (PE(18:1(9Z)/10:0(3-OH)))713
phospholipid biosynthesis (PE(18:1(9Z)/12:0(3-OH)))713
phospholipid biosynthesis (CL(18:1(9Z)/14:0/19:0cycv8c/19:0cycv8c) 2)817
phospholipid biosynthesis (CL(18:1(9Z)/16:0/16:0/19:0cycv8c) 2)1020
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/19:0cycv8c/18:1(9Z)) 2)817
phospholipid biosynthesis (PE(19:iso/10:0))713
phospholipid biosynthesis (PE(19:iso/12:0))713
phospholipid biosynthesis (CL(15:0cyclo/15:0cyclo/19:0cycv8c/19:0cycv8c))1016
phospholipid biosynthesis CDP-DG(14:0/10:0)714
phospholipid biosynthesis CDP-DG(14:0/12:0)714
phospholipid biosynthesis CDP-DG(14:0/15:0)714
phospholipid biosynthesis CDP-DG(14:0/19:1(9Z))713
phospholipid biosynthesis CDP-DG(15:0/10:0)714
phospholipid biosynthesis CDP-DG(15:0/12:0)714
phospholipid biosynthesis CDP-DG(16:0/10:0)714
phospholipid biosynthesis CDP-DG(10:0/10:0) II713
phospholipid biosynthesis CDP-DG(10:0/10:0) III713
phospholipid biosynthesis CDP-DG(10:0/10:0) IV713
phospholipid biosynthesis CDP-DG(10:0/12:0) II714
phospholipid biosynthesis CDP-DG(10:0/12:0) III714
phospholipid biosynthesis CDP-DG(10:0/12:0) IV714
phospholipid biosynthesis CDP-DG(10:0/14:0) II714
phospholipid biosynthesis CDP-DG(10:0/14:0) III714
phospholipid biosynthesis CDP-DG(10:0/14:0) IV714
phospholipid biosynthesis CDP-DG(10:0/15:0) III714
phospholipid biosynthesis CDP-DG(10:0/15:0) II714
phospholipid biosynthesis CDP-DG(10:0/16:0) II714
phospholipid biosynthesis CDP-DG(10:0/16:1(9Z)) II713
phospholipid biosynthesis CDP-DG(10:0/19:1(9Z)) II713
phospholipid biosynthesis CDP-DG(10:0/19:1(9Z)) III713
phospholipid biosynthesis CDP-DG(10:0/19:1(9Z)) IV713
phospholipid biosynthesis CDP-DG(10:0/19:1(9Z)) V713
phospholipid biosynthesis CDP-DG(10:0/18:0) III714
phospholipid biosynthesis CDP-DG(12:0/10:0) II714
phospholipid biosynthesis CDP-DG(12:0/10:0) III714
phospholipid biosynthesis CDP-DG(12:0/14:0) II714
phospholipid biosynthesis CDP-DG(12:0/14:0) III714
phospholipid biosynthesis CDP-DG(12:0/15:0) II714
phospholipid biosynthesis CDP-DG(12:0/15:0) III714
phospholipid biosynthesis CDP-DG(12:0/14:0) IV714
phospholipid biosynthesis CDP-DG(12:0/16:0) II713
phospholipid biosynthesis CDP-DG(12:0/16:1(9Z)) II713
phospholipid biosynthesis CDP-DG(12:0/18:1(9Z)) II713
phospholipid biosynthesis CDP-DG(12:0/10:0) IV714
phospholipid biosynthesis CDP-DG(12:0/19:1(9Z)) V713
phospholipid biosynthesis CDP-DG(12:0/19:1(9Z)) IV713
phospholipid biosynthesis CDP-DG(12:0/19:1(9Z)) III713
phospholipid biosynthesis CDP-DG(12:0/19:1(9Z)) II713
phospholipid biosynthesis CDP-DG(14:0/10:0) IV714
phospholipid biosynthesis CDP-DG(14:0/10:0) III714
phospholipid biosynthesis CDP-DG(14:0/10:0) II714
phospholipid biosynthesis CDP-DG(14:0/12:0) IV714
phospholipid biosynthesis CDP-DG(14:0/12:0) III714
phospholipid biosynthesis CDP-DG(14:0/12:0) II714
phospholipid biosynthesis CDP-DG(14:0/15:0) II714
phospholipid biosynthesis CDP-DG(14:0/19:1(9Z)) II713
phospholipid biosynthesis CDP-DG(15:0/12:0) II714
phospholipid biosynthesis CDP-DG(15:0/12:0) III714
phospholipid biosynthesis CL(14:0/16:0/14:0/16:1(9Z))1119
phospholipid biosynthesis (CL(10:0(3-OH)/17:0cycw7c/14:0/14:0))1119
phospholipid biosynthesis (CL(10:0/17:0cycw7c/14:0/14:0))1118
phospholipid biosynthesis (CL(12:0(3-OH)/12:0(3-OH)/12:0/12:0))1116
Tryptophan Metabolism II623
phospholipid biosynthesis (CL(12:0(3-OH)/12:0/12:0/12:0))814
phospholipid biosynthesis (CL(12:0(3-OH)/17:0cycw7c/12:0/12:0))814
phospholipid biosynthesis (CL(12:0/12:0(3-OH)/12:0/12:0))814
phospholipid biosynthesis (CL(12:0/17:0cycw7c/12:0/12:0))814
phospholipid biosynthesis (CL(14:0(3-OH)/14:0(3-OH)/14:0/14:0))815
phospholipid biosynthesis (CL(14:0(3-OH)/14:0/14:0/14:0))815
phospholipid biosynthesis (CL(14:0(3-OH)/16:0/16:0/16:0))815
phospholipid biosynthesis (CL(14:0(3-OH)/16:1(9Z)/14:0/14:0))815
phospholipid biosynthesis (CL(14:0(3-OH)/17:0cycw7c/14:0/14:0))817
phospholipid biosynthesis (CL(14:0/14:0(3-OH)/14:0/14:0))815
phospholipid biosynthesis (CL(15:0/14:0(3-OH)/14:0/14:0))815
phospholipid biosynthesis (CL(16:0/12:0/12:0/12:0)) 21016
phospholipid biosynthesis (CL(16:1(9Z)/10:0/14:0/14:0))1118
phospholipid biosynthesis (CL(16:1(9Z)/12:0/12:0/12:0))1117
phospholipid biosynthesis (CL(16:1(9Z)/14:0(3-OH)/14:0/14:0))815
phospholipid biosynthesis (CL(16:1(9Z)/19:0/14:0/14:0))815
phospholipid biosynthesis (CL(16:1(9Z)/19:0/16:0/16:0))1019
phospholipid biosynthesis (CL(16:1(9Z)/19:0/16:1(9Z)/19:0))1016
phospholipid biosynthesis (CL(17:0/16:1(9Z)/14:0/14:0))1017
phospholipid biosynthesis (CL(17:0/16:1(9Z)/16:0/16:0))1018
phospholipid biosynthesis (CL(17:0cycw7c/10:0(3-OH)/10:0/10:0))814
phospholipid biosynthesis (CL(17:0cycw7c/10:0(3-OH)/14:0/14:0))1017
phospholipid biosynthesis (CL(17:0cycw7c/10:0/14:0/14:0))1017
phospholipid biosynthesis (CL(17:0cycw7c/12:0/12:0/12:0))814
phospholipid biosynthesis (CL(18:0/10:0/10:0/10:0))1117
phospholipid biosynthesis (CL(18:0/12:0/12:0/12:0))1117
phospholipid biosynthesis (CL(18:1(11Z)/10:0/10:0/10:0))1016
phospholipid biosynthesis (CL(18:1(11Z)/12:0/12:0/12:0))814
phospholipid biosynthesis (CL(18:1(11Z)/17:0/14:0/14:0))814
phospholipid biosynthesis (CL(18:1(11Z)/19:0/14:0/14:0))1017
phospholipid biosynthesis (CL(18:1(11Z)/19:0/19:0/19:0))1016
phospholipid biosynthesis (CL(19:0cycw8c/10:0/10:0/10:0))814
phospholipid biosynthesis (CL(18:1(9Z)/16:0/16:0/14:0))917
phospholipid biosynthesis (CL(18:1(9Z)/16:0/16:0/17:0cycw7c))1119
phospholipid biosynthesis (CL(18:1(9Z)/16:0/16:1(9Z)/18:1(9Z)))918
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/17:0cycw7c))916
phospholipid biosynthesis (CL(15:0cyclo/15:0cyclo/15:0cyclo/15:0cyclo))916
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/18:1(9Z)/18:1(9Z)) 21019
Sarcosine Oncometabolite Pathway1321
Glycine Metabolism1127
Serine Metabolism1025
Biosynthesis of Unsaturated Fatty Acids1439
Biosynthesis of Unsaturated Fatty Acids (Tetracosanoyl-CoA)1435
Biosynthesis of Unsaturated Fatty Acids (Docosanoyl-CoA)1431
Biosynthesis of Unsaturated Fatty Acids (Icosanoyl-CoA)1427
Biosynthesis of Unsaturated Fatty Acids (Stearoyl-CoA)1322
One Carbon Pool by Folate I527
Choline Biosynthesis I415
Choline Biosynthesis II618
Glycine Betaine Biosynthesis I621
Glycine Betaine Biosynthesis II824
Folate Polyglutamylation39
Phosphatidylethanolamine Biosynthesis PE(14:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis512
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(11D3/11D3)516
Phosphatidylethanolamine Biosynthesis PE(11D3/11D5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/13D5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/9D3)516
Phosphatidylethanolamine Biosynthesis PE(11D3/9D5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/11M3)516
Phosphatidylethanolamine Biosynthesis PE(11D3/11M5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/13M5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/9M5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(11D5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(11D5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(11D5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(13D5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(13D5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(13D5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/11D3)516
Phosphatidylethanolamine Biosynthesis PE(9D3/11D5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/13D5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/9D3)516
Phosphatidylethanolamine Biosynthesis PE(9D3/9D5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/11M3)516
Phosphatidylethanolamine Biosynthesis PE(9D3/11M5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/13M5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/9M5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(9D5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(9D5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(9D5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/11D3)516
Phosphatidylethanolamine Biosynthesis PE(11M3/11D5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/13D5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/9D3)516
Phosphatidylethanolamine Biosynthesis PE(11M3/9D5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/11M3)516
Phosphatidylethanolamine Biosynthesis PE(11M3/11M5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/13M5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/9M5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(11M5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(11M5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(11M5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(13M5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(13M5/9D5)515
Phosphatidylethanolamine Biosynthesis PE(13M5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(13M5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(9M5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(9M5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(9M5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/9M5)516
Phosphatidylcholine Biosynthesis PC(16:0/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:0/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(20:0/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(20:1(13Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(20:1(13Z)/22:0)1120
Phosphatidylcholine Biosynthesis PC(20:1(13Z)/22:1(13Z))1120
Folate metabolism ( Folate metabolism )2039
L-Tetrahydro-folic acid + L-Serine = 5,10-Methylene-tetrahydro-folic acid + Glycine + H2O ( Folate metabolism )25
Glycine and Serine metabolism ( Glycine and Serine metabolism )3649
L-Tetrahydro-folic acid + L-Serine = 5,10-Methylene-tetrahydro-folic acid + Glycine + H2O ( Glycine and Serine metabolism )24
L-Serine + Pyruvic acid = Hydroxy-pyruvic acid + L-Alanine ( Glycine and Serine metabolism )14
Methionine and Cysteine metabolism ( Methionine and Cysteine metabolism )2342
Sphingolipid metabolism (integrated pathway)1167
Major receptors targeted by epinephrine and norepinephrine186
Sphingolipid metabolism overview415
Sphingolipid metabolism: integrated pathway163
Phosphatidylethanolamine Biosynthesis PE(16:0/20:1(13Z))1220
Phosphatidylethanolamine Biosynthesis PE(18:0/20:1(13Z))1220
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:1(13Z))1220
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:1(13Z))1219
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:1(13Z))1220
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:1(13Z))1220
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:1(13Z))1220
Phosphatidylethanolamine Biosynthesis PE(20:0/20:1(13Z))1220
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:1(13Z))1219
Phosphatidylethanolamine Biosynthesis PE(20:1(13Z)/20:1(13Z))1218
Phosphatidylethanolamine Biosynthesis PE(20:1(13Z)/22:0)1219
Phosphatidylethanolamine Biosynthesis PE(20:1(13Z)/22:1(13Z))1219
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis614
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/14:0) | PE(14:0/14:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/i-15:0) | PE(14:0/i-15:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/16:0) | PE(14:0/16:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/16:1(9Z)) | PE(14:0/16:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/i-17:0) | PE(14:0/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:0) | PE(14:0/18:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:1(9Z)) | PE(14:0/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:1(11Z)) | PE(14:0/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:2(9Z,12Z)) | PE(14:0/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:3(6Z,9Z,12Z)) | PE(14:0/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:3(9Z,12Z,15Z)) | PE(14:0/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:0) | PE(14:0/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:3(5Z,8Z,11Z)) | PE(14:0/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:3(8Z,11Z,14Z)) | PE(14:0/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:4(5Z,8Z,11Z,14Z)) | PE(14:0/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:4(8Z,11Z,14Z,17Z)) | PE(14:0/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(14:0/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/i-15:0) | PE(i-15:0/i-15:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/16:0) | PE(i-15:0/16:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/16:1(9Z)) | PE(i-15:0/16:1(9Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/i-17:0) | PE(i-15:0/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:0) | PE(i-15:0/18:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:1(9Z)) | PE(i-15:0/18:1(9Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:1(11Z)) | PE(i-15:0/18:1(11Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:2(9Z,12Z)) | PE(i-15:0/18:2(9Z,12Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:3(6Z,9Z,12Z)) | PE(i-15:0/18:3(6Z,9Z,12Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:3(9Z,12Z,15Z)) | PE(i-15:0/18:3(9Z,12Z,15Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:0) | PE(i-15:0/20:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:3(5Z,8Z,11Z)) | PE(i-15:0/20:3(5Z,8Z,11Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:3(8Z,11Z,14Z)) | PE(i-15:0/20:3(8Z,11Z,14Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:4(5Z,8Z,11Z,14Z)) | PE(i-15:0/20:4(5Z,8Z,11Z,14Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:4(8Z,11Z,14Z,17Z)) | PE(i-15:0/20:4(8Z,11Z,14Z,17Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(i-15:0/20:5(5Z,8Z,11Z,14Z,17Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/16:0) | PE(16:0/16:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/16:1(9Z)) | PE(16:0/16:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/i-17:0) | PE(16:0/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:0) | PE(16:0/18:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:1(9Z)) | PE(16:0/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:1(11Z)) | PE(16:0/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:2(9Z,12Z)) | PE(16:0/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:3(6Z,9Z,12Z)) | PE(16:0/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:3(9Z,12Z,15Z)) | PE(16:0/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:0) | PE(16:0/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:3(5Z,8Z,11Z)) | PE(16:0/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:3(8Z,11Z,14Z)) | PE(16:0/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:4(5Z,8Z,11Z,14Z)) | PE(16:0/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:4(8Z,11Z,14Z,17Z)) | PE(16:0/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(16:0/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/16:1(9Z)) | PE(16:1(9Z)/16:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/i-17:0) | PE(16:1(9Z)/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:0) | PE(16:1(9Z)/18:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:1(9Z)) | PE(16:1(9Z)/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:1(11Z)) | PE(16:1(9Z)/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:2(9Z,12Z)) | PE(16:1(9Z)/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:3(6Z,9Z,12Z)) | PE(16:1(9Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:3(9Z,12Z,15Z)) | PE(16:1(9Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:0) | PE(16:1(9Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:3(5Z,8Z,11Z)) | PE(16:1(9Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:3(8Z,11Z,14Z)) | PE(16:1(9Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | PE(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) | PE(16:1(9Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/i-17:0) | PE(i-17:0/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:0) | PE(i-17:0/18:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:1(9Z)) | PE(i-17:0/18:1(9Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:1(11Z)) | PE(i-17:0/18:1(11Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:2(9Z,12Z)) | PE(i-17:0/18:2(9Z,12Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:3(6Z,9Z,12Z)) | PE(i-17:0/18:3(6Z,9Z,12Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:3(9Z,12Z,15Z)) | PE(i-17:0/18:3(9Z,12Z,15Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:0) | PE(i-17:0/20:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:3(5Z,8Z,11Z)) | PE(i-17:0/20:3(5Z,8Z,11Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:3(8Z,11Z,14Z)) | PE(i-17:0/20:3(8Z,11Z,14Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:4(5Z,8Z,11Z,14Z)) | PE(i-17:0/20:4(5Z,8Z,11Z,14Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:4(8Z,11Z,14Z,17Z)) | PE(i-17:0/20:4(8Z,11Z,14Z,17Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(i-17:0/20:5(5Z,8Z,11Z,14Z,17Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:0) | PE(18:0/18:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:1(9Z)) | PE(18:0/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:1(11Z)) | PE(18:0/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:2(9Z,12Z)) | PE(18:0/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:3(6Z,9Z,12Z)) | PE(18:0/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:3(9Z,12Z,15Z)) | PE(18:0/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:0) | PE(18:0/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:3(5Z,8Z,11Z)) | PE(18:0/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:3(8Z,11Z,14Z)) | PE(18:0/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:4(5Z,8Z,11Z,14Z)) | PE(18:0/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:4(8Z,11Z,14Z,17Z)) | PE(18:0/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:0/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:1(9Z)) | PE(18:1(9Z)/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:1(11Z)) | PE(18:1(9Z)/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:2(9Z,12Z)) | PE(18:1(9Z)/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:3(6Z,9Z,12Z)) | PE(18:1(9Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:3(9Z,12Z,15Z)) | PE(18:1(9Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:0) | PE(18:1(9Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:3(5Z,8Z,11Z)) | PE(18:1(9Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:3(8Z,11Z,14Z)) | PE(18:1(9Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/18:1(11Z)) | PE(18:1(11Z)/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/18:2(9Z,12Z)) | PE(18:1(11Z)/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/18:3(6Z,9Z,12Z)) | PE(18:1(11Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/18:3(9Z,12Z,15Z)) | PE(18:1(11Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:0) | PE(18:1(11Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:3(5Z,8Z,11Z)) | PE(18:1(11Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:3(8Z,11Z,14Z)) | PE(18:1(11Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/18:2(9Z,12Z)) | PE(18:2(9Z,12Z)/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)) | PE(18:2(9Z,12Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)) | PE(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:0) | PE(18:2(9Z,12Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)) | PE(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:3(8Z,11Z,14Z)) | PE(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)) | PE(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)) | PE(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:0) | PE(18:3(6Z,9Z,12Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)) | PE(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)) | PE(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)) | PE(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:0) | PE(18:3(9Z,12Z,15Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)) | PE(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)) | PE(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:0) | PE(20:0/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:3(5Z,8Z,11Z)) | PE(20:0/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:3(8Z,11Z,14Z)) | PE(20:0/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:4(5Z,8Z,11Z,14Z)) | PE(20:0/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:4(8Z,11Z,14Z,17Z)) | PE(20:0/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:0/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)) | PE(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z)) | PE(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)) | PE(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z)) | PE(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) | PE(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) | PE(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)) | PE(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/14:1(9Z)) | PE(14:0/14:1(9Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/15:0) | PE(14:0/15:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:1(11Z)) | PE(14:0/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/22:0) | PE(14:0/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/14:1(9Z)) | PE(14:1(9Z)/14:1(9Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/15:0) | PE(14:1(9Z)/15:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/16:0) | PE(14:1(9Z)/16:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:0) | PE(14:1(9Z)/18:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:1(9Z)) | PE(14:1(9Z)/18:1(9Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:1(11Z)) | PE(14:1(9Z)/18:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:2(9Z,12Z)) | PE(14:1(9Z)/18:2(9Z,12Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:3(9Z,12Z,15Z)) | PE(14:1(9Z)/18:3(9Z,12Z,15Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/20:1(11Z)) | PE(14:1(9Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | PE(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/22:0) | PE(14:1(9Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/15:0) | PE(15:0/15:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/16:0) | PE(15:0/16:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:0) | PE(15:0/18:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:1(9Z)) | PE(15:0/18:1(9Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:1(11Z)) | PE(15:0/18:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:2(9Z,12Z)) | PE(15:0/18:2(9Z,12Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:3(9Z,12Z,15Z)) | PE(15:0/18:3(9Z,12Z,15Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/20:1(11Z)) | PE(15:0/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/20:4(5Z,8Z,11Z,14Z)) | PE(15:0/20:4(5Z,8Z,11Z,14Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/22:0) | PE(15:0/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:1(11Z)) | PE(16:0/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/22:0) | PE(16:0/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:1(11Z)) | PE(18:0/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/22:0) | PE(18:0/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:1(11Z)) | PE(18:1(9Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/22:0) | PE(18:1(9Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:1(11Z)) | PE(18:1(11Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/22:0) | PE(18:1(11Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:1(11Z)) | PE(18:2(9Z,12Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/22:0) | PE(18:2(9Z,12Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:1(11Z)) | PE(18:3(9Z,12Z,15Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:0) | PE(18:3(9Z,12Z,15Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:1(11Z)/20:1(11Z)) | PE(20:1(11Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:1(11Z)/20:4(5Z,8Z,11Z,14Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:1(11Z)/22:0) | PE(20:1(11Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:0) | PE(20:4(5Z,8Z,11Z,14Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(22:0/22:0) | PE(22:0/22:0)717
Protein Synthesis: Serine804
Phospholipid Biosynthesis CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))324
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/19:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(14:0/15:0cycw5/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(14:0/15:0cycw5/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(14:0/16:0/14:0/14:0)321
Phospholipid Biosynthesis CL(14:0/16:0/14:0/16:0)320
Phospholipid Biosynthesis CL(14:0/16:0/14:0/19:0cycw7)320
Phospholipid Biosynthesis CL(14:0/16:0/16:1(9Z)/14:0)320
Phospholipid Biosynthesis CL(14:0/16:0/18:1(9Z)/14:0)320
Phospholipid Biosynthesis CL(14:0/16:0/19:0cycw7/14:0)320
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/14:0/16:1(9Z))319
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/14:0/18:1(9Z))319
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/14:0/19:0cycw7)319
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/18:1(9Z)/14:0)319
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/19:0cycw7/14:0)319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/14:0/14:0)320
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/14:0/17:0cycw7)319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/14:0/18:1(9Z))319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/14:0/19:0cycw7)319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/17:0cycw7/14:0)319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/19:0cycw7/14:0)319
Phospholipid Biosynthesis CL(14:0/19:0cycw7/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(14:0/19:0cycw7/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(14:0/19:0cycw7/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/14:0/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/14:0/16:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/14:0/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/14:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/14:0/18:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/14:0/19:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/14:0/16:0)316
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/14:0/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/14:0/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/15:0cycw5/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/15:0cycw5/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/16:0)317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/18:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/16:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/18:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/16:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/16:0/14:0/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/16:0/17:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/18:1(9Z))319
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:1(9Z)/16:0)318
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:0/17:0cycw7/16:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/18:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/18:1(9Z)/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/16:0/18:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:0/19:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/19:0cycw7/16:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/19:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/14:0/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/14:0/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:0/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:0/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/16:0)318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/17:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/17:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/18:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/18:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/18:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/19:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/19:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/19:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/14:0/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/15:0cycw5/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/16:0/16:0)318
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/16:0/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/16:1(9Z)/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/16:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/16:0)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/18:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/18:1(9Z)/18:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/19:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/14:0/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/14:0/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/15:0cycw5/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/15:0cycw5/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/15:0cycw5/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/15:0cycw5/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/16:0/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/16:0/18:1(9Z))319
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/16:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/16:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/17:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/19:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/19:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/19:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/14:0/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/15:0cycw5/14:0)315
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/15:0cycw5)321
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/15:0cycw5/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/15:0cycw5/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/16:0/16:0)318
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/16:0/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/16:1(9Z)/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/16:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/17:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/16:0)321
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/18:1(9Z)/18:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/18:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/16:0)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(16:0/14:0/14:0/14:0)322
Phospholipid Biosynthesis CL(16:0/14:0/14:0/16:0)322
Phospholipid Biosynthesis CL(16:0/14:0/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(16:0/14:0/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(16:0/14:0/14:0/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/14:0/16:0/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/14:0/14:0)318
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(16:0/14:0/16:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:0/14:0/16:1(9Z)/16:1(9Z))323
Phospholipid Biosynthesis CL(16:0/14:0/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(16:0/14:0/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:0/14:0/18:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(16:0/14:0/19:0cycw7/14:0)321
Phospholipid Biosynthesis CL(16:0/14:0/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/15:0cycw5/14:0/15:0cycw5)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/14:0)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/16:1(9Z))317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/18:1(9Z))317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/16:0)320
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/16:1(9Z))319
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/18:1(9Z))320
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:1(9Z)/16:0)319
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/14:0/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/14:0/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(16:0/15:0cycw5/17:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/17:0cycw7/16:0)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/18:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/18:1(9Z)/16:0)320
Phospholipid Biosynthesis CL(16:0/15:0cycw5/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/18:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/19:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/19:0cycw7/16:0)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/19:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:0/16:0/14:0/14:0)323
Phospholipid Biosynthesis CL(19:0cycw7/14:0/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:0/14:0/16:1(9Z))322
Phospholipid Biosynthesis CL(19:0cycw7/14:0/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:0/14:0/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/14:0/18:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/14:0/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:0/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:0/18:1(9Z))326
Phospholipid Biosynthesis CL(16:0/16:0/16:0/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/15:0cycw5)322
Phospholipid Biosynthesis CL(19:0cycw7/14:0/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/14:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/16:0)325
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/16:0)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(19:0cycw7/14:0/19:0cycw7/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/14:0/15:0cycw5)315
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/16:0)326
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/16:0)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/15:0cycw5/14:0)315
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/14:0/14:0)322
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/14:0/16:0)322
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/14:0)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/16:1(9Z))323
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/15:0cycw5/17:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/16:0/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/16:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/17:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/17:0cycw7)321
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/18:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/16:0)324
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/16:1(9Z))324
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/17:0cycw7)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/18:1(9Z))324
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/17:0cycw7/16:0)321
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/16:0)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/16:0/14:0/14:0)317
Phospholipid Biosynthesis CL(19:0cycw7/16:0/14:0/16:0)317
Phospholipid Biosynthesis CL(19:0cycw7/16:0/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/16:0/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/16:0/17:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/17:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(19:0cycw7/16:0/16:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/16:0)325
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/16:1(9Z))324
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/18:1(9Z))324
Phospholipid Biosynthesis CL(19:0cycw7/16:0/17:0cycw7/16:0)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/18:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/19:0cycw7/16:0)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/19:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/17:0cycw7/14:0/16:0)318
Phospholipid Biosynthesis CL(16:0/17:0cycw7/14:0/17:0cycw7)317
Phospholipid Biosynthesis CL(19:0cycw7/16:0/19:0cycw7/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/19:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(16:0/17:0cycw7/16:0/14:0)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/16:0/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/16:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(16:0/17:0cycw7/16:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:0/17:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/14:0/14:0)324
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/14:0/16:0)324
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/14:0/18:1(9Z))323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:0/14:0)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:0/17:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:0/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:0/19:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:1(9Z)/16:1(9Z))326
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:1(9Z)/18:1(9Z))326
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/17:0cycw7/16:0)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/17:0cycw7/17:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/17:0cycw7/18:1(9Z))323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/14:0)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/16:0)327
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/16:1(9Z))326
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/17:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/18:1(9Z))326
Phospholipid Biosynthesis CL(19:0cycw7/16:0/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/19:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/14:0/14:0)317
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/14:0/16:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/16:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/19:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/19:0cycw7/16:0)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/19:0cycw7/18:1(9Z))323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/19:0cycw7/19:0cycw7)323
Phospholipid Biosynthesis CL(16:0/19:0cycw7/14:0/14:0)318
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/16:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/17:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/18:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/19:0cycw7/14:0)316
Phospholipid Biosynthesis CL(16:0/19:0cycw7/14:0/16:0)318
Phospholipid Biosynthesis CL(16:0/19:0cycw7/14:0/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/16:0/14:0)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/16:0/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/16:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/19:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/19:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/14:0/14:0)316
Phospholipid Biosynthesis CL(16:0/19:0cycw7/16:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/17:0cycw7/16:0)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/19:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(16:0/19:0cycw7/18:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/19:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/19:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/19:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/14:0/14:0)317
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/14:0/18:1(9Z))316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/14:0/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/16:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/18:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/18:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/18:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/19:0cycw7/14:0)316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/19:0cycw7/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/14:0/15:0cycw5)317
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/15:0cycw5)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/16:0)316
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/16:1(9Z))315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/14:0/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/15:0cycw5/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/15:0cycw5/18:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/15:0cycw5/19:0cycw7)317
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/17:0cycw7/16:0)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/17:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:0/16:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/16:0)319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/17:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/17:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/18:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/18:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/19:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/19:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/14:0/14:0)323
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/14:0/16:0)323
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/14:0/16:1(9Z))322
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/18:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/14:0/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:0/14:0)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:0/17:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:0/18:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:0/19:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/16:0)324
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/17:0cycw7/16:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/14:0/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/14:0/14:0)220
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/14:0/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/17:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/17:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/17:0cycw7/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/16:0)326
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/19:0cycw7/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/19:0cycw7/16:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/14:0/15:0cycw5)317
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/19:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/19:0cycw7/19:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/15:0cycw5)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/16:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/16:1(9Z))320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/14:0/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/15:0cycw5/14:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/15:0cycw5/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/15:0cycw5/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/16:0/18:1(9Z))320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/16:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/17:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/18:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/19:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/14:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/17:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/19:0cycw7)320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/17:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/16:0)320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/14:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/15:0cycw5)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/16:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/16:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/17:0cycw7)320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/18:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/19:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/14:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/15:0cycw5)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/16:0)324
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/16:1(9Z))323
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/17:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/19:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/14:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/15:0cycw5)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/16:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/16:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/17:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/18:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/19:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/14:0/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/14:0/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/16:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/16:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/14:0)322
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/17:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/19:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/19:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/14:0/14:0)324
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/14:0/16:0)324
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/14:0/18:1(9Z))323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/16:0/19:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/17:0cycw7/16:0)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/17:0cycw7/17:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/17:0cycw7/18:1(9Z))323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/14:0)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/16:0)325
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7/18:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/16:1(9Z))326
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/17:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/18:1(9Z))326
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/19:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/19:0cycw7/16:0)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/19:0cycw7/18:1(9Z))323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/19:0cycw7/19:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/14:0/14:0)323
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/16:1(9Z))324
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/17:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/18:1(9Z))324
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/14:0/16:1(9Z))322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/14:0/18:1(9Z))322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycw7/18:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/17:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/14:0/14:0)318
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/14:0/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/14:0/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/17:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/17:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/16:1(9Z))324
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/16:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/16:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/16:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/17:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/19:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/19:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/19:0cycw7/19:0cycw7)322
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/14:0/14:0)318
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/14:0/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/14:0/18:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/18:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/17:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/19:0cycw7/14:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/19:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/19:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/18:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/14:0)322
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/14:0/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/16:0/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/16:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/16:0)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/18:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/19:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/16:0/14:0/16:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/15:0cycw5)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/16:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/19:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/15:0cycw5)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/16:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(17:0cycw7/16:0/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/16:0/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/16:0/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/16:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/18:1(9Z))321
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/16:0)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/14:0)321
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/18:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/14:0/16:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/16:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/18:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/15:0cycw5)315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/16:0)316
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/16:1(9Z))315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/18:1(9Z))315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/14:0/14:0)317
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/14:0/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/16:0)318
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/15:0cycw5/14:0)317
Phospholipid Biosynthesis CL(10:0/10:0/10:0/10:0)316
Phospholipid Biosynthesis CL(16:0/12:0(3-OH)/16:0/12:0(3-OH))318
Phospholipid Biosynthesis CL(16:0/15:0/16:0/15:0)321
Phospholipid Biosynthesis CL(10:0/12:0/10:0/12:0)317
Phospholipid Biosynthesis CL(10:0/14:0/10:0/14:0)317
Phospholipid Biosynthesis CL(16:0/18:0/16:0/18:0)324
Phospholipid Biosynthesis CL(10:0/15:0/10:0/15:0)317
Phospholipid Biosynthesis CL(10:0/16:0/10:0/16:0)317
Phospholipid Biosynthesis CL(16:0/i-19:0/16:0/i-19:0)318
Phospholipid Biosynthesis CL(10:0/16:1(9Z)/10:0/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/10:0(3-OH)/16:1(9Z)/10:0(3-OH))318
Phospholipid Biosynthesis CL(10:0/18:0/10:0/18:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/12:0(3-OH)/16:1(9Z)/12:0(3-OH))318
Phospholipid Biosynthesis CL(10:0/18:1(9Z)/10:0/18:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0/16:1(9Z)/15:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:0/16:1(9Z)/18:0)323
Phospholipid Biosynthesis CL(16:1(9Z)/i-19:0/16:1(9Z)/i-19:0)318
Phospholipid Biosynthesis CL(18:0/10:0/18:0/10:0)318
Phospholipid Biosynthesis CL(18:0/12:0/18:0/12:0)318
Phospholipid Biosynthesis CL(10:0/19:1(9Z)/10:0/19:1(9Z))316
Phospholipid Biosynthesis CL(12:0/10:0/12:0/10:0)318
Phospholipid Biosynthesis CL(18:0/14:0/18:0/14:0)321
Phospholipid Biosynthesis CL(18:0/15:0/18:0/15:0)321
Phospholipid Biosynthesis CL(18:0/16:0/18:0/16:0)325
Phospholipid Biosynthesis CL(12:0/14:0/12:0/14:0)318
Phospholipid Biosynthesis CL(12:0/15:0/12:0/15:0)318
Phospholipid Biosynthesis CL(18:0/16:1(9Z)/18:0/16:1(9Z))324
Phospholipid Biosynthesis CL(12:0/16:0/12:0/16:0)318
Phospholipid Biosynthesis CL(18:0/18:0/18:0/18:0)324
Phospholipid Biosynthesis CL(12:0/16:1(9Z)/12:0/16:1(9Z))318
Phospholipid Biosynthesis CL(18:0/18:1(9Z)/18:0/18:1(9Z))324
Phospholipid Biosynthesis CL(12:0/18:0/12:0/18:0)318
Phospholipid Biosynthesis CL(18:0/19:1(9Z)/18:0/19:1(9Z))317
Phospholipid Biosynthesis CL(12:0/18:1(9Z)/12:0/18:1(9Z))318
Phospholipid Biosynthesis CL(12:0/19:1(9Z)/12:0/19:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/10:0(3-OH)/18:1(9Z)/10:0(3-OH))318
Phospholipid Biosynthesis CL(18:1(9Z)/15:0/18:1(9Z)/15:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/19:1(9Z)/18:1(9Z)/19:1(9Z))317
Phospholipid Biosynthesis CL(19:1(9Z)/14:0/19:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(19:1(9Z)/16:0/19:1(9Z)/16:0)316
Phospholipid Biosynthesis CL(19:1(9Z)/18:0/19:1(9Z)/18:0)316
Phospholipid Biosynthesis CL(19:1(9Z)/19:1(9Z)/19:1(9Z)/19:1(9Z))315
Phospholipid Biosynthesis CL(14:0/10:0/14:0/10:0)317
Phospholipid Biosynthesis CL(14:0/12:0/14:0/12:0)317
Phospholipid Biosynthesis CL(14:0/15:0/14:0/15:0)319
Phospholipid Biosynthesis CL(14:0/18:0/14:0/18:0)319
Phospholipid Biosynthesis CL(14:0/19:1(9Z)/14:0/19:1(9Z))316
Phospholipid Biosynthesis CL(15:0/10:0/15:0/10:0)317
Phospholipid Biosynthesis CL(15:0/12:0/15:0/12:0)317
Phospholipid Biosynthesis CL(15:0/14:0/15:0/14:0)320
Phospholipid Biosynthesis CL(15:0/15:0/15:0/15:0)318
Phospholipid Biosynthesis CL(15:0/16:0/15:0/16:0)319
Phospholipid Biosynthesis CL(15:0/16:1(9Z)/15:0/16:1(9Z))319
Phospholipid Biosynthesis CL(15:0/18:0/15:0/18:0)320
Phospholipid Biosynthesis CL(15:0/18:1(9Z)/15:0/18:1(9Z))319
Phospholipid Biosynthesis CL(15:0/19:1(9Z)/15:0/19:1(9Z))316
Phospholipid Biosynthesis CL(16:0/10:0/16:0/10:0)318
Phospholipid Biosynthesis CL(14:0/16:0/14:0/16:1(9Z))320
Phospholipid Biosynthesis CL(10:0(3-OH)/10:0/10:0(3-OH)/10:0)317
Phospholipid Biosynthesis CL(10:0(3-OH)/12:0(3-OH)/10:0(3-OH)/12:0(3-OH))317
Phospholipid Biosynthesis CL(10:0(3-OH)/12:0/10:0(3-OH)/12:0)317
Phospholipid Biosynthesis CL(10:0(3-OH)/15:0cycw5/10:0(3-OH)/15:0cycw5)316
Phospholipid Biosynthesis CL(10:0(3-OH)/16:1(9Z)/10:0(3-OH)/16:1(9Z))317
Phospholipid Biosynthesis CL(10:0(3-OH)/16:0/10:0(3-OH)/16:0)317
Phospholipid Biosynthesis CL(10:0(3-OH)/17:0cycw7/10:0(3-OH)/17:0cycw7)316
Phospholipid Biosynthesis CL(10:0(3-OH)/17:0cycw7/14:0/14:0)317
Phospholipid Biosynthesis CL(10:0(3-OH)/19:0cycw7/10:0(3-OH)/19:0cycw7)316
Phospholipid Biosynthesis CL(10:0(3-OH)/i-19:0/10:0(3-OH)/i-19:0)317
Phospholipid Biosynthesis CL(10:0/10:0(3-OH)/10:0/10:0(3-OH))317
Phospholipid Biosynthesis CL(10:0/12:0(3-OH)/10:0/12:0(3-OH))317
Phospholipid Biosynthesis CL(10:0/17:0cycw7/14:0/14:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/10:0(3-OH)/12:0(3-OH)/10:0(3-OH))317
Phospholipid Biosynthesis CL(12:0(3-OH)/10:0/12:0(3-OH)/10:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/12:0(3-OH)/12:0/12:0)316
Phospholipid Biosynthesis CL(12:0(3-OH)/12:0/12:0/12:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/14:0(3-OH)/12:0(3-OH)/14:0(3-OH))317
Phospholipid Biosynthesis CL(12:0(3-OH)/14:0/12:0(3-OH)/14:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/15:0/12:0(3-OH)/15:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/15:0cycw5/12:0(3-OH)/15:0cycw5)316
Phospholipid Biosynthesis CL(12:0(3-OH)/17:0cycw7/12:0(3-OH)/17:0cycw7)316
Phospholipid Biosynthesis CL(12:0(3-OH)/17:0cycw7/12:0/12:0)316
Phospholipid Biosynthesis CL(12:0(3-OH)/18:1(9Z)/12:0(3-OH)/18:1(9Z))317
Phospholipid Biosynthesis CL(12:0(3-OH)/19:0cycw7/12:0(3-OH)/19:0cycw7)316
Phospholipid Biosynthesis CL(12:0(3-OH)/i-19:0/12:0(3-OH)/i-19:0)317
Phospholipid Biosynthesis CL(12:0/10:0(3-OH)/12:0/10:0(3-OH))318
Phospholipid Biosynthesis CL(12:0/12:0(3-OH)/12:0/12:0)318
Phospholipid Biosynthesis CL(12:0/12:0/12:0/12:0)317
Phospholipid Biosynthesis CL(12:0/14:0(3-OH)/12:0/14:0(3-OH))318
Phospholipid Biosynthesis CL(12:0/17:0cycw7/12:0/12:0)317
Phospholipid Biosynthesis CL(12:0/i-19:0/12:0/i-19:0)318
Phospholipid Biosynthesis CL(14:0(3-OH)/12:0(3-OH)/14:0(3-OH)/12:0(3-OH))317
Phospholipid Biosynthesis CL(14:0(3-OH)/12:0/14:0(3-OH)/12:0)317
Phospholipid Biosynthesis CL(14:0(3-OH)/14:0(3-OH)/14:0/14:0)317
Phospholipid Biosynthesis CL(14:0(3-OH)/14:0/14:0/14:0)318
Phospholipid Biosynthesis CL(14:0(3-OH)/16:0/16:0/16:0)320
Phospholipid Biosynthesis CL(14:0(3-OH)/16:1(9Z)/14:0(3-OH)/16:1(9Z))317
Phospholipid Biosynthesis CL(14:0(3-OH)/16:1(9Z)/14:0/14:0)318
Phospholipid Biosynthesis CL(14:0(3-OH)/17:0cycw7/14:0(3-OH)/17:0cycw7)316
Phospholipid Biosynthesis CL(14:0(3-OH)/17:0cycw7/14:0/14:0)317
Phospholipid Biosynthesis CL(14:0/12:0(3-OH)/14:0/12:0(3-OH))317
Phospholipid Biosynthesis CL(14:0/14:0(3-OH)/14:0/14:0)318
Phospholipid Biosynthesis CL(15:0/10:0(3-OH)/15:0/10:0(3-OH))317
Phospholipid Biosynthesis CL(15:0/12:0(3-OH)/15:0/12:0(3-OH))317
Phospholipid Biosynthesis CL(15:0/14:0(3-OH)/14:0/14:0)318
Phospholipid Biosynthesis CL(15:0cycw5/10:0(3-OH)/15:0cycw5/10:0(3-OH))316
Phospholipid Biosynthesis CL(16:0/10:0(3-OH)/16:0/10:0(3-OH))318
Phospholipid Biosynthesis CL(16:0/14:0(3-OH)/16:0/14:0(3-OH))318
Phospholipid Biosynthesis CL(16:1(9Z)/10:0/14:0/14:0)319
Phospholipid Biosynthesis CL(16:1(9Z)/12:0/12:0/12:0)318
Phospholipid Biosynthesis CL(16:1(9Z)/14:0(3-OH)/14:0/14:0)319
Phospholipid Biosynthesis CL(16:1(9Z)/14:0(3-OH)/16:1(9Z)/14:0(3-OH))318
Phospholipid Biosynthesis CL(16:1(9Z)/19:0/14:0/14:0)319
Phospholipid Biosynthesis CL(16:1(9Z)/19:0/16:0/16:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/19:0/16:1(9Z)/19:0)318
Phospholipid Biosynthesis CL(17:0/16:1(9Z)/14:0/14:0)318
Phospholipid Biosynthesis CL(17:0/16:1(9Z)/16:0/16:0)320
Phospholipid Biosynthesis CL(17:0cycw7/10:0(3-OH)/10:0/10:0)316
Phospholipid Biosynthesis CL(17:0cycw7/10:0(3-OH)/14:0/14:0)317
Phospholipid Biosynthesis CL(17:0cycw7/10:0(3-OH)/17:0cycw7/10:0(3-OH))316
Phospholipid Biosynthesis CL(17:0cycw7/10:0/14:0/14:0)317
Phospholipid Biosynthesis CL(17:0cycw7/12:0(3-OH)/12:0/12:0)316
Phospholipid Biosynthesis CL(17:0cycw7/12:0(3-OH)/17:0cycw7/12:0(3-OH))316
Phospholipid Biosynthesis CL(17:0cycw7/12:0/12:0/12:0)316
Phospholipid Biosynthesis CL(17:0cycw7/i-19:0/17:0cycw7/i-19:0)316
Phospholipid Biosynthesis CL(18:0/10:0/10:0/10:0)318
Phospholipid Biosynthesis CL(18:0/12:0/12:0/12:0)318
Phospholipid Biosynthesis CL(18:1(11Z)/10:0/10:0/10:0)317
Phospholipid Biosynthesis CL(18:1(11Z)/12:0/12:0/12:0)317
Phospholipid Biosynthesis CL(18:1(11Z)/17:0/14:0/14:0)318
Phospholipid Biosynthesis CL(18:1(11Z)/19:0/14:0/14:0)318
Phospholipid Biosynthesis CL(18:1(11Z)/19:0/18:1(11Z)/19:0)317
Phospholipid Biosynthesis CL(18:1(11Z)/19:0/19:0/19:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/12:0(3-OH)/18:1(9Z)/12:0(3-OH))318
Phospholipid Biosynthesis CL(19:0/16:1(9Z)/14:0/14:0)319
Phospholipid Biosynthesis CL(19:0/16:1(9Z)/16:0/16:0)321
Phospholipid Biosynthesis CL(19:0/16:1(9Z)/19:0/16:1(9Z))318
Phospholipid Biosynthesis CL(19:0/18:1(11Z)/14:0/14:0)319
Phospholipid Biosynthesis CL(19:0/18:1(11Z)/19:0/18:1(11Z))318
Phospholipid Biosynthesis CL(19:0/18:1(11Z)/19:0/19:0)318
Phospholipid Biosynthesis CL(19:0cycw7/10:0(3-OH)/10:0/10:0)316
Phospholipid Biosynthesis CL(19:0cycw7/10:0(3-OH)/19:0cycw7/10:0(3-OH))316
Phospholipid Biosynthesis CL(19:0cycw7/12:0(3-OH)/12:0/12:0)316
Phospholipid Biosynthesis CL(19:0cycw7/12:0(3-OH)/19:0cycw7/12:0(3-OH))316
Phospholipid Biosynthesis CL(19:0cycw8/10:0/10:0/10:0)316
Phospholipid Biosynthesis CL(19:1(9Z)/16:1(9Z)/19:1(9Z)/16:1(9Z))316
Phospholipid Biosynthesis CL(i-19:0/10:0(3-OH)/10:0/10:0)318
Phospholipid Biosynthesis CL(i-19:0/10:0(3-OH)/i-19:0/10:0(3-OH))318
Phospholipid Biosynthesis CL(i-19:0/10:0/i-19:0/10:0)318
Phospholipid Biosynthesis CL(i-19:0/12:0(3-OH)/12:0/12:0)318
Phospholipid Biosynthesis CL(i-19:0/12:0(3-OH)/i-19:0/12:0(3-OH))318
Phospholipid Biosynthesis CL(i-19:0/12:0/i-19:0/12:0)318
Phospholipid Biosynthesis CL(i-19:0/14:0(3-OH)/14:0/14:0)319
Phospholipid Biosynthesis CL(i-19:0/14:0(3-OH)/i-19:0/14:0(3-OH))318
Phospholipid Biosynthesis CL(i-19:0/14:0/14:0/14:0)319
Phospholipid Biosynthesis CL(i-19:0/14:0/i-19:0/14:0)318
Phospholipid Biosynthesis CL(i-19:0/17:0cycw7/19:0/19:0)317
Phospholipid Biosynthesis CL(i-19:0/19:0cycw7/19:0/19:0)317
Phospholipid Biosynthesis CL(i-19:0/i-19:0/i-19:0/i-19:0)319
Phospholipid Biosynthesis CL(16:0/16:0/16:0/16:0)324
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/16:0/14:0)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/16:0/17:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/16:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/15:0cycw5/15:0cycw5)315
Oxidative stress and redox pathway019
Neuroinflammation and glutamatergic signaling122
Amino acid metabolism in triple-negative breast cancer cells016
phospholipid biosynthesis010
serine degradation03
superpathway of glycine biosynthesis04
cysteine and homocysteine interconversion09
Folic acid network070
AtMetExpress overview0109
Kennedy pathway012
Trans-sulfuration and one-carbon metabolism020
Sphingolipid pathway315
Selenium micronutrient network095
Vitamin B12 metabolism050
Folate metabolism156
Trans-sulfuration, one-carbon metabolism and related pathways053
Glycerophospholipid biosynthetic pathway3233
Biochemical pathways: part I0466
Amino acid metabolism094
Kennedy pathway from sphingolipids011
One-carbon metabolism and related pathways038
Ethanol effects on histone modifications017
PCO cycle824

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
phosphopantetheinyl transferaseBacillus subtilisPotency81.54780.141337.9142100.0000AID1490
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.35480.031622.3146100.0000AID588579
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency9.98190.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency1.00000.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)0.01500.00000.94539.9400AID1233122
CholinesteraseEquus caballus (horse)IC50 (µMol)0.01600.00002.22149.4000AID1233124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pyruvate kinase PKMHomo sapiens (human)EC50 (µMol)1,300.00000.00050.59206.0000AID1881862
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
L-cystine transportNeutral amino acid transporter AHomo sapiens (human)
amino acid transportNeutral amino acid transporter AHomo sapiens (human)
glutamine transportNeutral amino acid transporter AHomo sapiens (human)
L-alanine transportNeutral amino acid transporter AHomo sapiens (human)
L-cystine transportNeutral amino acid transporter AHomo sapiens (human)
proline transportNeutral amino acid transporter AHomo sapiens (human)
L-serine transportNeutral amino acid transporter AHomo sapiens (human)
threonine transportNeutral amino acid transporter AHomo sapiens (human)
hydroxyproline transportNeutral amino acid transporter AHomo sapiens (human)
synaptic transmission, glutamatergicNeutral amino acid transporter AHomo sapiens (human)
proline transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
cognitionNeutral amino acid transporter AHomo sapiens (human)
L-aspartate import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
transport across blood-brain barrierNeutral amino acid transporter AHomo sapiens (human)
chloride transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
L-serine import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
L-alanine import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
L-glutamate transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
amino acid transportNeutral amino acid transporter B(0)Homo sapiens (human)
glutamine transportNeutral amino acid transporter B(0)Homo sapiens (human)
glutamine secretionNeutral amino acid transporter B(0)Homo sapiens (human)
neutral amino acid transportNeutral amino acid transporter B(0)Homo sapiens (human)
L-serine transportNeutral amino acid transporter B(0)Homo sapiens (human)
erythrocyte differentiationNeutral amino acid transporter B(0)Homo sapiens (human)
symbiont entry into host cellNeutral amino acid transporter B(0)Homo sapiens (human)
protein homotrimerizationNeutral amino acid transporter B(0)Homo sapiens (human)
L-aspartate import across plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
transport across blood-brain barrierNeutral amino acid transporter B(0)Homo sapiens (human)
L-glutamine import across plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
L-cystine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
chloride channel activityNeutral amino acid transporter AHomo sapiens (human)
amino acid transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-alanine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-aspartate transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-cystine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-glutamine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-proline transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-serine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-threonine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
symporter activityNeutral amino acid transporter AHomo sapiens (human)
L-hydroxyproline transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
virus receptor activityNeutral amino acid transporter B(0)Homo sapiens (human)
protein bindingNeutral amino acid transporter B(0)Homo sapiens (human)
amino acid transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-aspartate transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-glutamine transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-serine transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
symporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
antiporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
ligand-gated channel activityNeutral amino acid transporter B(0)Homo sapiens (human)
signaling receptor activityNeutral amino acid transporter B(0)Homo sapiens (human)
metal ion bindingNeutral amino acid transporter B(0)Homo sapiens (human)
neutral L-amino acid transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
plasma membraneNeutral amino acid transporter AHomo sapiens (human)
centrosomeNeutral amino acid transporter AHomo sapiens (human)
intermediate filamentNeutral amino acid transporter AHomo sapiens (human)
plasma membraneNeutral amino acid transporter AHomo sapiens (human)
cell surfaceNeutral amino acid transporter AHomo sapiens (human)
membraneNeutral amino acid transporter AHomo sapiens (human)
melanosomeNeutral amino acid transporter AHomo sapiens (human)
synapseNeutral amino acid transporter AHomo sapiens (human)
extracellular exosomeNeutral amino acid transporter AHomo sapiens (human)
plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
basal plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
membraneNeutral amino acid transporter B(0)Homo sapiens (human)
melanosomeNeutral amino acid transporter B(0)Homo sapiens (human)
extracellular exosomeNeutral amino acid transporter B(0)Homo sapiens (human)
plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID1233122Inhibition of Electrophorus electricus acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured for 30 mins by Ellman's method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Allobetulin derived seco-oleananedicarboxylates act as inhibitors of acetylcholinesterase.
AID328866Binding affinity to Pyrococcus horikoshii sodium-coupled aspartate transporter2007Nature, Jan-25, Volume: 445, Issue:7126
Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter.
AID233320Bitter threshold value; NB denotes 'Not bitter'1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID1233124Inhibition of equine serum butyrylcholinesterase using butyrylthiocholineidioide as substrate preincubated for 20 mins followed by substrate addition measured for 30 mins by Ellman's method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Allobetulin derived seco-oleananedicarboxylates act as inhibitors of acetylcholinesterase.
AID1881862Activation of PKM2 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID224504Effect on rate of GTP hydrolysis in the GTP binding protein ras p21; Not determined1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Prediction of the GTPase activities by using the semiempirical molecular orbital theory.
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID443653Binding affinity to 30 mM pyridoxal-5'-phosphate assessed as formation of PLP-aldimine by ESI-MS analysis2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5'-phosphate cofactor.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID51033Concentration required for obtaining 50% of the fluorescence intensity of copper-free calcein 1, in bovine serum albumin2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
A green fluorescent chemosensor for amino acids provides a versatile high-throughput screening (HTS) assay for proteases.
AID500825Induction of nitrogen-starved wild type sigma1278b yeast Gap1-mediated trehalose activation at 10 mM2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23,520)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905640 (23.98)18.7374
1990's3726 (15.84)18.2507
2000's7408 (31.50)29.6817
2010's5166 (21.96)24.3611
2020's1580 (6.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials115 (0.48%)5.53%
Reviews754 (3.15%)6.00%
Case Studies319 (1.33%)4.05%
Observational5 (0.02%)0.25%
Other22,721 (95.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetylcarnitine
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.		2.0510O-acylcarnitinehuman metabolite
monoisopropanolamine
monoisopropanolamine: possible industrial pollutant; structure. 1-aminopropan-2-ol : Any amino alcohol that is propan-2-ol substituted by an amino group at position 1.		2.0510amino alcohol;
secondary alcohol		Escherichia coli metabolite
dinitrochlorobenzene
Dinitrochlorobenzene: A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds.. 1-chloro-2,4-dinitrobenzene : A C-nitro compound that is chlorobenzene carrying a nitro substituent at each of the 2- and 4-positions.		2.4420C-nitro compound;
monochlorobenzenes		allergen;
epitope;
sensitiser
2,3-dihydroxybenzoic acid
2,3-dihydroxybenzoic acid: RN given refers to parent cpd. dihydroxybenzoic acid : Any member of the class of hydroxybenzoic acids carrying two phenolic hydroxy groups on the benzene ring and its derivatives.. 2,3-dihydroxybenzoic acid : A dihydroxybenzoic acid that is benzoic acid substituted by hydroxy groups at positions 2 and 3. It occurs naturally in Phyllanthus acidus and in the aquatic fern Salvinia molesta.		8.4880dihydroxybenzoic acidhuman xenobiotic metabolite;
plant metabolite
alpha-hydroxyglutarate
2-hydroxyglutarate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-hydroxyglutaric acid.. 2-hydroxyglutaric acid : A 2-hydroxydicarboxylic acid that is glutaric acid in which one hydrogen alpha- to a carboxylic acid group is substituted by a hydroxy group.		3402-hydroxydicarboxylic acid;
dicarboxylic fatty acid		metabolite;
mouse metabolite
2-oxo-3-methylvalerate
alpha-keto-beta-methylvaleric acid: RN given refers to parent cpd. 3-methyl-2-oxovaleric acid : A 2-oxo monocarboxylic acid that is valeric acid carrying oxo- and methyl substituents at C-2 and C-3, respectively. An alpha-keto acid analogue and metabolite of isoleucine in man, animals and bacteria. Used as a clinical marker for maple syrup urine disease (MSUD).		2.02102-oxo monocarboxylic acid;
branched-chain keto acid		human metabolite
alpha-ketoisovalerate
alpha-ketoisovalerate: RN given refers to parent cpd. 3-methyl-2-oxobutanoate : A 2-oxo monocarboxylic acid anion that is the conjugate base of 3-methyl-2-oxobutanoic acid, arising from deprotonation of the carboxy group.. 3-methyl-2-oxobutanoic acid : A 2-oxo monocarboxylic acid that is the 2-oxo derivative of isovaleric acid.		2.02102-oxo monocarboxylic acid;
branched-chain keto acid		human metabolite;
Saccharomyces cerevisiae metabolite
provitamin c
provitamin C: RN given refers to parent cpd; NM refers to (L-xylo)-isomer; structure		2.0610hexose
alpha-ketobutyric acid
alpha-ketobutyric acid: RN given refers to parent cpd; structure. 2-oxobutanoic acid : A 2-oxo monocarboxylic acid that is the 2-oxo derivative of butanoic acid.		8.06502-oxo monocarboxylic acid;
short-chain fatty acid
2-phosphoglycerate
2-phosphoglycerate: RN given refers to cpd without isomeric designation. 2-phosphoglyceric acid : A monophosphoglyceric acid having the phospho group at the 2-position.		2.4120monophosphoglyceric acid;
tetronic acid derivative
2,3-diphosphoglycerate
2,3-Diphosphoglycerate: A highly anionic organic phosphate which is present in human red blood cells at about the same molar ratio as hemoglobin. It binds to deoxyhemoglobin but not the oxygenated form, therefore diminishing the oxygen affinity of hemoglobin. This is essential in enabling hemoglobin to unload oxygen in tissue capillaries. It is also an intermediate in the conversion of 3-phosphoglycerate to 2-phosphoglycerate by phosphoglycerate mutase (EC 5.4.2.1). (From Stryer Biochemistry, 4th ed, p160; Enzyme Nomenclature, 1992, p508). 2,3-bisphosphoglyceric acid : A bisphosphoglyceric acid that is glyceric acid carrying two phospho substituents at positions 2 and 3.		2.3920bisphosphoglyceric acid;
tetronic acid derivative		human metabolite
2-keto-4-methylvalerate
alpha-ketoisocaproic acid: RN given refers to parent cpd. 4-methyl-2-oxopentanoate : A 2-oxo monocarboxylic acid anion that is the conjugate base of 4-methyl-2-oxopentanoic acid.. 4-methyl-2-oxopentanoic acid : A 2-oxo monocarboxylic acid that is pentanoic acid (valeric acid) substituted with a keto group at C-2 and a methyl group at C-4. A metabolite that has been found to accumulate in maple syrup urine disease.		2.36202-oxo monocarboxylic acid;
branched-chain keto acid		algal metabolite;
human metabolite
3-chloroalanine
3-chloroalanine: RN given refers to parent cpd without isomeric designation. 3-chloroalanine : A chloroalanine obtained by replacement of one of the methyl hydrogens of alanine by a chloro group.		3.69100chloroalanine;
non-proteinogenic alpha-amino acid;
organochlorine compound
5-enolpyruvoylshikimate-3-phosphate
5-enolpyruvoylshikimate-3-phosphate: structure given in first source		2.0410
3-hydroxyanthranilic acid
3-Hydroxyanthranilic Acid: An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.. 3-hydroxyanthranilic acid : An aminobenzoic acid that is benzoic acid substituted at C-2 by an amine group and at C-3 by a hydroxy group. It is an intermediate in the metabolism of the amino acid tryptophan.. 3-hydroxyanthranilate : A hydroxybenzoate that is the conjugate base of 3-hydroxyanthranilic acid.		3.0310aminobenzoic acid;
monohydroxybenzoic acid		human metabolite;
mouse metabolite
3-hydroxykynurenine
3-hydroxykynurenine: RN given refers to cpd without isomeric designation. 3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.. hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.		3.4220hydroxykynureninehuman metabolite
acetoacetic acid
acetoacetic acid : A 3-oxo monocarboxylic acid that is butyric acid bearing a 3-oxo substituent.		3.14503-oxo fatty acid;
ketone body		metabolite
phosphoserine
Phosphoserine: The phosphoric acid ester of serine.		10.453400non-proteinogenic alpha-amino acid;
O-phosphoamino acid;
serine derivative		human metabolite
cysteine sulfinic acid
cysteine sulfinic acid: metabolite of sulfur-containing amino acids		2.3820
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		8.91040amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
4-hydroxyphenylacetic acid
4-hydroxyphenylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 4-hydroxyphenyl group.		1.9610monocarboxylic acid;
phenols		fungal metabolite;
human metabolite;
mouse metabolite;
plant metabolite
4-hydroxybenzoic acid
4-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.		2.4120monohydroxybenzoic acidalgal metabolite;
plant metabolite
aminolevulinic acid
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.		3.08504-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
5-hydroxytryptophan
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.. 5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.		4.92120hydroxytryptophanhuman metabolite;
neurotransmitter
ethylene glycol
Ethylene Glycol: A colorless, odorless, viscous dihydroxy alcohol. It has a sweet taste, but is poisonous if ingested. Ethylene glycol is the most important glycol commercially available and is manufactured on a large scale in the United States. It is used as an antifreeze and coolant, in hydraulic fluids, and in the manufacture of low-freezing dynamites and resins.. ethanediol : Any diol that is ethane or substituted ethane carrying two hydroxy groups.. ethylene glycol : A 1,2-glycol compound produced via reaction of ethylene oxide with water.		2.5320ethanediol;
glycol		metabolite;
mouse metabolite;
solvent;
toxin
acetic acid
Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.		8.96130monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
acetaldehyde
Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.. acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.. aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.. acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.		10.25170aldehydecarcinogenic agent;
EC 3.5.1.4 (amidase) inhibitor;
electron acceptor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
mutagen;
oxidising agent;
Saccharomyces cerevisiae metabolite;
teratogenic agent
acetoin
[no description available]		2.2510methyl ketone;
secondary alpha-hydroxy ketone		metabolite
acetone
methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).		4.15170ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
acetyl phosphate
acetyl dihydrogen phosphate : An acyl monophosphate in which the acyl group specified is acetyl.		1.9910acyl monophosphateEscherichia coli metabolite;
human metabolite;
mouse metabolite
adenine
[no description available]		7.38206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
adipic acid
adipic acid : An alpha,omega-dicarboxylic acid that is the 1,4-dicarboxy derivative of butane.		2.0510alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		food acidity regulator;
human xenobiotic metabolite
allantoin
[no description available]		2.6530imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary
ammonium hydroxide
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.		7.551070azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant
anthranilic acid
anthranilic acid: RN given refers to parent cpd; structure in Negwer, 5th ed, #565. anthranilic acid : An aminobenzoic acid that is benzoic acid having a single amino substituent located at position 2. It is a metabolite produced in L-tryptophan-kynurenine pathway in the central nervous system.		2.7430aminobenzoic acidhuman metabolite;
mouse metabolite
arsenic acid
arsenic acid: RN given refers to orthoarsenic acid(H3AsO4); see also sodium arsenate. arsenic acid : An arsenic oxoacid comprising one oxo group and three hydroxy groups attached to a central arsenic atom.		2.4220arsenic oxoacidEscherichia coli metabolite
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		1.9710acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
beta-alanine
[no description available]		4.91360amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
benzaldehyde
[no description available]		2.7130benzaldehydesEC 3.1.1.3 (triacylglycerol lipase) inhibitor;
EC 3.5.5.1 (nitrilase) inhibitor;
flavouring agent;
fragrance;
odorant receptor agonist;
plant metabolite
benzene
[no description available]		3.0950aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
benzoic acid
Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.		3.2460benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
benzyl alcohol
Benzyl Alcohol: A colorless liquid with a sharp burning taste and slight odor. It is used as a local anesthetic and to reduce pain associated with LIDOCAINE injection. Also, it is used in the manufacture of other benzyl compounds, as a pharmaceutic aid, and in perfumery and flavoring.. hydroxytoluene : Any member of the class of toluenes carrying one or more hydroxy substituents.. benzyl alcohol : An aromatic alcohol that consists of benzene bearing a single hydroxymethyl substituent.. aromatic alcohol : Any alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.. aromatic primary alcohol : Any primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.		2.0210benzyl alcoholsantioxidant;
fragrance;
metabolite;
solvent
betaine
glycine betaine : The amino acid betaine derived from glycine.		5.79350amino-acid betaine;
glycine derivative		fundamental metabolite
bis(4-nitrophenyl)phosphate
bis(4-nitrophenyl)phosphate: RN given refers to parent cpd		2.4420aryl phosphate
bromide
Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)		2.6730halide anion;
monoatomic bromine
1-butanol
1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.		3.86120alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent
butyric acid
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.		2.4110fatty acid 4:0;
straight-chain saturated fatty acid		human urinary metabolite;
Mycoplasma genitalium metabolite
cadaverine
[no description available]		2.3820alkane-alpha,omega-diamineDaphnia magna metabolite;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite
carbamates
[no description available]		10.77290amino-acid anion
carbamyl phosphate
Carbamyl Phosphate: The monoanhydride of carbamic acid with PHOSPHORIC ACID. It is an important intermediate metabolite and is synthesized enzymatically by CARBAMYL-PHOSPHATE SYNTHASE (AMMONIA) and CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING).		210acyl monophosphate;
one-carbon compound		Escherichia coli metabolite;
mouse metabolite
carbon monoxide
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed). carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.		6.07160carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent
formic acid
formic acid: RN given refers to parent cpd. formic acid : The simplest carboxylic acid, containing a single carbon. Occurs naturally in various sources including the venom of bee and ant stings, and is a useful organic synthetic reagent. Principally used as a preservative and antibacterial agent in livestock feed. Induces severe metabolic acidosis and ocular injury in human subjects.		13.37520monocarboxylic acidantibacterial agent;
astringent;
metabolite;
protic solvent;
solvent
aminooxyacetic acid
Aminooxyacetic Acid: A compound that inhibits aminobutyrate aminotransferase activity in vivo, thereby raising the level of gamma-aminobutyric acid in tissues.. (aminooxy)acetic acid : A member of the class of hydroxylamines that is acetic acid substituted at postion 2 by an aminooxy group. It is a compound which inhibits aminobutyrate aminotransferase activity in vivo, resulting in increased levels of gamma-aminobutyric acid in tissues.		8.0950amino acid;
hydroxylamines;
monocarboxylic acid		anticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
nootropic agent
carnitine
[no description available]		4.99120amino-acid betainehuman metabolite;
mouse metabolite
catechol
[no description available]		440catecholsallelochemical;
genotoxin;
plant metabolite
methane
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).		7.4340alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
choline
[no description available]		10.152220cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
aconitic acid
Aconitic Acid: A tricarboxylic acid with the formula (COOH)-CH2-C(COOH)=CH-COOH.. aconitic acid : A tricarboxylic acid that is prop-1-ene substituted by carboxy groups at positions 1, 2 and 3.		2.420tricarboxylic acid
citric acid, anhydrous
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.		4.98120tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		7.37580halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
hydrochloric acid
Hydrochloric Acid: A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE.. hydrogen chloride : A mononuclear parent hydride consisting of covalently bonded hydrogen and chlorine atoms.		3.84120chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite
coumarin
2H-chromen-2-one: coumarin derivative		8.3510coumarinsfluorescent dye;
human metabolite;
plant metabolite
cuminaldehyde
cuminaldehyde : A member of the class of benzaldehydes that is benzaldehyde substituted by an isopropyl group at position 4. It is a component of essential oils from Cumin and exhibits insecticidal activities.		2.4110benzaldehydesinsecticide;
plant metabolite;
volatile oil component
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		8.93120monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
octane
Octanes: Eight-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives.. octane : A straight chain alkane composed of 8 carbon atoms.		2.0510alkanexenobiotic
phloroglucinol
Phloroglucinol: A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.. phloroglucinol : A benzenetriol with hydroxy groups at position 1, 3 and 5.		2.9140benzenetriol;
phenolic donor		algal metabolite
2,3-diaminopropionic acid
3-aminoalanine : A diamino acid that is alanine in which one of the hydrogens of the methyl group is replaced by an amino group.		8.2960alanine derivative;
amino acid zwitterion;
beta-amino acid;
diamino acid;
non-proteinogenic alpha-amino acid		Escherichia coli metabolite
gallic acid
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.		2.6830trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
4-nitrophenylphosphate
nitrophenylphosphate: RN given refers to mono(4-nitrophenyl) ester of phosphoric acid. 4-nitrophenyl phosphate : An aryl phosphate resulting from the mono-esterification of phosphoric acid with 4-nitrophenol.		210aryl phosphatemouse metabolite
octanoic acid
octanoic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #1764. octanoic acid : A straight-chain saturated fatty acid that is heptane in which one of the hydrogens of a terminal methyl group has been replaced by a carboxy group. Octanoic acid is also known as caprylic acid.		4.7490medium-chain fatty acid;
straight-chain saturated fatty acid		antibacterial agent;
Escherichia coli metabolite;
human metabolite
hydrogen sulfide
Hydrogen Sulfide: A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed). hydrogen sulfide : A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.. thiol : An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.		6.65280gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride		Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent
nornicotine
nornicotine: agricultural or horticultural insecticide; RN given refers to (+-)-isomer; structure		2.0810
dihydrolipoic acid
dihydrolipoic acid: RN given refers to parent cpd without isomeric designation. dihydrolipoic acid : A thio-fatty acid that is reduced form of lipoic acid. A potent antioxidant shown to directly destroy superoxide, hydroperoxy and hydroxyl radicals; also has neuroprotective and anti-tumour effects.. dihydrolipoate : The conjugate base of dihydrolipoic acid.		2.0110thio-fatty acidantioxidant;
human metabolite;
neuroprotective agent
3-hydroxybutyric acid
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.. 3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.		4.5770(omega-1)-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
hydroxybutyric acid		human metabolite
bupropion
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.		2.0310aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
hippuric acid
hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl.		4.0531N-acylglycinehuman blood serum metabolite;
uremic toxin
2-aminoadipic acid
2-Aminoadipic Acid: A metabolite in the principal biochemical pathway of lysine. It antagonizes neuroexcitatory activity modulated by the glutamate receptor, N-METHYL-D-ASPARTATE; (NMDA).. 2-aminoadipic acid : An alpha-amino acid that is adipic acid bearing a single amino substituent at position 2. An intermediate in the formation of lysine.		3.150amino dicarboxylic acid;
dicarboxylic fatty acid;
non-proteinogenic alpha-amino acid		Caenorhabditis elegans metabolite;
mammalian metabolite
2,4-diaminobutyric acid
2,4-diaminobutyric acid: RN given refers to parent cpd without isomeric designation. 2,4-diaminobutyric acid : A diamino acid that is butyric acid in which a hydrogen at position 2 and a hydrogen at position 4 are replaced by amino groups.		2.0610diamino acid;
gamma-amino acid;
non-proteinogenic alpha-amino acid
methylmalonic acid
Methylmalonic Acid: A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA.. methylmalonic acid : A dicarboxylic acid that is malonic acid in which one of the methylene hydrogens is substituted by a methyl group.		2.4220C4-dicarboxylic acidhuman metabolite
n(g),n(g')-dimethyl-l-arginine
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine		2.0510alpha-amino acid
malic acid
malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.		5.571302-hydroxydicarboxylic acid;
C4-dicarboxylic acid		food acidity regulator;
fundamental metabolite
propionaldehyde
propionaldehyde: may cause respiratory irritation; RN given refers to parent cpd; structure. propanal : An aldehyde that consists of ethane bearing a formyl substituent. The parent of the class of propanals.		2.4420alpha-CH2-containing aldehyde;
propanals		Escherichia coli metabolite
phosphoglycolate
phosphoglycolate: RN given refers to parent acid. 2-phosphoglycolic acid : The O-phospho derivative of glycolic acid.		2.9740carboxyalkyl phosphateEscherichia coli metabolite;
mouse metabolite
1-aminocyclopropane-1-carboxylic acid
1-aminocyclopropanecarboxylic acid : A non-proteinogenic alpha-amino acid consisting of cyclopropane having amino and carboxy substituents both at the 1-position.		2.6930amino acid zwitterion;
monocarboxylic acid;
non-proteinogenic alpha-amino acid		ethylene releasers;
plant metabolite
phosphonoacetic acid
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.. phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.		3.0950monocarboxylic acid;
phosphonic acids		antiviral agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
3,4-dihydroxyphenylacetic acid
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.		2.9240catechols;
dihydroxyphenylacetic acid		human metabolite
aminocaproic acid
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.		2.730amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
creatine
[no description available]		10.78170glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
cytosine
[no description available]		7.08420aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
alanylalanine
alanylalanine: RN given refers to (DL)-isomer		1.9710dipeptide
alanine
[no description available]		2.6830alpha-amino acid;
amino acid zwitterion		fundamental metabolite
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		14.195112-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
5,6-dihydroorotate
4,5-dihydroorotic acid: RN given refers to cpd without isomeric designation; structure. dihydroorotic acid : A pyrimidinemonocarboxylic acid that results from the base-catalysed cyclisation of N(alpha)-carbethoxyasparagine.		2.4220monocarboxylic acid;
N-acylurea;
pyrimidinemonocarboxylic acid;
secondary amide
diacetyl
butane-2,3-dione : An alpha-diketone that is butane substituted by oxo groups at positions 2 and 3. It is a metabolite produced during the malolactic fermentation.		2.0810alpha-diketoneEscherichia coli metabolite;
Saccharomyces cerevisiae metabolite
dihydroxyacetone phosphate
Dihydroxyacetone Phosphate: An important intermediate in lipid biosynthesis and in glycolysis.. dihydroxyacetone phosphate : A member of the class of glycerone phosphates that consists of glycerone bearing a single phospho substituent.		2.420glycerone phosphates;
primary alpha-hydroxy ketone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
dihydroxyacetone
[no description available]		9.1650ketotriose;
primary alpha-hydroxy ketone		antifungal agent;
Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
dimethylglycine
dimethylglycine: metabolic product of calcium pangamate; mutagen when mixed with nitrite; RN given refers to parent cpd. N,N-dimethylglycine : An N-methylglycine that is glycine carrying two N-methyl substituents.		2.5120amino acid zwitterion;
N-methyl-amino acid;
N-methylglycines		Daphnia magna metabolite;
human metabolite;
mouse metabolite
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		10.33180sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
ethanolamine
[no description available]		7.891060ethanolamines;
primary alcohol;
primary amine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		8.38810aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
formamide
formimidic acid : A carboximidic acid that is formic acid in which the carbonyl oxygen is replaced by an imino group.. primary carboxamide : A carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.		1.9910carboximidic acid;
formamides;
monocarboxylic acid amide;
one-carbon compound		solvent
3-phosphoglycerate
3-phosphoglycerate : An organic anion obtained by deprotonation of at least one of the acidic groups of 3-phosphoglyceric acid.		3.9120monophosphoglyceric acid;
tetronic acid derivative		algal metabolite;
fundamental metabolite
hexachlorocyclohexane
Lindane: An organochlorine insecticide made up of greater than 99% gamma-Hexachlorocyclohexane. It has been used as a pediculicide and scabicide, and shown to cause cancer.. beta-hexachlorocyclohexane : The beta-isomer of hexachlorocyclohexane.		210chlorocyclohexane
glycine
[no description available]		22.582,43729alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glyceraldehyde
Glyceraldehyde: An aldotriose containing the propionaldehyde structure with hydroxy groups at the 2- and 3-positions. It is involved in the formation of ADVANCED GLYCOSYLATION END PRODUCTS.. glyceraldehyde : An aldotriose comprising propanal having hydroxy groups at the 2- and 3-positions. It plays role in the formation of advanced glycation end-products (AGEs), a deleterious accompaniment to ageing.. aldose : Aldehydic parent sugars (polyhydroxy aldehydes H[CH(OH)]nC(=O)H, n >= 2) and their intramolecular hemiacetals.		5.29100aldotriosefundamental metabolite
glyceric acid
glyceric acid: found in urine of patient with D-glyceric acidemia & hyperglycinaemia; RN given refers to parent cpd without isomeric designation. glycerol ether : Any ether having glyceryl as at least one of the O-substituents.. glyceric acid : A trionic acid that consists of propionic acid substituted at positions 2 and 3 by hydroxy groups.		10.31100trionic acidfundamental metabolite
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		8.191440alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
alpha-glycerophosphoric acid
[no description available]		3.2660glycerol monophosphatealgal metabolite;
human metabolite
glycolaldehyde
[no description available]		2.6930glycolaldehydesfundamental metabolite;
human metabolite
glycolic acid
glycolic acid: RN given refers to parent cpd. glycolic acid : A 2-hydroxy monocarboxylic acid that is acetic acid where the methyl group has been hydroxylated.		9.931202-hydroxy monocarboxylic acid;
primary alcohol		keratolytic drug;
metabolite
glyoxylic acid
glyoxylic acid: RN given refers to parent cpd. glyoxylic acid : A 2-oxo monocarboxylic acid that is acetic acid bearing an oxo group at the alpha carbon atom.		5.111402-oxo monocarboxylic acid;
aldehydic acid		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glycocyamine
glycocyamine: RN given refers to parent cpd; structure. guanidinoacetate : A monocarboxylic acid anion that is the conjugate base of guanidinoacetic acid, obtained by deprotonation of the carboxy group.. guanidinoacetic acid : The N-amidino derivative of glycine.		3.1450guanidinoacetic acids;
zwitterion		bacterial metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
rat metabolite
carbonic acid
Carbonic Acid: Carbonic acid (H2C03). The hypothetical acid of carbon dioxide and water. It exists only in the form of its salts (carbonates), acid salts (hydrogen carbonates), amines (carbamic acid), and acid chlorides (carbonyl chloride). (From Grant & Hackh's Chemical Dictionary, 5th ed)		2.0110carbon oxoacid;
chalcocarbonic acid		mouse metabolite
hydrogen cyanide
Hydrogen Cyanide: Hydrogen cyanide (HCN); A toxic liquid or colorless gas. It is found in the smoke of various tobacco products and released by combustion of nitrogen-containing organic materials.. hydrogen cyanide : A one-carbon compound consisting of a methine group triple bonded to a nitrogen atom		2.6430hydracid;
one-carbon compound		Escherichia coli metabolite;
human metabolite;
poison
hydrogen carbonate
Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.		6.37320carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
histamine
[no description available]		6.22270aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		6.62680elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
hydroxylamine
amino alcohol : An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.		4.24180hydroxylaminesalgal metabolite;
bacterial xenobiotic metabolite;
EC 1.1.3.13 (alcohol oxidase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
nitric oxide donor;
nucleophilic reagent
imidazole
imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.		3.1250imidazole
indole
[no description available]		4.62270indole;
polycyclic heteroarene		Escherichia coli metabolite
indoleacetic acid
indoleacetic acid: RN given refers to unlabeled parent cpd; structure in Merck Index, 9th ed, #4841. auxin : Any of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").. indole-3-acetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1H-indol-3-yl group.		2.6730indole-3-acetic acids;
monocarboxylic acid		auxin;
human metabolite;
mouse metabolite;
plant hormone;
plant metabolite
iodine
Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..		10.25170diatomic iodinenutrient
itaconic acid
itaconic acid : A dicarboxylic acid that is methacrylic acid in which one of the methyl hydrogens is substituted by a carboxylic acid group.		2.0710dicarboxylic acid;
dicarboxylic fatty acid;
olefinic compound		fungal metabolite;
human metabolite
2-keto-3-deoxyoctonate
[no description available]		2.3110
dihydroxyphenylalanine
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.		13.75631hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative		human metabolite
kynurenine
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.. kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.		10.5480aromatic ketone;
non-proteinogenic alpha-amino acid;
substituted aniline		human metabolite
pipecolic acid
pipecolic acid: RN given refers to cpd without isomeric designation. pipecolic acid : A piperidinemonocarboxylic acid in which the carboxy group is located at position C-2.. pipecolate : A piperidinecarboxylate that is the conjugate base of pipecolic acid.		2.0510piperidinemonocarboxylic acid
thioctic acid
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.		3.3970dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
malonic acid
malonic acid : An alpha,omega-dicarboxylic acid in which the two carboxy groups are separated by a single methylene group.. dicarboxylic acid : Any carboxylic acid containing two carboxy groups.		2.9640alpha,omega-dicarboxylic acidhuman metabolite
racemethionine
Racemethionine: A preparation of METHIONINE that includes a mixture of D-methionine and L-methionine isomers.		4.6831alpha-amino acid;
amino acid zwitterion;
sulfur-containing amino acid		algal metabolite;
Daphnia magna metabolite;
Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
methylmercaptan
methylmercaptan: intermediate in the manufacturing of jet fuels, pesticides, fungicides, plastics, synthesis of methionine; odor may cause nausea; narcotic in high concentrations; depresses urea biosynthesis; RN given refers to parent cpd; structure		3.4920alkanethiolhuman metabolite;
Saccharomyces cerevisiae metabolite
pyruvaldehyde
Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.. methylglyoxal : A 2-oxo aldehyde derived from propanal.		3.04402-oxo aldehyde;
propanals		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		7.78510alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
phytic acid
Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.. myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.		2.7130inositol phosphate
inositol
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.		7.02620cyclitol;
hexol
melatonin
[no description available]		10.33170acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
n'-acetylspermine
N(1)-acetylspermine : An acetylspermine carrying an acetyl group at position N(1).		2.110acetamides;
acetylspermine		human metabolite
nickel
Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.		4.72300metal allergen;
nickel group element atom		epitope;
micronutrient
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		4.24180pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		3.77110pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
nitrates
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.		5.95350monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
nitric acid
Nitric Acid: Nitric acid (HNO3). A colorless liquid that is used in the manufacture of inorganic and organic nitrates and nitro compounds for fertilizers, dye intermediates, explosives, and many different organic chemicals. Continued exposure to vapor may cause chronic bronchitis; chemical pneumonitis may occur. (From Merck Index, 11th ed). nitric acid : A nitrogen oxoacid of formula HNO3 in which the nitrogen atom is bonded to a hydroxy group and by equivalent bonds to the remaining two oxygen atoms.		2.0210nitrogen oxoacidprotic solvent;
reagent
nitrites
Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)		5.19190monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
nitrous oxide
Nitrous Oxide: Nitrogen oxide (N2O). A colorless, odorless gas that is used as an anesthetic and analgesic. High concentrations cause a narcotic effect and may replace oxygen, causing death by asphyxia. It is also used as a food aerosol in the preparation of whipping cream.. dinitrogen oxide : A nitrogen oxide consisting of linear unsymmetrical molecules with formula N2O. While it is the most used gaseous anaesthetic in the world, its major commercial use, due to its solubility under pressure in vegetable fats combined with its non-toxicity in low concentrations, is as an aerosol spray propellant and aerating agent for canisters of 'whipped' cream.		6.3380gas molecular entity;
nitrogen oxide		analgesic;
bacterial metabolite;
food packaging gas;
food propellant;
general anaesthetic;
greenhouse gas;
inhalation anaesthetic;
NMDA receptor antagonist;
raising agent;
refrigerant;
vasodilator agent
hydroxide ion
[no description available]		3.2860oxygen hydridemouse metabolite
hydroxypyruvic acid
hydroxypyruvic acid: RN given refers to parent cpd. 3-hydroxypyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a hydroxy group. It is an intermediate involved in the glycine and serine metabolism.		3.39702-oxo monocarboxylic acid;
3-hydroxy monocarboxylic acid;
primary alpha-hydroxy ketone		Escherichia coli metabolite;
human metabolite
orotic acid
Orotic Acid: An intermediate product in PYRIMIDINE synthesis which plays a role in chemical conversions between DIHYDROFOLATE and TETRAHYDROFOLATE.. orotic acid : A pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6.		4.09160pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite
oxaloacetic acid
Oxaloacetic Acid: A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE.. oxaloacetic acid : An oxodicarboxylic acid that is succinic acid bearing a single oxo group.		3.0640C4-dicarboxylic acid;
oxo dicarboxylic acid		geroprotector;
metabolite
oxalic acid
Oxalic Acid: A strong dicarboxylic acid occurring in many plants and vegetables. It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. It is used as an analytical reagent and general reducing agent.. oxalic acid : An alpha,omega-dicarboxylic acid that is ethane substituted by carboxyl groups at positions 1 and 2.		2.6630alpha,omega-dicarboxylic acidalgal metabolite;
human metabolite;
plant metabolite
oxamic acid
Oxamic Acid: Amino-substituted glyoxylic acid derivative.. oxamic acid : A dicarboxylic acid monoamide resulting from the formal condensation of one of the carboxy groups of oxalic acid with ammonia.		1.9510dicarboxylic acid monoamideEscherichia coli metabolite
4-aminobenzoic acid
4-Aminobenzoic Acid: An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS.. 4-ammoniobenzoate : A zwitterion obtained by transfer of a proton from the carboxy to the amino group of 4-aminobenzoic acid.. 4-aminobenzoic acid : An aminobenzoic acid in which the amino group is para to the carboxy group.		2.6730aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
4-hydroxyphenylpyruvic acid
4-hydroxyphenylpyruvic acid: RN given refers to parent cpd. 4-hydroxyphenylpyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a 4-hydroxyphenyl group.		2.02102-oxo monocarboxylic acid;
phenols		human metabolite
4-nitrophenol
4-nitrophenol: RN given refers to parent cpd. mononitrophenol : A nitrophenol that is phenol carrying a single nitro substituent at unspecified position.. 4-nitrophenol : A member of the class of 4-nitrophenols that is phenol in which the hydrogen that is para to the hydroxy group has been replaced by a nitro group.		1.99104-nitrophenolshuman xenobiotic metabolite;
mouse metabolite
palmitic acid
Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.		6.45560long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite
parathion
[no description available]		1.9510C-nitro compound;
organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
avicide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
mouse metabolite
pentachlorophenol
PENTA: structure given in first source		1.9510aromatic fungicide;
chlorophenol;
organochlorine pesticide;
pentachlorobenzenes		human xenobiotic metabolite
phenol
[no description available]		2.3920phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
phenethylamine
phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016. 2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position.		2.3110alkaloid;
aralkylamine;
phenylethylamine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
phosphoric acid
phosphoric acid: concise etchant is 37% H3PO4. phosphoric acid : A phosphorus oxoacid that consists of one oxo and three hydroxy groups joined covalently to a central phosphorus atom.		3.0750phosphoric acidsalgal metabolite;
fertilizer;
human metabolite;
NMR chemical shift reference compound;
solvent
phosphoenolpyruvate
Phosphoenolpyruvate: A monocarboxylic acid anion derived from selective deprotonation of the carboxy group of phosphoenolpyruvic acid. It is a metabolic intermediate in GLYCOLYSIS; GLUCONEOGENESIS; and other pathways.. phosphoenolpyruvate : A monocarboxylic acid anion resuting from selective deprotonation of the carboxy group of phosphoenolpyruvic acid.. phosphoenolpyruvic acid : A monocarboxylic acid that is acrylic acid substituted by a phosphonooxy group at position 2. It is a metabolic intermediate in pathways like glycolysis and gluconeogenesis.		3.92130carboxyalkyl phosphate;
monocarboxylic acid		fundamental metabolite
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		8.89120phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
phosphorylethanolamine
phosphorylethanolamine: RN given refers to parent cpd; structure. O-phosphoethanolamine : The ethanolamine mono-ester of phosphoric acid, and a metabolite of phospholipid metabolism. This phosphomonoester shows strong structural similarity to the inhibitory neurotransmitter GABA, and is decreased in post-mortem Alzheimer's disease brain.		3.85120phosphoethanolamine;
primary amino compound		algal metabolite;
human metabolite;
mouse metabolite
phthalic acid
phthalic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7178. phthalic acid : A benzenedicarboxylic acid cosisting of two carboxy groups at ortho positions.		2.2510benzenedicarboxylic acidhuman xenobiotic metabolite
picolinic acid
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206. picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.		2.0610pyridinemonocarboxylic acidhuman metabolite;
MALDI matrix material
porphobilinogen
[no description available]		2.3720aralkylamino compound;
dicarboxylic acid;
pyrroles		Escherichia coli metabolite;
metabolite;
mouse metabolite
pqq cofactor
PQQ Cofactor: A pyrrolo-quinoline having two adjacent keto-groups at the 4 and 5 positions and three acidic carboxyl groups. It is a coenzyme of some DEHYDROGENASES.. pyrroloquinoline quinone : A pyrroloquinoline having oxo groups at the 4- and 5-positions and carboxy groups at the 2-, 7- and 9-positions.		2.9240orthoquinones;
pyrroloquinoline cofactor;
tricarboxylic acid		anti-inflammatory agent;
antioxidant;
cofactor;
water-soluble vitamin (role)
propylene glycol
Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.		1.9710glycol;
propane-1,2-diols		allergen;
human xenobiotic metabolite;
mouse metabolite;
protic solvent
1-propanol
1-Propanol: A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.. propan-1-ol : The parent member of the class of propan-1-ols that is propane in which a hydrogen of one of the methyl groups is replaced by a hydroxy group.		3.0750propan-1-ols;
short-chain primary fatty alcohol		metabolite;
protic solvent
propionic acid
propionic acid : A short-chain saturated fatty acid comprising ethane attached to the carbon of a carboxy group.		3.1350saturated fatty acid;
short-chain fatty acid		antifungal drug
pteridines
[no description available]		3.67100azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
pteridines
purine
1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.		5.88190purine
putrescine
[no description available]		3.68100alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
pyrazinamide
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.		2.3520monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
pyrazole
1H-pyrazole : The 1H-tautomer of pyrazole.		2.0210pyrazole
pyridine
azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.		7.6730azaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines		environmental contaminant;
NMR chemical shift reference compound
pyridoxal
[no description available]		5.3180hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxal phosphate
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).. pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.		10.632210methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxamine
[no description available]		2.6630aminoalkylpyridine;
hydroxymethylpyridine;
monohydroxypyridine;
vitamin B6		Escherichia coli metabolite;
human metabolite;
iron chelator;
mouse metabolite;
nephroprotective agent;
plant metabolite;
Saccharomyces cerevisiae metabolite
pyridoxamine phosphate
pyridoxamine phosphate: RN given refers to parent cpd; structure. pyridoxamine 5'-phosphate : A vitamin B6 phosphate that is the phosphoric ester derivative of pyridoxamine.		1.9910aminoalkylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6 phosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxine
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).		8.03490hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxine 5-phosphate
pyridoxine 5-phosphate: RN given refers to parent cpd		2.3820vitamin B6 phosphateEscherichia coli metabolite;
mouse metabolite
pyrogallol
benzenetriol : A triol in which three hydroxy groups are substituted onto a benzene ring.		2.420benzenetriol;
phenolic donor		plant metabolite
pyruvic acid
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.		7.176902-oxo monocarboxylic acidcofactor;
fundamental metabolite
quinolinic acid
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.. pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.. quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.		2.9440pyridinedicarboxylic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite;
NMDA receptor agonist
thiosulfates
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.. thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.		5.26170divalent inorganic anion;
sulfur oxide;
sulfur oxoanion		human metabolite
dithionite
Dithionite: Dithionite. The dithionous acid ion and its salts.		3.2560sulfur oxide;
sulfur oxoanion
sarcosine
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis		11.82574N-alkylglycine zwitterion;
N-alkylglycine;
N-methyl-amino acid;
N-methylglycines		Escherichia coli metabolite;
glycine receptor agonist;
glycine transporter 1 inhibitor;
human metabolite;
mouse metabolite
selenic acid
Selenic Acid: A strong dibasic acid with the molecular formula H2SeO4. Included under this heading is the acid form, and inorganic salts of dihydrogen selenium tetraoxide.		2.4110selenium oxoacid
selenious acid
Selenious Acid: A selenium compound with the molecular formula H2SO3. It used as a source of SELENIUM, especially for patients that develop selenium deficiency following prolonged PARENTERAL NUTRITION.		2.6930selenium oxoacid
sulfites
Sulfites: Inorganic salts of sulfurous acid.. sulfites : Any sulfurous acid derivative that is a salt or an ester of sulfurous acid.. organosulfonate oxoanion : An organic anion obtained by deprotonation of the sufonate group(s) of any organosulfonic acid.. sulfite : A sulfur oxoanion that is the conjugate base of hydrogen sulfite (H2SO3).		4.63280divalent inorganic anion;
sulfur oxide;
sulfur oxoanion
spermidine
[no description available]		3.92130polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		4.37210polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
succinic acid
Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.		4.05140alpha,omega-dicarboxylic acid;
C4-dicarboxylic acid		anti-ulcer drug;
fundamental metabolite;
micronutrient;
nutraceutical;
radiation protective agent
sulfur dioxide
Sulfur Dioxide: A highly toxic, colorless, nonflammable gas. It is used as a pharmaceutical aid and antioxidant. It is also an environmental air pollutant.		1.9510sulfur oxideEscherichia coli metabolite;
food bleaching agent;
refrigerant
taurine
[no description available]		11.711352amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
thiamine
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.		9.35210primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thymine
[no description available]		6.79490pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
toluene
methylbenzene : Any alkylbenzene that is benzene substituted with one or more methyl groups.		9.4220methylbenzene;
toluenes;
volatile organic compound		cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent
trimethyloxamine
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure. trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.		4.1660tertiary amine oxideEscherichia coli metabolite;
metabolite;
osmolyte
trimethylamine
[no description available]		710methylamines;
tertiary amine		Escherichia coli metabolite;
human xenobiotic metabolite
tryptamine
[no description available]		6.9910aminoalkylindole;
aralkylamino compound;
indole alkaloid;
tryptamines		human metabolite;
mouse metabolite;
plant metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		9.88360pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
uric acid
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.		6.25200uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		9.891261isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
xanthine
7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.		2.4120xanthineSaccharomyces cerevisiae metabolite
isocitric acid
isocitric acid: RN given refers to unlabeled parent cpd. isocitric acid : A tricarboxylic acid that is propan-1-ol with a hydrogen at each of the 3 carbon positions replaced by a carboxy group.		2.7130secondary alcohol;
tricarboxylic acid		fundamental metabolite
2-amino-5-phosphonovalerate
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.		4.7280non-proteinogenic alpha-amino acidNMDA receptor antagonist
sk&f 81297
[no description available]		2.0210benzazepine
7-hydroxy-2-n,n-dipropylaminotetralin
7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation		210tetralins
8-hydroxy-2-(di-n-propylamino)tetralin
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively		2.3110phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.		4.1150non-proteinogenic alpha-amino acid
sk&f 82958
[no description available]		2.4120benzazepine
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist		3.77110
4-iodo-2,5-dimethoxyphenylisopropylamine
4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist. 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.		2.4320amphetamines;
dimethoxybenzene;
organoiodine compound
1-hydroxy-3-amino-2-pyrrolidone
1-hydroxy-3-amino-2-pyrrolidone: a CNS depressant; structure in first source		3.99140
ibotenic acid
Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.		8.3770non-proteinogenic alpha-amino acidneurotoxin
normetanephrine
Normetanephrine: A methylated metabolite of norepinephrine that is excreted in the urine and found in certain tissues. It is a marker for tumors.		4.5861catecholamine
sk&f-38393
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.. 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.. SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393		3.2760benzazepine;
catechols;
secondary amino compound
vanilmandelic acid
Vanilmandelic Acid: A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE.. vanillylmandelic acid : An aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid.		1.94102-hydroxy monocarboxylic acid;
aromatic ether;
phenols		human metabolite
(alpha-carboxycyclopropyl)glycine
(alpha-carboxycyclopropyl)glycine: structure given in first source; glutamate receptor agonist		2.0210alpha-amino acid
mandelic acid
SAMMA: mandelic acid condensation polymer		7.36202-hydroxy monocarboxylic acid;
benzenes		antibacterial agent;
human xenobiotic metabolite
1,10-phenanthroline
1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases		7.9340phenanthrolineEC 2.7.1.1 (hexokinase) inhibitor;
EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
1,2-dioctanoylglycerol
1,2-dioctanoylglycerol: functions as bioregulator of protein kinase C in human platelets		2.6830
1,3-dipropyl-8-cyclopentylxanthine
DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.		2.7430oxopurineadenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.		4.341monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		7.24750aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.		4.3760methylpyridines;
phenylpyridine;
tetrahydropyridine		neurotoxin
1-methylimidazole
1-methyl-1H-imidazole : A 1H-imidazole having a methyl substituent at the N-1 position.		210imidazoles
edelfosine
edelfosine: RN given refers to parent cpd. edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.. 1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.		2.4120glycerophosphocholine
14,15-epoxy-5,8,11-eicosatrienoic acid
14,15-epoxy-5,8,11-eicosatrienoic acid: RN given refers to cpd without isomeric designation		2.0310long-chain fatty acid
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one: structure given in first source; inhibits guanylyl cyclase. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one : A member of the class of oxadiazoloquinoxalines that is 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline substituted at position 1 by an oxo group.		3.2860oxadiazoloquinoxalineEC 4.6.1.2 (guanylate cyclase) inhibitor
2,2'-dipyridyl
2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.		3.0750bipyridinechelator;
ferroptosis inhibitor
2,4-dichlorophenoxyacetic acid
2,4-Dichlorophenoxyacetic Acid: An herbicide with irritant effects on the eye and the gastrointestinal system.. 2,4-D : A chlorophenoxyacetic acid that is phenoxyacetic acid in which the ring hydrogens at postions 2 and 4 are substituted by chlorines.		2.4620chlorophenoxyacetic acid;
dichlorobenzene		agrochemical;
defoliant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
environmental contaminant;
phenoxy herbicide;
synthetic auxin
2,4-dinitrophenol
2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.		2.3920dinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor
mercaptoethanol
Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.		4.78330alkanethiol;
primary alcohol		geroprotector
3,4-dichloroisocoumarin
3,4-dichloroisocoumarin : A member of the class of isocoumarins that is isocoumarin substituted by chloro groups at positions 3 and 4. It is a serine protease inhibitor.		1.9810isocoumarins;
organochlorine compound		geroprotector;
serine protease inhibitor
zopolrestat
zopolrestat: structure given in first source		2.0410
n-methyl-3,4-methylenedioxyamphetamine
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.. 3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.		2.0710amphetamines;
benzodioxoles		neurotoxin
amitrole
Amitrole: A non-selective post-emergence, translocated herbicide. According to the Seventh Annual Report on Carcinogens (PB95-109781, 1994) this substance may reasonably be anticipated to be a carcinogen. (From Merck Index, 12th ed) It is an irreversible inhibitor of CATALASE, and thus impairs activity of peroxisomes.. amitrole : A member of the class of triazoles that is 1H-1,2,4-triazole substituted by an amino group at position 3. Used to control annual grasses and aquatic weeds (but not on food crops because it causes cancer in laboratory animals). Its use within the EU was banned from September 2017 on the grounds of potential groundwater contamination and risks to aquatic life; there have also been concerns about its endocrine-disrupting properties.		2.3820aromatic amine;
triazoles		carotenoid biosynthesis inhibitor;
EC 1.11.1.6 (catalase) inhibitor;
herbicide
tramiprosate
tramiprosate: GABA receptor agonist and a glycosaminoglycan mimetic; has nootropic acitivity; structure; a sulfonate analog of GABA. 3-aminopropanesulfonic acid : An amino sulfonic acid that is the 3-amino derivative of propanesulfonic acid.		2.0610amino sulfonic acid;
zwitterion		algal metabolite;
anti-inflammatory agent;
anticonvulsant;
GABA agonist;
nootropic agent
3-methylcholanthrene
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.		1.9510ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
3-nitropropionic acid
3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.		2.0510C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin
4,5,6,7-tetrabromo-2-azabenzimidazole
4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor		3.1250
4-(2-aminoethyl)benzenesulfonylfluoride
[no description available]		3.0130
(4-amidinophenyl)methanesulfonyl fluoride
[no description available]		2.3720
4-aminopyridine
[no description available]		3.360aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker
p-chloromercuribenzoic acid
p-Chloromercuribenzoic Acid: An organic mercurial used as a sulfhydryl reagent.		3.1150chlorine molecular entity;
mercuribenzoic acid
chlorocresol
chlorocresol: injections for relief of intractable pain; RN given refers to parent cpd. 4-chloro-m-cresol : A hydroxytoluene that is 3-methylphenol which is substituted by a chlorine at position 4. A ryanodine receptor agonist.		2.0310hydroxytoluene;
monochlorobenzenes		antimicrobial agent;
disinfectant;
ryanodine receptor agonist
4-diphenylacetoxy-1,1-dimethylpiperidinium
4-diphenylacetoxy-1,1-dimethylpiperidinium: muscarinic receptor antagonist; RN given refers to parent cpd; do not confuse abbreviation 4-DAMP with a similar cpd which does not contain dimethyl groups. 4-DAMP(1+) : A quaternary ammonium salt obtained by formal methylation of the tertiary amino function of 4-diphenylacetoxy-N-methylpiperidine.		2.0110quaternary ammonium ioncholinergic antagonist;
muscarinic antagonist
homovanillic acid
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.		8.2360guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
phenytoin
[no description available]		7.8640imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
5,7-dichlorokynurenic acid
5,7-dichlorokynurenic acid: potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site		4.02140quinolines
5,8,11-eicosatriynoic acid
5,8,11-eicosatriynoic acid: a lipoxygenase inhibitor. 5,8,11-icosatriynoic acid : A C20 polyunsaturated fatty acid having three triple bonds in the 5-, 8- and 11-positions.		1.9510acetylenic fatty acid;
icosanoid;
long-chain fatty acid;
polyunsaturated fatty acid		EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor
ethylisopropylamiloride
ethylisopropylamiloride: structure in first source. ethylisopropylamiloride : A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group.		2.0210aromatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound		anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker
5-carboxamidotryptamine
5-carboxamidotryptamine: agonist of 5-HT receptor; structure given in first source		1.9910tryptamines
hydroxyindoleacetic acid
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.		3.2160indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
5-methoxytryptamine
5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.. 5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.		3.4820aromatic ether;
primary amino compound;
tryptamines		5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist
7-chlorokynurenic acid
7-chlorokynurenic acid: selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex; structure given in first source. 7-chlorokynurenic acid : A quinolinemonocarboxylic acid that is quinaldic acid which is substituted by a hydroxy group at position 4 and by a chlorine at position 7. It is a potent NMDA glutamate receptor antagonist which antagonizes the strychnine-insensitive glycine site of the NMDA receptor. It also prevents neurodegeneration produced by quinolinic acid.		9.9360organochlorine compound;
quinolinemonocarboxylic acid		neuroprotective agent;
NMDA receptor antagonist
7-nitroindazole
7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure		3.1650
8-(4-sulfophenyl)theophylline
8-(4-sulfophenyl)theophylline: adenosine antagonist		2.0310
8-cyclopentyl-1,3-dimethylxanthine
8-cyclopentyl-1,3-dimethylxanthine: prolongs epileptic seizures in rats		2.0810oxopurine
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		2.0110acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
2,2'-azobis(2-amidinopropane)
2,2'-azobis(2-amidinopropane): water-soluble free-radical initiator		2.110monoazo compound
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		3.4270acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetohydroxamic acid
acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.		2.0510acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
acetyl-dl-leucine
acetylleucine: used for treating vestibular-related imbalance and vertigo		1.9910leucine derivative;
N-acetyl-amino acid
n-acetylphenylalanine
N-acetylphenylalanine: RN given refers to (DL)-isomer. N-acetylphenylalanine : The N-acetyl derivative of phenylalanine.		1.9710N-acetyl-amino acid;
phenylalanine derivative		antidepressant;
metabolite
beta-aminoethyl isothiourea
beta-Aminoethyl Isothiourea: A radiation-protective agent that can inhibit DNA damage by binding to the DNA. It also increases the susceptibility of blood cells to complement-mediated lysis.		4.1450
tyrphostin ag 1024
tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor		2.110alkylbenzene
ag-1296
6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase		2.0210quinoxaline derivative
tyrphostin 25
[no description available]		210benzenetriol
albuterol
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).		2.9140phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alpha-cyano-4-hydroxycinnamate
alpha-cyano-4-hydroxycinnamate: specific inhibitor of pyruvate transport in rat liver mitochondria & human erythrocytes; structure		2.0310
alprenolol
Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.		2.3820secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
aluminum fluoride
[no description available]		3.1150aluminium coordination entity
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		3.1150adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
amifostine anhydrous
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.		2.0210diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
p-aminohippuric acid
p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.		1.9410N-acylglycineDaphnia magna metabolite
theophylline
[no description available]		3.85120dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		2.02101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
amitriptyline
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.		3.0410carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amlexanox
amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.		2.2510monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		2.0110dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amobarbital
Amobarbital: A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565). amobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.		2.8640barbiturates
anastrozole
[no description available]		2.0510nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
9-anthroic acid
9-anthroic acid: RN given refers to unlabeled parent cpd; chloride channel blocker; do not confuse with c-ANCA (anti-neutrophil cytoplasmic antibodies) which is frequently abbreviated as ANCA. 9-anthroic acid : An anthroic acid carrying the carboxy substituent at position 9.		2.420anthroic acid
2-amino-4-phosphonobutyric acid
2-amino-4-phosphonobutyric acid: glutamate antagonist in locust muscle; structure; do not confuse with L-AP4, which is the propionic acid version		2.6830
acetovanillone
apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.		3.0140acetophenones;
aromatic ketone;
methyl ketone		antirheumatic drug;
EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug;
plant metabolite
arotinolol
arotinolol: structure given in first source; arotinolol is the (+-)-isomer		2.0210aromatic amide;
thiophenes
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		7.44221benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate: a glutamate agonist		2.0110alpha-amino acid
atrazine
[no description available]		6.9810chloro-1,3,5-triazine;
diamino-1,3,5-triazine		environmental contaminant;
herbicide;
xenobiotic
aurintricarboxylic acid
Aurintricarboxylic Acid: A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues.. aurintricarboxylic acid : A member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'.		1.9910monohydroxybenzoic acid;
quinomethanes;
tricarboxylic acid		fluorochrome;
histological dye;
insulin-like growth factor receptor 1 antagonist
aztreonam
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.		3.3970
baclofen
[no description available]		2.0410amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
bay-k-8644
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.. Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644. methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.		2.4120(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester
benserazide
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.. benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.		6.34151carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzamidine
benzamidine: RN given refers to parent cpd. benzamidine : A carboxamidine that is benzene carrying an amidino group.		2.4220benzenes;
carboxamidine		serine protease inhibitor
benzo(a)pyrene
Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.		7.4420ortho- and peri-fused polycyclic arenecarcinogenic agent;
mouse metabolite
benzothiazide
benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.		3.6290benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
berberine
[no description available]		3.2150alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
bicalutamide
bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.		2.7430(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bisbenzimidazole
Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.		2.0410bibenzimidazole;
N-methylpiperazine		anthelminthic drug;
fluorochrome
bisindolylmaleimide i
bisindolylmaleimide I: a bis(indolyl)maleimide		4.68280
ro 31-7549
Ro 31-7549: structure		2.0110
bumetanide
[no description available]		2.6830amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bupivacaine
Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.		2.0310aromatic amide;
piperidinecarboxamide;
tertiary amino compound
caffeine
[no description available]		9.4210purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.6930aromatic ether;
nitrile;
polyether;
tertiary amino compound
calmidazolium
calmidazolium: powerful inhibitor of or red blood cell Ca++-ATPase & Ca++ transport into inside-out red blood cell vesicles; RN refers to chloride; structure in first source; an antagonist of calmodulin. calmidazolium : An imidazolium ion that is imidazolium cation substituted by a bis(4-chlorophenyl)methyl group at position 1 and a 2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl group at position 3. It acts as an antagonist of calmodulin, a calcium binding messenger protein.		2.4320imidazolium ionapoptosis inducer;
calmodulin antagonist
candesartan
candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.		2.7330benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		2.730dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carbamazepine epoxide
carbamazepine epoxide: metabolite of carbamazepine; RN given refers to unlabeled cpd. carbamazepine-10,11-epoxide : An epoxide and metabolite of carbamazepine.		2.0110dibenzoazepine;
epoxide;
ureas		allergen;
drug metabolite;
marine xenobiotic metabolite
carbetapentane
carbetapentane: RN given refers to parent cpd		2.0410benzenes
carbonyl cyanide m-chlorophenyl hydrazone
Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.		3.69100hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
cefuroxime
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.. cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.		2.0710carbamate ester;
cephalosporin
cetyltrimethylammonium ion
Cetrimonium: Cetyltrimethylammonium compound whose salts and derivatives are used primarily as topical antiseptics.. cetyltrimethylammonium ion : A quaternary ammonium ion in which the substituents on nitrogen are one hexadecyl and three methyl groups.		2.0810quaternary ammonium ion
cgp 12177
CGP 12177 : A benzimidazole that is benzimidazol-2-one substituted at position 4 by a 3-(tert-butylamino)-2-hydroxypropoxy group.		1.9910aromatic ether;
benzimidazoles;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist
cgs 15943
9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist. CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors.		2.0110aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline		adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant
chelerythrine
chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.		8.9120benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
chloral hydrate
[no description available]		2.0210aldehyde hydrate;
ethanediol;
organochlorine compound		general anaesthetic;
mouse metabolite;
sedative;
xenobiotic
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		2.0710benzodiazepine
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		3.6290aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorothiazide
Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.		1.9310benzothiadiazineantihypertensive agent;
diuretic
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		4.37210organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide
Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.		2.1310monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorpyrifos
Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.		8.0440chloropyridine;
organic thiophosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic
chlorthalidone
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.		1.9410isoindoles;
monochlorobenzenes;
sulfonamide
ciclopirox
[no description available]		2.4110cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
cilostamide
cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure		2.4420quinolines
cilostazol
[no description available]		2.7530lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		1.9710aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
eucalyptol
[no description available]		2.1510
ciprofibrate
[no description available]		210cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		8.1150aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
cirazoline
cirazoline: posseses agonist properties at alpha-adrenoreceptor sites; RN given refers to parent cpd		1.9910aromatic ether
citalopram
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.		8.88402-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		2.4620aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clofibric acid
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.		2.4220aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
clofilium
clofilium: RN given refers to parent cpd; structure		2.0210benzenes;
organic amino compound
clomipramine
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.		7.610dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clonazepam
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.		2.02101,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		2.6730clonidine;
imidazoline
clotrimazole
[no description available]		1.9810conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
4-cresol
4-cresol: RN given refers to parent cpd. p-cresol : A cresol that consists of toluene substituted by a hydroxy group at position 4. It is a metabolite of aromatic amino acid metabolism produced by intestinal microflora in humans and animals.		1.9610cresolEscherichia coli metabolite;
human metabolite;
uremic toxin
cx546
1-(1,4-benzodioxan-6-ylcarbonyl)piperidine: structure in first source		2.0110
cycloleucine
Cycloleucine: An amino acid formed by cyclization of leucine. It has cytostatic, immunosuppressive and antineoplastic activities.. 1-aminocyclopentanecarboxylic acid : A non-proteinogenic alpha-amino acid that is cyclopentane substituted at position 1 by amino and carboxy groups.		4.3460non-proteinogenic alpha-amino acidEC 2.5.1.6 (methionine adenosyltransferase) inhibitor
cyclothiazide
cyclothiazide: inhibits the desensitization of AMPA-type receptors; structure. cyclothiazide : 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted at positions 3, 5 and 6 by a 2-norbornen-5-yl group, chlorine, and a sulfonamide group, respectively. A thiazide diuretic, it has been used in the management of hypertension and oedema.		2.7130benzothiadiazineantihypertensive agent;
diuretic
cystamine
[no description available]		3.9840organic disulfide;
primary amino compound		EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor
dantrolene
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.. dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.		2.0510hydrazone;
imidazolidine-2,4-dione		muscle relaxant;
neuroprotective agent;
ryanodine receptor antagonist
dapi
DAPI: RN given refers to parent cpd.		3.83110indolesfluorochrome
debrisoquin
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.		2.420carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent
decanoic acid
decanoate : A fatty acid anion 10:0 that is the conjugate base of decanoic acid.. decanoic acid : A C10, straight-chain saturated fatty acid.		2.0610medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
anti-inflammatory agent;
antibacterial agent;
human metabolite;
plant metabolite;
volatile oil component
deferiprone
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.		2.08104-pyridonesiron chelator;
protective agent
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		3.71100acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
dephostatin
dephostatin: from Streptomyces sp. MJ742-NF5; structure given in first source		2.0210
desipramine
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.		2.8940dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		3.97130primary amine
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		2.0210alpha-amino acid;
fluoroamino acid		trypanocidal drug
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		2.66301,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazinon
Diazinon: A cholinesterase inhibitor that is used as an organothiophosphorus insecticide.. diazinon : A member of the class of pyrimidines that is pyrimidine carrying an isopropyl group at position 2, a methyl group at position 6 and a (diethoxyphosphorothioyl)oxy group at position 4.		2.0510organic thiophosphate;
pyrimidines		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
nematicide;
xenobiotic
diazoxide
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.		2.4320benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
dibenzothiophene
dibenzothiophene : A mancude organic heterotricyclic parent that consists of a thiophene ring flanked by two benzene rings ortho-fused across the 2,3- and 4,5-positions.		2.0310dibenzothiophenes;
mancude organic heterotricyclic parent		keratolytic drug
dibutyl phthalate
Dibutyl Phthalate: A plasticizer used in most plastics and found in water, air, soil, plants and animals. It may have some adverse effects with long-term exposure.. dibutyl phthalate : A phthalate ester that is the diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of butan-1-ol. Although used extensively as a plasticiser, it is a ubiquitous environmental contaminant that poses a risk to humans.		7.8930diester;
phthalate ester		EC 3.2.1.20 (alpha-glucosidase) inhibitor;
environmental contaminant;
metabolite;
plasticiser;
teratogenic agent
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		2.4220amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
dichlorvos
Dichlorvos: An organophosphorus insecticide that inhibits ACETYLCHOLINESTERASE.. dichlorvos : An alkenyl phosphate that is the 2,2-dichloroethenyl ester of dimethyl phosphate.		2.8940alkenyl phosphate;
dialkyl phosphate;
organochlorine acaricide;
organophosphate insecticide		anthelminthic drug;
antibacterial agent;
antifungal agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor
diethyl pyrocarbonate
Diethyl Pyrocarbonate: Preservative for wines, soft drinks, and fruit juices and a gentle esterifying agent.. diethyl pyrocarbonate : The diethyl ester of dicarbonic acid.		3.0950acyclic carboxylic anhydride
diethylcarbamazine
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.		1.9510N-carbamoylpiperazine;
N-methylpiperazine
pentetic acid
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.		2.7130pentacarboxylic acidcopper chelator
3,3'-diindolylmethane
3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist		2.0610indolesantineoplastic agent;
P450 inhibitor
dimercaprol
Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.		2.3520dithiol;
primary alcohol		chelator
dimethoate
Dimethoate: An organothiophosphorus cholinesterase inhibitor that is used as a systemic and contact insecticide.. dimethoate : A monocarboxylic acid amide that is N-methylacetamide in which one of the hydrogens of the methyl group attached to the carbonyl moiety is replaced by a (dimethoxyphosphorothioyl)sulfanediyl group.		2.0210monocarboxylic acid amide;
organic thiophosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic
diphenhydramine
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.		2.3620ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
diphenyleneiodonium
diphenyleneiodonium: structure in first source; NADPH oxidase inhibitor. dibenziodolium : An organic cation that is fluorene in which the methylene group is replaced by a positively charged iodine.		2.4320organic cation
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		2.3720piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
disulfiram
[no description available]		8.7630organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
diuron
Diuron: A pre-emergent herbicide.. diuron : A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which both of the hydrogens attached to one nitrogen are substituted by methyl groups, and one of the hydrogens attached to the other nitrogen is substituted by a 3,4-dichlorophenyl group.		2.89403-(3,4-substituted-phenyl)-1,1-dimethylurea;
dichlorobenzene		environmental contaminant;
mitochondrial respiratory-chain inhibitor;
photosystem-II inhibitor;
urea herbicide;
xenobiotic
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		3.94120branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
2-amino-7-phosphonoheptanoic acid
2-amino-7-phosphonoheptanoic acid: (D)-isomer active as an antagonist of N-methyl-D-aspartate excitation of central neurons; (L)-isomer inactive; RN given refers to cpd without isomeric designation		2.0310
racemetirosine
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)		2.6830
2,3-dimethoxy-1,4-naphthoquinone
2,3-dimethoxynaphthalene-1,4-dione : A naphthoquinone that is 1,4-naphthoquinone bearing two methoxy substituents at positions 2 and 3. Redox-cycling agent that induces intracellular superoxide anion formation and, depending on the concentration, induces cell proliferation, apoptosis or necrosis. Used to study the role of ROS in cell toxicity, apoptosis, and necrosis.		2.21101,4-naphthoquinones
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		2.0510aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
dsp 4
DSP 4: RN given refers to parent cpd		2.3720
e 4031
E 4031: class III anti-arrhythmia agent; structure given in UD		2.0210sulfonamide
ebselen
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.		2.7130benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
econazole
Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.		1.9810dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
edrophonium
Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.		1.9610phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
endosulfan
Endosulfan: A polychlorinated compound used for controlling a variety of insects. It is practically water-insoluble, but readily adheres to clay particles and persists in soil and water for several years. Its mode of action involves repetitive nerve-discharges positively correlated to increase in temperature. This compound is extremely toxic to most fish. (From Comp Biochem Physiol (C) 1993 Jul;105(3):347-61). endosulfan : A cyclic sulfite ester that is 1,5,5a,6,9,9a-hexahydro-6,9-methano-2,4,3-benzodioxathiepine 3-oxide substituted by chloro groups at positions 6, 7, 8, 9, 10 and 10.		2.0310cyclic sulfite ester;
cyclodiene organochlorine insecticide		acaricide;
agrochemical;
GABA-gated chloride channel antagonist;
persistent organic pollutant
endothall
endothall: minor descriptor (72-82); online & Index Medicus search DICARBOXYLIC ACIDS (72-82)		2.0710
enflurane
Enflurane: An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate.. enflurane : An ether in which the oxygen atom is connected to 2-chloro-1,1,2-trifluoroethyl and difluoromethyl groups.		1.9910ether;
organochlorine compound;
organofluorine compound		anaesthetic
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		4.08150
ethacrynic acid
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.		2.9140aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
ether
Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.		2.4920ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant
etidronate
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.		2.36201,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.		2.4220aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
felbamate
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.		2.3920carbamate esteranticonvulsant;
neuroprotective agent
fenofibrate
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE		2.110aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fenoldopam
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.		1.9810benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fipronil
fipronil: has low mammalian toxicity; structure given in first source. fipronil : A racemate comprising equimolar amounts of (R)- and (S)-fipronil.. 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile : A member of the class of pyrazoles that is 1H-pyrazole that is substituted at positions 1, 3, 4, and 5 by 2,6-dichloro-4-(trifluoromethyl)phenyl, cyano, (trifluoromethyl)sulfinyl, and amino groups, respectively.		2.4420(trifluoromethyl)benzenes;
dichlorobenzene;
nitrile;
primary amino compound;
pyrazoles;
sulfoxide
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.5420conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flufenamic acid
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.		2.3520aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluphenazine
[no description available]		2.4420N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.		2.4420ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		4.88110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		10.8481(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
flurbiprofen
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.		3.4820fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fomepizole
Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.		2.420pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		1.9710carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
fpl 64176
FPL 64176: an activator of L-type calcium channels; structure given in first source. FPL 64176 : 1H-Pyrrole substituted at C-2 and -5 by methyl groups, at C-3 by methoxycarbonyl and at C-4 by a 2-benzylbenzoyl group.		2.0110carboxylic ester;
pyrroles		calcium channel agonist
furazolidone
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514). furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.		2.1110nitrofuran antibiotic;
oxazolidines		antibacterial drug;
antiinfective agent;
antitrichomonal drug;
EC 1.4.3.4 (monoamine oxidase) inhibitor
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		2.0210chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
fusaric acid
Fusaric Acid: A picolinic acid derivative isolated from various Fusarium species. It has been proposed for a variety of therapeutic applications but is primarily used as a research tool. Its mechanisms of action are poorly understood. It probably inhibits DOPAMINE BETA-HYDROXYLASE, the enzyme that converts dopamine to norepinephrine. It may also have other actions, including the inhibition of cell proliferation and DNA synthesis.		1.9610aromatic carboxylic acid;
pyridines
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		3.6290gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
gentamicin
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.		3.0140
glutaral
Glutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.. glutaraldehyde : A dialdehyde comprised of pentane with aldehyde functions at C-1 and C-5.		3.3970dialdehydecross-linking reagent;
disinfectant;
fixative
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		2.9640monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
glyphosate
glyphosate: active cpd in herbicidal formulation Roundup; inhibits EC 2.5.1.19, 5-enolpyruvylshikimate-3-phosphate synthase; structure. glyphosate : A phosphonic acid resulting from the formal oxidative coupling of the methyl group of methylphosphonic acid with the amino group of glycine. It is one of the most commonly used herbicides worldwide, and the only one to target the enzyme 5-enolpyruvyl-3-shikimate phosphate synthase (EPSPS).		3.5380glycine derivative;
phosphonic acid		agrochemical;
EC 2.5.1.19 (3-phosphoshikimate 1-carboxyvinyltransferase) inhibitor;
herbicide
gö6983
[no description available]		3.4270indoles;
maleimides
go 6976
[no description available]		3.91120indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor
guaifenesin
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.		4.86110methoxybenzenes
guanethidine
Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.		1.9410azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanidine
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.		4.52240carboxamidine;
guanidines;
one-carbon compound
1-(5-isoquinolinesulfonyl)-2-methylpiperazine
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.		6.79310isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor
ha 1004
N-(2-guanidinoethyl)-5-isoquinolinesulfonamide: structure given in first source		3.5220isoquinolines
fasudil
fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.		2.7130isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		11.02210aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
halothane
[no description available]		3.0750haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
harmaline
Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.		3.9850harmala alkaloidoneirogen
hexadecanesulfonyl fluoride
AM 374: a palmitylsulfonyl fluoride; inhibits anandamide amidase; structure given in first source		1.9810acyl fluoride
homarine
homarine: structure		210non-proteinogenic alpha-amino acid
ethidium
Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.		3.1150phenanthridinesfluorochrome;
intercalator
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		2.1310azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydroxyurea
[no description available]		4.28180one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hypericin
[no description available]		2.110
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		3.4211monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		2.7230benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
ifenprodil
ifenprodil: NMDA receptor antagonist		3.150piperidines
ifosfamide
[no description available]		4.4111ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		9.5980dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indirubin-3'-monoxime
indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.0510
indolepropanol phosphate
indolepropanol phosphate: binds specifically to the alpha subunit, but not to the beta subunit of tryptophan synthase. 3-(indol-3-yl)propyl phosphate : An monoalkyl phosphate compound having an O-3-(indol-3-yl)propyl substituent.		2.6630indoles;
monoalkyl phosphate
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		3.5990aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
indoprofen
Indoprofen: A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p21). indoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein.		2.4110gamma-lactam;
isoindoles;
monocarboxylic acid		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
iodoacetamide
[no description available]		3.4880
iproniazid
[no description available]		2.3520carbohydrazide;
pyridines
avapro
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.		210azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
1-methyl-3-isobutylxanthine
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.		4.081503-isobutyl-1-methylxanthine
isocarboxazid
Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)		1.9410benzenes
isoflurane
Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.		3.6690organofluorine compoundinhalation anaesthetic
isoguvacine
isoguvacine: A GABA agonist; RN given refers to parent cpd; structure		2.0610tetrahydropyridine
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		9.37210carbohydrazideantitubercular agent;
drug allergen
4-piperidinecarboxylic acid
4-piperidinecarboxylic acid: structure in first source		2.0610
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		11.78580catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isradipine
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.		2.0110benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
juglone
juglone: structure. juglone : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogen at position 5 has been replaced by a hydroxy group. A plant-derived 1,4-naphthoquinone with confirmed antibacterial and antitumor activities.		2.0610hydroxy-1,4-naphthoquinonegeroprotector;
herbicide;
reactive oxygen species generator
staurosporine aglycone
staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor		2.7530
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		6.86132cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		1.9910aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
khellin
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024). khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.		2.0210furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
kinetin
Kinetin: A furanyl adenine found in PLANTS and FUNGI. It has plant growth regulation effects.. cytokinin : A phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.. kinetin : A member of the class of 6-aminopurines that is adenine carrying a (furan-2-ylmethyl) substituent at the exocyclic amino group.		2.9406-aminopurines;
furans		cytokinin;
geroprotector
kynurenic acid
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.		10.39590monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
2-amino-3-phosphonopropionic acid
2-amino-3-phosphonopropionic acid: metabotropic glutamate receptor antagonist; do not confuse AP-3 used as an abbreviation for this with enhancer-binding protein AP-3 (a trans-activator) or clathrin assembly protein AP-3. 2-amino-3-phosphonopropanoic acid : A non-proteinogenc alpha-amino acid that is alanine in which one of the hydrogens of the terminal methyl group has been replaced by a dihydroxy(oxido)-lambda(5)-phosphanyl group.		7.6930alanine derivative;
non-proteinogenic alpha-amino acid;
phosphonic acids		human metabolite;
metabotropic glutamate receptor antagonist
mimosine
Mimosine: 3-Hydroxy-4-oxo-1(4H)-pyridinealanine. An antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca.		2.4110alpha-amino acid
pyrrolidine-2,4-dicarboxylic acid
pyrrolidine-2,4-dicarboxylic acid: a glutamate uptake inhibitor		2.0110
lansoprazole
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.		2.0310benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lauric acid
dodecanoic acid : A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.		2.3920medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
antibacterial agent;
plant metabolite
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		7.4120(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole
[no description available]		2.0710nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
qx-314
QX-314: triethyl analog of lidocaine; RN & NM refer to ion		2.4220monocarboxylic acid amidelocal anaesthetic
lithium hydroxide
lithium hydroxide: used for tryptophan determinations in proteins & foods; RN given refers to cpd with MF of Li-OH		1.9810alkali metal hydroxide
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		2.7130biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
ly 171883
LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.		2.3820acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
ly 303511
LY 303511: inhibitor of phosphatidylinositol 3-kinase		2.0410N-arylpiperazine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		5.79850chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
malathion
Malathion: A wide spectrum aliphatic organophosphate insecticide widely used for both domestic and commercial agricultural purposes.. malathion : A racemate comprising equimolar amounts of (R) and (S)-malathion. It is a broad spectrum organophosphate proinsecticide used to control a wide range of pests including Coleoptera, Diptera, fruit flies, mosquitos and spider mites.. diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate : A diester that is diethyl succinate in which position 2 is substituted by a (dimethoxyphosphorothioyl)thio group.		2.0310diester;
ethyl ester;
organic thiophosphate
maprotiline
Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.		1.9710anthracenes
mecamylamine
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.		2.6730primary aliphatic amine
mechlorethamine
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.		2.6230nitrogen mustard;
organochlorine compound		alkylating agent
mefenamic acid
Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.		7.4820aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
memantine
[no description available]		3.8530adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
vitamin k 3
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.		2.78301,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
meperidine
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.		2.0210ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
mephenytoin
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.		210imidazolidine-2,4-dioneanticonvulsant
mesalamine
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.		2.4320amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
mescaline
Mescaline: Hallucinogenic alkaloid isolated from the flowering heads (peyote) of Lophophora (formerly Anhalonium) williamsii, a Mexican cactus used in Indian religious rites and as an experimental psychotomimetic. Among its cellular effects are agonist actions at some types of serotonin receptors. It has no accepted therapeutic uses although it is legal for religious use by members of the Native American Church.. mescaline : A phenethylamine alkaloid that is phenethylamine substituted at positions 3, 4 and 5 by methoxy groups.		1.9510methoxybenzenes;
phenethylamine alkaloid;
primary amino compound		hallucinogen
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		3.98120guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methoxyamine
methoxyamine: analytical reagent for aldehydes and ketones; strong irritant, can probably produce methemoglobinemia; RN given refers to parent cpd; structure		210organooxygen compound
methoxyflurane
Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180). methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.		1.9510ether;
organochlorine compound;
organofluorine compound		hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic
nocodazole
[no description available]		10.08420aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
methyl salicylate
methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990. methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid.		2.0110benzoate ester;
methyl ester;
salicylates		flavouring agent;
insect attractant;
metabolite
methyl methanesulfonate
[no description available]		3.6290methanesulfonate esteralkylating agent;
apoptosis inducer;
carcinogenic agent;
genotoxin;
mutagen
methylphenidate
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.		1.9410beta-amino acid ester;
methyl ester;
piperidines
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		3.8440aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		1.9510C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		2.2110aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.		2.7130aromatic ether;
primary amino compound		anti-arrhythmia drug
mianserin
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.		1.9910dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
miconazole
Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		1.9810dichlorobenzene;
ether;
imidazoles
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		9.1231imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.7430dihydroxyanthraquinoneanalgesic;
antineoplastic agent
ml 7
ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).		2.4420N-sulfonyldiazepane;
organoiodine compound		EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
molsidomine
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.. molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.		2.9340ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
monodansylcadaverine
monodansylcadaverine: inhibits cross linkage of fibrin. monodansylcadaverine : A sulfonamide obtained by formal condensation of the sulfo group of 5-(dimethylamino)naphthalene-1-sulfonic acid with one of the amino groups of cadaverine.		2.0610aminonaphthalene;
primary amino compound;
sulfonamide;
tertiary amino compound		EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor;
fluorochrome;
protective agent
muscimol
Muscimol: A neurotoxic isoxazole isolated from species of AMANITA. It is obtained by decarboxylation of IBOTENIC ACID. Muscimol is a potent agonist of GABA-A RECEPTORS and is used mainly as an experimental tool in animal and tissue studies.. muscimol : A member of the class of isoxazoles that is 1,2-oxazol-3(2H)-one substituted by an aminomethyl group at position 5. It has been isolated from mushrooms of the genus Amanita.		2.6930alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
n-(6-aminohexyl)-1-naphthalenesulfonamide
N-(6-aminohexyl)-1-naphthalenesulfonamide: calmodulin antagonist; RN given refers to parent cpd		1.9610naphthalenes;
sulfonic acid derivative
n-acetyl-4-nitrophenylserinol
N-acetyl-4-nitrophenylserinol: RN given refers to cpd without isomeric designation; structure		3.0510
ethylmaleimide
Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.		5.35580maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
n-methylephedrine
N-methylephedrine: RN given refers to parent cpd		2.0410amphetamines
clorgyline
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.. clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.		2.6830aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
apnea
Apnea: A transient absence of spontaneous respiration.		1.9410purine nucleoside
nafamostat
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic		3.5110benzoic acids;
guanidines
nalidixic acid
[no description available]		2.68301,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
activins
Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.		2.9340
neostigmine
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.		1.9310quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.0110cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nialamide
Nialamide: An MAO inhibitor that is used as an antidepressive agent.		3.5690organonitrogen compound;
organooxygen compound
nicardipine
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.		210benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		3.4170C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nimesulide
nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.		2.4220aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nimodipine
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.		2.46202-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nipecotic acid
nipecotic acid: RN given refers to cpd without isomeric designation. nipecotic acid : A piperidinemonocarboxylic acid that is piperidine in which one of the hydrogens at position 3 is substituted by a carboxylic acid group.		7.3110beta-amino acid;
piperidinemonocarboxylic acid
nisoxetine
nisoxetine: potent inhibitor for norepinephrine uptake into rat brain synaptosomes & brain; NM refers to (+-)-isomer; RN given refers to parent cpd; structure. nisoxetine : A secondary amino compound that is N-methyl-3-phenylpropan-1-amine substituted at position 3 by a 2-methoxyphenoxy group.		2.4220aromatic ether;
secondary amino compound		adrenergic uptake inhibitor;
antidepressant
nitidine
nitidine: RN given refers to parent cpd; synonym NSC 146397 refers to chloride; structure		2.2110phenanthridines
nitroglycerin
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.		2.9540nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
norfenefrine
norfenefrine: RN given refers to cpd without isomeric designation; structure		210phenols
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.7130fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
nortriptyline
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.		1.9410organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.		2.4320aromatic ether;
C-nitro compound;
sulfonamide		antineoplastic agent;
cyclooxygenase 2 inhibitor
octopamine
Octopamine: An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates.. octopamine : A member of the class of phenylethanolamines that is phenol which is substituted at the para- position by a 2-amino-1-hydroxyethyl group. A biogenic phenylethanolamine which has been found to act as a neurotransmitter, neurohormone or neuromodulator in invertebrates.		2.6830phenylethanolamines;
tyramines		neurotransmitter
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		3.13503-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
olomoucine
olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.		2.69302,6-diaminopurines;
ethanolamines		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		2.110aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
oxidopamine
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).		3.74100benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
oxotremorine
Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.		1.9810N-alkylpyrrolidine
oxymetazoline
Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251). oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.		210carboxamidine;
imidazolines;
phenols		alpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
oxyphenbutazone
Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.		2.3420phenols;
pyrazolidines		antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
quinone
benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).		7.68301,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite
fenclonine
Fenclonine: A selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin.		5.26100phenylalanine derivative
p-fluorophenylalanine
p-Fluorophenylalanine: 3-(p-Fluorophenyl)-alanine.. 4-fluorophenylalanine : A phenylalanine derivative in which the hydrogen at position 4 on the benzene ring is replaced by a fluoro group.		1.9510fluoroamino acid;
monofluorobenzenes;
non-proteinogenic alpha-amino acid;
phenylalanine derivative
palmidrol
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.		2.0510endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine		anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		1.9410benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pargyline
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.		10.43120aromatic amine
pd 153035
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source. PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.		2.0510aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
pd 169316
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor		2.0110imidazoles
pd 98059
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.		5.73810aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pemoline
Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.		1.94101,3-oxazolescentral nervous system stimulant
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		3.2260barbituratesGABAA receptor agonist
pentoxifylline
[no description available]		7.0110oxopurine
perphenazine
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.		1.9510N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		3.3670barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenolsulfonphthalein
Phenolsulfonphthalein: Red dye, pH indicator, and diagnostic aid for determination of renal function. It is used also for studies of the gastrointestinal and other systems.. phenol red : 3H-2,1-Benzoxathiole 1,1-dioxide in which both of the hydrogens at position 3 have been substituted by 4-hydroxyphenyl groups. A pH indicator changing colour from yellow below pH 6.8 to bright pink above pH 8.2, it is commonly used as an indicator in cell cultures and in home swimming pool test kits. It is also used in the (now infrequently performed) phenolsulfonphthalein (PSP) test for estimation of overall blood flow through the kidney.		2.01102,1-benzoxathiole;
arenesulfonate ester;
phenols;
sultone		acid-base indicator;
diagnostic agent;
two-colour indicator
phenoxybenzamine
Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.		4.1450aromatic amine
oxophenylarsine
oxophenylarsine: inhibits protein-tyrosine-phosphatase. phenylarsine oxide : An arsine oxide derived from phenylarsine.		2.940arsine oxidesantineoplastic agent;
apoptosis inducer;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		2.6430pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
phenylmethylsulfonyl fluoride
Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.		4.42220acyl fluorideserine proteinase inhibitor
phloretin
[no description available]		1.9510dihydrochalconesantineoplastic agent;
plant metabolite
o-phthalaldehyde
o-Phthalaldehyde: A reagent that forms fluorescent conjugation products with primary amines. It is used for the detection of many biogenic amines, peptides, and proteins in nanogram quantities in body fluids.. phthalaldehyde : A dialdehyde in which two formyl groups are attached to adjacent carbon centres on a benzene ring.		9.5880benzaldehydes;
dialdehyde		epitope
pifithrin
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source		2.7430aromatic ketone
pindolol
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.		4.4851indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
pioglitazone
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.		3.6630aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
piperidine-4-sulfonic acid
piperidine-4-sulfonic acid: specific GABA agonist		2.0410
pirenzepine
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.		4.3211pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
potassium chloride
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.		5.02410inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
potassium iodide
Potassium Iodide: An inorganic compound that is used as a source of iodine in thyrotoxic crisis and in the preparation of thyrotoxic patients for thyroidectomy. (From Dorland, 27th ed). potassium iodide : A metal iodide salt with a K(+) counterion. It is a scavenger of hydroxyl radicals.		2.6530potassium saltexpectorant;
radical scavenger
4-aminobenzoic acid
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.. 4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.		1.9510aminobenzoate;
aromatic amino-acid anion		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert. 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.		2.4420arenesulfonic acid;
azobenzenes;
methylpyridines;
monohydroxypyridine;
organic phosphate;
pyridinecarbaldehyde		purinergic receptor P2X antagonist
praziquantel
azinox: Russian drug		2.110isoquinolines
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		2.9140aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		1.9410benzoic acids;
sulfonamide		uricosuric drug
procaine
Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.		2.3520benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
propentofylline
[no description available]		2.0210oxopurine
propidium
Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.		3.4170phenanthridines;
quaternary ammonium ion		fluorochrome;
intercalator
propofol
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.		8.360phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		5.09140naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
propyl gallate
Propyl Gallate: Antioxidant for foods, fats, oils, ethers, emulsions, waxes, and transformer oils.		2.1310trihydroxybenzoic acid
protoporphyrin ix
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685. protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.		2.0210
pyrilamine
Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.		2.3820aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
pyrimethamine
Maloprim: contains above 2 cpds		7.9140aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
quipazine
Quipazine: A pharmacologic congener of serotonin that contracts smooth muscle and has actions similar to those of tricyclic antidepressants. It has been proposed as an oxytocic.		2.0110piperazines;
pyridines
resorcinol
resorcinol: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7951. resorcinol : A benzenediol that is benzene dihydroxylated at positions 1 and 3.		2.5220benzenediol;
phenolic donor;
resorcinols		erythropoietin inhibitor;
sensitiser
riluzole
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.		8.8621benzothiazoles
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		2.110alkylamine
risperidone
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.		10.81681,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
ritanserin
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.. ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.		1.9710organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
ro 31-8220
Ro 31-8220: a protein kinase C inhibitor		4.31190imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
rofecoxib
[no description available]		2.2110butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
rolipram
[no description available]		4.3270pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
saccharin
Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.		2.69301,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic
sanguinarine
benzophenanthridine alkaloid : A specific group of isoquinoline alkaloids that occur only in higher plants and are constituents mainly of the Papaveraceae family.		7.5820alkaloid antibiotic;
benzophenanthridine alkaloid;
botanical anti-fungal agent
sb 239063
SB 239063: structure in first source. SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.		2.0510imidazoles
sb 202190
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase		3.6290imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
suberoyl bis-hydroxamic acid
suberoyl bis-hydroxamic acid: antineoplastic, Histone Deacetylase inhibitor		2.0510hydroxamic acid
sevoflurane
Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.		2.5820ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
linsidomine
linsidomine: RN given refers to parent cpd; structure		2.9340morpholines
sk&f 97541
3-aminopropyl(methyl)phosphinic acid: structure given in first source; GABA-A receptor antagonist		2.0110
sodium fluoride
[no description available]		2.9240fluoride saltmutagen
fluoroacetic acid
fluoroacetic acid: N1 same as NM; RN given refers to parent cpd. fluoroacetic acid : A haloacetic acid that is acetic acid in which one of the methyl hydrogens is substituted by fluorine.		2.5320haloacetic acid;
organofluorine compound		EC 4.2.1.3 (aconitate hydratase) inhibitor
iodoacetic acid
Iodoacetic Acid: A derivative of ACETIC ACID that contains one IODINE atom attached to its methyl group.. iodoacetic acid : A haloacetic acid that is acetic acid in which one of the hydrogens of the methyl group is replaced by an iodine atom.		3.0850haloacetic acid;
organoiodine compound		alkylating agent
sotalol
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.		1.9710ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		3.150aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
stearic acid
octadecanoic acid : A C18 straight-chain saturated fatty acid component of many animal and vegetable lipids. As well as in the diet, it is used in hardening soaps, softening plastics and in making cosmetics, candles and plastics.		2.6630long-chain fatty acid;
saturated fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
human metabolite;
plant metabolite
streptonigrin
[no description available]		1.9610pyridines;
quinolone		antimicrobial agent;
antineoplastic agent
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		2.7230dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine
Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.		2.0310quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		2.6930isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfanilamide
[no description available]		2.3620substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		1.9610
sulfinpyrazone
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.		1.9410pyrazolidines;
sulfoxide		uricosuric drug
sulfisoxazole
Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.		1.9410isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
sulfobromophthalein
Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.		1.98102-benzofurans;
organobromine compound;
organosulfonic acid;
phenols		dye
sulforaphane
sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.		2.7330isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
sulpiride
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.		7.4720benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
sumatriptan
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.		2.110sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		3.1350naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
4-methylglutamic acid
4-methylglutamic acid : A glutamic acid derivative that is glutamic acid substituted by a methyl group at position 4.		2.0210amino dicarboxylic acid;
glutamic acid derivative
1,4-bis(2-(3,5-dichloropyridyloxy))benzene
1,4-bis(2-(3,5-dichloropyridyloxy))benzene: potent phenobarbital-like inducer of microsomal monooxygenase activity; structure given in first source		2.0310
temozolomide
[no description available]		7.7730imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
tetracaine
Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.		2.1110benzoate ester;
tertiary amino compound		local anaesthetic
3-hydroxyaspartic acid
3-hydroxyaspartic acid: RN given refers to cpd without isomeric designation. 3-hydroxyaspartic acid : A hydroxy-amino acid that is aspartic acid in which one of the methylene hydrogens has been replaced by a hydroxy group.		3.1250amino dicarboxylic acid;
aspartic acid derivative;
C4-dicarboxylic acid;
hydroxy-amino acid
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		2.2510phthalimides;
piperidones
theobromine
Theobromine: 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9). theobromine : A dimethylxanthine having the two methyl groups located at positions 3 and 7. A purine alkaloid derived from the cacao plant, it is found in chocolate, as well as in a number of other foods, and is a vasodilator, diuretic and heart stimulator.		1.9510dimethylxanthineadenosine receptor antagonist;
bronchodilator agent;
food component;
human blood serum metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
thioridazine
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.		1.9510phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
ticlopidine
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.		2.0110monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
nikethamide
Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)		1.9510pyridinecarboxamide
tranexamic acid
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.		7.4110amino acid
trapidil
Trapidil: A coronary vasodilator agent.		2.0210triazolopyrimidines
trazodone
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.		3.3811monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
tremorine
[no description available]		2.8710N-alkylpyrrolidine
triclosan
[no description available]		210aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
trifluoperazine
[no description available]		2.8940N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trigonelline
trigonelline: in hydra among other organisms; RN given refers to hydroxide inner salt; structure. N-methylnicotinic acid : A pyridinium ion consisting of nicotinic acid having a methyl substituent on the pyridine nitrogen.. N-methylnicotinate : An iminium betaine that is the conjugate base of N-methylnicotinic acid, arising from deprotonation of the carboxy group.		210alkaloid;
iminium betaine		food component;
human urinary metabolite;
plant metabolite
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.6430aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		2.7130chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
tyramine
[no description available]		3.86120monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
tyrphostin a9
[no description available]		2.110alkylbenzenegeroprotector
urethane
[no description available]		2.8940carbamate esterfungal metabolite;
mutagen
vesamicol
vesamicol: RN given refers to parent cpd; structure		210piperidines
w 7
W 7: RN given refers to parent cpd; structure; calmodulin antagonist		3.2560
wb 4101
N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine bearing a [(2',6'-dimethoxyphenoxy)ethylamino]methyl group at position 2. An alpha1A-adrenergic selective antagonist.		1.9710aromatic ether;
benzodioxine;
secondary amino compound		alpha-adrenergic antagonist
pirinixic acid
pirinixic acid: structure		2.7430aryl sulfide;
organochlorine compound;
pyrimidines
zinc chloride
zinc chloride: RN given refers to parent cpd. zinc dichloride : A compound of zinc and chloride ions in the ratio 1:2. It exists in four crystalline forms, in each of which the Zn(2+) ions are trigonal planar coordinated to four chloride ions.		2.7530inorganic chloride;
zinc molecular entity		astringent;
disinfectant;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
Lewis acid
zolpidem
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.		2.0310imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		8.68100mitomycinalkylating agent;
antineoplastic agent
corticosterone
[no description available]		9.0915011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		2.894011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		1.951016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
lysergic acid diethylamide
Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.. lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.		2.3720ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound		dopamine agonist;
hallucinogen;
serotonergic agonist
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		4.55260alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
phentolamine
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.		2.6730imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
sorbitol
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).		3.690glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
alloxan
Alloxan: Acidic compound formed by oxidation of URIC ACID. It is isolated as an efflorescent crystalline hydrate.. alloxan : A member of the class of pyrimidones, the structure of which is that of perhydropyrimidine substituted at C-2, -4, -5 and -6 by oxo groups.		2.8740pyrimidonehyperglycemic agent;
metabolite
thymidine
[no description available]		5.44640pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.8840nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
benzimidazole
1H-benzimidazole : The 1H-tautomer of benzimidazole.		2.730benzimidazole;
polycyclic heteroarene
triethylenemelamine
Triethylenemelamine: Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.		1.94101,3,5-triazinesalkylating agent;
insect sterilant
bromouracil
Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms.. 5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen.		1.9810nucleobase analogue;
pyrimidines		mutagen
hydroxyproline
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.		8.996904-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
thyroxine
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.		4.171702-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		2.89401-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		4.3190ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
spironolactone
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.		2.21103-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
aldosterone
[no description available]		3.528011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
penicillamine
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.		3.97140non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
cysteine
[no description available]		3.1250cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		3.216017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
dehydroepiandrosterone
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.		4.554017-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
dichlororibofuranosylbenzimidazole
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.		4.32190
2-acetylaminofluorene
2-Acetylaminofluorene: A hepatic carcinogen whose mechanism of activation involves N-hydroxylation to the aryl hydroxamic acid followed by enzymatic sulfonation to sulfoxyfluorenylacetamide. It is used to study the carcinogenicity and mutagenicity of aromatic amines.		2.43202-acetamidofluorenesantimitotic;
carcinogenic agent;
epitope;
mutagen
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		3.91130penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
metaraminol
Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.. metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.		2.3420phenylethanolaminesalpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent
pilocarpine
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.		8.3160pilocarpineantiglaucoma drug
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		3.82110organic heterobicyclic compound;
organonitrogen heterocyclic compound
triiodothyronine
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.		5.51612-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
diethylnitrosamine
Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.		7.7130nitrosaminecarcinogenic agent;
hepatotoxic agent;
mutagen
isoflurophate
Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.		7.611130dialkyl phosphate
biguanides
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.		8.730guanidines
carbon tetrachloride
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.		2.7930chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
cantharidin
Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.		3.1350cyclic dicarboxylic anhydride;
monoterpenoid		EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
herbicide
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		18.821,8638alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
4-nitroquinoline-1-oxide
4-nitroquinoline N-oxide : A quinoline N-oxide carrying a nitro substituent at position 4.		2.0310C-nitro compound;
quinoline N-oxide		carcinogenic agent
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		6.18450C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		17.421,1453aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		15.444814amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		16.118563aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
cyanides
Cyanides: Inorganic salts of HYDROGEN CYANIDE containing the -CN radical. The concept also includes isocyanides. It is distinguished from NITRILES, which denotes organic compounds containing the -CN radical.. cyanides : Salts and C-organyl derivatives of hydrogen cyanide, HC#N.. isocyanide : The isomer HN(+)#C(-) of hydrocyanic acid, HC#N, and its hydrocarbyl derivatives RNC (RN(+)#C(-)).. cyanide : A pseudohalide anion that is the conjugate base of hydrogen cyanide.		5.35590pseudohalide anionEC 1.9.3.1 (cytochrome c oxidase) inhibitor
physostigmine
Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.		3.0550carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		6.25470glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		2.041017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
tubocurarine
Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.		2.6630bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
9,10-dimethyl-1,2-benzanthracene
9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.		2.0110ortho-fused polycyclic arene;
tetraphenes		carcinogenic agent
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		8.2260aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
aminopyrine
Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.		2.0110pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
tetrabenazine
9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.		7.3620benzoquinolizine;
cyclic ketone;
tertiary amino compound
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		6.49590adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
cephalothin
Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.		2.7330azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
uridine
[no description available]		4.87360uridinesdrug metabolite;
fundamental metabolite;
human metabolite
uridine monophosphate
Uridine Monophosphate: 5'-Uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. uridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having uracil as the nucleobase.		2.3820pyrimidine ribonucleoside 5'-monophosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
uridine diphosphate
Uridine Diphosphate: A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety.		4.5170pyrimidine ribonucleoside 5'-diphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		3.2160kanamycinsbacterial metabolite
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		4.21170pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
galactose
galactopyranose : The pyranose form of galactose.		8.491240D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		8.43241monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
phenylephrine
Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.		10.66181phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		13.55282amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		5.45650ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
p-aminoazobenzene
p-Aminoazobenzene: Used in the form of its salts as a dye and as an intermediate in manufacture of Acid Yellow, diazo dyes, and indulines.. 4-(phenylazo)aniline : Azobenzene substituted at one of the 4-positions by an amino group. It has a role as a dye and an allergen.		1.9610
p-dimethylaminoazobenzene
p-Dimethylaminoazobenzene: A reagent used mainly to induce experimental liver cancer. According to the Fourth Annual Report on Carcinogens (NTP 85-002, p. 89) published in 1985, this compound may reasonably be anticipated to be a carcinogen. (Merck, 11th ed)		4.2870azobenzenes
phenylethyl alcohol
Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.		3.2660benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		18.411,3713amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
cysteamine
Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.		8.97140amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
phlorhizin
[no description available]		2.6430aryl beta-D-glucoside;
dihydrochalcones;
monosaccharide derivative		antioxidant;
plant metabolite
methoxamine
Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .		1.9510amphetaminesalpha-adrenergic agonist;
antihypotensive agent
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		7.45630adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
methicillin
Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.		2.7130penicillin allergen;
penicillin		antibacterial drug
n,n-dimethyltryptamine
N,N-Dimethyltryptamine: An N-methylated indoleamine derivative and serotonergic hallucinogen which occurs naturally and ubiquitously in several plant species including Psychotria veridis. It also occurs in trace amounts in mammalian brain, blood, and urine, and is known to act as an agonist or antagonist of certain SEROTONIN RECEPTORS.. N,N-dimethyltryptamine : A tryptamine derivative having two N-methyl substituents on the side-chain.		1.9510tryptamine alkaloid;
tryptamines
methylene blue
Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.. methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.		2.3920organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
4-toluenesulfonic acid
4-toluenesulfonic acid: RN given refers to parent cpd; other RNs in 9th CI Form Index. toluene-4-sulfonic acid : An arenesulfonic acid that is benzenesulfonic acid in which the hydrogen at position 4 is replaced by a methyl group.		2.0210arenesulfonic acid;
toluenes
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		16.058503amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
ethyl methanesulfonate
Ethyl Methanesulfonate: An antineoplastic agent with alkylating properties. It also acts as a mutagen by damaging DNA and is used experimentally for that effect.. ethyl methanesulfonate : A methanesulfonate ester resulting from the formal condensation of methanesulfonic acid with ethanol.		3.6190methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
genotoxin;
mutagen;
teratogenic agent
methacholine chloride
Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)		2.3920quaternary ammonium salt
aniline
[no description available]		7.9740anilines;
primary arylamine
2-aminoisobutyric acid
2-aminoisobutyric acid: RN given refers to unlabeled cpd. 2-aminoisobutyric acid : A rare, non-protein amino acid and end-product of pyrimidine metabolism, excreted in urine and found in some antibiotics of fungal origin. With the exception of a few bacteria, it is non-metabolisable, and therefore used in bioassays.		4.871102,2-dialkylglycine zwitterion;
2,2-dialkylglycine
dimethylnitrosamine
Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.		3.5120nitrosaminegeroprotector;
mutagen
androstenedione
Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.		2.011017-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
carbaryl
Carbaryl: A carbamate insecticide and parasiticide. It is a potent anticholinesterase agent belonging to the carbamate group of reversible cholinesterase inhibitors. It has a particularly low toxicity from dermal absorption and is used for control of head lice in some countries.. carbaryl : A carbamate ester obtained by the formal condensation of 1-naphthol with methylcarbamic acid.		7.6930carbamate ester;
naphthalenes		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant
cytidine monophosphate
Cytidine Monophosphate: Cytidine (dihydrogen phosphate). A cytosine nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. cytidine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having cytosine as the nucleobase.		3.0750cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-monophosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
cytidine diphosphate
Cytidine Diphosphate: Cytidine 5'-(trihydrogen diphosphate). A cytosine nucleotide containing two phosphate groups esterified to the sugar moiety. Synonyms: CRPP; cytidine pyrophosphate.		3.85120cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite
uridine triphosphate
Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.		3.2760pyrimidine ribonucleoside 5'-triphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
lactose
Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.		10130lactose
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		16.667994aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
1,2-dipalmitoylphosphatidylcholine
1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.		3.0340
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		15.17112amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
desoxycorticosterone
Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE		2.693020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		3.690alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
gallamine triethiodide
Gallamine Triethiodide: A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)		2.3520
cytidine
[no description available]		3.4980cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytidine triphosphate
Cytidine Triphosphate: Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.		2.9140cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		5.66790antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
ficusin
Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.		2.0110psoralensplant metabolite
egtazic acid
Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.		4.53240diether;
tertiary amino compound;
tetracarboxylic acid		chelator
chloroform
Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.		2.6430chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant
fluocinolone acetonide
Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.		2.011011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
organic heteropentacyclic compound;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
gliotoxin
Gliotoxin: A fungal toxin produced by various species of Trichoderma, Gladiocladium fimbriatum, Aspergillus fumigatus, and Penicillium. It is used as an immunosuppressive agent.. gliotoxin : A pyrazinoindole with a disulfide bridge spanning a dioxo-substituted pyrazine ring; mycotoxin produced by several species of fungi.		2.5720dipeptide;
organic disulfide;
organic heterotetracyclic compound;
pyrazinoindole		antifungal agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
immunosuppressive agent;
mycotoxin;
proteasome inhibitor
dimethylformamide
Dimethylformamide: A formamide in which the amino hydrogens are replaced by methyl groups.. N,N-dimethylformamide : A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups.		3.4720formamides;
volatile organic compound		geroprotector;
hepatotoxic agent;
polar aprotic solvent
norethynodrel
Norethynodrel: A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and ENDOMETRIOSIS. As a contraceptive (CONTRACEPTIVE AGENTS), it has usually been administered in combination with MESTRANOL.		1.9410oxo steroid
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		10.875724-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
triaziquone
Triaziquone: Alkylating antineoplastic agent used mainly for ovarian tumors. It is toxic to skin, gastrointestinal tract, bone marrow and kidneys.. triaziquone : A member of the class of 1,4-benzoquinones that is 1,4-benzoquinone in which three of the ring hydrogens are replaced by aziridin-1-yl groups.		1.95101,4-benzoquinones;
aziridines		alkylating agent;
antineoplastic agent
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		2.6830antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		3.2760beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
mannitol
[no description available]		3.67100mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
cytarabine
[no description available]		3.5890beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
dithionitrobenzoic acid
Dithionitrobenzoic Acid: A standard reagent for the determination of reactive sulfhydryl groups by absorbance measurements. It is used primarily for the determination of sulfhydryl and disulfide groups in proteins. The color produced is due to the formation of a thio anion, 3-carboxyl-4-nitrothiophenolate.. dithionitrobenzoic acid : An organic disulfide that results from the formal oxidative dimerisation of 2-nitro-5-thiobenzoic acid. An indicator used to quantify the number or concentration of thiol groups.		4.06150nitrobenzoic acid;
organic disulfide		indicator
ornithine
Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.		9.18990non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
dinitrofluorobenzene
Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.. 1-fluoro-2,4-dinitrobenzene : The organofluorine compound that is benzene with a fluoro substituent at the 1-position and two nitro substituents in the 2- and 4-positions.		2.3620C-nitro compound;
organofluorine compound		agrochemical;
allergen;
chromatographic reagent;
EC 2.7.3.2 (creatine kinase) inhibitor;
protein-sequencing agent;
spectrophotometric reagent
asparagine
Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.		15.625023amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
histidine
Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.		16.197272amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
n-pentanol
n-pentanol: RN given refers to parent cpd. pentan-1-ol : A short-chain primary fatty alcohol that is pentane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It has been isolated from Melicope ptelefolia.		2.4120pentanol;
short-chain primary fatty alcohol		human metabolite;
plant metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		15.256124L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
threonine
Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.		20.493,0796amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
mestranol
[no description available]		2.352017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		14.264631erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
isoleucine
Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.		11.864250aspartate family amino acid;
isoleucine;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		17.899655arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
ethane
Ethane: A two carbon alkane with the formula H3C-CH3.. ethane : An alkane comprising of two carbon atoms.		2.4820alkane;
gas molecular entity		plant metabolite;
refrigerant
ethylene
Plastipore: high density polyethylene sponge biocompatible material; used as posts in dental bridges		8.0240alkene;
gas molecular entity		plant hormone;
refrigerant
acetylene
[no description available]		2.0310alkyne;
gas molecular entity;
terminal acetylenic compound
methylamine
methyl group : An alkyl group that is the univalent group derived from methane by removal of a hydrogen atom.		3.8130methylamines;
one-carbon compound;
primary aliphatic amine		mouse metabolite
boranes
Boranes: The collective name for the boron hydrides, which are analogous to the alkanes and silanes. Numerous boranes are known. Some have high calorific values and are used in high-energy fuels. (From Grant & Hackh's Chemical Dictionary, 5th ed). borane : The simplest borane, consisting of a single boron atom carrying three hydrogens.. boranes : The molecular hydrides of boron.		2.0310boranes;
mononuclear parent hydride
propane
Propane: A three carbon alkane with the formula H3CCH2CH3.		2.6730alkane;
gas molecular entity		food propellant
vinyl chloride
Vinyl Chloride: A gas that has been used as an aerosol propellant and is the starting material for polyvinyl resins. Toxicity studies have shown various adverse effects, particularly the occurrence of liver neoplasms.. chloroethene : A monohaloethene that is ethene in which one of the hydrogens has been replaced by a chloro group.		210chloroethenes;
gas molecular entity;
monohaloethene		carcinogenic agent
ethylamine
ethylamine : A two-carbon primary aliphatic amine.		2.5120primary aliphatic aminehuman metabolite
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		2.7130aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
ethanethiol
ethanethiol: RN given refers to parent cpd; structure. ethanethiol : An alkanethiol that is ethane substituted by a thiol group at position 1. It is added to odorless gaseous products such as liquefied petroleum gas (LPG) to provide a garlic scent which helps warn of gas leaks.		6.9910alkanethiolrodenticide
methylene chloride
Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.		2.0510chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
cyclopropane
cyclopropane : A cycloalkane composed of three carbon atoms to form a ring.		2.0710cycloalkane;
cyclopropanes		inhalation anaesthetic
ethylene oxide
Ethylene Oxide: A colorless and flammable gas at room temperature and pressure. Ethylene oxide is a bactericidal, fungicidal, and sporicidal disinfectant. It is effective against most micro-organisms, including viruses. It is used as a fumigant for foodstuffs and textiles and as an agent for the gaseous sterilization of heat-labile pharmaceutical and surgical materials. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p794). oxirane : A saturated organic heteromonocyclic parent that is a three-membered heterocycle of two carbon atoms and one oxygen atom.		1.9510gas molecular entity;
oxacycle;
saturated organic heteromonocyclic parent		allergen;
mouse metabolite;
mutagen
tetramethylammonium
tetramethylammonium: RN given refers to parent cpd. tetramethylammonium : The simplest quaternary ammonium cation, comprising a central nitrogen linked to four methyl groups.		210quaternary ammonium ion
dichlorodifluoromethane
dichlorodifluoromethane: refrigerant,aerosol propellant		2.0610
methanesulfonic acid
[no description available]		2.0210alkanesulfonic acid;
one-carbon compound		Escherichia coli metabolite
tert-amyl alcohol
2-methylbutan-2-ol : A tertiary alcohol that is propan-1-ol in which both of the hydrogens at position 1 have been replaced by methyl groups.		210aliphatic alcohol;
tertiary alcohol		protic solvent
acetone cyanohydrin
acetone cyanohydrin: RN given refers to unlabeled cpd; structure		1.9910cyanohydrin
trifluoroethanol
Trifluoroethanol: A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.		3.2560fluoroalcohol
tert-butylhydroperoxide
tert-Butylhydroperoxide: A direct-acting oxidative stress-inducing agent used to examine the effects of oxidant stress on Ca(2+)-dependent signal transduction in vascular endothelial cells. It is also used as a catalyst in polymerization reactions and to introduce peroxy groups into organic molecules.. tert-butyl hydroperoxide : An alkyl hydroperoxide in which the alkyl group is tert-butyl. It is widely used in a variety of oxidation processes.		1.9810alkyl hydroperoxideantibacterial agent;
oxidising agent
dalapon
dalapon: RN given refers to parent cpd; structure		210carboxylic acid;
organohalogen compound
trichloroacetic acid
Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts.. trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.		3.95140monocarboxylic acid;
organochlorine compound		carcinogenic agent;
metabolite;
mouse metabolite
trifluoroacetic acid
Trifluoroacetic Acid: A very strong halogenated derivative of acetic acid. It is used in acid catalyzed reactions, especially those where an ester is cleaved in peptide synthesis.. trifluoroacetic acid : A monocarboxylic acid that is the trifluoro derivative of acetic acid.		3.7830fluoroalkanoic acidhuman xenobiotic metabolite;
NMR chemical shift reference compound;
reagent
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		1.981011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
bromthymol blue
Bromthymol Blue: A pH sensitive dye that has been used as an indicator in many laboratory reactions.. bromothymol blue : A member of the class of 2,1-benzoxathioles that is 2,1-benzoxathiole 1,1-dioxide in which both of the hydrogens at position 3 have been substituted by 3-bromo-4-hydroxy-5-isopropyl-2-methylphenyl groups.		1.96102,1-benzoxathiole;
arenesulfonate ester;
organobromine compound;
polyphenol;
sultone		acid-base indicator;
dye;
two-colour indicator
gibberellic acid
gibberellic acid: RN given refers to (1alpha,2beta,4aalpha,4bbeta,10beta)-isomer; structure. gibberellin A3 : A C19-gibberellin that is a pentacyclic diterpenoid responsible for promoting growth and elongation of cells in plants. Initially identified in Gibberella fujikuroi,it differs from gibberellin A1 in the presence of a double bond between C-3 and C-4.		2.0210C19-gibberellin;
gibberellin monocarboxylic acid;
lactone;
organic heteropentacyclic compound		mouse metabolite;
plant metabolite
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		6.73170benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
tabun
tabun: proposed as military nerve gas and exptl cholinesterase inhibitor; extremely poisonous; structure		2.1510
tromethamine
Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)		3.83120primary amino compound;
triol		buffer
quinic acid
(-)-quinic acid : The (-)-enantiomer of quinic acid.		1.9410
triparanol
Triparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.		1.9510stilbenoidanticoronaviral agent
isobutyl alcohol
isobutyl alcohol: RN given refers to parent cpd		2.4320alkyl alcohol;
primary alcohol		Saccharomyces cerevisiae metabolite
2-butanol
2-butanol: RN given is for parent cpd without isomeric designation. butan-2-ol : A secondary alcohol that is butane substituted by a hydroxy group at position 2.		210secondary alcohol
trichloroethylene
Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.		2.0810chloroethenesinhalation anaesthetic;
mouse metabolite
acrylamide
[no description available]		2.9740acrylamides;
N-acylammonia;
primary carboxamide		alkylating agent;
carcinogenic agent;
Maillard reaction product;
mutagen;
neurotoxin
acrylic acid
acrylic acid: RN given refers to parent cpd. acrylic acid : A alpha,beta-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.		7.3620alpha,beta-unsaturated monocarboxylic acidmetabolite
n-methylacetamide
N-methylacetamide: RN given refers to parent cpd. N-methylacetamide : A monocarboxylic acid amide that is the N-methyl derivative of acetamide.		2.4320acetamides;
monocarboxylic acid amide		metabolite
peracetic acid
Peracetic Acid: A liquid that functions as a strong oxidizing agent. It has an acrid odor and is used as a disinfectant.. peracetic acid : A peroxy acid that is acetic acid in which the OH group is substituted by a hydroperoxy group. It is a versatile oxidising agent that is used as a disinfectant.		2.0210a peroxy aciddisinfectant;
oxidising agent
methyl chloroformate
[no description available]		2.0210
nitroethane
nitroethane : A nitroalkane that is ethane substituted by a nitro group.		2.0510primary nitroalkane
pantothenic acid
Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE.. pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.. vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.. (R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group.. (R)-pantothenic acid : A pantothenic acid having R-configuration.		4.25190pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
cumene hydroperoxide
cumene hydroperoxide: RN given refers to parent cpd. cumene hydroperoxide : A peroxol that is cumene in which the alpha-hydrogen is replaced by a hydroperoxy group.		2.4420peroxolenvironmental contaminant;
Mycoplasma genitalium metabolite;
oxidising agent
taurocholic acid
Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.		3.690amino sulfonic acid;
bile acid taurine conjugate		human metabolite
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		2.21106-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
vitamin k5
vitamin k5: RN given refers to parent cpd		2.4110naphthols
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		3.2560organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
diquat
Diquat: A contact herbicide used also to produce desiccation and defoliation. (From Merck Index, 11th ed). diquat : The organic cation formed formally by addition of an ethylene bridge between the nitrogen atoms of 2,2'-bipyridine. Most often available as the dibromide.		2.1510organic cationdefoliant;
herbicide
pyocyanine
Pyocyanine: Antibiotic pigment produced by Pseudomonas aeruginosa.. pyocyanine : An iminium betaine that is 5-methylphenazin-5-ium which is substituted at position 1 by an oxidanidyl group. An antibiotic pigment produced by Pseudomonas aeruginosa.		3.7530iminium betaine;
phenazines		antibacterial agent;
bacterial metabolite;
biological pigment;
virulence factor
1-naphthoic acid
naphthoic acid : An aromatic carboxylic acid that consists of a naphthalene skeleton substituted by one or more carboxy groups.		2.0410naphthoic acidbacterial xenobiotic metabolite;
fungal xenobiotic metabolite
penicillanic acid
Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.		4.08150penicillanic acids
xylitol
xylooligosaccharide: structure in first source. pentitol : An alditol obtained by reduction of any pentose.. xylooligosaccharide : An oligosaccharide comprised of xylose residues.		2.6430
n-vinyl-2-pyrrolidinone
N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source		2.2110pyrrolidin-2-ones
salicylaldehyde
o-hydroxybenzaldehyde: structure in first source		9.8190hydroxybenzaldehydenematicide;
plant metabolite
aminacrine
Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.. 9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections.		2.1310aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		4.5230mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
quinoline
[no description available]		2.0310azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinolines
2-naphthylamine
2-Naphthylamine: A naphthalene derivative with carcinogenic action.. 2-naphthylamine : A naphthylamine carrying the amino group at position 2.		2.4520naphthylaminecarcinogenic agent
diphenyl
diphenyl: RN given refers to unlabeled cpd; structure		2.4120aromatic fungicide;
benzenes;
biphenyls		antifungal agrochemical;
antimicrobial food preservative
proflavine
Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds.		2.3620aminoacridinesantibacterial agent;
antiseptic drug;
carcinogenic agent;
chromophore;
intercalator
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		3.2660xanthene
phenothiazine
10H-phenothiazine : The 10H-tautomer of phenothiazine.		7.1110phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
veratryl alcohol
(3,4-dimethoxyphenyl)methanol : A member of the class of benzyl alcohols that is benzyl alcohol in which the hydrogens at positions 3 and 4 of the phenyl group are substituted by methoxy groups.		1.9910benzyl alcohols;
dimethoxybenzene;
primary alcohol		fungal metabolite
synephrine
[no description available]		1.9910ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
propylparaben
Parabens: Methyl, propyl, butyl, and ethyl esters of p-hydroxybenzoic acid. They have been approved by the FDA as antimicrobial agents for foods and pharmaceuticals. (From Hawley's Condensed Chemical Dictionary, 11th ed, p872)		2.6730benzoate ester;
paraben;
phenols		antifungal agent;
antimicrobial agent
benzotriazole
benzotriazole: inhibitor of atmospheric metal corrosion; also component of motion picture film & Neva brake fluid. benzotriazole : The simplest member of the class of benzotriazoles that consists of a benzene nucleus fused to a 1H-1,2,3-triazole ring.		2.0510benzotriazolesenvironmental contaminant;
xenobiotic
benzothiophene
[no description available]		7.6101-benzothiophenes;
benzothiophene
2-methylindole
2-methylindole: SKATOLE refers to 3-methylindole; RN given refers to parent cpd; structure. 2-methyl-1H-indole : A methylindole that is 1H-indole substituted by a methyl group at position 2.		1.9810methylindole
2-chloroaniline
[no description available]		1.9610
1,2-diaminobenzene
1,2-diaminobenzene: RN given refers to parent cpd. 1,2-phenylenediamine : A phenylenediamine in which the two amino groups are ortho to each other.		1.9810phenylenediaminehydrogen donor
4-chloro-1,2-diaminobenzene
4-chloro-1,2-diaminobenzene: RN given refers to parent cpd		2.0710monochlorobenzenes
thioglycerol
thioglycerol: potentiates action of bradykinin in guinea-pig ileum; RN given refers to parent cpd; structure. monothioglycerol : A thiol that is glycerol in which one of the primary hydroxy groups is replaced by a thiol group.		2.0510propane-1,2-diols;
thiol		reducing agent;
vulnerary
2-methyltetrahydrofuran
2-methyltetrahydrofuran: structure in first source		7.0810
4-butyrolactone
4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.		3.3970butan-4-olidemetabolite;
neurotoxin
soman
Soman: An organophosphorus compound that inhibits cholinesterase. It causes seizures and has been used as a chemical warfare agent.		3.1250phosphonic ester
phosphoribosyl pyrophosphate
Phosphoribosyl Pyrophosphate: The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.. 5-phosphoribosyl diphosphate : A ribose diphosphate carrying an additional phosphate group at position 5.. 5-O-phosphono-alpha-D-ribofuranosyl diphosphate : A derivative of alpha-D-ribose having a phosphate group at the 5-position and a diphosphate at the 1-position.		2.42205-O-phosphono-D-ribofuranosyl diphosphateEscherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite
furaldehyde
Furaldehyde: A heterocyclic compound consisting of a furan where the hydrogen at position 2 is substituted by a formyl group.. furfural : An aldehyde that is furan with the hydrogen at position 2 substituted by a formyl group.		2.6620aldehyde;
furans		Maillard reaction product;
metabolite
arsanilic acid
Arsanilic Acid: An arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals.		2.0410organoarsonic acid
pyrrolidonecarboxylic acid
Pyrrolidonecarboxylic Acid: A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of GLUTAMINE or GLUTATHIONE metabolism.. 5-oxo-L-proline : An optically active form of 5-oxoproline having L-configuration.		5.171505-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
3-aminobenzoic acid
3-aminobenzoic acid: RN given refers to parent cpd. 3-aminobenzoic acid : An aminobenzoic acid carrying an amino group at position 3.		2.0610aminobenzoic acid
trehalose
alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.		8.71100trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
methyl gallate
methyl gallate: has both immunosuppressive and phytogenic antineoplastic activities; isolated from Acer saccharinum. methyl 3,4,5-trihydroxybenzoate : A gallate ester obtained by the formal condensation of gallic acid with methanol. It exhibits anti-oxidant, anti-tumor, anti-microbial and anti-inflammatory properties.		2.1310gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite
dicloran
2,6-dichloro-4-nitroaniline : A nitroaniline that is 4-nitroaniline in which the hydrogens at positions 2 and 6 are replaced by chlorines. An agricultural fungicide, it is not approved for use in the European Union.		2.0410aromatic fungicide;
dichlorobenzene;
nitroaniline		antifungal agrochemical
4-bromophenacyl bromide
4-bromophenacyl bromide: phospholipidase A(2) inhibitor; structure		210
4-nitrotoluene
4-nitrotoluene: RN given refers to parent cpd; structure in Merck Index, 9th ed, #6470. mononitrotoluene : A nitrotoluene bearing a single nitro substituent at any position. A "closed class".. 4-nitrotoluene : A mononitrotoluene that consists of toluene bearing a nitro substituent at the 4-position.		1.9310mononitrotoluene
4-nitroaniline
[no description available]		2.3820nitroanilinebacterial xenobiotic metabolite
4-nitrobenzyl chloride
4-nitrobenzyl chloride: structure given in first source. p-nitrobenzyl chloride : A C-nitro compound that is nitrobenzene in which the hydrogen at position 4 is replaced by a chloromethyl group.		210benzyl chlorides;
C-nitro compound		mutagen
2-diethylaminoethanol
2-diethylaminoethanol: RN given refers to unlabeled parent cpd. 2-diethylaminoethanol : A member of the class of ethanolamines that is aminoethanol in which the hydrogens of the amino group are replaced by ethyl groups.		2.3620ethanolamines;
primary alcohol;
tertiary amino compound
4-vinylpyridine
4-vinylpyridine: reagent for blocking cysteine function in proteins; RN given refers to parent cpd		1.9710
phenylhydrazine
[no description available]		1.9410phenylhydrazinesxenobiotic
quinuclidines
Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.		2.4820quinuclidines;
saturated organic heterobicyclic parent
ethyl phenylacetate
[no description available]		2.1710benzenes
boric acid
[no description available]		3.0750boric acidsastringent
2-phenylethyl acetate
phenethyl acetate : The acetate ester of 2-phenylethanol.		2.1710acetate estermetabolite;
Saccharomyces cerevisiae metabolite
phenylisothiocyanate
phenylisothiocyanate: structure. phenyl isothiocyanate : An isothiocyanate having a phenyl group attached to the nitrogen; used for amino acid sequencing in the Edman degradation.		7.8940isothiocyanateallergen;
reagent
4-nitroacetanilide
[no description available]		2.0110
epichlorohydrin
Epichlorohydrin: A chlorinated epoxy compound used as an industrial solvent. It is a strong skin irritant and carcinogen.. epichlorohydrin : An epoxide that is 1,2-epoxypropene in which one of the methyl hydrogens is substituted by chlorine.		3.4111epoxide;
organochlorine compound
acrolein
[no description available]		9.4460enalherbicide;
human xenobiotic metabolite;
toxin
acrylonitrile
[no description available]		2.0510aliphatic nitrile;
volatile organic compound		antifungal agent;
carcinogenic agent;
fungal metabolite;
mutagen;
polar aprotic solvent
glyoxal
[no description available]		3.0950dialdehydeagrochemical;
allergen;
pesticide;
plant growth regulator
isethionic acid
Isethionic Acid: A colorless, syrupy, strongly acidic liquid that can form detergents with oleic acid.. isethionic acid : An alkanesulfonic acid in which the sulfo group is directly linked to a 2-hydroxyethyl group.		1.9510alkanesulfonic acidhuman metabolite
sarin
Sarin: An organophosphorus ester compound that produces potent and irreversible inhibition of cholinesterase. It is toxic to the nervous system and is a chemical warfare agent.. isopropyl methylphosphonofluoridate : A phosphinic ester that is the isopropyl ester of methylphosphonofluoridic acid.. sarin : A racemate composed of equal amounts of (R)- and (S)-sarin. A potent and irreversible inhibitor of acetylcholinesterase that is toxic to the nervous system and is employed as a chemical warfare agent.		7.9640fluorine molecular entity;
phosphinic ester
2-methylpentane
Hexanes: Six-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives. Various polyneuropathies are caused by hexane poisoning.		1.9610alkane
3-hydroxybutanal
[no description available]		3.3560
3-chloropropionic acid
3-chloropropionic acid: structure		2.1110
biuret
Biuret: Used as feed supplement for sheep and cattle since it is a good non-protein nitrogen source. In strongly alkaline solution biuret gives a violet color with copper sulfate.. biuret : A member of the class of condensed ureas that is the compound formed by the condensation of two molecules of urea; the parent compound of the biuret group of compounds. Used as a non-protein nitrogen source in ruminant feed.		2.1510condensed ureas
acetic anhydride
acetic anhydride: RN given refers to unlabeled cpd; structure. acetic anhydride : An acyclic carboxylic anhydride derived from acetic acid.		2.4220acyclic carboxylic anhydridemetabolite;
reagent
succinic anhydride
[no description available]		1.9810cyclic dicarboxylic anhydride;
tetrahydrofurandione
3-phenylenediamine
1,3-phenylenediamine : A phenylenediamine taht is benzene substituted at positions 1 and 3 with amino functions.		2.3110phenylenediamine
2,6-lutidine
2,6-dimethylpyridine : A member of the class of methylpyridines that is pyridine carrying methyl substituents at positions 2 and 6.		2.1110methylpyridines
cyanuric acid
cyanuric acid: RN given refers to parent cpd. isocyanuric acid : The keto tautomer of cyanuric acid.. cyanuric acid : The enol tautomer of isocyanuric acid.		2.15101,3,5-triazinanes;
1,3,5-triazines;
heteroaryl hydroxy compound		xenobiotic
bromobenzene
[no description available]		2.2110bromoarene;
bromobenzenes;
volatile organic compound		hepatotoxic agent;
mouse metabolite;
non-polar solvent
cyclohexanol
Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.		3.1550cyclohexanols;
secondary alcohol		solvent
thiophenol
thiophenol : A thiol in which the sulfanyl group is attached to a phenyl group.		2.2110aryl thiol
1,3-dibromopropane
1,3-dibromopropane: see also record for dibromopropane		1.9810
n-methylaminoethanol
N-methylaminoethanol: structure. N-methylethanolamine : An ethanolamine compound having an N-methyl substituent.		1.9710ethanolamines
methyl cellosolve
methyl cellosolve: widely used industrial solvent for resins, lacquers, dyes & inks; may cause anemia macrocytosis, appearance of young granulocytes in blood; RN given refers to parent cpd		2.8940glycol etherprotic solvent;
solvent
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		5.77330pyrrole;
secondary amine
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		3.94120mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
cyclohexane
Cyclohexane: C6H12. cyclohexane : An alicyclic hydrocarbon comprising a ring of six carbon atoms; the cyclic form of hexane, used as a raw material in the manufacture of nylon.		2.1110cycloalkane;
volatile organic compound		non-polar solvent
piperidine
[no description available]		2.4720azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine		base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent
morpholine
[no description available]		7.7630morpholines;
saturated organic heteromonocyclic parent		NMR chemical shift reference compound
1-hexanol
1-hexanol: RN given refers to parent cpd. hexanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of six carbon atoms.. hexan-1-ol : A primary alcohol that is hexane substituted by a hydroxy group at position 1.		2.3720hexanol;
primary alcohol		alarm pheromone;
antibacterial agent;
fragrance;
plant metabolite
behenic acid
behenic acid: RN given refers to parent cpd; structure. docosanoic acid : A straight-chain, C22, long-chain saturated fatty acid.		2.2110long-chain fatty acid;
straight-chain saturated fatty acid		plant metabolite
ergotamine
Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.		1.9410peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
phenformin
Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.		2.4620biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
propylene
propylene: structure		2.0410alkene;
gas molecular entity		refrigerant;
xenobiotic
diethylhexyl phthalate
Diethylhexyl Phthalate: An ester of phthalic acid. It appears as a light-colored, odorless liquid and is used as a plasticizer for many resins and elastomers.. bis(2-ethylhexyl) phthalate : A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.		2.4420diester;
phthalate ester		androstane receptor agonist;
apoptosis inhibitor;
plasticiser
chloranil
Chloranil: A quinone fungicide used for treatment of seeds and foliage.. tetrachloro-1,4-benzoquinone : A member of the class of 1,4-benzoquiones that is 1,4-benzoquinone in which all four hydrogens are substituted by chlorines.		1.98101,4-benzoquinones;
organochlorine compound		EC 2.7.1.33 (pantothenate kinase) inhibitor;
metabolite
trinitrotoluene
Trinitrotoluene: A 2,4,6-trinitrotoluene, which is an explosive chemical that can cause skin irritation and other toxic consequences.. 2,4,6-trinitrotoluene : A trinitrotoluene having the nitro groups at positions 2, 4 and 6.		7.0310trinitrotolueneexplosive
framycetin
Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.		3.5690aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
tetralin
tetralin: structure given in first source. tetralin : An ortho-fused bicyclic hydrocarbon that is 1,2,3,4-tetrahydro derivative of naphthalene.		710ortho-fused bicyclic hydrocarbon;
tetralins
pyrazolanthrone
pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.		4.48220anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
meglumine
Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.		3.3411hexosamine;
secondary amino compound
uridine diphosphate glucose
Uridine Diphosphate Glucose: A key intermediate in carbohydrate metabolism. Serves as a precursor of glycogen, can be metabolized into UDPgalactose and UDPglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid. Also serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids.. UDP-alpha-D-glucose : The alpha-anomer of UDP-alpha-D-glucose. It is used in nucleotide sugars metabolism.		3.0950UDP-D-glucosefundamental metabolite
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		3.2660naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
shikimic acid
Shikimic Acid: A tri-hydroxy cyclohexene carboxylic acid important in biosynthesis of so many compounds that the shikimate pathway is named after it.. shikimic acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid substituted by hydroxy groups at positions 3, 4 and 5 (the 3R,4S,5R stereoisomer). It is an intermediate metabolite in plants and microorganisms.		5.07140alpha,beta-unsaturated monocarboxylic acid;
cyclohexenecarboxylic acid;
hydroxy monocarboxylic acid		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
nitrilotriacetic acid
Nitrilotriacetic Acid: A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.)		2.6530NTA;
tricarboxylic acid		carcinogenic agent;
nephrotoxic agent
protocatechualdehyde
protocatechualdehyde: found in wheat grains, wheat seedlings, & other plants; RN given refers to parent cpd; see also rancinamycins; structure		6.9710dihydroxybenzaldehyde
ethyl acetate
ethyl acetate : The acetate ester formed between acetic acid and ethanol.		2.0810acetate ester;
ethyl ester;
volatile organic compound		EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor;
metabolite;
polar aprotic solvent;
Saccharomyces cerevisiae metabolite
iminodiacetic acid
iminodiacetic acid: used as hepatobiliary imaging agent when labeled with Tc; RN given refers to parent cpd; structure. iminodiacetic acid : An amino dicarboxylic acid that is glycine in which one of the hydrogens attached to the nitrogen is substituted by a carboxymethyl group.		2.0510amino dicarboxylic acid;
glycine derivative;
non-proteinogenic alpha-amino acid		chelator
n-heptane
Heptanes: Seven-carbon alkanes with the formula C7H16.. heptane : A straight-chain alkane with seven carbon atoms. It has been found in Jeffrey pine (Pinus jeffreyi).		2.4120alkane;
volatile organic compound		non-polar solvent;
plant metabolite
sodium cyanide
Sodium Cyanide: A highly poisonous compound that is an inhibitor of many metabolic processes and is used as a test reagent for the function of chemoreceptors. It is also used in many industrial processes.. sodium cyanide : A cyanide salt containing equal numbers of sodium cations and cyanide anions.		210cyanide salt;
one-carbon compound;
sodium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor
pregnenolone
[no description available]		2.934020-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid		human metabolite;
mouse metabolite
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		2.6930methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
3-o-methylglucose
3-O-Methylglucose: A non-metabolizable glucose analogue that is not phosphorylated by hexokinase. 3-O-Methylglucose is used as a marker to assess glucose transport by evaluating its uptake within various cells and organ systems. (J Neurochem 1993;60(4):1498-504). 3-O-methyl-D-glucose : A D-aldohexose that is D-glucose in which the hydrogen of the hydroxy group at position 3 has been substituted by a methyl group. It is a non-metabolisable glucose analogue that is not phosphorylated by hexokinase and is used as a marker to assess glucose transport by evaluating its uptake within various cells and organ systems.		2.4820D-aldohexose derivative
2-fluoroadenosine
[no description available]		2.0710adenosines;
organofluorine compound
ditiocarb
Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.		2.3820dithiocarbamic acidschelator;
copper chelator
D-proline
[no description available]		2.0610D-alpha-amino acid zwitterion;
D-alpha-amino acid;
proline		mouse metabolite
potassium cyanide
[no description available]		2.6830cyanide salt;
one-carbon compound;
potassium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
neurotoxin
aziridine
[no description available]		8.1650azacycloalkane;
aziridines;
saturated organic heteromonocyclic parent		alkylating agent
cycloguanil
cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source. cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil.		1.9910triazinesantifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
D-tryptophan
[no description available]		210D-alpha-amino acid;
tryptophan zwitterion;
tryptophan		bacterial metabolite
catechin
Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.		3.83110catechinantioxidant;
plant metabolite
thiamine pyrophosphate
Thiamine Pyrophosphate: The coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the PYRUVATE DEHYDROGENASE COMPLEX and the KETOGLUTARATE DEHYDROGENASE COMPLEX.. thiamine(1+) diphosphate chloride : An organic chloride salt of thiamine(1+) diphosphate.		4.5780organic chloride salt;
vitamin B1
homoarginine
L-homoarginine : An L-lysine derivative that is the L-enantiomer of homoarginine.		1.9910homoarginine;
L-lysine derivative;
non-proteinogenic L-alpha-amino acid		biomarker;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
human metabolite;
rat metabolite;
xenobiotic metabolite
diazooxonorleucine
Diazooxonorleucine: An amino acid that inhibits phosphate-activated glutaminase and interferes with glutamine metabolism. It is an antineoplastic antibiotic produced by an unidentified species of Streptomyces from Peruvian soil. (From Merck Index, 11th ed). 6-diazo-5-oxo-L-norleucine : A non-proteinogenic L-alpha-amino acid that is L-norleucine which is substituted at position 5 by an oxo group and at position 6 by a diazo group. It is as inhibitor of various glutamine-utilising enzymes.		4.24190amino acid zwitterion;
diazo compound;
ketone;
non-proteinogenic L-alpha-amino acid		analgesic;
antibacterial agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
bacterial metabolite;
EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor;
EC 3.5.1.2 (glutaminase) inhibitor;
EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor;
EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor;
EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor;
glutamine antagonist
dibenzo(a,l)pyrene
dibenzo(a,l)pyrene: structure in first source		2.0410ortho- and peri-fused polycyclic arenehuman metabolite;
mutagen
perylene
Perylene: A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic.. perylene : An ortho- and peri-fused polycyclic arene comprising of five benzene rings that is anthracene in which the d,e and k,l sides are fused to benzene rings.		2.110ortho- and peri-fused polycyclic arene;
perylenes
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		4.48220azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		3.74110acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		4.06140indazole
benzoxazoles
1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.		2.45201,3-benzoxazoles;
mancude organic heterobicyclic parent
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		2.9640adamantanes;
polycyclic alkane
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		3.7100cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		4.61260isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		6.526001,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		5.516601,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrimidine
pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.		3.4780diazine;
pyrimidines		Daphnia magna metabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		6.43151diazine;
pyrazines		Daphnia magna metabolite
nitroblue tetrazolium
Nitroblue Tetrazolium: Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease.		1.9710organic cation
methylphenazonium methosulfate
Methylphenazonium Methosulfate: Used as an electron carrier in place of the flavine enzyme of Warburg in the hexosemonophosphate system and also in the preparation of SUCCINIC DEHYDROGENASE.		2.3920azaheterocycle sulfate salt;
phenazines
ephedrine
Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.		2.0410phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
allylisopropylacetamide
Allylisopropylacetamide: An allylic compound that acts as a suicide inactivator of CYTOCHROME P450 by covalently binding to its heme moiety or surrounding protein.		2.3720
3-methoxytyrosine
3-O-methyldopa : A L-tyrosine derivative that is the 3-methoxy derivative of L-dopa.		210aromatic L-alpha-amino acid zwitterion;
L-tyrosine derivative;
monomethoxybenzene;
non-proteinogenic L-alpha-amino acid		human metabolite
muscarine
Muscarine: A toxic alkaloid found in Amanita muscaria (fly fungus) and other fungi of the Inocybe species. It is the first parasympathomimetic substance ever studied and causes profound parasympathetic activation that may end in convulsions and death. The specific antidote is atropine.		2.2110monosaccharide
hydrazine
diamine : Any polyamine that contains two amino groups.		8.66772azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
thiocyanate
thiocyanate: RN given refers to parent cpd. thiocyanate : A pseudohalide anion obtained by deprotonation of the thiol group of thiocyanic acid.		2.0110pseudohalide anion;
sulfur molecular entity		human metabolite
paraoxon
[no description available]		3.2460aryl dialkyl phosphate;
organophosphate insecticide		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
mouse metabolite
hemicholinium 3
Hemicholinium 3: A potent inhibitor of the high affinity uptake system for CHOLINE. It has less effect on the low affinity uptake system. Since choline is one of the components of ACETYLCHOLINE, treatment with hemicholinium can deplete acetylcholine from cholinergic terminals. Hemicholinium 3 is commonly used as a research tool in animal and in vitro experiments.		2.3620
dexamethasone 21-phosphate
dexamethasone 21-phosphate: has anti-inflammatory activity. dexamethasone phosphate : A steroid phosphate that is the 21-O-phospho derivative of dexamethasone.		1.981011beta-hydroxy steroid;
17-hydroxy steroid;
3-oxo-Delta(4) steroid;
fluorinated steroid;
steroid phosphate;
tertiary alpha-hydroxy ketone		glucocorticoid receptor agonist
monocrotaline
Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.		2.520pyrrolizidine alkaloid
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		2.4520N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
linuron
Linuron: A selective pre- and post-emergence herbicide. (From Merck Index, 11th ed). linuron : A member of the class of phenylureas that is N-methyl urea substituted by a methoxy group at position 1 and a 3,4-dichlorophenyl group at position 3.		2.0310dichlorobenzene;
phenylureas		agrochemical;
environmental contaminant;
herbicide;
xenobiotic
diazomethane
Diazomethane: A diazonium compound with the formula CH2N2.. diazomethane : The simplest diazo compound, in which a diazo group is attached to a methylene group.		2.3720diazo compoundalkylating agent;
antineoplastic agent;
carcinogenic agent;
poison
perfluorooctanoic acid
perfluorooctanoic acid: RN given refers to parent cpd. perfluorooctanoic acid : A fluoroalkanoic acid that is perfluorinated octanoic acid.		2.4110fluoroalkanoic acidcarcinogenic agent;
endocrine disruptor;
environmental contaminant;
surfactant;
xenobiotic
trifluoroethene
[no description available]		2.0210
aminoimidazole carboxamide
Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.		5.35210aminoimidazole;
monocarboxylic acid amide		mouse metabolite
methysergide
Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.		1.9910ergoline alkaloid
thymidine monophosphate
Thymidine Monophosphate: 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.. dTMP : The neutral species of thymidine 5'-monophosphate (2'-deoxythymidine 5'-monophosphate).		6.58150thymidine 5'-monophosphatefundamental metabolite
cuprizone
[no description available]		7.2110organonitrogen compound;
organooxygen compound
mipafox
mipafox: structure		2.1310phosphoramide
citrulline
citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position.		13.79361amino acid zwitterion;
citrulline		Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite
perfluorobutyric acid
perfluorobutyric acid: ion pairing reagent; RN given refers to parent cpd. perfluorobutyric acid : A monocarboxylic acid that is perfluorinated butyric acid.		1.9910fluoroalkanoic acidchromatographic reagent;
environmental contaminant;
xenobiotic
betamethasone
Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)		1.941011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
5-methylpyrazole-3-carboxylic acid
5-methylpyrazole-3-carboxylic acid: structure. 5-methyl-pyrazole-3-carboxylic acid : A memebr of the class of pyrazoles that is 1H-pyrazole with methyl and carboxylic acid group substituents at positions 5 and 3 respectively.		2.0410monocarboxylic acid;
pyrazoles		metabolite
ethylene sulfide
[no description available]		2.0310organosulfur heterocyclic compound;
saturated organic heteromonocyclic parent
lithocholic acid
Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.		2.4110bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid		geroprotector;
human metabolite;
mouse metabolite
nandrolone
Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.		1.941017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
4-methylcatechol
[no description available]		6.9710methylcatecholantioxidant;
carcinogenic agent;
hapten;
human metabolite;
plant metabolite
4-toluenesulfonyl fluoride
4-toluenesulfonyl fluoride: inhibitor of peptide hydrolases; structure in second source		2.9340
hydantoins
Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.		3.96140imidazolidine-2,4-dione
fluorobenzenes
Fluorobenzenes: Derivatives of BENZENE that contain FLUORINE.. monofluorobenzene : The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.. fluorobenzenes : Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.		2.3720monofluorobenzenesNMR chemical shift reference compound
homocystine
[no description available]		4.6590amino acid zwitterion;
homocystines		human metabolite
hydantoic acid
hydantoic acid: norallophanic acid; structure		1.9610monocarboxylic acid;
N-acylglycine;
ureas		rat metabolite;
xenobiotic metabolite
propadiene
[no description available]		2.520allenes
carbonyl sulfide
carbonyl sulfide: structure. carbonyl sulfide : A one-carbon compound in which the carbon atom is attached to an oxygen and a sulfur atom via double bonds.		2.0210one-carbon compound;
organosulfur compound
3,3-dimethyl-2-butanol
[no description available]		210
limestone
Calcium Carbonate: Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.. calcium carbonate : A calcium salt with formula CCaO3.		3.4270calcium salt;
carbonate salt;
inorganic calcium salt;
one-carbon compound		antacid;
fertilizer;
food colouring;
food firming agent
hopane
hopane: RN given refers to cpd without isomeric designation		2.2110terpenoid fundamental parent;
triterpene
mesoxalic acid
mesoxalic acid: structure		2.0210oxo dicarboxylic acid
fusarium
Fusarium: A mitosporic Hypocreales fungal genus, various species of which are important parasitic pathogens of plants and a variety of vertebrates. Teleomorphs include GIBBERELLA.		9.08150
indirubin
[no description available]		2.0310
plumbagin
plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.		7.4220hydroxy-1,4-naphthoquinone;
phenols		anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite
phosphoadenosine phosphosulfate
Phosphoadenosine Phosphosulfate: 3'-Phosphoadenosine-5'-phosphosulfate. Key intermediate in the formation by living cells of sulfate esters of phenols, alcohols, steroids, sulfated polysaccharides, and simple esters, such as choline sulfate. It is formed from sulfate ion and ATP in a two-step process. This compound also is an important step in the process of sulfur fixation in plants and microorganisms.. 3'-phospho-5'-adenylyl sulfate : An adenosine bisphosphate having monophosphate groups at the 3'- and 5'-positions and a sulfo group attached to the phosphate at position 5'.		2.3920acyl sulfate;
adenosine bisphosphate;
purine ribonucleoside bisphosphate		Escherichia coli metabolite;
mouse metabolite
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		2.3520isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
cytisine
[no description available]		2.9310alkaloid;
bridged compound;
lactam;
organic heterotricyclic compound;
secondary amino compound		nicotinic acetylcholine receptor agonist;
phytotoxin;
plant metabolite
ninhydrin
Ninhydrin: 2,2-Dihydroxy-1H-indene-1,3-(2H)-dione. Reagent toxic to skin and mucus membranes. It is used in chemical assay for peptide bonds, i.e., protein determinations and has radiosensitizing properties.. ninhydrin : A member of the class of indanones that is indane-1,3-dione bearing two additional hydroxy substituents at position 2.		3.0510aromatic ketone;
beta-diketone;
indanones;
ketone hydrate		colour indicator;
human metabolite
bicuculline
Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.		3.87120benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
kainic acid
Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.		10.19470dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
bufotenin
Bufotenin: A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a tool in CNS studies and misused as a psychedelic.. bufotenin : A tertiary amine that consists of N,N-dimethyltryptamine bearing an additional hydroxy substituent at position 5.		2.420tertiary amine;
tryptamine alkaloid		coral metabolite;
hallucinogen
fructose-1,6-diphosphate
beta-D-fructofuranose 1,6-bisphosphate : A D-fructofuranose 1,6-bisphosphate with a beta-configuration at the anomeric position.		2.4110D-fructofuranose 1,6-bisphosphatemouse metabolite
thymoquinone
thymoquinone: constituent of cedarwood; can cause dermatitis; structure. thymoquinone : A member of the class of 1,4-benzoquinones that is 1,4-bezoquinone in which the hydrogens at positions 2 and 5 are replaced by methyl and isopropyl groups, respectively. It is a natural compound isolated from Nigella sativa which has demonstrated promising chemotherapeutic activity.		2.08101,4-benzoquinonesadjuvant;
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
cardioprotective agent;
plant metabolite
salicylaldehyde isonicotinoyl hydrazone
salicylaldehyde isonicotinoyl hydrazone: structure in first source		2.0110
indoline
indoline: structure given in first source		2.4320indoles
dithiol
dithiol: structure		2.4220
isomaltose
[no description available]		2.4120
4-hydroxybutyric acid
4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.		2.06104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
oxetane
oxetane: structure. oxetane : A saturated organic heteromonocyclic parent that is a four-membered ring comprising of three carbon atoms and an oxygen atom.		710oxetanes;
saturated organic heteromonocyclic parent
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		3.3350
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		3.5680thiazolidine
cyanogen bromide
Cyanogen Bromide: Cyanogen bromide (CNBr). A compound used in molecular biology to digest some proteins and as a coupling reagent for phosphoroamidate or pyrophosphate internucleotide bonds in DNA duplexes.		5.12460
thioacetic acid
ethanethioic S-acid : A thioacetic acid that is acetic acid in which the oxygen atom of the hydroxy group has been replaced by a sulfur atom.		1.9710thioacetic acid
oleanolic acid
[no description available]		2.2110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
tetranitromethane
[no description available]		2.6730organonitrogen compound
echothiophate iodide
Echothiophate Iodide: A potent, long-acting cholinesterase inhibitor used as a miotic in the treatment of glaucoma.. ecothiopate iodide : The iodide salt of ecothiopate. An irreversible acetylcholinesterase inhibitor, it is used an ocular antihypertensive in the treatment of open-angle glaucoma, particularly when other drugs have proved inadequate.		2.0310iodide salt;
quaternary ammonium salt		antiglaucoma drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
hematoxylin
Hematoxylin: A dye obtained from the heartwood of logwood (Haematoxylon campechianum Linn., Leguminosae) used as a stain in microscopy and in the manufacture of ink.		2.4110organic heterotetracyclic compound;
oxacycle;
polyphenol;
tertiary alcohol		histological dye;
plant metabolite
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.3720furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		3.568017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
luminol
Luminol: 5-Amino-2,3-dihydro-1,4-phthalazinedione. Substance that emits light on oxidation. It is used in chemical determinations.		2.1110
flavone
flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.		2.4120flavonesmetabolite;
nematicide
gluconic acid
gluconic acid: zinc gluconate has anti-inflammatory activity; RN given refers to (D)-isomer; all RRs refers to (D)-isomer unless otherwise noted. ketogluconic acid : A gluconic acid that contains a ketonic carbonyl group.. D-gluconic acid : A gluconic acid having D-configuration.		2.4420gluconic acidchelator;
Penicillium metabolite
copper gluconate
Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.		2.8940organic molecular entity
uridine diphosphate n-acetylglucosamine
Uridine Diphosphate N-Acetylglucosamine: Serves as the biological precursor of insect chitin, of muramic acid in bacterial cell walls, and of sialic acids in mammalian glycoproteins.		3.1350
1,2-dinitrobenzene
[no description available]		2.0310dinitrobenzene
cellobiose
beta-cellobiose : A cellobiose with beta configuration at the reducing-end glucose residue.		7.7330cellobioseepitope
syringic acid
syringic acid: RN given refers to parent cpd; structure in third source. syringic acid : A dimethoxybenzene that is 3,5-dimethyl ether derivative of gallic acid.		2.4110benzoic acids;
dimethoxybenzene;
phenols		plant metabolite
mandelonitrile, (+-)-isomer
[no description available]		2.0310cyanohydrin
methoxyhydroxyphenylglycol
Methoxyhydroxyphenylglycol: Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover.		6.07162methoxybenzenes;
phenols
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		8.72100amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
dicyclohexylcarbodiimide
1,3-dicyclohexylcarbodiimide : A carbodiimide compound having a cyclohexyl substituent on both nitrogen atoms.		8.2160carbodiimideATP synthase inhibitor;
cross-linking reagent;
peptide coupling reagent
aminoacetonitrile
Aminoacetonitrile: Cyanomethylamine.		2.0410
uranyl acetate
uranyl acetate: used after fixation in uranaffin procedure; RN given refers to parent cpd		2.0810
pentamethonium
pentamethonium: RN given refers to parent cpd. pentamethonium : A quarternary ammonium cation that is cadaverine in which the terminal amino hydrogens are substituted methyl groups. Its bromide and iodide salt exhibits ganglionic blocking activity and used in the treatment of hypertension.		1.9910quaternary ammonium ionantihypertensive agent;
vasodilator agent
maleimide
[no description available]		2.0410dicarboximide;
maleimides		EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		9.09150dialdehydebiomarker
aceturic acid
aceturic acid: structure. N-acetylglycine : An N-acylglycine where the acyl group is specified as acetyl.		2.3720N-acetyl-amino acid;
N-acylglycine		human metabolite
myristic acid
Myristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed). tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.. tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3.		3.94130long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite
trinitrobenzenesulfonic acid
Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.		2.6630arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent
eosine yellowish-(ys)
Eosine Yellowish-(YS): A versatile red dye used in cosmetics, pharmaceuticals, textiles, etc., and as tissue stain, vital stain, and counterstain with HEMATOXYLIN. It is also used in special culture media.. eosin YS dye : An organic sodium salt that is 2',4',5',7'-tetrabromofluorescein in which the carboxy group and the phenolic hydroxy group have been deprotonated and the resulting charge is neutralised by two sodium ions.		2.420organic sodium salt;
organobromine compound		fluorochrome;
histological dye
resazurin
resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure		2.420phenoxazine
aminopenicillanic acid
aminopenicillanic acid: RN given refers to parent cpd; structure. 6-aminopenicillanic acid : A penicillanic acid compound having a (6R)-amino substituent. The active nucleus common to all penicillins, it may be substituted at the 6-amino position to form the semisynthetic penicillins, resulting in a variety of antibacterial and pharmacologic characteristics.		7.3720amino acid zwitterion;
penicillanic acids		allergen
neutral red
Neutral Red: A vital dye used as an indicator and biological stain. Various adverse effects have been observed in biological systems.. neutral red : A hydrochloride obtained by combining the free base of neutral red with one equivalent of hydrochloric acid. Neutral red acts as a pH indicator, changing from red to yellow between pH 6.8 and 8.0.		2.0210hydrochlorideacid-base indicator;
dye;
two-colour indicator
nicotinic acid hydrazide
nicotinic acid hydrazide: structural homolog of isoniazid; structure given in first source		210
lithium carbonate
Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.		2.0510carbonate salt;
lithium salt		antimanic drug
4-chloromercuribenzenesulfonate
4-Chloromercuribenzenesulfonate: A cytotoxic sulfhydryl reagent that inhibits several subcellular metabolic systems and is used as a tool in cellular physiology.		2.9240arenesulfonic acid;
arylmercury compound
glycyl-glycyl-glycine
glycyl-glycyl-glycine : A tripeptide in which three glycine units are linked via peptide bonds in a linear sequence.		2.730tripeptide zwitterion;
tripeptide
glycylglycine
[no description available]		9.78100dipeptide zwitterion;
dipeptide		human metabolite
methanesulfonyl fluoride
methanesulfonyl fluoride: structure		1.9510
18-hydroxycorticosterone
[no description available]		1.971011beta-hydroxy steroid;
18-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo steroid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
glycerylphosphorylcholine
Glycerylphosphorylcholine: A component of PHOSPHATIDYLCHOLINES or LECITHINS, in which the two hydroxy groups of GLYCEROL are esterified with fatty acids. (From Stedman, 26th ed)		3.260glycerophosphocholine
diepoxybutane
diepoxybutane: difunctional alkylating agent; RN given refers to cpd with unspecified isomeric designation; structure		1.9810epoxidemutagen
isoserine
isoserine: RN given refers to cpd without isomeric designation		4.44220
congo red
Congo Red: An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.. Congo Red : An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.		2.9610bis(azo) compound
3-hydroxyflavone
3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.		2.8130flavonols;
monohydroxyflavone
potassium carbonate
potassium carbonate : A potassium salt that is the dipotassium salt of carbonic acid.		2.420carbonate salt;
potassium salt		catalyst;
fertilizer;
flame retardant
allethrins
Allethrins: Synthetic analogs of the naturally occurring insecticides cinerin, jasmolin, and pyrethrin. (From Merck Index, 11th ed)		2.2510cyclopropanecarboxylate esterpyrethroid ester insecticide
diphenylamine
Diphenylamine: In humans it may be irritating to mucous membranes. Methemoglobinemia has been produced experimentally. In veterinary use, it is one of active ingredients in topical agents for prevention and treatment of screwworm infestation. An indicator in tests for nitrate poisoning.. diphenylamine : An aromatic amine containing two phenyl substituents. It has been used as a fungicide for the treatment of superficial scald in apples and pears, but is no longer approved for this purpose within the European Union.		2.5120aromatic amine;
bridged diphenyl fungicide;
secondary amino compound		antifungal agrochemical;
antioxidant;
carotogenesis inhibitor;
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor;
ferroptosis inhibitor;
radical scavenger
3-tyramine
3-tyramine: MH Tyramine refers to 4-tyramine; RN given refers to parent cpd. m-tyramine : A primary amino compound that is 2-phenylethanamine substituted by a hydroxy group at position 3.		210primary amino compound;
tyramines		human urinary metabolite;
neurotransmitter
levulinic acid
levulinic acid: inhibits 5-aminolevulinic acid dehydratase; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5316. 4-oxopentanoic acid : An oxopentanoic acid with the oxo group in the 4-position.		1.9410oxopentanoic acid;
straight-chain saturated fatty acid		plant metabolite
n-methylhydroxylamine
[no description available]		2.3920
2,2-dimethylmalonate
dimethylmalonic acid : A dicarboxylic acid that is malonic acid in which both methylene hydrogens have been replaced by methyl groups.		1.9810dicarboxylic acidfatty acid synthesis inhibitor
(s)-binol
(1,1'-binaphthalene)-2,2'-diol: structure in first source		2.0510naphthols
alpha-naphthoflavone
alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).		2.4220extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
dansyl chloride
dansyl chloride: RN given refers to unlabeled cpd		7.4620aminonaphthalene;
sulfonic acid derivative
toyocamycin
Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.		2.0310antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside		antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
1-aminoanthracene
[no description available]		2.0110anthracenamine
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		4.99380acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
chorismic acid
Chorismic Acid: A cyclohexadiene carboxylic acid derived from SHIKIMIC ACID and a precursor for the biosynthesis of UBIQUINONE and the AROMATIC AMINO ACIDS.. chorismic acid : The (3R,4R)-stereoisomer of 5-[(1-carboxyethenyl)oxy]-6-hydroxycyclohexa-1,3-diene-1-carboxylic acid.		3.97405-[(1-carboxyethenyl)oxy]-6-hydroxycyclohexa-1,3-diene-1-carboxylic acidEscherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
diazoacetic ester
diazoacetic ester: structure		2.0510
methoxyacetic acid
methoxyacetic acid: RN given refers to parent cpd. methoxyacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a methoxy group.		1.9710ether;
monocarboxylic acid		antineoplastic agent;
apoptosis inducer;
human xenobiotic metabolite;
mutagen
3-iodoaniline
3-iodoaniline: the 125I cpd used for radiolabeling biotin; structure given in first source		2.0110
hexamethylene glycol
hexane-1,6-diol : A diol that is hexane substituted by hydroxy groups at positions 1 and 6.		2.1710diol;
primary alcohol
c.i. 42510
Rosaniline Dyes: Compounds that contain the triphenylmethane aniline structure found in rosaniline. Many of them have a characteristic magenta color and are used as COLORING AGENTS.. basic fuchsin : A four-component mixture of chemically related dyes comprising pararosanilin, rosanilin, magenta II and new fuchsin in varying amounts. rosanilin : A hydrochloride that is the monohydrochloride of 4-[(4-aminophenyl)(4-iminocyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline. One of the major constituents of Basic fuchsin, together with pararosanilin, magenta II and new fuchsin.		1.9710
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		3.3370cyclic ketone;
erythromycin
dehydroepiandrosterone sulfate
Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.		2.051017-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite
2'-deoxy-5'-adenosine monophosphate
2'-deoxy-5'-adenosine monophosphate: RN given refers to parent cpd. 2'-deoxyadenosine 5'-monophosphate : A purine 2'-deoxyribonucleoside 5'-monophosphate having adenine as the nucleobase.		1.99102'-deoxyadenosine 5'-phosphate;
purine 2'-deoxyribonucleoside 5'-monophosphate		fundamental metabolite
homoserine
homoserine : An alpha-amino acid that is glycine substituted at the alpha-position by a 2-hydroxyethyl group.. L-homoserine : The L-enantiomer of homoserine.		6.85370amino acid zwitterion;
homoserine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite
nitrosoguanidines
Nitrosoguanidines: Nitrosylated derivatives of guanidine. They are used as MUTAGENS in MOLECULAR BIOLOGY research.		3.89130
2-piperidone
2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.		2.4420delta-lactam;
piperidones		EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
methoxytryptophol
[no description available]		210indoles
diphenyliodonium
diphenyliodonium: RN given refers to the parent coumpound; inhibitor of neutrophil superoxide generating oxidase; structure has been determined		2.0710
ethylnitrosourea
Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.		3.1450N-nitrosoureasalkylating agent;
carcinogenic agent;
genotoxin;
mutagen
4-nitrophenyl acetate
[no description available]		2.9340C-nitro compound;
phenyl acetates
hydroxyethyl methacrylate
hydroxyethyl methacrylate: many of cited refs are for gel which refers to polymeric form of above cpd: POLYHYDROXYETHYL METHACRYLATE. 2-hydroxyethyl methacrylate : An enoate ester that is the monomethacryloyl derivative of ethylene glycol.		2.0410enoate esterallergen;
polymerisation monomer
lithium citrate
lithium citrate: RN given refers to the trilithium salt. lithium citrate (anhydrous) : A lithium salt that is the anhydrous form of the trilithium salt of citric acid. The tetrahydrate form is used as a source of lithium for the treatment of anxiety disorders, bipolar disorder, and depression.		2.0510lithium salt
hexafluoroisopropanol
1,1,1,3,3,3-hexafluoropropan-2-ol : An organofluorine compound formed by substitution of all the methyl protons in propan-2-ol by fluorine. It is a metabolite of inhalation anesthetic sevoflurane.		2.0510organofluorine compound;
secondary alcohol		drug metabolite
3-cyanoalanine
3-cyanoalanine: RN given refers to cpd without isomeric designation. 3-cyanoalanine : An alanine derivative obtained by replacement of one of the methyl hydrogens in alanine with a cyano group		2.6730alanine derivative;
aliphatic nitrile;
non-proteinogenic alpha-amino acid
2-aminobenzimidazole
2-aminobenzimidazole: metabolite of benomyl; RN given refers to parent cpd. 2-aminobenzimidazole : A member of the class of benzimidazoles that is benzimidazole in which the hydrogen at position 2 is replaced by an amino group.		2.0210benzimidazolesmarine xenobiotic metabolite
methylparaoxon
[no description available]		210C-nitro compound
deoxycytidine
[no description available]		7.9240pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
deoxyuridine
[no description available]		4.4570pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2,6-dichloroindophenol
2,6-Dichloroindophenol: A dye used as a reagent in the determination of vitamin C.. 2,6-dichloroindophenol : A quinone imine that is indophenol substituted by chloro groups at positions 2 and 6.. N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine : 1,4-benzoquinone imine having a 3,5-dichloro-4-hydroxyphenyl substituent attached to the nitrogen atom.		2.0110dichlorobenzene;
quinone imine
cytidine diphosphate choline
Cytidine Diphosphate Choline: Donor of choline in biosynthesis of choline-containing phosphoglycerides.		3.4880nucleotide-(amino alcohol)s;
phosphocholines		human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite
methylphosphonic acid
methylphosphonic acid : A one-carbon compound that is phosphonic acid in which the hydrogen attached to the phosphorus is substituted by a methyl group.		2.1310one-carbon compound;
phosphonic acids
chlormequat
Chlormequat: A plant growth regulator that is commonly used on ornamental plants.. chlormequat : A quaternary ammonium ion that is choline in which the hydroxy group has been replaced by a chlorine. Its salts (particularly the chloride salt, known as chlormequat chloride) are used as plant growth retardants.		1.9510quaternary ammonium ionplant growth retardant
pyrrolnitrin
Pyrrolnitrin: 3-Chloro-4-(3-chloro-2-nitrophenyl)pyrrole. Antifungal antibiotic isolated from Pseudomonas pyrrocinia. It is effective mainly against Trichophyton, Microsporium, Epidermophyton, and Penicillium.. pyrrolnitrin : A member of the class of pyrroles carrying chloro and 3-chloro-2-nitrophenyl substituents at positions 3 and 4 respectively.		3.0510alkaloid;
C-nitro compound;
monochlorobenzenes;
pyrroles		antifungal drug;
bacterial metabolite
deoxycytidine monophosphate
Deoxycytidine Monophosphate: Deoxycytidine (dihydrogen phosphate). A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions.. 2'-deoxycytosine 5'-monophosphate : A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having cytosine as the nucleobase.		2.01102'-deoxycytidine phosphate;
pyrimidine 2'-deoxyribonucleoside 5'-monophosphate		Escherichia coli metabolite;
mouse metabolite
allylglycine
Allylglycine: An inhibitor of glutamate decarboxylase and an antagonist of GAMMA-AMINOBUTYRIC ACID. It is used to induce convulsions in experimental animals.		7.0210
phenylglyoxal
[no description available]		2.6730phenylacetaldehydes
dimethoxon
dimethoxon: pesticide		2.0210organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
4-dimethylaminopyridine
4-dimethylaminopyridine: catalyst for acetylation of hydroxy cpds; structure		210dialkylarylamine;
tertiary amino compound
tetramethylpyrazine
tetramethylpyrazine: found in Ligusticum chuanxiong. tetramethylpyrazine : A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii).		2.0710alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
dihydroferulic acid
dihydroferulic acid: structure in first source. dihydroferulic acid : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 3 has been replaced by a 4-hydroxy-3-methoxyphenyl group.		2.0410guaiacols;
monocarboxylic acid;
phenylpropanoid		antioxidant;
human xenobiotic metabolite;
mouse metabolite;
plant metabolite
ethylenediamine-n,n'-bis(2-hydroxyphenylacetic acid)
ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid): synthetic iron chelator; RN given refers to parent cpd; structure in 3rd source		2.2110
n-methylacrylamide
N-methylacrylamide: structure in first source		2.0210
durapatite
Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).		3.72100
sodium hydroxide
Sodium Hydroxide: A highly caustic substance that is used to neutralize acids and make sodium salts. (From Merck Index, 11th ed)		3.5690alkali metal hydroxide
zinc oxide
Zinc Oxide: A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.		2.110zinc molecular entity
thorium dioxide
Thorium Dioxide: Thorium oxide (ThO2). A radiographic contrast agent that was used in the early 1930s through about 1954. High rates of mortality have been linked to its use and it has been shown to cause liver cancer.		210thorium molecular entity
arsenic trioxide
Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.		2.4220
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		4.75100glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		3.79110alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
tocopherols
[no description available]		2.0310
lysergol
lysergol: structure given in first source; RN given refers to (8beta)-isomer. lysergol : An alkaloid of the ergoline family that occurs as a minor constituent in some species of fungi and in the morning glory family of plants. Its structure is that of ergoline with a methyl group at N-6 and a beta-hydroxymethyl substituent at C-8.		1.9910ergoline alkaloid
selenomethionine
[no description available]		7.7430selenoamino acid;
selenomethionines		plant metabolite
selenocystine
selenocystine: RN given refers to parent cpd; structure		1.9410diselenide;
selenoamino acid
2,4-dinitrothiocyanatobenzene
2,4-dinitro-1-thiocyanatobenzene : A thiocyanate compound having a 2,4-dinitrophenyl group attached to the sulfur atom.		2.3110C-nitro compound;
thiocyanates		hapten;
tolerogen
1-aminopyrene
[no description available]		2.110
digoxigenin
Digoxigenin: 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide. A cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.. digoxigenin : A hydroxy steroid that consists of 5beta-cardanolide having a double bond at the 20(22)-position as well as hydroxy groups at the 3beta-, 12beta- and 14beta-positions. It has been isolated from the plant species of the genus Digitalis.		2.422012beta-hydroxy steroid;
14beta-hydroxy steroid;
3beta-hydroxy steroid;
3beta-sterol		hapten;
plant metabolite
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		1.9410cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
stearylamine
stearylamine: RN given refers to parent cpd. octadecan-1-amine : An 18-carbon primary aliphatic amine.		6.9810primary aliphatic aminefilm-forming compound
phenyltrimethylammonium
phenyltrimethylammonium: d9-cpd suppresses methylation artifacts in gas chromatography of serum extracts; RN given refers to parent cpd. trimethylphenylammonium : A quaternary ammonium ion obtained by methylation of N,N-dimethylaniline.		1.9610quaternary ammonium ion
paraquat
Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.		2.7330organic cationgeroprotector;
herbicide
2'-deoxyadenosine triphosphate
2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd		2.51202'-deoxyadenosine 5'-phosphate;
purine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
s,n,n'-tripropylthiocarbamate
Reward: An object or a situation that can serve to reinforce a response, to satisfy a motive, or to afford pleasure.. vernolate : A monounsaturated fatty acid anion that is the conjugate base of vernolic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		4.260tertiary amine
tetrabutylammonium
tetrabutylammonium: lipophilic probe; RN given refers to parent cpd		7.0510quaternary ammonium ion
2-tert-butylhydroquinone
2-tert-butylhydroquinone: an anticarcinogenic and chemopreventive agent. 2-tert-butylhydroquinone : A member of the class of hydroquinones in which one of the ring hydrogens of hydroquinone is replaced by a tert-butyl group.		2.0210hydroquinonesfood antioxidant
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		2.4420benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
methionine sulfoximine
methionine sulfoximine : A non-proteinogenic alpha-amino acid that is the sulfoximine derivative of methionine .		3.2260methionine derivative;
non-proteinogenic alpha-amino acid;
sulfoximide
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		3.5280aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
diallyl trisulfide
[no description available]		2.0210organic trisulfideanti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
antioxidant;
antiprotozoal drug;
apoptosis inducer;
estrogen receptor antagonist;
insecticide;
platelet aggregation inhibitor;
vasodilator agent
pimozide
Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.		3.4520benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
azetidyl-2-carboxylic acid
azetidyl-2-carboxylic acid: a proline analog (with 4-membered ring in place of 5); a toxic non-protein amino acid that is misincorporated into protein in place of proline; induces nonfunctional heat-shock proteins; inhibits acquired thermotolerance; RN given refers to (L)-isomer; found in beets and Liliaceae. (S)-azetidine-2-carboxylic acid : The (S)-enantiomer of azetidine-2-carboxylic acid.. azetidinecarboxylic acid : A member of the class of azetidines that is azetidine substituted by at least one carboxy group at unspecified position.		2.0610azetidine-2-carboxylic acid
flumethasone
Flumethasone: An anti-inflammatory glucocorticoid used in veterinary practice.		1.941011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
phenethyl isothiocyanate
phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.		2.1310isothiocyanateantineoplastic agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
metabolite
fluorescein
Fluorescein: A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium such as the aqueous humor.. fluorescein (lactone form) : A xanthene dye that is highly fluorescent, detectable even when present in minute quantities. Used forensically to detect traces of blood, in analytical chemistry as an indicator in silver nitrate titrations and in microscopy.		4.05502-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium
thioflavin t
thioflavin T: RN given refers to chloride; structure. thioflavine T : An organic chloride salt having 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium as the counterion. It is widely used to visualise and quantify the presence of amyloids, both in vitro and in vivo.		2.1110organic chloride saltfluorochrome;
geroprotector;
histological dye
fucose
Fucose: A six-member ring deoxysugar with the chemical formula C6H12O5. It lacks a hydroxyl group on the carbon at position 6 of the molecule.. L-fucopyranose : The pyranose form of L-fucose.. fucose : Any deoxygalactose that is deoxygenated at the 6-position.		6.72460fucopyranose;
L-fucose		Escherichia coli metabolite;
mouse metabolite
sulfur hexafluoride
Sulfur Hexafluoride: Sulfur hexafluoride. An inert gas used mainly as a test gas in respiratory physiology. Other uses include its injection in vitreoretinal surgery to restore the vitreous chamber and as a tracer in monitoring the dispersion and deposition of air pollutants.. sulfur hexafluoride : A sulfur coordination entity consisting of six fluorine atoms attached to a central sulfur atom. It is the most potent greenhouse gas currently known, with a global warming potential of 23,900 times that of CO2 over a 100 year period (SF6 has an estimated lifetime in the atmosphere of between 800 and 3,000 years).		2.0510sulfur coordination entitygreenhouse gas;
NMR chemical shift reference compound;
ultrasound contrast agent
uridine diphosphate glucuronic acid
Uridine Diphosphate Glucuronic Acid: A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis. It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.. UDP-alpha-D-glucuronic acid : A UDP-sugar having alpha-D-glucuronic acid as the sugar component.		2.0210UDP-D-glucuronic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
acadesine
[no description available]		2101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
sulfuryl fluoride
sulfuryl fluoride: fumigant		2.730sulfuryl halidefumigant insecticide
methyl methanethiosulfonate
S-methyl methanethiosulfonate : A sulfonic acid derivative obtained by condensaton of methanesulfonic acid with methanethiol.		2.6830sulfonic acid derivative;
thiosulfonate ester		metabolite
uridine diphosphate galactose
Uridine Diphosphate Galactose: A nucleoside diphosphate sugar which can be epimerized into UDPglucose for entry into the mainstream of carbohydrate metabolism. Serves as a source of galactose in the synthesis of lipopolysaccharides, cerebrosides, and lactose.. UDP-alpha-D-galactose : A UDP-D-galactose in which the anomeric centre of the galactose moiety has alpha-configuration.		2.4120UDP-D-galactosemouse metabolite
2,2-bis(bromomethyl)-1,3-propanediol
2,2-bis(bromomethyl)-1,3-propanediol: structure given in first source		2.110primary alcohol
n-(3-aminopropyl)cyclohexylamine
[no description available]		1.9810
fluorescein-5-isothiocyanate
Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.		3.6390fluorescein isothiocyanate
sabinene
sabinene: RN given refers to cpd without isomeric designation. sabinene : A thujene that is a bicyclic monoterpene isolated from the essential oils of various plant species.		3.3860thujeneplant metabolite
mannose
mannopyranose : The pyranose form of mannose.		12.82630D-aldohexose;
D-mannose;
mannopyranose		metabolite
dithiothreitol
1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.		5.074301,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent
ecdysone
[no description available]		2.723014alpha-hydroxy steroid;
22-hydroxy steroid;
25-hydroxy steroid;
2beta-hydroxy steroid;
3beta-sterol;
6-oxo steroid;
ecdysteroid		prohormone
uridine diphosphate xylose
Uridine Diphosphate Xylose: The decarboxylation product of UDPglucuronic acid, which is used for formation of the xylosides of seryl hydroxyl groups in mucoprotein synthesis. Also forms plant xylans.		2.7330UDP-sugarfundamental metabolite
cyclic cmp
Cyclic CMP: A cyclic nucleotide formed from CYTIDINE TRIPHOSPHATE by the action of cytidylate cyclase. It is a potential cyclic nucleotide intracellular mediator of signal transductions.. 3',5'-cyclic CMP : A 3',5'-cyclic pyrimidine nucleotide having cytosine as the nucleobase.		2.04103',5'-cyclic pyrimidine nucleotidehuman metabolite
tranylcypromine
Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.		2.21102-phenylcyclopropan-1-amine
denatonium benzoate
[no description available]		2.0710
nafenopin
Nafenopin: A peroxisome proliferator that is used experimentally to promote liver tumors. It has been used as an antihyperlipoproteinemic agent.. nafenopin : A racemate comprising equimolar amounts of (R)- and (S)-nafenopin. It is a peroxisome proliferator that is used experimentally to promote liver tumors. It has been used as an hypolipidemic agent.. 2-methyl-2-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]propanoic acid : A monocarboxylic acid that is 2-hydroxy-2-methylpropanoic acid in which ther tertiary hydroxy group has been converted into the corresponding p-(1,2,3,4-tetrahydronaphthalen-1-yl)phenyl ether.		710aromatic ether;
monocarboxylic acid
streptomycin
[no description available]		4.38220antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
carbonates
Carbonates: Salts or ions of the theoretical carbonic acid, containing the radical CO2(3-). Carbonates are readily decomposed by acids. The carbonates of the alkali metals are water-soluble; all others are insoluble. (From Grant & Hackh's Chemical Dictionary, 5th ed). carbonates : Organooxygen compounds that are salts or esters of carbonic acid, H2CO3.		4.6790carbon oxoanion
5-azacytosine
5-azacytosine: structure given in first source. 5-azacytosine : A monoamino-1,3,5-triazine that is cytosine in which the aromatic CH at position 5 is replaced by a nitrogen.		1.9810monoamino-1,3,5-triazine
calcium propionate
[no description available]		2.1310dicarboxylic acid
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		2.0310adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
cladribine
[no description available]		2.0710organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
mono-(2-ethylhexyl)phthalate
mono-(2-ethylhexyl)phthalate: RN given refers to parent cpd. mono(2-ethylhexyl) phthalate : The mono(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.		2.1310phthalic acid monoester
acetylthiocholine
Acetylthiocholine: An agent used as a substrate in assays for cholinesterases, especially to discriminate among enzyme types.		2.3920
butyrylthiocholine
Butyrylthiocholine: A sulfur-containing analog of butyrylcholine which is hydrolyzed by butyrylcholinesterase to butyrate and thiocholine. It is used as a reagent in the determination of butyrylcholinesterase activity.. butyrylthiocholine : A quaternary ammonium ion obtained by the formal condensation of the carboxy group of butyric acid with the thiol group of thiocholine. It is used as a reagent for determination of butyrylcholinesterase activity.		210quaternary ammonium ion
metanephrine
Metanephrine: Product of epinephrine O-methylation. It is a commonly occurring, pharmacologically and physiologically inactive metabolite of epinephrine.		1.9610catecholamine
buthionine sulfoximine
Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.		3.3460diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
norleucine
Norleucine: An unnatural amino acid that is used experimentally to study protein structure and function. It is structurally similar to METHIONINE, however it does not contain SULFUR.. L-norleucine : A non-proteinogenic L-alpha-amino acid comprising hexanoic acid carrying an amino group at C-2. It does not occur naturally.		3.23602-aminohexanoic acid;
L-alpha-amino acid zwitterion;
non-proteinogenic L-alpha-amino acid
carboxin
Carboxin: A systemic agricultural fungicide and seed treatment agent.. carboxin : An anilide obtained by formal condensation of the amino group of aniline with the carboxy group of 2-methyl-5,6-dihydro-1,4-oxathiine-3-carboxylic acid. A fungicide for control of bunts and smuts that is normally used as a seed treatment.		2.0110anilide fungicide;
anilide;
enamide;
organosulfur heterocyclic compound;
oxacycle;
secondary carboxamide		antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
dihydrostreptomycin sulfate
Dihydrostreptomycin Sulfate: A semi-synthetic aminoglycoside antibiotic that is used in the treatment of TUBERCULOSIS.		2.3420
1-nitropyrene
[no description available]		2.110nitroarenecarcinogenic agent
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.4420beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
diadenosine tetraphosphate
P(1),P(4)-bis(5'-adenosyl) tetraphosphate : A diadenosyl tetraphosphate compound having the two 5'-adenosyl residues attached at the P(1)- and P(4)-positions.		2.4120diadenosyl tetraphosphateEscherichia coli metabolite;
mouse metabolite
o,o-diethyl o-3,5,6-trichloro-2-pyridyl phosphate
[no description available]		2.0410
iodinated glycerol
iodinated glycerol: secretolytic agent; RN given refers to cpd without iodine locant		2.0510dioxolane
n-methylacridine
N-methylacridine: RN given refers to acridinium parent cpd		1.9610
2-amino-1-butanol
2-amino-1-butanol: structure		1.9610
limonene
Limonene: A naturally-occurring class of MONOTERPENES which occur as a clear colorless liquid at room temperature. Limonene is the major component in the oil of oranges which has many uses, including as flavor and fragrance. It is recognized as safe in food by the Food and Drug Administration (FDA).. limonene : A monoterpene that is cyclohex-1-ene substituted by a methyl group at position 1 and a prop-1-en-2-yl group at position 4 respectively.		2.1510cycloalkene;
p-menthadiene		human metabolite
4-pentynoic acid
4-pentynoic acid: structure		2.0610
acetoxyacetylaminofluorene
Acetoxyacetylaminofluorene: An alkylating agent that forms DNA ADDUCTS at the C-8 position in GUANINE, resulting in single strand breaks. It has demonstrated carcinogenic action.. N-acetoxy-2-acetamidofluorene : A 2-acetamidofluorene compound in which the parent 2-acetamidofluorene is substituted on nitrogen by an acetoxy group.		1.97102-acetamidofluorenescarcinogenic agent;
mutagen
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		10.361041amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
3-deazaadenosine
3-deazaadenosine: RN given refers to parent cpd.		7.3820
d-glutamate
[no description available]		2.0310D-alpha-amino acid;
glutamic acid		Escherichia coli metabolite;
mouse metabolite
iridium
Iridium: A metallic element with the atomic symbol Ir, atomic number 77, and atomic weight 192.22.		7.0510cobalt group element atom;
platinum group metal atom
lanthanum
[no description available]		1.9510f-block element atom;
lanthanoid atom;
scandium group element atom
manganese
Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.		5.41610elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient
mercury
Mercury: A silver metallic element that exists as a liquid at room temperature. It has the atomic symbol Hg (from hydrargyrum, liquid silver), atomic number 80, and atomic weight 200.59. Mercury is used in many industrial applications and its salts have been employed therapeutically as purgatives, antisyphilitics, disinfectants, and astringents. It can be absorbed through the skin and mucous membranes which leads to MERCURY POISONING. Because of its toxicity, the clinical use of mercury and mercurials is diminishing.. mercury(0) : Elemental mercury of oxidation state zero.		5.7270elemental mercury;
zinc group element atom		neurotoxin
molybdenum
Molybdenum: A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.95. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase.		4.13160chromium group element atommicronutrient
palladium
Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.		3.470metal allergen;
nickel group element atom;
platinum group metal atom
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		4.9891elemental platinum;
nickel group element atom;
platinum group metal atom
plutonium
Plutonium: A naturally radioactive element of the actinide metals series. It has the atomic symbol Pu, and atomic number 94. Plutonium is used as a nuclear fuel, to produce radioisotopes for research, in radionuclide batteries for pacemakers, and as the agent of fission in nuclear weapons.		1.9610actinoid atom;
f-block element atom
rhenium
Rhenium: A metal, atomic number 75, atomic weight 186.207, symbol Re.		7.0710manganese group element atom
rhodium
Rhodium: A hard and rare metal of the platinum group, atomic number 45, atomic weight 102.905, symbol Rh.. rhodium atom : A cobalt group element atom of atomic number 45.		2.4320cobalt group element atom
scandium
Scandium: An element of the rare earth family of metals. It has the atomic symbol Sc, atomic number 21, and atomic weight 45.		8.0750d-block element atom;
rare earth metal atom;
scandium group element atom
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		3.4270copper group element atom;
elemental silver		Escherichia coli metabolite
terbium
Terbium: An element of the rare earth family of metals. It has the atomic symbol Tb, atomic number 65, and atomic weight 158.92.		3.0850f-block element atom;
lanthanoid atom
titanium
Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.		8.7290titanium group element atom
tungsten
Tungsten: A metallic element with the atomic symbol W, atomic number 74, and atomic weight 183.85. It is used in many manufacturing applications, including increasing the hardness, toughness, and tensile strength of steel; manufacture of filaments for incandescent light bulbs; and in contact points for automotive and electrical apparatus.		2.4420chromium group element atommicronutrient
cadmium
Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.		4.25180cadmium molecular entity;
zinc group element atom
chromium
Chromium: A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens.. chromium ion : An chromium atom having a net electric charge.. chromium atom : A chromium group element atom that has atomic number 24.		8.3470chromium group element atom;
metal allergen		micronutrient
europium
Europium: An element of the rare earth family of metals. It has the atomic symbol Eu, atomic number 63, and atomic weight 152. Europium is used in the form of its salts as coatings for cathode ray tubes and in the form of its organic derivatives as shift reagents in NMR spectroscopy.		2.6730f-block element atom;
lanthanoid atom
gadolinium
Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.		3.1450f-block element atom;
lanthanoid atom
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		3.1250copper group element atom;
elemental gold
helium
Helium: A noble gas with the atomic symbol He, atomic number 2, and atomic weight 4.003. It is a colorless, odorless, tasteless gas that is not combustible and does not support combustion. It was first detected in the sun and is now obtained from natural gas. Medically it is used as a diluent for other gases, being especially useful with oxygen in the treatment of certain cases of respiratory obstruction, and as a vehicle for general anesthetics.		2.9140monoatomic helium;
noble gas atom;
s-block element atom		food packaging gas
uranium
Uranium: A radioactive element of the actinide series of metals. It has an atomic symbol U, atomic number 92, and atomic weight 238.03. U-235 is used as the fissionable fuel in nuclear weapons and as fuel in nuclear power reactors.		3.0550actinoid atom;
f-block element atom;
monoatomic uranium
vanadium
Vanadium: A metallic element with the atomic symbol V, atomic number 23, and atomic weight 50.94. It is used in the manufacture of vanadium steel. Prolonged exposure can lead to chronic intoxication caused by absorption usually via the lungs.		3.2360elemental vanadium;
vanadium group element atom		micronutrient
xenon
Xenon: A noble gas with the atomic symbol Xe, atomic number 54, and atomic weight 131.30. It is found in the earth's atmosphere and has been used as an anesthetic.		2.4520monoatomic xenon;
noble gas atom;
p-block element atom
aluminum chloride
Aluminum Chloride: A compound with the chemical formula AlCl3; the anhydrous salt is used as a catalyst in organic chemical synthesis, and hydrated salts are used topically as antiperspirants, and for the management of HYPERHYDROSIS.		1.9910aluminium coordination entityLewis acid
cupric chloride
cupric chloride: RN given refers to unlabeled parent cpd. copper(II) chloride : An inorganic chloride of copper in which the metal is in the +2 oxidation state.		2.3820copper molecular entity;
inorganic chloride		EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
magnesium sulfate
Magnesium Sulfate: A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083). magnesium sulfate : A magnesium salt having sulfate as the counterion.		3.0650magnesium salt;
metal sulfate;
organic magnesium salt		anaesthetic;
analgesic;
anti-arrhythmia drug;
anticonvulsant;
calcium channel blocker;
cardiovascular drug;
fertilizer;
tocolytic agent
mercuric chloride
Mercuric Chloride: Mercury chloride (HgCl2). A highly toxic compound that volatizes slightly at ordinary temperature and appreciably at 100 degrees C. It is corrosive to mucous membranes and used as a topical antiseptic and disinfectant.. mercury dichloride : A mercury coordination entity made up of linear triatomic molecules in which a mercury atom is bonded to two chlorines. Water-soluble, it is highly toxic. Once used in a wide variety of applications, including preserving wood and anatomical specimens, embalming and disinfecting, as an intensifier in photography, as a mordant for rabbit and beaver furs, and freeing gold from lead, its use has markedly declined as less toxic alternatives have been developed.		3.2260mercury coordination entitysensitiser
acetylglucosamine
Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.		8.531010N-acetyl-D-glucosamineepitope
galactosamine
2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.		5.94350D-galactosamine;
primary amino compound		toxin
sodium nitrate
sodium nitrate : The inorganic nitrate salt of sodium.		2.1510inorganic nitrate salt;
inorganic sodium salt		fertilizer;
NMR chemical shift reference compound
cesium chloride
cesium chloride: RN given refers to unlabeled cpd. caesium chloride : The inorganic chloride salt of caesium; each caesium ion is coordinated by eight chlorine ions.		2.4120inorganic caesium salt;
inorganic chloride		phase-transfer catalyst;
vasoconstrictor agent
hypochlorous acid
Hypochlorous Acid: An oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent.. hypochlorous acid : A chlorine oxoacid with formula HOCl; a weak, unstable acid, it is the active form of chlorine in water.		7.9340chlorine oxoacid;
reactive oxygen species		EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
human metabolite
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		9.55240delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
ferric chloride
ferric chloride: RN given refers to cpd with MF of Fe-Cl3; used to induce experimental arterial thrombosis to evaluate antithrombotic agents		1.9610iron coordination entityastringent;
Lewis acid
bromine
Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested.		3.73110diatomic bromine
barium sulfate
Barium Sulfate: A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.. barium sulfate : A metal sulfate with formula BaO4S. Virtually insoluble in water at room temperature, it is mostly used as a component in oil well drilling fluid it occurs naturally as the mineral barite.		1.9410barium salt;
inorganic barium salt;
metal sulfate		radioopaque medium
s-methylcysteine
S-methylcysteine: RN given refers to parent cpd without isomeric designation. S-methylcysteine : A cysteine derivative that is L-cysteine in which the hydrogen attached to the sulfur is replaced by a methyl group.		3.1950S-alkyl-L-cysteine zwitterion;
S-alkyl-L-cysteine		human urinary metabolite;
plant metabolite
zinc sulfate
Zinc Sulfate: A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995). zinc sulfate : A metal sulfate compound having zinc(2+) as the counterion.		2.6730metal sulfate;
zinc molecular entity		fertilizer
potassium nitrate
potassium nitrate: RN given refers to cpd with MF of K-HNO3; when combined with charcoal and sulfur it can form EXPLOSIVE AGENTS. potassium nitrate : The inorganic nitrate salt of potassium.		7.3520inorganic nitrate salt;
potassium salt		fertilizer
sodium sulfate
[no description available]		2.3720inorganic sodium salt
tricalcium phosphate
tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.		4.04150calcium phosphate
ferrous chloride
ferrous chloride: induces convulsions; RN given refers to parent cpd		210iron coordination entity
chromates
Chromates: Salts of chromic acid containing the CrO(2-)4 radical.. chromate(2-) : A chromium oxoanion resulting from the removal of two protons from chromic acid.		2.8740chromium oxoanion;
divalent inorganic anion		oxidising agent
copper sulfate
Copper Sulfate: A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.. copper(II) sulfate : A metal sulfate compound having copper(2+) as the metal ion.		1.9810metal sulfateemetic;
fertilizer;
sensitiser
tungstate
[no description available]		2.7330divalent inorganic anion;
tungsten oxoanion
metoprine
metoprine: histamine methyltransferase antagonist		210
silver nitrate
Silver Nitrate: A silver salt with powerful germicidal activity. It has been used topically to prevent OPHTHALMIA NEONATORUM.		2.3720inorganic nitrate salt;
silver salt		astringent
sodium thiosulfate
sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.		1.9910inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
sodium chromate(vi)
sodium chromate(VI): RN given refers to cpd with (MF) CR-H2-O4.Na. sodium chromate : An inorganic sodium salt consisting of sodium and chromate ions in a 2:1 ratio.		2.0110inorganic sodium saltcarcinogenic agent;
diagnostic agent;
oxidising agent;
poison
potassium sulfate
potassium sulfate: RN given refers to cpd with MF of K2-H2SO4		1.9410inorganic potassium salt;
potassium salt
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		10.56710dihydrogen
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		4.78330diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
chlorine
Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.		4.3200diatomic chlorine;
gas molecular entity		bleaching agent
beryllium fluoride
beryllium difluoride : The fluoride salt of beryllium (+2 oxidation state). In the solid state it exists as a glass, with four-coordinate Be(2+) tetrahedral centres and two-coordinate fluoride centres. As a gas it adopts a linear triatomic structure and in the liquid state a fluctuating tetrahedral structure. In protein crystallography it is used as a mimic of phosphate.		2.0210beryllium molecular entity;
fluoride salt
deuterium oxide
Deuterium Oxide: The isotopic compound of hydrogen of mass 2 (deuterium) with oxygen. (From Grant & Hackh's Chemical Dictionary, 5th ed) It is used to study mechanisms and rates of chemical or nuclear reactions, as well as biological processes.		4.570deuterated compound;
water		NMR solvent
fluorosulfonic acid
perfluorosulfonic acid: sulfonated tetrafluoroethylene-based fluoropolymer–copolymer		2.8330sulfur oxoacidNMR solvent
molybdate ion
molybdate : A divalent inorganic anion obtained by removal of both protons from molybdic acid		2.4420divalent inorganic anion;
molybdenum oxoanion		Escherichia coli metabolite
sulfonyl chloride
[no description available]		2.0210sulfuryl halide
sulfur trioxide
sulfur trioxide: RN given refers to parent cpd		3.0910sulfur oxide
galactose
aldohexose : A hexose with a (potential) aldehyde group at one end.		6.23280
sizofiran
Sizofiran: A beta-D-glucan obtained from the Aphyllophoral fungus Schizophyllum commune. It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach.		2.0110
phosphoryl chloride
phosphoryl chloride: structure		2.4120phosphorus coordination entity
ozone
Ozone: The unstable triatomic form of oxygen, O3. It is a powerful oxidant that is produced for various chemical and industrial uses. Its production is also catalyzed in the ATMOSPHERE by ULTRAVIOLET RAY irradiation of oxygen or other ozone precursors such as VOLATILE ORGANIC COMPOUNDS and NITROGEN OXIDES. About 90% of the ozone in the atmosphere exists in the stratosphere (STRATOSPHERIC OZONE).. ozone : An elemental molecule with formula O3. An explosive, pale blue gas (b.p. -112degreeC) that has a characteristic, pungent odour, it is continuously produced in the upper atmosphere by the action of solar ultraviolet radiation on atmospheric oxygen. It is an antimicrobial agent used in the production of bottled water, as well as in the treatment of meat, poultry and other foodstuffs.		2.5520elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen		antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer
sodium selenite
disodium selenite : An inorganic sodium salt composed of sodium and selenite ions in a 2:1 ratio.		3.2660inorganic sodium salt;
selenite salt		nutraceutical
cadmium chloride
Cadmium Chloride: A cadmium halide in the form of colorless crystals, soluble in water, methanol, and ethanol. It is used in photography, in dyeing, and calico printing, and as a solution to precipitate sulfides. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). cadmium dichloride : A cadmium coordination entity in which cadmium(2+) and Cl(-) ions are present in the ratio 2:1. Although considered to be ionic, it has considerable covalent character to its bonding.		2.6930cadmium coordination entity
cadmium sulfate
cadmium sulfate: RN given refers to cpd with MF of Cd-H2SO4		2.0510cadmium salt
calcium nitrate
calcium nitrate: an amylopsin activator. calcium nitrate : Inorganic nitrate salt of calcium.		2.0110calcium salt;
inorganic nitrate salt		fertilizer
cobaltous nitrate
cobaltous nitrate: RN given refers to Co(+2) salt. cobalt dinitrate : A cobalt salt in which the cobalt metal is in the +2 oxidation state and the counter-anion is nitrate.		2.0110cobalt salt;
inorganic nitrate salt
4-chloro-7-nitrobenzofurazan
4-Chloro-7-nitrobenzofurazan: A benzofuran derivative used as a protein reagent since the terminal N-NBD-protein conjugate possesses interesting fluorescence and spectral properties. It has also been used as a covalent inhibitor of both beef heart mitochondrial ATPase and bacterial ATPase.. 4-chloro-7-nitrobenzofurazan : A benzoxadiazole that is 2,1,3-benzoxadiazole which is substituted at position 4 by chlorine and at position 7 by a nitro group.		3.5380benzoxadiazole;
C-nitro compound;
organochlorine compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.6.1.3 (adenosinetriphosphatase) inhibitor;
fluorescent probe;
fluorochrome
barium chloride
barium chloride: RN given refers to parent cpd. barium chloride : The inorganic dichloride salt of barium.		2.4220barium salt;
inorganic chloride		potassium channel blocker
trolamine salicylate
Arthritis: Acute or chronic inflammation of JOINTS.		3.8330
rhamnose
[no description available]		3.0550L-rhamnose
clodronic acid
Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.		1.95101,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent
chloramine
[no description available]		2.4320halide
ammonium chloride
Ammonium Chloride: An acidifying agent that has expectorant and diuretic effects. Also used in etching and batteries and as a flux in electroplating.. ammonium chloride : An inorganic chloride having ammonium as the counterion.		4.55260ammonium salt;
inorganic chloride		ferroptosis inhibitor
ethionine
L-ethionine : An S-ethylhomocysteine that has S-configuration at the chiral centre.		4.99130S-ethylhomocysteineantimetabolite;
carcinogenic agent
cysteic acid
Cysteic Acid: Beta-Sulfoalanine. An amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate. It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.. cysteic acid : An amino sulfonic acid that is the sulfonic acid analogue of cysteine.		3.4780alanine derivative;
amino sulfonic acid;
carboxyalkanesulfonic acid;
cysteine derivative;
non-proteinogenic alpha-amino acid		animal metabolite
n-ethyl-n-hydroxyethylnitrosamine
N-ethyl-N-(2-hydroxyethyl)nitrosamine : A nitrosamine that is N-nitrosodiethylamine in which one of the ethyl froups has been replaced by a 2-hydroxyethyl group. It is used to induce renal and liver tumours in rodents.		6.9610nitrosamine;
primary alcohol		carcinogenic agent
4-aminobutanol
4-aminobutanol: structure given in first source		2.0110
titanium dioxide
titanium dioxide: used medically as protectant against externally caused irritation & sunlight; high concentrations of dust may cause irritation to respiratory tract; RN given refers to titanium oxide (TiO2); structure. titanium dioxide : A titanium oxide with the formula TiO2. A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications.		8.5370titanium oxidesfood colouring
sodium tungstate(vi)
sodium tungstate(VI): inactivates molybdoenzymes in Anabaena; RN given refers to tungstic acid [H2WO4], di-Na salt. sodium tungstate : An inorganic sodium salt having tungstate as the counterion. Combines with hydrogen peroxide for the oxidation of secondary amines to nitrones.		2.0310inorganic sodium saltreagent
4-chlorophenoxyacetic acid
4-chlorophenoxyacetic acid: RN given refers to parent cpd; structure. (4-chlorophenoxy)acetic acid : A chlorophenoxyacetic acid that is phenoxyacetic acid carrying a chloro substituent at position 4.		2.0110chlorophenoxyacetic acid;
monochlorobenzenes		phenoxy herbicide
tiletamine hydrochloride
Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.		2.3820
etorphine
Etorphine: A narcotic analgesic morphinan used as a sedative in veterinary practice.		7.6930
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		2.420selegiline;
terminal acetylenic compound		geroprotector
thiamphenicol
[no description available]		7.4620monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		1.9810beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
cromolyn sodium
Cromolyn Sodium: A chromone complex that acts by inhibiting the release of chemical mediators from sensitized MAST CELLS. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.. disodium cromoglycate : An organic sodium salt that is the disodium salt of cromoglycic acid.		1.9510organic sodium saltanti-asthmatic drug;
drug allergen
eedq
EEDQ: peptide coupling reagent		1.9610
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		14.372530acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
sodium bisulfide
sodium bisulfide: RN given refers to sodium sulfide (Na(SH)); see also record for sodium sulfide (Na2S)		2.1310
fluorides
[no description available]		4.98400halide anion;
monoatomic fluorine
benomyl
[no description available]		210aromatic amide;
benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		acaricide;
anthelminthic drug;
antifungal agrochemical;
microtubule-destabilising agent;
tubulin modulator
lisuride
Lisuride: An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS).		2.110monocarboxylic acid amideantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist
chromium
chromium hexavalent ion: a human respiratory carcinogen		7.0610chromium cation;
monoatomic hexacation
1-deoxynojirimycin
1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.		2.05102-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid		anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
phenyl valerate
[no description available]		7.0110
iodine
[no description available]		2.6630halide anion;
monoatomic iodine		human metabolite
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		2.0410aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
4-nitrophenyl 4'-guanidinobenzoate
4-nitrophenyl 4'-guanidinobenzoate: kallikrein substrate; acrosin antagonist in sperm; serine esterase inhibitor; RN given refers to parent cpd; structure		1.9610
phosphotyrosine
Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.		5.33560L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid;
O(4)-phosphotyrosine		Escherichia coli metabolite;
immunogen
bromocriptine
Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.		2.6830indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		8.22070benzenes;
phenyl acetates
cetylpyridinium chloride anhydrous
tserigel: according to first source contains polyvinylbutyral & cetylpyridinium chloride; UD only lists cetylpyridinium chloride as constituent. cetylpyridinium chloride : A pyridinium salt that has N-hexadecylpyridinium as the cation and chloride as the anion. It has antiseptic properties and is used in solutions or lozenges for the treatment of minor infections of the mouth and throat.		5.5141chloride salt;
organic chloride salt		antiseptic drug;
surfactant
methylformamide
N-methylformamide : A member of the class of formamides having a N-methyl substituent.		6.9310formamides
isopentyl alcohol
isopentyl alcohol: RN given refers to unlabeled parent cpd. isoamylol : An primary alcohol that is butan-1-ol in which a hydrogen at position 3 has been replaced by a methyl group.		210alkyl alcohol;
primary alcohol;
volatile organic compound		antifungal agent;
Saccharomyces cerevisiae metabolite;
xenobiotic metabolite
pyrrolidine
[no description available]		2.9440azacycloalkane;
pyrrolidines;
saturated organic heteromonocyclic parent
triamcinolone
Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.		2.864011beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
tributyl phosphate
tributyl phosphate: a detergent. tributyl phosphate : A trialkyl phosphate that is the tributyl ester of phosphoric acid.		2.0210trialkyl phosphate
dimethylacetamide
hallucinogen : Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking.. N,N-dimethylacetamide : A member of the class of acetamides that is acetamide in which the hydrogens attached to the N atom have been replaced by two methyl groups respectively. Metabolite observed in cancer metabolism.		2.0310acetamides;
monocarboxylic acid amide		human metabolite
pregnanolone
Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.		2.43203-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
pyrene
pyrene: structure in Merck Index, 9th ed, #7746. pyrene : An ortho- and peri-fused polycyclic arene consisting of four fused benzene rings, resulting in a flat aromatic system.		2.110ortho- and peri-fused polycyclic arenefluorescent probe;
persistent organic pollutant
isothiuronium
Isothiuronium: An undecenyl THIOUREA which may have topical anti-inflammatory activity.		1.9910
pirimicarb
pirimicarb: structure. pirimicarb : An aminopyrimidine that is N,N,4,5-tetramethylpyrimidin-2-amine substituted by a (dimethylcarbamoyl)oxy group at position 4.		2.0210aminopyrimidine;
carbamate ester;
tertiary amino compound		agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic
dimethyltin
[no description available]		2.0210organotin compound
4-methoxyamphetamine
4-methoxyamphetamine: para-methoxy derivative to amphetamine with hallucinogenic properties; minor descriptor (75-86); on line & INDEX MEDICUS search AMPHETAMINES (75-86); RN given refers to parent compound without isomeric designation		1.9410
8-bromo cyclic adenosine monophosphate
8-Bromo Cyclic Adenosine Monophosphate: A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.. 8-Br-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP bearing an additional bromo substituent at position 8 on the adenine ring. An activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.		4.261803',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist
dihydroxyethyldithiocarbamate
dihydroxyethyldithiocarbamate: mobilizes metallothionein-bound cadmium from tissue; increases biliary excretion of cadmium in rats		2.0510
transferrin
Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.		4.62270
tridemorph
tridemorph: RN given refers to cpd with unspecified isomeric designation; structure. tridemorph : A mixture of 4-alkyl-2,6-dimethylmorpholines, where 'alkyl' is a mixture of C11 to C14 homologues of which 60-70% is tridecyl. A systemic fungicide, it is no longer approved for use within the European Union.. 2,6-dimethyl-4-tridecylmorpholine : A member of the class of morpholines that is 2,6-dimethylmorpholine in which the hydrogen attached to the nitrogen is replaced by a tridecyl group. The configuration at positions 2 and 6 is unknown or unspecified.		2.6930morpholines;
tertiary amino compound		antifungal agrochemical
glisoxepide
glisoxepide: oral sulfonylurea hypoglycemic agent which stimulates insulin secretion; minor descriptor (75-85); on-line & Index Medicus search SULFONYLUREA COMPOUNDS (75-85); RN given refers to parent cpd		1.9810sulfonamide
2-chlorodibenzofuran
2-chlorodibenzofuran: structure		2.0710
alkenes
[no description available]		3.95130
calcium oxalate
Calcium Oxalate: The calcium salt of oxalic acid, occurring in the urine as crystals and in certain calculi.. calcium oxalate : The calcium salt of oxalic acid, which in excess in the urine may lead to formation of oxalate calculi (kidney stones).		2.0510organic calcium salt
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		175995glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
adenylyl imidodiphosphate
Adenylyl Imidodiphosphate: 5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation.		2.9140adenosine 5'-phosphate
azoxymethane
Azoxymethane: A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas.		2.1110
cefazolin
Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.		2.4420beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
bis(4-methyl-1-homopiperazinylthiocarbonyl)disulfide
Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide: An inhibitor of the last step of noradrenaline biosynthesis.		3.9840
torpedo
Torpedo: A genus of the Torpedinidae family consisting of several species. Members of this family have powerful electric organs and are commonly called electric rays.		9140
1-menaphthyl sulfate
1-menaphthyl sulfate: RN given refers to parent cpd		2.420
sodium azide
Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).		4.1850inorganic sodium saltantibacterial agent;
explosive;
mitochondrial respiratory-chain inhibitor;
mutagen
azides
Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.		6.47350pseudohalide anionmitochondrial respiratory-chain inhibitor
adenosine diphosphate ribose
Adenosine Diphosphate Ribose: An ester formed between the aldehydic carbon of RIBOSE and the terminal phosphate of ADENOSINE DIPHOSPHATE. It is produced by the hydrolysis of nicotinamide-adenine dinucleotide (NAD) by a variety of enzymes, some of which transfer an ADP-ribosyl group to target proteins.		5.33160ADP-sugarEscherichia coli metabolite;
mouse metabolite
enterobactin
[no description available]		8.461050catechols;
crown compound;
macrotriolide;
polyphenol		bacterial metabolite;
siderophore
4,5-dihydroxy-4,5-dihydrobenzo(a)pyrene
4,5-dihydroxy-4,5-dihydrobenzo(a)pyrene: RN given refers to cpd without isomeric designation		1.9610
1-(9-fluorenyl)methyl chloroformate
1-(9-fluorenyl)methyl chloroformate: used for tagging silica-based derivatization reagents in HPLC		2.7330
dimethyl suberimidate
Dimethyl Suberimidate: The methyl imidoester of suberic acid used to produce cross links in proteins. Each end of the imidoester will react with an amino group in the protein molecule to form an amidine.		1.9610
s-adenosylmethionine
acylcarnitine: structure in first source. S-adenosyl-L-methioninate : A sulfonium betaine that is a conjugate base of S-adenosyl-L-methionine obtained by the deprotonation of the carboxy group.		2.5420sulfonium betainehuman metabolite
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9910azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
acetylgalactosamine
Acetylgalactosamine: The N-acetyl derivative of galactosamine.		4.76310N-acetyl-D-hexosamine;
N-acetylgalactosamine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
amdinocillin
Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.		2.3920penicillinantibacterial drug;
antiinfective agent
4-ipomeanol
4-ipomeanol: lung-toxic furanoterpenoid produced in moldy sweet potatoes in response to fungus infection; RN given refers to cpd without isomeric designation; structure		2.1110aromatic ketone
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		2.4920amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		8.38402taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		10.04390beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
substance p
[no description available]		8.6190peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
promegestone
Promegestone: A synthetic progestin which is useful for the study of progestin distribution and progestin tissue receptors, as it is not bound by transcortin and binds to progesterone receptors with a higher association constant than progesterone.. promegestone : A progestin consisting of 17beta-propionylestra-4,9-dien-3-one substituted at position 17 by a methyl group.		2.944020-oxo steroid;
3-oxo-Delta(4) steroid		antineoplastic agent;
progesterone receptor agonist;
progestin
dobutamine
Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.		2.4620catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
3-fluoroalanine
3-fluoroalanine: antibacterial agent active against gram-positive & gram-negative bacteria; generated by C-fluorination of key component of bacterial cell wall; synthesized by photofluorination of D-alanine; RN given refers to cpd with unspecified isomeric designation; structure		2.3920
ribavirin
Rebetron: Rebetron is tradename		2.21101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
phorbol 12,13-dibutyrate
Phorbol 12,13-Dibutyrate: A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems.		4.72290butyrate ester;
phorbol ester;
tertiary alpha-hydroxy ketone
fluorescamine
Fluorescamine: A nonfluorescent reagent for the detection of primary amines, peptides and proteins. The reaction products are highly fluorescent.		3.7730
zinterol
[no description available]		2.4220
methyldopa
Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.		4.4370L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
bezafibrate
[no description available]		1.9710aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
1-methyl-4-phenylpyridinium
1-Methyl-4-phenylpyridinium: An active neurotoxic metabolite of 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to PARAQUAT, has also been used as an herbicide.. N-methyl-4-phenylpyridinium : A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position.		2.9640pyridinium ionapoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin
vecuronium bromide
Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.		2.0310organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
vx
VX nerve agent : A organic thiophosphate that is the ethyl ester of S-{2-[di(propan-2-yl)amino]ethyl} O hydrogen methylphosphonothioate. A toxic nerve agent used in chemical warfare.		2.7430organic thiophosphate;
tertiary amino compound		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
neurotoxin
ng-nitroarginine methyl ester
NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.		4.04140alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
quisqualic acid
Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis.		3.68100non-proteinogenic alpha-amino acid
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
[no description available]		2.7330chromanol;
monocarboxylic acid;
phenols		antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radical scavenger;
Wnt signalling inhibitor
1-carboxyglutamic acid
1-Carboxyglutamic Acid: Found in various tissues, particularly in four blood-clotting proteins including prothrombin, in kidney protein, in bone protein, and in the protein present in various ectopic calcifications.		4.86110
dh 990
DH 990: RN given refers to cpd without isomeric designation; structure		1.9810
7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide: 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity.		2.0410epoxideintercalator
serine isopropylhydrazide
serine isopropylhydrazide: RN given refers to (DL)-isomer		3.1960
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		2.0710aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
enkephalin, methionine
Enkephalin, Methionine: One of the endogenous pentapeptides with morphine-like activity. It differs from LEU-ENKEPHALIN by the amino acid METHIONINE in position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.		2.0510
laurocapram
laurocapram: enhances percutaneous absorption of different chemicals; structure given in first source		2.0110
dihydroalprenolol
Dihydroalprenolol: Hydrogenated alprenolol derivative where the extra hydrogens are often tritiated. This radiolabeled form of ALPRENOLOL, a beta-adrenergic blocker, is used to label the beta-adrenergic receptor for isolation and study.		2.0610
propiconazole
Orbit: Bony cavity that holds the eyeball and its associated tissues and appendages.		2.0810conazole fungicide;
cyclic ketal;
dichlorobenzene;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		2.4110penicillin allergen;
penicillin		antibacterial drug
paroxetine
Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.		2.0310aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		2.4220alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
mezlocillin
Kassinin: Dodecapeptide tachykinin found in the central nervous system of the amphibian Kassina senegalensis. It is similar in structure and action to other tachykinins, but is especially effective in contracting smooth muscle tissue and stimulating the micturition reflex.		210
oltipraz
oltipraz : A 1,2-dithiole that is 3H-1,2-dithiole-3-thione substituted at positions 4 and 5 by methyl and pyrazin-2-yl groups respectively.		2.03101,2-dithiole;
pyrazines		angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug
chlorsulfuron
chlorsulfuron: RN given refers to parent cpd; structure given in first source. chlorsulfuron : An N-sulfonylurea that is N-carbamoyl-2-chlorobenzenesulfonamide in which one of the hydrogens attached to the non-sulfonylated nitrogen has been replaced by a 4-methoxy-6-methyl-1,3,5-triazin-2-yl group. A herbicide used for the control of broadleaf weeds in wheat, barley and oats.		210methoxy-1,3,5-triazine;
monochlorobenzenes;
N-sulfonylurea		agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide
pergolide
Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		210diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
colforsin
Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.		7.341020acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
doxofylline
doxofylline : An oxopurine that is a derivative of xanthine, methylated at N-1 and N-3 and carrying a 1,3-dioxolan-2-ylmethyl group at N-7, used in the treatment of asthma.		2.1310oxopurineanti-asthmatic drug;
antitussive;
bronchodilator agent
cefaclor anhydrous
Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		210cephalosporinantibacterial drug;
drug allergen
fomesafen
fomesafen: a protoporphyrinogen oxidase-inhibiting herbicide. fomesafen : An N-sulfonylcarboxamide that is N-(methylsulfonyl)benzamide in which the phenyl ring is substituted by a nitro group at position 2 and a 2-chloro-4-(trifluoromethyl)phenoxy group at position 5. A protoporphyrinogen oxidase inhibitor, it was specially developed for use (generally as the corresponding sodium salt, fomesafen-sodium) for post-emergence control of broad-leaf weeds in soya.		3.4880aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
1-isopropylhydrazine
1-isopropylhydrazine: RN given refers to parent cpd		1.9310
haloperidol decanoate
[no description available]		1.9810organic molecular entity
metsulfuron methyl
metsulfuron methyl : A N-sulfonylurea in which the sulfonyl group is attached to a 2-(methoxycarbonyl)phenyl group while a (4-methoxy-6-methyl-1,3,5-triazin-2-yl group replaces one of the amino hydrogens of the remaining urea group.		2.43201,3,5-triazines;
benzoate ester;
N-sulfonylurea		environmental contaminant;
herbicide;
xenobiotic
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		2.4220delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
milacemide
milacemide: ampakine activity at AMPA Receptors; structure given in first source		4.0320
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		2.6320delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
idazoxan
Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.		210benzodioxine;
imidazolines		alpha-adrenergic antagonist
quinpirole
Quinpirole: A dopamine D2/D3 receptor agonist.. quinpirole : A pyrazoloquinoline that is (4aR,8aR)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]quinoline substituted by a propyl group at position 5. It acts as a dopamine agonist.		3.1250pyrazoloquinolinedopamine agonist
pravastatin
Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		7.43203-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
imazapyr, (+-)-isomer
imazapyr: RN given refers to parent cpd without isomeric designation. imazapyr : A racemate comprising equimolar amounts of (R)- and (S)-imazapyr. An inhibitor of acetohydroxyacid synthase, it is used (generally as the isopropylamine salt, known as imazapyr-isopropylammonium) as a herbicide, particularly for the control of perennial grasses, broad-leaved weeds, woody plants, brambles, etc., on non-crop land. It is not approved for use within the European Union.. 2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)nicotinic acid : A pyridinemonocarboxylic acid that is nicotinic acid which is substituted at position 2 by a 4,5-dihydro-imidazol-2-yl group, which in turn is substituted at positions 4, 4, and 5 by isopropyl, ethyl, and oxo groups, respectively.		2.4620imidazolines;
imidazolone;
pyridinemonocarboxylic acid;
pyridines
cabergoline
Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.		2.0510N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
atomoxetine hydrochloride
Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.		2.610hydrochlorideadrenergic uptake inhibitor;
antidepressant
mifepristone
Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.		3.28603-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
itraconazole
Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.		7.610aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
ractopamine
ractopamine: veterinary growth stimulant. ractopamine : A diastereoisomeric mixture of approximately equal amounts of all four possible diastereoisomers of 4-(1-hydroxy-2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)phenol. A beta-adrenergic agonist, it is used (generally as the hydrochloride salt) as a feed additive for use in pigs and other livestock to promote protein deposition, resulting in leaner meat. The R,R diastereoisomer, butopamine, is responsible for most of the leanness-enhancing effects. While use of ractopamine has been banned in over 120 countries including throughout the EU, in the US it used in an estimated 80% of all beef, pork and turkey production.. 4-(1-hydroxy-2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)phenol : A secondary amino compound that is 4-(2-amino-1-hydroxyethyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 4-(p-hydroxyphenyl)butan-2-yl group.		2.1310benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound
chlorimuron ethyl
chlorimuron ethyl: structure in first source. chlorimuron-ethyl : An ethyl ester resulting from the formal condensation of the carboxy group of chlorimuron with ethanol. A proherbicide for chloimuron, it is used as herbicide for the control of broad-leaved weeds in peanuts, soya beans, and other crops.		210aromatic ether;
ethyl ester;
N-sulfonylurea;
organochlorine pesticide;
pyrimidines;
sulfamoylbenzoate		agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
proherbicide
fluorodopa f 18
fluorodopa F 18: RN given refers to (L)-isomer		2.0210(18)F radiopharmaceutical;
6-fluoro-L-dopa
fura-2
Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.		2.7330
eticlopride
eticlopride: blocks dopamine-D2 binding sites; structure given in first source; RN given refers to (S)-isomer		2.0810salicylamides
imiquimod
Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.		2.2510imidazoquinolineantineoplastic agent;
interferon inducer
fadrozole
Fadrozole: A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.		2.0510imidazopyridine
aromasil
[no description available]		2.051017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
englitazone
englitazone: structure given in first source; RN given refers to (+-)-isomer		2.0310
clopidogrel
Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.		2.0110methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		2.0610phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
mibefradil
Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.		2.0310tetralinsT-type calcium channel blocker
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.7430pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil
1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.		1.9710monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.7430organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide
ibutilide: RN & structure in first source; RN refers to the fumarate salt		2.0210benzenes;
organic amino compound
enadoline
enadoline: kappa-opioid receptor agonist; RN given refers to cpd without isomeric designation; PD 129290 (CAM 570; CI 977) is the S,S(-)-enantiomer; PD 129289 (CAM 569) is the corresponding R,R(+)-enantiomer		1.9810
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		4.1831aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
atorvastatin
[no description available]		540aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
lamivudine
[no description available]		2.420monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
irinotecan
[no description available]		2.9540carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
pobilukast
pobilukast: a leukotriene receptor antagonist; an antiasthmatic agent; structure in first source; RN refers to (R-(R*,S*)-isomer		2.6730
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		2.5220biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		2.03101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zanamivir
Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.		2.0610guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
3-iodobenzylguanidine
3-Iodobenzylguanidine: A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.		2.4220organoiodine compound
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		11.03370adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
ferric citrate
ferric citrate: RN given refers to Fe(+3)[1:1] salt. iron(III) citrate : An iron chelate resulting from the combination of iron(3+) and citrate(3-).		1.9610iron chelateanti-anaemic agent;
nutraceutical
coomassie brilliant blue r
kenacid blue: RN given refers to cpd with unknown MF		1.9710
d-lactic acid
(R)-lactic acid : An optically active form of lactic acid having (R)-configuration.		2102-hydroxypropanoic acidEscherichia coli metabolite;
human metabolite
4-propionyloxy-4-phenyl-n-methylpiperidine
4-propionyloxy-4-phenyl-N-methylpiperidine: causes parkinsonism; structure in first source		2.0210
vanadates
Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.. vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.		5.05410trivalent inorganic anion;
vanadium oxoanion		EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
acridine orange
Acridine Orange: A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.. acridine orange : Fluorescent dye useful for cell cycle determination. It is cell-permeable, and interacts with DNA and RNA by intercalation or electrostatic attractions respectively.. acridine orange free base : A member of the class of aminoacridines that is acridine carrying two dimethylamino substituents at positions 3 and 6. The hydrochloride salt is the fluorescent dye 'acridine orange', used for cell cycle determination.		4.0440aminoacridines;
aromatic amine;
tertiary amino compound		fluorochrome;
histological dye
trifluoromethanesulfonic acid
trifluoromethanesulfonic acid: deblocking reagent for peptide synthesis; RN given refers to parent cpd. triflic acid : A one-carbon compound that is methanesulfonic acid in which the hydrogens attached to the methyl carbon have been replaced by fluorines.		2.4220one-carbon compound;
perfluoroalkanesulfonic acid
isothiocyanic acid
[no description available]		2.4720hydracid;
one-carbon compound
potassium phosphate
potassium phosphate: used in dental materials and to treat hypophosphatemia; RN given refers to cpd with unspecified MF. tripotassium phosphate : An inorganic potassium salt that is the tripotassium salt of phosphoric acid.		2.0410inorganic phosphate salt;
inorganic potassium salt
octyl glucoside
octyl-beta-D-glucoside: RN given refers to (beta)-isomer. octyl beta-D-glucopyranoside : An beta-D-glucoside in which the anomeric hydrogen of beta-D-glucopyranose is substituted by an octyl group.		1.9910beta-D-glucosideplant metabolite
trazodone hydrochloride
Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.		7.45391hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
carmoterol
carmoterol: CHF4226.01 and CHF4232.01 are diastereoisomers; structure in first source		4.0930
adamantanine
adamantanine: inhibitor of amino acid transport; RN given refers to parent cpd		2.1310
u 37883a
U 37883A: an antagonist of vascular ATP-sensitive potassium channel openers; structure given in first source		1.9910
methionine methyl ester
[no description available]		2.3520
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		5.56220D-glucopyranoseepitope;
mouse metabolite
mevastatin
mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.		2.03102-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
methionylpuromycin
[no description available]		1.9810
2',7'-dichlorofluorescein
2',7'-dichlorofluorescein: RN given refers to parent cpd		2.04102-benzofuransfluorochrome
ursolic acid
[no description available]		2.0110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
norharman
norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.		1.9610beta-carbolines;
mancude organic heterotricyclic parent		fungal metabolite;
marine metabolite
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		4.05140organic bromide saltcolorimetric reagent;
dye
thymidine 5'-triphosphate
thymidine 5'-triphosphate: RN given refers to parent cpd. dTTP : A thymidine phosphate having a triphosphate group at the 5'-position.		2.4120pyrimidine 2'-deoxyribonucleoside 5'-triphosphate;
thymidine phosphate		Escherichia coli metabolite;
mouse metabolite
3-methylhistidine
3-methylhistidine: marker for myofibrillar-protein breakdown; RN given refers to (L)-isomer. 3-methylhistidine : A methylhistidine in which the methyl group is located at N-3.. N(pros)-methyl-L-histidine : A L-histidine derivative that is L-histidine substituted by a methyl group at position 3 on the imidazole ring.		1.9810L-histidine derivative;
non-proteinogenic L-alpha-amino acid;
zwitterion		human metabolite;
Saccharomyces cerevisiae metabolite
betulinic acid
[no description available]		2.0410hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
platanic acid
platanic acid: inhibits HIV replication; isolated from Syzigium claviflorum; structure in first source. platanic acid : A pentacyclic triterpenoid that is 30-norlupan-28-oic acid substituted by a 3beta-hydroxy and an oxo group at position 20. It is isolated from the leaves of Syzygium claviflorum and exhibits anti-HIV activity.		2.0310hydroxy monocarboxylic acid;
methyl ketone;
pentacyclic triterpenoid		anti-HIV agent;
metabolite
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		2.110azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
amprenavir
[no description available]		2.4220carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		2.0610acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
5-methylcytosine
5-Methylcytosine: A methylated nucleotide base found in eukaryotic DNA. In ANIMALS, the DNA METHYLATION of CYTOSINE to form 5-methylcytosine is found primarily in the palindromic sequence CpG. In PLANTS, the methylated sequence is CpNpGp, where N can be any base.. 5-methylcytosine : A pyrimidine that is a derivative of cytosine, having a methyl group at the 5-position.		2.7130methylcytosine;
pyrimidines		human metabolite
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		3.5680flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
n-acetylaspartic acid
N-acetyl-L-aspartic acid : An N-acyl-L-aspartic acid in which the acyl group is specified as acetyl.		3.8630N-acetyl-L-amino acid;
N-acyl-L-aspartic acid		antioxidant;
human metabolite;
mouse metabolite;
nutraceutical;
rat metabolite
5-dimethylaminonaphthalene-1-sulfonamide
[no description available]		2.0410
fluorexon
fluorexon: structure		2.4220xanthene dyefluorochrome
2'-deoxycytidine 5'-triphosphate
2'-deoxycytidine 5'-triphosphate: RN given refers to unlabeled parent cpd		2.08102'-deoxycytidine phosphate;
pyrimidine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
25-hydroxycholesterol
[no description available]		2.73025-hydroxy steroid;
oxysterol		human metabolite
3-hydroxynorvaline
3-hydroxynorvaline: RN given refers to cpd without isomeric designation; structure. 3-hydroxynorvaline : A non-proteinogenic amino-acid derivative that is norvaline (2-aminopentanoic acid) in which a hydrogen at position 3 is replaced by a hydroxy group.		2.3820non-proteinogenic alpha-amino acid;
non-proteinogenic amino acid derivative
norvaline
norvaline: differs from valine in being 1 carbon longer instead of branched; RN given refers to (L)-isomer; structure. L-2-aminopentanoic acid : A 2-aminopentanoic acid that has S-configuration.		3.23602-aminopentanoic acid;
L-alpha-amino acid zwitterion		bacterial metabolite;
hypoglycemic agent;
neuroprotective agent
aica ribonucleotide
AICA ribonucleotide: purine precursor that has antineoplastic activity. AICA ribonucleotide : A 1-(phosphoribosyl)imidazolecarboxamide that is acadesine in which the hydroxy group at the 5' position has been converted to its monophosphate derivative.		5.261901-(phosphoribosyl)imidazolecarboxamide;
aminoimidazole		cardiovascular drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
4-nitrophenylgalactoside
4-nitrophenylgalactoside: RN refers to (beta-D)-isomer. 4-nitrophenyl-beta-D-galactoside : A beta-D-galactopyranoside having a 4-nitrophenyl substituent at the anomeric position.		2.0710beta-D-galactoside;
monosaccharide derivative		affinity label
thomsen-friedenreich antigen
Thomsen-Friedenreich antigen: do not confuse with T antigens, which are viral		2.4620
2',5'-dideoxyadenosine
[no description available]		2.0310deoxyribonucleoside
1-beta-d-arabinofuranosylcytosine 5'-monophosphate
1-beta-D-arabinofuranosylcytosine 5'-monophosphate: RN given refers to dihydrogen phosphate		2.0110
nile red
nile red : An organic heterotetracyclic compound that is 5H-benzo[a]phenoxazin-5-one substituted at position 9 by a diethylamino group.		1.9810aromatic amine;
cyclic ketone;
organic heterotetracyclic compound;
tertiary amino compound		fluorochrome;
histological dye
metaperiodate
Periodic Acid: A strong oxidizing agent.		4.78330iodine oxoacid
fluorophosphate
fluorophosphate: inhibits Phosphorylas phosphatase irreversibly; RN given refers to parent cpd		2.4920fluorine molecular entity;
phosphoric acid derivative
fructose-1-phosphate
fructose-1-phosphate: RN in Chemline for alpha-D-fructopyranose-cpd:126-25-0; RN given refers to (D)-isomer. D-fructose 1-phosphate : The D-enantiomer of fructose 1-phosphate.. keto-D-fructose 1-phosphate : The open chain form of D-fructose 1-phosphate.		2.1310D-fructose 1-phosphate
n-acetylserine
acetyl-L-serine : An acetyl-amino acid in which the amino acid specified is L-serine.. N-acetyl-L-serine : An N-acetyl-L-amino acid in which the amino acid specified is L-serine. Metabolite observed in cancer metabolism.		4.63270acetyl-L-serine;
N-acetyl-L-amino acid		human metabolite
surfactin peptide
surfactin peptide: antineoplastic product isolated from Bacillus sp.		1.9810
pyrrolidine dithiocarbamate
pyrrolidine dithiocarbamic acid: spelled pyrolidine in J Nutr 1979 reference; RN given refers to parent cpd. pyrrolidine dithiocarbamate : A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine.		2.4320dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
peroxynitric acid
[no description available]		210nitrogen oxoacid
glutathione disulfide
Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.		2.730glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
hypusine
hypusine: N-terminal amino alcohol deriv of Lys occurring in bovine brain & in the urine of children with familial hyperlysinemia; minor descriptor (75-82); online & Index Medicus search LYSINE/AA (75-82). hypusine : An L-lysine derivative that is L-lysine bearing a (2R)-4-amino-2-hydroxybutyl substituent at position N(6).		6.9810
4-nitrobenzylthioinosine
4-nitrobenzylthioinosine: inhibitor of nucleoside transport; acts on ENT1		2.4620purine nucleoside
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		6.49340cephalosporinfungal metabolite
tetraiodothyroacetic acid
tetraiodothyroacetic acid: RN given refers to parent cpd; structure. 3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'.		2.42202-halophenol;
aromatic ether;
iodophenol;
monocarboxylic acid		apoptosis inducer;
human metabolite;
thyroid hormone
tetrahydrocorticosterone
tetrahydrocorticosterone: RN given refers to (3alpha,5beta,11beta)-isomer		2.021021-hydroxy steroid
mci-196
colestimide: a 2-methylimidazole-epichlorohydrin polymer; bile acid and methotrexate anion-exchange resin		3.4111
goralatide
goralatide: from fetal calf bone marrow; exerts a high inhibitory activity on the proliferation of hematopoietic pluripotent stem cells. goralatide : A tetrapeptide that is Ser-Asp-Lys-Pro in which the N-terminal amino group carries an acetyl group. It is selective inhibitor of primitive haematopoietic cell proliferation and exhibits anti-inflammatory, anti-fibrotic, and pro-angiogenic properties.		210oligopeptide;
tetrapeptide		anti-inflammatory agent;
pro-angiogenic agent
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		2.830benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
2-methoxyestradiol
2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.		2.151017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
naphthalimides
Naphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.		2.4420
salicylhydroxamic acid
[no description available]		2.0110hydroxamic acid;
phenols		antibacterial drug;
EC 1.11.2.2 (myeloperoxidase) inhibitor;
EC 3.5.1.5 (urease) inhibitor;
trypanocidal drug
n-acetylvaline
N-acetylvaline: RN given refers to the (DL)-isomer		1.9710L-valine derivative;
N-acetyl-L-amino acid
benzeneboronic acid
[no description available]		2.4120boronic acids
thiamorpholine
thiamorpholine: RN given refers to parent cpd. thiomorpholine : A saturated organic heteromonocyclic parent that is an analogue of morpholine where the oxygen atom is replaced by sulfur.		2.0710saturated organic heteromonocyclic parent;
thiomorpholines
bromosuccinimide
Bromosuccinimide: A brominating agent that replaces hydrogen atoms in benzylic or allylic positions. It is used in the oxidation of secondary alcohols to ketones and in controlled low-energy brominations. (From Miall's Dictionary of Chemistry, 5th ed; Hawley's Condensed Chemical Dictionary, 12th ed,).		2.3920dicarboximide;
organobromine compound;
pyrrolidinone		reagent
2,4-diaminopyrimidine
2,6-diaminopyrimidine: structure in first source. pyrimidine-2,4-diamine : An aminopyrimidine in which a pyrimidine nucleus is substituted with amino groups at C-2 and C-4.		1.9810aminopyrimidine
1,7-phenanthroline
[no description available]		3.69100phenanthroline
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		4.582501,2,3-triazole
1,5-difluoro-2,4-dinitrobenzene
1,5-difluoro-2,4-dinitrobenzene: structure		1.9610
guanidinopropionic acid
guanidinopropionic acid: alters creatine metabolism; structure. 3-guanidinopropanoic acid : A guanidine compound bearing an N-(2-carboxyethyl) substituent. It is a creatine analogue that has been found to decreases plasma glucose levels		2.4420guanidines;
zwitterion		hypoglycemic agent
perfluorobutane sulfonate
perfluorobutanesulfonic acid: a surfactant; structure in first source. perfluorobutanesulfonic acid : A perfluoroalkanesulfonic acid that is butane-1-sulfonic acid in which all of the hydrogens of the butyl group have been replaced by fluorines.		2.610perfluoroalkanesulfonic acidsurfactant
ethylthiol trifluoroacetate
[no description available]		1.9910
isocoumarins
Isocoumarins: Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule.. isocoumarin : The simplest member of the class of isocoumarins that is 1H-isochromene which is substituted by an oxo group at position 1.		2.3920isocoumarins
5-hydroxyflavone
[no description available]		2.4110flavones
djenkolic acid
djenkolic acid: amino acid isolated from djenkol bean; RN given refers to (L)-isomer; structure. L-djenkolic acid : A dithioacetal consisting of two molecules of L-cysteine joined via their sulfanyl groups to methylene.		210dithioacetal;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid		plant metabolite;
toxin
phenylacetylglycine
phenylacetylglycine : A N-acylglycine that is glycine substituted on nitrogen with a phenylacetyl group.		2.0310monocarboxylic acid amide;
monocarboxylic acid;
N-acylglycine		human metabolite;
mouse metabolite
hydracrylic acid
3-hydroxypropionic acid : A 3-hydroxy monocarboxylic acid that is propionic acid in which one of the hydrogens attached to the terminal carbon is replaced by a hydroxy group.		2.02103-hydroxy monocarboxylic acid;
omega-hydroxy-short-chain fatty acid		Escherichia coli metabolite;
human metabolite
serinol
serinol: RN given refers to cpd without isomeric designation		2.4420
n-acetyltyrosine
N-acetyl-L-tyrosine : An N-acetyltyrosine in which the chiral centre has L configuration.		210N-acetyltyrosine;
N-acyl-L-tyrosine		biomarker;
EC 2.1.1.4 (acetylserotonin O-methyltransferase) inhibitor;
human urinary metabolite
guanidinoethane sulfonate
[no description available]		1.9610guanidines;
organosulfonic acid;
zwitterion
methyl 2-tetradecylglycidate
methyl 2-tetradecylglycidate: structure		2.0310
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		4.34412-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
sertraline
Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.		7.520dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
selfotel
selfotel: a N-methyl-D-aspartate (NMDA) antagonist; used to treat stroke-induced impairment		2.6830non-proteinogenic alpha-amino acid
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		2.07101,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
soquinolol
soquinolol: structure given in first source		2.0110
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.0810organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
mesulergine
mesulergine: RN given refers to parent cpd; CU 32-085 is synonymous to mono-HCl; metabolized into dopaminergic agonists; structure given in first source. mesulergine : A member of the class of ergot alkaloids that is known to act on serotonin and dopamine receptors.		2.420ergot alkaloid;
sulfamides		antiparkinson drug;
dopamine agonist;
serotonergic antagonist
artemether
Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		7.1110artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
glycine amide
glycine amide: RN given refers to parent cpd		1.9710amino acid amide;
glycine derivative
5-methylhydantoin
5-methylhydantoin: RN given refers to cpd without isomeric designation		2.0710imidazolidine-2,4-dione
1,2,3,4-tetrahydroquinoline
1,2,3,4-tetrahydroquinoline: structure in first source. 1,2,3,4-tetrahydroquinoline : A member of the class of quinolines that is the 1,2,3,4-tetrahydro derivative of quinoline.		2.0610quinolines
fructose-6-phosphate
fructose-6-phosphate: RN given refers to parent cpd with unspecified isomeric designation. fructose 6-phosphate : A ketohexose monophosphate consisting of fructose having a phosphate group located at the 6-position.		2.4720D-fructose 6-phosphate
5-fluoroorotic acid
5-fluoroorotic acid: inhibits the dietary induction of serine dehydratase. 5-fluoroorotic acid : A pyrimidinemonocarboxylic that is orotic acid which is substituted by fluorine at position 5. It is used in yeast molecular genetics to detect expression of the URA3 gene, which encodes orotine-5'-monophosphate dicarboxylase. A yeast with and active URA3 gene converts 5-fluoroorotic acid to fluorodeoxyuridine, which is toxic to cells.		2.4120
indole-3-carboxylic acid
indole-3-carboxylic acid : An indole-3-carboxylic acid carrying a carboxy group at position 3.		2.0310indol-3-yl carboxylic acidbacterial metabolite;
human metabolite
ethyl tyrosine ester
ethyl tyrosine ester: RN given refers to L-isomer. ethyl L-tyrosinate : An L-tyrosyl ester that is L-tyrosine in which the hydrogen of the carboxy group has been replaced by an ethyl group.		1.9710ethyl ester;
L-tyrosyl ester
leucyltyrosine
leucyltyrosine: RN given refers to L-Tyr,L-Leu-isomer; RN for cpd without isomeric designation not avail 4/93		2.420dipeptidemetabolite
diphenyltin
[no description available]		2.0410
n-acetyltryptamine
N-acetyltryptamine: antagonizes the melatonin-induced inhibition of dopamine release from retina; RN given refers to parent cpd. N-acetyltryptamine : A tryptamine compound having an acetyl substituent attached to the side-chain amino function.		210acetamides;
indoles
tyrosine methyl ester
tyrosine methyl ester: RN given refers to (L)-isomer. methyl L-tyrosinate : An L-tyrosyl ester that is the methyl ester of L-tyrosine.		2.3920L-tyrosyl ester;
methyl ester
5-hydroxymethylcytosine
5-(hydroxymethyl)cytosine : A nucleobase analogue that is cytosine in which the hydrogen at position 5 is replaced by a hydroxymethyl group.		2.2110aminopyrimidine;
aromatic primary alcohol;
nucleobase analogue;
pyrimidone		human metabolite;
mouse metabolite
morpholinopropane sulfonic acid
3-(N-morpholino)propanesulfonic acid : A Good's buffer substance, pKa = 7.2 at 20 degreeC.		2.0110MOPS;
morpholines;
organosulfonic acid
leucyl-glycyl-glycine
leucyl-glycyl-glycine: RN given refers to (L-Leu)-isomer. Leu-Gly-Gly : A tripeptide composed of one L-leucine and two glycine residues joined in sequence.		2.420tripeptidemetabolite
acetylleucine
[no description available]		1.9710L-leucine derivative;
N-acetyl-L-amino acid		metabolite
n-acetylglutamic acid
N-acetylglutamic acid: RN given refers to (L)-isomer. N-acetyl-L-glutamic acid : An N-acyl-L-amino acid that is L-glutamic acid in which one of the amine hydrogens is substituted by an acetyl group.		2.4220N-acetyl-L-amino acid;
N-acyl-L-glutamic acid		human metabolite;
Saccharomyces cerevisiae metabolite
bicinchoninic acid
[no description available]		1.9710
D-serine
[no description available]		2.4320D-alpha-amino acid;
serine zwitterion;
serine		Escherichia coli metabolite;
human metabolite;
NMDA receptor agonist
D-alanine
[no description available]		2.4320alanine zwitterion;
alanine;
D-alpha-amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
Escherichia coli metabolite;
human metabolite
D-tyrosine
[no description available]		210D-alpha-amino acid zwitterion;
D-alpha-amino acid;
tyrosine		Escherichia coli metabolite
aprofen
aprofen: RN given refers to parent cpd; structure		1.9610
n-methylscopolamine
N-Methylscopolamine: A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.		2.0310
uk 68798
[no description available]		2.0210aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		2.4220carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
trichlorosucrose
trichlorosucrose: sweetness intensity roughly 600 times that of sucrose and is nonnutritive and noncaloric; largely unabsorbed in the gastrointestinal tract. sucralose : A disaccharide derivative consisting of 4-chloro-4-deoxy-alpha-D-galactopyranose and 1,6-dichloro-1,6-dideoxy-beta-D-fructofuranose units linked by a glycosidic bond.		2.4110disaccharide derivative;
organochlorine compound		environmental contaminant;
sweetening agent;
xenobiotic
dicolinium iodide
dicolin: RN given refers to diiodide; structure		2.0410
D-valine
D-valine : The D-enantiomer of valine.		2.0610D-alpha-amino acid zwitterion;
D-alpha-amino acid;
valine
phenylalanine
[no description available]		210D-alpha-amino acid zwitterion;
D-alpha-amino acid;
phenylalanine
penicillin n
penicillin N: RN given refers to (2S-(2alpha,5alpha,6beta(S*)))-isomer; structure in Merck, 9th ed, #6887		7.3920penicillin
ubenimex
ubenimex: growth inhibitor		2.4420
7-hydroxystaurosporine
[no description available]		2.9440
epicatechin
(-)-epicatechin : A catechin with (2R,3R)-configuration.		2.4110catechin;
polyphenol		antioxidant
6-hydroxyflavone
6-hydroxyflavone: antioxidant; structure in first source		2.4110hydroxyflavonoid
4-o-methyl-12-o-tetradecanoylphorbol 13-acetate
[no description available]		2.7330
phorbol-12,13-diacetate
phorbol-12,13-diacetate: RN given refers to (1aR-(1a alpha,1b beta,4a beta,7a alpha,7b alpha,8 alpha,9 beta,9a alpha))-isomer		2.0110
honokiol
[no description available]		2.610biphenyls
nobiletin
nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.		2.7730methoxyflavoneantineoplastic agent;
plant metabolite
leupeptin
[no description available]		2.0110aldehyde;
tripeptide		bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor
alkannin
alkannin: a naphthazarin used to promote wound healing, from the plant Alkanna tinctoria; RN given refers to (S)-isomer; structure		2.4110hydroxy-1,4-naphthoquinone
pneumocandin c(0)
pneumocandin C(0): structure given in first source; isolated from Zalerion arboricola		210
tosyllysine chloromethyl ketone
Tosyllysine Chloromethyl Ketone: An inhibitor of SERINE ENDOPEPTIDASES. Acts as an alkylating agent and is known to interfere with the translation process.		2.3620sulfonic acid derivative
rebeccamycin
rebeccamycin: from actinomycete strain C-38,383; structure given in first source. rebeccamycin : An N-glycosyl compound consisting of a heteropolycyclic ring system with a glucosyl group attached to one of the indolic nitrogens.		210indolocarbazole;
N-glycosyl compound;
organic heterohexacyclic compound;
organochlorine compound
nicosulfuron
nicosulfuron: inhibits ACETOLACTATE SYNTHASE; Accent is DuPont brand name. nicosulfuron : A N-sulfonylurea that is 2-(carbamoylsulfamoyl)-N,N-dimethylpyridine-3-carboxamide substituted by a 4,6-dimethoxypyrimidin-2-yl group at the amino nitrogen.		2.520N-sulfonylurea;
pyridines;
pyrimidines		environmental contaminant;
herbicide;
xenobiotic
xanthosine 5'-triphosphate
xanthosine 5'-phosphate : xanthosine phosphate compounds having phosphate groups at position 5'.. 5'-xanthylic acid : A purine ribonucleoside 5'-monophosphate having xanthine as the nucleobase.		1.9910purine ribonucleoside 5'-monophosphate;
xanthosine 5'-phosphate		Escherichia coli metabolite;
metabolite;
mouse metabolite
calpeptin
[no description available]		2.7130amino acid amide
gliclazide
18alpha-glycyrrhetinic acid: a gap junction inhibitor		2.5220
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		2.6830carbamate ester;
oxazolidinone		metabolite
diisopropylphosphate
[no description available]		1.9710dialkyl phosphate
perfluorooctane sulfonic acid
perfluorooctane-1-sulfonic acid : A perfluoroalkanesulfonic acid that is octane-1-sulfonic acid in which all seventeen of the hydrogens that are attached to carbons hvae been replaced by fluorines.		2.7220perfluoroalkanesulfonic acidantilipemic drug;
persistent organic pollutant
malonamic acid
malonamic acid: structure		210beta-alanine derivative
n-formylglycine
glycal : A cyclic enol ether derivative of a sugar having a double bond specifically between carbon atoms 1 and 2 in the ring.		1.9610N-acylglycine;
N-formyl amino acid
2-(methylamino)isobutyric acid
alpha-(methylamino)isobutyric acid : A non-proteinogenic alpha-amino acid that is isobutyric acid in which the alpha-hydrogen has been replaced by a methylamino group.		3.68100alanine derivative;
alpha-amino acid zwitterion;
non-proteinogenic alpha-amino acid;
secondary amino compound		human urinary metabolite
1-hydroxybenzotriazole
1-hydroxybenzotriazole: RN given refers to parent cpd		2.0710benzotriazoles
4-nitrophenyl butyrate
p-nitrophenyl butyrate : A butyrate ester resulting from the formal condensation of the hydroxy group of 4-nitrophenol with the carboxy group of butyric acid.		2.0410butyrate ester;
C-nitro compound
4,4'-dipyridyl disulfide
4,4'-dipyridyl disulfide : An organic disulfide obtained by formal oxidative dimerisation of 4-thiopyridine.		1.9910organic disulfide;
pyridines
6-carboxyfluorescein
6-carboxyfluorescein: originally sold as 6-carboxyfluorescein, but commercial product is a mixture of two isomers; correct name is 5(6)-carboxyfluorescein		1.9910monocarboxylic acid
leucylleucine
Leu-Leu : A dipeptide formed from two L-leucine residues.		2.420dipeptide;
L-aminoacyl-L-amino acid zwitterion		human metabolite;
Mycoplasma genitalium metabolite
phenylalanylleucine
phenylalanylleucine: RN given refers to (L)-isomer		1.9710dipeptide zwitterion;
dipeptide		plant metabolite
n-ethyl-5-phenylisoxazolium-3'-sulfonate
N-ethyl-5-phenylisoxazolium-3'-sulfonate: reagent for rapid modification of carboxyl groups in proteins; structure		1.9710
methyl tryptophan, (l-trp)-isomer
[no description available]		2.3920
rosiglitazone
[no description available]		2.7230aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
12-hydroxydodecanoic acid
12-hydroxylauric acid : A medium-chain fatty acid that is the 12-hydroxylated derivative of lauric acid.		1.9910omega-hydroxy-medium-chain fatty acidhuman metabolite
alpha-acetolactate
alpha-acetolactate: RN given refers to cpd without isomeric designation		2.2510
4-nitrophenethyl bromide
[no description available]		2.3110
tricine
N-tris(hydroxymethyl)methylglycine : A Good's buffer substance, pKa = 8.15 at 20 degreeC.		2.7230tricine
n-hydroxysuccinimide
N-hydroxysuccinimide: structure		2.7230
leucyl-alanine
Leu-Ala : A dipeptide composed of L-leucine and L-alanine joined by a peptide linkage.		2.420dipeptidemetabolite
gamma-glutamine-4-nitroanilide
gamma-glutamine-4-nitroanilide: substrate for glutaminase B.; RN given refers to (L)-isomer		2.6630
tryptophan ethyl ester
tryptophan ethyl ester: RN given refers to (DL)-isomer		1.9710
2-bromopalmitate
2-bromopalmitate: inhibitor of fatty acid oxidation; RN given refers to parent cpd. 2-bromohexadecanoic acid : A bromo fatty acid that is hexadecanoic (palmitic) acid carrying a single bromo substituent at position 2.		2.44202-bromocarboxylic acid;
bromo fatty acid;
long-chain fatty acid;
straight-chain fatty acid		fatty acid oxidation inhibitor
bexarotene
[no description available]		210benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
s20098
[no description available]		210acetamides
2-(4-toluidino)-6-naphthalenesulfonic acid
2-(4-toluidino)-6-naphthalenesulfonic acid: RN given refers to parent cpd; structure		2.0310
1-ethyl-2-benzimidazolinone
1-ethyl-2-benzimidazolinone: structure in first source		2.110imidazoles
leucyl-leucyl-leucine
leucyl-leucyl-leucine: RN given refers to (L-Leu-L-Leu-L-Leu)-isomer. Leu-Leu-Leu : A tripeptide formed from three L-leucine residues.		2.420tripeptidemetabolite
5-ethylphenazine
[no description available]		2.0510
aminomethanesulfonic acid
[no description available]		1.9710
d-aspartic acid
[no description available]		11.86170aspartic acid;
D-alpha-amino acid		mouse metabolite
zwittergent 3-12
zwittergent 3-12: zwitterionic detergent. lauryl sulfobetaine : An ammonium betaine in which the ammonium nitrogen is substituted by dodecyl, 3-sulfatopropyl and two methyl groups.		1.9610ammonium betainedetergent
3,4-dihydroxymandelic acid
3,4-dihydroxymandelic acid: metabolite of L-dopa; RN given refers to parent cpd without isomeric designation. 3,4-dihydroxymandelic acid : A catechol that is the 3,4-dihydroxy derivative of mandelic acid; a metabolite of L-dopa.		2.17102-hydroxy monocarboxylic acid;
catechols		antioxidant;
drug metabolite;
human metabolite;
mouse metabolite
epidepride
epidepride: structure given in first source		1.9810dimethoxybenzene
mosher's acid
Mosher's acid: structure in first source		2.0610
tyrosylleucine
[no description available]		1.9710dipeptidemetabolite
sdds
SDDS: structure		2.610benzenes;
sulfonamide
coenzyme a
[no description available]		11.24470adenosine 3',5'-bisphosphatecoenzyme;
Escherichia coli metabolite;
mouse metabolite
n-acetylalanine
N-acetylalanine: immunodominant determinant of acidic surface antigen from culture filtrate of human strain of Staph aureus. N-acetyl-L-alanine : An N-acetyl-L-amino acid that is L-alanine in which one of the hydrogens attached to the nitrogen is replaced by an acetyl group.		2.940L-alanine derivative;
N-acetyl-L-amino acid		human metabolite;
Saccharomyces cerevisiae metabolite
o-methylserine
O-methylserine: RN given refers to compound with no isomeric designation. O-methylserine : A serine derivative that is L-serine with a methyl group replacing the hydrogen on the hydroxy side chain.		3.1150L-serine derivative;
non-proteinogenic L-alpha-amino acid		metabolite
n-butyrylglycine
butyrylglycine : A N-acylglycine obtained by formal condensation of the carboxy group of butyric acid with the amino group of glycine.		1.9610N-acylglycinehuman urinary metabolite
Trp-Trp
tryptophyltryptophan: an antigelation agent. Trp-Trp : A dipeptide formed from two L-tryptophan residues.		1.9710dipeptideMycoplasma genitalium metabolite
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		10.151703-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
1-aminocyclobutanecarboxylic acid
1-aminocyclobutanecarboxylic acid: RN given refers to unlabeled cpd		1.9710L-alpha-amino acid
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		5400iditolfungal metabolite
2-thienylalanine
2-thienylalanine: potent inhibitor of phenylalanine absorption in intestine which promotes its excretion by the kidney; minor descriptor (75-85); on-line & Index Medicus search ALANINE/AA (75-85); RN given refers to parent cpd without isomeric designation		2.0110
17-alpha-hydroxypregnenolone
17-alpha-Hydroxypregnenolone: A 21-carbon steroid that is converted from PREGNENOLONE by STEROID 17-ALPHA-HYDROXYLASE. It is an intermediate in the delta-5 pathway of biosynthesis of GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.. 17alpha-hydroxypregnenolone : A hydroxypregnenolone carrying an alpha-hydroxy group at position 17.		2.021017alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
3beta-hydroxy-Delta(5)-steroid;
hydroxypregnenolone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
7-ketocholesterol
7-ketocholesterol: inhibits uptake of cholesterol in rabbit aorta. 7-ketocholesterol : A cholestanoid that consists of cholesterol bearing an oxo substituent at position 7.		2.02103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
7-oxo steroid;
cholestanoid		neuroprotective agent
fluocinolone
[no description available]		2.0110fluorinated steroid
5-bromouridine
5-bromouridine : A uridine having a bromo substituent at the 5-position.		1.9810uridinesmutagen
4-nitrophenyl beta-d-xyloside
4-nitrophenyl beta-D-xyloside : A xyloside that is beta-D-xylopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.		1.9510C-nitro compound;
xyloside		chromogenic compound
3,4-dihydroxyphenylglycol
3,4-dihydroxyphenylglycol: noradrenaline metabolite in mouse brain; RN given refers to cpd without isomeric designation. 3,4-dihydroxyphenylethyleneglycol : A tetrol composed of ethyleneglycol having a 3,4-dihydroxyphenyl group at the 1-position.		4.9281catechols;
tetrol		metabolite;
mouse metabolite
isomalathion
[no description available]		2.0310
5'-adenylyl (beta,gamma-methylene)diphosphonate
5'-adenylyl (beta,gamma-methylene)diphosphonate: do not confuse with alpha,beta-methyleneadenosine 5'-triphosphate		2.0210nucleoside triphosphate analogue
homocysteine
Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.		12.521322amino acid zwitterion;
homocysteine;
serine family amino acid		fundamental metabolite;
mouse metabolite
alpha,beta-methyleneadenosine 5'-triphosphate
alpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpd		2.4720nucleoside triphosphate analogue
methylglucoside
[no description available]		1.9610
salsolinol
salsolinol: RN given refers to cpd without isomeric designation; EP to SALSOLINE ALKALOIDS (78-82); on-line search SALSOLINE ALKALOIDS (78-82); Index Medicus search ISOQUINOLINES (78-82). (S)-salsolinol : A 1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol that has S-configuration.		2.08101-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diolhuman urinary metabolite
1,5-i-aedans
1,5-I-AEDANS: fluorescent probes which are sulfhydryl reagents; combine reactivity of iodoacetamide toward sulfhydryl groups with spectral properties of naphthalenesulfonic acids; structure. 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid : An aminonaphthalenesulfonic acid fluorophore with a structure consisting of ethylenediamine substituted on the nitrogens with iodoacetyl and 5-sulfonyl-1-naphthyl groups.		1.9710aminonaphthalenesulfonic acidfluorescent probe
8-((4-chlorophenyl)thio)cyclic-3',5'-amp
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP: lowers cAMP in heart & fat cells; cAMP-dependent kinase inhibitor. 8-(4-chlorophenylthio)-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the hydrogen at position 2 on the purine fragment is replaced by a 4-chlorophenylthio group.		2.92403',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
aryl sulfide;
organochlorine compound		protein kinase agonist
4-n,n-dimethylaminoazobenzene-4'-sulfonyl chloride
4-N,N-dimethylaminoazobenzene-4'-sulfonyl chloride: chromophoric labelling reagent for amino acids, peptides, proteins; structure		2.940
ac 263,222
imazapic: imidazolinone herbicide. imazapic : A racemate comprising equimolar amounts of (R)- and (S)-imazapic. It is a selective imidazolinone herbicide for pre- and post-emergent control of some annual and perennial grasses and broadleaf weeds. It kills plants by inhibiting the activity of the enzyme acetohydroxy acid synthase (AHAS).. 5-methyl-2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]pyridine-3-carboxylic acid : A pyridinemonocarboxylic acid that is 5-methylpyridine-3-carboxylic acid which is substituted at position 2 by a 4,5-dihydro-imidazol-2-yl group, which in turn is substituted at positions 4, 4, and 5 by isopropyl, methyl, and oxo groups, respectively.		2.2510imidazolines;
imidazolone;
methylpyridines;
pyridinemonocarboxylic acid
thiomethylgalactoside
[no description available]		2.3920
glycyltryptophan
glycyltryptophan: RN given refers to (L)-isomer. Gly-Trp : A dipeptide formed from glycine and L-tryptophan residues.		2.420dipeptidemetabolite
7-amino-4-methylcoumarin
7-amino-4-methylcoumarin: RN given refers to parent cpd		1.98107-aminocoumarinsfluorochrome
2-nitro-5-thiocyanobenzoic acid
2-nitro-5-thiocyanobenzoic acid: inhibits iron-containing nitrile hydratases		1.9910
5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid
5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid: structure given in first source		2.0110
mci 9038
[no description available]		3.5120peptide
gamma-tocopherol
gamma-Tocopherol: A natural tocopherol with less antioxidant activity than ALPHA-TOCOPHEROL. It exhibits antioxidant activity by virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus. As in BETA-TOCOPHEROL, it also has three methyl groups on the 6-chromanol nucleus but at different sites.. gamma-tocopherol : A tocopherol in which the chroman-6-ol core is substituted by methyl groups at positions 7 and 8. It is found particularly in maize (corn) oil and soya bean (soybean) oils.		2.0810tocopherol;
vitamin E		algal metabolite;
food antioxidant;
plant metabolite
propionyl-coenzyme a
propionyl-coenzyme A: RN given refers to parent cpd		2.0110acyl-CoAEscherichia coli metabolite;
metabolite;
mouse metabolite
5-alpha-dihydroprogesterone
5-alpha-Dihydroprogesterone: A biologically active 5-alpha-reduced metabolite of plasma PROGESTERONE. It is the immediate precursor of 5-alpha-pregnan-3-alpha-ol-20-one (ALLOPREGNANOLONE), a neuroactive steroid that binds with GABA(A) RECEPTOR.. 5alpha-pregnane-3,20-dione : A C21-steroid hormone that is 5alpha-pregnane substituted by oxo groups at positions 3 and 20. It is a metabolite of progestrone.		2.021020-oxo steroid;
3-oxo-5alpha-steroid;
C21-steroid hormone		human metabolite;
progestogen
glycyltyrosine
Gly-Tyr : A dipeptide composed of glycine and L-tyrosine joined by a peptide linkage.		1.9710dipeptidemetabolite
glycylleucine
Gly-Leu : A dipeptide composed of glycine and L-leucine joined by a peptide linkage.		2.420dipeptide zwitterion;
dipeptide		metabolite
histidine methyl ester
histidine methyl ester: RN given refers to (L)-isomer; structure given in first source. histidine methyl ester : An alpha-amino acid ester that is the methyl ester of histidine.		1.9710histidine derivative
n(alpha)-acetyllysine
N(alpha)-acetyllysine: RN given refers to (L)-isomer. acetyl-L-lysine : An N-acetyl-L-amino acid that is the N-acetyl derivative of L-lysine.. N(2)-acetyl-L-lysine : An acetyl-L-lysine where the acetyl group is located at the N(2)-posiiton.		1.9810acetyl-L-lysine;
amino acid zwitterion		human metabolite
4-nitrophenyl beta-d-glucoside
4-nitrophenyl beta-D-glucoside: RN given refers to (beta)-anomer; see also (alpha)-anomer: 3767-28-0; cpd with unspecified anomer: 5779-46-4. 4-nitrophenyl beta-D-glucoside : A beta-D-glucoside that is beta-D-glucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.		1.9910beta-D-glucoside;
C-nitro compound		chromogenic compound
firefly luciferin
Firefly Luciferin: A benzothaizole which is oxidized by LUCIFERASES, FIREFLY to cause emission of light (LUMINESCENCE).. Photinus luciferin : A 1,3-thiazolemonocarboxylic acid consisting of 3,5-dihydrothiophene-4-carboxylic acid having a 6-hydroxybenzothiazol-2-yl group at the 2-position.		7.53201,3-thiazolemonocarboxylic acid;
benzothiazoles;
imidothioate		luciferin
2-nitrophenyl-beta-d-glucopyranoside
[no description available]		210
glycyl-l-phenylalanine
glycylphenylalanine: RN given refers to (DL)-isomer. Gly-Phe : A dipeptide formed from glycine and L-phenylalanine residues.		2.420dipeptide zwitterion;
dipeptide		human metabolite;
metabolite
4-nitrophenyl alpha-glucoside
4-nitrophenyl alpha-glucoside: RN given refers to (alpha)-anomer; see also (beta)-anomers: 29857-05-4, 2492-87-7; cpd with unspecified anomer: 5779-46-4. 4-nitrophenyl alpha-D-glucoside : An alpha-D-glucoside that is beta-D-glucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.		2.110alpha-D-glucoside;
C-nitro compound;
monosaccharide derivative		chromogenic compound
droxidopa
Droxidopa: A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION.. droxidopa : A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension		12.67946catechols;
L-tyrosine derivative		antihypertensive agent;
prodrug;
vasoconstrictor agent
glycidyl nitrate
glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.		6.09390
aspartyl-phenylalanine
aspartyl-phenylalanine: metabolite of aspartame; may inhibit angiotensin converting enzyme; RN given refers to all (L)-isomer		2.0510dipeptidehuman blood serum metabolite;
human xenobiotic metabolite
n-(9h-(fluoren-9-ylmethoxy)carbonyl)glycine
N-(9H-(fluoren-9-ylmethoxy)carbonyl)glycine: in contrast to a closely related analog NPC 15669, this compound is inactive as an inhibitor of neutrophil recruitment		2.0210
glycylsarcosine
glycylsarcosine : A dipeptide obtained by formal condensation of the carboxy group of glycine with the amino group of sarcosine.		2.0510dipeptide zwitterion;
dipeptide
dansyl fluoride
dansyl fluoride: structure in second source		2.6730
thiazolidine-4-carboxylic acid, (r)-isomer
l-4-thiazolidinecarboxylic acid: structure in first source. L-thioproline : An optically active version of thioproline having L-configuration.. thioproline : A sulfur-containing amino acid that is proline in which the methylene group at position 4 is replaced by a sulfur atom.		2.0610thiazolidinemonocarboxylic acid;
thioproline		geroprotector;
metabolite
dithiobis(succinimidylpropionate)
dithiobis(succinimidylpropionate): used to study interactions of structural proteins; RN given refers to unlabeled cpd		1.9810
beta-hydroxyphenylalanine
beta-hydroxyphenylalanine: RN given refers to beta cpd		3.8120
stearoyl-coenzyme a
[no description available]		1.991011,12-saturated fatty acyl-CoA;
long-chain fatty acyl-CoA		Escherichia coli metabolite;
mouse metabolite
arabitol
arabitol: RN given refers to cpd without isomeric designation. arabinitol : A pentitol that is the sugar alcohol produced by the reduction of arabinose or lyxose. It is found in serum or urine of human infected with Candida albicans.. D-arabinitol : The D-enantiomer of arabinitol.		2.1710arabinitol
n-acetylphenylalanine ethyl ester
N-acetylphenylalanine ethyl ester: RN given refers to (L)-isomer		1.9710
leucylleucine
leucylleucine: RN given refers to (DL-Leu-DL-Leu)-isomer		2.0510peptide
pyrimidine dimers
Pyrimidine Dimers: Dimers found in DNA chains damaged by ULTRAVIOLET RAYS. They consist of two adjacent PYRIMIDINE NUCLEOTIDES, usually THYMINE nucleotides, in which the pyrimidine residues are covalently joined by a cyclobutane ring. These dimers block DNA REPLICATION.		2.7230
dansyl hydrazine
[no description available]		210
diprotin a
[no description available]		2.0810peptide
glucuronic acid
Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.		2.420D-glucuronic acidalgal metabolite
isovaline
isovaline: RN given refers to parent cpd(L)-isomer		7.7330
2,2',4,4'-tetrabromodiphenyl ether
[no description available]		2.4110aromatic ether;
organobromine compound
2,2-dimethyl-beta-alanine
[no description available]		3.150
imidazoleacetic acid
imidazoleacetic acid: RN given refers to cpd without specific location of acetic acid attachment identified; structure. imidazol-5-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-5-yl group.. imidazol-4-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-4-yl group.		2.3720imidazoles;
monocarboxylic acid		metabolite;
mouse metabolite
2,3-naphthalenedicarboxaldehyde
2,3-naphthalenedicarboxaldehyde: used in colorimetric determination of cholesterol; RN from CA Form Index Vol 90; N1 same as NM		2.4220
nitrophenylgalactosides
Nitrophenylgalactosides: Includes ortho-, meta-, and para-nitrophenylgalactosides.. 2-nitrophenyl beta-D-galactoside : A beta-D-galactoside having a 2-nitrophenyl substituent at the anomeric position.		2.0710beta-D-galactoside;
C-nitro compound		chromogenic compound
alanylphenylalanine
alanylphenylalanine: RN given refers to (L-Ala-L-PheAla)-isomer		1.9710dipeptidemetabolite
glycyl-leucyl-tyrosine
glycyl-leucyl-tyrosine: structure given in first source		2.420oligopeptide
glycyl-glycyl-proline
Gly-Gly-Pro : A tripeptide composed of glycine, glycine and L-proline amino acids joined in sequence by peptide linkages.		2.0510tripeptide zwitterion;
tripeptide
phencyclone
phencyclone: structure in first source		2.0410cyclic ketone
glycylaspartic acid
glycylaspartic acid: RN given refers to (L)-isomer		2.0510dipeptidemetabolite
glycyl-histidyl-glycine
[no description available]		2.0510oligopeptide
s-(2,4-dinitrophenyl)glutathione
S-(2,4-dinitrophenyl)glutathione : A glutathione conjugate in which the thiol hydrogen of glutathione has been replaced by a 2,4-dinitrophenyl group.		1.9910glutathione conjugate
hexylglutathione
S-hexylglutathione : An S-substituted glutathione that is glutathione in which the hydrogen of the thiol has been replaced by a hexyl group (PDB entry: 1PN9).		210S-substituted glutathione
n-glycylglutamic acid
N-glycylglutamic acid: RN given refers to (L)-isomer. Gly-Glu : A dipeptide formed from glycyl and L-glutamic acid residues.		2.0510dipeptidemetabolite
poly-o-acetylserine
O-acetylserine: RN given refers to (DL)-isomer. O-acetyl-L-serine : An acetyl-L-serine where the acetyl group is attached to the side-chain oxygen. It is an intermediate in the biosynthesis of the amino acid cysteine in bacteria.		7.94820acetate ester;
acetyl-L-serine;
amino acid zwitterion		bacterial metabolite;
Saccharomyces cerevisiae metabolite
2,2,5,7,8-pentamethyl-1-hydroxychroman
2,2,5,7,8-pentamethyl-1-hydroxychroman: a Vitamin E derivative. chromanol : Any member of the class of chromanes that is chromane substituted by one or more hydroxy groups.		2.0310
n-succinimidyl-3-(4-hydroxyphenyl)propionate
N-succinimidyl-3-(4-hydroxyphenyl)propionate: acylates free amino groups on proteins		1.9910
s-2-aminoethyl cysteine
S-2-aminoethyl cysteine: inhibits protein synthesis in mammalian cells; RN given refers to parent cpd; structure. L-thialysine : A cysteine derivative that is the S-(2-aminoethyl) analogue of L-cysteine; reported to have cytotoxic effects.		2.420L-cysteine thioether;
non-proteinogenic L-alpha-amino acid		EC 5.4.3.2 (lysine 2,3-aminomutase) inhibitor;
metabolite;
protein synthesis inhibitor
n-acetylasparagine
N-acetylasparagine: RN given refers to (L)-isomer		1.9810asparagine derivative
4-hydroxycyclophosphamide
4-hydroxycyclophosphamide: primary activation metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation. 4-hydroxycyclophosphamide : A phosphorodiamide that consists of 2-amino-1,3,2-oxazaphosphinan-4-ol 2-oxide having two 2-chloroethyl groups attached to the exocyclic nitrogen.		1.9910nitrogen mustard;
organochlorine compound;
phosphorodiamide		alkylating agent;
metabolite
phorbolol myristate acetate
[no description available]		3.5380
foxes
Foxes: Any of several carnivores in the family CANIDAE, that possess erect ears and long bushy tails and are smaller than WOLVES. They are classified in several genera and found on all continents except Antarctica.		2.110
kemptide
[no description available]		2.940
combretastatin
combretastatin: cytotoxic principle from South African tree COMBRETUM caffrum; structure given in first source; acts at COLCHICINE site of TUBULIN		4.3730
n-hydroxysuccinimide suberic acid ester
disuccinimidyl suberate: used as protein cross-linking agent		1.9810
aminomalonic acid
aminomalonic acid: aspartase-ammonia ligase inhibitor. aminomalonic acid : An amino dicarboxylic acid that is malonic acid in which one of the methylene hydrogens has been replaced by an amino group.		2.2510amino dicarboxylic acidDaphnia magna metabolite;
human metabolite
serine hydroxamate
serine hydroxamate: RN given refers to (L)-isomer. serine hydroxamate : A hydroxamic acid obtained by formal condensation of the carboxy group of serine with the amino group of hydroxylamine.		5.01390hydroxamic acid;
serine derivative		EC 6.1.1.11 (serine--tRNA ligase) inhibitor
benzyloxycarbonyltryptophan
benzyloxycarbonyltryptophan: receptor antagonist for peptides from gastrin family; RN given refers to (L)-isomer		2.0510
histidylglycine
histidylglycine: RN given refers to all (L)-isomer. His-Gly : A dipeptide formed from L-histidine and glycine residues.		2.0510dipeptidemetabolite
histidinoalanine
histidinoalanine: cross-linking amino acid in calcified tissue collagen; RN given refers to (L)-isomer		6.9610dipeptide zwitterion;
dipeptide		metabolite
pregnanetriol
Pregnanetriol: A metabolite of 17-ALPHA-HYDROXYPROGESTERONE, normally produced in small quantities by the GONADS and the ADRENAL GLANDS, found in URINE. An elevated urinary pregnanetriol is associated with CONGENITAL ADRENAL HYPERPLASIA with a deficiency of STEROID 21-HYDROXYLASE.		2.0410corticosteroid hormone
lanthionine
lanthionine: a thioether analogue of cystine; RN given refers to (DL)-isomer; structure; a component of lantibiotics (BACTERIOCINS). lanthionine : An alanine derivative in which two alanine residues are linked on their beta-carbons by a thioether linkage.		4.5370alanine derivative;
non-proteinogenic alpha-amino acid;
organic sulfide		bacterial metabolite
cobalt
Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.		10.92340cobalt group element atom;
metal allergen		micronutrient
p-methoxy-n-methylphenethylamine
p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.		2.3520aromatic ether;
secondary amino compound		metabolite
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		5.3513017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
hydrogen sulfite
[no description available]		2.0510sulfur oxoanionhuman metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid: structure in first source		3.2960polyamino carboxylic acid;
tetracarboxylic acid		chelator
1-amino-1,3-dicarboxycyclopentane
1-amino-1,3-dicarboxycyclopentane: RN given refers to (cis)-isomer		2.1310
chlorates
Chlorates: Inorganic salts of chloric acid that contain the ClO3- ion.		2.3720chlorine oxoanion;
monovalent inorganic anion
ici 164384
ICI 164384: structure given in first source. ICI-164384 : A 3-hydroxy steroid that is 17beta-estradiol substituted by a 11-[butyl(methyl)amino]-11-oxoundecyl group at position 7R. It is a steroidal antioestrogen that inhibits the cell proliferation of breast-carcinoma cell lines.		2.392017beta-hydroxy steroid;
3-hydroxy steroid;
tertiary carboxamide		anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist
enkephalin, d-penicillamine (2,5)-
Enkephalin, D-Penicillamine (2,5)-: A disulfide opioid pentapeptide that selectively binds to the DELTA OPIOID RECEPTOR. It possesses antinociceptive activity.. DPDPE : A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.		3.4170heterodetic cyclic peptidedelta-opioid receptor agonist
u 73122
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.		3.2660aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
arginyl-glycyl-aspartic acid
arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system		3.5180oligopeptide
wr 1065
WR-1065 : An alkanethiol that is the N-3-aminopropyl derivative of cysteamine. Used as the S-phosphorylated prodrug, amifostine, for cytoprotection in cancer chemotherapy and radiotherapy.		2.0210alkanethiol;
diamine		antioxidant;
drug metabolite;
radiation protective agent
vitamin b 6
Vitamin B 6: VITAMIN B 6 refers to several PICOLINES (especially PYRIDOXINE; PYRIDOXAL; & PYRIDOXAMINE) that are efficiently converted by the body to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, and aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into PYRIDOXAMINE phosphate. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). Most of vitamin B6 is eventually degraded to PYRIDOXIC ACID and excreted in the urine.		4.75120
1,4-dihydropyridine
[no description available]		2.9240
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		3.2860beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
s-nitrosoglutathione
[no description available]		2.7230glutathione derivative;
nitrosothio compound		bronchodilator agent;
nitric oxide donor;
platelet aggregation inhibitor;
signalling molecule
acrylodan
[no description available]		2.0110
chlorethylclonidine
chlorethylclonidine: RN refers to 2-chloroethyl derivative		1.9910
fluo-3
Fluo-3: fluorescent Ca(2+) indicator; permits continuous monitoring of Ca without interference with use of UV-sensitive caged compounds		2.4120xanthene dyefluorochrome
laurdan
laurdan: RN from CA Index Guide		2.1110
2-(2-cresyl)-4h-1-3-2-benzodioxaphosphorin-2-oxide
2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide: cyclic metabolite of tri-o-cresyl phosphate; synergist for cholinesterase inhibitors		2.0210
fpl 55712
FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors		3.67100aromatic ketone
paxilline
paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.		4.95360diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol		anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker
fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether
fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether: structure CF2=C(CF3)OCH2F; a vinyl ether		2.0710organofluorine compound
fructose 2,6-diphosphate
fructose 2,6-diphosphate: phosphofructokinase activator synthesized via Mg-ATP & fructose-6-P. beta-D-fructofuranose 2,6-bisphosphate : A D-fructofuranose 2,6-bisphosphate with a beta-configuration at the anomeric centre.		2.7130D-fructofuranose 2,6-bisphosphatehuman metabolite;
mouse metabolite
cyanates
Cyanates: Organic salts of cyanic acid containing the -OCN radical.. cyanates : Salts and esters of cyanic acid, HOC#N; compounds carrying the cyanate functional group -O-C#N.. isocyanates : Organonitrogen compounds that are derivatives of isocyanic acid; compounds containing the isocyanate functional group -N=C=O (as opposed to the cyanate group, -O-C#N).		3.260
pregnenolone sulfate
pregnenolone sulfate: RN given refers to (3 beta)-isomer		2.7330steroid sulfateEC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite
epibatidine
epibatidine: a powerful, though toxic, pain killer produced by the poison arrow frog, Epipedobates tricolor; structure given in first source; more potent than morphine but acts at nicotine rather than opiate receptors		3.3920
beta-n-methylamino-l-alanine
beta-N-methylamino-L-alanine: glutamate agonist. L-BMAA : A non-proteinogenic L-alpha-amino acid that is L-alanine in which one of the methyl hydrogens is replaced by a methylamino group. A non-proteinogenic amino acid produced by cyanobacteria, it is a neurotoxin that has been postulated as a possible cause of neurodegenerative disorders of aging such as Alzheimer's disease, amyotrophic lateral sclerosis, and the amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS-PDC) syndrome of Guam.		5.3480diamino acid;
L-alanine derivative;
non-proteinogenic L-alpha-amino acid;
secondary amino compound		bacterial metabolite;
neurotoxin
fura-2-am
fura-2-am: pentaester precursor of fura-2		2.0810
((18)O)water
((18)O)water : A form of water consisting of two hydrogen atoms covalently bonded to an oxygen-18 atom.. oxygen-18 atom : The stable isotope of oxygen with relative atomic mass 17.999160 and 0.205 atom percent natural abundance.		2.2510isotopically modified compound;
water
valylvaline
valylvaline: RN given refers to (L)-isomer. Val-Val : A dipeptide formed from two L-valine residues.		2.420dipeptideMycoplasma genitalium metabolite
fluorocitrate
fluorocitrate: competitve inhibitor of aconitase; effects morphology of kidney tubules in fluorocitrate poisoning; RN given refers to cpd with unspecified isomeric designation		3.1650carbonyl compound
3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate
3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate: a surfactant; structure given in first source		2.39201,1-diunsubstituted alkanesulfonate
bremazocine
bremazocine: potent, log-acting opiate kappa-agonist & centrally acting analgesic; RN given refers to (2R)-isomer; structure given in first source		210
n-hydroxy-4-aminoazobenzene
N-hydroxy-4-aminoazobenzene: RN given refers to parent cpd		1.9610
dihydroergocristine
Dihydroergocristine: A 9,10alpha-dihydro derivative of ERGOTAMINE that contains an isopropyl sidechain at the 2' position of the molecule.. dihydroergocristine : Ergocristine in which a single bond replaces the double bond between positions 9 and 10. It is used as the mesylate salt for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease.		2.0110ergot alkaloidadrenergic antagonist;
vasodilator agent
prodan
prodan: do not confuse with prodan in Chemline, RN 16893-85-9 which is disodium hexafluorosilicate		2.11102-acyl-6-dimethylaminonaphthalene
inositol 1-phosphate
1D-myo-inositol 1-phosphate : An inositol having myo- configuration substituted at position 1 by a phosphate group.		1.9710
dimyristoylphosphatidylglycerol
[no description available]		2.3920
arginyl-glycyl-aspartyl-serine
arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets		2.0310
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol
HU 211: structure given in first source; HU 211 is active & HU 210 is inactive as canibinoids; functional N-methyl-D-aspartate receptor blocker; RN given is for (6aS-trans)-isomer		2.0110
perindopril
Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline		2.110alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
enkephalin, ser(2), leu(5), thr(6)-
enkephalin, Ser(2), Leu(5), Thr(6)-: specific probe for the delta-opiate receptor subtype in brain membranes		2.3920oligopeptide
phorbol-12-myristate
[no description available]		2.0510
procyanidin
Proanthocyanidins: Dimers and oligomers of flavan-3-ol units (CATECHIN analogs) linked mainly through C4 to C8 bonds to leucoanthocyanidins. They are structurally similar to ANTHOCYANINS but are the result of a different fork in biosynthetic pathways.		2.520proanthocyanidin
dihydrokainate
[no description available]		3.1150dicarboxylic acid
sr 95531
[no description available]		2.4620methoxybenzenes
dityrosine
dityrosine: o,o'-biphenol analog of tyrosine; isolated from insoluble protein of human cataractous lenses; structure. dityrosine : A biphenyl compound comprising two tyrosine residues linked at carbon-3 of their benzene rings.		7.420biphenyls;
non-proteinogenic alpha-amino acid;
tyrosine derivative		biomarker
phosphites
Phosphites: Inorganic salts or organic esters of phosphorous acid that contain the (3-)PO3 radical. (From Grant & Hackh's Chemical Dictionary, 5th ed). phosphite(3-) : A trivalent inorganic anion obtained by removal of all three protons from phosphorous acid.		2.4110phosphite ion;
trivalent inorganic anion
(2-(trimethylammonium)ethyl)methanethiosulfonate
(2-(trimethylammonium)ethyl)methanethiosulfonate: RN given for bromide; used in dopamine analysis		2.9240
fingolimod hydrochloride
Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).		2.3110hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
parinaric acid
parinaric acid: long-chain polyenoic fatty acid; RN given refers to cpd without isomeric designation. parinaric acid : An octadecatetraenoic acid containing a conjugated system of double bonds at positions 9, 11, 13 and 15.		2.0810octadecatetraenoic acid
3,5-dihydroxyphenylglycine
3,5-dihydroxyphenylglycine: a potent agonst of metabotropic glutamate receptors		2.7130alpha-amino acid
n-chlorotaurine
N-chlorotaurine: inhibits both inducible nitric oxide synthase and IkappaB kinase		2.0310
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol: NM refers to free form; BMY 14802-1 is the HCl; structure given in first source		1.9710N-arylpiperazine
ml 9
[no description available]		2.4120
alpha-methylphenylalanine
alpha-methylphenylalanine: induces chronic hyperphenylalaninemia in suckling rats; models for the study of inborn errors of metabolism; RN given refers to parent cpd without isomeric designation		3.4920benzenes;
monocarboxylic acid
parthenolide
[no description available]		3.1310germacranolide
tesmilifene
[no description available]		7.0310diarylmethane
rx 821002
2-methoxyidazoxan: 2-methoxy analog of idazoxan. 2-methoxyidazoxan : A benzodioxine that is idazoxan substituted at position 2 by a methoxy group.		210benzodioxine;
cyclic ketal;
imidazolines		alpha-adrenergic antagonist
npc 12626
NPC 12626: N-methyl-D-aspartate receptor antagonist; structure given in first source; NPC 17742, the (2R,4R,5S)-isomer, is the most potent isomer in the mixture NPC 12626		1.9710
benzamil
[no description available]		2.4120guanidines;
pyrazines
dynorphin (1-8)
dynorphin (1-8): opioid octapeptide from porcine hypothalamus; comprises the N-terminal eight residues of dynorphin		1.9810
carboxyamido-triazole
carboxyamido-triazole: structure given in first source; coccidiostat; U.S. patent No. 4,590,201		2.0210
senktide
[no description available]		2.0410
kt 5823
KT 5823: indolocarbazole; activates human neutrophils & fails to inhibit cGMP-dependent protein kinase phosphorylation of vimentin. KT 5823 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-methoxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1-methyl-1,5-dihydro-2H-pyrrol-2-one.		2.4220gamma-lactam;
hemiaminal;
indolocarbazole;
methyl ester;
organic heterooctacyclic compound		EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.		3.39702-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		4.57250
prolinamide
prolinamide: RN given refers to cpd without isomeric designation. L-prolinamide : The carboxamide derivative of L-proline.		2.4620amino acid amide;
L-proline derivative;
pyrrolidinecarboxamide
leucinamide
leucinamide: leucine aminopeptidase alternative substrate to leucyl beta naphthylamide; RN given refers to parent cpd(S)-isomer		2.0110
neoeriocitrin
neoeriocitrin: protects against autophagy-inhibiting effects of okadaic acid; isolated from Drynariae rhizome; structure in first source. neoeriocitrin : A flavanone glycoside that is eriodictyol substituted by a 2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage.		2.41104'-hydroxyflavanones;
disaccharide derivative;
flavanone glycoside;
neohesperidoside;
trihydroxyflavanone		plant metabolite
3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione: isolated from Streptomyces griseoluteus fermentation broth; RN given refers to cpd without isomeric designation; structure		1.9310
1-phenyl-2-decanoylamino-3-morpholino-1-propanol
RV 538: noninactivating inhibitor of ceramide-UDPG glucosyltransferase; RN given for unspecified HCl; structure given in first source		2.6930
valerates
Valerates: Derivatives of valeric acid, including its salts and esters.		2.6530short-chain fatty acid anion;
straight-chain saturated fatty acid anion		plant metabolite
florfenicol
florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.		7.4620organochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone		antimicrobial agent
oxymatrine
oxysophoridine: an alkaloid isolated from Sophra alope; structure in first source		2.4110alkaloid;
tertiary amine oxide
thromboxanes
thromboxane : A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.		2.110
dodecyl-beta-d-maltoside
dodecyl beta-D-maltoside : A glycoside resulting from attachment of a dodecyl group to the reducing-end anomeric centre of a beta-maltose molecule.		2.0210disaccharide derivative;
glycoside		detergent
n-(3,5-dichlorophenyl)-2-hydroxysuccinimide
[no description available]		2.0110
s-sulphocysteine
S-sulphocysteine: residues in physiologically significant proteins treated with sulfite; RN given refers to parent cpd; structure. S-sulfo-L-cysteine : An S-substituted L-cysteine where the S-substituent is specified as a sulfo group.		1.9610organic thiosulfate;
S-substituted L-cysteine		human metabolite;
plant metabolite
globomycin
[no description available]		1.9910cyclodepsipeptide
trypanothione
trypanothione disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of N(1),N(8)-bis(glutathionyl)-spermidine from the insect-parasitic trypanosomatid Crithidia fasciculata.		2.4320organic disulfide
2-(2,3-dicarboxycyclopropyl)glycine
[no description available]		210
ponasterone a
ponasterone A: RN given refers to (2 beta,3 beta,5 beta,22R)-isomer		2.412014alpha-hydroxy steroid;
20-hydroxy steroid;
22-hydroxy steroid;
2beta-hydroxy steroid;
3beta-hydroxy steroid;
6-oxo steroid;
phytoecdysteroid
icrf 193
4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione: structure given in first source; RN given refers to cpd without isomeric designation. ICRF-193 : An N-alkylpiperazine that is butane which is substituted by a 3,5-dioxopiperazin-1-yl group at positions 2 and 3. The meso isomer.		2.730
n-(3,5-dichlorophenyl)-2-hydroxysuccinamic acid
[no description available]		2.0110
phenylalanyl-prolyl-arginine-chloromethyl ketone
phenylalanyl-prolyl-arginine-chloromethyl ketone: do not confuse with Pro-Phe-Arg-CH2-Cl or with Phe-Phe-Arg-CH2-Cl, both sometimes also referred to as PPACK		3.8130
brassinolide
brassinolide: plant growth promoting steroidal lactone from rape pollen; RN given refers to (2alpha,3alpha,5alpha,22R,23R,24S)-isomer; structure in first source		2.111022-hydroxy steroid;
23-hydroxy steroid;
2alpha-hydroxy steroid;
3alpha-hydroxy steroid;
brassinosteroid		plant growth stimulator;
plant hormone
delta-philanthotoxin
delta-philanthotoxin: from wasp Philanthus triangulum; blocks transmission postsynaptically at excitory synapses		2.0510
3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate
3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate: purinergic receptors agonist; structure given in first source		3.1250purine ribonucleoside triphosphate
ici 198615
ICI 198615: an LTD4 receptor antagonist; SRS-A antagonist; structure given in first source		2.6730
1-(4-ethynylphenyl)-4-propyl-2,6,7-trioxabicyclo(2.2.2)octane
1-(4-ethynylphenyl)-4-propyl-2,6,7-trioxabicyclo(2.2.2)octane: GABA(A) receptor ligand for autoradiography		1.9810
4'-phosphopantetheine
D-pantetheine 4'-phosphate : Pantetheine 4'-phosphate with D (R) configuration at the 2' position.		3.4270pantetheine 4'-phosphateprosthetic group
2-aminobicyclo(2,2,1)heptane-2-carboxylic acid
2-aminobicyclo(2,2,1)heptane-2-carboxylic acid: amino acid analog; releases insulin; RN given refers to unlabeled cpd without isomeric designation		3.4980monoterpenoid
cp 65,526
azidoprazosin: labeled with 125I		1.9810
2-iodomelatonin
[no description available]		210acetamides
nitisinone
[no description available]		2.0210(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
chymosin
Chymosin: The predominant milk-clotting enzyme from the true stomach or abomasum of the suckling calf. It is secreted as an inactive precursor called prorennin and converted in the acid environment of the stomach to the active enzyme. EC 3.4.23.4.		2.8840
n-(4-(2-benzimidazolyl)phenyl)maleimide
[no description available]		2.0110
bw 373u86
BW 373U86: a nonpeptidic delta opioid receptor agonist		2.0510diarylmethane
3-mercaptopicolinic acid
3-mercaptopicolinic acid: gluconeogenesis inhibitor; may also inhibit ATP-dependentphosphoenolpyruvate carboxykinase		3.0750
n-(3-oxohexanoyl)-3-aminodihydro-2(3h)-furanone
N-(3-oxohexanoyl)-3-aminodihydro-2(3H)-furanone: cpd synthesized by luminous bacteria excreted into medium that induces luciferase synthesis at threshold concentration; structure in first source. N-(3-oxohexanoyl)homoserine lactone : A N-acyl homoserine lactone that is the monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 3-oxohexanoic acid with the amino group of homoserine lactone.		2.0310N-acyl homoserine lactone;
secondary carboxamide
thiodigalactoside
thiodigalactoside: RN given refers to beta-D-galactopyranoside (D-Gal)-isomer		1.9610
3-n-methylspiperone
3-N-methylspiperone: (11(C))-labeled cpd used in positron tomography; dopamine agonist & dopamine receptor ligand; structure given in first source		1.9910aromatic ketone
al-01567
alconil: structure given in first source		2.1510
benzylpenicilloyl g
benzylpenicilloyl G: lactam ring opened so inactive; do not confuse with benzylpenicilloyl V		1.9710
cp 115953
CP 115953: enhances topoisomerase II-mediated DNA cleavage; structure given in first source		1.9810
caprylates
Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis.		5.06130fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite
campestanol
ergostanol: structure		2.08103beta-sterol;
C28-steroid
beta-phenylcysteine
[no description available]		2.5320
viroisin
viroisin: virotoxin from Amanita virosa; RN given refers to (3R-trans)-isomer; see also related record for virotoxins		710
pramipexole
Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.		7.5220benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
razadyne
Razadyne: Name of the FDA approved preparation from J&J.		2.1110
ezogabine
ezogabine: structure in first source. ezogabine : A substituted aniline that is benzene-1,2,4-triamine bearing ethoxycarbonyl and 4-fluorobenzyl substituents at positions N-1 and N-4 respectively. An anticonvulsant used to treat seizures associated with epilepsy in adults.		2.0710carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline		anticonvulsant;
potassium channel modulator
6-deoxyerythronolide b
6-deoxyerythronolide B: Streptomyces erythreus metabolite; presumed intermediate in biosynthesis of erythromycins; structure given in first source		710erythronolide
egta acetoxymethyl ester
EGTA acetoxymethyl ester: membrane-permeable form of EGTA		210
4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline
4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline: structure given in first source; selective antagonist for the glycine site on the N-methyl-D-aspartate (NMDA) receptor		2.4120
alpha-(difluoromethyl)arginine
alpha-(difluoromethyl)arginine: irreversible inhibitor of arginine decarboxylase		2.0410
6-iodopenicillanic acid
6-iodopenicillanic acid: RN given refers to parent cpd(2S-(2alpha,5alpha,6beta))-isomer		2.6730
4-o-alpha-d-galactopyranosyl-d-galactose
4-O-alpha-D-galactopyranosyl-D-galactose: carbohydrate part of receptor on human uroepithelial cells; RN given refers to (alpha-D,D)-isomer		210O-acyl carbohydrate
thymidine 3',5'-diphosphate
[no description available]		1.9710
methylthio-adp
[no description available]		2.0110
n-(4-(7-diethylamino-4-methylcoumarin-3-yl)phenyl)maleimide
N-(4-(7-diethylamino-4-methylcoumarin-3-yl)phenyl)maleimide: structure given in first source. 7-diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin : A member of the class of coumarins that is 2H-chromen-2-one substituted by 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl, methyl, and diethylamino groups at positions 3, 4 and 7, respectively. It is a thiol-reactive fluorescent dye.		1.9610benzenes;
coumarins;
maleimides;
tertiary amino compound		fluorescent dye
nectrisine
nectrisine: produced by the fungus, Nectria lucida F-4490; structure given in first source		2.0410
phytosphingosine
phytosphingosine: differ with an additional hydroxyl at C-4 & no double bond between C-4 & C-5		4.0140amino alcohol;
sphingoid;
triol		mouse metabolite;
Saccharomyces cerevisiae metabolite
7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole
[no description available]		2.7130
luzindole
luzindole: melatonin receptor antagonist; structure given in first source. luzindole : A member of the class of indoles that is tryptamine in which one of the amino hydrogens is replaced by an acetyl group while the hydrogen at position 2 is replaced by a benzyl group.		210acetamides;
indoles		melatonin receptor antagonist
4-(n-(iodoacetoxy)ethyl-n-methyl)amino-7-nitrobenz-2-oxa-1,3-diazole
4-(N-(iodoacetoxy)ethyl-N-methyl)amino-7-nitrobenz-2-oxa-1,3-diazole: fluorescent probe		1.9810
dansylarginine n-(3-ethyl-1,5-pentanediyl)amide
dansylarginine N-(3-ethyl-1,5-pentanediyl)amide: fluorescent inhibitor of thrombin; structure		1.9910
erythrose 4-phosphate
erythrose 4-phosphate: RN given refers to (R-(R*,R*))-isomer. D-erythrose 4-phosphate : An erythrose phosphate that is D-erythrose carrying a phosphate group at position 4. It is an intermediate in the pentose phosphate pathway and Calvin cycle.		210erythrose phosphateEscherichia coli metabolite;
human metabolite;
mouse metabolite
n-benzyloxycarbonylprolylprolinal
N-benzyloxycarbonylprolylprolinal: inhibitor of prolyl endopeptidase		1.9910
o-carbamylserine
O-carbamylserine: RN given refers to (D)-iosmer		3.260
procyanidin b2
procyanidin B2 : A proanthocyanidin consisting of two molecules of (-)-epicatechin joined by a bond between positions 4 and 8' in a beta-configuration. Procyanidin B2 can be found in Cinchona pubescens (Chinchona, in the rind, bark and cortex), in Cinnamomum verum (Ceylon cinnamon, in the rind, bark and cortex), in Crataegus monogyna (Common hawthorn, in the flower and blossom), in Uncaria guianensis (Cat's claw, in the root), in Vitis vinifera (Common grape vine, in the leaf), in Litchi chinensis (litchi, in the pericarp), in the apple, in Ecdysanthera utilis and in red wine.		2.610biflavonoid;
hydroxyflavan;
polyphenol;
proanthocyanidin		antioxidant;
metabolite
chaetoglobosins
chaetoglobosins: like CYTOCHALASINS but with an indoyl in place of a phenyl ring at C10; chaetoglobosins A-J; metabolites of Chaetomium species; RN given refers to chaetoglobosin A; structure. chaetoglobosin A : A cytochalasan alkaloid isolated from Chaetomium globosum and Calonectria morganii.		2.2510
cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine: prodrug for HPMPC; specific name and structure not given in first source		2.0510
carbene
carbene: electrically neutral species H2C: and its derivatives, in which the carbon is covalently bonded to two univalent groups of any kind or a divalent group and bears two nonbonding electrons; carbene is the name of the parent hydride :CH2 ; hence, the name dichlorocarbene for :CCl2. However, names for acyclic and cyclic hydrocarbons containing one or more divalent carbon atoms are derived from the name of the corresponding all-4-hydrocarbon using the suffix -ylidene; methylene carbene also available. carbene : The electrically neutral species H2C(2.) and its derivatives, in which the carbon is covalently bonded to two univalent groups of any kind or a divalent group and bears two nonbonding electrons, which may be spin-paired (singlet state) or spin-non-paired (triplet state).		8.3160carbene;
methanediyl
phosphoramide
phosphoramide: RN given refers to triamide. phosphoramide : A compound in which one or more of the OH groups of phosphoric acid have been replaced with an amino or substituted amino group. The term is commonly confined to the phosphoric triamides, P(=O)(NR2)3, since replacement of one or two OH groups produces phosphoramidic acids: P(=O)(OH)(NR2)2 , P(=O)(OH)2(NR2).		2.0110
peroxynitrous acid
Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).		3.84110nitrogen oxoacid
fullerene c60
Fullerenes: A polyhedral CARBON structure composed of around 60-80 carbon atoms in pentagon and hexagon configuration. They are named after Buckminster Fuller because of structural resemblance to geodesic domes. Fullerenes can be made in high temperature such as arc discharge in an inert atmosphere.. fullerene : A compound composed solely of an even number of carbon atoms, which form a cage-like fused-ring polycyclic system with twelve five-membered rings and the rest six-membered rings. The term has been broadened to include any closed cage structure consisting entirely of three-coordinate carbon atoms.		2.8430fullerenegeroprotector
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		3.3260methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
tazobactam
Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.		3.94120penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
gefitinib
[no description available]		2.4520aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
2-azidoadenosine 5'-triphosphate
[no description available]		2.420
2-nitrophenylgalactoside
2-nitrophenylgalactoside: RN given refers to cpd without isomeric designation		2.0710
ribulose-1,5 diphosphate
ribulose-1,5 diphosphate: RN given refers to cpd without isomeric designation. D-ribulose 1,5-bisphosphate : A ribulose phosphate that is D-ribulose attached to phosphate groups at positions 1 and 5. It is an intermediate in photosynthesis.		3.0510ribulose phosphateEscherichia coli metabolite;
plant metabolite
5-(2-aminoadipyl)cysteinylvaline
5-(2-aminoadipyl)cysteinylvaline: tripeptide present in fermentations of Penicillium chrysogenum; RN given refers to ((D-Val)-(S))-isomer		210
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.		2.0310adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
tyrosyl-glycyl-glycine
tyrosyl-glycyl-glycine: RN given refers to L-isomer; this may not be the same as IMREG-1. Tyr-Gly-Gly : A tripeptide composed of one L-tyrosine and two glycine residues joined in sequence.		2.0510tripeptide zwitterion;
tripeptide		metabolite
cdp ethanolamine
[no description available]		3.4880nucleotide-(amino alcohol)s;
phosphoethanolamine		mouse metabolite
3-iodo-alpha-methyltyrosine
3-iodo-alpha-methyltyrosine: used for SPECT imaging of brain tumors; RN given refers to unlabeled cpd without stereoisomeric designation		210
aerobactin
[no description available]		3.67100L-lysine derivativeEscherichia coli metabolite;
siderophore;
virulence factor
proctolin
proctolin: neurotransmitter in arthropods or invertebrates		1.9810
c & b metabond
Super-bond: an adhesive resin composed of 4-methacryloxyethyltrimellitic anhydride (4-META), methylmethacrylates (MMA) and tri-n-butylborane (TBB)		210
cgp 42112a
CGP 42112A: a hexapeptide analog of angiotensin II; activation of Receptor, Angiotensin, Type 2 results in vasodilation. CGP-42112A : A hexapeptide consisting of L-tyrosine, L-lysine, L-histidine, L-proline and L-isoleucine amino acid residues coupled in sequence and in which the amino group of the L-tyrosyl residue is substituted by a (pyridin-3-ylcarbonyl)nitrilo group and in which the L-lysyl side chain amino group is substituted by a {N(2)-[(benzyloxy)carbonyl]-L-arginyl}nitrilo group. It is a potent angiotensin II receptor type 2 (AT2 receptor) agonist.		1.9910benzyl ester;
oligopeptide;
pyridinecarboxamide		angiotensin receptor agonist;
anti-inflammatory agent;
antineoplastic agent;
neuroprotective agent;
vasodilator agent
deltorphin ii, ala(2)-
deltorphin II, Ala(2)-: isolated from skin extracts of frogs belonging to the genus Phyllomedusa; has affinity to opioid receptors		2.9240
n(6)-carboxymethyllysine
N(6)-carboxymethyllysine: RN given refers to (L)-isomer; structure given in first source. N(6)-carboxymethyl-L-lysine : An L-lysine derivative with a carboxymethyl substituent at the N(6)-position.		2.9340L-lysine derivative;
non-proteinogenic L-alpha-amino acid		antigen
5,5'-bis(8-(phenylamino)-1-naphthalenesulfonate)
[no description available]		2.4420
n-acetylglucosaminylasparagine
N-acetylglucosaminylasparagine: RN given refers to parent cpd; presence in urine characteristic of aspartylglucosaminuria; structure. N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine : An N(4)-glycosyl-L-asparagine having (beta-N-acetyl-D-glucosaminyl as the glycosyl component.		1.9710amino acid zwitterion;
glucosaminylamine;
N(4)-glycosyl-L-asparagine
n,n-dimethylarginine
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine. N(omega),N(omega)-dimethyl-L-arginine : A L-arginine derivative having two methyl groups both attached to the primary amino moiety of the guanidino group.		2.0510dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor
cyclic adp-ribose
Cyclic ADP-Ribose: A pyridine nucleotide that mobilizes CALCIUM. It is synthesized from nicotinamide adenine dinucleotide (NAD) by ADP RIBOSE CYCLASE.		2.0310cyclic purine nucleotide;
nucleotide-sugar		metabolite;
ryanodine receptor agonist
f-chemotactic peptide
F-chemotactic peptide: potent chemoattractant for human neutrophils		210
1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone
1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone: structure given in first source. 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one : A differentiation-inducing factor that is hexaphenone bearing two chloro substituents at positions 3 and 5, two hydroxy substituents at positions 2 and 6 as well as a single methoxy substituent at position 4. A secreted, chlorinated molecule that controls cell fate during development of Dictyostelium cells.		5.78280dichlorobenzene;
differentiation-inducing factor;
monomethoxybenzene;
resorcinols		eukaryotic metabolite;
signalling molecule
bq 610
BQ 610: endothelin A receptor antagonist; endothelin-1 antagonist		2.0510
phosphohistidine
phosphohistidine: RN given refers to N-phosphono-L-histidine		2.8940
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide: a highly-selective, nonpeptide delta opioid receptor agonist; structure given in first source		2.0210diarylmethane
3-acetylpyridine adenine dinucleotide
[no description available]		2.420organic molecular entity
3,3'-dithiobis(sulfosuccinimidyl propionate)
3,3'-dithiobis(sulfosuccinimidyl propionate): structure given in first source		2.0210
gamma-glutamylcysteine
L-gamma-glutamyl-L-cysteine : A molecular entity formed when L-cysteine amino group binds to the gamma-carbonyl of L-glutamic acid.		2.4320gamma-glutamylcysteineEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
9-o-acetyl-n-acetylneuraminic acid
[no description available]		1.9810N-acetyl-O-acetylneuraminic acid
vadimezan
vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.		3.5620monocarboxylic acid;
xanthones		antineoplastic agent
dehydroalanine
2-ammonioprop-2-enoate : An amino acid zwitterion resulting from a transfer of a proton from the carboxy group to the amino group of 2-aminoacrylic acid.. 2-aminoacrylic acid : A 2,3-dehydroamino acid that is alanine which has been dehydrogenated to introduce a double bond between positions 2 and 3.		4.452202,3-dehydroamino acid;
alpha,beta-unsaturated monocarboxylic acid;
amino acid zwitterion;
enamine;
non-proteinogenic alpha-amino acid		alkylating agent;
human metabolite;
mouse metabolite
2',6'-dimethyltyrosine
2',6'-dimethyltyrosine: structure given in first source		210
8-oxo-dado
2'-deoxy-7,8-dihydro-8-oxoadenosine: structure given in first source		2.0710
hypothiocyanite ion
hypothiocyanous acid : A sulfur oxoacid that is sulfenic acid in which the hydrogen attached to the sulfur has been replaced by a cyano group.		2.1710one-carbon compound;
sulfur oxoacid		antibacterial agent;
antifungal agent;
antiviral agent;
human metabolite;
oxidising agent;
rat metabolite
glycerophosphoinositol 4,5-bisphosphate
glycerophosphoinositol 4,5-bisphosphate: do not confuse with phosphatidylinositols which have fatty acids esterified at the C-1 and C-2 hydroxyl groups of glycerol		3.96130
dibutyryl cyclic-3',5'-cytidine monophosphate
[no description available]		2.0410
s-propylcysteine
S-propylcysteine: RN given refers to (DL-Cys)-isomer		210cysteine derivative;
organic sulfide
beta-lipotropin, gln(9)-
corynebactin: a triscatechol derivative of a cyclic triserine lactone; siderophore synthesized by Corynebacterium diphtheriae. corynebactin : A crown compound that is enterobactin in which the pro-R hydrogens at positions 2, 6 and 10 of the trilactone backbone are replaced by methyl groups, and in which a glycine spacer separates the trilactone backbone from each of the catecholamide arms. It is the endogenous siderophore of Bacillus subtilis, used for the acquisition of iron.		2.0110catechols;
crown compound;
macrocyclic lactone		bacterial metabolite;
metabolite
4'-amino-6-hydroxyflavone
4'-amino-6-hydroxyflavone: a p53/56(lyn) inhibitor; structure given in first source		1.9910flavones
ectoine
[no description available]		2101,4,5,6-tetrahydropyrimidines;
carboxamidine;
monocarboxylic acid;
zwitterion		osmolyte
sk&f 102922
5-(2-(8-phenyloctyl)phenyl)-4,6-dithianonanedioic acid: RN & structure in first source; leukotriene receptor antagonist		1.9710
4-methylumbelliferylcellobioside
4-methylumbelliferylcellobioside: substrate for cellobiohydrolase I		1.9910coumarins;
glycoside
pre 084
2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate: structure given in first source		2.4820morpholines
methotrexate
[no description available]		6.58390dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
1-diphosphoinositol pentakisphosphate
1-diphosphoinositol pentakisphosphate: present as soluble ionic species in the cytosol of amoeba (Dictyostelium discoideum); rapidly metabolized in intact cells & can by synthesized in cell lysates from myo-inositol hexakisphosphate in the presence of ATP. 1-diphospho-1D-myo-inositol 2,3,4,5,6-pentakisphosphate : A myo-inositol pentakisphosphate that consists of myo-inositol having the five phospho groups located at positions 2, 3, 4, 5 and 6 as well as a diphospho group at position 1.		2.7430
n-iodoacetyl-3-(125i)iodotyrosine
N-iodoacetyl-3-iodotyrosine: structure given in first source		210
ro 32-0432
[no description available]		2.0710
4-amidinophenylbenzoate
4-amidinophenylbenzoate: proteinase inhibitor		1.9610
dihydroethidium
dihydroethidium: RN given is for the (+-)-isomer		2.0210
lysyllysine
lysyllysine: RN given refers to (L-Lys)-isomer. Lys-Lys : A dipeptide formed from two L-lysine residues.		2.4420dipeptideMycoplasma genitalium metabolite
thrazarine
thrazarine: from Streptomyces coerulescens MH802-fF5; structure given in first source		3.0750
tamsulosin
[no description available]		2.04105-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
cki 7
N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide: casein kinase I inhibitor; structure given in first source. N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide : A member of the class of isoquinolines that is isoquinoline-8-sulfonamide which is substituted by chlorine at position 5 and in which the sulfonamide nitrogen is substituted by a 2-aminoethyl group. It is an inhibitor of casein kinase I.		2.0210isoquinolines;
organochlorine compound;
primary amino compound;
sulfonamide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
epidermal pentapeptide
epidermal pentapeptide: consists of amino acids pGlu, Glu, Asp, Ser, Gly with pGlu at N-terminal end		1.9810
1-naphthylacetylspermine
[no description available]		2.4720naphthalenes
cgp 36742
(3-aminopropyl)(n-butyl)phosphinic acid: interacts preferably with GABA-B RECEPTORS (IC50=38 μM) and GABA-C receptors (IC50=62 μM) over GABA-A RECEPTORS (IC50=508 μM)		2.4220
snp nonapeptide
SNP nonapeptide: amino acid sequence 180-188 from the recombinant 65 kDa heat shock protein of Mycobacterium bovis BCG; contains a T-cell epitope recognized by both arthritogenic & protective T-cell clones in vitro		2.0310
sulbactam
[no description available]		3.5680penicillanic acids
kifunensine
kifunensine: inhibitor of the glycoprotein processing mannosidase I; from actinomycete Kitasatosporia kifunense 9482; structure given in first source; RN given refers to (5R-(5alpha,6beta,7alpha,8alpha,8aalpha))-isomer; RN for cpd without isomeric designation not avail 10/90		2.0510
glucuronic acid 3-sulfate
D-glucuronic acid 3-sulfate : A monosaccharide sulfate that is D-glucuronic acid esterified at O-3 by sulfuric acid.		1.9710monosaccharide sulfate
sm 11044
SM 11044: structure given in first source		3.0950
l 703606
L 703606: structure given in first source		2.0410
omega-n-methylarginine
omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.		2.4320amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
abiraterone
[no description available]		2.17103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
hexestrol diphosphate
cytostatin: an inhibitor of cell adhesion isolated from Streptomyces; structure in first source		210
5'-(4-fluorosulfonylbenzoyl)adenosine
5'-(4-fluorosulfonylbenzoyl)adenosine: affinity label of the inhibitory DPNH site of bovine liver dehydrogenase; adenosylhomocysteinase antagonist; structure		2.3820
sq 26180
SQ 26180: monobactam, monocyclic beta-lactam from Chromobacterium violaceum; structure given in first source		1.9610monobactam
(1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl)methanethiosulfonate
(1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl)methanethiosulfonate: thiol-specific spin label; structure given in first source. (1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl)methanethiosulfonate : An aminooxyl that is pyrroline substituted by an oxidanediyl group at position 1, by methyl groups at positions 2, 2, 5 and 5, and by a [(methylsulfonyl)sulfanyl]methyl group at position 3. It is a highly reactive thiol-specific spin label.		210aminoxyls;
pyrroline;
thiosulfonate ester		spin label
4-hydroxy-equilenin
4-hydroxy-equilenin: structure given in first source; is the major catechol metabolite of the equine estrogens EQUILENIN and EQUILIN; induces DNA damage		2.0210
leucinal
leucinal: RN given refers to (S)-isomer		2.0210
8-chloroadenosine-3',5'-cyclic monophosphorothioate
8-chloroadenosine-3',5'-cyclic monophosphorothioate: inhibits growth of human cancer cells; the Rp-isomer is more potent than the Sp-isomer; RN given refers to the (S)- isomer		2.4320
carbapenems
[no description available]		5.38100
butoxamine
Butoxamine: A beta-2 selective adrenergic antagonist. It is used primarily in animal and tissue experiments to characterize BETA-2 ANDRENERGIC RECEPTORS.		2.9410
4-iodophenylalanine
4-iodophenylalanine: RN given refers to cpd without isomeric designation. 4-iodophenylalanine : A phenylalanine derivative that is phenylalanine carrying an iodo group at position 4 on the benzene ring.		2104-iodophenylalanine
pomalidomide
3-aminophthalimidoglutarimide: structure in first source		2.2510aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
3-benzyl-6-chloro-2-pyrone
3-benzyl-6-chloro-2-pyrone: structure given in first source		2.3920
xylose
xylopyranose: structure in first source		8.15550D-xylose
bh 3
BH 3: RN given refers to parent cpd		2.0110
cystathionine ketimine
cystathionine ketimine: structure given in first source. cystathionine ketimine : A 1-thia-4-azacyclohepta-3-ene-3,5-dicarboxylic acid that has R-configuration. It is cyclic sulfur-containing imino acid detected in bovine brain extracts.		2101-thia-4-azacyclohepta-3-ene-3,5-dicarboxylic acid;
sulfur-containing amino acid		human urinary metabolite;
mammalian metabolite;
rat metabolite;
reactive oxygen species generator
beta-lactams
2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.		11.93290beta-lactam antibiotic allergen;
beta-lactam
phytol
[no description available]		2.0110
proline
Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.		17.138694amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
cucurbitaceae
Cucurbitaceae: The gourd plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida. It is sometimes placed in its own order, Cucurbitales. 'Melon' generally refers to CUCUMIS; CITRULLUS; or MOMORDICA.		2.830
bis(1,10-phenanthroline)copper(2+) ion
bis(1,10-phenanthroline)copper(2+) ion: RN given refers to (Cu+2) cation		1.9810
azidohomoalanine
azidohomoalanine: structure in first source		2.0410
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		7.2153secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
bdp 12
1-(quinoxalin-6-ylcarbonyl)piperidine: modulates AMPA receptor desensitization ; an analog of 1-(1,3-benzodioxol-5-ylcarbonyl)piperidine		2.0310N-acylpiperidine
irofulven
irofulven: structure in first source		2.0210cyclohexenones
peptide elongation factor 2
Peptide Elongation Factor 2: Peptide Elongation Factor 2 catalyzes the translocation of peptidyl-tRNA from the A site to the P site of eukaryotic ribosomes by a process linked to the hydrolysis of GTP to GDP.		3.6490
patellamide d
patellamide D: from marine invertebrate Lissoclinum patella; structure given in first source		2.0810cyclic peptide
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.03109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
5-fluorouridine 5'-phosphate
5-fluorouridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having 5-fluorouracil as the pyrimidine component.		2.5320organofluorine compound;
pyrimidine ribonucleoside 5'-monophosphate		drug metabolite
4-aminophenylalanine
4-aminophenylalanine: RN given refers to cpd without isomeric designation. 4-amino-L-phenylalanine : The L-enantiomer of 4-aminophenylalanine.. 4-aminophenylalanine : A phenylalanine derivative that is phenylalanine carrying an amino group at position 4 on the benzene ring.		1.94104-aminophenylalanine;
amino acid zwitterion
3-methylaspartic acid
3-methylaspartic acid: RN given refers to cpd without isomeric designation		1.9910
tezosentan
tezosentan: structure in first source		2.110
o-phosphohomoserine
O-phosphohomoserine: RN given refers to L-isomer		6.9310O-phosphorylhomoserineEscherichia coli metabolite
2-(4-methoxyphenoxy)propanoic acid
2-(4-methoxyphenoxy)propanoic acid: a sweetness inhibitor; structure given in first source		2.0110aromatic ether;
carboxylic acid
ribulose
ribulose: 5-carbon keto sugar; minor descriptor (75-85); on-line & Index Medicus search PENTOSES (75-85); RN given refers to (erythro)-isomer		2.2110ribuloseEscherichia coli metabolite;
human metabolite
evodiamine
[no description available]		7.0810beta-carbolines
beta-phenylisoserine
beta-phenylisoserine: structure in first source		8.5380
glycine tert-butyl ester
tert-butyl glycinate: structure in first source		1.9910
2,3-dihydroxybenzoylserine
2,3-dihydroxybenzoylserine: RN given refers to (L)-isomer		3.5990L-serine derivativeEscherichia coli metabolite
arginylarginine 2-naphthylamide
arginylarginine 2-naphthylamide: substrate for dipeptidyl peptidase III		2.0510
pentacyanoferrate (ii)
[no description available]		2.0810
3-hydroxyasparagine
3-hydroxyasparagine: RN given refers to threo-DL-isomer		2.3110
histidylphenylalanine
His-Phe : A dipeptide obtained by formal condensation of the carboxy group of L-histidine with the amino group of L-phenylalanine.		2.0510dipeptide
n-acetylthreonine
N-acetyl-L-threonine : A N-acetyl-L-amino acid that is the N-acetyl derivative of L-threonine.		7.3920L-threonine derivative;
N-acetyl-L-amino acid
prolyl-tyrosine
prolyl-tyrosine: structure given in first source. Pro-Tyr : A dipeptide formed from L-proline and L-tyrosine residues.		2.4120dipeptidemetabolite
beta-aspartyl phosphate
4-phospho-L-aspartic acid : The 4-phospho derivative of L-aspartic acid.. 4-phospho-L-aspartate : An L-alpha-amino acid anion arsing from deprotonation of the carboxy and phosphate OH groups of 4-phospho-L-aspartic acid.		2.0610aminoacyl phosphate;
L-aspartic acid derivative;
non-proteinogenic L-alpha-amino acid		Escherichia coli metabolite
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		7.0210aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
ruboxistaurin
ruboxistaurin: inhibits protein kinase C beta; structure in first source		2.4420
10-deacetylbaccatine iii
10-deacetylbaccatine III: structure given in first source		2.0210secondary alpha-hydroxy ketone;
tetracyclic diterpenoid
phorbols
Phorbols: The parent alcohol of the tumor promoting compounds from CROTON OIL (Croton tiglium).		2.6630diterpene;
terpenoid fundamental parent
cyanopindolol
[no description available]		2.0310indoles
vinylglycine
vinylglycine: irreversible inhibitor of aspartate aminotransferase; structure. L-vinylglycine : A non-proteinogenic L-alpha-amino acid with a structure in which a vinyl group is bonded to the alpha-carbon of glycine.		2.0110glycine derivative;
L-alpha-amino acid zwitterion;
non-proteinogenic L-alpha-amino acid		EC 4.4.1.14 (1-aminocyclopropane-1-carboxylate synthase) inhibitor
besonprodil
besonprodil: CI-1041 is also known as PD19680; NMDA receptor antagonist for treatment of Parkinson's disease; structure in first source		2.0510
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		2.8730methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
hydroxyl radical
Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.		3.87120oxygen hydride;
oxygen radical;
reactive oxygen species
olmesartan
olmesartan: an active metabolite of CS 866		2.0410biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
adenosine 3'-phosphate-5'-phosphate
adenosine 3',5'-bismonophosphate : An adenosine bisphosphate having two monophosphate groups at the 3'- and 5'-positions.		2.4220adenosine bisphosphateEscherichia coli metabolite;
mouse metabolite
tipifarnib
[no description available]		2.0210imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
philanthotoxin 343
philanthotoxin 343: structure given in first source (see article's footnote); identical to philanthotoxin 433 except that the number of methylene groups between the respective amine moieties is 3,4,3 instead of 4,3,3		2.0210N-acyl-amino acid
gougerotin
[no description available]		2.3420
ungeremine
ungeremine: RN given refers to parent cpd; structure		1.9610
lombricine
L-lombricine : The L-enantiomer of lombricine.		4.15170amino acid zwitterion;
lombricine
fenton's reagent
Fenton's reagent: used for oxidizing sugars & alcohols		2.0210
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		4.953602,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
carbodiimides
Carbodiimides: Compounds with the general formula RN=C=NR, where R is a hydrocarbyl group.. methanediimine : A carbodiimide in which both nitrogens are unsubstituted.		2.6430carbodiimide
flaviolin
flaviolin: isolated from mutants of Wangiella dermatitidis; structure given in first source. flaviolin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone having three hydroxy substituents placed at the 2-, 5- and 7-positions.		2.0210
abrine
abrine: from seeds of Abrus precatorius; structure in first source. N(alpha)-methyl-L-tryptophan : A N-methyl-L-alpha-amino acid that is the N(alpha)-methyl derivative of L-tryptophan.		210L-tryptophan derivative;
N-methyl-L-alpha-amino acid zwitterion;
N-methyl-L-alpha-amino acid		Escherichia coli metabolite
i-677
4-oxalysine: from Streptomyces reseoviridofuscus; RN given refers to cpd without isomeric designation. O-(2-aminoethyl)-L-serine : An L-alpha-amino acid that is L-serine in which the hydroxy group at position 3 is converted to the corresponding 2-aminoethyl ether. An antimetabolic antibiotic obtained from Streptomyces reseoviridofuscus.		3.5790L-serine derivative;
non-proteinogenic L-alpha-amino acid		antimetabolite;
antimicrobial agent;
antineoplastic agent;
metabolite
3-deoxy-d-arabino-heptulosonate-7-phosphate
3-deoxy-D-arabino-heptulosonate-7-phosphate: do not confuse with 5-DAHP (5-dehydro-3-deoxyarabinoheptulosonic acid-7-phosphate) or with 2,4-DAHP (2,4-diaminohypoxanthine) which are also referred to as DAHP. 7-phospho-2-dehydro-3-deoxy-D-arabino-heptonic acid : A ketoaldonic acid phosphate consisting of 2-dehydro-3-deoxy-D-arabino-heptonic acid having a phospho group at the 7-position.		710ketoaldonic acid phosphateEscherichia coli metabolite
secologanin
(-)-secologanin : An iridoid monoterpenoid that is acetaldehyde in which on of the hydrogens of the methyl group has been replaced by a 2-(beta-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-4-yl group which is substituted at positions 3 and 5 by a vinyl and a methoxycarbonyl group, respectively (the 2S,3R,4S stereoisomer).		2.0710aldehyde;
beta-D-glucoside;
enoate ester;
methyl ester;
pyrans;
secoiridoid glycoside		plant metabolite
adenosine 5'-phosphoroimidazolide
[no description available]		1.9710
strictosidine
[no description available]		2.0710alkaloid ester;
beta-D-glucoside;
indole alkaloid;
methyl ester
leonurine
leonurine: has neuroprotective activity; isolated from leaves of Leonurus artemisia; has uterotonic effect; structure		2.4110trihydroxybenzoic acid
phenylarsonous acid
phenylarsonous acid: RN given from Chem Abst Guide 1985; RN not in Chemline 11/85		2.0510arsonous acids
aminoimidazole ribotide
5-amino-1-(5-phospho-beta-D-ribosyl)imidazole : A 1-(phosphoribosyl)imidazole that is 5-aminoimidazole in which the proton at position 1 has been replaced by a 5-phospho-beta-D-ribofuranosyl group.		1.96101-(phosphoribosyl)imidazole;
aminoimidazole		bacterial metabolite
ammonium borate
ammonium borate: RN refers to H3BO3		1.9610
homocysteinesulfinic acid
homocysteinesulfinic acid: RN given refers to cpd without isomeric designation		1.9910alpha-amino acid
capsidiol
capsidiol: isolated from cultured cells of Nicotiana silvestris; structure given in first source. capsidiol : An eremophilane sesquiterpenoid that is (+)-5-epi-aristolochene bearing additional 1beta- and 3alpha-hydroxy substituents. It is a phytoalexin produced in Nicotiana and Capsicum plant species in response to pathogen attack.		2.0210eremophilane sesquiterpenoid;
octahydronaphthalenes;
sesquiterpene phytoalexin		antifungal agent;
plant metabolite
2-gluthionyl-3,5,6-trichloro-1,4-benzoquinone
2-gluthionyl-3,5,6-trichloro-1,4-benzoquinone: glutathione conjugate of tetrachloro-1,4-benzoquinone; irreversibly inhibits glutathione S-transferase		1.9810
thymidine 5'-diphosphate
thymidine 5'-diphosphate: see also record for thymidine 3',5'-diphosphate, RN 2863-04-9. dTDP : A thymidine phosphate having a diphosphate group at the 5'-position.		2.0710pyrimidine 2'-deoxyribonucleoside 5'-diphosphate;
thymidine phosphate		Escherichia coli metabolite;
mouse metabolite
tanshinone ii a
tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source		2.4110abietane diterpenoid
serine o-sulfate
serine O-sulfate: RN given refers to (L)-isomer. L-serine O-sulfate : A non-proteinogenic L-alpha-amino acid that is the O-sulfo derivative of L-serine.		4.43220L-serine derivative;
non-proteinogenic L-alpha-amino acid;
O-sulfoamino acid
paromomycin
Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		1.9510amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
4-nitrocatechol sulfate
4-nitrocatechol sulfate: RN given refers to 2-sulfate moiety locant. 2-hydroxy-5-nitrophenyl hydrogen sulfate : An aryl sulfate that is 4-nitrocatechol in which the hydroxy group that is meta to the nitro group has been converted into the corresponding hydrogen sulfate. It is used (commonly as its dipotassium salt) as a chromogenic substrate for sulphatase.		1.99104-nitrophenols;
aryl sulfate		chromogenic compound
technetium tc 99m pentetate
Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents.		2.0710
metaperiodate
metaperiodate: RN given refers to periodic acid, Na salt; structure. periodate : A monovalent inorganic anion obtained by deprotonation of periodic acid.		3.260iodine oxoanion;
monovalent inorganic anion
4-nitrophenylmaltoside
[no description available]		2.110
4-hydroxybenzoyl-coenzyme a
4-hydroxybenzoyl-CoA : A hydroxybenzoyl-CoA that is the S-(4-hydroxybenzoyl) derivative of coenzyme A.		210hydroxybenzoyl-CoA
coenzyme a disulfide
coenzyme A disulfide: the normally oxidized form of Co A. CoA-disulfide : An organic disulfide obtained via oxidative dimerisation of coenzyme A.		210organic disulfide
aminopterin
Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.		2.8740dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
pregnane-20-one
pregnane-20-one: RN given refers to cpd without isomeric designation; progesterone metabolite		2.0410
n,n-di-n-propylserotonin
N,N-di-n-propylserotonin: structure given in first source		2.0110
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		6.37520biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
isofuranodiene
isofuranodiene: structure		2.0710
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		6.32480amino acid zwitterion;
angiotensin II		human metabolite
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		8.4780
lignin
Lignin: The most abundant natural aromatic organic polymer found in all vascular plants. Lignin together with cellulose and hemicellulose are the major cell wall components of the fibers of all wood and grass species. Lignin is composed of coniferyl, p-coumaryl, and sinapyl alcohols in varying ratios in different plant species. (From Merck Index, 11th ed). lignin : A polyphenylpropanoid derived from three monolignol monomers: trans-p-coumaryl alcohol, coniferol and trans-sinapyl alcohol. There is extensive cross-linking and no defined primary structure.		2.5320
ropivacaine
Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.		2.1110piperidinecarboxamide;
ropivacaine		local anaesthetic
3-o-methyl-6-fluoro-dopa
3-O-methyl-6-fluoro-dopa: RN refers to (18F-labeled-L)-isomer		2.0210
sb 203580
[no description available]		5.36550imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
sb 216763
[no description available]		4.25170indoles;
maleimides
erlotinib hydrochloride
[no description available]		2.4820hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
homocysteic acid
homocysteic acid: promotes growth in hypophysectomized rats; RN given refers to parent cpd. homocysteic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group has benn oxidised to the corresponding sulfonic acid.. L-homocysteic acid : A homocysteic acid with L-configuration.		2.6930homocysteic acidNMDA receptor agonist
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		6.54370divalent inorganic anion;
phosphite ion
limonin
[no description available]		2.1110epoxide;
furans;
hexacyclic triterpenoid;
lactone;
limonoid;
organic heterohexacyclic compound		inhibitor;
metabolite;
volatile oil component
nickel monoxide
[no description available]		2.1110
3-hydroxyglutaric acid
3-hydroxyglutaric acid : A 3 hydroxy carboxylic acid that is glutaric acid which is substituted by a hydroxy group at position 3. It is a diagnostic marker for glutaric aciduria type I.		2.03103-hydroxy carboxylic acid;
alpha,omega-dicarboxylic acid		human blood serum metabolite;
human urinary metabolite
esketamine
esketamine : The S- (more active) enantiomer of ketamine.		2.2510ketamineanalgesic;
intravenous anaesthetic;
NMDA receptor antagonist
aceglutamide
N-acetyl-L-glutamine : An N(2)-acetylglutamine that has L-configuration.		1.9810N-acetyl-L-amino acid;
N(2)-acetylglutamine;
N(2)-acyl-L-glutamine		human metabolite
u 54494a
U 54494A: RN given refers to (trans)-isomer; structure given in first source		1.9810
melagatran
[no description available]		3.110azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor
propargylglycine
propargylglycine: RN given refers to cpd without isomeric designation; structure		2.9240
aflatoxin b1
Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.. aflatoxin B1 : An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.		7.7230aflatoxin;
aromatic ether;
aromatic ketone		carcinogenic agent;
human metabolite
emd 53998
EMD 53998: EMD 53998 is racemic; EMD 57439 is the (-)-isomer; EMD 57033 is the (+)-isomer		2.0110
thialysine ketimine
thialysine ketimine: structure given in first source		1.98101,4-thiazine;
thiomorpholinemonocarboxylic acid
isospaglumic acid
isospaglumic acid: mediator in the sensitivity of animals to hyperbaric oxygenation; Naaxia is the tradename; apparently can have both a neuroprotective and a neurotoxic effect. Ac-Asp-Glu : A dipeptide composed of N-acetyl-L-aspartic acid and L-glutamic acid joined by a peptide linkage.		1.9610dipeptidehuman metabolite
bd 1047
N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity		2.7830primary amine
aspartimide
aspartimide: formed under acid or basic conditions in the synthesis of aspartic acid-containing peptides		2.0710dicarboximide;
primary amino compound;
pyrrolidinone		Maillard reaction product
3-isoxazolidone
3-isoxazolidone: structure. isoxazolidinone : An oxazolidinone in which the N and O atoms are adjacent.		6.9410oxazolidinone
4-deoxyneosamine c
4-deoxyneosamine C: structure		2.110glucosamines;
trideoxyhexose derivative
glycyl-glycyl-valine
[no description available]		2.0510oligopeptide
carbocysteine
Carbocysteine: A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action.. S-carboxymethyl-L-cysteine : An L-cysteine thioether that is L-cysteine in which the hydrogen of the thiol group has been replaced by a carboxymethyl group.		2.4110L-cysteine thioether;
non-proteinogenic L-alpha-amino acid		mucolytic
2-methylbutyrylglycine
2-methylbutyrylglycine: metabolite of L-isoleucine. N-(2-methylbutanoyl)glycine : A N-acylglycine that is glycine substituted by a 2-methylbutanoyl group at the N atom.		1.9610N-acylglycinehuman metabolite
aziridine-2-carboxylic acid
aziridine-2-carboxylic acid: structure given in first source		2.2110
l 35
L 35: a negative effector of hemoglobin; RN & structure given in first source		1.9410
capnine
capnine: sulfonolipid found in Capnocytophaga bacteria; structure given in first source; see also record for capnoids		1.9610organosulfonic acid
8-chloro-fad
[no description available]		210
cp 100356
CP 100356: modulates multidrug resistance; structure in first source		1.9810
n-(3-pyridylmethyl)adriamycin
[no description available]		2.4110
4-nitrophenyl phosphonate
4-nitrophenyl phosphonate: catalyzes hydrolysis of p-nitrophenyl esters		2.4320
chelidonine
chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)		7.3110alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
amythiamicin a
amythiamicin A: isolated from Amycolatopsis		1.9810
uic-94003
UIC-94003: structure in first source		2.0110
anabasine
Anabasine: A piperidine botanical insecticide.. (S)-anabasine : The (S)-enantiomer of anabasine.. anabasine : A pyridine alkaloid that is pyridine substituted by a piperidin-2-yl group at position 3.		2.0810anabasine
lapatinib
[no description available]		2.4110furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
sorafenib
[no description available]		7.6320(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
lacosamide
Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.		2.4620N-acyl-amino acid
cp 101,606
traxoprodil mesylate: a selective NMDA antagonist; structure given in first source		2.0210
4-chloro-alpha-cyanocinnamic acid
4-chloro-alpha-cyanocinnamic acid: a MALDI matrix		2.0510
benzyl-beta-d-xyloside
benzyl-beta-D-xyloside: RN given refers to (beta-D)-isomer		1.9510
demecolcine
Demecolcine: An alkaloid isolated from Colchicum autumnale L. and used as an antineoplastic.. (-)-demecolcine : A secondary amino compound that is (S)-colchicine in which the N-acetyl group is replaced by an N-methyl group. Isolable from the autumn crocus, Colchicum autumnale, it is less toxic than colchicine and is used as an antineoplastic.		1.9910alkaloid;
secondary amino compound		antineoplastic agent;
microtubule-destabilising agent
cholic acid
Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.. cholic acid : A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.		1.981012alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
erythritol
[no description available]		1.9410butane-1,2,3,4-tetrolantioxidant;
human metabolite;
plant metabolite
deoxycholic acid
Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.		2.3520bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
cortisone
[no description available]		5.4212011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
3-nitrotyrosine
3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.		4.93802-nitrophenols;
C-nitro compound;
nitrotyrosine;
non-proteinogenic alpha-amino acid
sodium sulfide
sodium sulfide: see also record for sodium bisulfide; actisoufre is the sodium sulfide component of sulfur-containing thermal springs which is also found in Saccharomyces cerevisiae		3.0850
stigmastanol
stigmastanol: saturated analog of beta-sitosterol; RN given refers to (3beta,5alpha)-isomer. stigmastanol : A 3-hydroxy steroid that is 5alpha-stigmastane which is substituted at the 3beta position by a hydroxy group.		2.08103-hydroxy steroid;
phytosterols		anticholesteremic drug;
plant metabolite
anisomycin
Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.		9.89340monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.9640
metribolone
Metribolone: A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.. 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one : A synthetic non-aromatisable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.		3.155017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid		androgen
withaferin a
withaferin A: an antiestrogen and phytogenic antineoplastic agent isolated from leaves of Withania somnifera Dun.; structure. withaferin A : A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 27 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Physalis longifolia, it exhibits cytotoxic activity.		8.044027-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide		antineoplastic agent;
apoptosis inducer
homoharringtonine
Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.		2.7330alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
acivicin
[no description available]		3.4880isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
2-amino-3,3-dimethylbutanoic acid
tert-butylglycine : A glycine derivative that is glycine with a tertiary butyl group at position 2.		1.9810non-proteinogenic alpha-amino acidmetabolite
wortmannin
[no description available]		5.73810acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
withanolides
Withanolides: Ergostane derivatives of 28 carbons with oxygens at C1, C22, and C26 positions and the side chain cyclized. They are found in WITHANIA plant genus and have cytotoxic and other effects.		3.0440
glycyl-glycyl-sarcosine
glycyl-glycyl-sarcosine: structure given in first source		2.0510
sorbinil
sorbinil: aldose reductase inhibitor. sorbinil : An azaspiro compound having a monofluoro-substituted chromane skeleton spiro-linked to an imidazolidinedione ring.		2.0410azaspiro compound;
chromanes;
imidazolidinone;
organofluorine compound;
oxaspiro compound		antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor
3,4-dihydroxyphenylpropionic acid
3,4-dihydroxyphenylpropionic acid: metabolite of caffeic acid; RN given refers to parent cpd; structure. 3-(3,4-dihydroxyphenyl)propanoic acid : A monocarboxylic acid that is 3-phenylpropionic acid substituted by hydroxy groups at positions 3 and 4. Also known as dihydrocaffeic acid, it is a metabolite of caffeic acid and exhibits antioxidant activity.		2.0410(dihydroxyphenyl)propanoic acidantioxidant;
human xenobiotic metabolite
indole-3-acetonitrile
indole-3-acetonitrile: occurs in edible cruciferous vegetables. indole-3-acetonitrile : A nitrile that is acetonitrile where one of the methyl hydrogens is substituted by a 1H-indol-3-yl group.		2.0110indoles;
nitrile		auxin;
human xenobiotic metabolite;
plant hormone;
plant metabolite
trimethoprim, sulfamethoxazole drug combination
Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.		2.4110
2,5-bis(5-hydroxymethyl-2-thienyl)furan
[no description available]		2.520thiophenes
bortezomib
[no description available]		10.4551amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
mrs 1191
MRS 1191: a selective A3 adenosine receptor antagonist; structure given in first source		2.0510cinnamate ester
mrs 1220
9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline: structure in first source		2.0510quinazolines
aglafoline
aglafoline: a platelet activating factor antagonist; structure given in first source; isolated from Aglaia elliptifolia. aglafolin : A heterotricyclic compound based on a 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a and methoxy groups at C-6 and C-8. A platelet aggregation inhibitor found in Aglaia elliptifolia and Aglaia odorata.		2.110methyl ester;
organic heterotricyclic compound		metabolite;
platelet aggregation inhibitor
dihydropyridines
Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.		3.5280
lanatosides
Lanatosides: Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale, The Extra Pharmacopoeia, 30th ed, p670)		3.1210
protoverin
Protoveratrines: Mixtures of closely related hypotensive alkaloids from Veratrum album (Liliaceae). They have been used in the treatment of hypertension but have largely been replaced by drugs with fewer adverse effects.		1.9410
leupeptins
Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.		5.86300
carboplatin
[no description available]		4.411
anatoxin a
anatoxin a: found in Anabaena; was indexed to cyanobacterial toxin (MARINE TOXINS) 1978-2006; also see anatoxin-a(s)		2.0210tropane alkaloid
lithium chloride
Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.		4.62260inorganic chloride;
lithium salt		antimanic drug;
geroprotector
leptomycin b
[no description available]		4.15160
s-adenosylhomocysteine
S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.. S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.		3.150adenosines;
amino acid zwitterion;
homocysteine derivative;
homocysteines;
organic sulfide		cofactor;
EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor;
EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor;
epitope;
fundamental metabolite
glyceraldehyde 3-phosphate
Glyceraldehyde 3-Phosphate: An aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.. glyceraldehyde 3-phosphate : An aldotriose phosphate that is the 3-phospho derivative of glyceraldehyde. It is an important metabolic intermediate in several central metabolic pathways in all organisms.		3.2660glyceraldehyde 3-phosphatemouse metabolite
5'-methylthioadenosine
5'-methylthioadenosine: structure. 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.		2.3820thioadenosinealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glycogen
glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.		8.41611
ribulose 5-phosphate
ribulose 5-phosphate: RN given refers to cpd without isomeric designation. D-ribulose 5-phosphate : The D-enantiomer of ribulose 5-phosphate that is one of the end-products of the pentose phosphate pathway.. ribulose 5-phosphate : A ribulose phosphate in which the phosphate group is attached at position 5.		3.0510ribulose 5-phosphatemouse metabolite
sorbose
sorbopyranose : The pyranose form of sorbose.. L-sorbopyranose : The L-stereoisomer of sorbopyranose.		3.4720L-sorbose;
sorbopyranose
arabinose
[no description available]		4.58100L-arabinoseEscherichia coli metabolite;
mouse metabolite
n-acetylneuraminic acid
N-Acetylneuraminic Acid: An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518). N-acetylneuraminic acid : An N-acylneuraminic acid where the N-acyl group is specified as acetyl.		4.6480N-acetylneuraminic acidsantioxidant;
bacterial metabolite;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
human metabolite;
mouse metabolite
mannose-6-phosphate
beta-D-mannose 6-phosphate : A D-mannopyranose 6-phosphate with a beta-configuration at the anomeric position.		7.6730D-mannopyranose 6-phosphate
fibrin
Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.		3.98140peptide
bradykinin
[no description available]		4.67280oligopeptidehuman blood serum metabolite;
vasodilator agent
canavanine
L-canavanine : A non-proteinogenic L-alpha-amino acid that is L-homoserine substituted at oxygen with a guanidino (carbamimidamido) group. Although structurally related to L-arginine, it is non-proteinogenic.		8.5590amino acid zwitterion;
non-proteinogenic L-alpha-amino acid		phytogenic insecticide;
plant metabolite
hexacyanoferrate iii
hexacyanoferrate III: RN given refers to parent cpd		2.420
glucosamine
D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.		9.21250D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
polygalacturonic acid
galacturonic acid: N1 same as NM; RN given refers to parent cpd with unspecified isomeric designation. D-galactopyranuronic acid : The pyranose form of D-galacturonic acid. D-galacturonic acid : The D-enantiomer of galacturonic acid. It is the main component of pectin.		2.9240D-galacturonic acid
elastin
[no description available]		9.2770oligopeptide
carnosine
polaprezinc: stimulates bone growth		3.2160amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent
mevalonic acid
Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.		4.221803,5-dihydroxy-3-methylpentanoic acid
formiminoglutamic acid
Formiminoglutamic Acid: Measurement of this acid in the urine after oral administration of histidine provides the basis for the diagnostic test of folic acid deficiency and of megaloblastic anemia of pregnancy.. N-formimidoyl-L-glutamic acid : The N-formimidoyl derivative of L-glutamic acid		4.3820dicarboxylic acid;
L-glutamic acid derivative
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		2.0410(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
cytidine diphosphate glycerol
cytidine diphosphate glycerol: acts as a donor of glycerol residues for teichoic acid synthesis; acyl derivatives are involved in phospholipid synthesis; minor descriptor (75-83); on-line Index Medicus search NUCLEOSIDE DIPHOSPHATE SUGARS (75-83); RN given refers to (S)-isomer. CDP-glycerol : A nucleotide-alditol having cytidine-5'-diphosphate and glycerol as the nucleotide and alditol components respectively.		2.0110nucleotide-alditol
diaminopimelic acid
Diaminopimelic Acid: A diamino derivative of heptanedioic acid with amino groups at C-2 and C-6 and the general formula (COOH)CH(NH2)CH2CH2CH2CH(NH2)(COOH).. LL-2,6-diaminopimelic acid : A 2,6-diaminopimelic acid in which both chiral centres have S configuration. It is a component of bacterial cell wall.		2.68302,6-diaminopimelic acid;
amino acid zwitterion		Escherichia coli metabolite
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		5130heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
dopaquinone
[no description available]		2.6101,2-benzoquinones;
amino acid zwitterion;
L-phenylalanine derivative		human metabolite;
mouse metabolite
pantetheine
Pantetheine: An intermediate in the pathway of coenzyme A formation in mammalian liver and some microorganisms.. pantetheine : An amide obtained by formal condensation of the carboxy group of pantothenic acid and the amino group of cysteamine.		8.6290pantetheines;
thiol		human metabolite;
metabolite;
mouse metabolite
dithioerythritol
[no description available]		1.95101,4-dimercaptobutane-2,3-diolreducing agent
n-methylglutamate
N-methyl-L-glutamic acid : A N-methyl-L-alpha-amino acid with L-glutamic acid as the amino acid component.. methyl-L-glutamic acid : A non-proteinogenic L-alpha-amino acid that is L-glutamic acid substituted with a methyl group.		2.1110methyl-L-glutamic acid;
N-methyl-L-alpha-amino acid		bacterial xenobiotic metabolite
theanine
theanine: RN given refers to (L)-isomer; precursor of ethylamine; found in green tea. N(5)-ethyl-L-glutamine : A N(5)-alkylglutamine where the alkyl group is ethyl. It has been isolated from green tea.		7.9430amino acid zwitterion;
N(5)-alkyl-L-glutamine		geroprotector;
neuroprotective agent;
plant metabolite
o-succinylhomoserine
O-succinylhomoserine: RN given refers to (L)-isomer		2.3720hemisuccinate;
o-succinylhomoserine		Escherichia coli metabolite;
Saccharomyces cerevisiae metabolite
inositol 1,4,5-trisphosphate
Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.		8.95130myo-inositol trisphosphatemouse metabolite
cysteinylglycine
cysteinylglycine: RN given refers to (L)-isomer; RN for cpd without isomeric designation not in Chemlne 7/13/83. L-cysteinylglycine : A dipeptide consisting of glycine having an L-cysteinyl attached to its alpha-amino group. It is an intermediate metabolite in glutathione metabolism.		2.7130dipeptide zwitterion;
dipeptide		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite
glutamyl-glutamic acid
glutamyl-glutamic acid: RN given for (L,L)-isomer. Glu-Glu : A dipeptide composed of two L-glutamic acid units joined by a peptide linkage.		2.4220dipeptideMycoplasma genitalium metabolite
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		4.627011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
casein hydrolysate
casein hydrolysate: an ingredient of trypticase soy broth; casitone is a tryptic digest of casein		2.0210
D-leucine
[no description available]		210D-alpha-amino acid zwitterion;
D-alpha-amino acid;
leucine		bacterial metabolite;
Saccharomyces cerevisiae metabolite
puromycin
[no description available]		5.96360puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
taxifolin
(+)-taxifolin : A taxifolin that has (2R,3R)-configuration.		2.4110taxifolinmetabolite
maltotetraose
alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp : A maltotetraose tetrasaccharide consisting of three alpha-D-glucopyranose residues and a D-glucopyranose residue joined in sequence by (1->4) glycosidic bonds.		2.1510maltotetraose tetrasaccharide
tosylphenylalanyl chloromethyl ketone
Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.		3.150alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
tartaric acid
tartaric acid: RN given refers to cpd with unspecified isomeric designation. D-tartaric acid : The D-enantiomer of tartaric acid.		2.4220tartaric acidEscherichia coli metabolite
monoiodotyrosine
Monoiodotyrosine: A product from the iodination of tyrosine. In the biosynthesis of thyroid hormones (THYROXINE and TRIIODOTHYRONINE), tyrosine is first iodized to monoiodotyrosine.. iodotyrosine : A tyrosine derivative which has at least one iodo-substituent on the benzyl moiety.. monoiodotyrosine : An iodotyrosine carrying a single iodo substituent.. 3-iodo-L-tyrosine : The monoiodotyrosine that is L-tyrosine carrying an iodo-substituent at position C-3 of the benzyl group.		2.3720amino acid zwitterion;
L-tyrosine derivative;
monoiodotyrosine;
non-proteinogenic L-alpha-amino acid		EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor;
human metabolite;
mouse metabolite
taurolithocholic acid
Taurolithocholic Acid: A bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. It is a cholagogue and choleretic.. taurolithocholic acid : The bile acid taurine conjugate of lithocholic acid.		2.4320bile acid taurine conjugate;
monocarboxylic acid amide		human metabolite
ketodihydrosphingosine
ketodihydrosphingosine: RN given refers to cpd without isomeric designation. 3-dehydrosphinganine : A 2-amino-1-hydroxyoctadecan-3-one that has S-configuration.		4.791002-amino-1-hydroxyoctadecan-3-onemouse metabolite
nicotinamide-beta-riboside
N-ribosylnicotinamide : A pyridine nucleoside consisting of nicotinamide with a beta-D-ribofuranosyl moiety at the 1-position.		2.2510N-glycosylnicotinamide;
pyridine nucleoside		geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
nitroarginine
Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.		2.7530guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
trimethyllysine
trimethyllysine: stimulates growth of tumor cells; RN given refers to (S)-isomer		2.1310alpha-amino-acid cationhuman metabolite;
mouse metabolite
1,3,6,8-tetrahydroxynaphthalene
1,3,6,8-tetrahydroxynaphthalene: intermediate in polyketide biosynthesis. naphthalene-1,3,6,8-tetrol : A naphthalenetetrol that is naphthalene substituted by hydroxy groups at positions 1, 3, 6 and 8.		2.4220naphthalenetetrol
n-acetylglucosamine-1-phosphate
N-acetylglucosamine-1-phosphate: found in proteinase I from Dictyostelium discoideum. N-acetyl-D-glucosamine 1-phosphate : A N-acyl-D-glucosamine 1-phosphate in which the acyl group specified is acetyl.. 2-acetamido-2-deoxy-D-glucopyranose 1-phosphate : A N-acetyl-D-glucosamine 1-phosphate that is 2-deoxy-D-glucopyranose 1-(dihydrogen phosphate) substituted by an acetamido group at position 2.		6.9910N-acetyl-D-glucosamine 1-phosphateEscherichia coli metabolite;
human metabolite;
mouse metabolite
pantothenylcysteine 4'-phosphate
N-[(R)-4-phosphopantothenoyl]-L-cysteine : The N-[(R)-4-phosphopantothenoyl] derivative of L-cysteine.		2.0210L-cysteine derivativeEscherichia coli metabolite;
mouse metabolite
adenosine 5'-o-(3-thiotriphosphate)
adenosine 5'-O-(3-thiotriphosphate): RN given refers to cpd with unspecified locant for thio group; see also records for 1-thio & 2-thio-isomers. adenosine 5'-[gamma-thio]triphosphate : A nucleoside triphosphate analogue that is ATP in which one of the oxygens attached to 3-phosphate group is replaced by sulfur.		2.420nucleoside triphosphate analogue
dehydroascorbic acid
Dehydroascorbic Acid: The reversibly oxidized form of ascorbic acid. It is the lactone of 2,3-DIKETOGULONIC ACID and has antiscorbutic activity in man on oral ingestion.. L-dehydroascorbate : An organic anion and the conjugate base of L-dehydroascorbic acid, arising from deprotonation of the acidic C2-position.. L-dehydroascorbic acid : Dehydroascorbic acid having the L-configuration.		210dehydroascorbic acid;
vitamin C		coenzyme;
mouse metabolite
cortodoxone
Cortodoxone: 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.. 11-deoxycortisol : A deoxycortisol that is cortisol in which the hydroxy group at position 11 has been replaced by a hydrogen.		1.9810deoxycortisol;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
glutathionylspermidine
[no description available]		210glutathione derivativeEscherichia coli metabolite
fructans
(2->6)-beta-D-fructan : A fructan compound consisting of repeating (2->6)-beta-linked fructofuranose units.		2.4520
cellulase
Cellulase: An endocellulase with specificity for the hydrolysis of 1,4-beta-glucosidic linkages in CELLULOSE, lichenin, and cereal beta-glucans.. beta-cellotriose : A cellotriose with a beta-configuration at the anomeric position.		3.1250cellotriose
strychnine
Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.		7.09430monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		210cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.7930alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
griseofulvin
Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.		2.36201-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
actinorhodin
actinorhodin: structure. actinorhodin : A member of the class of benzoisochromanequinone that is produced by Streptomyces coelicolor A3(2) and exhibits antibiotic activity.		1.9710
monensin
Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies.. monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.		3.92130cyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal		antifungal agent;
coccidiostat;
ionophore
cefoxitin
Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.		2.4110beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
7-aminocephalosporanic acid
7beta-aminocephalosporanic acid : The alpha,beta-unsaturated monocarboxylic acid that is the active nucleus for the synthesis of cephalosporins and intermediates.		2.0810alpha,beta-unsaturated monocarboxylic acid;
amino acid zwitterion
linezolid
[no description available]		2.8220acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
canaline
canaline: structure		1.9610amino acid zwitterion;
non-proteinogenic L-alpha-amino acid		antimetabolite;
antineoplastic agent;
phytogenic insecticide;
plant metabolite
2,5-dihydrophenylalanine
2,5-dihydrophenylalanine: structure		1.9510non-proteinogenic L-alpha-amino acid
phalloidine
Phalloidine: Very toxic polypeptide isolated mainly from AMANITA phalloides (Agaricaceae) or death cup; causes fatal liver, kidney and CNS damage in mushroom poisoning; used in the study of liver damage.. phalloidin : A homodetic bicyclic heptapeptide having a sulfide bridge.		2.9340homodetic cyclic peptide
ryanodine
Ryanodine: A methylpyrrole-carboxylate from RYANIA that disrupts the RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL to modify CALCIUM release from SARCOPLASMIC RETICULUM resulting in alteration of MUSCLE CONTRACTION. It was previously used in INSECTICIDES. It is used experimentally in conjunction with THAPSIGARGIN and other inhibitors of CALCIUM ATPASE uptake of calcium into SARCOPLASMIC RETICULUM.. ryanodine : An insecticide alkaloid isolated from South American plant Ryania speciosa.		2.9440
ginsenoside re
[no description available]		7.071012beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
nephroprotective agent;
neuroprotective agent;
plant metabolite
ginsenoside rg1
[no description available]		2.051012beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		neuroprotective agent;
pro-angiogenic agent
phorbol
phorbol: RN given refers to (1aR-(1a alpha,1b beta,4a beta,7a alpha,7b alpha,8 alpha,9 beta,9b beta))-isomer; synonym isophorbol refers to (4a alpha)-isomer; structure in Merck Index, 9th ed, #7143. phorbol : A diterpenoid with the structure of tigliane hydroxylated at C-4, -9, -12(beta), -13 and -20, with an oxo group at C-3 and unsaturation at the 1- and 6-positions.		2.3820cyclic ketone;
enone;
tertiary alcohol;
tertiary alpha-hydroxy ketone;
tetracyclic diterpenoid
micheliolide
micheliolide: has antineoplastic activity; structure in first source		2.4110sesquiterpene lactone
ochratoxin a
ochratoxin A: structure in first source & in Merck, 9th ed, #6549. ochratoxin A : A phenylalanine derivative resulting from the formal condensation of the amino group of L-phenylalanine with the carboxy group of (3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1H-2-benzopyran-7-carboxylic acid (ochratoxin alpha). It is among the most widely occurring food-contaminating mycotoxins, produced by Aspergillus ochraceus, Aspergillus carbonarius and Penicillium verrucosum.		2.0710isochromanes;
monocarboxylic acid amide;
N-acyl-L-phenylalanine;
organochlorine compound;
phenylalanine derivative		Aspergillus metabolite;
calcium channel blocker;
carcinogenic agent;
mycotoxin;
nephrotoxin;
Penicillium metabolite;
teratogenic agent
acetylleucyl-leucyl-norleucinal
acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.		2.9240aldehyde;
tripeptide		cysteine protease inhibitor
n-formylmethionine leucyl-phenylalanine
N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.		4.15160tripeptide
diprenorphine
Diprenorphine: A narcotic antagonist similar in action to NALOXONE. It is used to remobilize animals after ETORPHINE neuroleptanalgesia and is considered a specific antagonist to etorphine.		3.150morphinane alkaloid
c(alpha)-formylglycine
C(alpha)-formylglycine: An unusual amino acid residue found at active site of sulfatases. It is created through the conversion of an active site cysteine or serine residue by C(alpha)-formylglycine (FGly)-generating enzyme. Although the term formylglycine has been used in the literature to refer to C(alpha)-formylglycine it is found in most chemical sources as a synonom for N-formyglycine.. L-3-oxoalanine : The L-enantiomer of 3-oxoalanine.		4.5703-oxoalanine;
amino acid zwitterion;
L-alanine derivative;
non-proteinogenic L-alpha-amino acid		Escherichia coli metabolite
sodium arsenite
sodium arsenite : An inoganic sodium salt with formula with formula NaAsO2.		3.2660arsenic molecular entity;
inorganic sodium salt		antibacterial agent;
antifungal agent;
antineoplastic agent;
carcinogenic agent;
herbicide;
insecticide;
rodenticide
pyochelin
pyochelin: phenolic iron-binding cpd from Pseudomonas aeruginosa; promotes the growth of bacterium when added to iron-deficient media. pyochelin : A member of the class of thiazolidines that is (4R)-3-methyl-1,3-thiazolidine-4-carboxylic acid which is substituted at position 2 by a (4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl group. A siderophore that is produced by Pseudomonas aeruginosa (via condensation of salicylic acid and two molecules of cysteine) as a mixture of two easily interconvertible diastereoisomers, pyochelin I (major) and pyochelin II (minor). The enantiomeric compounds, enant-pyochelin, are produced by Pseudomonas fluorescens.		2.0210monocarboxylic acid;
phenols;
thiazolidines		metabolite;
siderophore
yersiniabactin
yersiniabactin: from clinical isolates of Yersinia enterocolitica; an iron-chelating virulence factor of Yersinia pestis; yersiniabactin is a thiazole phenol analog of pyochelin; biosynthesized from salicylate, cysteine and malonyl CoA. yersiniabactin : A member of the class of thiazolidines that is (4S)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid which is substituted at position 2 by a (1S)-1-hydroxy-1-{(4R)-2-[(4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl}-2-methylpropan-2-yl group. A siderophore found in the gram-negative bacterium species, Yersinia enterocolitica and Yersinia pestis.		2.4220monocarboxylic acid;
phenols;
secondary alcohol;
thiazolidines		bacterial metabolite;
siderophore
actinonin
actinonin: natural hydroxamic acid, pseudopeptide antibiotic isolated from Streptomyces species; structure		2.0110
ergonovine
Ergonovine: An ergot alkaloid (ERGOT ALKALOIDS) with uterine and VASCULAR SMOOTH MUSCLE contractile properties.. ergometrine : A monocarboxylic acid amide that is lysergamide in which one of the hydrogens attached to the amide nitrogen is substituted by a 1-hydroxypropan-2-yl group (S-configuration). An ergot alkaloid that has a particularly powerful action on the uterus, its maleate (and formerly tartrate) salt is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.		1.9410ergot alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		diagnostic agent;
fungal metabolite;
oxytocic;
toxin
metrizamide
Metrizamide: A solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.		1.9710amino sugar
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		4.7490cyclodextrin
indoleglycerol phosphate
indoleglycerol phosphate: inducer of tryptophan synthase. (1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate : The (1S,2R)-diastereomer of 1-C-(indol-3-yl)glycerol 3-phosphate.		3.791101-C-(indol-3-yl)glycerol 3-phosphate
maleic acid
maleic acid: RN given refers to parent cpd(Z)-isomer which is maleic acid; all RR's given refer to (Z)-isomer; (E)-isomer is fumaric acid. maleic acid : A butenedioic acid in which the double bond has cis- (Z)-configuration.		7.6630butenedioic acidalgal metabolite;
mouse metabolite;
plant metabolite
acetyl coenzyme a
Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.		5.81290acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite
e-z cinnamic acid
cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid		3.8530cinnamic acidplant metabolite
ergosterol
[no description available]		1.95103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		fungal metabolite;
Saccharomyces cerevisiae metabolite
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		8.82110antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		4.86330retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
equilenin
Equilenin: An estrogenic steroid produced by HORSES. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the URINE of pregnant mares.. equilenin : A 3-hydroxy steroid that is estrone which carries two double bonds at positions 6 and 8. It is found in the urine of pregnant mare's and extensively used for estrogen replacement therapy in postmenopausal women.		2.021017-oxo steroid;
3-hydroxy steroid		antioxidant;
mammalian metabolite
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		11.76450icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
alpha-cyclodextrin
alpha-cyclodextrin : A cycloamylose composed of six alpha-(1->4) linked D-glucopyranose units.		2.4820cyclodextrin
fumaric acid
fumaric acid: see also record for ferrous fumarate; use FUMARATES for general fumaric acid esters. fumaric acid : A butenedioic acid in which the C=C double bond has E geometry. It is an intermediate metabolite in the citric acid cycle.		2.4320butenedioic acidfood acidity regulator;
fundamental metabolite;
geroprotector
desthiobiotin
desthiobiotin: RN given refers to cpd without isomeric designation; structure. (4R,5S)-dethiobiotin : The (4R,5S)-isomer of dethiobiotin.		2.2110dethiobiotin
prostaglandin h2
Prostaglandin H2: A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins.		3.0810olefinic compound;
oxylipin;
prostaglandins H;
secondary alcohol		mouse metabolite
farnesol
Farnesol: A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). (2-trans,6-trans)-farnesol : The (2-trans,6-trans)-stereoisomer of farnesol.. farnesol : A farnesane sesquiterpenoid that is dodeca-2,6,10-triene substituted by methyl groups at positions 3, 7 and 11 and a hydroxy group at position 1.		2.4110farnesolplant metabolite
4-nitrophenylphosphorylcholine
p-nitrophenylphosphocholine : A phosphocholine that is the 4-nitrophenyl ester of choline phosphate.		210phosphocholinesepitope;
hapten
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		4.45210resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
methionine sulfone
methionine sulfone: RN given refers to unlabeled parent cpd without isomeric designation. methionine sulfone : A methionine derivative in which the sulfur has been oxidised to the corresponding sulfone.. L-methionine sulfone : An L-methionine derivative in which the sulfur has been oxidised to the corresponding sulfone.		2.0810L-alpha-amino acid zwitterion;
L-methionine derivative;
methionine sulfone;
non-proteinogenic L-alpha-amino acid		animal metabolite
retinol
Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).		10.1990retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
ribothymidine
ribothymidine : A methyluridine having a single methyl substituent at the 5-position on the uracil ring.		2.0710methyluridineantigen;
Escherichia coli metabolite;
human metabolite
latrunculin a
latrunculin A: 16-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin B; structure given in first source. latrunculin A : A bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes.		2.0110cyclic hemiketal;
macrolide;
oxabicycloalkane;
thiazolidinone		actin polymerisation inhibitor;
metabolite;
toxin
cyanoginosin lr
cyanoginosin LR: cyclic heptapeptide from cyanobacterium Microcystis aeruginosa. microcystin-LR : A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.		2.730microcystinbacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
environmental contaminant;
xenobiotic
palmitoleic acid
hexadecenoate : A long-chain unsaturated fatty acid anion that is the conjugate base of hexadecenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		2.0310hexadec-9-enoic acidalgal metabolite;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
human blood serum metabolite
oleic acid
Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.		9.16160octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		4.22170macrolide lactambacterial metabolite;
immunosuppressive agent
om99-2
OM99-2: eight-residue memapsin 2 inhibitor; structure in first source		2.0210
farnesyl pyrophosphate
farnesyl pyrophosphate: a sesquiterpene that dimerizes to SQUALENE; RN given refers to cpd without isomeric designation. 2-trans,6-trans-farnesyl diphosphate : The trans,trans-stereoisomer of farnesyl diphosphate.		2.0110farnesyl diphosphateEscherichia coli metabolite;
mouse metabolite
ferulic acid
ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.		2.830ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
pectins
Pectins: High molecular weight polysaccharides present in the cell walls of all plants. Pectins cement cell walls together. They are used as emulsifiers and stabilizers in the food industry. They have been tried for a variety of therapeutic uses including as antidiarrheals, where they are now generally considered ineffective, and in the treatment of hypercholesterolemia.. alpha-D-galacturonic acid : The alpha-anomer of D-galacturonic acid.		2.4320D-galactopyranuronic acid
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		5.06400benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
eicosapentaenoic acid
icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.		9.3341icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
alpha-methyl-4-carboxyphenylglycine
alpha-methyl-4-carboxyphenylglycine: glutamate receptor antagonist. (S)-alpha-methyl-4-carboxyphenylglycine : A non-proteinogenic alpha-amino acid that is alanine in which the alpha-hydrogen is replaced by a 4-carboxyphenyl group (the S-enantiomer). It is a non-selective group I/group II metabotropic glutamate receptor (mGluR) antagonist.		2.0210non-proteinogenic alpha-amino acidmetabotropic glutamate receptor antagonist
thapsigargin
Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.		4.31190butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid
Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.		2.45202-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
glutaryl-7-aminocephalosporanic acid
glutaryl-7-aminocephalosporanic acid: structure given in first source; product of the enzymatic oxidation of cephalosporin C using D-amino-acid oxidase		2.0610cephalosporin
mupirocin
Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.		210alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
2',3'-dideoxycytidine 5'-triphosphate
[no description available]		2.0110
keratan sulfate
Keratan Sulfate: A sulfated mucopolysaccharide initially isolated from bovine cornea. At least two types are known. Type I, found mostly in the cornea, contains D-galactose and D-glucosamine-6-O-sulfate as the repeating unit; type II, found in skeletal tissues, contains D-galactose and D-galactosamine-6-O-sulfate as the repeating unit.. keratan sulfate : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-beta-Gal-(1->4)-beta-GlcNAc-(1->] and containing sulfo groups located at random positions.. keratan 6'-sulfate : A keratan sulfate with random sulfation at the 6'-position.		3.0650
fosfomycin
Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.		210epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
s-hydroxymethylglutathione
S-(hydroxymethyl)glutathione : An S-substituted glutathione that is glutathione in which the mercapto hydrogen has been replaced by a hydroxymethyl group.		2.4120S-substituted glutathioneEscherichia coli metabolite;
mouse metabolite
adenylosuccinate
aspartyl adenylate: RN given refers to (L)-isomer		2.1310
cefoxitin
Tn antigen: immediate precursor in biosynthesis of Thomsen-Friedenreich (T) antigen; present in about 90% of human carcinoma tissue; proposed as universal carcinoma marker. O-(N-acetyl-alpha-D-galactosaminyl)-L-serine : A non-proteinogenic L-amino acid that is N-acetyl-alpha-D-galactosamine linked via an alpha glycosidic bond to the O at position 3 of L-serine.		340L-serine derivative;
non-proteinogenic L-alpha-amino acid		tumour antigen
geranylgeranyl pyrophosphate
geranylgeranyl pyrophosphate: RN given refers to (E,E,E)-isomer. geranylgeranyl diphosphate : A polyprenol diphosphate having geranylgeranyl as the polyprenyl component.. 2-trans,6-trans,10-trans-geranylgeranyl diphosphate : The all-trans-isomer of geranylgeranyl diphosphate.		2.1110geranylgeranyl diphosphatemouse metabolite
isofagomine
[no description available]		2.0310piperidines
phenylalanyl-prolyl-arginine
[no description available]		210oligopeptide
stigmatellin
stigmatellin: isolated from myxobacterium Stigmatella aurantiaca; structure in first source. stigmatellin A : A member of the class of chromones that is isolated from Stigmatella aurantiaca Sg a15.		1.9810aromatic ether;
chromones;
olefinic compound;
phenols		bacterial metabolite;
quinol oxidation site inhibitor
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea
N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source		2.7830
y 27632
Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.		3.2960aromatic amide
prostaglandin d2
Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).		2.4420prostaglandins Dhuman metabolite;
mouse metabolite
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		1.9410olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
n-acetylmethionine
N-acetylmethionine: RN given refers to L-isomer. N-acetylmethionine : A methionine derivative that is methionine in which one of the amine hydrogens is substituted by an acetyl group.		1.9710L-methionine derivative;
N-acetyl-L-amino acid;
N-acetylmethionine		nutraceutical
epothilone a
Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).		2.0210epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
eptifibatide
[no description available]		2.0210homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
6-bromoindirubin-3'-oxime
6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.0510
gamma-glutamyl hydroxamate
glutamine hydroxamate : A hydroxamic acid that is L-glutamine hydroxylated at N-5.		1.9810amino acid zwitterion;
glutamic acid derivative;
hydroxamic acid
L-cycloserine
L-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has S configuration. An antibiotic isolated from Erwinia uredovora.		2.06104-amino-1,2-oxazolidin-3-oneanti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
h 89
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.		6.16490N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
isoleucylvaline
isoleucylvaline: RN given refers to all (L)-isomer. Ile-Val : A dipeptide formed from L-isoleucine and L-valine residues.		1.9710dipeptidemetabolite
afimoxifene
afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.		4.4380phenols;
tertiary amino compound		antineoplastic agent;
estrogen receptor antagonist;
metabolite
imidazolidines
[no description available]		2.0410azacycloalkane;
imidazolidines;
saturated organic heteromonocyclic parent
decitabine
[no description available]		2.08102'-deoxyribonucleoside
colfosceril palmitate
colfosceril palmitate: used in the treatment of unilateral pulmonary interstitial emphysema; component of Exosurf. 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine : A phosphatidylcholine 32:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl). A synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of pulmonary surfactants.		2.54201-acyl-2-hexadecanoyl-sn-glycero-3-phosphocholine;
phosphatidylcholine 32:0		mouse metabolite;
surfactant
phorbol-12,13-didecanoate
phorbol-12,13-didecanoate: RN given refers to (1aR-(1a alpha,1b beta,4a beta,7a alpha,7b alpha,8 alpha,9 beta,9a alpha))-isomer		2.0710
texas red
Texas red: hydrophilic Texas red; structure given in first source		2.4220organic heteroheptacyclic compoundfluorochrome
iridoids
Iridoids: A type of MONOTERPENES, derived from geraniol. They have the general form of cyclopentanopyran, but in some cases, one of the rings is broken as in the case of secoiridoid. They are different from the similarly named iridals (TRITERPENES).		2.4620
kt 5720
KT 5720: indolocarbazole; synthetic derivative of K 252a. KT 5720 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of hexyl (3S)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2R,3S,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.		2.9440carboxylic ester;
gamma-lactam;
hemiaminal;
indolocarbazole;
organic heterooctacyclic compound;
semisynthetic derivative;
tertiary alcohol		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		6.06470actinomycinmutagen
aphidicolin
Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication.		3.5180tetracyclic diterpenoidantimicrobial agent;
antimitotic;
antineoplastic agent;
antiviral drug;
apoptosis inducer;
Aspergillus metabolite;
DNA synthesis inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
fungal metabolite
azaserine
Azaserine: Antibiotic substance produced by various Streptomyces species. It is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent.. azaserine : A carboxylic ester resulting from the formal condensation of the carboxy group of diazoacetic acid with the alcoholic hydroxy group of L-serine. An antibiotic produced by a Streptomyces species.		5.21520carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid		antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		1.9510L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
enkephalin, leucine
Enkephalin, Leucine: One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.. Leu-enkephalin : A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.		3.6190pentapeptide;
peptide zwitterion		analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.		4.53230amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		7.0210nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
5-ethynyl-2'-deoxyuridine
5-ethynyl-2'-deoxyuridine: structure in first source		2.0710
shikonin
shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities		2.4110hydroxy-1,4-naphthoquinone
riboflavin
vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).		4.11160flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
tyrosine o-sulfate
O(4')-sulfo-L-tyrosine : An O-sulfoamino acid that is L-tyrosine in which the phenolic hydrogen has been replaced by a sulfo group.		3.7830aryl sulfate;
L-tyrosine derivative;
O-sulfoamino acid		human metabolite
Phe-Tyr
Phe-Tyr : A dipeptide formed from L-phenylalanine and L-tyrosine residues.		1.9710dipeptidemetabolite
potassium thiocyanate
potassium thiocyanate: RN given refers to cpd with MF of K-CHNS. potassium thiocyanate : A potassium salt which is the monopotassium salt of thiocyanic acid.		1.9710potassium salt
potassium permanganate
Potassium Permanganate: Permanganic acid (HMnO4), potassium salt. A highly oxidative, water-soluble compound with purple crystals, and a sweet taste. (From McGraw-Hill Dictionary of Scientific and Technical Information, 4th ed)		1.9510
potassium bicarbonate
potassium hydrogencarbonate : A potassium salt that is the monopotassium salt of carbonic acid. It has fungicidal properties and is used in organic farming for the control of powdery mildew and apple scab.		2.2110organic salt;
potassium salt		antifungal agrochemical;
buffer;
food acidity regulator;
raising agent
sodium chlorate
sodium chlorate : An inorganic sodium salt that has chlorate as the counter-ion. An oxidising agent, it is used for bleaching paper and as a herbicide. It is also used in the manufacture of dyes, explosives and matches.		210chlorate salt;
inorganic sodium salt		herbicide
sodium acetate, anhydrous
Sodium Acetate: The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant.		1.9910organic sodium saltNMR chemical shift reference compound
sodium benzoate
Sodium Benzoate: The sodium salt of BENZOIC ACID. It is used as an antifungal preservative in pharmaceutical preparations and foods. It may also be used as a test for liver function.. sodium benzoate : An organic sodium salt resulting from the replacement of the proton from the carboxy group of benzoic acid by a sodium ion.		5.27111organic sodium saltalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
oxazolidine
oxazolidine: structure given in first source		2.0110oxazolidine
bromochloroacetic acid
Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.		6.144102-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound
11-mercaptoundecanoic acid
[no description available]		7.1710
n-isovalerylglycine
N-isovalerylglycine: urinary metabolite of isovaleric acid in isovaleric acidemia (sweaty feet syndrome). N-isovalerylglycine : An N-acylglycine in which the acyl group is specified as isovaleryl.		1.9610N-acylglycinehuman urinary metabolite
cinnamaldehyde
3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.		2.41103-phenylprop-2-enal;
cinnamaldehydes		antifungal agent;
EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor;
flavouring agent;
hypoglycemic agent;
plant metabolite;
sensitiser;
vasodilator agent
glycosides
[no description available]		6.99430
isomethyleugenol
Methylation: Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed)		12.631801isomethyleugenol
retinaldehyde
Retinaldehyde: A diterpene derived from the carotenoid VITAMIN A which functions as the active component of the visual cycle. It is the prosthetic group of RHODOPSIN (i.e., covalently bonded to ROD OPSIN as 11-cis-retinal). When stimulated by visible light, rhodopsin transforms this cis-isomer of retinal to the trans-isomer (11-trans-retinal). This transformation straightens-out the bend of the retinal molecule and causes a change in the shape of rhodopsin triggering the visual process. A series of energy-requiring enzyme-catalyzed reactions convert the 11-trans-retinal back to the cis-isomer.. all-trans-retinal : A retinal in which all four exocyclic double bonds have E- (trans-) geometry.		2.4120retinal;
vitamin A		gap junctional intercellular communication inhibitor;
human metabolite;
mouse metabolite
piperine
piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.		2.520benzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide		food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
squalene
Addavax: an oil-water nanoemulsion and adjuvant containing squalene, Tween 80, and sorbitane trioleate		1.9510triterpenehuman metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		6.83260stilbene
phenyl-n-tert-butylnitrone
phenyl-N-tert-butylnitrone: a spin-trapping agent		210
prolinol
prolinol: RN given refers to cpd without isomeric designation; structure. prolinol : An amino alcohol formed by reduction of the amino acid proline.		2.0610
flavin-adenine dinucleotide
Flavin-Adenine Dinucleotide: A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)		4.94370flavin adenine dinucleotide;
vitamin B2		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prosthetic group
3-hydroxybutyryl-coenzyme a
3-hydroxybutyryl-coenzyme A: RN given refers to cpd without isomeric designation. 3-hydroxybutanoyl-CoA : A hydroxybutanoyl-CoA having 3-hydroxybutanoyl as the S-acyl component.		2.46203-hydroxyacyl-CoA;
hydroxybutanoyl-CoA		mouse metabolite
malonyl coenzyme a
Malonyl Coenzyme A: A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.. omega-carboxyacyl-CoA : An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of any alpha,omega-dicarboxylic acid.		3.2660malonyl-CoAsEC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor;
Escherichia coli metabolite;
metabolite;
mouse metabolite
arginine vasopressin
Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.		2.9740vasopressincardiovascular drug;
hematologic agent;
mitogen
pyrophosphate
Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.		11.6220diphosphate ion
palmitoyl coenzyme a
Palmitoyl Coenzyme A: A fatty acid coenzyme derivative which plays a key role in fatty acid oxidation and biosynthesis.. palmitoyl-CoA : A long-chain fatty acyl-CoA resulting from the formal condensation of the carboxy group of hexadecanoic acid with the thiol group of coenzyme A.		5.6214011,12-saturated fatty acyl-CoA;
3-substituted propionyl-CoA;
long-chain fatty acyl-CoA;
palmitoyl bioconjugate		Escherichia coli metabolite;
mouse metabolite
tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine
tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine: a delta opioid antagonist		2.4620
dihydrosphingosine 1-phosphate
dihydrosphingosine 1-phosphate: RN given refers to (R-(R*,S*))-isomer. sphinganine 1-phosphate : A sphingoid 1-phosphate that is the monophosphorylated derivative of sphinganine.		2.4120sphingoid 1-phosphatemouse metabolite
triiodothyronine, reverse
[no description available]		2.41103,3',5'-triiodothyronine;
amino acid zwitterion
6-[(2-fluorophenyl)methyl]-2,4-dimethyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
[no description available]		2.4110organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
azidopine
azidopine: structure given in first source		210benzamides
methylacetylphosphonate
methylacetylphosphonate: inhibitor of pyruvate dehydrogenase complex, don't confuse with methyl acetylphosphonate		2.1710
glucobrassicin
glucobrassicin: isolated from Brussels sprouts; structure given in first source. glucobrassicin : An indolylmethylglucosinolic acid that is 1-thio-beta-D-glucopyranose having a 2-(1H-indol-3-yl)-N-(sulfooxy)ethanimidoyl group attached to the anomeric sulfur.		2.0110indolyl carbohydrate;
indolylmethylglucosinolic acid
methylatropine
methylatropine: RN given refers to endo-(+-)-isomer; structure in Negwer, 5th ed, #3766		6.9310
tropisetron
Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.		1.9710indolyl carboxylic acid
isopropyl thiogalactoside
Isopropyl Thiogalactoside: A non-metabolizable galactose analog that induces expression of the LAC OPERON.. isopropyl beta-D-thiogalactopyranoside : An S-glycosyl compound consisting of beta-D-1-thiogalactose having an isopropyl group attached to the anomeric sulfur.		3.2860S-glycosyl compound
leuprolide
Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.0510oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
fludarabine
[no description available]		2.4420purine nucleoside
propylthiouracil
Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.		2.7230pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
sesquiterpenes
[no description available]		5.06130
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		4.2960aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
methylthiouracil
Methylthiouracil: A thiourea antithyroid agent that inhibits the synthesis of thyroid hormone. It is used in the treatment of hyperthyroidism.		1.9410pyrimidone
3,3',4,5'-tetrahydroxystilbene
3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.		210catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
thioinosine
Thioinosine: Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503)		2.4620
caffeic acid
trans-caffeic acid : The trans-isomer of caffeic acid.		2.0710caffeic acidgeroprotector;
mouse metabolite
methyl caffeate
methyl caffeate: from plant Gaillardia pulchella. methyl caffeate : An alkyl caffeate ester formed by the formal condensation of caffeic acid with methyl alcohol.		2.3110alkyl caffeate ester;
methyl ester
n-acetyltryptophan
N-acetyl-L-tryptophan : A N-acetyl-L-amino acid that is the N-acetyl derivative of L-tryptophan.		2.6930L-tryptophan derivative;
N-acetyl-L-amino acid		metabolite
n-benzoylalanine
N-benzoylalanine: RN given refers to parent cpd (L-Ala)-isomer. N-benzoylalanine : An N-acylamino acid that is the N-benzoyl derivative of alanine.. N-benzoyl-L-alanine : An N-acyl-L-alanine resulting from the formal condensation of L-alanine with the carboxy group of benzoic acid.		1.9710N-acyl-L-alanine;
N-benzoylalanine		metabolite
phenylalanine methyl ester
phenylalanine methyl ester: RN given refers to (L)-isomer. methyl L-phenylalaninate : An alpha-amino acid ester that is the methyl ester of L-phenylalanine.		2.3920alpha-amino acid ester;
L-phenylalanine derivative
urocanic acid
Urocanic Acid: 4-Imidazoleacrylic acid.. urocanic acid : An alpha,beta-unsaturated monocarboxylic acid that is prop-2-enoic acid substituted by a 1H-imidazol-4-yl group at position 3. It is a metabolite of hidtidine.. trans-urocanic acid : A urocanic acid in which the double bond of the carboxyethene moiety has E configuration.		1.9810urocanic acidhuman metabolite
dieldrin
Dieldrin: An organochlorine insecticide whose use has been cancelled or suspended in the United States. It has been used to control locusts, tropical disease vectors, in termite control by direct soil injection, and non-food seed and plant treatment. (From HSDB). dieldrin : An organochlorine compound resulting from the epoxidation of the double bond of aldrin. It is the active metabolite of the proinsecticde aldrin.		2.6930epoxide;
organochlorine compound;
organochlorine insecticide		carcinogenic agent;
xenobiotic
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		4.5180aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
hc 030031
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide: a TRPA1 channel blocker		2.0810
benztropine
Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.		2.0310diarylmethane
5-methoxyuridine
5-methoxyuridine : A derivative of uridine, bearing an additional methoxy substituent at position 5 on the uracil ring.		1.9510uridines
penicillic acid
Penicillic Acid: A mycotoxin with antibiotic and carcinogenic activity produced by various strains of PENICILLIUM and ASPERGILLUS. It has been found in tobacco, sausages, and corn.		2.0110
thiouracil
Thiouracil: Occurs in seeds of Brassica and Crucifera species. Thiouracil has been used as antithyroid, coronary vasodilator, and in congestive heart failure although its use has been largely supplanted by other drugs. It is known to cause blood dyscrasias and suspected of terato- and carcinogenesis.. thiouracil : A nucleobase analogue that is uracil in which the oxo group at C-2 is replaced by a thioxo group.		1.9310nucleobase analogue;
thiocarbonyl compound		antithyroid drug;
metabolite
thiohydantoins
Thiohydantoins: Sulfur analogs of hydantoins with one or both carbonyl groups replaced by thiocarbonyl groups.		2.6330
urb 597
cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester: a fatty acid amide hydrolase inhibitor; structure in first source		2.0310biphenyls
sulindac
Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.		210monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		4.17160capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
coniferyl alcohol
coniferyl alcohol: structure. coniferol : A phenylpropanoid that is one of the main monolignols, produced by the reduction of the carboxy functional group in cinnamic acid and the addition of a hydroxy and a methoxy substituent to the aromatic ring.		1.9810guaiacols;
phenylpropanoid		animal metabolite;
monolignol;
mouse metabolite;
pheromone;
plant metabolite;
volatile oil component
cysteine sulfinic acid
3-sulfino-L-alanine : The organosulfinic acid arising from oxidation of the sulfhydryl group of L-cysteine.		2.0310organosulfinic acid;
S-substituted L-cysteine		Escherichia coli metabolite;
human metabolite;
metabotropic glutamate receptor agonist;
mouse metabolite
tosylarginine methyl ester
Tosylarginine Methyl Ester: Arginine derivative which is a substrate for many proteolytic enzymes. As a substrate for the esterase from the first component of complement, it inhibits the action of C(l) on C(4).		1.9610guanidines;
L-arginine ester;
methyl ester;
sulfonamide
n-glycylalanine
Gly-Ala : A dipeptide formed from glycine and L-alanine residues.		2.4820dipeptidemetabolite
(s-acetamidomethyl)cysteine
(S-acetamidomethyl)cysteine: RN given refers to parent cpd & (L)-isomer; RN for cpd without isomeric designation not avail 3/93		6.9810
oxazolone
Oxazolone: Immunologic adjuvant and sensitizing agent.		3.7930
chlorogenic acid
caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.		2.5720cinnamate ester;
tannin		food component;
plant metabolite
tg 003
TG 003: a Clk inhibitor; structure in first source		2.0210
threoninol
[no description available]		2.0410
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		2.34202-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
serine methyl ester
serine methyl ester: RN given for (HCl, (L)-isomer)		3.6690
thiosemicarbazide
thiosemicarbazide: glutamate decarboxylase antagonist; structure given in first source. hydrazinecarbothioamide : A member of the class of thioureas that is thiourea in which a hydrogen of one of the amino groups is replaced by an amino group.		2.2510hydrazines;
thiocarboxamide;
thioureas
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		8.69100one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
safranine t
safranin O : An organic chloride salt having 3,7-diamino-2,8-dimethyl-5-phenylphenazin-5-ium as the counterion. It is commonly used for staining Gram negative bacteria.		1.9810organic chloride saltfluorochrome;
histological dye
sodium propionate
sodium propionate: was term of propionic acid (1986-2006). sodium propionate : An organic sodium salt comprising equal numbers of sodium and propionate ions.		2.1310organic sodium saltantifungal drug;
food preservative
D-fructopyranose
[no description available]		7.86400cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
thioacetamide
Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.		7.0210thiocarboxamidehepatotoxic agent
5-doxylstearate
[no description available]		2.0310aminoxyls
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		2.7330cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
glycylvaline
glycylvaline: RN given refers to (DL)-isomer		2.730dipeptidehuman metabolite
o-methyl threonine
O-methyl threonine: RN given refers to cpd without isomeric designation. O-methyl-L-threonine : An L-threonine derivative that is L-threonine with a methyl group replacing the hydrogen on the hydroxy side chain.		1.9310ether;
L-threonine derivative;
non-proteinogenic L-alpha-amino acid		antibacterial agent;
bleaching agent
epsilon-tert-butyloxycarbonyl-lysine
epsilon-tert-butyloxycarbonyl-lysine: RN given refers to (L)-isomer		2.0510
capsazepine
capsazepine: modified capsaicin molecule; a capsaicin receptor antagonist. capsazepine : A benzazepine that is 2,3,4,5-tetrahydro-1H-2-benzazepine which is substituted by hydroxy groups at positions 7 and 8 and on the nitrogen atom by a 2-(p-chlorophenyl)ethylaminothiocarbonyl group. A synthetic analogue of capsaicin, it was the first reported capsaicin receptor antagonist.		2.0710benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
fumonisin b1
fumonisin B1: isolated from Fusarium moniliforme MRC 826; structure given in first source; has cancer-promoting activity; inhibits ceramide synthase. fumonisin B1 : A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol.		3.2460diester;
fumonisin;
primary amino compound;
triol		carcinogenic agent;
metabolite
fumonisin b2
fumonisin B2: produced by Fusarium moniliforme MRC 826; structure given in first source; has cancer-promoting ability. fumonisin B2 : A fumonisin that is (2S,3S,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,14,15-triol in which the hydroxy groups at positions 14 and 15 have each been esterified by condensation with the 1-carboxy group of 3-carboxyglutaric acid (giving a 3-carboxyglutarate ester group with R configuration in each case).		1.9810diester;
diol;
fumonisin;
primary amino compound		Aspergillus metabolite;
carcinogenic agent
tamoxifen
[no description available]		10.69434stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
4-methylumbelliferyl glucoside
4-methylumbelliferyl glucoside: RN given refers to (beta)-isomer. 4-methylumbelliferyl beta-D-glucoside : A beta-D-glucoside having a 4-methylumbelliferyl substituent at the anomeric position.		1.9910beta-D-glucoside;
coumarins;
monosaccharide derivative		chromogenic compound
nadp
[no description available]		7.041040
scandium triflate
scandium triflate: structure in first source		2.2510
8-azidoadenosine 5'-triphosphate
[no description available]		1.9910
ethionamide
Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.		2.110pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
1-pyrenebutanol
1-pyrenebutanol: a fluorescent substrate of P450eryF; structure in first source		2.0210
srpin340
SRPIN340: Serine-Arginine-Rich Protein Kinase Inhibitor		2.4110
sc 514
SC 514: inhibits IkappaB kinase-2; structure in first source		2.0210ring assembly;
thiophenes
3'-o-(n-methylanthraniloyl)adenosine 5'-diphosphate
3'-O-(N-methylanthraniloyl)adenosine 5'-diphosphate : A purine ribonucleoside 5'-diphosphate that is ADP substituted at position 3' by an N-methylanthraniloyl group.		2.0210purine ribonucleoside 5'-diphosphate
methyl-thiohydantoin-tryptophan
methyl-thiohydantoin-tryptophan: structure in first source		2.3110organonitrogen compound;
organooxygen compound
kl001
KL001: inhibits degradation of the cryptochrome; structure in first source		2.1110
lincomycin
Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.		2.6330carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
valinomycin
Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.		4.4670cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
thiopental
Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		3.3811barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic
u 0126
U 0126: protein kinase kinase inhibitor; structure in first source		5.08410aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
laccase
Laccase: A copper-containing oxidoreductase enzyme that catalyzes the oxidation of 4-benzenediol to 4-benzosemiquinone. It also has activity towards a variety of O-quinols and P-quinols. It primarily found in FUNGI and is involved in LIGNIN degradation, pigment biosynthesis and detoxification of lignin-derived products.		2.0110
glycylproline
Gly-Pro : A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.		2.420dipeptide zwitterion;
dipeptide		metabolite
6-methyl-2-(phenylethynyl)pyridine
6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.		2.9540acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
lithium
Lithium: An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.		5.01400alkali metal atom
deacylcortivazol
deacylcortivazol: acts through glucocorticoid receptors; structure given in first source		1.9910
cobaltous chloride
cobaltous chloride: RN given refers to unlabeled cpd; RN in Chemline for cobalt trichloride: 10241-04-0; RN for 60-labeled cpd: 14543-09-0; RN for 57-labeled cpd: 164113-89-1; RN for 58-labeled cpd: 29377-09-1; structure. cobalt dichloride : A cobalt salt in which the cobalt metal is in the +2 oxidation state and the counter-anion is chloride. It is used as an indicator for water in desiccants.		2.9640cobalt salt;
inorganic chloride		allergen;
calcium channel blocker;
sensitiser;
two-colour indicator
nitrogen dioxide
Nitrogen Dioxide: Nitrogen oxide (NO2). A highly poisonous gas. Exposure produces inflammation of lungs that may only cause slight pain or pass unnoticed, but resulting edema several days later may cause death. (From Merck, 11th ed) It is a major atmospheric pollutant that is able to absorb UV light that does not reach the earth's surface.		6.9810nitrogen oxide
thiouridine
Thiouridine: A photoactivable URIDINE analog that is used as an affinity label.. 4-thiouridine : A thiouridine in which the oxygen replaced by sulfur is that at C-4.		1.9410nucleoside analogue;
thiouridine		affinity label;
antimetabolite
dermatan sulfate
Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.		4.5780amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
hydroxylysine
Hydroxylysine: A hydroxylated derivative of the amino acid LYSINE that is present in certain collagens.. hydroxylysine : A hydroxy-amino acid in which the amino acid specified is lysine. A "closed" class.. erythro-5-hydroxy-L-lysine : A 5-hydroxylysine consisting of L-lysine having an (R)-hydroxy group at the 5-position.. 5-hydroxylysine : A hydroxylysine that is lysine substituted by a hydroxy group at position 5.		10.17905-hydroxylysine;
hydroxy-L-lysine		human metabolite
raclopride
Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.		2.4220salicylamides
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		3.150beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine
[no description available]		2.7330cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester
[no description available]		3.4170
deltorphin
deltorphin: isolated from skin of Phyllomedusa sauvagei; has affinity to opioid receptor; note deltorphin I and deltorphin II are available, they have Ala in position 2		2.4220peptide
rtki cpd
RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors		2.4220
n-(4-azido-2,3,5,6-tetrafluorobenzyl)-3-maleimidopropionamide
N-(4-azido-2,3,5,6-tetrafluorobenzyl)-3-maleimidopropionamide: structure given in first source; a heterobifunctional photo-cross-linker		210
8-bromoguanosino-3',5'-cyclic monophosphorothioate
[no description available]		2.4420
phorbol 12-phenylacetate 13-acetate 20-homovanillate
phorbol 12-phenylacetate 13-acetate 20-homovanillate: behavior contrasts with resiniferatoxin and capsaicin in the lack of cooperativity in binding vanilloid (capsaicin) receptor		2.0210
cystine
[no description available]		11.241812
u-50488
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine		1.9810dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine		analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist
sch 23390
SCH 23390: a selective D1-receptor antagonist. SCH 23390 : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 7 and a hydroxy substituent at position 8.		2.4720benzazepine
tandutinib
[no description available]		2.0310aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
safingol
safingol: RN given refers to the (R-(R*,S*))-isomer		4.39210amino alcohol
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		2.8301,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
ha 1100
HA 1100: intracellular calcium antagonist		1.9910
neboglamine
neboglamine: potential memory enhancer		2.4220
oxalylglycine
oxalylglycine: structure given in first source. N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes.		1.9810amino dicarboxylic acid;
N-acylglycine		EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor
4-amino-4-deoxyarabinose
[no description available]		2.0210
2,3,4-tri-o-acetylarabinopyranosyl isothiocyanate
2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate: RN given refers to (alpha-D)-isomer		2.1110
peptide t amide
peptide T amide: octapeptide segment of HIV envelope gp120; used in AIDS therapy		2.1310
inositol 1,4,6-trisphosphate
inositol 1,4,6-trisphosphate: inhibits (1,4,5)P3/(1,3,4,5)P4-polyphosphate 5-phosphatase; structure in first source. 1D-myo-inositol 3,4,6-trisphosphate : A myo-inositol trisphosphate having the three phosphate groups at the 3-, 4-, and 6-positions.		2.0310myo-inositol trisphosphate
dipalmitoylphosphatidylserine
[no description available]		7.0110phosphatidyl-L-serine
apramycin
apramycin : An aminoglycoside that is 2-deoxystreptamine that is substituted on the oxygen at position 4 by an (8R)-2-amino-8-O-(4-amino-4-deoxy-alpha-D-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-D-glycero-alpha-D-allo-octodialdo-1,5:8,4-dipyranos-1-yl) group.		2.03102-deoxystreptamine derivative;
aminoglycoside;
organic heterobicyclic compound		antibacterial drug;
antimicrobial agent
calixarenes
Calixarenes: Phenolic metacyclophanes derived from condensation of PHENOLS and ALDEHYDES. The name derives from the vase-like molecular structures. A bracketed [n] indicates the number of aromatic rings.. calixarenes : Originally macrocyclic compounds capable of assuming a basket (or "calix") shaped conformation. They are formed from p-hydrocarbyl phenols and formaldehyde. The term now applies to a variety of derivatives by substitution of the hydrocarbon cyclo{oligo[(1,3-phenylene)methylene]}.. calixarene : A macrocycle composed of 1,3-phenylene groups linked by methylene groups. The number of 1,3-phenylene units in the macrocycle is denoted by the "n" in calix[n]arene name.		3.3510
18-crown-6 2,3,11,12-tetracarboxylic acid
18-crown-6 2,3,11,12-tetracarboxylic acid: structure in first source; RN given for (2R*,3R*,11*,12*)-isomer		2.0310
xylose-glucose
[no description available]		1.9710
mycobactin
mycobactins: cell wall iron transporting growth factor from Mycobacterium tuberculosis		210
albomycin
albomycin: iron containing antibiotic. albomycin : A mixture of iron(III) hydroxamate antibiotics produced by various Streptomyces species (e.g. Streptomyces subtropicus) and consisting of iron(III) complexed to pentapeptide trihydroxamate siderophores.		2.0510
olivomycins
Olivomycins: A mixture of several closely related glycosidic antibiotics obtained from Actinomyces (or Streptomyces) olivoreticuli. They are used as fluorescent dyes that bind to DNA and prevent both RNA and protein synthesis and are also used as antineoplastic agents.		2.3520
cytellin
cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982		2.0810
phosphonic acid
phosphonic acid : A phosphorus oxoacid that consists of a single pentavalent phosphorus covalently bound via single bonds to a single hydrogen and two hydroxy groups and via a double bond to an oxygen. The parent of the class of phosphonic acids.		7.2110
salinomycin
salinomycin: from Streptomyces albus; RN given refers to parent cpd; structure		2.1310polyketide;
spiroketal		animal growth promotant;
potassium ionophore
ginsenosides
ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.		7.9740
phosphothreonine
Phosphothreonine: The phosphoric acid ester of threonine. Used as an identifier in the analysis of peptides, proteins, and enzymes.. O-phospho-L-threonine : A L-threonine derivative phosphorylated at the side-chain hydroxy function.		6.5600L-threonine derivative;
non-proteinogenic L-alpha-amino acid;
O-phosphoamino acid		Escherichia coli metabolite
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline: structure given in first source; neuroprotectant for cerebral ischemia; AMPA receptor antagonist		3.5480naphthalenes;
sulfonic acid derivative
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		4.67290
serine ethanolamine phosphate
serine ethanolamine phosphate: found in lens of cod and haddock; RN given refers to (L)-isomer; structure		3.5590amino acid zwitterion;
non-proteinogenic alpha-amino acid;
O-phosphoamino acid;
phosphoethanolamine;
serine derivative
sb 218078
[no description available]		2.0610indolocarbazole
nafadotride
nafadotride: structure given in first source. nafadotride : A naphthalenecarboxamide resulting from the formal condensation of the carboxylic acid group of 4-cyano-1-methoxynaphthalene-2-carboxylic acid with the primary amino group of 1-(1-butylpyrrolidin-2-yl]methanamine. It is a highly potent, competitive, preferential dopamine D3 receptor antagonist, centrally active upon systemic administration.		2.0510aromatic ether;
naphthalenecarboxamide;
nitrile;
pyrrolidines;
tertiary amino compound		dopaminergic antagonist
sodium dodecyl sulfate
Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.		5.12460organic sodium saltdetergent;
protein denaturant
sto 609
STO 609: structure in first source		2.4420naphthoic acid
blister
blebbistatin: structure in first source. blebbistatin : A pyrroloquinoline that is 1,2,3,3a-tetrahydro-H-pyrrolo[2,3-b]quinolin-4-one substituted by a hydroxy group at position 3a, a methyl group at position 6 and a phenyl group at position 1. It acts as an inhibitor of ATPase activity of non-muscle myosin II.		2.1310cyclic ketone;
pyrroloquinoline;
tertiary alcohol;
tertiary alpha-hydroxy ketone		inhibitor
chloramine-t
chloramine-T: RN given refers to unlabeled parent cpd. chloramine T : An organic sodium salt derivative of toluene-4-sulfonamide with a chloro substituent in place of an amino hydrogen.		7.3520organic sodium saltallergen;
antifouling biocide;
disinfectant
2-chloro-5-hydroxyphenylglycine
2-chloro-5-hydroxyphenylglycine: activates mGlu(5) receptors; structure in first source		2.0210
6-cyano-7-nitroquinoxaline-2,3-dione
6-Cyano-7-nitroquinoxaline-2,3-dione: A potent excitatory amino acid antagonist with a preference for non-NMDA iontropic receptors. It is used primarily as a research tool.		3.82110quinoxaline derivative
2,4-dinitrophenylhydrazine
2,4-dinitrophenylhydrazine: structure. 2,4-dinitrophenylhydrazine : A C-nitro compound that is phenylhydrazine substituted at the 2- and 4-positions by nitro groups.		2.3820C-nitro compound;
phenylhydrazines		reagent
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3h)-quinazolinone
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone: a mitochondrial division inhibitor		2.520
fg 9041
FG 9041: structure given in first source		2.6730quinoxaline derivative
homoserine lactone
homoserine lactone: a putative signal for starvation in E. coli; structure in first source. homoserinium lactone : The conjugate acid of homoserine lactone; major species at pH 7.3.. homoserine lactone : A butan-4-olide having an amino substituent at the 2-position.		7.4820ammonium ion derivative;
organic cation
alpha-chymotrypsin
Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.		9.092270
4-(3-isothiocyanatopyrrolidin-1-yl)-7-(n,n-dimethylaminosulfonyl)-2,1,3-benzoxadiazole
4-(3-isothiocyanatopyrrolidin-1-yl)-7-(N,N-dimethylaminosulfonyl)-2,1,3-benzoxadiazole: structure in first source		2.1310
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.		2.0610benzenes;
thiadiazolidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
2-amino-3-phenylmethoxybutanedioic acid
[no description available]		2.0310aspartic acid derivative
sb 415286
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source		2.7330C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline		antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		3.6190
sc 560
SC560 : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors, SC-560 is selective for COX-1.		2.0110aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug
sodium borohydride
sodium borohydride: RN given refers to parent cpd		2.420inorganic sodium salt;
metal tetrahydridoborate
seryl-proline
Ser-Pro : A dipeptide formed from L-serine and L-proline residues.		2.4220dipeptidemetabolite
osteoprotegerin
Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.		2.0110long-chain fatty acid
cathepsin g
Cathepsin G: A serine protease found in the azurophil granules of NEUTROPHILS. It has an enzyme specificity similar to that of chymotrypsin C.		3.830
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol: (-)-CP-55,940 and (+)-CP-56,667 are enantiomers; RN refers to CP-55,940		2.7230alkylbenzene;
ring assembly
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor		2.4920benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
myelin basic protein
Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.		4.55250
sulfosuccinimidyl 6-(biotinamido)hexanoate
[no description available]		2.0410
tcn 201
[no description available]		2.0710
alsterpaullone
alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.		2.0310C-nitro compound;
caprolactams;
organic heterotetracyclic compound		anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
4-nitrobenzohydroxamic acid
4-nitrobenzohydroxamic acid: structure in first source		2.0510
4,5,6,7-tetrabromobenzimidazole
4,5,6,7-tetrabromobenzimidazole: structure in first source		2.0810
n-octyl-5-dithio-2-nitrobenzoic acid
n-octyl-5-dithio-2-nitrobenzoic acid: used for determination & derivatization of protein thiols; interacts with SH-groups in the transmembrane domain of transport proteins; structure given in first source		1.9810
methanethiosulfonate
methanethiosulfonate: used for measurement of rhodanese activity; RN given refers to parent cpd		2.9240
diethyl maleate
diethyl maleate : A maleate ester resulting from the formal condensation of both carboxy groups of maleic acid with ethanol. A colourless liquid at room temperature (m.p. -10degreeC) with boiling point 220degreeC at 1 atm., it is commonly used as a dienophile for Diels-Alder-type cycloaddition reactions in organic synthesis.		2.3720ethyl ester;
maleate ester		glutathione depleting agent
isoliensinine
isoliensinine: isolated from the Chinese herbal medicine lotus plumule; structure in first source		2.1310isoquinolines
ku 55933
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source		3.1950
sphingosine
sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.		11.58932sphing-4-eninehuman metabolite;
mouse metabolite
quercetin
[no description available]		3.69907-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
bilirubin
[no description available]		2.9440biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		4.46220prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprost
Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.		2.0310monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
leukotriene a4
Leukotriene A4: (2S-(2 alpha,3 beta(1E,3E,5Z,8Z)))-3-(1,3,5,8-Tetradecatetraenyl)oxiranebutanoic acid. An unstable allylic epoxide, formed from the immediate precursor 5-HPETE via the stereospecific removal of a proton at C-10 and dehydration. Its biological actions are determined primarily by its metabolites, i.e., LEUKOTRIENE B4 and cysteinyl-leukotrienes. Alternatively, leukotriene A4 is converted into LEUKOTRIENE C4 by glutathione-S-transferase or into 5,6-di-HETE by the epoxide-hydrolase. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene A4 : A leukotriene that is the (5S,6S)-epoxy derivative of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid.		2.1310epoxy fatty acid;
leukotriene;
long-chain fatty acid;
oxylipin;
polyunsaturated fatty acid		human metabolite;
mouse metabolite;
plant metabolite
arachidonyltrifluoromethane
arachidonyltrifluoromethane: structure given in first source; inhibits 85-kDa phospholipase A2. AACOCF3 : A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group		2.420fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound		EC 3.1.1.4 (phospholipase A2) inhibitor
apigenin
Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.		3.1350trihydroxyflavoneantineoplastic agent;
metabolite
luteolin
[no description available]		3.01403'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
linoleic acid
Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.		5.05130octadecadienoic acid;
omega-6 fatty acid		algal metabolite;
Daphnia galeata metabolite;
plant metabolite
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		3.78110D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
vitamin k semiquinone radical
vitamin K semiquinone radical: found in active preparations of vitamin K-dependent carboxylase. vitamin K : Any member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.		5.77170
beta carotene
beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.		2.610carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
11-cis-retinal
Rhodopsin: A purplish-red, light-sensitive pigment found in RETINAL ROD CELLS of most vertebrates. It is a complex consisting of a molecule of ROD OPSIN and a molecule of 11-cis retinal (RETINALDEHYDE). Rhodopsin exhibits peak absorption wavelength at about 500 nm.. 11-cis-retinal : A retinal having 2E,4Z,6E,8E-double bond geometry.		4.72290retinalchromophore;
human metabolite;
mouse metabolite
leukotriene b4
Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.		9.4480dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
leukotriene c4
Leukotriene C4: The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some VASCULAR SMOOTH MUSCLE. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene C4 : A leukotriene that is (5S,7E,9E,11Z,14Z)-5-hydroxyicosa-7,9,11,14-tetraenoic acid in which a glutathionyl group is attached at position 6 via a sulfide linkage.		8.88120leukotrienebronchoconstrictor agent;
human metabolite;
mouse metabolite
thromboxane a2
Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.		2.9540epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite
retinol palmitate
retinol palmitate: RN given refers to parent cpd; structure. retinyl palmitate : A palmitate ester of retinol with undefined geometry about the C=C bonds.. all-trans-retinyl palmitate : An all-trans-retinyl ester obtained by formal condensation of the carboxy group of palmitic (hexadecanoic acid) with the hydroxy group of all-trans-retinol. It is used in cosmetic products to treat various skin disorders such as acne, skin aging, wrinkles, dark spots, and also protect against psoriasis.		1.9910all-trans-retinyl ester;
retinyl palmitate		antioxidant;
Escherichia coli metabolite;
human xenobiotic metabolite
hymecromone
Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.		1.9910hydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
8,11,14-eicosatrienoic acid
8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.		2.4220fatty acid 20:3;
long-chain fatty acid		fungal metabolite;
human metabolite;
nutraceutical
furylfuramide
Furylfuramide: Used formerly as antimicrobial food additive. It causes mutations in many cell cultures and may be carcinogenic.. (Z)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide : A member of the class of acrylamides that is acrylamide which is substituted at positions 2 and 3 by 2-furyl and 5-nitro-2-furyl groups, respectively (the trans isomer). Formerly used as a food preservative, it was withdrawn from the market following suspicions of carcenogenicity.		1.9910acrylamides;
C-nitro compound;
nitrofuran antibiotic;
primary carboxamide
alprostadil
[no description available]		3.3970prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
vitamin d 2
Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.		1.9410hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
cholecalciferol
Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.		2.3720D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
quercetin 3-o-glucopyranoside
quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells		2.4110beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone		antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite
rutin
Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.		7.4420disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
kaempferol
[no description available]		2.13107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
leukotriene d4
Leukotriene D4: One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene D4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R).		3.3870dipeptide;
leukotriene;
organic sulfide		bronchoconstrictor agent;
human metabolite;
mouse metabolite
leukotriene e4
Leukotriene E4: A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene E4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R).		3.84120amino dicarboxylic acid;
L-cysteine thioether;
leukotriene;
non-proteinogenic L-alpha-amino acid;
secondary alcohol
6-ketoprostaglandin f1 alpha
6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.		1.9710prostaglandins Falphahuman metabolite;
mouse metabolite
lipoxin a4
lipoxin A4: an antifibrolytic agent; structure given in first source; a role in ASPIRIN antiinflammatory activity. lipoxin A4 : A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.		9.0850hydroxy polyunsaturated fatty acid;
lipoxin;
long-chain fatty acid		human metabolite;
metabolite
gamma-linolenic acid
gamma-Linolenic Acid: An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed). gamma-linolenic acid : A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12.		1.9910linolenic acid;
omega-6 fatty acid		human metabolite;
mouse metabolite;
plant metabolite
alpha-linolenic acid
linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.		2.610linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		2.4120harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
genistein
[no description available]		5.52107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.0110antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
clavulanic acid
Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.		3.9120oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
erucic acid
[no description available]		2.0110docosenoic acid
tentoxin
tentoxin: cyclic peptide from fungus Alternaria tenuis Auct.; structure		2.0110lactam
jasmonic acid
jasmonic acid: a derivative of alpha-linolenic acid that has a role in plant response to herbivory analogous to the role of prostanoids in inflammation in mammals;. jasmonic acid : An oxo monocarboxylic acid that is (3-oxocyclopentyl)acetic acid substituted by a (2Z)-pent-2-en-1-yl group at position 2 of the cyclopentane ring.		2.0310oxo monocarboxylic acidjasmonates;
plant metabolite
astaxanthine
astaxanthine: a keto form of carotene; pigment in flesh of Scottish salmon (Salmo salar) crustacoa-lobster (Homarus gammarus, flamingo feathers; structure; a carotenoid without vitamin A activity, has shown anti-oxidant and anti-inflammatory activities. astaxanthin : A carotenone that consists of beta,beta-carotene-4,4'-dione bearing two hydroxy substituents at positions 3 and 3' (the 3S,3'S diastereomer). A carotenoid pigment found mainly in animals (crustaceans, echinoderms) but also occurring in plants. It can occur free (as a red pigment), as an ester, or as a blue, brown or green chromoprotein.		2.0710carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite
lutein
Lutein: A xanthophyll found in the major LIGHT-HARVESTING PROTEIN COMPLEXES of plants. Dietary lutein accumulates in the MACULA LUTEA.. xanthophyll : A subclass of carotenoids consisting of the oxygenated carotenes.		1.9410carotenolfood colouring;
plant metabolite
cucurbitacin i
cucurbitacin I: toxic constituent in edible gourd; see also records for cucurbitacins & specific cucurbitacins. cucurbitacin I : A cucurbitacin that is 9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene substituted by hydroxy groups at positions 2, 16, 20 and 25 and oxo groups at positions 1, 11 and 22.		2.0310cucurbitacin;
tertiary alpha-hydroxy ketone		antineoplastic agent;
plant metabolite
mezerein
mezerein: toxic component of plant Daphne mezereum with anti-leukemic activity against P-388 & P-1210 in mice; can act as a tumor promoter; RN given refers to (12beta(E,E))-isomer; structure		1.9610diterpenoid
humulene
humulene: structure given in first source. (1E,4E,8E)-alpha-humulene : The (1E,4E,8E)-isomer of alpha-humulene.		2.4820alpha-humulene
baicalein
[no description available]		2.9610trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
chrysin
chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.		2.11107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
diosmin
[no description available]		2.0510dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant
fisetin
[no description available]		2.76203'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
mangiferin
shamimin: isolated from the leaves of Bombax ceiba; structure in first source		7.920C-glycosyl compound;
xanthones		anti-inflammatory agent;
antioxidant;
hypoglycemic agent;
plant metabolite
myricetin
[no description available]		2.41107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
scutellarein
scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.		2.4110tetrahydroxyflavonemetabolite
wogonin
wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.		2.4110dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
polydatin
trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.		2.4110beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator
pterostilbene
[no description available]		2.4110diether;
methoxybenzenes;
stilbenol		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger
chicoric acid
chicoric acid: inhibits HIV-1 integrase		2.4110organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor
iridin
iridin : A glycosyloxyisoflavone that is irigenin substituted by a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage.		2.41104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
caffeic acid phenethyl ester
phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.		2.7330alkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent
rosmarinic acid
rosmarinic acid: RN given refers to parent cpd; promote OT project. (R)-rosmarinic acid : A stereoisomer of rosmarinic acid having (R)-configuration.. rosmarinic acid : The 1-carboxy-2-(2,4-dihydroxyphenyl)ethyl ester of trans-caffeic acid.		2.0210rosmarinic acidgeroprotector;
plant metabolite
acteoside
acteoside: a protein kinase C inhibitor with hepatoprotective, anti-asthmatic, and analgesic activities; a phenylethanoid glycoside related to isoacteoside; from leaves of Lippia multiflora (Verbenaceae). acteoside : A glycoside that is the alpha-L-rhamnosyl-(1->3)-beta-D-glucoside of hydroxytyrosol in which the hydroxy group at position 4 of the glucopyranosyl moiety has undergone esterification by formal condensation with trans-caffeic acid.		2.3110catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite
rottlerin
rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.		3.6390aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
7-hydroxyflavone
7-hydroxyflavone : A hydroxyflavonoid in which the flavone nucleus is substituted at position 7 by a hydroxy group.		2.4110hydroxyflavonoid
soraphen a
[no description available]		2.0510cyclic hemiketal;
ether;
macrolide;
olefinic compound		bacterial metabolite;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
teratogenic agent
anandamide
anandamide : An N-acylethanolamine 20:4 resulting from the formal condensation of carboxy group of arachidonic acid with the amino group of ethanolamine.		3.0740endocannabinoid;
N-acylethanolamine 20:4		human blood serum metabolite;
neurotransmitter;
vasodilator agent
thiocillin
thiocillin: closely related to microccin P; RN given refers to mono-Na salt(2S-(2alpha,5alpha,6beta(Z)))-isomer		2.0510azamacrocycle;
lactam
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		2.3920epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
l 683590
immunomycin: from Streptomyces hygroscopicus; structure given in first source		210ether;
lactol;
macrolide;
secondary alcohol		antifungal agent;
bacterial metabolite;
immunosuppressive agent
cilnidipine
[no description available]		2.06102-methoxyethyl ester;
C-nitro compound;
dihydropyridine		antihypertensive agent;
calcium channel blocker;
cardiovascular drug
7432 s
Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.		210cephalosporin;
dicarboxylic acid		antibacterial drug
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid
4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: A non-penetrating amino reagent (commonly called SITS) which acts as an inhibitor of anion transport in erythrocytes and other cells.		2.8940stilbenoid
glyceryl 2-arachidonate
glyceryl 2-arachidonate: binds to cannabinoid receptors; structure in first source. 2-arachidonoylglycerol : An endocannabinoid and an endogenous agonist of the cannabinoid receptors (CB1 and CB2). It is an ester formed from omega-6-arachidonic acid and glycerol.		2.11102-acylglycerol 20:4;
endocannabinoid		human metabolite
1-palmitoyl-2-oleoylphosphatidylethanolamine
1-palmitoyl-2-oleoylphosphatidylethanolamine: RN given refers to (Z)-isomer; RN for cpd without isomeric designation not available 12/88. 1-palmitoyl-2-oleoyl phosphatidylethanolamine : A phosphatidylethanolamine in which the phosphatidyl acyl groups at C-1 and C-2 are palmitoyl and oleoyl respectively.		2.4720(18R,21S)-24-amino-21-hydroxy-21-oxido-15-oxo-16,20,22-trioxa-21lambdalambda(5)-phosphatetracosan-18-yl icosanoate;
phosphatidylethanolamine
1-palmitoyl-2-oleoylglycero-3-phosphoglycerol
[no description available]		2.1510phosphatidylglycerol
tocotrienol, delta
delta-tocotrienol : A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2 and 8 and a farnesyl chain at position 2.		2.610tocotrienol;
vitamin E		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
NF-kappaB inhibitor;
plant metabolite;
radiation protective agent;
Saccharomyces cerevisiae metabolite
4-hydroxyestradiol
4-hydroxyestradiol: catechol estrogen. 4-hydroxy-17beta-estradiol : A 4-hydroxy steroid that consists of 17beta-estradiol having an additional hydroxy group at position 4.		2.21104-hydroxy steroidmetabolite
fondaparinux
Fondaparinux: Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.. fondaparinux : A synthetic pentasaccharide which, apart from the O-methyl group at the reducing end of the molecule, consists of monomeric sugar units which are identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycans heparin and heparan sulfate.		2.0510amino sugar;
oligosaccharide sulfate;
pentasaccharide derivative		anticoagulant
pitavastatin
pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.		2.0210cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
zinostatin
Zinostatin: An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic.		2.0310
11-deoxyprostaglandin e1
11-deoxyprostaglandin E1: RN given refers to (13E,15S)-isomer		2.0510prostanoid
16,16-dimethylprostaglandin e2
16,16-Dimethylprostaglandin E2: A synthetic prostaglandin E analog that protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers. The protective effect is independent of acid inhibition. It is also a potent inhibitor of pancreatic function and growth of experimental tumors.. 16,16-dimethylprostaglandin E2 : A prostanoid that is prostaglandin E2 in which both of the hydrogens at position 16 have been replaced by methyl groups. A synthetic analogue of prostaglandin E2, it is a potent inhibitor of pancreatic function and growth of experimental tumors. It also protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers.		1.9610cyclopentanones;
monocarboxylic acid;
prostanoid;
secondary allylic alcohol		anti-ulcer drug;
gastrointestinal drug;
radiation protective agent
thromboxane b2
Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.		1.9910thromboxanes Bhuman metabolite;
mouse metabolite
20-hydroxy-5,8,11,14-eicosatetraenoic acid
20-hydroxy-5,8,11,14-eicosatetraenoic acid: stimulator of renal sodium, potassium atpase; RN given is for the (all-Z) isomer. 20-HETE : A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 20.		2.9940HETE;
hydroxy monocarboxylic acid		human metabolite;
mouse metabolite
8,9-epoxyeicosatrienoic acid
8,9-epoxyeicosatrienoic acid: RN given refers to cpd without isomeric designation. 8,9-EET : An EET obtained by formal epoxidation of the 8,9-double bond of arachidonic acid.		2.0310EETmouse metabolite
4-hydroxy-2-nonenal
4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.		2.94404-hydroxynon-2-enal;
4-hydroxynonenal
oleylamide
oleylamide: plastic additive; can cause contact urticaria; RN given refers to (Z)-isomer; a sleep inducing factor. aliphatic amide : A carboxamide in which the amide linkage is bonded directly to an aliphatic system.. oleamide : A fatty amide derived from oleic acid.		2.0810primary fatty amidehuman metabolite;
plant metabolite
n-arachidonylglycine
N-arachidonylglycine: structure in first source. N-arachidonoylglycine : Biologically active derivative of anandamide		2.4620fatty amide;
N-acylglycine
1-monooleoyl-rac-glycerol
Peceol: lipid excipient containing readily dispersible mixture of mono- & diglycerides of oleic acid. 1-oleoylglycerol : A 1-monoglyceride where the acyl group is oleoyl.. monooleoylglycerol : A monoglyceride in which the acyl group is oleoyl with the position of acylation unspecified.		2.31101-acylglycerol 18:1;
monooleoylglycerol		plant metabolite
menaquinone 6
menaquinone 6: RN given refers to (all-E)-isomer		2.0210
sphingosine 1-phosphate
sphingosine 1-phosphate: RN given refers to (R-(R*,S*-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1		3.6690sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
ceramide 1-phosphate
ceramide 1-phosphate : A phosphosphingolipid consisting of any ceramide phosphorylated at position 1. N-octadecanoylsphingosine 1-phosphate : A ceramide 1-phosphate that is the N-octadecananoyl (stearoyl) derivative of sphingosine.		2.0110N-acylsphingosine 1-phosphate
phenylephrine hydrochloride
Nose: A part of the upper respiratory tract. It contains the organ of SMELL. The term includes the external nose, the nasal cavity, and the PARANASAL SINUSES.. phenylephrine hydrochloride : A hydrochloride that is the monohydrochloride salt of phenylephrine.		3.9640hydrochloride
3-amino-1-methyl-5h-pyrido(4,3-b)indole
3-amino-1-methyl-5H-pyrido(4,3-b)indole: structure		1.9610pyridoindole
4-dimethylaminocinnamaldehyde
[no description available]		1.9710cinnamaldehydes
hydromorphone
Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.		1.9510morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
ly 163892
loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.		2.1310carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nalorphine
Nalorphine: A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete.		2.3520morphinane alkaloid
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		3.81110morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
vitamin k 1
Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.		2.4320phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		5.89940antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
3',4',7-trihydroxyisoflavone
3',4',7-trihydroxyisoflavone: from Streptomyces sp OH-1049; structure given in first source. 3',4',7-trihydroxyisoflavone : A 7-hydroxyisoflavone that is daidzein substituted by a hydroxy group at position 3'.		2.05107-hydroxyisoflavonesantineoplastic agent;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor;
metabolite
gamma-cyclodextrin
gamma-cyclodextrin : A cycloamylose composed of eight alpha-(1->4) linked D-glucopyranose units.		710cyclodextrin
brefeldin a
[no description available]		3.79110macrolide antibioticPenicillium metabolite
alvocidib
alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.		3.1450dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fenretinide
Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.		2.0510monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
ic 261
IC 261: a caseine kinase-1 inhibitor; structure in first source		2.4320
n-methylalanine
N-methylalanine: RN given refers to parent cpd(DL-Ala)-isomer. methyl-L-alanine : Any alanine derivative that is L-alanine having one or more methyl groups attached to the amino group.. N-methyl-L-alanine : A methyl-L-alanine in which one of the the amino hydrogen of L-alanine is replaced by a methyl group.		2.0610amino acid zwitterion;
methyl-L-alanine
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		4.84330morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
pactamycin
Pactamycin: Antibiotic produced by Streptomyces pactum used as an antineoplastic agent. It is also used as a tool in biochemistry because it inhibits certain steps in protein synthesis.		1.9510
4-aminocrotonic acid
[no description available]		2.0110
acipimox
acipimox: lipolysis inhibitor		2.1110pyrazinecarboxylic acid
bay u9773
BAY u9773: a leukotriene C4 antagonist. BAYu9773 : A dicarboxylic acid that is that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 4S and a (4-carboxyphenyl)sulfanediyl group at 5R. It is a dual cysteinyl leukotriene receptor antagonist that acts at the CysLT1 and CysLT2 receptors (IC50 = 0.44 and 0.30 muM, respectively).		210benzoic acids;
dicarboxylic acid;
organic sulfide;
polyunsaturated fatty acid;
secondary alcohol		leukotriene antagonist
istradefylline
[no description available]		2.0310oxopurine
cicaprost
cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))-isomer		2.7130monoterpenoid
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		3.1450heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
dexmedetomidine
[no description available]		2.830medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
fluticasone
Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.		2.111011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
herbimycin
herbimycin: herbicidal antibiotic produced by Streptomyces sp.; see also herbimycin B; structure for herbimycin A in second source. herbimycin : A 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It is an ansamycin antibiotic that induces apoptosis and displays antitumour effects.		2.69301,4-benzoquinones;
lactam;
macrocycle		antimicrobial agent;
apoptosis inducer;
herbicide;
Hsp90 inhibitor;
tyrosine kinase inhibitor
hu 243
HU 243: RN refers to tritium-labeled compound		2.0110
preclamol
preclamol: centrally acting dopamine receptor agonist with selectivity for autoreceptors		1.9710
15-deoxy-delta(12,14)-prostaglandin j2
15-deoxy-delta(12,14)-prostaglandin J2: 15-deoxy-PGJ2 is also available; check for double bonds (indicated by delta) at 12 and 14 positions. 15-deoxy-Delta(12,14)-prostaglandin J2 : A prostaglandin J derivative comprising prostaglandin J2 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions.		2.0710prostaglandins Jelectrophilic reagent;
insulin-sensitizing drug;
metabolite
lysophosphatidic acid
lysophosphatidic acid: RN given refers to parent cpd. 1-oleoyl-sn-glycerol 3-phosphate : A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.. lysophosphatidic acid : A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.		3.54801-acyl-sn-glycerol 3-phosphate
lysophosphatidylcholines
lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.		5.462101-O-acyl-sn-glycero-3-phosphocholine
mdl 100907
Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.		2.4320
cytochalasin b
Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.		210cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
org 24598
org 24598: structure in first source		2.2510
neurokinin a
Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI.		7.4420
neurokinin b
Neurokinin B: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ A with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the URINARY BLADDER and UTERUS.		210polypeptide
pd 123319
PD123319 : An imidazopyridine consisting of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine having 4-(dimethylamino)-3-methylbenzyl, diphenylacetyl and carboxy and groups at positions 1, 5 and 6 respectively		2.4420imidazopyridineangiotensin receptor antagonist;
endothelin receptor antagonist;
vasoconstrictor agent
calyculin a
calyculin A: RN given refers to (5S-(5alpha(2R*(1S*,3S*,4S*,5R*,6R*,7E,9E,11E,13Z),3R*),7beta(E(S*)),*beta,9alpha))-isomer		9.96370
obelin
obelin: calcium-sensitive photoprotein obtained from the hydroid Obelia geniculata		210
sq 29548
SQ 29548: SQ-26538 is the ((1S-1alpha,2beta(5Z),3beta(1E,3R*),4alpha))-isomer; thromboxane A2 antagonist; thromboxane receptor antagonist		1.9910
onapristone
onapristone: induces vaginal bleeding and luteal regression in monkeys; structure given in first source; progesterone antagonist		2.0510
cl 316243
disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate: structure given in first source		1.9910
kn 93
KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.		4.35190monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound		EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector
kn 62
KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II		3.96130piperazines
su 6656
SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.		2.0310
7,7-dimethyl-5,8-eicosadienoic acid
7,7-dimethyl-5,8-eicosadienoic acid: RN given refers to (Z,Z)-isomer; RN for cpd without isomeric designation not available 6/89		210long-chain fatty acid
biliverdine
[no description available]		2.0210
2,3-diaminobutanoic acid
2,3-diaminobutanoic acid: structure in first source		2.0610
(E)-3-(2-Hydroxyphenyl)-2-propenal
[no description available]		2.4110cinnamaldehydes
andrographolide
[no description available]		2.4920carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol		anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite
licochalcone a
licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer		7.0510chalcones
1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone
1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone: G-1 was able to induce both c-fos expression and proliferation in the ERalpha-negative/GPR30-positive SKBR3 breast cancer cells, the requirement for ERalpha expression in GPR30/EGFR signaling may depend on the specific cellular context of different tumor types		2.1310agonist
fluvoxamine
Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.		2.4420(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
casein kinase ii
Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.		8.992830
ag-490
[no description available]		2.9240catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
ag 30
AG 30: structure given in first source; do not confuse with AG-30 antimicrobial peptide		2.0110
semaxinib
semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.		2.0510olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
su 11248
[no description available]		2.0510monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
palbociclib
[no description available]		2.110aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fosbretabulin
fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source		4.7250
ergothioneine
ergothioneine thione form : A L-histidine derivative that is N(alpha),N(alpha),N(alpha)-trimethyl-L-histidine in which the hydrogen at position 2 on the imdazole ring is replaced by a thioxo group.		7.25101,3-dihydroimidazole-2-thiones;
amino-acid betaine;
L-histidine derivative;
sulfur-containing amino acid		antioxidant;
chelator;
fungal metabolite;
plant metabolite;
xenobiotic metabolite
lead
Lead: A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.2, symbol Pb.		4.7471carbon group element atom;
elemental lead;
metal atom		neurotoxin
tin
[no description available]		1.9410carbon group element atom;
elemental tin;
metal atom		micronutrient
11-hydroxy-5,8,12,14-eicosatetraenoic acid
11-hydroxy-5,8,12,14-eicosatetraenoic acid: RN given refers to cpd without isomeric designation		2.0110
12-hydroxy-5,8,10,14-eicosatetraenoic acid
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)		2.7330
15-hydroxy-5,8,11,13-eicosatetraenoic acid
15-hydroxy-5,8,11,13-eicosatetraenoic acid: potent & selective inhibitor of platelet lipoxygenase; RN given refers to cpd without isomeric designation		2.6930
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine: structure given in first source. 1,1',3,3'-tetraethyl-5,5',6,6'-tetrachloroimidacarbocyanine : The cationic form of a C3 cyanine dye having 1,3-diethyl-5,6-dichloroindoleinine units at each end.		2.0510cyanine dye;
indolium ion		fluorochrome
diamide
Diamide: A sulfhydryl reagent which oxidizes sulfhydryl groups to the disulfide form. It is a radiation-sensitizing agent of anoxic bacterial and mammalian cells.		8.12501,1'-azobis(N,N-dimethylformamide)
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)		3.1350
antimony
Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.		2.3620metalloid atom;
pnictogen
cesium
Cesium: A member of the alkali metals. It has an atomic symbol Cs, atomic number 50, and atomic weight 132.91. Cesium has many industrial applications, including the construction of atomic clocks based on its atomic vibrational frequency.		4.6990alkali metal atom
barium
Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.		3.68100alkaline earth metal atom;
elemental barium
oleylamine
oleylamine: promotes fusion of mouse A(9) fibroblasts; RN given refers to parent cpd with unspecified isomeric designation; structure		7.3920
triphenyltin
triphenyltin: triphenyltin derivatives widely used as pesticides; all of first source is triphenyltin cpds		2.4110
rubidium
Rubidium: An element that is an alkali metal. It has an atomic symbol Rb, atomic number 37, and atomic weight 85.47. It is used as a chemical reagent and in the manufacture of photoelectric cells.		5.09140alkali metal atom
trimethyltin
trimethyltin : An organotin compound that consists of stannane in which three of the four hydrogens are substituted by methyl groups.		2.4420
aluminum
Aluminum: A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.		2.8840boron group element atom;
elemental aluminium;
metal atom
levorphanol
Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.		2.3620morphinane alkaloid
strontium
Strontium: An element of the alkaline earth family of metals. It has the atomic symbol Sr, atomic number 38, and atomic weight 87.62.		2.6730alkaline earth metal atom
thallium
Thallium: A heavy, bluish white metal, atomic number 81, atomic weight [204.382; 204.385], symbol Tl.. thallium : A metallic element first identified and named from the brilliant green line in its flame spectrum (from Greek thetaalphalambdalambdaomicronsigma, a green shoot).		2.3920boron group element atom
arsenic
Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)		4.65280metalloid atom;
pnictogen		micronutrient
indium
Indium: A metallic element, atomic number 49, atomic weight 114.818, symbol In. It is named from its blue line in the spectrum.. indium atom : A metallic element first identified and named from the brilliant indigo (Latin indicum) blue line in its flame spectrum.		3.2360boron group element atom
4-hydroxyaminoquinoline-1-oxide
4-Hydroxyaminoquinoline-1-oxide: A potent mutagen and carcinogen. It is a reduction product of 4-NITROQUINOLINE-1-OXIDE. It binds with nucleic acids and inactivates both bacteria and bacteriophage.		2.3820
naltrexone
Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.		2.4320cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		2.06106-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
dextrorphan
Dextrorphan: Dextro form of levorphanol. It acts as a noncompetitive NMDA receptor antagonist, among other effects, and has been proposed as a neuroprotective agent. It is also a metabolite of DEXTROMETHORPHAN.		2.3720morphinane alkaloid
gallium
Gallium: A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.. gallium atom : A metallic element predicted as eka-aluminium by Mendeleev in 1870 and discovered by Paul-Emile Lecoq de Boisbaudran in 1875. Named in honour of France (Latin Gallia) and perhaps also from the Latin gallus cock, a translation of Lecoq.		2.6430boron group element atom
methylnaltrexone
methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer		2.1710phenanthrenes
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		7.96860chalcogen;
nonmetal atom		macronutrient
methylazoxymethanol acetate
Methylazoxymethanol Acetate: The aglycone of CYCASIN. It acts as a potent carcinogen and neurotoxin and inhibits hepatic DNA, RNA, and protein synthesis.		210azoxy compound
geldanamycin
[no description available]		3.4170
isoalloxazine
isoalloxazine: structure		2.7130benzo[g]pteridine-2,4-dione
plastoquinone
[no description available]		2.7130plastoquinone
veratrine
Veratrine: A voltage-gated sodium channel activator.		1.9810alkaloid
dimyristoylphosphatidylcholine
1,2-di-O-myristoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).. dimyristoyl phosphatidylcholine : A phosphatidylcholine where the phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).		2.91401,2-diacyl-sn-glycero-3-phosphocholine;
phosphatidylcholine 28:0;
tetradecanoate ester		antigen;
mouse metabolite
ecdysterone
Ecdysterone: A steroid hormone that regulates the processes of MOLTING or ecdysis in insects. Ecdysterone is the 20-hydroxylated ECDYSONE.. 20-hydroxyecdysone : An ecdysteroid that is ecdysone substituted by a hydroxy group at position 20.		2.964014alpha-hydroxy steroid;
20-hydroxy steroid;
22-hydroxy steroid;
25-hydroxy steroid;
2beta-hydroxy steroid;
3beta-sterol;
ecdysteroid;
phytoecdysteroid		animal metabolite;
plant metabolite
deoxyribose
[no description available]		6.9310deoxypentosehuman metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate
2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid: metabolic product of biphenyl; from Pseudomonas putida; RN given refers to cpd without isomeric designation; structure. 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid : Penta-2,4-dienoic acid in which the hydrogen at position 2 is substituted by hydroxy and one of the hydrogens at position 5 is substituted by a benzoyl group. It is a metabolic product of biphenyl from Pseudomonas putida.		2.4220
fumarates
Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)		3.75110butenedioate;
C4-dicarboxylate		human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite
beryllium
Beryllium: An element with the atomic symbol Be, atomic number 4, and atomic weight 9.01218. Short exposure to this element can lead to a type of poisoning known as BERYLLIOSIS.. beryllium atom : Alkaline earth metal atom with atomic number 4.		2.0210alkaline earth metal atom;
elemental beryllium;
metal allergen		adjuvant;
carcinogenic agent;
epitope
pyrrolysine
pyrrolysine: encoded by a stop codon in archaea. L-pyrrolysine : A N(6)-acyl-L-lysine having (2R,3R)-3-methyl-3,4-dihydro-2H-pyrrol-2-ylcarbonyl as the N(6)-acyl group.. pyrrolysine : An N-acyl-amino acid that is lysine in which one of the amino nitrogens at position N6 is replaced by a 3-methyl-3,4-dihydro-2H-pyrrole-2-carbonyl group.		2.0410amino acid zwitterion;
N(6)-acyl-L-lysine;
proteinogenic amino acid;
pyrrolysine
tyrosine
[no description available]		2.0110alpha-amino-acid radical
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		17.311,4203cysteiniumfundamental metabolite
thyronines
Thyronines: A group of metabolites derived from THYROXINE and TRIIODOTHYRONINE via the peripheral enzymatic removal of iodines from the thyroxine nucleus. Thyronine is the thyroxine nucleus devoid of its four iodine atoms.. thyronine : A tyrosine derivative where the phenolic hydrogen of tyrosine is substituted by 4-hydroxyphenyl.		2.4420thyronine
silicon
Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].		2.6330carbon group element atom;
metalloid atom;
nonmetal atom
n-acetylmuramic acid
N-acetylmuramic acid: RN given refers to D-Glucopyranose, (R)-isomer. N-acetyl-D-muramic acid : The pyranose form of N-acetylmuramic acid.		2.0210N-acetylmuramic acid
phosphorus
Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.		5.47670monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
boron
Boron: A trace element with the atomic symbol B, atomic number 5, and atomic weight [10.806; 10.821]. Boron-10, an isotope of boron, is used as a neutron absorber in BORON NEUTRON CAPTURE THERAPY.		3.3870boron group element atom;
metalloid atom;
nonmetal atom		micronutrient
heroin
Heroin: A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed). heroin : A morphinane alkaloid that is morphine bearing two acetyl substituents on the O-3 and O-6 positions. As with other opioids, heroin is used as both an analgesic and a recreational drug. Frequent and regular administration is associated with tolerance and physical dependence, which may develop into addiction. Its use includes treatment for acute pain, such as in severe physical trauma, myocardial infarction, post-surgical pain, and chronic pain, including end-stage cancer and other terminal illnesses.		2.0510morphinane alkaloidmu-opioid receptor agonist;
opioid analgesic;
prodrug
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid: chromogen in glucose oxidase-peroxidase method for determining serum glucose; used in free radical scavenging assays; structure in first source		2.0310
alanyl-alanyl-alanine
alanyl-alanyl-alanine: RN given refers to all (L)-isomer. Ala-Ala-Ala : A tripeptide composed of three L-alanine units joined by peptide linkages.		2.0110tripeptidemetabolite
pepstatin
pepstatin: inhibits the aspartic protease endothiapepsin		210pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
ximelagatran
ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.		3.110amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
phytochlorin
phytochlorin: RN given refers to (2S-trans)-isomer; structure given in the first source		2.2110
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		5.2740cephalosporin;
oxime O-ether		antibacterial drug
norbinaltorphimine
norbinaltorphimine: kappa opiate receptor antagonist; structure given in first source		1.9810isoquinolines
ici 118551
ICI 118551: RN given refers to (R*,R*)-(+-)-isomer; structure in first source; ICI 111581 is hydrochloride of ICI 118551. ICI 118551 : An indane substituted at position 7 by a methyl group and at position 4 by a 3-(isopropylamino)-2-hydroxybutoxy group (the 2R,3S-diastereomer).		2.1510aromatic ether;
indanes;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist
dermorphin
dermorphin: opiate-like peptide present in amphibian skin		1.9910oligopeptide
enkephalin, ala(2)-mephe(4)-gly(5)-
Enkephalin, Ala(2)-MePhe(4)-Gly(5)-: An enkephalin analog that selectively binds to the MU OPIOID RECEPTOR. It is used as a model for drug permeability experiments.		4.5390
cytogenin
[no description available]		1.9810
marfey's reagent
Marfey's reagent: structure given in first source		7.4120
pregabalin
Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.		2.9540gamma-amino acidanticonvulsant;
calcium channel blocker
5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole-3',5'-monophosphorothioate
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole-3',5'-monophosphorothioate: structure given in first source		2.730
biphalin
biphalin: enkephalin dimer; two fragments of Ala(2)-enkephalin are connected by a diamine bridge to form above cpd; structure given in first source		7.110
uroguanylin
uroguanylin: amino acid sequence given in first source; stimulates intestinal guanylate cyclase; GenBank Z83746 (pig)		210
beta-isopropylmalate
beta-isopropylmalate: RN given refers to (threo-(D)-isomer)		2.4120
guanylin
guanylin: from rat jejunum; contains 15 amino acids; activator of intestinal guanylate cyclase; stimulates this enzyme through the same receptor binding region as the heat-stable enterotoxins; amino acid sequence given in first source; GenBank Z73607 (pig)		2.0210
udp-n-acetylmuramic acid pentapeptide
[no description available]		2.0510
antiarrhythmic peptide
antiarrhythmic peptide: atrial peptide from bovine atria; hexapeptide composed of hydroxyproline(1), proline(1), glycine(3) & alanine(1); both N-terminal & carboxy-terminal residues are glycine		2.0310
vx680
[no description available]		2.2110N-arylpiperazine
n-acetylsphingosine
N-acetylsphingosine: inhibits phospholipase D. N-acetylsphingosine : A N-acylsphingosine that has an acetamido group at position 2.		3.1250N-acylsphingosine
triolein
Triolein: (Z)-9-Octadecenoic acid 1,2,3-propanetriyl ester.. triolein : A triglyceride formed by esterification of the three hydroxy groups of glycerol with oleic acid. Triolein is one of the two components of Lorenzo's oil.		2.3620triglycerideCaenorhabditis elegans metabolite;
plant metabolite
docosapentaenoic acid
docosapentaenoic acid : Any straight-chain, C22 fatty acid having five C=C double bonds.. (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid : The all-cis-isomer of a C22 polyunsaturated fatty acid having five double bonds in the 7-, 10-, 13-, 16- and 19-positions.		3.1310docosapentaenoic acid;
omega-3 fatty acid		algal metabolite;
human metabolite
bafilomycin a
[no description available]		2.0210
resiniferatoxin
resiniferatoxin: phorbol related diterpene ester; potent agonist of vanilloid TRPV1 receptors. resiniferatoxin : A heteropentacyclic compound found in Euphorbia poissonii with molecular formula C37H40O9. It is an agonist of the transient receptor potential cation channel subfamily V member 1 (TrpV1).		2.0710carboxylic ester;
diterpenoid;
enone;
monomethoxybenzene;
organic heteropentacyclic compound;
ortho ester;
phenols;
tertiary alpha-hydroxy ketone		analgesic;
neurotoxin;
plant metabolite;
TRPV1 agonist
abscisic acid
Abscisic Acid: Abscission-accelerating plant growth substance isolated from young cotton fruit, leaves of sycamore, birch, and other plants, and from potatoes, lemons, avocados, and other fruits.. (S)-2-trans-abscisic acid : A 2-trans-abscisic acid with (S)-configuration at the chiral centre.. (+)-abscisic acid : The naturally occurring (1'S)-(+) enantiomer of abscisic acid. It is an important sesquiterpenoid plant hormone which acts as a regulator of plant responses to environmental stresses such as drought and cold.		4.622402-trans-abscisic acid
n-caproylsphingosine
N-(hexanoyl)sphing-4-enine : An N-acylsphingosine consisting of sphing-4-enine bearing a hexanoyl group on nitrogen.		2.0210N-acylsphingosine
carbocyanines
Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.		2.0510cyanine dye;
organic iodide salt		fluorochrome
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		8.25601,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
syntide-2
syntide-2: amino acid sequence given in first source		2.110
cinidon-ethyl
Lotus: A genus of the PEA FAMILY. The genus Lotus, formerly known as Tetragonolobus, is unrelated to other plants with the common name of lotus (NELUMBO and NYMPHAEA).. cinidon ethyl : A carboxylic ester and organochlorine compound that is the ethyl ester of cinidon.		3.0240ethyl ester;
isoindoles;
monochlorobenzenes		herbicide
cgp 37849
2-amino-4-methyl-5-phosphono-3-pentenoic acid: N-methyl-D-aspartate receptor antagonist; structure given in first source; RN given refers to cpd without isomeric designation; CGP-40116 is the (R)-enantiomer of CGP-37849; CGP-40017 is the L-isomer		2.0810
ammonium sulfate
Ammonium Sulfate: Sulfuric acid diammonium salt. It is used in CHEMICAL FRACTIONATION of proteins.. ammonium sulfate : An inorganic sulfate salt obtained by reaction of sulfuric acid with two equivalents of ammonia. A high-melting (decomposes above 280degreeC) white solid which is very soluble in water (70.6 g/100 g water at 0degreeC; 103.8 g/100 g water at 100degreeC), it is widely used as a fertilizer for alkaline soils.		5.06440ammonium salt;
inorganic sulfate salt		fertilizer
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid: An inhibitor of anion conductance including band 3-mediated anion transport.		2.940
12-o-retinoylphorbol-13-acetate
[no description available]		2.7430
proguanil
Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.		1.9910biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
mastoparan
[no description available]		1.9710mastoparans;
peptidyl amide		antimicrobial agent
tetrodotoxin
Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.		4.49230azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
apratoxin a
apratoxin A: a potent cytotoxin with a novel skeleton, has been isolated from the marine cyanobacterium Lyngbya majuscula Harvey ex Gomont; structure in first source. apratoxin A : An aprotoxin having the common aprotoxin cyclodepsipeptide skeleton where the isoleucyl residue carries an N-methyl substituent and the side-chain adjacent to the lactone is tert-butyl.		2.05101,3-thiazoles;
apratoxin		antineoplastic agent;
metabolite
selenium
Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.		7.29440chalcogen;
nonmetal atom		micronutrient
selenocysteine
Selenocysteine: A naturally occurring amino acid in both eukaryotic and prokaryotic organisms. It is found in tRNAs and in the catalytic site of some enzymes. The genes for glutathione peroxidase and formate dehydrogenase contain the TGA codon, which codes for this amino acid.. selenocysteine : An alpha-amino acid that consists of alanine where one of the methyl hydrogens is substituted with a seleno group.		5.65240
tellurium
Tellurium: An element that is a member of the chalcogen family. It has the atomic symbol Te, atomic number 52, and atomic weight 127.60. It has been used as a coloring agent and in the manufacture of electrical equipment. Exposure may cause nausea, vomiting, and CNS depression.		3.1210chalcogen;
metalloid atom
polonium
Polonium: A radioactive element that is a member of the chalcogen family. It has the atomic symbol Po, atomic number 84, and the atomic weight of the isotope with the longest half-life (209Po) is 208.98. It decays by alpha-emission.. polonium atom : A radioactive metallic element discovered in 1898 by Marie Sklodowska Curie and named after her home country, Poland (Latin Polonia).		1.9410chalcogen;
metal atom
oxalates
Oxalates: Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure.		6.12250
1,1-diethyl-2-hydroxy-2-nitrosohydrazine
1,1-diethyl-2-hydroxy-2-nitrosohydrazine: RN given in first source; RN refers to ion(1-); do not confuse with DEA-NO cpd		2.0410organic anion
stannin
stannin: amino acid sequence given in first source; a 10 kDa peptide expressed in trimethyltin-sensitive cells; may play a role in selective toxicity of organotin cpds; homologs have been identified in rabbit, human and Drosophila; from rat brain		2.0210
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Fluvastatin: An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.. (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid diastereoisomer in which both chiral centres have S configuration.. fluvastatin : A racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. An HMG-CoA reductase inhibitor, it is used (often as the corresponding sodium salt) to reduce triglycerides and LDL-cholesterol, and increase HDL-chloesterol, in the treatment of hyperlipidaemia.		3.8121(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(-)-catechin-3-O-gallate
(-)-catechin-3-O-gallate : A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of (-)-catechin.		2.4110flavans;
gallate ester;
polyphenol		metabolite
dizocilpine maleate
Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.		6.31570maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
antimycin a
Antimycin A: An antibiotic substance produced by Streptomyces species. It inhibits mitochondrial respiration and may deplete cellular levels of ATP. Antimycin A1 has been used as a fungicide, insecticide, and miticide. (From Merck Index, 12th ed). antimycin A : A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.		3.2160amidobenzoic acid
prolylglycine
prolylglycine: RN given refers to (L)-isomer. L-prolylglycine : A dipeptide consisting of glycine having an L-prolyl group attached to its alpha-amino nitrogen.		1.9710dipeptide zwitterion;
dipeptide
methylazoxymethanol
methylazoxymethanol: a neuroteratogen; reacts with guanine residues of DNA & RNA forming 7-methylguanine adduct products; carcinogenicity probably related to biological decomposition into methyldiazonium ion, the ultimate methylating agent; structure in first source		210azoxy compound
bongkrekic acid
Bongkrekic Acid: An antibiotic produced by Pseudomonas cocovenenans. It is an inhibitor of MITOCHONDRIAL ADP, ATP TRANSLOCASES. Specifically, it blocks adenine nucleotide efflux from mitochondria by enhancing membrane binding.. bongkrekic acid : A tricarboxylic acid that is docosa-2,4,8,10,14,18,20-heptaenedioic acid substituted at positions 2 ,5 and 17 by methyl groups, at positions 6 by a methoxy group and at position 20 by a carboxymethyl group. It is produced by the bacterium Burkholderia gladioli and implicated in outbreaks of food-borne illness involving coconut and corn-based products in Indonesia and China.		210ether;
olefinic compound;
tricarboxylic acid		apoptosis inhibitor;
ATP/ADP translocase inhibitor;
bacterial metabolite;
EC 2.5.1.18 (glutathione transferase) inhibitor;
toxin
ascofuranone
ascofuranone: structure. ascofuranone : A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde which is substituted by a (2E,6E)-7-[(2S)-5,5-dimethyl-4-oxotetrahydrofuran-2-yl]-3-methylocta-2,6-dien-1-yl group at position 3, chlorine at position 5, and a methyl group at position 6. A meroterpenoid produced by the soil fungus, Acremonium sclerotigenum. It is a promising drug candidate against the tropical disease, African trypanosomiasis.		2.0510dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid;
tetrahydrofuranone		angiogenesis inhibitor;
antilipemic drug;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite
dolichol monophosphate mannose
Dolichol Monophosphate Mannose: A lipophilic glycosyl carrier of the monosaccharide mannose in the biosynthesis of oligosaccharide phospholipids and glycoproteins.		1.9710
1-palmitoyl-2-oleoylphosphatidylcholine
1-palmitoyl-2-oleoylphosphatidylcholine: RN given refers to (Z)-isomer		3.4670
nitrocefin
nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source		2.4120
latrunculin b
latrunculin B: 14-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin A; structure given in first source. latrunculin B : A macrolide consisting of a 14-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica.		2.7230cyclic hemiketal;
macrolide;
oxabicycloalkane;
thiazolidinone		actin polymerisation inhibitor;
metabolite;
toxin
uniconazole
uniconazole: structural analog of diniconazole; RN refers to ((E)-(+-))-isomer; structure given in first source. uniconazole : A racemate comprising equimolar amounts of uniconazole-P and its enantiomer, (R)-uniconazole.. (1E)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol : A member of the class of triazoles that is 1,2,4-triazole which is substituted at position 1 by a 1-(p-chlorophenyl)-3-hydroxy-4,4-dimethylpent-1-en-2-yl group.		2.1510monochlorobenzenes;
secondary alcohol;
triazoles
1-oleoyl-2-acetylglycerol
[no description available]		2.39201,2-diglyceride
myxothiazol
myxothiazol: strobilurin analogue; methoxyacrylamide derivative; antifungal antibiotic from Myxococcus fulvus; structure given in first source. myxothiazol : A 2,4'-bi-1,3-thiazole substituted at the 4-position with a (1E,3S,4R,5E)-7-amino-3,5-dimethoxy-4-methyl-7-oxohepta-1,5-dien-1-yl] group and at the 2'-position with a (2S,3E,5E)-7-methylocta-3,5-dien-2-yl group. It is an inhibitor of coenzyme Q - cytochrome c reductase.		2.2510
ly 53857
LY 53857: RN given refers to maleate[1:1](8beta)-isomer		1.9910
dioleoyl phosphatidylethanolamine
dioleoyl phosphatidylethanolamine: chemical name in article is incorrect - phosphatidylethandamine instead of phosphatidylethanolamine. dioleoyl phosphatidylethanolamine : A phosphatidylethanolamine in which the phosphatidyl acyl groups are both oleoyl.		210phosphatidylethanolamine
sphingosine phosphorylcholine
sphingosine phosphorylcholine: a wound healing agent		2.4720
concanamycin a
concanamycin A: from Streptomyces diastatochromogenes S-45; inhibits vacuolar H+ ATPase. concanamycin A : A concanamycin in which the lactone ring contains 4 double bonds and is substituted by 4 methyl groups, 2 hydroxy groups, 2 methoxy groups and an ethyl group.		2.0210carbamate ester;
concanamycin		antifungal agent;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
metabolite
manumycin
manumycin: an NSAID; RN given for (1S-(1alpha,3(2E,4E,6S*),5alpha,5(1E,3E,5E),6alpha))-isomer; a farnesyl protein transferase inhibitor; from Streptomyces parvulus; MF C31-H38-N2-O7; structure given in first source. manumycin A : A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties.		2.4620enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol		antiatherosclerotic agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
marine metabolite
plastochromanol 8
plastochromanol 8: has antiproliferative activity against 3T3-L1 cells and anti-adipogenic activity; structure; plastochromanol 3 is gamma-tocotrienol		2.1510
7-(3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo(2.2.1)heptan-2-yl)-5-heptenoic acid
7-(3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo(2.2.1)heptan-2-yl)-5-heptenoic acid: structure given in first source; thromboxane A2/prostaglandin H2 receptor agonist; RN given refers to the (125I) labeled cpd		2.420
microcystin rr
microcystin RR: structure given in first source; isolated cyanobacterium		1.9810microcystin;
organic molecular entity		bacterial metabolite;
environmental contaminant;
xenobiotic
1-palmitoyl-2-linoleoylphosphatidylcholine
[no description available]		210
thermozymocidin
thermozymocidin: a serine palmitoyltransferase inhibitor; FTY720 is an analog		2.8130alpha-amino fatty acid;
hydroxy monocarboxylic acid;
non-proteinogenic alpha-amino acid;
sphingoid		antifungal agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor;
fungal metabolite;
immunosuppressive agent
olivanic acid
olivanic acid: beta-lactam antibiotics produced by Streptomyces olivaceus ATCC 31365; all have carbapenum nucleus; structures in sixth source		1.9810
myxococcus xanthus antibiotic ta
Myxococcus xanthus antibiotic TA: polyketide wide-spectrum antibiotic produced by Myxococcus xanthus		2.3820
broussochalcone a
broussochalcone A: RN given for (E)-isomer; inhibits neutrophil respiratory burst; structure in first source		2.2110
pironetin
pironetin: a microbial secondary metabolite having the activity of shortening plant height from Streptomyces sp.; structure in first source		2.0510aliphatic alcohol
o-(5-o-(feruloyl)-alpha-arabinofuranosyl)-(1-3)-o-beta-xylopyranosyl-(1-4)-xylopyranose
O-(5-O-(feruloyl)-alpha-arabinofuranosyl)-(1-3)-O-beta-xylopyranosyl-(1-4)-xylopyranose: structure given in first source		210
tautomycetin
tautomycetin: isolated from Streptomyces griseochromogenes		2.110sesquiterpenoid
bacteriochlorophylls
Bacteriochlorophylls: Pyrrole containing pigments found in photosynthetic bacteria.		8.0850
antibiotic 1233a
antibiotic 1233A: beta-lactone antibiotic from Cephalosporium; hydroxymethylglutaryl-CoA synthase & 3C protease, viral inhibitor; structure in first source		2.0110long-chain fatty acid
ubiquinone q3
[no description available]		1.9910
1,2-linoleoylphosphatidylcholine
1,2-linoleoylphosphatidylcholine: used for premature induction of labor in rabbits; RN given refers to (all Z)-isomer		2.0510
1-stearoyl-2-arachidonylphosphatidylcholine
1-stearoyl-2-arachidonylphosphatidylcholine: RN given refers to (all-Z)-isomer		2.1510
everolimus
[no description available]		2.5820cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
emerin
emerin: a serine-rich protein; responsible for Emery-Dreifuss muscular dystrophy (EDMD)		8.1450
ratjadone
ratjadone: structure in first source		2.0210
u 75302
U 75302: RN refers to (R-(R*,S*-(E,Z)))-isomer; leukotriene B4 antagonist		2.0310
dehydrobutyrine
(Z)-2-aminobutenoic acid : A 2,3-dehydroamino acid resulting from the formal elimination of water from the side-chain of threonine.. 2-aminobut-2-enoic acid zwitterion : An amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of 2-aminobut-2-enoic acid; major species at pH 7.3.		2.78302,3-dehydroamino acid;
enamine;
threonine derivative
cdw17 antigen
[no description available]		3.0950
ganglioside, gd1b
[no description available]		2.0210
ganglioside, gd2
[no description available]		1.9910
i(3)so3-galactosylceramide
Sulfoglycosphingolipids: GLYCOSPHINGOLIPIDS with a sulfate group esterified to one of the sugar groups.. 1-(3-O-sulfo-beta-D-galactosyl)-N-tetracosanoylsphingosine : A D-galactosyl-N-acylsphingosine having a sulfo group at the 3-position on the galactose ring and tetracosanoyl as the N-acyl group.		3.0550galactosylceramide sulfate;
N-acyl-beta-D-galactosylsphingosine
tanespimycin
CP 127374: analog of herbimycin A		2.03101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
verlukast
verlukast: LTD4 receptor antagonist		210
carumonam
carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.		1.9810monobactamantibacterial drug
paclobutrazol
paclobutrazol: RN given refers to (R*,R*)-(+-)-isomer. paclobutrazol : A racemate comprising equimolar amounts of (2R,3R)- and (2S,3S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol. It acts as a plant-growth retardant and fungicide via inhibition of gibberellin biosynthesis.		2.110
beta-escin
[no description available]		2.730
melibiose
alpha-D-Galp-(1->6)-alpha-D-Glcp : A glycosylglucose consisting of alpha-D-galactopyranose and alpha-D-glucopyranose residues joined in sequence by a (1->6) glycosidic bond.		9.6950glycosylglucose
4,5-diaminofluorescein diacetate
[no description available]		3.6530
erythro-dihydrosphingosine
erythro-dihydrosphingosine: structure in first source		7.0110amino alcohol
mdl 105519
MDL 105519: a potent ligand at the N-methyl-D-aspartate (NMDA) receptor-associated glycine recognition site; structure given in first source		2.4120
s-nitroso-n-acetylpenicillamine
S-Nitroso-N-Acetylpenicillamine: A sulfur-containing alkyl thionitrite that is one of the NITRIC OXIDE DONORS.		2.7130nitroso compound;
nitrosothio compound		nitric oxide donor;
vasodilator agent
sb 222200
[no description available]		2.0410quinolines
ro 25-6981
Ro 25-6981: blocks NMDA receptors containg NR2B subunit; structure in first source. Ro 25-6981 : A member of the class of piperidines that is 4-benzylpiperidine substituted by a 3-hydroxy-3-(4-hydroxyphenyl)-2-methylpropyl group at position 1 (the 1R,2S-stereoisomer). It is a potent antagonist of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor.		3.9230benzenes;
phenols;
piperidines;
secondary alcohol;
tertiary amino compound		anticonvulsant;
antidepressant;
neuroprotective agent;
NMDA receptor antagonist
sb 269970
SB 269970: a 5-HT(7) antagonist; structure in first source		2.0310sulfonamide
aminopurvalanol a
aminopurvalanol A: casein kinase I alpha inhibitor; structure in first source		2.110monochlorobenzenes;
purvalanol		protein kinase inhibitor
iem 1460
IEM 1460: structure in first source		2.0710
cgk 733
[no description available]		2.0510diarylmethane
lactacystin
[no description available]		8.73100lactam;
S-substituted L-cysteine
n-stearoyltyrosine
[no description available]		2.0510tyrosine derivative
gadolinium dtpa
Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)		2.4420gadolinium coordination entityMRI contrast agent
porphyra-334
porphyra-334: structure in first source		2.610
morphinans
Morphinans: Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS.		2.3620isoquinoline alkaloid fundamental parent;
morphinane alkaloid
ergoline
Ergolines: A series of structurally-related alkaloids that contain the ergoline backbone structure.. ergoline : An indole alkaloid whose structural skeleton is found in many naturally occurring and synthetic ergolines which are known to bind to neurotransmitter receptors, such as dopamine, noradrenaline and serotonin receptors and function as unselective agonists or antagonists at these receptors.		3.2460diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound
carboxyl radical
[no description available]		2.0310carbon oxide;
organic radical anion		xenobiotic metabolite
adenosine-3',5'-cyclic phosphorothioate
adenosine-3',5'-cyclic phosphorothioate: RP-cAMP-S is a protein kinase A inhibitor; SP-cAMP-S is a protein kinase A agonist. (Sp)-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having adenine as the nucleobase (the Sp-stereoisomer).. (Rp)-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having adenine as the nucleobase (the Rp-stereoisomer).		3.2660nucleoside 3',5'-cyclic phosphorothioate
sq-23377
Ionomycin: A divalent calcium ionophore that is widely used as a tool to investigate the role of intracellular calcium in cellular processes.. ionomycin : A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes.		4.45220cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite
adenosine 5'-phosphorothioate
adenosine 5'-phosphorothioate: RN given refers to parent cpd		1.9510
8-bromo-beta-phenyl-1,n(2)-ethenoguanosine 3',5'-cyclic monophosphorothioate
8-bromo-beta-phenyl-1,N(2)-ethenoguanosine 3',5'-cyclic monophosphorothioate: RN refers to (S)-isomer; protein kinase G inhibitor; structure given in first source		2.0110
fostriecin
fostriecin: compound contains a conjugated triene and an unsaturated lactone; from Streptomyces pulveraceus; structure given in second source. fostriecin : A structurally unique, naturally-occurring phosphate monoester isolated from the soil bacterium Streptomyces pulveraceus. It inhibits DNA topoisomerase II as well as several protein phosphatase including PP2A and PPA4, and exhibits potent antitumor activity against several cancer cell lines.		2.42202-pyranones;
olefinic compound;
phosphate monoester;
polyketide;
primary allylic alcohol;
secondary allylic alcohol;
triol		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
topoisomerase II inhibitor
fk 866
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source		2.0810benzamides;
N-acylpiperidine
d-phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide
TT2-32: induces a biphasic activation of phosphotyrosine phosphatase activity in human colon tumor cell line, SW620		210
hexarelin
hexarelin: a synthetic growth hormone releasing peptide; structurally similar to GHRP-6, with the substitution of D-Trp with its 2-methyl derivative; more potent & stable and less toxic than GHRP-6		2.110
soblidotin
soblidotin: a dolastatin 10 derivative; RN refers to (2S-(1(1R*(R*),2S*),2R*(1S*,2S*)))-isomer; structure given in first source. soblidotin : A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity.		3.1510tetrapeptideantineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
beta-elemene
beta-elemene: increases tumor cell immunogenicity by inducing, at least in part, elevated expression of heat shock protein 70 on tumor cell surface. beta-elemene : A sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4.. (-)-beta-elemene : The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration.		2.4110beta-elemeneantineoplastic agent
ac 7700
AC 7700: a vascular disrupting agent; structure in first source		12.36247
pd 184352
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source		2.0710aminobenzoic acid
vildagliptin
[no description available]		2.0810amino acid amide
oxi 4503
Oxi 4503: diphosphate prodrug of cambretastatin A1		4.0920
tryptophanol
tryptophanol: RN given refers to cpd without isomeric designation		2.0510
phenylalanylglycine
phenylalanylglycine: RN given refers to (DL)-isomer. Phe-Gly : A dipeptide formed from L-phenylalanine and glycine residues.		2.420dipeptidemetabolite
leucyl-phenylalanine
Leu-Phe : A dipeptide formed from L-leucine and L-phenylalanine residues.		1.9710dipeptidemetabolite
glycyl-alanyl-phenylalanine
[no description available]		2.0510oligopeptide
glycyl-alanyl-leucine
glycyl-alanyl-leucine: RN given refers to all (L)-isomer; RN for cpd without isomeric designation not avail 9/91		1.9710peptide
methionylglycine
methionylglycine: RN given refers to (L)-isomer. Met-Gly : A dipeptide formed from L-methionine and glycine residues.		2.0510dipeptidemetabolite
phenylalanylphenylalanine
Phe-Phe : A dipeptide formed from two L-phenylalanine residues.		1.9710dipeptide;
L-aminoacyl-L-amino acid zwitterion		human blood serum metabolite;
Mycoplasma genitalium metabolite
histidylhistidine
histidylhistidine: RN given for L-,L-isomer		2.0510dipeptideMycoplasma genitalium metabolite
valylleucine
valylleucine: RN given refers to all L-isomer. Val-Leu : A dipeptide formed from L-valine and L-leucine residues.		2.420dipeptidemetabolite
bromopyruvate
[no description available]		8.06402-oxo monocarboxylic acid anion
alanylglycine
[no description available]		2.420dipeptide zwitterion;
dipeptide		metabolite
alpha-glutamyltryptophan
Trp-Glu : A dipeptide formed from L-tryptophan and L-glutamic acid residues.		2.420dipeptidemetabolite
methionylglutamic acid
Met-Glu : A dipeptide formed from L-methionine and L-glutamic acid residues.		2.0510dipeptidemetabolite
valyl-valyl-valine
[no description available]		2.0110peptide
phenylalanylproline
Phe-Pro : A dipeptide formed from L-phenylalanine and L-proline residues.		1.9710dipeptidemetabolite
staurosporine
staurosporinium : Conjugate acid of staurosporine.		6.29570ammonium ion derivative
aminomethyltransferase
Aminomethyltransferase: A one-carbon group transferase that transfers lipoamide-linked methylamine groups to tetrahydrofolate (TETRAHYDROFOLATES) to form methylenetetrahydrofolate and AMMONIA. It is one of four components of the glycine decarboxylase complex.		3.2260
prolylisoleucine
prolylisoleucine: RN refers to (L)-isomer. Pro-Ile : A dipeptide formed from L-proline and L-isoleucine residues.		1.9710dipeptidemetabolite
sun
[no description available]		2.0810
phenylalanyl-valine
phenylalanyl-valine: structure in first source. Phe-Val : A dipeptide formed from L-phenylalanine and L-valine residues.		2.0510dipeptidemetabolite
prolyl-serine
Pro-Ser : A dipeptide formed from L-proline and L-serine residues.		2.0110dipeptidemetabolite
dipalmitoleoylphosphatidylethanolamine
dipalmitoleoylphosphatidylethanolamine: a membrane lipid		2.110
phosphocreatine
Phosphocreatine: An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996). phosphagen : Any of a group of guanidine or amidine phosphates that function as storage depots for high-energy phosphate in muscle with the purpose of regenerating ATP from ADP during muscular contraction.. N-phosphocreatine : A phosphoamino acid consisting of creatine having a phospho group attached at the primary nitrogen of the guanidino group.		4.4670phosphagen;
phosphoamino acid		human metabolite;
mouse metabolite
grayanotoxin i
grayanotoxin I: RN given refers to (3beta,6beta,14R)-isomer; structure. grayanotoxin I : A tetracyclic diterpenoid that is grayanotoxane in which the pro-R hydrogen at position 14 is substituted by an acetoxy group and in which the 3beta-, 5-, 6beta-, 10-, and 16- positions are substituted by hydroxy groups.		2.4120acetate ester;
pentol;
secondary alcohol;
tertiary alcohol;
tetracyclic diterpenoid		antihypertensive agent;
metabolite;
neuromuscular agent;
phytotoxin
taxane
taxane: produced by Taxomyces andreanae		3.4811diterpene;
terpenoid fundamental parent
9h-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-n-(1-methylethyl)-
9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-: an epichaperome (purine-scaffold) inhibitor; structure in first source		2.0410
sl 327
SL 327: a MEK inhibitor. SL-327 : A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.		2.0410
fenpyroximate
fenpyroximate: structure in first source		2.0710pyrazole acaricide;
tert-butyl ester		mitochondrial NADH:ubiquinone reductase inhibitor
triacsin c
triacsin C: from Streptomyces No. 1228; structure given in first source; an acyl-CoA synthetase antagonist. triacsin C : A nitroso compound that is N-undecylnitrous hydrazide carrying double bonds at positions 1,2,4, and 7. It is a long-chain fatty acyl CoA synthetase inhibitor and interferes with lipid metabolism by inhibiting the de novo synthesis of glycerolipids and cholesterol esters.		2.0210hydrazone;
nitroso compound;
olefinic compound		antimalarial;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
vasodilator agent
n-acetylglucosaminono-1,5-lactone o-(phenylcarbamoyl)oxime
N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime: structure given in first source		2.0710
phosphatidylinositol 5-phosphate
phosphatidylinositol 5-phosphate : A phosphatidylinositol monophosphate carrying the phosphate group at the 5-position.		2.1310glycerophosphoinositol phosphate
ferrihydrite
ferric oxyhydroxide: an antiferromagnetic material; constitutes the core of natural ferritin; mol form 5Fe2O3.9H2O		2.1510
clasto-lactacystin beta-lactone
clasto-lactacystin beta-lactone: active metabolite of lactacystin; inhibits 20 S proteasome; structure in first source		2.730
8-bromoadenosine-3',5'-cyclic monophosphorothioate
(Sp)-8-bromo-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having 8-bromoadenine as the nucleobase (the Sp-stereoisomer).		2.0510
gw 501516
GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.		2.07101,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
bay 58-2667
BAY 58-2667: activates guanylyl cyclase; structure in first source. cinaciguat : A benzoic acid that is 4-(aminomethyl)benzoic acid in which the amino group is substituted by 4-carboxybutyl and 2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl groups. It is a soluble guanylate cyclase activator, used for the treatment of acute decompensated heart failure.		2.0210aromatic ether;
benzoic acids;
dicarboxylic acid;
tertiary amino compound		antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent
dolastatin 10
dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.		1.99101,3-thiazoles;
tetrapeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent
neotame
neotame: structure in first source. neotame : A dipeptide composed of N-(3,3-dimethylbutyl)-L-aspartic acid and methyl L-phenylalanate units joined by a peptide linkage.		210dipeptideenvironmental contaminant;
sweetening agent;
xenobiotic
sacubitril
[no description available]		2.610biphenyls
pachastrissamine
pachastrissamine: a cytotoxic anhydrophytosphingosine from a marine sponge, Pachastrissa sp. ; structure in first source		2.0210
bms 191095
BMS 191095: a mitochondrial K(ATP) opener; structure in first source		2.1310
kb r7943
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate: inhibits the reverse mode of Na+/Ca++ exchange in cells expressing NCX1; structure in first source		2.0110
pd 0325901
mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).		2.5120difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound		antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		2.0410benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
jasplakinolide
jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R*,4E,6S*,8R*)-isomer; structure in first source. jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer.		2.0510cyclodepsipeptide;
phenols		actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent
ipamorelin
[no description available]		210
sincalide
Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.		2.420oligopeptide
avibactam
avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.		9.3931azabicycloalkane;
hydroxylamine O-sulfonic acid;
monocarboxylic acid amide;
ureas		antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
etomoxir
[no description available]		2.0110aromatic ether
2164u90
2164U90: a potent inhibitor of the ileal bile acid active transport system; structure given in first source		2.0110
brl 37344
BRL 37344: SB 206606 is the (R,R)-isomer		1.9910monocarboxylic acid
paliperidone palmitate
Paliperidone Palmitate: A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.. 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate : A fatty acid ester obtained by the formal condensation of the carboxy group of hexadecanoic acid with the hydroxy group of 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one.. paliperidone palmitate : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone palmitate. A long-acting injectable formulation of paliperidone (the major active metabolite of risperidone) that is used for treatment of schizophrenia.		2.03101,2-benzoxazoles;
fatty acid ester;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine
pentagastrin
Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.		1.9510organic molecular entity
flag peptide
FLAG peptide: engineered as a tag for immunoaffinity purification of genetically-engineered proteins; amino acid sequence given in first source; a polar octapeptide. FLAG peptide : An eight amino acid peptide consisting of L-aspartic acid, L-tyrosine, L-lysine, four L-aspartic acid residues, and L-lysine joined in sequence by peptide linkages. It is widely used as a fusion tag for the purification and detection of a wide variety of recombinant proteins.		2.9140peptide
nu 7026
2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source		2.0510organic heterotricyclic compound;
organooxygen compound
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		4.17160aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
17-hydroxywortmannin
17-hydroxywortmannin: inhibits secretion of human neutrophils		6.9710
carbobenzoxy-leucyl-leucyl-norvalinal
carbobenzoxy-leucyl-leucyl-norvalinal: structure given in first source		2.0210peptide
1,3-bis(bis(pyridin-2-ylmethyl)amino)propan-2-ol
1,3-bis(bis(pyridin-2-ylmethyl)amino)propan-2-ol: structure in first source		2.5220
lipid a
Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).		3.0850dodecanoate ester;
lipid A;
tetradecanoate ester		Escherichia coli metabolite
conagenin
conagenin: from Streptomyces roseosporus; structure given in first source		3.78110
n-acetylcysteine lysinate
N-acetylcysteine lysinate: tradename		2.0710
hmr 1556
HMR 1556: an I(Ks) channel blocker; structure in first source		2.0310
sr 59230a
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate: structure given in first source		2.9410
gw 4064
[no description available]		2.0510stilbenoid
zd 6126
[no description available]		4.3730
mart-1 antigen
MART-1 Antigen: A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.		2.0510
shu 9119
SHU 9119: an agouti mimetic; structure in first source		210
g(m2) ganglioside
G(M2) Ganglioside: A glycosphingolipid that accumulates due to a deficiency of hexosaminidase A or B (BETA-N-ACETYLHEXOSAMINIDASES), or GM2 activator protein, resulting in GANGLIOSIDOSES, heredity metabolic disorders that include TAY-SACHS DISEASE and SANDHOFF DISEASE.. ganglioside GM2 (18:0) : A sialotriaosylceramide that is N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on the sphingosine nitrogen is octadecanoyl. A constituent of natural ganglioside GM2.		2.3920N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine;
sialotriaosylceramide		antigen
ica 27243
N-(6-Chloropyridin-3-yl)-3,4-difluorobenzamide: a KCNQ2/3 channel activator; structure in first source		2.0710
ic 87114
IC 87114: structure in first source		2.1106-aminopurines;
biaryl;
quinazolines		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
nb 506
NB 506: an indolocarbazole antitumor agent; structure given in first source; a DNA topoisomerase I inhibitor		210
ginsenoside rg3
ginsenoside Rg3: from Red ginseng; inhibits lung metastasis of tumor cells; structure given in first source. (20S)-ginsenoside Rg3 : A ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.		2.0610ginsenoside;
glycoside;
tetracyclic triterpenoid		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
es-285
spisulosine: from marine organism, Spisula polynyma; structure in first source. 1-deoxysphinganine : A bioactive sphingoid, sphinganine, in which the terminal hydroxy group has been replaced by a hydrogen.		6.3242amino alcohol;
sphingoid		antineoplastic agent
tocotrienols
tocotrienol : A tocol in which the hydrocarbon chain at position 2 contains three double bonds.		2.610diterpenoid
l 706000
L 706000: a spirobenzopyran piperidine; structure given in first source		2.0210
rotigaptide
rotigaptide: an antiarrhythmic peptide		2.0310
samarium
sphingomyelin 16:0 : A sphingomyelin in which the total number of carbons contained in the sphingoid base and fatty acyl groups is 16 with zero double bonds.. sphingomyelin d18:1/16:0 : A sphingomyelin d18:1 in which the fatty acyl group contains 16 carbons and is fully saturated.. N-hexadecanoylsphingosine-1-phosphocholine : A sphingomyelin 34:1 in which the N-acyl group and sphingoid base are specified as hexadecanoyl and sphingosine respectively.		2.0810sphingomyelin d18:1/16:0mouse metabolite
cc 1065
CC 1065: from Streptomyces zelensis; structure in second sourc		1.9610
npi 2358
NPI 2358: antineoplastic; structure in first source. plinabulin : A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione substituted by benzylidene and (5-tert-butyl-1H-imidazol-4-yl)methylidene groups at positions 3 and 6, respectively. It is a vascular disrupting agent and a microtubule destabalising agent which was in clinical trials (now discontinued) for the treatment of non-small cell lung cancer.		3.16102,5-diketopiperazines;
benzenes;
imidazoles;
olefinic compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
tetramethylrhodamine
tetramethylrhodamine: RN given refers to perchlorate; structure		2.0110xanthene dye
u 18666a
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.		2.0610hydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor
cgp 55845a
CGP 55845A: GABA-B receptor antagonist; RN refers to cpd with no isomeric designation; CGP 55845 is the (1S,2S)-isomer		2.2110
benzyloxycarbonyl-isoleucyl-glutamyl(o-tert-butyl)-alanyl-leucinal
benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal: inhibits chymotrypsin activity of the proteasome		2.3920
g(m1) ganglioside
G(M1) Ganglioside: A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.. ganglioside GM1 : A sialotetraosylceramide consisting of a branched pentasaccharide made up from one sialyl residue, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage.		2.3920alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine;
sialotetraosylceramide
vortioxetine
Vortioxetine: A piperazine derivative that acts as a serotonin reuptake inhibitor, as a 5-HT3 receptor antagonist, and 5-HT1A receptor agonist. It is used for the treatment of anxiety and depression.. vortioxetine : An N-arylpiperazine in which the aryl group is specified as 2-[(2,4-dimethylphenyl)sulfanyl]phenyl. Used (as its hydrobromide salt) for treatment of major depressive disorder.		2.1510aryl sulfide;
N-arylpiperazine		antidepressant;
anxiolytic drug;
serotonergic agonist;
serotonergic antagonist
aluminum oxide
Aluminum Oxide: An oxide of aluminum, occurring in nature as various minerals such as bauxite, corundum, etc. It is used as an adsorbent, desiccating agent, and catalyst, and in the manufacture of dental cements and refractories.		2.0410
cgp 20712a
CGP 20712A: structure given in first source; CGP 26505, a beta1-selective beta-adrenoceptor antagonist, is the (S)-isomer of CGP 20712A		2.4620
nutlin 1
nutlin 1: an MDM2 antagonist; structure in first source		2.0510
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane: used in PET and SPECT imaging of dopamine transporters; structure in first source		2.0810
methionine sulfoxide
methionine sulfoxide: RN given refers to cpd without isomeric designation. L-methionine (R)-S-oxide : The (R)-oxido diastereomer of L-methionine S-oxide.		2.7630amino acid zwitterion;
L-methionine S-oxide		Escherichia coli metabolite
bx795
BX795: structure in first source		2.110ureas
arl-67156
6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP: an inhibitor of ecto-ATPase		2.1310
eponemycin
eponemycin: structure given in first source; isolated from Streptomyces hygroscpicus No. P247-71; active against B16 melanoma		3.6390
dihydroeponemycin
dihydroeponemycin: structure in first source		4.3760
cystathionine
Cystathionine: Sulfur-containing amino acid formed as an intermediate in the conversion of METHIONINE to CYSTEINE.. cystathionine : A modified amino acid generated by enzymic means from homocysteine and serine.		8.21500cysteine derivative
a 443654
A 443654: an Akt kinase inhibitor; structure in first source		2.0310indoles
vitamin u
Vitamin U: A vitamin found in green vegetables. It is used in the treatment of peptic ulcers, colitis, and gastritis and has an effect on secretory, acid-forming, and enzymatic functions of the intestinal tract.. S-methyl-L-methioninate : A sulfonium betaine that is a conjugate base of S-methyl-L-methionine obtained by the deprotonation of the carboxy group.		210methyl-L-methionine;
sulfonium betaine
ly 379268
LY 379268: group II metabotropic glutamate receptor agonist; structure in first source. LY 379268 : An organic heterobicyclic compound that is (1R,5S)-2-oxabicyclo[3.1.0]hexane carrying amino, carboxy, and carboxy groups at positions 4R, 4R and 6R, respectively. It is a potent agonist of group II metabotropic glutamate receptors mGluR2 and mGluR3 (EC50 = 2.69 nM and 4.48 nM, respectively) that exhibits antipsychotic-like action in animal models of schizophrenia.		2.2110amino dicarboxylic acid;
bridged compound;
organic heterobicyclic compound		antipsychotic agent;
anxiolytic drug;
metabotropic glutamate receptor agonist;
neuroprotective agent
homocarnosine
homocarnosine: RN given refers to parent cpd. homocarnosine : A histidine derivative that is histidine in which one of the hydrogens attached to the alpha-amino group has been replaced by a 4-aminobutanoyl group.		2.0510dipeptide zwitterion;
dipeptide;
homocarnosine;
L-histidine derivative;
N-acyl-L-alpha-amino acid anion;
N-acyl-L-alpha-amino acid		human metabolite
thapsigargicin
thapsigargicin: a hexaoxygenated tetraacylated sesquiterpene lactone tetraester isolated from roots of Thapsia garganica; structure given in first source; it induces mast cell degranulation and histamine release; it (and thapsitranstagin) is an analog of thapsigargin;		2.0510
trans-sodium crocetinate
trans-sodium crocetinate: vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma		2.0510
sotrastaurin
sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.		2.1710indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines		anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent
alpha-synuclein
alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.		8.85990
scytophycin c
scytophycin C: structure in first source		2.0410diterpene lactone
eledoisin
Eledoisin: A peptide extracted from the posterior salivary glands of certain small octopi (Eledone spp., Mollusca), or obtained by synthesis. Its actions resemble those of SUBSTANCE P; it is a potent vasodilator and increases capillary permeability. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1364)		2.420peptide
7-aminoactinomycin d
7-aminoactinomycin D: staining reagent used in flow cytometry		2.0810
angiotensin amide
Angiotensin Amide: The octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction.		1.9310oligopeptide
adrenocorticotropic hormone
ACTH (1-4): N-terminal tetrapeptide of ACTH		1.9510
2-furoyl-ligrlo-amide
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist		2.7830
artemisitene
artemisitene: RN given for (3R-(3alpha,5abeta,6beta,8abeta,12beta,12aR*))-isomer; structure in first source		2.2110
arginyl-glycyl-serine
arginyl-glycyl-serine: synthetic RGS peptide specifically inhibits the binding of P1,P4-diadenosine 5'-tetraphosphate to its membrane receptor; do not confuse with RGS proteins (Regulator of G-protein Signaling)		1.9910oligopeptide
sl0101
SL0101: p90 Ribosomal S6 Kinase; structure in first source		2.0410
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		3.96130
n-arachidonoyl l-serine
N-arachidonoyl L-serine: an endocannabinoid-like brain constituent with vasodilatory properties; structure in first source. N-arachidonoyl-L-serine : An N-acyl-amino acid resulting from the formal condensation of the carboxy group of arachidonic acid with the amino group of L-serine. It is an endocannabinoid-like lipid isolated from bovine brains.		3.6790N-(fatty acyl)-L-alpha-amino acidcannabinoid receptor agonist;
mammalian metabolite;
neuroprotective agent;
pro-angiogenic agent;
vasodilator agent
spliceostatin a
spliceostatin A: antiangiogenic agent that blocks expression of VEGF; structure in first source		2.1110
n-isobutyrylglycine
N-isobutyrylglycine: found in urine of patients with glyceric acidemia. N-isobutyrylglycine : An N-acylglycine in which the acyl group is specified as isobutryl.		1.9610N-acylglycinehuman urinary metabolite
ucn 1028 c
calphostin C: structure given in first source; isolated from Cladosporium cladosporioides		4.02140
ribose
ribopyranose : The pyranose form of ribose.		10.69270D-ribose;
ribopyranose
acebutolol
alpha-D-glucosyl-(1->4)-alpha-D-mannose : An alpha-D-glucosyl-(1->4)-D-mannopyranose in which the anomeric hydroxy group has alpha configuration.		5.09170alpha-D-glucosyl-(1->4)-D-mannopyranose
callipeltin d
callipeltin D: structure in first source		2.0410
regorafenib
[no description available]		2.2110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
erastin
erastin: an antineoplastic agent; structure in first source. erastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer.		2.1310aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide		antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor
griseoviridin
griseoviridin: produced by Streptomyces griseus		6.9310
epoxomicin
[no description available]		4.2250morpholines;
tripeptide		proteasome inhibitor
abt-737
[no description available]		2.4110aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
brimonidine tartrate
Brimonidine Tartrate: A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.		210
3-cyano-n-(1,3-diphenyl-1h-pyrazol-5-yl)benzamide
3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide: affects mGluR5 receptors; structure in first source		2.0510
fg-4592
roxadustat: structure in first source. roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH).		2.2110aromatic ether;
isoquinolines;
N-acylglycine		EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
ascochlorin
ascochlorin: structure in first source. ascochlorin : A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde which is substituted by a (1E,3E)-3-methyl-1-[(1R,2R,6R)-1,2,6-trimethyl-3-oxocyclohexyl]penta-1,3-dien-5-yl group at position 3, chlorine at position 5, and a methyl group at position 6. A meroterpenoid produced by several fungi including Ascochyta viciae . It exhibits anticancer, antifungal and antiprotozoal activities.		2.0510cyclohexanones;
dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid		angiogenesis inhibitor;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite
nystatin a1
Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.		2.6830nystatins
asperazine
asperazine: structure in first source		210
nu 7441
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source		2.0810dibenzothiophenes
marizomib
marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source		2.0610beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide		antineoplastic agent;
proteasome inhibitor
bi 2536
[no description available]		2.4820
potassium cyanate
potassium cyanate: RN given refers to cpd with MF of K-CHNO		210cyanate salt;
one-carbon compound		herbicide
verubulin
verubulin: antineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps; structure in first source		2.0610
nutlin-3a
nutlin 3: an MDM2 antagonist; structure in first source		8.6890stilbenoid
alogliptin
alogliptin: structure in first source. alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.		2.0810nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
cp 154526
CP 154526: structure in first source		2.0710
pyrazolone
pyrazolone: non-steroid antirheumatic agent. pyrazolone : A member of the class of pyrazoles in which one of the carbons of the pyrazole ring is substituted by an oxo group.		7.0610
methylphenidate
N-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide: a fatty acid amide hydrolase inhibitor; structure in first source		2.0310
dorsomorphin
dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.		2.7530aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
monomethyl auristatin e
[no description available]		2.0310
pyroxasulfone
pyroxasulfone: an herbicide		2.610
sitagliptin phosphate
Sitagliptin Phosphate: A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.		2.0810
pf 573228
6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first source		2.0810quinolines
veratridine
Veratridine: A benzoate-cevane found in VERATRUM and Schoenocaulon. It activates SODIUM CHANNELS to stay open longer than normal.		7.730
idelalisib
idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.		2.110aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
cgp 57380
CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1		2.1510pyrazolopyrimidine
nepetalactol
nepetalactol: a sex pheromone isolated from the potato aphid, Macrosiphum euphorbiae; structure in first source. cis-trans-nepetalactol : A cyclopentapyran that is 1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran substituted at position 1 by a hydroxy group and at positions 4 and 7 by methyl groups (the 4aS,7S,7aR-diastereomer)		2.2110cyclopentapyran;
lactol
mk-8745
MK-8745: inhibits aurora kinase A; structure in first source		2.4110
trametinib
[no description available]		3.710acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
mln8054
[no description available]		2.0310benzazepine
pha 767491
PHA 767491: a Cdc7 inhibitor; structure in first source		2.0810pyrrolopyridine
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		5.31170
meralluride
[no description available]		1.9310
imidazolone
imidazolone: a reaction product of arginine with 3-deoxyglucosone which markedly accumulates in uremic serum; structure in first source		2.0210organonitrogen heterocyclic compound
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc
Sialyl Lewis X Antigen: A sialylated version of Lewis X antigen expressed on cell surfaces. It is a ligand for SELECTINS.. alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc : A branched amino tetrasaccharide consisting of a sialyl residue, linked (2->3) to a galactosyl residue that in turn is linked (1->4) to a glucosaminyl residue, which is also carrying a fucosyl residue at the 3-position.		2.730amino tetrasaccharide;
glucosamine oligosaccharide		epitope
aplyronine a
aplyronine A: depolymerizes actin; potent antitumor cpd from the sea hare Aplysia kurodai; structure in first source		4.7390
2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose
2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose: fluorescent probe for glucose uptake activity in E coli; structure given in first source		2.4920
n-acetylmannosamine
N-acetylmannosamine: RN given refers to cpd without isomeric designation. N-acetylmannosamine : Any mannosamine carrying an N-acetyl substituent		1.9710
palmitoylcarnitine
Palmitoylcarnitine: A long-chain fatty acid ester of carnitine which facilitates the transfer of long-chain fatty acids from cytoplasm into mitochondria during the oxidation of fatty acids.. O-palmitoyl-L-carnitine : An O-acyl-L-carnitine in which the acyl group is specified as palmitoyl (hexadecanoyl).		2.0210O-palmitoylcarnitine;
saturated fatty acyl-L-carnitine		EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
human metabolite;
mouse metabolite
technetium tc 99m exametazime
Technetium Tc 99m Exametazime: A gamma-emitting RADIONUCLIDE IMAGING agent used in the evaluation of regional cerebral blood flow and in non-invasive dynamic biodistribution studies and MYOCARDIAL PERFUSION IMAGING. It has also been used to label leukocytes in the investigation of INFLAMMATORY BOWEL DISEASES.		3.411
ly2603618
[no description available]		2.110ureas
calcimycin
Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.		4.4210benzoxazole
veliparib
[no description available]		2.2510benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
syringomycin
syringomycin: from Pseudomonas syringae; phytotoxin; small peptide containing molecule. syringomycin : A class of cyclodepsipeptides which are secreted by the plant pathogen Pseudomonas syringae. Composed from nine nonribosomally synthesised amino acids bonded to a fatty acid hydrocarbon tail.		1.9710
delta-1-pyrroline-5-carboxylate
delta-1-pyrroline-5-carboxylate: (L)-isomer is the biologically active form; RN given refers to cpd without isomeric designation; structure		2.6101-pyrroline-5-carboxylate
sepharose
agarose : A linear polysaccharide made up from alternating D-galactose and 3,6-anhydro-alpha-L-galactopyranose residues joined by alpha-(1->3)- and beta-(1->4)-linkages.		3.85120
scopolamine hydrobromide
[no description available]		3.0950
pituitrin
Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).		5.45200
podophyllin
Podophyllin: Caustic extract from the roots of Podophyllum peltatum and P. emodi. It contains PODOPHYLLOTOXIN and its congeners and is very irritating to mucous membranes and skin. Podophyllin is a violent purgative that may cause CNS damage and teratogenesis. It is used as a paint for warts, skin neoplasms, and senile keratoses.		1.9410
cyclohexylalanine
cyclohexylalanine: RN given refers to cpd without isomeric designation		1.9910
phytosterols
Phytosterols: A class of organic compounds known as sterols or STEROIDS derived from plants.. phytosterols : Sterols similar to cholesterol which occur in plants and vary only in carbon side chains and/or presence or absence of a double bond.		2.7230
apis
apiose: RN given refers to (D)-isomer; structure		1.9410carbohydrate
enerbol
Life: The state that distinguishes organisms from inorganic matter, manifested by growth, metabolism, reproduction, and adaptation. It includes the course of existence, the sum of experiences, the mode of existing, or the fact of being. Over the centuries inquiries into the nature of life have crossed the boundaries from philosophy to biology, forensic medicine, anthropology, etc., in creative as well as scientific literature. (Random House Unabridged Dictionary, 2d ed; Dr. James H. Cassedy, NLM History of Medicine Division)		2.0410
dihydrotachysterol
Dihydrotachysterol: A VITAMIN D that can be regarded as a reduction product of vitamin D2.. dihydrotachysterol : A hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent.		1.9610
clove
Madagascar: One of the Indian Ocean Islands off the southeast coast of Africa. Its capital is Antananarivo. It was formerly called the Malagasy Republic. Discovered by the Portuguese in 1500, its history has been tied predominantly to the French, becoming a French protectorate in 1882, a French colony in 1896, and a territory within the French union in 1946. The Malagasy Republic was established in the French Community in 1958 but it achieved independence in 1960. Its name was changed to Madagascar in 1975. (From Webster's New Geographical Dictionary, 1988, p714)		2.0510
acid phosphatase
Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.		9.15170
2-methyltryptophan
2-methyltryptophan: RN given for (L)-isomer. 2-methyl-L-tryptophan : An L-tryptophan derivative in which the hydrogen at position 2 on the indole ring is replaced by a methyl group.		1.9810amino acid zwitterion;
L-tryptophan derivative		bacterial metabolite
chikusetsu saponin iva
chikusetsu saponin IVa: from the tubers of Hemsleya pengxianensis (Cucurbitaceae)		2.2110triterpenoid saponinmetabolite
glyx-13 peptide
GLYX-13 peptide: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator		2.7730
icatibant
icatibant: a potent bradykinin (B2) receptor antagonist; WIN 65365 is an L-Tic(7) stereoisomer. icatibant : A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acute attacks of hereditary angioedema in adult patients.		2.4220
cyanidin-3-o-beta-glucopyranoside
cyanidin-3-O-beta-glucopyranoside: a natural compound distributed in several fruits & vegetables, such as strawberry, rhubarb, cherry, red cabbage, red onion, cranberries, etc.		2.4620
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		8.71330organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
mdv 3100
[no description available]		2.8630(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent
radicamine b
radicamine B: structure in first source		2.0410
tin mesoporphyrin
tin mesoporphyrin: structure given in first source; RN given refers to dihydrogen, (SP-4-2)-isomer; RN for cpd without isomeric designation not available 5/88		2.0310
5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione
5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione: an excitatory amino acid antagonist; structure in first source		2.5220
protectin d1
protectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress; structure in first source. protectin D1 : A dihydroxydocosahexaenoic acid that is (4Z,7Z,11E,13E,15Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at positions 10 and 17 (the 10R,17S-stereoisomer). Protectin D1 is one of the specialised proresolving mediators. When produced in neural tissues, it is called neuroprotectin D1		2.4820dihydroxydocosahexaenoic acid;
protectin;
secondary allylic alcohol		anti-inflammatory agent;
apoptosis inhibitor;
hepatoprotective agent;
human xenobiotic metabolite;
neuroprotective agent;
PPARgamma agonist;
specialised pro-resolving mediator
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		4.95360
picogreen
PicoGreen: a DNA-specific dye; has strong affinity for double-stranded DNA and is designed to quantify these molecules in solution; a UV-excitable dye; no further information available 6/96. PicoGreen : A cyanine dye that is 1-phenylquinoline which is substituted at position 2 by a bis[3-(dimethylamino)propyl]amino group and at position 4 by a (3-methyl-1,3-benzothiazol-3-ium-2-yl)methylene group. The counter ion is not stated. A fluorochrome that selectively binds double-stranded DNA and has characteristics similar to that of SYBR-Green I.		2.0510benzothiazoles;
cyanine dye;
quinolines;
tertiary amine		fluorescent dye
alx 1393
ALX 1393: a GlyT2 inhibitor		5.21140
gw 4869
GW 4869: inhibits neutral sphingomyelinase; structure in first source		2.0510
melitten
Melitten: Basic polypeptide from the venom of the honey bee (Apis mellifera). It contains 26 amino acids, has cytolytic properties, causes contracture of muscle, releases histamine, and disrupts surface tension, probably due to lysis of cell and mitochondrial membranes.		2.7830
nosiheptide
nosiheptide: from Streptomyces actuosus; structure		2.4720polyol
cholecystokinin
Cholecystokinin: A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.		4.6990
ceruletide
Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.		2.5820oligopeptidediagnostic agent;
gastrointestinal drug
motilin
Motilin: A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect.		1.9910
dynorphins
Dynorphins: A class of opioid peptides including dynorphin A, dynorphin B, and smaller fragments of these peptides. Dynorphins prefer kappa-opioid receptors (RECEPTORS, OPIOID, KAPPA) and have been shown to play a role as central nervous system transmitters.		2.420
atrial natriuretic factor
Atrial Natriuretic Factor: A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS.		3.87120polypeptide
pleurocidin
pleurocidin: isolated from the skin secretions of the winter flounder Pleuronectes americanus; amino acid sequence in first source		2.0410
lhrh, his(5)-trp(7)-tyr(8)-
LHRH, His(5)-Trp(7)-Tyr(8)-: isolated from chicken hypothalamus; also ostrich; RN given refers to all-(L)-isomer		2.0210
ganirelix
[no description available]		1.9810polypeptide
hirugen
hirugen: amino acid sequence given in first source		210
neuropeptide f
neuropeptide F: amino acid sequence given in first source; MW 4433 Da; from tubellarian Artioposthia triangulata		2.2110
hes1 protein, human
HES1 protein, human: RefSeq NM_005524		2.4220
drosocin
drosocin: amino acid sequence given in first source for drosocin and its precursor; GenBank Z21942		2.0210
glycoprotein e2, hepatitis c virus
glycoprotein E2, Hepatitis C virus: RN refers to quasispecies 4E; amino acid sequence known; caution: HCV also stands for hog cholera virus		2.0710
hevein
hevein: 43-amino acid residue protein from the rubber tree; homology with thionins and WHEAT GERM AGGLUTININS; not strictly a lectin since it does not act as an agglutinin but has the hevein motif characteristic of lectins;		7.4220
peptide i
peptide I: 15-amino acid sequence given in first source; part of a receptor for protein kinase C (RACK)		2.3620
humanin
humanin: suppresses neuronal cell death induced by the Swedish mutant of amyloid precursor protein; suppresses neuronal cell death induced by three different types of FAD genes and amyloid beta; amino acid sequence in first source		2.9540
nociceptin
[no description available]		2.4420organic molecular entity;
polypeptide		human metabolite;
rat metabolite
protein kinase inhibitor peptide
protein kinase inhibitor peptide: 18 amino acid residues given in first source; corresponds to the inhibitory domain of the heat-stable protein kinase inhibitor		1.9910
fibrinopeptide b
Fibrinopeptide B: Two small peptide chains removed from the N-terminal segment of the beta chains of fibrinogen by the action of thrombin. Each peptide chain contains 20 amino acid residues. The removal of fibrinopeptides B is not required for coagulation.		1.9610
protein kinase inhibitor peptide (6-24)
protein kinase inhibitor peptide (6-24): amino acid sequence given in first source		2.0410
gastrins
Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.		4.4670
gramicidin a
Gramicidin: A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN.		3.4880
cobrotoxin
Cobra Neurotoxin Proteins: Toxins, contained in cobra (Naja) venom that block cholinergic receptors; two specific proteins have been described, the small (short, Type I) and the large (long, Type II) which also exist in other Elapid venoms.		1.9810
glucagon
Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.		7.13490peptide hormone
big gastrin
big gastrin: isolated from Zollinger-Ellison syndrome gastrinomas & hog antral mucosa; have encountered tetratricontapeptide & nonadecapeptide gastrin; big-big gastrin significantly higher in patients with duodenal ulcers; big gastrin refers gastrin which has a longer peptide chain than the normal heptadecapeptide gastrin		2.0610
beta-endorphin
beta-Endorphin: A 31-amino acid peptide that is the C-terminal fragment of BETA-LIPOTROPIN. It acts on OPIOID RECEPTORS and is an analgesic. Its first four amino acids at the N-terminal are identical to the tetrapeptide sequence of METHIONINE ENKEPHALIN and LEUCINE ENKEPHALIN.. beta-endorphin : A polypeptide consisting of 31 amino acid residues in the sequence Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu. It is an endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous system and results from processing of the precursor protein proopiomelanocortin (POMC).		2.0210
anthopleurin b
[no description available]		2.0210
neuropeptide y
Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.		2.1110
lantibiotic pep5
lantibiotic Pep5: from staphylococcus epidermidis 5; antibiotic with membrane-disruptive action; induces autolysis in staphylococci		3.1210
htn1 protein, human
HTN1 protein, human: RefSeq NM_002159		210
ularitide
Ularitide: a 32-amino acid peptide derived from (95-126 residues) of ANP PROHORMONE (1-126 residues); not biologically inactivated by a peptidase from dog kidney cortex membranes		1.9810
s6c sarafotoxin
sarafotoxins s6: several isotoxins from Atractaspis engaddensis; has strong cardiotoxic activity; all contain 21 amino acid residues; see also endothelium-derived vasoconstrictor factor		1.9710
iberiotoxin
[no description available]		2.0510
lactoferricin b
lactoferricin B: amino acid sequence given in first source		2.0510
angiotensinogen
Angiotensinogen: An alpha-globulin of about 453 amino acids, depending on the species. It is produced by the liver in response to lowered blood pressure and secreted into blood circulation. Angiotensinogen is the inactive precursor of the ANGIOTENSINS produced in the body by successive enzyme cleavages. Cleavage of angiotensinogen by RENIN yields the decapeptide ANGIOTENSIN I. Further cleavage of angiotensin I (by ANGIOTENSIN CONVERTING ENZYME) yields the potent vasoconstrictor octapeptide ANGIOTENSIN II; and then, via other enzymes, other angiotensins also involved in the hemodynamic-regulating RENIN-ANGIOTENSIN SYSTEM.		4.1950
cortistatin 14
cortistatin: a cortical neuropeptide; shows strong structural similarity to somatostatin; a neuronal depressant; has sleep-modulating activity; amino acid sequence given in first source		2.0710
tannins
Tannins: Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). The two main types are HYDROLYZABLE TANNINS and CONDENSED TANNINS. Historically, the term has applied to many compounds and plant extracts able to render skin COLLAGEN impervious to degradation. The word tannin derives from the Celtic word for OAK TREE which was used for leather processing.		2.3920
oligonucleotides
[no description available]		6.32600
anticodon
Anticodon: The sequential set of three nucleotides in TRANSFER RNA that interacts with its complement in MESSENGER RNA, the CODON, during translation in the ribosome.		4.79320
glucagon-like peptide 1
Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.		3.5780
alpha-endorphin
alpha-Endorphin: An endogenous opioid peptide derived from BETA-LIPOTROPIN of the pro-opiomelanocortin (POMC) system. It is the 16-amino acid sequence of the N-terminal of BETA-ENDORPHIN and differs from GAMMA-ENDORPHIN by one amino acid (beta-endorphin 1-17).		1.9910
msh, 4-nle-7-phe-alpha-
[no description available]		210polypeptidedermatologic drug
c-peptide
C-Peptide: The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.		3.1250
natriuretic peptide, c-type
Natriuretic Peptide, C-Type: A PEPTIDE of 22 amino acids, derived mainly from cells of VASCULAR ENDOTHELIUM. It is also found in the BRAIN, major endocrine glands, and other tissues. It shares structural homology with ATRIAL NATRIURETIC FACTOR. It has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. Several high molecular weight forms containing the 22 amino acids have been identified.		1.9910
ristocetin
Ristocetin: An antibiotic mixture of two components, A and B, obtained from Nocardia lurida (or the same substance produced by any other means). It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro.. ristocetin : A heterodetic cyclic peptide that is produced by species of Amycolatopsis and Nocardia.		3.9740glycopeptide;
heterodetic cyclic peptide;
macrocycle;
tetrasaccharide derivative		antibacterial drug;
antimicrobial agent;
bacterial metabolite;
platelet-activating factor receptor agonist
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		4.9370glycoside
endothelin-1
Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)		4.06140
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		8.4414301,2-diacyl-sn-glycero-3-phosphocholine
kn 92
KN 92: KN 93 isomer; a calcium/calmodulin-dependent kinase II inhibitor;		2.4620
buparlisib
NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source		2.2510aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
vanchrobactin
vanchrobactin: from Vibrio anguillarum serotype O2. vanchrobactin : A catechol-type natural product that is composed of 2,3-dihydroxybenzoic acid, D-arginine and L-serine joined in sequence by peptide linkages. It is a siderophore synthesized by the bacterial fish pathogen Vibrio anguillarum.		2.0510catechols;
dipeptide;
guanidines;
monocarboxylic acid;
primary alcohol;
triol		bacterial metabolite;
marine metabolite;
siderophore
chlorophyll a
Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.		5.23160chlorophyll;
methyl ester		cofactor
phenylmercuric acetate
Phenylmercuric Acetate: A phenyl mercury compound used mainly as a fungicide. Has also been used as a herbicide, slimicide, and bacteriocide.		2.0210arylmercury compound;
benzenes
4-aminophenylmercuriacetate
4-aminophenylmercuriacetate: covalently linked to agarose for purification of FAD & COA with chromatography		2.0210
vendex
Torque: The rotational force about an axis that is equal to the product of a force times the distance from the axis where the force is applied.		2.1310organotin acaricide
thimerosal
Thimerosal: An ethylmercury-sulfidobenzoate that has been used as a preservative in VACCINES; ANTIVENINS; and OINTMENTS. It was formerly used as a topical antiseptic. It degrades to ethylmercury and thiosalicylate.. thimerosal : An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.		2.3110alkylmercury compoundantifungal drug;
antiseptic drug;
disinfectant;
drug allergen
pevonedistat
pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.		2.1710cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate		antineoplastic agent;
apoptosis inducer
ku 0063794
Ku 0063794: an mTOR inhibitor; structure in first source		2.4820benzyl alcohols;
monomethoxybenzene;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
mTOR inhibitor
dihydroceramide
dihydroceramide: lacks the 4-5 trans double bond of the sphingosine moiety of ceramides; structure in first source. N-acylsphinganine : A ceramide consisting of sphinganine in which one of the amino hydrogens is substituted by a fatty acyl group.. dihydroceramide : An N-acylsphingoid obtained by formal condensation of the carboxy group of any fatty acid with the amino group of any dihydrosphingoid base.		2.7430
nocistatin
nocistatin: a peptide that blocks nociceptin action in pain transmission; amino acid sequence in first source		7.4220
sodium salicylate
[no description available]		2.940organic molecular entity
sphingosine kinase
[no description available]		3.360
ubiquinone
Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.		3.5180
4-o-galactopyranosylxylose
4-O-galactopyranosylxylose: used to diagnose hypolactasia via presence of D-xylose after cleavage by lactase		1.9710
elaiomycin
elaiomycin: naturally occurring azoxyalkene; RN given refers to cpd without isomeric designation; structure		6.9310
calpain
Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.		5.98340
lucifer yellow
lucifer yellow: RN given refers to di-Li salt		2.7430organic lithium saltfluorochrome
thiocystine
thiocystine: produced in the hydrolysis of proteins		1.9610
menotropins
Menotropins: Extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, FOLLICLE STIMULATING HORMONE and LUTEINIZING HORMONE. Menotropins are used to treat infertility. The FSH:LH ratio and degree of purity vary in different preparations.		2.4110
chitosan
[no description available]		3.0240
9-(tetrahydro-2-furyl)-adenine
[no description available]		210
mycosporine-2-glycine
mycosporine-2-glycine: structure in first source		2.6120
s-nitro-n-acetylpenicillamine
S-nitro-N-acetylpenicillamine: a NO donor		2.7230
mesna
Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.		2.0210organosulfonic acid
bucladesine
Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.		4.161703',5'-cyclic purine nucleotide
sodium hypochlorite
Sodium Hypochlorite: It is used as an oxidizing and bleaching agent and as a disinfectant. (From Grant & Hackh's Chemical Dictionary, 5th ed). sodium hypochlorite : An inorganic sodium salt in which hypochlorite is the counterion. It is used as a bleaching and disinfecting agent and is commonly found in household bleach.		2.3920inorganic sodium saltbleaching agent;
disinfectant
sodium nitrite
Sodium Nitrite: Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines.. sodium nitrite : An inorganic sodium salt having nitrite as the counterion. Used as a food preservative and antidote to cyanide poisoning.		2.1510inorganic sodium salt;
nitrite salt		antidote to cyanide poisoning;
antihypertensive agent;
antimicrobial food preservative;
food antioxidant;
poison
stearates
Stearates: Salts and esters of the 18-carbon saturated, monocarboxylic acid--stearic acid.		2.0310
sodium glutamate
Sodium Glutamate: One of the FLAVORING AGENTS used to impart a meat-like flavor.. monosodium glutamate : An organic sodium salt that is the monosodium salt of glutamic acid.		3.150monosodium glutamateflavouring agent
merocyanine dye
merocyanine dye: fluorescent dye used for studying axons 2 position on pyrimidine ring may be S or O; RN given refers to Na salt; structure		2.4120
(2-sulfonatoethyl)methanethiosulfonate
(2-sulfonatoethyl)methanethiosulfonate: RN given for Na salt		2.4420
sodium ethylxanthate
Sex: The totality of characteristics of reproductive structure, functions, PHENOTYPE, and GENOTYPE, differentiating the MALE from the FEMALE organism.		2.3820
piperacillin, tazobactam drug combination
Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.		2.3110
chiniofon
Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.		4.6660
arginine
Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.		210
gadofosveset trisodium
gadofosveset trisodium: a low molecular weight molecule chelated to Gadolinium, that strongly binds to plasma proteins; Vasovist is an injectable for imaging the vascular system by magnetic resonance angiography		2.0310
olaparib
[no description available]		2.5420cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
thiostrepton
Thiostrepton: One of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria. In veterinary medicine, it has been used in mastitis caused by gram-negative organisms and in dermatologic disorders.. thiostrepton : A heterodetic cyclic peptide, in which the cyclisation step involves a formal lactonisation between the carboxy group of a quinaldic acid-based residue and a secondary alcohol. An antibiotic that inhibits bacterial protein synthesis. Also acts as an antitumor agent.		2.4220
picrotoxinin
picrotoxinin: toxic component of PICROTOXIN; structure; noncompetitive antagonist of ionotropic GABA-A receptors. picrotoxinin : A picrotoxane sesquiterpenoid that is 3a,4,5,6,7,7a-hexahydro-1H-indene-3,7-dicarboxylic acid which is substituted at positions 3a, 6, and 7a by methyl, isopropenyl, and hydroxy groups, respectively; in which the double bond at position 2-3 has been epoxidised; and in which the carboxy groups at positions 3 and 7 have undergone gamma-lactone formation by O-alkylation to positions 4 and 5, respectively. A component of picrotoxin.		2.6930
srt1720
[no description available]		2.2510
papuamide a
papuamide A: from marine sponge of genus Theonella; structure in first source		2.0110
plx 4720
PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source		2.6320aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
cx 4945
[no description available]		2.5220
s-adenosylmethionine
(R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.		7.24540organic cation;
sulfonium compound		coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
mln 8237
MLN 8237: an aurora kinase A inhibitor		2.2110benzazepine
uridine diphosphate n-acetylmuramic acid
Uridine Diphosphate N-Acetylmuramic Acid: A nucleoside diphosphate sugar which is formed from UDP-N-acetylglucosamine and phosphoenolpyruvate. It serves as the building block upon which peptidoglycan is formed.. UDP-N-acetyl-alpha-D-muramate(3-) : A UDP-N-acetyl-D-muramate(3-) in which the anomeric centre of the pyranose fragment has alpha-configuration.		2.0510UDP-N-acetylmuramate(3-)
sgi 1776
SGI 1776: a Pim kinase inhibitor; structure in first source		2.2110imidazoles
picrotoxin
Picrotoxin: A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the GAMMA-AMINOBUTYRIC ACID-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates.. picrotoxin : A mixture consisting of equimolar amounts of picrotoxinin and picrotin found in the climbing plant Anamirta cocculus.		3.87120
2',3'-o-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate
2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate: analog of ATP; do not confuse with TNP-ATP record		3.1150C-nitro compound;
spiroketal		antagonist
pci 32765
ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.		2.110acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
papuamide b
papuamide B: from marine sponge of genus Theonella; structure in first source. papuamide B : A cyclodepsipeptide that is isolated from Papua New Guinea collections of the marine sponges Theonella mirabilis and Theonella swinhoei. It exhbits anti-HIV-1 activity and cytotoxicity against some human cancer cell lines.		2.0110cyclodepsipeptide;
olefinic compound;
secondary alcohol;
tertiary alcohol		anti-HIV-1 agent;
antineoplastic agent;
marine metabolite
quizartinib
[no description available]		7.610benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
rg 1678
(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone: a GlyT1 inhibitor; structure in first source		6.8733
mk 2206
MK 2206: a protein kinase inhibitor and antineoplastic agent		2.7930organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
pervanadate
pervanadate: from a mixture of orthovanadate and hydrogen peroxide		3.6290
egg white
Egg White: The white of an egg, especially a chicken's egg, used in cooking. It contains albumin. (Random House Unabridged Dictionary, 2d ed)		2.8740
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene
[no description available]		2.0210BODIPY compound
quetiapine fumarate
Quetiapine Fumarate: A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.		2.0310fumarate salt
chlorin e4
chlorin e4: RN given for (2S-trans)-isomer; structure in first source		7.2110
cardiovascular agents
Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.		2.9840
trelstar
Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.		2.0110
nafarelin
Nafarelin: A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS.. nafarelin : An oligopeptide comprising of 5-oxo-L-proline, L-histidine, L-tryptophan, L-serine, L-tyrosine, 3-(2-naphthyl)-D-alanine, L-leucine, L-arginine and L-prolylglycinamide residues joined sequence by peptide linkages. It is a gonadotropin releasing hormone agonist that is used to treat central precocious puberty in children and endometriosis in women.		1.9810oligopeptideanti-estrogen;
gonadotropin releasing hormone agonist
neurotensin
neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91		4.1850peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
fibrinopeptide a
Fibrinopeptide A: Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.		2.3820
apelin-13 peptide
apelin-13 peptide: amino acid sequence in first source. apelin-13 : A 13 amino acid oligopeptide which is the ligand for the apelin receptor (also known as the APJ receptor). It exhibits hypotensive and neuroprotective effects, and may be a potential prognostic biomarker for acute ischemic stroke and multiple sclerosis.		2.110oligopeptideantihypertensive agent;
autophagy inhibitor;
biomarker;
human metabolite;
neuroprotective agent
pf 750
N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide: a fatty acid amide hydrolase inhibitor; structure in first source		2.0310quinolines
nitrogenase
Nitrogenase: An enzyme system that catalyzes the fixing of nitrogen in soil bacteria and blue-green algae (CYANOBACTERIA). EC 1.18.6.1.		3.79110
taurolithocholic acid 3-sulfate
taurolithocholic acid sulfate(2-) : A steroid sulfate oxoanion arising from deprotonation of both sulfo groups of taurolithocholic acid sulfate; major species at pH 7.3.		2.4320steroid sulfate oxoanionhuman metabolite
tetrahydrozoline
2-methylserine: RN given refers to cpd without isomeric designation. 2-methylserine zwitterion : An amino acid zwitterion arising from transfer of a proton from the carboxy to the amino group of 2-methylserine; major species at pH 7.3. 2-methylserine : A hydroxy-amino acid that is serine which is substituted by a methyl group at position 2.		3.76110amino acid zwitterion;
hydroxy-amino acid
inositol 1,4-bis(phosphate)
inositol 1,4-bis(phosphate): induced in human platelets by thrombin; RN given refers to cpd without isomeric designation. 1D-myo-inositol 1,4-bisphosphate(4-) : An organophosphate oxoanion arising from deprotonation of the phosphate OH groups of 1D-myo-inositol 1,4-bisphosphate; major species at pH 7.3.		1.9710
s-ethylcysteine
S-ethylcysteine: RN given refers to cpd with unspecified isomeric designation. S-ethyl-L-cysteine zwitterion : A S-alkyl-L-cysteine zwitterion obtained by transfer of a proton from the carboxy to the amino group of S-ethyl-L-cysteine; major species at pH 7.3.		2.8940S-alkyl-L-cysteine zwitterion;
S-alkyl-L-cysteine		antitubercular agent
p-ethynylphenylalanine
p-ethynylphenylalanine: structure in first source		2.1110
pf 3758309
PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source		2.1110organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
phosphinothricin
phosphinothricin: RN given refers to parent cpd with unspecified isomeric designation; structure. phosphinothricin(1-) : Conjugate base of phosphinothricin arising from deprotonation of the phosphinate function.		2.1110organic anion
mahanine
mahanine: structure in first source		2.110
11,12-epoxy-5,8,14-eicosatrienoic acid
11,12-epoxy-5,8,14-eicosatrienoic acid: RN given refers to cpd without isomeric designation. (11S,12R)-EET : An 11,12-EET in which the epoxy moiety has 11S,12R-configuration.. 11,12-EET : An EET obtained by formal epoxidation of the 11,12-double bond of arachidonic acid.		2.031011,12-EEThuman xenobiotic metabolite
peptones
Peptones: Derived proteins or mixtures of cleavage products produced by the partial hydrolysis of a native protein either by an acid or by an enzyme. Peptones are readily soluble in water, and are not precipitable by heat, by alkalis, or by saturation with ammonium sulfate. (Dorland, 28th ed)		8.65100
lysophosphatidylserine
lysophosphatidylserine: stimulates histamine secretion from isolated mast cells in mouse plasma. lysophosphatidylserine : An acylglycerophosphoserine resulting from partial hydrolysis of a phosphatidylserine, which removes one of the fatty acid groups. The structure is depicted in the image where R(1) = acyl, R(2) = H or where R(1) = H, R(2) = acyl. Formula C7H13NO9PR, where R represents the hydrocarbon chain of the fatty acyl group.. 1-stearoyl-sn-glycero-3-phosphoserine : A 1-acyl-sn-glycerophosphoserine in which the acyl group is specified as stearoyl (octadecanoyl).		7101-acyl-sn-glycero-3-phosphoserine
plx4032
[no description available]		2.6920aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
mk-7655
relebactam: structure in first source		2.4110
cytochromes c1
Cytochromes c1: The 30-kDa membrane-bound c-type cytochrome protein of mitochondria that functions as an electron donor to CYTOCHROME C GROUP in the mitochondrial and bacterial RESPIRATORY CHAIN. (From Enzyme Nomenclature, 1992, p545)		2.3820
ganglioside, gd1a
[no description available]		1.9810
glycolipids
[no description available]		13.311020
beta-sultam
beta-sultam: structure in first source		2.4220
v158411
V158411: a Chk1 inhibitor; structure in first source		2.1310
piperidines
Piperidines: A family of hexahydropyridines.		6.26450
sr1001
SR1001: a selective RORalpha and RORgamma inverse agonist; structure in first source		2.0610sulfonamide
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
ML-265: a small molecule activator of PKM2		2.4110organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
resolvin d1
resolvin D1: an anti-inflammatory lipid mediator; structure in first source. resolvin D1 : A resolvin that is docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid which is substituted by hydroxy groups at the 7, 8, and 17 positions (the 7S,8R,17S-stereoisomer).		2.110hydroxy polyunsaturated fatty acid;
resolvin;
triol		anti-inflammatory agent
bryostatin 1
bryostatin 1: a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S*-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-isomer; structure given in first source; activates protein kinase c. bryostatin 1 : A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.		3.470
thymosin
Thymosin: Thymosin. A family of heat-stable, polypeptide hormones secreted by the thymus gland. Their biological activities include lymphocytopoiesis, restoration of immunological competence and enhancement of expression of T-cell characteristics and function. They have therapeutic potential in patients having primary or secondary immunodeficiency diseases, cancer or diseases related to aging.		2.6830
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		4.72280
dabrafenib
[no description available]		3.7101,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
zwittermicin a
zwittermicin A: isolated from Bacillus cereus; structure in first source. (+)-zwittermicin A : The (+)-enantiomer of zwittermicin A. It is a water-soluble natural antibiotic from the fermentation of the soil-borne bacterium Bacillus cereus and shows significant activity against phytopathogenic fungi.		7.04104,8-diamino-N-[1-amino-3-(carbamoylamino)-1-oxopropan-2-yl]-2,3,5,7,9-pentahydroxynonanamide;
peptide antibiotic		antifungal agent;
bacterial metabolite
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline
[no description available]		2.4110benzenes;
sulfonamide
ribociclib
ribociclib: inhibits both CDK4 and CDK6		2.1510
colistin
Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.		2.3920
phenylserine
phenylserine: structure in first source		4.45230
exenatide
Exenatide: A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.		2.4620
gsk 2334470
GSK 2334470: a PDK1 inhibitor; structure in first source		2.0710indazoles
lrrk2-in1
LRRK2-IN1: inhibits leucine-rich repeat kinase 2; structure in first source		2.5220aromatic amine;
aromatic ether;
N-acylpiperidine;
N-alkylpiperazine;
pyrimidobenzodiazepine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
uridine diphosphate n-acetylgalactosamine
Uridine Diphosphate N-Acetylgalactosamine: A nucleoside diphosphate sugar which serves as a source of N-acetylgalactosamine for glycoproteins, sulfatides and cerebrosides.. UDP-N-acetyl-D-galactosamine(2-) : Dianion of UDP-N-acetyl-D-galactosamine arising from deprotonation of the diphosphate OH groups; major species at pH 7.3.. UDP-N-acetyl-D-galactosamine : A UDP-sugar having N-acetyl-D-galactosamine as the sugar component.		3.2560nucleotide-sugar oxoanionhuman metabolite
lgk974
LGK974: a potent and specific small-molecule inhibitor of Porcupine (PORCN) acyltransferase. LGK974 : A carboxamide, the structure of which is that of acetamide substituted on carbon by a 2',3-dimethyl-2,4'-bipyridin-5-yl group and on nitrogen by a 5-(pyrazin-2-yl)pyridin-2-yl group. It is a highly potent, selective and orally bioavailable Porcupine inhibitor (a Wnt signalling inhibitor).		2.4110bipyridines;
pyrazines;
pyridines;
secondary carboxamide		Wnt signalling inhibitor
fructose-1,6-diphosphate
fructose-1,6-diphosphate: RN refers to (D)-isomer		3.6290
bix 01294
BIX 01294: structure in first source		2.0810
kp372-1
KP372-1: mixture of two isomers present in equal amounts; Akt kinase inhibitor; structure in first source		2.0310
lactivicin
lactivicin: non-beta-lactam antibiotic binds to penicillin-binding proteins; structure given in first source		7.0510
achromobactin
achromobactin: isolated from Erwinia chrysanthemi; structure in first source. achromobactin : A citrate siderophore possessing four carboxylate groups suitable for iron coordination.		2.0610tetracarboxylic acid anionsiderophore
ve 821
3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide: an antineoplastic agent; structure in first source		2.1310aromatic amide
methylcellulose
Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.		1.9410
butyrolactone i
butyrolactone I: selective inhibitor of cdk2 & cdc2 kinase; structure given in first source		2.9140butenolide
pf-4708671
[no description available]		2.0810
penicilloate
penicilloic acid: metabolites of penicillins obtained by alkaline cleavage; RN given refers to cpd with unknown MF; structure. penicilloic acid : A thiazolidinedicarboxylic acid obtained via hydrolysis of the beta-lactam ring of a penicillin.		7.110
bocillin fl
BOCILLIN FL: used for detecting pencillin-binding proteins; structure in first source		2.0710
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
infigratinib: structure in first source. BGJ-398 : A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor.		2.4110aminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas		antineoplastic agent;
fibroblast growth factor receptor antagonist
vasoactive intestinal peptide
Vasoactive Intestinal Peptide: A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).		2.9340
natriuretic peptide, brain
Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.		2.610polypeptide
heme
Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.		5.24500
chondroitin
Chondroitin: A mucopolysaccharide constituent of chondrin. (Grant & Hackh's Chemical Dictionary, 5th ed)		7.01410
heparitin sulfate
Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.		6.29190
tuftsin
Tuftsin: N(2)-((1-(N(2)-L-Threonyl)-L-lysyl)-L-prolyl)-L-arginine. A tetrapeptide produced in the spleen by enzymatic cleavage of a leukophilic gamma-globulin. It stimulates the phagocytic activity of blood polymorphonuclear leukocytes and neutrophils in particular. The peptide is located in the Fd fragment of the gamma-globulin molecule.		2.0310peptide
beta-methyltryptophan
beta-methyltryptophan: structure in first source		2.1310
dihydronicotinamide
[no description available]		2.1310
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		10.89190ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
4-hydroxy-6-methyl-2-pyrone
4-hydroxy-6-methyl-2-pyrone: structure in first source		2.1102-pyranones
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		3.2260carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		3.67100
chlortetracycline
Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.		2.8940
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		2.8740
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		2.4320
salicylates
Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.		4.6690monohydroxybenzoateplant metabolite
dicumarol
Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.		1.9410hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
piroxicam
[no description available]		2.4520benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
atpenin a5
atpenin A5: from Penicillium sp. FO-125; MW C15-H21-N-O5-Cl2		2.0310
bactobolin
bactobolin: from Pseudomonas sp. BN-183; has MF C14-H20-Cl2-N2-O6; RN given refers to parent cpd(R*)-isomer		210amino acid amide
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		2.1101,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
isoxicam
isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.		2.110benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		5.74160benzenes;
hydroxycoumarin;
methyl ketone
l 701324
L 701324: a glycine/NMDA receptor antagonist		3.6990quinolines
antimycin
[no description available]		2.0510
delaminomycin a
delaminomycin A: an extracellular matrix receptor antagonist isolated from Streptomyces albulus; structure in first source		1.9810
dolutegravir
[no description available]		2.2510difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor
cheliensisin a
cheliensisin A: structure in first source		2.110
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		8.391670
d-4f peptide
D-4F peptide: an apo A-I mimetic peptide synthesized from D-amino acids; may play a role in reducing inflammatory responses to influenza virus in mice; may also have anti-atherosclerotic properties		2.0510
microcystin
microcystin: microcystins have the general structure cyclo(D-Ala-L-X-D-erythro--methylisoasp-L-Y-Adda-D-isoGlu-N-methyldehydroAla) where X and Y are variable L-amino acids;. microcystin : A family of cyclic heptapeptide hepatotoxins produced by a number of cyanobacteria, the most notable of which is Microcystis, from which the name of the family is derived. Microcystins consist of a heptapeptide macrocycle made up of five non-protein amino acids and two protein amino acids.		2.9240peptide
calca protein, human
CALCA protein, human: RefSeq NM_001741		2.0410
kaolinite
Kaolin: The most common mineral of a group of hydrated aluminum silicates, approximately H2Al2Si2O8-H2O. It is prepared for pharmaceutical and medicinal purposes by levigating with water to remove sand, etc. (From Merck Index, 11th ed) The name is derived from Kao-ling (Chinese: high ridge), the original site. (From Grant & Hackh's Chemical Dictionary, 5th ed). kaolin : An aluminosilicate soft white mineral named after the hill in China (Kao-ling) from which it was mined for centuries. In its natural state kaolin is a white, soft powder consisting principally of the mineral kaolinite, and varying amounts of other minerals such as muscovite, quartz, feldspar, and anatase. It is used in the manufacture of china and porcelain and also widely used in the production of paper, rubber, paint, drying agents, and many other products.		2.3520aluminosilicate mineral;
mixture		antidiarrhoeal drug;
excipient
spliceosomal peptide p140
spliceosomal peptide P140: synthetic peptide, sequence 131-151 of the U1-70K protein phosphorylated at Ser140, which is recognized by lupus CD4+ T cells for the treatment of patients with systemic lupus erythematosus		2.1110
charybdotoxin
[no description available]		2.7530
rhodostomin
rhodostomin: amino acid sequence given in first source; an Arg-Gly-Asp (RGD)-containing polypeptide purified from the venom of Calloselasma rhodostoma		210
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		7.53690
phytoestrogens
Phytoestrogens: Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS.		2.4620
ferrienterochelin
ferrienterochelin: ferric ion enterochelin complex		3.3470
saxitoxin
Saxitoxin: A compound that contains a reduced purine ring system but is not biosynthetically related to the purine alkaloids. It is a poison found in certain edible mollusks at certain times; elaborated by GONYAULAX and consumed by mollusks, fishes, etc. without ill effects. It is neurotoxic and causes RESPIRATORY PARALYSIS and other effects in MAMMALS, known as paralytic SHELLFISH poisoning.. saxitoxin : An alkaloid isolated from the marine dinoflagellates and cyanobacteria that causes paralytic shellfish poisoning.		2.0210alkaloid;
carbamate ester;
guanidines;
ketone hydrate;
paralytic shellfish toxin;
pyrrolopurine		cyanotoxin;
marine metabolite;
neurotoxin;
sodium channel blocker;
toxin
okadaic acid
Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.		6.151240ketal
mycobacillin
Mycobacillin: A cyclic polypeptide antibiotic isolated from culture filtrates of Bacillus subtilis that acts as an antifungal agent.		1.9310
phosphatidylethanol
phosphatidylethanol: formed in rat brain by phospholipase D. phosphatidylethanol : A glycerophospholipid that is the monoethyl ester of any phosphatidic acid.		2.420
azd1208
[no description available]		2.2110
gsk2578215a
GSK2578215A: an inhibitor of LRRK2 kinase; structure in first source		2.2110
tan 67
TAN 67: a non-peptidic selective delta-opioid receptor agonist; structure given in first source		2.0510
gsk2830371
GSK2830371: inhibits Wip1 phosphatase; structure in first source		2.4110
trp-lys-tyr-met-val-met
Trp-Lys-Tyr-Met-Val-Met: a synthetic peptide, stimulates phosphoinositide hyrolysis in human leukocytes		2.0210
laidlomycin
laidlomycin: polycyclic, polyether, monocarboxylic acid posessing inhibitory activity against various Mycoplasma species, especially Acholeplasma laidlawii; structure		1.9910
agar
Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.		3.6190
arsenic trisulfide
[no description available]		2.0310
ziyuglycoside i
ziyuglycoside I: isolated from the leaves of Hex pupurea; structure in first source		2.1710
phleomycin d1
phleomycin D1 : A glycopeptide originally isolated from the bacterium Streptomyces verticillus which contains a (4'R)-4',5'-dihydro-2,4'-bi-1,3-thiazole-2',4-diyl moiety with a a 4-guanidylbutylaminocarbonyl group attached to the 4-position of the terminal thiazole ring. Like all phleomycins, phleomycin D1 can form complexes with redox-active metals such as Co, Cu, and Fe.		2.7330bi-1,3-thiazole;
chelate-forming peptide;
disaccharide derivative;
glycopeptide;
guanidines		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
mycalolide b
mycalolide B: structure given in first source; isolated from the marine sponge Mycale		1.9910
hirudin
Hirudin: A 65-residue polypeptide from LEECHES.		2.9140
glutaminase
[no description available]		5.02130
cyclin d1
Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.		7.02570
i-antigen
I-antigen: used as a marker for well-differentiated leukemia cells; carbohydrate structure of immunodominant epitope is Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3R which is very similar to that of sialyl SSEA-1		2.0110
ganoderic acid
ganoderic acid: from the fruiting body of Ganoderma; structure in first source		2.1510
caseins
Caseins: A mixture of related phosphoproteins occurring in milk and cheese. The group is characterized as one of the most nutritive milk proteins, containing all of the common amino acids and rich in the essential ones.		12.771330
coprogen
coprogen: siderochrome found in Penicillium & Neurospora; structure. coprogen : An iron(III) hydroxamate isolated from fungi and bacteria including Penicillium species and Neurospora crassa. It is a growth factor for coprophilous fungi.		1.9710Fe(III)-complexed hydroxamate siderophore;
homoallylic alcohol		Penicillium metabolite
cefiderocol
cefiderocol: structure in first source. cefiderocol : A fourth-generation siderophore cephalosporin antibiotic having {1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidinium-1-yl}methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively, developed to combat a variety of bacterial pathogens, including beta-lactam- and carbapenem-resistant organisms.		3.5110carboxylic acid;
cephalosporin		antibacterial drug;
siderophore
mitotracker green fm
[no description available]		2.0710
oligomycins
Oligomycins: A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X).		3.690
teixobactin
teixobactin: isolated from an Aquabacteria soil bacterium. teixobactin : A cyclodepsipeptide that is isolated from the previously unculturable bacterial species Eleftheria terrae and is active against gram-positive bacteria.		2.1510cyclodepsipeptide;
macrocycle;
peptide antibiotic		antibacterial agent
g(m3) ganglioside
G(M3) Ganglioside: A ganglioside present in abnormally large amounts in the brain and liver due to a deficient biosynthetic enzyme, G(M3):UDP-N-acetylgalactosaminyltransferase. Deficiency of this enzyme prevents the formation of G(M2) ganglioside from G(M3) ganglioside and is the cause of an anabolic sphingolipidosis.. alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/24:1(15Z)) : A sialotriaosylceramide consisting of beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc attached to the primary hydroxy function of ceramide(d18:1/24:1(15Z)).		3.2460alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide;
sialodiosylceramide;
sialotriaosylceramide		mouse metabolite
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor		3.1250
nitrophenols
Nitrophenols: PHENOLS carrying nitro group substituents.		4.95390
bassianolide
bassianolide: cyclodepsipeptide from mycelia of Beauveria bassiana; inhibits isotonic contractions induced by acetylcholine. bassianolide : A cyclodepsipeptide consisting of a cyclic tetramer of the depsipeptide D-Hiv-N-methyl-L-leucine (where D-Hiv = D-alpha-hydroxyisovaleric acid). Found in the fungal species Beauveria bassiana and Verticillium lecanii, it has insecticidal properties and is used as a commercial biopesticide to control of insects of agricultural, veterinary and medical significance. For elucidation of the structure, see Suzuki et al., Tetrahedron Lett. 1977 v25, 2167-2170.		2.730cyclodepsipeptide;
cyclooctadepsipeptide		antineoplastic agent;
fungal metabolite;
insecticide
bictegravir
bictegravir: HIV Integrase Inhibitors. bictegravir : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid with the amino group of 2,4,6-trifluorobenzylamine. It is a second-generation integrase strand transfer inhibitor (INSTI) and used (as its sodium salt) for the treatment of HIV-1.		2.2510monocarboxylic acid amide;
organic heterotetracyclic compound;
secondary carboxamide;
trifluorobenzene		HIV-1 integrase inhibitor
lewis x antigen
Lewis X Antigen: A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, Lewis X antigen is a stage-specific embryonic antigen.		2.6830
difopein
difopein: consists of two R18 coding sequences joined by a short linker peptide; amino acid sequence in first source		2.1310
glucagon-like peptide 2
Glucagon-Like Peptide 2: A 33-amino acid peptide derived from the C-terminal of PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. It stimulates intestinal mucosal growth and decreased apoptosis of ENTEROCYTES. GLP-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.		2.2110
tws 119
[no description available]		2.1310
angiotensin i
Angiotensin I: A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.. angiotensin I : A ten amino acid peptide formed by renin cleavage of angiotensinogen. Angiotensin I has no direct biological function except that high levels can stimulate catecholamine production. It is metabolized to its biologically active byproduct angiotensin II, a potent vasoconstrictor, by angiotensin converting enzyme (ACE) through cleavage of the two terminal amino acids.. angiotensin I dizwitterion : A peptide zwitterion that is the dizwitterionic form of angiotensin I having both carboxy groups deprotonated and the aspartyl amino group and arginine side-chain protonated. It is the major species at pH 7.3.		7.420angiotensin;
peptide zwitterion		human metabolite;
neurotransmitter agent
cobamamide
cobamamide : A member of the class of cobalamins that is vitamin B12 in which the cyano group is replaced by a 5'-deoxyadenos-5'-yl moiety. It is one of the two metabolically active form of vitamin B12.		2.0410
hyaluronoglucosaminidase
Hyaluronoglucosaminidase: An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS.		5.25170
chloroeremomycin
chloroeremomycin: structure given in first source. chloroeremomycin : A complex glycopeptide antibiotic that is isolated from Amycolatopsis orientalis.. chloroeremomycin(2+) : An organic cation obtained by deprotonation of the carboxy group and protonation of the three amino functions of chloroeremomycin; major species at pH 7.3.		2.0110organic cation
sb 747651a
SB 747651A: inhibits mitogen- and stress-activated kinase 1; structure in first source		2.110
etamycin
etamycin: antibiotic substance (macrolide lactone) produced by Streptomyces griseus & allied Streptomyces; active against gram-positive Mycobacterium tuberculosis & some fungi & other coccal infections; see also neoviridogriseins; structure		1.9310
nephrin
nephrin: gene nephrin is mutated in congenital nephrotic syndrome; amino acid sequence in first source; GenBank F19541; RefSeq NM_019459 (mouse), NM_004646 (human), NM_022628 (rat)		2.4110
salmochelin s4
salmochelin S4: isolated from Salmonella enterica; structure in first source		2.0210C-glycosyl compound;
macrotriolide
shinorine
shinorine: structure in first source. shinorine : A mycosporine-like amino acid that is the ketimine resulting from the formal condensation of the amino group of L-serine with the keto group of (5S)-5-hydroxy-5-(hydroxymethyl)-2-methoxycyclohex-2-en-1-one and in which the hydrogen at position 3 of the cyclohexenone moiety has been replaced by the amino group of glycine. It is an active ingredient found in environmentally friendly sunscreen creams.		2.610
ginkgolide b
[no description available]		2.0110
gibberellins
[no description available]		8.3460
cns 1261
CNS 1261: a potential SPECT agent for imaging NMDA receptor activation; structure in first source		2.0510
daptomycin
[no description available]		7.520
nonactin
nonactin: macrolide tetrolide antibiotic isolated from cycloheximide-producing species of Streptomyces; minor descriptor (75-86); on-line & INDEX MEDICUS search ANTIBIOTICS (75-86)		7.4110
vitamin b 12
Vitamin B 12: A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues. INTRINSIC FACTOR is important for the assimilation of vitamin B 12.		15.54462
ferric ammonium citrate
ferric ammonium citrate: RN given refers to unspecified NH4-Fe(+3) salt. ferric ammonium citrate : A mixture of indefinite composition that contains ferric and ammonium cations and citrate(3-) anions, ferric ammonium citrate may be obtained as red crystals or a brownish yellow powder or as green crystals or powder. It is added to foods as an acidity regulator and anticaking agent. It is also used as a positive oral contrast agent in magnetic resonance imaging, and was formerly administered orally as a source of iron for the treatment of iron-deficiency anaemia.		2.0810
transforming growth factor alpha
Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.		3.5480
6-hydroxy-1,4,5,6-tetrahydronicotinamide adenine dinucleotide
6-hydroxy-1,4,5,6-tetrahydronicotinamide adenine dinucleotide: structure given in first source; RN from Chemical Abstracts Index Guide		2.2110
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		4.46220
alpha1-purothionin protein, wheat
purothionin: polypeptide of relatively low MW; toxic to vertebrates and some bacteria & yeasts; purothionin A-I is believed to be identical to beta-purothionin; RN given refers to cpd with unknown MF		1.9210
flavin mononucleotide
Flavin Mononucleotide: A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues.		3.69100
silybin
Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers.		2.0110
triciribine
triciribine: structure. triciribine : A nucleoside analogue in which the nucleobase portion is a 1,4,5,6,8-pentaazaacenaphthylene ring system substituted with an amino group at position 3, and a methyl group at position 5 and is bound to the beta-D-ribofuranosyl moiety by an N(1)-glycosidic linkage.		2.0810
cytochalasin d
Cytochalasin D: A fungal metabolite that blocks cytoplasmic cleavage by blocking formation of contractile microfilament structures resulting in multinucleated cell formation, reversible inhibition of cell movement, and the induction of cellular extrusion. Additional reported effects include the inhibition of actin polymerization, DNA synthesis, sperm motility, glucose transport, thyroid secretion, and growth hormone release.. cytochalasin D : An organic heterotricyclic compound that is a mycotoxin produced by Helminthosporium and other moulds which is cell permeable and a potent inhibitor of actin polymerisation and DNA synthesis.		3.73100
peptide yy
Peptide YY: A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.. peptide YY : A 36-membered human gut polypeptide consisting of Tyr, Pro, Ile, Lys, Pro, Glu, Ala, Pro, Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Asn, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, His, Tyr, Leu, Asn, Leu, Val, Thr, Arg, Gln, Arg and Tyr-NH2 residues joined in sequence.		7.4320
lactoferrin
Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.		3.3970
crambin protein, crambe abyssinica
crambin protein, Crambe abyssinica: 44 amino acid, molecular weight 5000, water-insoluble protein found in the seed of the plant Crambe abyssinica		1.9910
peptide t
Peptide T: N-(N-(N(2)-(N-(N-(N-(N-D-Alanyl L-seryl)-L-threonyl)-L-threonyl) L-threonyl)-L-asparaginyl)-L-tyrosyl) L-threonine. Octapeptide sharing sequence homology with HIV envelope protein gp120. It is potentially useful as antiviral agent in AIDS therapy. The core pentapeptide sequence, TTNYT, consisting of amino acids 4-8 in peptide T, is the HIV envelope sequence required for attachment to the CD4 receptor.		2.1310
digitonin
Digitonin: A glycoside obtained from Digitalis purpurea; the aglycone is digitogenin which is bound to five sugars. Digitonin solubilizes lipids, especially in membranes and is used as a tool in cellular biochemistry, and reagent for precipitating cholesterol. It has no cardiac effects.. digitonin : A spirostanyl glycoside that is digitogenin in which the 3-hydroxy group is substituted by a beta-D-glucopyranosyl-(1->3)-beta-D-galactopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->3)]-beta-D-glucopyranosyl-(1->4)-beta-D-galactopyranosyl group. It is a steroidal saponin isolated from the foxglove plant, Digitalis purpurea. It is used extensively as a mild non-ionic detergent for extracting proteins from membranes for structure and function studies.		3.0750
catalpol
catalpol: component of dihuang; RN given refers to (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-isomer; RN for cpd without isomeric designation not avail 12/92		210
o-methyl-serine dodecylamide hydrochloride
O-methyl-serine dodecylamide hydrochloride: a lysosomotropic detergent		9.7590
salinipostin a
salinipostin A: isolated from a marine-derived Salinospora sp. bacterium; structure in first source		2.2510
thromboplastin
Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.		4.48230
muramidase
Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17.		6.79490
cord factors
Cord Factors: Toxic glycolipids composed of trehalose dimycolate derivatives. They are produced by MYCOBACTERIUM TUBERCULOSIS and other species of MYCOBACTERIUM. They induce cellular dysfunction in animals.		1.9910
ribosomal protein l7-l12
[no description available]		2.0110
rhamnogalacturonan i
rhamnogalacturonan I: pectic polysaccharide from sycamore cell walls; composed of galactosyluronic acid, rhamnosyl, galactosyl, arabinosyl & fucosyl residues. rhamnogalacturonan I : A family of polysaccharides that all contain a linear backbone composed of repeating units of the disaccharide alpha-D-GalpA-(l->2)-alpha-L-Rhap joined by alpha-(1->4) linkages.		2.1710
lanthiopeptin
lanthiopeptin: Isolated from Streptoverticillium griseoverticillatum; contains 15 amino acids; structure given in first source. cinnamycin : A type B lantibiotic consisting of a 19 amino acid tetracyclic polypeptide produced by Streptomyces cinnamoneus.		210heterodetic cyclic peptide;
L-cysteine thioether;
macrocycle;
type B lantibiotic
amyloid beta-peptides
amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined		3.82110
chondroitin sulfates
Chondroitin Sulfates: Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.		5.72270
exudates
Malaysia: A parliamentary democracy with a constitutional monarch in southeast Asia, consisting of 11 states (West Malaysia) on the Malay Peninsula and two states (East Malaysia) on the island of BORNEO. It is also called the Federation of Malaysia. Its capital is Kuala Lumpur. Before 1963 it was the Union of Malaya. It reorganized in 1948 as the Federation of Malaya, becoming independent from British Malaya in 1957 and becoming Malaysia in 1963 as a federation of Malaya, Sabah, Sarawak, and Singapore (which seceded in 1965). The form Malay- probably derives from the Tamil malay, mountain, with reference to its geography. (From Webster's New Geographical Dictionary, 1988, p715 & Room, Brewer's Dictionary of Names, 1992, p329)		2.2510
angiogenin
angiogenin: human tumor protein which stimulates growth of blood vessels; contains 123 amino acids; member of the pancreatic ribonuclease superfamily; MW 14,400		1.9810
nandrolone phenpropionate
arylomycin A2: a signal peptidase inhibitor; structure in first source		2.0510
tautomycin
tautomycin: an inhibitor of protein phosphatases 1 and 2A; isolated from Streptomyces spiroverticillatus; MF: C42-H70-O12; exists as a tautomeric mixture in solution		2.9440
trehalose monomycolate
trehalose monomycolate : Any trehalose bearing a single O-mycolate substituent; obtained via extraction of the cell wall of Mycobacterium bovis.		1.9910
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.44202-aminopurines;
oxopurine		antimetabolite;
antiviral drug
levoleucovorin
Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.		5.512205-formyltetrahydrofolic acidantineoplastic agent;
metabolite
8-oxodeoxyguanosine triphosphate
8-oxodeoxyguanosine triphosphate: mutagenic nucleotide; hydrolyzed by 8-oxodGTPase to 8-oxodGMP. 8-oxo-dGTP : A purine 2'-deoxyribonucleoside 5'-triphosphate having 8-oxo-7,8-dihydroguanine as the nucleobase.		2.110purine 2'-deoxyribonucleoside 5'-triphosphatemutagen
cyclic gmp
Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.		6.939103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
deoxyguanosine
[no description available]		2.9340purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
deoxyguanosine triphosphate
[no description available]		1.9810deoxyguanosine phosphate;
guanyl deoxyribonucleotide;
purine 2'-deoxyribonucleoside 5'-triphosphate		Arabidopsis thaliana metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
dihydrofolate
dihydrofolic acid : A folic acid derivative acted upon by dihydrofolate reductase to produce tetrahydrofolic acid. It interacts with bacteria during cell division and is targeted by various drugs to prevent nucleic acid synthesis.		210dihydrofolic acidsEscherichia coli metabolite;
mouse metabolite
guanosine diphosphate
Guanosine Diphosphate: A guanine nucleotide containing two phosphate groups esterified to the sugar moiety.		4.54240guanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanosine pentaphosphate
Guanosine Pentaphosphate: Guanosine 5'-triphosphate 2'(3')-diphosphate. A guanine nucleotide containing five phosphate groups. Three phosphate groups are esterified to the sugar moiety in the 5' position and the other two in the 2' or 3' position. This nucleotide serves as a messenger to turn off the synthesis of ribosomal RNA when amino acids are not available for protein synthesis.. guanosine 3'-diphosphate 5'-triphosphate : A guanosine bisphosphate having a diphosphate at the 3'-position and a triphosphate at the 5'-position.		3.5180guanosine 5'-phosphate;
guanosine bisphosphate		Escherichia coli metabolite;
mouse metabolite
guanosine monophosphate
Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.. guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase.		3.3870guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite
guanosine triphosphate
Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.		7.22740guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanine
[no description available]		7.885802-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		8.5180guanosines;
purines D-ribonucleoside		fundamental metabolite
guanosine tetraphosphate
Guanosine Tetraphosphate: Guanosine 5'-diphosphate 2'(3')-diphosphate. A guanine nucleotide containing four phosphate groups. Two phosphate groups are esterified to the sugar moiety in the 5' position and the other two in the 2' or 3' position. This nucleotide serves as a messenger to turn off the synthesis of ribosomal RNA when amino acids are not available for protein synthesis. Synonym: magic spot I.. guanosine 3',5'-bis(diphosphate) : A guanosine bisphosphate having diphosphate groups at both the 3' and 5'-positions.		4.33200guanosine bisphosphateEscherichia coli metabolite;
mouse metabolite
hypoxanthine
[no description available]		3.5280nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite
inosinic acid
Inosine Monophosphate: Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.		3.3670inosine phosphate;
purine ribonucleoside 5'-monophosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
inosine
[no description available]		4.5880inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1-methyladenine
1-methyladenine : Adenine substituted with a methyl group at position N-1.		210
sapropterin
sapropterin: RN given refers to parent cpd; co-factor required for catalytic activity of nitric oxide synthases. (6R)-5,6,7,8-tetrahydrobiopterin : A 5,6,7,8-tetrahydrobiopterin in which the stereocentre at position 6 has R-configuration.. sapropterin : A tetrahydropterin that is 2-amino-5,6,7,8-tetrahydropteridin-4(3H)-one in which a hydrogen at position 6 is substituted by a 1,2-dihydroxypropyl group (6R,1'R,2'S-enantiomer).		5.25905,6,7,8-tetrahydrobiopterincoenzyme;
cofactor;
diagnostic agent;
human metabolite
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		13.711782folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
3-methyladenine
N3-methyladenine: structure in first source		3.1750
queuine
[no description available]		210pyrrolopyrimidineEscherichia coli metabolite
viomycin
[no description available]		7.8640heterodetic cyclic peptide;
peptide antibiotic		antitubercular agent
guanosine 5'-o-(3-thiotriphosphate)
Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.		5.32210nucleoside triphosphate analogue
7,8-dihydrobiopterin
7,8-dihydrobiopterin: RN given refers to (S-(R*,S*))-isomer. 7,8-dihydrobiopterin : A dihydropterin that is biopterin dihydrogenated at positions 7 and 8.. L-erythro-7,8-dihydrobiopterin : A 7,8-dihydrobiopterin in which the 1,2-dihydroxypropyl group has (1R,2S)-configuration; naturally occurring form.		2.06107,8-dihydrobiopterin
pheophytin a
pheophytin a: structure given in first source; RN given refers to (3S-(3alpha(2E,7S*,11S*),4beta,21beta))-isomer		4.2131
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		3.3870cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		11.72336benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.4420dacarbazine
ganciclovir
[no description available]		2.7302-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
olanzapine
Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.		8.31115benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
pralidoxime
pralidoxime: RN given refers to parent cpd; chloride was minor descriptor (75-80); on-line & Index Medicus search PRALIDOXIME COMPOUNDS (66-80). pralidoxime : A pyridinium ion that is 1-methylpyridinium substituted by a (hydroxyimino)methyl group at position 2.		2.7230pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
zaprinast
zaprinast: anaphylaxis inhibitor; structure		1.9910triazolopyrimidines
5,10-methylenetetrahydrofolic acid
5,10-methylenetetrahydrofolic acid: RN refers to parent cpd(L-Glu)-isomer		6.32190benzamides;
methylenetetrahydrofolic acid
ro 3306
RO 3306: structure in first source		2.0510
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		6.3470nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
2,2'-(hydroxynitrosohydrazono)bis-ethanamine
2,2'-(hydroxynitrosohydrazono)bis-ethanamine: a nitric oxide (NO) generating compound. 1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane : A nitroso compound that is triazane in which the the nitrogen at position 1 is substituted by two 2-aminoethyl groups, that at position 2 is substituted by a hydroxy group, and that at position 3 is substituted by an oxo group.		2.4520
guanylyl imidodiphosphate
Guanylyl Imidodiphosphate: A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+. The nucleotide is a potent stimulator of ADENYLYL CYCLASES.. guanosine 5'-[beta,gamma-imido]triphosphate : A nucleoside triphosphate analogue that is GTP in which the oxygen atom bridging the beta- to the gamma- phosphate is replaced by a nitrogen atom A non-hydrolyzable analog of GTP, it binds tightly to G-protein in the presence of Mg(2+).		3.2560nucleoside triphosphate analogue
5,10-methenyltetrahydrofolate
(6R)-5,10-methenyltetrahydrofolic acid : The 5,10-methenyl derivative of tetrahydrofolic acid arising from enzymatic cyclisation of 5-formyltetrahydrofolic acid.		2.0210methylenetetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
8-hydroxyguanosine
8-hydroxyguanosine: immunostimulant for B lymphocytes; structure given in first source		2.0110purine nucleoside
guanosine 5'-o-(2-thiodiphosphate)
[no description available]		2.4120nucleoside diphosphate analogue
cytarabine
Guanosine Diphosphate Fucose: A nucleoside diphosphate sugar formed from GDPmannose, which provides fucose for lipopolysaccharides of bacterial cell walls, and for blood group substances and other glycoproteins.		1.9810GDP-fucose
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		2.8330citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
hymenialdisine
[no description available]		2.0710
azilsartan
azilsartan: an angiotensin type 1 receptor blocker; receptor blocker. azilsartan : A benzimidazolecarboxylic acid that is benzimidazole-7-carboxylic acid substituted at position 2 by a methoxy group and at position 1 by a 2'-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl group. Used (as the prodrug, azilsartan medoxomil) for treatment of hypertension.		2.1101,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent
5,6,7,8-tetrahydrofolic acid
5,6,7,8-tetrahydrofolic acid: RN given refers to (DL)-isomer		4.4210tetrahydrofolic acid
8-bromocyclic gmp
8-bromo-3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic GMP bearing an additional bromo substituent at position 8 on the guanine ring. A membrane permeable cGMP analogue that activates protein kinase G (PKG). It is 4.3-fold more potent than cGMP in activating PKG1alpha and promotes relaxation of tracheal and vascular smooth muscle tissue in vitro.		3.63903',5'-cyclic purine nucleotide;
organobromine compound		muscle relaxant;
protein kinase G agonist
8-hydroxyguanine
7,8-dihydro-8-oxoguanine: was substituted for guanine at G(8), G(9), G(14), or G(15) in the human telomeric oligonucleotide 5'-d[AGGGTTAG(8)G(9)GTT AG(14)G(15)GTTAGGGTGT]-3'. 7,8-dihydro-8-oxoguanine : An oxopurine that is guanine in which the hydrogen at position 8 is replaced by an oxo group and in which the nitrogens at positions 7 and 9 each bear a hydrogen.		2.9240oxopurine
hesperadin
[no description available]		2.4520
trypan blue
Trypan Blue: A diazo-naphthalene sulfonate that is widely used as a stain.. trypan blue : An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid).		3.0950
cyclic guanosine diphosphate-ribose
cyclic guanosine diphosphate-ribose: structure in first source; cyclic GDP-ribose is refractory to the cADPR-hydrolyase activity of ADP-ribosyl cyclases		2.0310
methylnitronitrosoguanidine
Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position		2.6830nitroso compoundalkylating agent
bis(3',5')-cyclic diguanylic acid
[no description available]		2.0510cyclic purine dinucleotide;
guanyl ribonucleotide		immunomodulator;
signalling molecule
8-hydroxy-2'-deoxyguanosine
8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.		2.7130guanosinesbiomarker
clozapine n-oxide
clozapine N-oxide: structure given in first source		2.5120dibenzodiazepine
8-((4-chlorophenyl)thio)cyclic-3',5'-gmp
8-(4-chlorophenylthio)-cGMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic GMP in which the hydrogen at position 2 on the purine fragment is replaced by a 4-chlorophenylthio group.		2.4203',5'-cyclic purine nucleotide;
aryl sulfide;
organochlorine compound;
ribonucleotide		protein kinase agonist
7-methylguanosine
7-methylguanosine : A positively charged methylguanosine in which a single methyl substituent is located at position 7.		6.9910methylguanosine;
organic cation		metabolite
10-formyltetrahydrofolate
10-formyltetrahydrofolic acid : A form of tetrahydrofolate that acts as a donor of formyl groups in anabolism. In these reactions 10-formyltetrahydrofolic acid is used as a substrate in formyltransferase reactions, which is important in purine biosynthesis.		4.2950formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
guanylyl-(3'-5')-guanosine
[no description available]		2.0110nucleoside analogue;
purines
prodigiosin
Prodigiosin: 4-Methoxy-5-((5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl)- 2,2'-bi-1H-pyrrole. A toxic, bright red tripyrrole pigment from Serratia marcescens and others. It has antibacterial, anticoccidial, antimalarial, and antifungal activities, but is used mainly as a biochemical tool.. prodigiosin : A member of the class of tripyrroles that is a red-coloured pigment with antibiotic properties produced by Serratia marcescens.		2.8840
echinochrome a
echinochrome A: red pigment of sea urchin eggs (Arbacia pustulosa)		2.1110
5-methyltetrahydrofolate
5-methyltetrahydrofolate : A group of heterocyclic compounds based on the 5-methyl-5,6,7,8-tetrahydropteroic acid skeleton conjugated with one or more L-glutamic acid or L-glutamate units.		5.0980
nucleoside q
Nucleoside Q: A modified nucleoside which is present in the first position of the anticodon of tRNA-tyrosine, tRNA-histidine, tRNA-asparagine and tRNA-aspartic acid of many organisms. It is believed to play a role in the regulatory function of tRNA. Nucleoside Q can be further modified to nucleoside Q*, which has a mannose or galactose moiety linked to position 4 of its cyclopentenediol moiety.. queuosine : A nucleoside found in tRNA that has an additional cyclopentenyl ring added via an NH group to the methyl group of 7-methyl-7-deazaguanosine. The cyclopentenyl ring may carry other substituents.		2.02107-deazaguanine ribonucleoside
anguibactin
anguibactin: a peptide biosynthesized by nonribosomal peptide synthetases; siderophore isolated from Vibrio anguillarum 775 harboring the pJM1 plasmid		2.4320
magnesium gtp
magnesium GTP: RN given refers to unlabeled cpd Mg salt		1.9910
diazo-2
diazo-2: calcium chelator		2.0110
molybdenum cofactor
molybdenum cofactor: also see records for molybdopterin cytosine dinucleotide and molybdopterin guanine dinucleotide. MoO2-molybdopterin cofactor(2-) : An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of MoO2-molybdopterin cofactor.. MoO2-molybdopterin cofactor : An Mo-molybdopterin cofactor in which the coordinated molybdenum species is MoO2.		2.4120Mo-molybdopterin cofactor;
organophosphate oxoanion
sp2509
SP2509: inhibits histone demethylase LSD1; SP2513 is the pharmacologically inactive enantiomer; structure in first source		2.2110
alcian blue
Alcian Blue: A copper-containing dye used as a gelling agent for lubricants, for staining of bacteria and for the dyeing of histiocytes and fibroblasts in vivo.		1.9810
lipoteichoic acid
lipoteichoic acid: lipopolysaccharides with an acyl group anchored to the cell membrane of gram-positive bacteria; functions as an adhesion molecule to facilitate the binding of bacteria to cells, colonization, and invasion; interacts with CD14 to induce NF-κB activation and inflammatory cytokine production; can function as surface antigen; inhibits remineraliztion of artificial lesions and surface-softened enamels;. lipoteichoic acid : A teichoic acid which is covalently bound to a lipid.		2.1710
eye
[no description available]		4.81100
maltodextrin
maltodextrin : A dextrin in which the D-glucose units are linked by alpha-(1->4) glycosidic bonds.		2.420
molybdopterin guanine dinucleotide
molybdopterin guanine dinucleotide: structure given in first source		210
lacticin 481
lacticin 481: amino acid sequence given in first source; a lantibiotic; GenBank X71410 (L. lactis)		3.1250
carbidopa
Carbidopa: An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.. carbidopa : The hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.		6.31121
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		3.87120
technetium tc 99m bicisate
[no description available]		2.0310
trypsinogen
Trypsinogen: The inactive proenzyme of trypsin secreted by the pancreas, activated in the duodenum via cleavage by enteropeptidase. (Stedman, 25th ed)		9.76100
metallothionein
Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.		3.6190
cog1410
COG1410: apolipoprotein E-based peptide that improves functional recovery in a murine model of traumatic brain injury		2.1510
dinitrobenzenes
Dinitrobenzenes: Benzene derivatives which are substituted with two nitro groups in the ortho, meta or para positions.		3.3670
phosphorus radioisotopes
Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.		5.82940
phosphatidylbutanol
[no description available]		2.0110
preproenkephalin
preproenkephalin: initial enkephalin precursor		2.0510
leptin
Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.		5.21150
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		4.460
tetrafluoroaluminate
tetrafluoroaluminate: induces inositol phosphate formation		2.4120
pneumocandin b(0)
pneumocandin B(0): structure given in first source; isolated from Zalerion arboricola		210
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		2.0210
sodefrin
sodefrin: a decapeptide; isolated from the cloacal glands of newt Cynops pyrrhogaster; exhibits female-attracting activity		210
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Confusional Senile Dementia
[description not available]		010.822000
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		117.822000
Congenital Zika Syndrome
[description not available]		02.5920
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		011.683380
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.5920
Blood Pressure, High
[description not available]		07.56501
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		07.56501
Degenerative Disc Disease
[description not available]		02.3110
Intervertebral Disc Degeneration
Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.		07.3110
Colorectal Cancer
[description not available]		010.32541
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		010.32541
Avian Diseases
[description not available]		02.4620
Innate Inflammatory Response
[description not available]		08.621070
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		08.621070
Cancer of Pancreas
[description not available]		05.49580
Carcinoma, Ductal, Pancreatic
[description not available]		03.8490
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		17.49580
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		03.8490
Sarcopenia
Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.		02.5420
Carcinoma, Non-Small Cell Lung
[description not available]		08.69322
Cancer of Lung
[description not available]		011.211163
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		08.69322
Lung Neoplasms
Tumors or cancer of the LUNG.		011.211163
Autosomal Dominant Cerebellar Ataxia, Type II
[description not available]		03.6690
Spinocerebellar Ataxias
A group of predominately late-onset, cerebellar ataxias which have been divided into multiple subtypes based on clinical features and genetic mapping. Progressive ataxia is a central feature of these conditions, and in certain subtypes POLYNEUROPATHY; DYSARTHRIA; visual loss; and other disorders may develop. (From Joynt, Clinical Neurology, 1997, Ch65, pp 12-17; J Neuropathol Exp Neurol 1998 Jun;57(6):531-43)		08.6690
Benign Neoplasms
[description not available]		015.682594
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		020.682594
Koch's Disease
[description not available]		04.9120
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		04.9120
Adult Premature Aging Syndrome
[description not available]		02.3110
Idiopathic Parkinson Disease
[description not available]		014.412064
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		014.412064
Benign Neoplasms, Brain
[description not available]		06.23321
Astrocytoma, Grade IV
[description not available]		05.09400
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		06.23321
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		05.09400
Acute Kidney Failure
[description not available]		06.78231
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		06.78231
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		06.06271
Cirrhosis
[description not available]		05.15150
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		05.15150
Genetic Predisposition
[description not available]		014.521703
Diffuse Parenchymal Lung Disease
[description not available]		02.4110
Sclerosis, Systemic
[description not available]		02.730
Scleroderma, Systemic
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.		02.730
Lung Diseases, Interstitial
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.		02.4110
Breast Cancer
[description not available]		013.872426
Breast Neoplasms
Tumors or cancer of the human BREAST.		013.872426
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		03.4680
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		03.4680
Asthma, Bronchial
[description not available]		03.79100
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		03.79100
46, XY Gonadal Dysgenesis
[description not available]		02.5320
Gonadal Dysgenesis, 46, XX
[description not available]		02.3110
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		011.632371
Cancer of Prostate
[description not available]		06.75540
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		06.75540
Cardiovascular Stroke
[description not available]		06.94261
Injury, Ischemia-Reperfusion
[description not available]		04.74280
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		06.94261
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		04.74280
Cortical Lewy Body Disease
[description not available]		03.95120
Lewy Body Disease
A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)		08.95120
Adenocarcinoma, Endometrioid
[description not available]		02.3110
Microsatellite Instability
The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.		07.7630
Cancer of Endometrium
[description not available]		04.580
Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.		04.580
Carcinoma, Endometrioid
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.		02.3110
Depression, Involutional
Form of depression in those MIDDLE AGE with feelings of ANXIETY.		05.6292
Depressive Disorder, Major
Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)		05.6292
Bowel Diseases, Inflammatory
[description not available]		03.3450
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.		08.3450
Poultry Diseases
Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.		03.6290
Circoviridae Infections
Virus diseases caused by the CIRCOVIRIDAE.		02.4110
Anaplastic Astrocytoma
[description not available]		03.2860
Adenoma Sebaceum
Facial ANGIOFIBROMA in tuberous sclerosis		04.67100
Neurocytoma
A benign brain tumor composed of neural elements which most often arise from the SEPTUM PELLUCIDUM and the walls of the lateral ventricles. Immunohistochemistry and electron microscopy evaluations may reveal expression of neuron specific enolase and synaptophysin and cells containing microtubuli, neurosecretory granules, and presynaptic vesicles. (From Acta Med Port 1994 Feb;7(2):113-9)		02.4110
Anaplastic Ependymoma
[description not available]		02.5420
Astrocytoma
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)		08.2860
Ependymoma
Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)		02.5420
Tuberous Sclerosis
Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.		09.67100
Malignant Melanoma
[description not available]		010.21470
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		05.21470
Uveal Neoplasms
Tumors or cancer of the UVEA.		02.4620
Diathesis
[description not available]		03.6690
Cirrhosis, Liver
[description not available]		04.79120
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		011.71210
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		04.79120
Degenerative Diseases, Central Nervous System
[description not available]		07.9380
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		07.9380
Absence Seizure
[description not available]		07.44640
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		07.44640
Acute Liver Injury, Drug-Induced
[description not available]		03.6390
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		03.6390
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		08.351310
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		08.05820
Cerebral Palsy, Athetoid
[description not available]		02.4620
Clasp-Knife Spasticity
[description not available]		02.7130
Cerebral Palsy
A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)		02.4620
Muscle Spasticity
A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a free interval) followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)		02.7130
Genome Instability
[description not available]		04.15140
Colitis Gravis
[description not available]		02.5820
Colitis, Ulcerative
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.		02.5820
2019 Novel Coronavirus Disease
[description not available]		06.13190
Cadmium Poisoning
Poisoning occurring after exposure to cadmium compounds or fumes. It may cause gastrointestinal syndromes, anemia, or pneumonitis.		02.4110
Disbacteriosis
[description not available]		03.8830
Caries, Dental
[description not available]		04.1960
Dental Caries
Localized destruction of the tooth surface initiated by decalcification of the enamel followed by enzymatic lysis of organic structures and leading to cavity formation. If left unchecked, the cavity may penetrate the enamel and dentin and reach the pulp.		04.1960
Cataract, Membranous
[description not available]		04.99150
Cataract
Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)		09.99150
Dementia Praecox
[description not available]		021.4826492
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.		123.4826492
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		07.5350
Fowl Paralysis
[description not available]		02.4110
Arthritis, Juvenile Chronic
[description not available]		02.5820
Arthritis, Juvenile
Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.		02.5820
Carcinoma, Epidermoid
[description not available]		06.47410
Cancer of Cervix
[description not available]		03.95120
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		06.47410
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		03.95120
Aldosteronism with Hyperplasia of the Adrenal Cortex
[description not available]		02.4110
Acute Brain Injuries
[description not available]		06.41151
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		06.41151
Cardiac Hypertrophy
Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.		09.83300
Cardiomegaly
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.		04.83300
MODS
[description not available]		02.4110
HIV Coinfection
[description not available]		04.22160
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		02.4110
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		04.22160
Kahler Disease
[description not available]		03.92130
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		08.92130
Cancer of Esophagus
[description not available]		05140
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		05140
Cochlear Hearing Loss
[description not available]		03.1350
Symptom Cluster
[description not available]		06.1290
Contracture
Prolonged shortening of the muscle or other soft tissue around a joint, preventing movement of the joint.		02.8220
Hearing Loss, Sensorineural
Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM.		03.1350
Syndrome
A characteristic symptom complex.		011.1290
Histiocytosis
General term for the abnormal appearance of histiocytes in the blood. Based on the pathological features of the cells involved rather than on clinical findings, the histiocytic diseases are subdivided into three groups: HISTIOCYTOSIS, LANGERHANS CELL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; and HISTIOCYTIC DISORDERS, MALIGNANT.		02.4110
Cerebral Ischemia
[description not available]		05.88360
Infarct
[description not available]		02.3920
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		05.88360
E coli Infections
[description not available]		05.43230
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		05.43230
Infectious Diseases
[description not available]		08.3310
Communicable Diseases
An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.		03.3310
Atherogenesis
[description not available]		05.75181
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		05.75181
Alloxan Diabetes
[description not available]		05.12440
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		04.54220
Central Retinal Edema, Cystoid
[description not available]		02.4110
Diabetic Retinopathy
Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.		05.21101
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		04.54220
Macular Edema
Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)		02.4110
Esophageal Squamous Cell Carcinoma
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.		04.1950
Liver Dysfunction
[description not available]		04.4280
Liver Diseases
Pathological processes of the LIVER.		04.4280
Germinoblastoma
[description not available]		05.35220
B-Cell Lymphoma
[description not available]		04.04140
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		05.35220
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		04.04140
Dehydration
The condition that results from excessive loss of water from a living organism.		09.3570
Birth Weight
The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.		04.2970
Cancer of Eye
[description not available]		03.0950
Epiphora
[description not available]		02.4110
Lacrimal Apparatus Diseases
Diseases of the LACRIMAL APPARATUS.		02.4110
Protein Aggregation, Pathological
A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.		03.91100
Glycine Encephalopathy
[description not available]		02.4110
ADDH
[description not available]		02.920
Attention Deficit Disorder with Hyperactivity
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)		02.920
Chronic Kidney Diseases
[description not available]		05.0270
Chronic Kidney Failure
[description not available]		04.4580
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		04.4580
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		05.0270
Diabetes Mellitus, Adult-Onset
[description not available]		010.81871
Diabetic Glomerulosclerosis
[description not available]		06.32131
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		010.81871
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		06.32131
Chronic Fatigue and Immune Dysfunction Syndrome
[description not available]		02.520
Fatigue Syndrome, Chronic
A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)		02.520
T-Cell Lymphoma
[description not available]		02.4110
Lymphoma, T-Cell
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.		02.4110
Fetal Growth Restriction
[description not available]		05.6150
Fetal Growth Retardation
Failure of a FETUS to attain expected GROWTH.		05.6150
Alveolitis, Fibrosing
[description not available]		02.3920
Pulmonary Fibrosis
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.		02.3920
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		07.98261
Vascular Calcification
Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.		02.4110
Exertional Heat Illness
[description not available]		02.8330
Bovine Diseases
[description not available]		04.7971
Glial Cell Tumors
[description not available]		07.58511
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		07.58511
Epilepsy Syndromes
[description not available]		03.3740
Epileptic Syndromes
EPILEPTIC SEIZURES that are of similar type and age of onset and have other similar features (e.g., clinical course, EEG findings, genetic association and neuropathology).		03.3740
Albuminuria
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.		04.1831
Insulin Sensitivity
[description not available]		011.621640
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		011.621640
Cells, Neoplasm Circulating
[description not available]		02.4110
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		04.14130
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		04.14130
Diseases, Metabolic
[description not available]		06.21120
Metabolic Diseases
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)		011.21120
Cancer of Ovary
[description not available]		04.85320
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		09.85320
Plasmodium falciparum Malaria
[description not available]		03.4470
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		03.4470
Lung Adenocarcinoma
[description not available]		03.5860
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		03.5860
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		04.15160
Adenocarcinoma Of Kidney
[description not available]		03.5470
Cancer of Kidney
[description not available]		04.04140
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		03.5470
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		04.04140
Blue-Eared Pig Disease
[description not available]		02.8630
Swine Diseases
Diseases of domestic swine and of the wild boar of the genus Sus.		03.1630
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		09.36721
Weight Gain
Increase in BODY WEIGHT over existing weight.		09.19160
Amino Acid Metabolism Disorders, Inborn
[description not available]		08.55750
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		03.86120
Cholangiocellular Carcinoma
[description not available]		03.91100
Angiogenesis, Pathologic
[description not available]		09.18241
Cholangiocarcinoma
A malignant tumor arising from the epithelium of the BILE DUCTS.		03.91100
Disease Exacerbation
[description not available]		011.52743
Metastase
[description not available]		08.8382
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		08.8382
Cancer of Stomach
[description not available]		04.85320
Stomach Neoplasms
Tumors or cancer of the STOMACH.		04.85320
Drug Refractory Epilepsy
[description not available]		02.9330
Microcephaly
A congenital abnormality in which the CEREBRUM is underdeveloped, the fontanels close prematurely, and, as a result, the head is small. (Desk Reference for Neuroscience, 2nd ed.)		012.18310
Liver Steatosis
[description not available]		03.2560
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		08.2560
Hypertriglyceridemia
A condition of elevated levels of TRIGLYCERIDES in the blood.		03.4170
Palmoplantaris Pustulosis
[description not available]		05.25200
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		05.25200
Arachnodactyly
An abnormal bone development that is characterized by extra long and slender hands and fingers, such that the clenched thumb extends beyond the ulnar side of the hand. Arachnodactyly can include feet and toes. Arachnodactyly has been associated with several gene mutations and syndromes.		02.3920
Bile Duct Cancer
[description not available]		03.4760
Bile Duct Neoplasms
Tumors or cancer of the BILE DUCTS.		03.4760
Endometrioma
An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.		07.4720
Endometriosis
A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.		07.4720
Infections, Vibrio
[description not available]		02.9740
Sterility, Female
[description not available]		05.8680
Infertility, Female
Diminished or absent ability of a female to achieve conception.		05.8680
Fatigue, Mental
[description not available]		04.7122
Leishmaniasis, American
[description not available]		02.4110
Leishmaniasis, Cutaneous
An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.		02.4110
Cardiomyopathy, Congestive
[description not available]		04.19150
Cardiomyopathy, Dilated
A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.		04.19150
Polycystic Ovarian Syndrome
[description not available]		05.86120
Polycystic Ovary Syndrome
A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.		05.86120
Affective Psychosis, Bipolar
[description not available]		07.19211
Bipolar Disorder
A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.		012.19211
Preterm Birth
[description not available]		03.8120
Premature Birth
CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).		03.8120
Hallucination of Body Sensation
[description not available]		02.7130
Hallucinations
Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.		02.7130
Astrocytosis
[description not available]		03.680
Sarcoma, Epithelioid
[description not available]		06.2341
Local Neoplasm Recurrence
[description not available]		06.13101
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		06.2341
Soft Tissue Neoplasms
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.		03.420
Hepatocellular Carcinoma
[description not available]		07.781030
Cancer of Liver
[description not available]		07.851100
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		07.781030
Liver Neoplasms
Tumors or cancer of the LIVER.		07.851100
Amelogenesis Imperfecta
A clinically and genetically heterogeneous group of hereditary conditions characterized by malformed DENTAL ENAMEL, usually involving DENTAL ENAMEL HYPOPLASIA and/or TOOTH HYPOMINERALIZATION.		02.5320
Coats Disease
[description not available]		03.5860
Acroosteolysis, Giaccai Type
[description not available]		010.79215
Hereditary Sensory and Autonomic Neuropathies
A group of inherited disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and clinically by loss of sensation and autonomic dysfunction. There are five subtypes. Type I features autosomal dominant inheritance and distal sensory involvement. Type II is characterized by autosomal inheritance and distal and proximal sensory loss. Type III is DYSAUTONOMIA, FAMILIAL. Type IV features insensitivity to pain, heat intolerance, and mental deficiency. Type V is characterized by a selective loss of pain with intact light touch and vibratory sensation. (From Joynt, Clinical Neurology, 1995, Ch51, pp142-4)		112.79215
Retinal Telangiectasis
A group of rare, idiopathic, congenital retinal vascular anomalies affecting the retinal capillaries. It is characterized by dilation and tortuosity of retinal vessels and formation of multiple aneurysms, with different degrees of leakage and exudates emanating from the blood vessels.		03.5860
Aneuploid
[description not available]		08.3150
Group A Strep Infection
[description not available]		03.9240
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		03.9240
Adenocarcinoma, Basal Cell
[description not available]		08.62581
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		08.62581
Acute Myelogenous Leukemia
[description not available]		04.43200
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		04.43200
ALS - Amyotrophic Lateral Sclerosis
[description not available]		011.45482
Amyotrophic Lateral Sclerosis
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)		113.45482
Peripheral Nerve Diseases
[description not available]		04.02140
Anterior Horn Cell Disease
[description not available]		03.1650
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		04.02140
Motor Neuron Disease
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)		03.1650
Anoxemia
[description not available]		06.39610
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		06.39610
Campylobacter Infection
[description not available]		02.5720
Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.		03.0840
Carcinoma, Anaplastic
[description not available]		04.76310
Cancer of Nasopharynx
[description not available]		03.1850
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		04.76310
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		03.1850
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		03.9940
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		03.9940
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		010.121410
Epithelial Ovarian Cancer
[description not available]		07.8830
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.8830
Cryptogenic Infantile Spasms
[description not available]		04.8370
Spasms, Infantile
An epileptic syndrome characterized by the triad of infantile spasms, hypsarrhythmia, and arrest of psychomotor development at seizure onset. The majority present between 3-12 months of age, with spasms consisting of combinations of brief flexor or extensor movements of the head, trunk, and limbs. The condition is divided into two forms: cryptogenic (idiopathic) and symptomatic (secondary to a known disease process such as intrauterine infections; nervous system abnormalities; BRAIN DISEASES, METABOLIC, INBORN; prematurity; perinatal asphyxia; TUBEROUS SCLEROSIS; etc.). (From Menkes, Textbook of Child Neurology, 5th ed, pp744-8)		04.8370
Weight Reduction
[description not available]		02.8230
Weight Loss
Decrease in existing BODY WEIGHT.		07.8230
Cancer of Salivary Gland
[description not available]		02.5720
Salivary Gland Neoplasms
Tumors or cancer of the SALIVARY GLANDS.		02.5720
Infections, Proteus
[description not available]		02.6920
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		05.12101
Infections, RNA Virus
[description not available]		02.520
Impaired Glucose Tolerance
[description not available]		04.14150
Glucose Intolerance
A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.		04.14150
TDP-43 Proteinopathies
Diseases characterized by the presence of abnormally phosphorylated, ubiquitinated, and cleaved DNA-binding protein TDP-43 in affected brain and spinal cord. Inclusions of the pathologic protein in neurons and glia, without the presence of AMYLOID, is the major feature of these conditions, thus making these proteinopathies distinct from most other neurogenerative disorders in which protein misfolding leads to brain amyloidosis. Both frontotemporal lobar degeneration and AMYOTROPHIC LATERAL SCLEROSIS exhibit this common method of pathogenesis and thus they may represent two extremes of a continuous clinicopathological spectrum of one disease.		02.8330
Amyloidosis
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.		011.41230
Cancer of Mouth
[description not available]		03.97130
Mouth Neoplasms
Tumors or cancer of the MOUTH.		03.97130
Fatty Liver, Nonalcoholic
[description not available]		05.58130
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		05.58130
Enlarged Liver
[description not available]		02.4110
Hypertrophy
General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).		08.83110
Bone Cancer
[description not available]		06.33190
Neoplastic Processes
The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity.		02.4110
Osteogenic Sarcoma
[description not available]		04.45220
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		06.33190
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		09.45220
Acute Edematous Pancreatitis
[description not available]		04.370
Acute Disease
Disease having a short and relatively severe course.		011.72329
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		04.370
Chronic Hepatitis B
[description not available]		02.4110
Hepatitis B, Chronic
INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.		02.4110
Bladder Cancer
[description not available]		04.19160
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		04.19160
Cancer of Rectum
[description not available]		04.1131
Rectal Neoplasms
Tumors or cancer of the RECTUM.		04.1131
Chronic Illness
[description not available]		08.09211
Cardiac Failure
[description not available]		06.18300
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		08.09211
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		06.18300
Cancer of Head
[description not available]		04.8110
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		04.8110
Infections, Plasmodium
[description not available]		05.11100
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		05.11100
Chromosomal Breakage
[description not available]		02.9640
Infections, Orthomyxoviridae
[description not available]		03.6890
Orthomyxoviridae Infections
Virus diseases caused by the ORTHOMYXOVIRIDAE.		03.6890
B-Cell Chronic Lymphocytic Leukemia
[description not available]		03.8100
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		03.8100
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		015.37873
Schistosoma japonicum Infection
[description not available]		02.4110
Congenital Myotonic Dystrophy
[description not available]		03.8440
Myotonic Dystrophy
Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2.		03.8440
Infections, Staphylococcal
[description not available]		03.86100
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		03.86100
Autosomal Recessive Chronic Granulomatous Disease
[description not available]		02.4110
Granulomatous Disease, Chronic
A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern.		02.4110
Infections, Pseudomonas
[description not available]		03.2150
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		03.2150
Cytokine Release Syndrome
A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.		03.3310
Carditis
[description not available]		02.9540
Coxsackie Virus Infections
[description not available]		02.4520
Myocarditis
Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.		02.9540
Generalized Resistance To 1,25-Dihydroxyvitamin D
[description not available]		02.5820
Arthritis, Degenerative
[description not available]		04.3441
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		04.3441
Familial Hypophosphatemic Rickets
A hereditary disorder characterized by HYPOPHOSPHATEMIA; RICKETS; OSTEOMALACIA; renal defects in phosphate reabsorption and vitamin D metabolism; and growth retardation. Autosomal and X-linked dominant and recessive variants have been reported.		02.5820
Autism Spectrum Disorder
Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)		09.8960
Edema-Proteinuria-Hypertension Gestosis
[description not available]		04.1760
Pre-Eclampsia
A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.		09.1760
Abnormalities, Autosome
[description not available]		05150
Sterility, Male
[description not available]		08.4114
Hypospermatogenesis
[description not available]		02.4110
Chromosomal Translocation
[description not available]		010.29200
Infertility, Male
The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.		08.4114
Black Fever
[description not available]		02.4110
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.		02.4110
Muscle Disorders
[description not available]		03.2960
Muscular Diseases
Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.		03.2960
Classical Swine Fever
An acute, highly contagious disease affecting swine of all ages and caused by the CLASSICAL SWINE FEVER VIRUS. It has a sudden onset with high morbidity and mortality.		02.4720
Diabetic Cardiomyopathies
Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.		02.4110
Child Mental Disorders
[description not available]		02.920
Abnormality, Heart
[description not available]		02.9240
Aqueductal Stenosis
[description not available]		02.4320
Abnormalities, Congenital, Nervous System
[description not available]		02.4620
Heart Defects, Congenital
Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.		02.9240
Neurodevelopmental Disorders
These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).		02.920
Disease Resistance
The capacity of an organism to defend itself against pathological processes or the agents of those processes. This most often involves innate immunity whereby the organism responds to pathogens in a generic way. The term disease resistance is used most frequently when referring to plants.		03.5470
Francisella tularensis Infection
[description not available]		02.4110
Tularemia
A plague-like disease of rodents, transmissible to man. It is caused by FRANCISELLA TULARENSIS and is characterized by fever, chills, headache, backache, and weakness.		02.4110
Sexually Transmitted Diseases
Diseases due to or propagated by sexual contact.		02.610
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		05.32121
Cyst
[description not available]		02.520
Autoimmune Disease
[description not available]		08.1750
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		03.1750
Duncan Disease
[description not available]		02.4110
Lymphoproliferative Disorders
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.		02.4110
Thrombopenia
[description not available]		02.9540
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		02.9540
Arteriosclerosis, Coronary
[description not available]		04.99140
Heart Disease, Ischemic
[description not available]		03.99130
Coronary Artery Disease
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.		09.99140
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		03.99130
Cryptogenic Fibrosing Alveolitis
[description not available]		02.8930
Idiopathic Pulmonary Fibrosis
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.		02.8930
Encephalopathy, Subacute Spongiform, Gerstmann-Straussler Type
[description not available]		02.5220
Convulsions, Febrile
[description not available]		02.4110
Aura
[description not available]		07.39240
Absence Status
[description not available]		03.1950
Seizures, Febrile
Seizures that occur during a febrile episode. It is a common condition, affecting 2-5% of children aged 3 months to five years. An autosomal dominant pattern of inheritance has been identified in some families. The majority are simple febrile seizures (generally defined as generalized onset, single seizures with a duration of less than 30 minutes). Complex febrile seizures are characterized by focal onset, duration greater than 30 minutes, and/or more than one seizure in a 24 hour period. The likelihood of developing epilepsy (i.e., a nonfebrile seizure disorder) following simple febrile seizures is low. Complex febrile seizures are associated with a moderately increased incidence of epilepsy. (From Menkes, Textbook of Child Neurology, 5th ed, p784)		02.4110
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		07.39240
Status Epilepticus
A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)		03.1950
Cancer of the Retina
[description not available]		02.7930
Eye Cancer, Retinoblastoma
[description not available]		03.6390
Retinoblastoma
A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)		08.6390
Low Back Ache
[description not available]		02.4110
Low Back Pain
Acute or chronic pain in the lumbar or sacral regions, which may be associated with musculo-ligamentous SPRAINS AND STRAINS; INTERVERTEBRAL DISK DISPLACEMENT; and other conditions.		02.4110
Herpes Simplex Virus Infection
[description not available]		03.1750
B Virus Infection
[description not available]		02.4720
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		03.1750
Christmas Disease
[description not available]		02.9640
Hemophilia B
A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)		07.9640
Amyloid Deposits
[description not available]		03.5480
Cardiomyopathy, Hypertrophic Obstructive
[description not available]		04.17140
Cardiomyopathy, Hypertrophic
A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).		04.17140
Cancer of the Thyroid
[description not available]		05.47220
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		05.47220
Autosomal Dominant Juvenile Parkinson Disease
[description not available]		06.27321
Abnormal Movements
[description not available]		04.05110
Parkinsonian Disorders
A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.		06.27321
Acrodermatitis
Inflammation involving the skin of the extremities, especially the hands and feet. Several forms are known, some idiopathic and some hereditary. The infantile form is called Gianotti-Crosti syndrome.		04.2190
Encephalopathy, Toxic
[description not available]		05.3170
Dermatoses
[description not available]		03.7100
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		03.7100
Apoplexy
[description not available]		04.8370
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		09.8370
Hyperlipemia
[description not available]		03.93130
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		03.93130
Hyperuricemia
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.		02.4110
Carcinoma, Squamous Cell of Head and Neck
[description not available]		04.0240
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		04.0240
Asymmetric Diabetic Proximal Motor Neuropathy
[description not available]		03.6180
Diabetic Neuropathies
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)		03.6180
Dyslipidemia
[description not available]		03.9140
Small Fiber Neuropathy
Disorder of the peripheral nerves that primarily impair small nerve fibers. The affected small nerve fibers include myelinated A-delta fibers (see A FIBERS) and unmyelinated C FIBERS. Because these small fibers innervate skin and help control autonomic function, their neuropathy presents with neuropathic pain, reduced thermal and pain sensitivity, and autonomic dysfunction (e.g. abnormal sweating or facial flushing). Small fiber neuropathy can be idiopathic or associated with underlying diseases (e.g., AMYLOIDOSIS; DIABETES MELLITUS; SARCOIDOSIS; or VASCULITIS).		02.610
Dyslipidemias
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.		03.9140
Autoimmune Diabetes
[description not available]		05.13170
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		05.13170
Tauopathies
Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.		09.34180
Age-Related Osteoporosis
[description not available]		03.5680
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		03.5680
Deficiency, Mental
[description not available]		05.36230
Intellectual Disability
Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)		05.36230
Breathlessness
[description not available]		02.610
Dyspnea
Difficult or labored breathing.		02.610
Newcastle Disease
An acute febrile, contagious, viral disease of birds caused by an AVULAVIRUS called NEWCASTLE DISEASE VIRUS. It is characterized by respiratory and nervous symptoms in fowl and is transmissible to man causing a severe, but transient conjunctivitis.		02.610
Brain Hemorrhage, Cerebral
[description not available]		02.610
Cerebral Hemorrhage
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.		02.610
Astheno Teratozoospermia
[description not available]		02.610
Viral Diseases
[description not available]		03.8830
Virus Diseases
A general term for diseases caused by viruses.		03.8830
Cognitive Decline
[description not available]		011.34111
Cognitive Dysfunction
Diminished or impaired mental and/or intellectual function.		06.34111
Benign Infantile Myoclonic Epilepsy
[description not available]		02.610
Epilepsies, Myoclonic
A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.		02.610
Retinal Diseases
Diseases involving the RETINA.		03.4670
Muscular Dystrophy
[description not available]		08.4780
Muscular Dystrophies
A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS.		03.4780
Hypernutrition
[description not available]		02.610
Cardiomyopathies, Primary
[description not available]		04.98140
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		04.98140
Spider Veins
[description not available]		02.610
Telangiectasis
Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders.		02.610
Familial Nonmedullary Thyroid Cancer
[description not available]		02.8430
Placental Insufficiency
Failure of the PLACENTA to deliver an adequate supply of nutrients and OXYGEN to the FETUS.		07.7630
MS (Multiple Sclerosis)
[description not available]		05.18111
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		05.18111
FMR1-Related Primary Ovarian Insufficiency
[description not available]		03.5210
Primary Ovarian Insufficiency
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections. The most commonly known genetic cause is the expansion of a CGG repeat to 55 to 199 copies in the 5' untranslated region in the X-linked FMR1 gene.		03.5210
Compensatory Hyperinsulinemia
A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.		04.3470
Hyperinsulinism
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.		04.3470
Menopause
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.		03.1250
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		04.46220
Benign Psychomotor Epilepsy, Childhood
[description not available]		04.4270
Epilepsy, Temporal Lobe
A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).		04.4270
Infections, Legionella pneumophila
[description not available]		03.1650
Cancer of Colon
[description not available]		06.67501
Colonic Neoplasms
Tumors or cancer of the COLON.		06.67501
Ovarian Diseases
Pathological processes of the OVARY.		02.610
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		08.5990
Akinetic-Rigid Variant of Huntington Disease
[description not available]		04.12150
Huntington Disease
A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)		04.12150
Rheumatoid Arthritis
[description not available]		09.14160
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		04.14160
Flaccid Quadriplegia
[description not available]		02.5120
Hydramnios
[description not available]		02.610
Calcification, Pathologic
[description not available]		02.9340
Calcinosis
Pathologic deposition of calcium salts in tissues.		02.9340
Intra-Abdominal Infections
[description not available]		03.9911
Intraabdominal Infections
Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.		03.9911
Nanism
[description not available]		03.1150
Dwarfism
A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.		03.1150
Bunyaviridae Infections
Virus diseases caused by the BUNYAVIRIDAE.		02.610
Severe Fever with Thrombocytopenia Syndrome
A tick-borne infection with SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME BUNYAVIRUS of the genus Phlebovirus. It is associated with fever, THROMBOCYTOPENIA; LEUKOCYTOPENIA, and multiorgan dysfunction. It is found in parts of Asia including China, Japan, Korea and Vietnam and can be transmitted from infected domestic animals and humans.		02.610
Angor Pectoris
[description not available]		02.610
Angina Pectoris
The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.		02.610
Brain Disorders
[description not available]		06.37210
Brain Diseases
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.		06.37210
Adjustment Sleep Disorder
[description not available]		02.610
Nervous System Disorders
[description not available]		09.56211
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.		09.56211
Encephalopathy, Traumatic
[description not available]		03.8330
Brain Injuries, Traumatic
A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.		03.8330
a-Synucleinopathies
[description not available]		02.7620
Grippe
[description not available]		03.5480
Influenza, Human
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.		03.5480
Complications of Diabetes Mellitus
[description not available]		04.2360
Psychoses
[description not available]		010.31283
Psychotic Disorders
Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)		112.31283
Age-Related Memory Disorders
[description not available]		06.67191
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		06.67191
Anaplastic Large-Cell Lymphoma
[description not available]		02.2110
Lymphoma, Large-Cell, Anaplastic
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called hallmark cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.		02.2110
Invasiveness, Neoplasm
[description not available]		06.73520
Acidemia Propionic
[description not available]		02.2110
Propionic Acidemia
Autosomal recessive metabolic disorder caused by mutations in PROPIONYL-COA CARBOXYLASE genes that result in dysfunction of branch chain amino acids and of the metabolism of certain fatty acids. Neonatal clinical onset is characterized by severe metabolic acidemia accompanied by hyperammonemia, HYPERGLYCEMIA, lethargy, vomiting, HYPOTONIA; and HEPATOMEGALY. Survivors of the neonatal onset propionic acidemia often show developmental retardation, and intolerance to dietary proteins. Late-onset form of the disease shows mild mental and/or developmental retardation, sometimes without metabolic acidemia.		07.2110
Acute Lymphoid Leukemia
[description not available]		03.91120
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		03.91120
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		03.94120
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		03.94120
Infections, Pasteurella
[description not available]		02.2110
Benign Cerebellar Neoplasms
[description not available]		02.5720
Arachnoidal Cerebellar Sarcoma, Circumscribed
[description not available]		02.9540
Experimental Neoplasms
[description not available]		06.49740
Medulloblastoma
A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)		02.9540
Bacterial Eye Infections
[description not available]		02.2110
Keratitis
Inflammation of the cornea.		02.2110
Neurovisceral Storage Disease with Vertical Supranuclear Ophthalmoplegia
[description not available]		02.2110
Niemann-Pick Disease, Type C
An autosomal recessive lipid storage disorder that is characterized by accumulation of CHOLESTEROL and SPHINGOMYELINS in cells of the VISCERA and the CENTRAL NERVOUS SYSTEM. Type C (or C1) and type D are allelic disorders caused by mutation of the NPC1 gene, which encodes a protein that mediates intracellular cholesterol transport from LYSOSOMES. Clinical signs include hepatosplenomegaly and chronic neurological symptoms. Type D is a variant in people with a Nova Scotia ancestry.		02.2110
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.9340
Familial Precocious Puberty
[description not available]		02.2510
Puberty, Precocious
Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.		02.2510
Granulocytic Leukemia, Chronic
[description not available]		03.4270
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		03.4270
Carbohydrate Metabolism, Inborn Error
[description not available]		05.84160
Cancer of Skin
[description not available]		04.69270
Skin Neoplasms
Tumors or cancer of the SKIN.		04.69270
Giant Axonal Neuropathy
Rare autosomal recessive disorder of INTERMEDIATE FILAMENT PROTEINS. The disease is caused by mutations in the gene that codes gigaxonin protein. The mutations result in disorganization of axonal NEUROFILAMENT PROTEINS, formation of the characteristic giant axons, and progressive neuropathy. The clinical features of the disease include early-onset progressive peripheral motor and sensory neuropathies often associated with central nervous system involvement (INTELLECTUAL DISABILITY, seizures, DYSMETRIA, and CONGENITAL NYSTAGMUS).		02.2510
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		013.825411
Cardiac Remodeling, Ventricular
[description not available]		03.4670
Arrhythmia
[description not available]		05.22110
Cardiac Arrest, Sudden
[description not available]		02.5120
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		05.22110
Death, Sudden, Cardiac
Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)		02.5120
Anti-Phospholipid Antibody Syndrome
[description not available]		02.4820
Antiphospholipid Syndrome
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).		07.4820
Congenital Limb Deformities
[description not available]		05.36120
Abnormalities, Multiple
Congenital abnormalities that affect more than one organ or body structure.		05.5150
Xeroderma
[description not available]		05.71130
Ichthyosis
Any of several generalized skin disorders characterized by dryness, roughness, and scaliness, due to hypertrophy of the stratum corneum epidermis. Most are genetic, but some are acquired, developing in association with other systemic disease or genetic syndrome.		05.71130
Retinal Degeneration
A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)		09.85130
Lassitude
[description not available]		04.4851
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		09.4851
Libman-Sacks Disease
[description not available]		03.6190
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.		03.6190
HPV Infection
[description not available]		02.4620
Condition, Preneoplastic
[description not available]		02.6630
Squamous Intraepithelial Lesions of the Cervix
A cytological test finding often from PAP SMEARS that shows abnormal lesions of SQUAMOUS EPITHELIAL CELLS of the CERVIX. It is a diagnostic criterion used in the Bethesda System for UTERINE CERVICAL NEOPLASMS and represents the PAP TEST result that is abnormal. Although squamous intraepithelial lesions test result does not mean UTERINE CERVICAL NEOPLASMS it requires follow-ups (e.g., HPV DNA TESTS; and COLPOSCOPY).		02.2510
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		02.6630
Papillomavirus Infections
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.		02.4620
Bacterial Disease
[description not available]		03.8920
Bacterial Infections
Infections by bacteria, general or unspecified.		03.8920
Acute Mesenteric Arterial Embolus
[description not available]		02.2510
Androgen-Independent Prostatic Cancer
[description not available]		03.460
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.		03.460
Diabetes Mellitus, Gestational
[description not available]		03.9140
Diabetes, Gestational
Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.		03.9140
Ewing Sarcoma
[description not available]		05.6890
Sarcoma, Ewing
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.		05.6890
Anxiety Neuroses
[description not available]		03.9240
Anxiety Disorders
Persistent and disabling ANXIETY.		08.9240
Pain, Chronic
[description not available]		03.9221
Back Ache
[description not available]		03.6411
Back Pain
Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.		03.6411
Chronic Pain
Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.		08.9221
Atypical Lipomatous Tumor
[description not available]		02.2510
Liposarcoma
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)		07.2510
Malnourishment
[description not available]		02.2510
Malnutrition
An imbalanced nutritional status resulting from insufficient intake of nutrients to meet normal physiological requirement.		02.2510
Injury, Myocardial Reperfusion
[description not available]		04.01130
Behavior Disorders
[description not available]		08.53201
Mental Disorders
Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.		08.53201
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		05.27200
Infections, Coronavirus
[description not available]		02.6620
Communicable Diseases, Emerging
Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.		02.2510
Pneumonia, Viral
Inflammation of the lung parenchyma that is caused by a viral infection.		02.6620
Coronavirus Infections
Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).		02.6620
Clinically Isolated CNS Demyelinating Syndrome
[description not available]		03.1650
Demyelinating Diseases
Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.		03.1650
Tooth Erosion
Progressive loss of the hard substance of a tooth by chemical processes that do not involve bacterial action. (Jablonski, Dictionary of Dentistry, 1992, p296)		02.2510
Extravascular Hemolysis
[description not available]		04.42220
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		04.42220
Acute Onset Aura Migraine
[description not available]		04.2360
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		03.6290
Migraine with Aura
A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)		04.2360
Lentiginosis, Perioral
[description not available]		03.6730
Peutz-Jeghers Syndrome
A hereditary disease caused by autosomal dominant mutations involving CHROMOSOME 19. It is characterized by the presence of INTESTINAL POLYPS, consistently in the JEJUNUM, and mucocutaneous pigmentation with MELANIN spots of the lips, buccal MUCOSA, and digits.		03.6730
Experimental Mammary Neoplasms
[description not available]		04.12160
Cholangiitis, Sclerosing
[description not available]		02.7220
Cholangitis, Sclerosing
Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.		02.7220
Primary Peritonitis
[description not available]		02.3110
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		02.3110
Eye Disorders
[description not available]		04.0650
Inborn Errors of Metabolism
[description not available]		011.47170
Eye Diseases
Diseases affecting the eye.		04.0650
Metabolism, Inborn Errors
Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.		06.47170
Infections, Meningococcal
[description not available]		02.5420
Meningococcal Infections
Infections with bacteria of the species NEISSERIA MENINGITIDIS.		02.5420
Carcinoma, Oat Cell
[description not available]		03.1150
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		03.1150
Aerobic Glycolysis, Oncologic
[description not available]		03.6420
Chromosomal Instability
An increased tendency to acquire CHROMOSOME ABERRATIONS when various processes involved in chromosome replication, repair, or segregation are dysfunctional.		03.1750
Chromosomal Triplication
[description not available]		02.3110
Disease
A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.		09.1730
Babesia Infection
[description not available]		02.3110
Alcoholic Liver Diseases
[description not available]		02.4620
Liver Diseases, Alcoholic
Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.		02.4620
Benign Meningeal Neoplasms
[description not available]		02.3110
Angioblastic Meningioma
[description not available]		02.3110
Meningeal Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.		02.3110
Meningioma
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)		02.3110
Ache
[description not available]		06.58330
Burns
Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.		03.2660
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		06.58330
Cardiovirus Infections
Infections caused by viruses of the genus CARDIOVIRUS, family PICORNAVIRIDAE.		02.4620
Intraductal Papillary Mucinous Neoplasms of the Pancreas
[description not available]		07.610
Leishmania Infection
[description not available]		02.3110
Leishmaniasis
A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).		02.3110
Cancer, Embryonal
[description not available]		02.3110
Cancer of Testis
[description not available]		02.7230
Neoplasms, Germ Cell and Embryonal
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.		02.3110
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.		02.7230
Electron Transfer Flavoprotein Alpha Subunit Deficiency
[description not available]		02.3110
Developmental Psychomotor Disorders
[description not available]		04.84120
Autism
[description not available]		08.0540
Fra(X) Syndrome
[description not available]		03.5880
Autistic Disorder
A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V)		03.0540
Fragile X Syndrome
A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226)		03.5880
Abnormalities, Congenital
[description not available]		02.8940
EBV Infections
[description not available]		04.760
Lymphocytopenia
[description not available]		03.2310
Lymphopenia
Reduction in the number of lymphocytes.		03.2310
Epstein-Barr Virus Infections
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).		04.760
Malignant Mesothelioma
[description not available]		07.3110
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)		07.4820
Central Nervous System Toxoplasmosis
[description not available]		02.3110
Toxoplasmosis, Cerebral
Infections of the BRAIN caused by the protozoan TOXOPLASMA gondii that primarily arise in individuals with IMMUNOLOGIC DEFICIENCY SYNDROMES (see also AIDS-RELATED OPPORTUNISTIC INFECTIONS). The infection may involve the brain diffusely or form discrete abscesses. Clinical manifestations include SEIZURES, altered mentation, headache, focal neurologic deficits, and INTRACRANIAL HYPERTENSION. (From Joynt, Clinical Neurology, 1998, Ch27, pp41-3)		02.3110
Enterovirus Infections
Diseases caused by ENTEROVIRUS.		03.3310
Female Genital Diseases
[description not available]		02.1510
Genital Diseases, Female
Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).		02.1510
Carcinoma, Ductal, Breast
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.		03.1450
Cerebral Infarction, Middle Cerebral Artery
[description not available]		03.86110
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		03.86110
Cancer of Intestines
[description not available]		02.9440
Intestinal Neoplasms
Tumors or cancer of the INTESTINES.		02.9440
Infections, Picornaviridae
[description not available]		02.1510
Ataxia Telangiectasia Syndrome
[description not available]		06.29220
Ataxia Telangiectasia
An autosomal recessive inherited disorder characterized by choreoathetosis beginning in childhood, progressive CEREBELLAR ATAXIA; TELANGIECTASIS of CONJUNCTIVA and SKIN; DYSARTHRIA; B- and T-cell immunodeficiency, and RADIOSENSITIVITY to IONIZING RADIATION. Affected individuals are prone to recurrent sinobronchopulmonary infections, lymphoreticular neoplasms, and other malignancies. Serum ALPHA-FETOPROTEINS are usually elevated. (Menkes, Textbook of Child Neurology, 5th ed, p688) The gene for this disorder (ATM) encodes a cell cycle checkpoint protein kinase and has been mapped to chromosome 11 (11q22-q23).		06.29220
Lymph Node Metastasis
[description not available]		07.1172
Dysostoses
Defective bone formation involving individual bones, singly or in combination.		02.1510
Chondrodystrophic Myotonia
[description not available]		03.2460
American Trypanosomiasis
[description not available]		02.1510
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		02.1510
Bacterial Infections, Gram-Negative
[description not available]		02.7930
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		02.7930
Leukemia, Lymphoblastic, Acute, T Cell
[description not available]		03.3860
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.		03.3860
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		012152
B16 Melanoma
[description not available]		04.02140
Deafness, Transitory
[description not available]		02.7930
Dyskinesia Syndromes
[description not available]		05.17111
Movement Disorders
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.		05.17111
Hearing Loss
A general term for the complete or partial loss of the ability to hear from one or both ears.		07.7930
Deficiency, Pyridoxine
[description not available]		07.29251
Psoriasis Arthropathica
[description not available]		02.5220
Arthritis, Psoriatic
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.		02.5220
Adult-Onset Vitelliform Macular Dystrophy
[description not available]		02.1510
Anaplasma Infection
[description not available]		02.1510
Delayed Effects, Prenatal Exposure
[description not available]		03.92120
Alcohol Drinking
Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.		03.77100
Microglossia
[description not available]		02.520
Circulatory Collapse
[description not available]		02.1510
Shock
A pathological condition manifested by failure to perfuse or oxygenate vital organs.		02.1510
Nerve Degeneration
Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.		07.76380
Hypercapnia
A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.		02.3920
Airway Remodeling
The structural changes in the number, mass, size and/or composition of the airway tissues.		02.1710
Acute Post-Traumatic Stress Disorder
[description not available]		06.3542
Stress Disorders, Post-Traumatic
A class of traumatic stress disorders with symptoms that last more than one month.		18.3542
Hemorrhage, Subarachnoid
[description not available]		02.7830
Subarachnoid Hemorrhage
Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.		02.7830
Ophthalmoplegia, Progressive Supranuclear
[description not available]		02.7530
Supranuclear Palsy, Progressive
A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)		02.7530
Chemical Dependence
[description not available]		02.2110
Substance-Related Disorders
Disorders related to substance use or abuse.		02.2110
Blood Poisoning
[description not available]		03.6690
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		08.6690
Cranial Nerve II Diseases
[description not available]		02.1510
Optic Nerve Diseases
Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.		02.1510
Adiadochokinesis
[description not available]		02.5420
Child Development Deviations
[description not available]		03.8840
Atrophy
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.		09.260
Cerebellar Ataxia
Incoordination of voluntary movements that occur as a manifestation of CEREBELLAR DISEASES. Characteristic features include a tendency for limb movements to overshoot or undershoot a target (dysmetria), a tremor that occurs during attempted movements (intention TREMOR), impaired force and rhythm of diadochokinesis (rapidly alternating movements), and GAIT ATAXIA. (From Adams et al., Principles of Neurology, 6th ed, p90)		02.5420
Developmental Disabilities
Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)		03.8840
Hemiplegia, Crossed
[description not available]		02.1710
Hemiplegia
Severe or complete loss of motor function on one side of the body. This condition is usually caused by BRAIN DISEASES that are localized to the cerebral hemisphere opposite to the side of weakness. Less frequently, BRAIN STEM lesions; cervical SPINAL CORD DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; and other conditions may manifest as hemiplegia. The term hemiparesis (see PARESIS) refers to mild to moderate weakness involving one side of the body.		02.1710
Infections, Helicobacter
[description not available]		03.4670
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		03.4670
Starvation
Lengthy and continuous deprivation of food. (Stedman, 25th ed)		04.52250
Fasting Hypoglycemia
HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.		04.67110
Autonomic Failure, Pure
[description not available]		02.1710
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.		09.67110
Central Nervous System Neoplasm
[description not available]		02.9640
Central Nervous System Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.		02.9640
Argininosuccinate Synthase Deficiency Disease
[description not available]		02.4520
Icterus Gravis Neonatorum
[description not available]		02.1510
Jaundice, Neonatal
Yellow discoloration of the SKIN; MUCOUS MEMBRANE; and SCLERA in the NEWBORN. It is a sign of NEONATAL HYPERBILIRUBINEMIA. Most cases are transient self-limiting (PHYSIOLOGICAL NEONATAL JAUNDICE) occurring in the first week of life, but some can be a sign of pathological disorders, particularly LIVER DISEASES.		02.1510
Citrullinemia
A group of diseases related to a deficiency of the enzyme ARGININOSUCCINATE SYNTHASE which causes an elevation of serum levels of CITRULLINE. In neonates, clinical manifestations include lethargy, hypotonia, and SEIZURES. Milder forms also occur. Childhood and adult forms may present with recurrent episodes of intermittent weakness, lethargy, ATAXIA, behavioral changes, and DYSARTHRIA. (From Menkes, Textbook of Child Neurology, 5th ed, p49)		02.4520
Milk-Alkali Syndrome
[description not available]		02.1710
Hypercalcemia
Abnormally high level of calcium in the blood.		02.1710
Allodynia
[description not available]		05.65280
Abdominal Migraine
[description not available]		03.9440
Migraine Disorders
A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)		03.9440
Deficiency, Vitamin B 12
[description not available]		06.71160
Vitamin B 12 Deficiency
A nutritional condition produced by a deficiency of VITAMIN B 12 in the diet, characterized by megaloblastic anemia. Since vitamin B 12 is not present in plants, humans have obtained their supply from animal products, from multivitamin supplements in the form of pills, and as additives to food preparations. A wide variety of neuropsychiatric abnormalities is also seen in vitamin B 12 deficiency and appears to be due to an undefined defect involving myelin synthesis. (From Cecil Textbook of Medicine, 19th ed, p848)		011.71160
Depression, Endogenous
[description not available]		03.76110
Depressive Disorder
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.		03.76110
Cutis Elastica
[description not available]		03.0850
Ehlers-Danlos Syndrome
A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability.		03.0850
Eczema, Atopic
[description not available]		02.7530
Dermatitis, Atopic
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.		02.7530
Prodromal Characteristics
[description not available]		02.1710
Overweight
A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.		04.8121
Adenoma, Basal Cell
[description not available]		06.59111
Adenoma
A benign epithelial tumor with a glandular organization.		011.59111
Cystic Fibrosis of Pancreas
[description not available]		04.02140
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.		04.02140
Electron Transport Chain Deficiencies, Mitochondrial
[description not available]		02.7630
Mitochondrial Diseases
Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.		02.7630
Allergic Reaction
[description not available]		02.9240
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		02.9240
DDPAC
[description not available]		02.5520
Frontotemporal Dementia
The most common clinical form of FRONTOTEMPORAL LOBAR DEGENERATION, this dementia presents with personality and behavioral changes often associated with disinhibition, apathy, and lack of insight.		02.5520
Infection, Toxoplasma gondii
[description not available]		02.5820
Toxoplasmosis
The acquired form of infection by Toxoplasma gondii in animals and man.		02.5820
Break-Bone Fever
[description not available]		02.3820
Dengue
An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.		02.3820
Adipocere
[description not available]		05.41140
Deficiency, Glucosephosphatase
[description not available]		02.1710
Glycogen Storage Disease Type I
An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.		02.1710
Atrophy, Muscle
[description not available]		03.78100
Muscular Atrophy
Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.		03.78100
Albers-Schoenberg Disease
[description not available]		02.6830
Osteopetrosis
Excessive formation of dense trabecular bone leading to pathological fractures; OSTEITIS; SPLENOMEGALY with infarct; ANEMIA; and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).		02.6830
Day Blindness
[description not available]		02.4420
Bone Loss, Osteoclastic
[description not available]		04.3470
Labhart-Willi Syndrome
[description not available]		02.2110
Prader-Willi Syndrome
An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)		07.2110
Glaucoma
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)		07.4820
Intraocular Pressure
The pressure of the fluids in the eye.		02.7630
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		07.15530
Nociceptive Pain
Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.		02.5220
Bilateral Headache
[description not available]		02.4520
Headache
The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.		07.4520
Cardiac Diseases
[description not available]		04.0750
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		04.0750
Atrial Remodeling
Long-term changes in the electrophysiological parameters and/or anatomical structures of the HEART ATRIA that result from prolonged changes in atrial rate, often associated with ATRIAL FIBRILLATION or long periods of intense EXERCISE.		02.2110
Auricular Fibrillation
[description not available]		02.9340
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		02.9340
Angiosarcoma
[description not available]		02.4620
Hemangiosarcoma
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)		02.4620
Catheter-Associated Infections
[description not available]		02.2110
Co-infection
[description not available]		02.2110
Carcinoma, Neuroendocrine
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)		03.4420
Infections, Hantavirus
[description not available]		02.2110
Hantavirus Infections
Infections with viruses of the genus HANTAVIRUS. This is associated with at least four clinical syndromes: HEMORRHAGIC FEVER WITH RENAL SYNDROME caused by viruses of the Hantaan group; a milder form of HFRS caused by SEOUL VIRUS; nephropathia epidemica caused by PUUMALA VIRUS; and HANTAVIRUS PULMONARY SYNDROME caused by SIN NOMBRE VIRUS.		02.2110
Aseptic Necrosis of Femur Head
[description not available]		02.2110
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		05.58710
Infections, Yersinia
[description not available]		02.2110
Cranial Nerve II Injuries
[description not available]		02.4920
Canine Diseases
[description not available]		03.0850
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome
[description not available]		02.7730
Rett Syndrome
An inherited neurological developmental disorder that is associated with X-LINKED INHERITANCE and may be lethal in utero to hemizygous males. The affected female is normal until the age of 6-25 months when progressive loss of voluntary control of hand movements and communication skills; ATAXIA; SEIZURES; autistic behavior; intermittent HYPERVENTILATION; and HYPERAMMONEMIA appear. (From Menkes, Textbook of Child Neurology, 5th ed, p199)		02.7730
MPTP Neurotoxicity Syndrome
[description not available]		02.7830
Cancer of the Uterus
[description not available]		02.4120
Uterine Neoplasms
Tumors or cancer of the UTERUS.		02.4120
Cystadenocarcinoma, Serous
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)		02.520
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		06.33380
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous
[description not available]		03.6930
Ovarian Hyperstimulation Syndrome
A complication of OVULATION INDUCTION in infertility treatment. It is graded by the severity of symptoms which include OVARY enlargement, multiple OVARIAN FOLLICLES; OVARIAN CYSTS; ASCITES; and generalized EDEMA. The full-blown syndrome may lead to RENAL FAILURE, respiratory distress, and even DEATH. Increased capillary permeability is caused by the vasoactive substances, such as VASCULAR ENDOTHELIAL GROWTH FACTORS, secreted by the overly-stimulated OVARIES.		03.6930
Nerve Pain
[description not available]		04.89120
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		04.89120
Retrolental Fibroplasia
[description not available]		02.2110
Retinopathy of Prematurity
A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)		07.2110
Cronobacter Infections
[description not available]		02.7530
Enterobacteriaceae Infections
Infections with bacteria of the family ENTEROBACTERIACEAE.		02.7530
Cirrhoses, Experimental Liver
[description not available]		02.7230
Bright Disease
A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.		02.9740
Glomerulonephritis, Lupus
[description not available]		02.2110
Glomerulonephritis
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.		07.9740
Lupus Nephritis
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).		02.2110
Polyarthritis
[description not available]		03.6530
Arthritis
Acute or chronic inflammation of JOINTS.		03.6530
Ventricular Dysfunction
A condition in which HEART VENTRICLES exhibit impaired function.		02.0810
Cardiometabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.		04.2160
Metabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.		04.2160
Prediabetes
[description not available]		02.7330
Pregnancy in Diabetes
[description not available]		02.420
Prediabetic State
The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).		02.7330
Cocaine Abuse
[description not available]		03.77100
Cocaine-Related Disorders
Disorders related or resulting from use of cocaine.		03.77100
Acute Post-operative Pain
[description not available]		02.9640
Pain, Postoperative
Pain during the period after surgery.		02.9640
Constriction, Pathological
[description not available]		03.3260
Constriction, Pathologic
The condition of an anatomical structure's being constricted beyond normal dimensions.		03.3260
Carcinoma, Mucoepidermoid
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)		02.0810
Cancer of Parotid
[description not available]		02.0810
Parotid Neoplasms
Tumors or cancer of the PAROTID GLAND.		02.0810
Acrocephalosyndactylia
Congenital craniostenosis with syndactyly.		03.8110
Lesion of Sciatic Nerve
[description not available]		02.7530
Aortic Stenosis
[description not available]		02.4220
Aortic Valve Stenosis
A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.		02.4220
Autolysis, Dental Pulp
[description not available]		02.0810
Periapical Diseases
Diseases of the PERIAPICAL TISSUE surrounding the root of the tooth, which is distinguished from DENTAL PULP DISEASES inside the TOOTH ROOT.		02.0810
Exposure, Dental Pulp
[description not available]		02.0810
Dental Pulp Exposure
The result of pathological changes in the hard tissue of a tooth caused by carious lesions, mechanical factors, or trauma, which render the pulp susceptible to bacterial invasion from the external environment.		02.0810
Anodontia
Congenital absence of the teeth; it may involve all (total anodontia) or only some of the teeth (partial anodontia, hypodontia), and both the deciduous and the permanent dentition, or only teeth of the permanent dentition. (Dorland, 27th ed)		02.7630
Anhidrotic Ectodermal Dysplasia
[description not available]		08.150
47,XX,+21
[description not available]		03.98130
Down Syndrome
A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)		03.98130
Angiomatosis Retinae
[description not available]		02.7330
von Hippel-Lindau Disease
An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.		02.7330
Dementias, Transmissible
[description not available]		02.9740
Anemia, Fanconi
[description not available]		02.7530
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		07.7530
Craniofacial Abnormalities
Congenital structural deformities, malformations, or other abnormalities of the cranium and facial bones.		02.0810
Anterior Cerebral Circulation Infarction
[description not available]		03.1650
Eye Abnormalities
Congenital absence of or defects in structures of the eye; may also be hereditary.		02.9440
Polysyndactyly
[description not available]		02.7130
Abnormalities, Teeth
[description not available]		02.4720
Congenital Foot Deformities
[description not available]		02.9240
Brain Infarction
Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.		03.1650
Antibody Deficiency Syndrome
[description not available]		02.9740
Verruca
[description not available]		02.4420
Congenital Immunodeficiency Disease
[description not available]		02.0810
Primary Immunodeficiency Diseases
Genetic immunologic deficiency diseases and syndromes due to mutations in genes involved in IMMUNITY generally characterized by an increased susceptibility to infectious diseases. They are often associated with AUTOIMMUNE DISEASE manifestations.		02.0810
Immunologic Deficiency Syndromes
Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.		02.9740
Warts
Benign epidermal proliferations or tumors; some are viral in origin.		02.4420
Cancer of Mediastinum
[description not available]		02.5120
Chemodectoma
[description not available]		02.0810
Mediastinal Neoplasms
Tumors or cancer of the MEDIASTINUM.		02.5120
Affective Disorders
[description not available]		04.7161
Mood Disorders
Those disorders that have a disturbance in mood as their predominant feature.		04.7161
Adverse Drug Event
[description not available]		03.4711
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		03.4711
Bacteroidaceae Infections
Infections with bacteria of the family BACTEROIDACEAE.		02.4820
Epileptiform Neuralgia
[description not available]		02.0810
Trigeminal Neuralgia
A syndrome characterized by recurrent episodes of excruciating pain lasting several seconds or longer in the sensory distribution of the TRIGEMINAL NERVE. Pain may be initiated by stimulation of trigger points on the face, lips, or gums or by movement of facial muscles or chewing. Associated conditions include MULTIPLE SCLEROSIS, vascular anomalies, ANEURYSMS, and neoplasms. (Adams et al., Principles of Neurology, 6th ed, p187)		02.0810
Nephritis
Inflammation of any part of the KIDNEY.		02.0810
Leukemia, Acute Monocytic
[description not available]		02.6730
Leukemia, Monocytic, Acute
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.		02.6730
Angle Class III
[description not available]		02.520
Dysembryoma
[description not available]		02.0810
Teratoma
A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642)		02.0810
Cancer of Gastrointestinal Tract
[description not available]		04.3740
Epithelial Neoplasms
[description not available]		02.110
Animal Mammary Carcinoma
[description not available]		02.7530
Anemia, Cooley's
[description not available]		02.0810
beta-Thalassemia
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.		02.0810
Iron Overload
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)		02.4820
Drug Withdrawal Symptoms
[description not available]		03.2860
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		03.2860
Autosomal Hemophilia A
[description not available]		02.9140
Hemophilia A
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.		02.9140
Congenital Poikiloderma
[description not available]		02.110
Erythema
Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.		02.110
Stomatitis, Vesicular
[description not available]		02.110
Leucocythaemia
[description not available]		06.01270
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		06.01270
Neuralgia, Sciatic
[description not available]		02.4720
Sciatica
A condition characterized by pain radiating from the back into the buttock and posterior/lateral aspects of the leg. Sciatica may be a manifestation of SCIATIC NEUROPATHY; RADICULOPATHY (involving the SPINAL NERVE ROOTS; L4, L5, S1, or S2, often associated with INTERVERTEBRAL DISK DISPLACEMENT); or lesions of the CAUDA EQUINA.		02.4720
Blood Clot
[description not available]		05.05160
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		05.05160
Cancer of Granulosa Cells
[description not available]		02.110
Psychoses, Drug
[description not available]		03.0850
Muscle Relaxation
That phase of a muscle twitch during which a muscle returns to a resting position.		03.72100
Electrocardiogram QT Prolonged
[description not available]		05.5892
Long QT Syndrome
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.		05.5892
Ovine Diseases
[description not available]		02.4120
Tick Infestations
Infestations with soft-bodied (Argasidae) or hard-bodied (Ixodidae) ticks.		02.110
Anemia, Hemolytic, Acquired
[description not available]		03.0650
Cyanosis
A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.		02.8940
Enlarged Spleen
[description not available]		02.7630
Anemia, Hemolytic
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).		03.0650
Hemoglobinopathies
A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.		03.260
Angiitis
[description not available]		02.110
Vasculitis
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.		02.110
ACD-MPV
[description not available]		02.110
Persistent Fetal Circulation Syndrome
A syndrome of persistent PULMONARY HYPERTENSION in the newborn infant (INFANT, NEWBORN) without demonstrable HEART DISEASES. This neonatal condition can be caused by severe pulmonary vasoconstriction (reactive type), hypertrophy of pulmonary arterial muscle (hypertrophic type), or abnormally developed pulmonary arterioles (hypoplastic type). The newborn patient exhibits CYANOSIS and ACIDOSIS due to the persistence of fetal circulatory pattern of right-to-left shunting of blood through a patent ductus arteriosus (DUCTUS ARTERIOSUS, PATENT) and at times a patent foramen ovale (FORAMEN OVALE, PATENT).		02.110
Demineralization, Tooth
[description not available]		02.4820
Anoxia-Ischemia, Brain
[description not available]		04.66100
Hypoxia-Ischemia, Brain
A disorder characterized by a reduction of oxygen in the blood combined with reduced blood flow (ISCHEMIA) to the brain from a localized obstruction of a cerebral artery or from systemic hypoperfusion. Prolonged hypoxia-ischemia is associated with ISCHEMIC ATTACK, TRANSIENT; BRAIN INFARCTION; BRAIN EDEMA; COMA; and other conditions.		04.66100
Sarcoma 180
An experimental sarcoma of mice.		03.260
Critical Illness
A disease or state in which death is possible or imminent.		03.8721
Vaginal Diseases
Pathological processes of the VAGINA.		02.110
Focal Segmental Glomerulosclerosis
[description not available]		02.4820
Glomerulosclerosis, Focal Segmental
A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.		02.4820
Neovascularization, Optic Disc
[description not available]		02.110
Retinal Neovascularization
Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.		02.110
Muscular Weakness
[description not available]		02.4720
Muscle Weakness
A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)		02.4720
Pemphigus Foliaceus
[description not available]		02.110
Pemphigus
Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.		02.110
Rigor Mortis
Muscular rigidity which develops in the cadaver usually from 4 to 10 hours after death and lasts 3 or 4 days.		02.110
Cumulative Trauma Disorders
Harmful and painful condition caused by overuse or overexertion of some part of the musculoskeletal system, often resulting from work-related physical activities. It is characterized by inflammation, pain, or dysfunction of the involved joints, bones, ligaments, and nerves.		02.110
Suicidal Ideation
A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.		02.110
Kidney Stones
[description not available]		03.630
Cystinuria
An inherited disorder due to defective reabsorption of CYSTINE and other BASIC AMINO ACIDS by the PROXIMAL RENAL TUBULES. This form of aminoaciduria is characterized by the abnormally high urinary levels of cystine; LYSINE; ARGININE; and ORNITHINE. Mutations involve the amino acid transport protein gene SLC3A1.		03.2160
Kidney Calculi
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.		03.630
Orphan Diseases
Rare diseases that have not been well studied.		02.110
Hepatitis B Virus Infection
[description not available]		04.4580
Hepatitis B
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.		04.4580
Goldblatt Syndrome
[description not available]		02.4920
Hypertension, Renovascular
Hypertension due to RENAL ARTERY OBSTRUCTION or compression.		02.4920
Response Evaluation Criteria in Solid Tumors
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.		04.411
Candida Infection
[description not available]		02.4920
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		02.4920
African Lymphoma
[description not available]		03.3770
Burkitt Lymphoma
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.		03.3770
Cystosarcoma Phyllodes
[description not available]		02.110
Benign Supratentorial Neoplasms
[description not available]		02.110
Refractory Depression
[description not available]		03.511
Depressive Disorder, Treatment-Resistant
Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)		03.511
Lymphoma, Primary Effusion
A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.		02.110
AIRE Deficiency
[description not available]		02.110
Hyperactivity, Motor
[description not available]		02.9840
Alopecia Cicatrisata
[description not available]		02.4620
Alopecia
Absence of hair from areas where it is normally present.		02.4620
Myeloproliferative Disorders
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.		02.7430
Academic Disorder, Developmental
[description not available]		03.6630
Learning Disabilities
Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.		03.6630
Pericementitis
[description not available]		02.7530
Periodontitis
Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)		02.7530
Lead Encephalopathy, Childhood
[description not available]		02.110
Limb-Girdle Muscular Dystrophies
[description not available]		02.7530
Muscular Dystrophies, Limb-Girdle
A heterogenous group of inherited muscular dystrophy that can be autosomal dominant or autosomal recessive. There are many forms (called LGMDs) involving genes encoding muscle membrane proteins such as the sarcoglycan (SARCOGLYCANS) complex that interacts with DYSTROPHIN. The disease is characterized by progressing wasting and weakness of the proximal muscles of arms and legs around the HIPS and SHOULDERS (the pelvic and shoulder girdles).		02.7530
Toxocariasis
Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.		02.110
Osteoarthritis of Knee
[description not available]		02.1110
Osteoarthritis, Knee
Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)		02.1110
Encephalomyelitis, Subacute Necrotizing
[description not available]		03.420
Leigh Disease
A group of metabolic disorders primarily of infancy characterized by the subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, dysphagia, and lactic acidosis. Pathological features include spongy degeneration of the neuropile of the basal ganglia, thalamus, brain stem, and spinal cord. Patterns of inheritance include X-linked recessive, autosomal recessive, and mitochondrial. Leigh disease has been associated with mutations in genes for the PYRUVATE DEHYDROGENASE COMPLEX; CYTOCHROME-C OXIDASE; ATP synthase subunit 6; and subunits of mitochondrial complex I. (From Menkes, Textbook of Child Neurology, 5th ed, p850).		03.420
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		03.1750
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		03.1750
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Disorder characterized by symptoms of CATATONIA; HYPOVENTILATION; DYSKINESIAS; ENCEPHALITIS; and SEIZURES followed by a reduced CONSCIOUSNESS. It is often followed by a viral-like prodrome. Many cases are self-limiting and respond well to IMMUNOMODULATORY THERAPIES against the NMDA RECEPTORS antibodies.		02.1110
Plasmodium vivax Malaria
[description not available]		02.110
Malaria, Vivax
Malaria caused by PLASMODIUM VIVAX. This form of malaria is less severe than MALARIA, FALCIPARUM, but there is a higher probability for relapses to occur. Febrile paroxysms often occur every other day.		02.110
Deficiency, Folic Acid
[description not available]		08.97311
Folic Acid Deficiency
A nutritional condition produced by a deficiency of FOLIC ACID in the diet. Many plant and animal tissues contain folic acid, abundant in green leafy vegetables, yeast, liver, and mushrooms but destroyed by long-term cooking. Alcohol interferes with its intermediate metabolism and absorption. Folic acid deficiency may develop in long-term anticonvulsant therapy or with use of oral contraceptives. This deficiency causes anemia, macrocytic anemia, and megaloblastic anemia. It is indistinguishable from vitamin B 12 deficiency in peripheral blood and bone marrow findings, but the neurologic lesions seen in B 12 deficiency do not occur. (Merck Manual, 16th ed)		08.97311
Amentia
[description not available]		06.49240
Acute Onset Vascular Dementia
[description not available]		02.9540
Dementia
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.		06.49240
Dementia, Vascular
An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)		02.9540
Harelip
[description not available]		0340
Cleft Palate, Isolated
[description not available]		03.360
Cleft Lip
Congenital defect in the upper lip where the maxillary prominence fails to merge with the merged medial nasal prominences. It is thought to be caused by faulty migration of the mesoderm in the head region.		0340
Cleft Palate
Congenital fissure of the soft and/or hard palate, due to faulty fusion.		03.360
Hyperhomocysteinemia
Condition in which the plasma levels of homocysteine and related metabolites are elevated (		04.75110
Alcoholic Fatty Liver
[description not available]		07.4920
Airflow Obstruction, Chronic
[description not available]		02.4720
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.		02.4720
Prognathism
A condition marked by abnormal protrusion of the mandible. (Dorland, 27th ed)		02.1110
Alagille Syndrome 1
[description not available]		02.4420
Alagille Syndrome
A multisystem disorder that is characterized by aplasia of intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC), and malformations in the cardiovascular system, the eyes, the vertebral column, and the facies. Major clinical features include JAUNDICE, and congenital heart disease with peripheral PULMONARY STENOSIS. Alagille syndrome may result from heterogeneous gene mutations, including mutations in JAG1 on CHROMOSOME 20 (Type 1) and NOTCH2 on CHROMOSOME 1 (Type 2).		02.4420
Bradyarrhythmia
[description not available]		02.1310
Bradycardia
Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.		02.1310
A-Thalassemia
[description not available]		02.9640
alpha-Thalassemia
A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted.		02.9640
Brain Swelling
[description not available]		03.2760
Brain Edema
Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)		03.2760
Osteomyelitis
INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.		02.4820
Aspiration, Respiratory
[description not available]		02.1110
Lung Injury, Acute
[description not available]		02.1110
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		02.1110
Anhedonia
Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).		02.1110
Granulocytic Leukemia
[description not available]		04.32200
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		04.32200
Blastocyst Disintegration
[description not available]		02.1110
Elevated ICP (Intracranial Pressure)
[description not available]		02.1110
Intracranial Hypertension
Increased pressure within the cranial vault. This may result from several conditions, including HYDROCEPHALUS; BRAIN EDEMA; intracranial masses; severe systemic HYPERTENSION; PSEUDOTUMOR CEREBRI; and other disorders.		02.1110
Hakim Syndrome
[description not available]		02.1110
Hydrocephalus, Normal Pressure
A form of compensated hydrocephalus characterized clinically by a slowly progressive gait disorder (see GAIT DISORDERS, NEUROLOGIC), progressive intellectual decline, and URINARY INCONTINENCE. Spinal fluid pressure tends to be in the high normal range. This condition may result from processes which interfere with the absorption of CSF including SUBARACHNOID HEMORRHAGE, chronic MENINGITIS, and other conditions. (From Adams et al., Principles of Neurology, 6th ed, pp631-3)		02.1110
Chronic Motor and Vocal Tic Disorder
[description not available]		03.511
Tourette Syndrome
A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)		08.511
Salmonella Infections, Animal
Infections in animals with bacteria of the genus SALMONELLA.		02.9240
Experimental Radiation Injuries
[description not available]		03.0550
Injuries
Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.		04.3140
Wounds and Injuries
Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.		04.3140
Abscess, Amebic
[description not available]		02.1110
Brain Inflammation
[description not available]		02.4620
Keratitis, Acanthamoeba
[description not available]		02.1110
Amebiasis
Infection with any of various amebae. It is an asymptomatic carrier state in most individuals, but diseases ranging from chronic, mild diarrhea to fulminant dysentery may occur.		02.1110
Encephalitis
Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.		02.4620
Acanthamoeba Keratitis
Infection of the cornea by an ameboid protozoan which may cause corneal ulceration leading to blindness.		02.1110
Arterial Diseases, Carotid
[description not available]		02.7530
Carotid Artery Diseases
Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.		02.7530
Diabetic Feet
[description not available]		02.1110
Diabetic Foot
Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.		02.1110
ACL Injuries
[description not available]		02.1110
Injuries, Knee
[description not available]		02.1110
Knee Injuries
Injuries to the knee or the knee joint.		02.1110
Endotoxemia
A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.		02.4820
Chronic Pancreatitis
[description not available]		02.4720
Pancreatitis, Chronic
INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.		02.4720
Cystic Kidney Diseases
[description not available]		02.4520
Kidney Diseases, Cystic
A heterogeneous group of hereditary and acquired disorders in which the KIDNEY contains one or more CYSTS unilaterally or bilaterally (KIDNEY, CYSTIC).		02.4520
Binge Alcohol Consumption
[description not available]		02.1110
Trypanosomiasis
Infection with protozoa of the genus TRYPANOSOMA.		02.3920
Acute Bacterial Prostatitis
[description not available]		02.1110
Prostatitis
Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.		02.1110
Bile Duct Obstruction
[description not available]		02.3820
Cholestasis
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).		02.3820
Ductal Carcinoma
[description not available]		07.1110
Carcinoma, Ductal
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.		02.1110
Seasonal Affective Disorders
[description not available]		02.1110
Seasonal Affective Disorder
A syndrome characterized by depressions that recur annually at the same time each year, usually during the winter months. Other symptoms include anxiety, irritability, decreased energy, increased appetite (carbohydrate cravings), increased duration of sleep, and weight gain. SAD (seasonal affective disorder) can be treated by daily exposure to bright artificial lights (PHOTOTHERAPY), during the season of recurrence.		07.1110
Inadequate Sleep
[description not available]		02.3820
Tuberculosis, Drug-Resistant
[description not available]		02.1110
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		02.1110
Merkel Cell Cancer
[description not available]		02.1310
Carcinoma, Merkel Cell
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)		02.1310
Leukemia, Lymphocytic, T Cell
[description not available]		03.2860
Leukemia, T-Cell
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.		03.2860
Bloom Syndrome
An autosomal recessive disorder characterized by telangiectatic ERYTHEMA of the face, photosensitivity, DWARFISM and other abnormalities, and a predisposition toward developing cancer. The Bloom syndrome gene (BLM) encodes a RecQ-like DNA helicase.		02.4520
Injuries, Spinal Cord
[description not available]		03.4170
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		03.4170
Hypertrophy, Right Ventricular
Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.		02.4820
Pulmonary Hypertension
[description not available]		02.9740
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		02.9740
Blood Pressure, Low
[description not available]		04.3880
Hypotension
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.		04.3880
Encephalomyopathies, Mitochondrial
[description not available]		02.9640
Cold Panniculitis
[description not available]		02.1310
Asymptomatic Colonization
[description not available]		03.0410
Bacteriuria
The presence of bacteria in the urine which is normally bacteria-free. These bacteria are from the URINARY TRACT and are not contaminants of the surrounding tissues. Bacteriuria can be symptomatic or asymptomatic. Significant bacteriuria is an indicator of urinary tract infection.		03.0410
Amyloid Neuropathy Type 1
[description not available]		02.9640
Amyloid Neuropathies, Familial
Inherited disorders of the peripheral nervous system associated with the deposition of AMYLOID in nerve tissue. The different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (PREALBUMIN); APOLIPOPROTEIN A-I; and GELSOLIN.		02.9640
Agitation, Psychomotor
[description not available]		02.1310
Psychomotor Agitation
A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.		02.1310
Hutchinson Gilford Progeria Syndrome
[description not available]		02.4620
Progeria
An abnormal congenital condition, associated with defects in the LAMIN TYPE A gene, which is characterized by premature aging in children, where all the changes of cell senescence occur. It is manifested by premature graying; hair loss; hearing loss (DEAFNESS); cataracts (CATARACT); ARTHRITIS; OSTEOPOROSIS; DIABETES MELLITUS; atrophy of subcutaneous fat; skeletal hypoplasia; elevated urinary HYALURONIC ACID; and accelerated ATHEROSCLEROSIS. Many affected individuals develop malignant tumors, especially SARCOMA.		07.4620
Luft Disease
[description not available]		05.1550
Ataxias, Hereditary
[description not available]		06.2870
Mitochondrial Myopathies
A group of muscle diseases associated with abnormal mitochondria function.		05.1550
Chromosome-Defective Micronuclei
[description not available]		02.1310
Acute Hypercapnic Respiratory Failure
[description not available]		02.4920
Respiratory Insufficiency
Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)		02.4920
Autolysis
The spontaneous disintegration of tissues or cells by the action of their own autogenous enzymes.		02.8840
Blunt Injuries
[description not available]		02.1310
Drug Overdose
Accidental or deliberate use of a medication or street drug in excess of normal dosage.		02.4620
Entamoeba histolytica Infection
[description not available]		02.9440
Carcinoma, Papillary
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)		02.520
Anemia, Hypoplastic
[description not available]		02.3820
Graft-Versus-Host Disease
[description not available]		07.6630
Anemia, Aplastic
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.		02.3820
Graft vs Host Disease
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.		02.6630
Ankylosing Spondylarthritis
[description not available]		02.1510
Spondylitis, Ankylosing
A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.		02.1510
Chronic Infantile Neurologic, Cutaneous, and Articular Syndrome
[description not available]		02.1310
Cryopyrin-Associated Periodic Syndromes
A group of rare autosomal dominant diseases, commonly characterized by atypical URTICARIA (hives) with systemic symptoms that develop into end-organ damage. The atypical hives do not involve T-cell or autoantibody. Cryopyrin-associated periodic syndrome includes three previously distinct disorders: Familial cold autoinflammatory syndrome; Muckle-Wells Syndrome; and CINCA Syndrome, that are now considered to represent a disease continuum, all caused by NLRP3 PROTEIN mutations.		02.1310
Experimental Leukemia
[description not available]		08.83120
Indigestion
[description not available]		02.1310
Dyspepsia
Impaired digestion, especially after eating.		02.1310
Margins of Excision
The edges of tissue removed in a surgery for assessment of the effectiveness of a surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. When the margin is negative or not involved by tumor (e.g., CANCER) it suggests all of the tumor has been removed by the surgery.		02.1310
Epiretinal Membrane
A membrane on the vitreal surface of the retina resulting from the proliferation of one or more of three retinal elements: (1) fibrous astrocytes; (2) fibrocytes; and (3) RETINAL PIGMENT EPITHELIUM. Localized epiretinal membranes may occur at the posterior pole of the eye without clinical signs or may cause marked loss of vision as a result of covering, distorting, or detaching the FOVEA CENTRALIS. Epiretinal membranes may cause vascular leakage and secondary retinal edema. In younger individuals some membranes appear to be developmental in origin and occur in otherwise normal eyes. The majority occur in association with RETINAL HOLES, ocular concussions, retinal inflammation, or after ocular surgery. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p291)		02.1310
Atherosclerotic Parkinsonism
[description not available]		03.4980
Parkinson Disease, Secondary
Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)		03.4980
Recrudescence
[description not available]		03.72100
Alcoholic Hepatitis
[description not available]		02.1510
Hepatitis, Alcoholic
INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.		02.1510
Rida
[description not available]		02.1510
Caprine Diseases
[description not available]		02.1510
Berger Disease
[description not available]		02.1310
Glomerulonephritis, IGA
A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.		02.1310
Angina Pectoris, Stable
[description not available]		04.4311
Angina, Stable
Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.		04.4311
Acoustic Perceptual Disorder
[description not available]		06.1721
Camurati-Engelmann Disease
[description not available]		02.1510
Chondrosarcoma
A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)		08.84120
Corridor Disease
[description not available]		02.4720
Mastitis, Bovine
INFLAMMATION of the UDDER in cows.		02.520
Atrophy, Muscular, Peroneal
[description not available]		04.28180
Charcot-Marie-Tooth Disease
A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343)		04.28180
Cholera Infantum
[description not available]		02.4820
Acquired Immune Deficiency Syndrome
[description not available]		02.1510
Diffuse Large B-Cell Lymphoma
[description not available]		02.7130
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		02.1510
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		02.7130
Morphine Abuse
[description not available]		03.1150
Morphine Dependence
Strong dependence, both physiological and emotional, upon morphine.		03.1150
Chronic Progressive External Ophthalmoplegia
[description not available]		02.0410
Apraxia
[description not available]		08.7921
Ptosis, Eyelid
[description not available]		02.6930
Apraxias
A group of cognitive disorders characterized by the inability to perform previously learned skills that cannot be attributed to deficits of motor or sensory function. The two major subtypes of this condition are ideomotor (see APRAXIA, IDEOMOTOR) and ideational apraxia, which refers to loss of the ability to mentally formulate the processes involved with performing an action. For example, dressing apraxia may result from an inability to mentally formulate the act of placing clothes on the body. Apraxias are generally associated with lesions of the dominant PARIETAL LOBE and supramarginal gyrus. (From Adams et al., Principles of Neurology, 6th ed, pp56-7)		03.7921
Blepharoptosis
Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle.		02.6930
Lipidoses
Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.		04.660
Bacterial Endocarditides
[description not available]		02.4620
Endocarditis, Bacterial
Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.		02.4620
Infections, Roseolovirus
[description not available]		02.0410
Cacosmia
[description not available]		02.4720
Itching
[description not available]		02.0510
Dermatitis
Any inflammation of the skin.		02.9140
Pruritus
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.		02.0510
Metabolic Acidosis
[description not available]		010.65191
Acidosis
A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.		010.65191
Deaf Mutism
[description not available]		02.7130
Hyperkeratosis Palmaris et Plantaris
[description not available]		02.4620
Deafness
A general term for the complete loss of the ability to hear from both ears.		02.7130
Attachment Loss, Periodontal
[description not available]		02.0510
Adult Periodontitis
[description not available]		02.0510
Dental Plaque
A film that attaches to teeth, often causing DENTAL CARIES and GINGIVITIS. It is composed of MUCINS, secreted from salivary glands, and microorganisms.		02.8940
Pocket, Periodontal
[description not available]		02.0510
Aggressive Periodontitis
Inflammation and loss of PERIODONTIUM that is characterized by rapid attachment loss and bone destruction in the presence of little local factors such as DENTAL PLAQUE and DENTAL CALCULUS. This highly destructive form of periodontitis often occurs in young people and was called early-onset periodontitis, but this disease also appears in old people.		03.6430
Hemorrhage, Gingival
[description not available]		02.0510
Gingival Hemorrhage
The flowing of blood from the marginal gingival area, particularly the sulcus, seen in such conditions as GINGIVITIS, marginal PERIODONTITIS, injury, and ASCORBIC ACID DEFICIENCY.		02.0510
Periodontal Pocket
An abnormal extension of a gingival sulcus accompanied by the apical migration of the epithelial attachment and bone resorption.		02.0510
Multiple System Atrophy Syndrome
[description not available]		02.9640
Multiple System Atrophy
A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)		07.9640
Aging, Premature
Changes in the organism associated with senescence, occurring at an accelerated rate.		02.0510
Benign Frontal Childhood Epilepsy
[description not available]		02.9440
Capdepont Teeth
[description not available]		02.0410
Dentin Dysplasia
An apparently hereditary disorder of dentin formation, marked by a normal appearance of coronal dentin associated with pulpal obliteration, faulty root formation, and a tendency for peripheral lesions without obvious cause. (From Dorland, 27th ed)		02.0410
Acute Promyelocytic Leukemia
[description not available]		08.5280
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.		03.5280
Basal Cell Cancer
[description not available]		02.0410
Polyploid
[description not available]		02.7230
Left Ventricular Dysfunction
[description not available]		03.6630
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		03.6630
Heroin Abuse
[description not available]		02.3820
Heroin Dependence
Strong dependence or addiction, both physiological and emotional, upon HEROIN.		02.3820
Burns, Chemical
Burns caused by contact with or exposure to CAUSTICS or strong ACIDS.		02.0510
Corneal Angiogenesis
[description not available]		02.0510
Eye Burns
Injury to any part of the eye by extreme heat, chemical agents, or ultraviolet radiation.		02.0510
Corneal Neovascularization
New blood vessels originating from the corneal blood vessels and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.		02.0510
Anoxia, Fetal
[description not available]		02.7230
Fetal Hypoxia
Deficient oxygenation of FETAL BLOOD.		02.7230
Carcinoma, Intraepithelial
[description not available]		02.0510
Carcinoma in Situ
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.		02.0510
Electrolytes
Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)		04.1460
Hypothermia, Accidental
[description not available]		03.2360
Hypothermia
Lower than normal body temperature, especially in warm-blooded animals.		03.2360
Gout
Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.		02.8740
Hyperoxia
An abnormal increase in the amount of oxygen in the tissues and organs.		07.7330
Acathisia, Drug-Induced
[description not available]		02.4520
Infection
[description not available]		02.3720
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		02.3720
Urinary Calculi
Low-density crystals or stones in any part of the URINARY TRACT. Their chemical compositions often include CALCIUM OXALATE, magnesium ammonium phosphate (struvite), CYSTINE, or URIC ACID.		02.6530
Cot Death
[description not available]		02.4520
Addiction, Opioid
[description not available]		02.0510
Opioid-Related Disorders
Disorders related to or resulting from abuse or misuse of OPIOIDS.		02.0510
Vesicoureteral Reflux
[description not available]		02.4520
Abnormalities, Urogenital
[description not available]		02.4620
Vesico-Ureteral Reflux
Retrograde flow of urine from the URINARY BLADDER into the URETER. This is often due to incompetence of the vesicoureteral valve leading to ascending bacterial infection into the KIDNEY.		02.4520
Lymphoma, T Cell, Peripheral
[description not available]		02.0510
Lymphoma, T-Cell, Peripheral
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.		02.0510
Acid beta-Glucosidase Deficiency
[description not available]		04.480
Gaucher Disease
An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.		04.480
Thrombocytopathy
[description not available]		02.4420
Blood Platelet Disorders
Disorders caused by abnormalities in platelet count or function.		02.4420
Dyskinesia, Medication-Induced
[description not available]		04.3370
Dyskinesia, Drug-Induced
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)		04.3370
Rupture, Spontaneous
Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.		02.0510
Bare Lymphocyte Syndrome
[description not available]		02.6930
Severe Combined Immunodeficiency
Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).		02.6930
Neurilemoma
[description not available]		02.0510
Neurilemmoma
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)		02.0510
Classic Galactosemia
[description not available]		02.8840
Galactosemias
A group of inherited enzyme deficiencies which feature elevations of GALACTOSE in the blood. This condition may be associated with deficiencies of GALACTOKINASE; UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; or UDPGLUCOSE 4-EPIMERASE. The classic form is caused by UDPglucose-Hexose-1-Phosphate Uridylyltransferase deficiency, and presents in infancy with FAILURE TO THRIVE; VOMITING; and INTRACRANIAL HYPERTENSION. Affected individuals also may develop MENTAL RETARDATION; JAUNDICE; hepatosplenomegaly; ovarian failure (PRIMARY OVARIAN INSUFFICIENCY); and cataracts. (From Menkes, Textbook of Child Neurology, 5th ed, pp61-3)		02.8840
Carotid Artery Narrowing
[description not available]		02.4420
Carotid Stenosis
Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp 822-3)		02.4420
Brittle Bone Disease
[description not available]		06.12190
Osteogenesis Imperfecta
COLLAGEN DISEASES characterized by brittle, osteoporotic, and easily fractured bones. It may also present with blue sclerae, loose joints, and imperfect dentin formation. Most types are autosomal dominant and are associated with mutations in COLLAGEN TYPE I.		06.12190
Diffuse Myofascial Pain Syndrome
[description not available]		02.0510
Pain, Intractable
Persistent pain that is refractory to some or all forms of treatment.		02.0510
Fibromyalgia
A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)		02.0510
Adult GM1 Gangliosidosis
[description not available]		02.4220
Gangliosidosis, GM1
An autosomal recessive neurodegenerative disorder caused by the absence or deficiency of BETA-GALACTOSIDASE. It is characterized by intralysosomal accumulation of G(M1) GANGLIOSIDE and oligosaccharides, primarily in neurons of the central nervous system. The infantile form is characterized by MUSCLE HYPOTONIA, poor psychomotor development, HIRSUTISM, hepatosplenomegaly, and facial abnormalities. The juvenile form features HYPERACUSIS; SEIZURES; and psychomotor retardation. The adult form features progressive DEMENTIA; ATAXIA; and MUSCLE SPASTICITY. (From Menkes, Textbook of Child Neurology, 5th ed, pp96-7)		02.4220
Bernard-Soulier Syndrome
A familial coagulation disorder characterized by a prolonged bleeding time, unusually large platelets, and impaired prothrombin consumption.		08.3870
Endotoxin Shock
[description not available]		02.730
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		02.730
Central Nervous System Disease
[description not available]		03.9850
Central Nervous System Diseases
Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.		03.9850
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		02.0510
Hyperpotassemia
[description not available]		02.4420
Hyperkalemia
Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)		02.4420
Benign Essential Tremor
[description not available]		03.6530
Essential Tremor
A relatively common disorder characterized by a fairly specific pattern of tremors which are most prominent in the upper extremities and neck, inducing titubations of the head. The tremor is usually mild, but when severe may be disabling. An autosomal dominant pattern of inheritance may occur in some families (i.e., familial tremor). (Mov Disord 1988;13(1):5-10)		03.6530
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		03.65100
Hyponatremia
Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)		02.6930
Brugada ECG Pattern
[description not available]		02.0510
Brugada Syndrome
An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.		02.0510
Diabetic Angiopathies
VASCULAR DISEASES that are associated with DIABETES MELLITUS.		02.730
Adult Spinal Muscular Atrophy
[description not available]		03.1350
Muscular Atrophy, Spinal
A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)		03.1350
Bronze Diabetes
[description not available]		02.7130
Hemochromatosis
A disorder of iron metabolism characterized by a triad of HEMOSIDEROSIS; LIVER CIRRHOSIS; and DIABETES MELLITUS. It is caused by massive iron deposits in parenchymal cells that may develop after a prolonged increase of iron absorption. (Jablonski's Dictionary of Syndromes & Eponymic Diseases, 2d ed)		02.7130
Antibiotic-Associated Colitis
[description not available]		02.0510
Enterocolitis, Pseudomembranous
An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.		02.0510
Agnogenic Myeloid Metaplasia
[description not available]		02.0510
Thrombocythemia
[description not available]		02.0510
Primary Myelofibrosis
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.		02.0510
Anemia With Multinucleated Erythroblasts
[description not available]		02.0510
Pyrexia
[description not available]		02.6930
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		07.6930
Hypoventilation
A reduction in the amount of air entering the pulmonary alveoli.		02.0510
Acquired Nephrogenic Diabetes Insipidus
[description not available]		02.4320
Glucose Metabolic Disorder
[description not available]		02.0510
Diabetes, Phosphate
[description not available]		02.0510
Hypophosphatemia, Familial
An inherited condition of abnormally low serum levels of PHOSPHATES (below 1 mg/liter) which can occur in a number of genetic diseases with defective reabsorption of inorganic phosphorus by the PROXIMAL RENAL TUBULES. This leads to phosphaturia, HYPOPHOSPHATEMIA, and disturbances of cellular and organ functions such as those in X-LINKED HYPOPHOSPHATEMIC RICKETS; OSTEOMALACIA; and FANCONI SYNDROME.		02.0510
Hydrocolpos
A fluid-filled VAGINA that is obstructed.		02.0510
Leukemia, Pre-B-Cell
[description not available]		02.0510
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.		02.0510
Deficiency, Factor 5
[description not available]		02.0510
Rhabdomyosarcoma 2
[description not available]		02.4620
Rhabdomyosarcoma, Alveolar
A form of RHABDOMYOSARCOMA occurring mainly in adolescents and young adults, affecting muscles of the extremities, trunk, orbital region, etc. It is extremely malignant, metastasizing widely at an early stage. Few cures have been achieved and the prognosis is poor. Alveolar refers to its microscopic appearance simulating the cells of the respiratory alveolus. (Holland et al., Cancer Medicine, 3d ed, p2188)		02.4620
Wallerian Degeneration
Degeneration of distal aspects of a nerve axon following injury to the cell body or proximal portion of the axon. The process is characterized by fragmentation of the axon and its MYELIN SHEATH.		02.4520
Brain Diseases, Metabolic, Familial
[description not available]		04.3340
Hyperammonemia
Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.		02.4520
Hallervorden-Spatz Disease
[description not available]		02.0510
Pantothenate Kinase-Associated Neurodegeneration
A rare autosomal recessive degenerative disorder which usually presents in late childhood or adolescence. Clinical manifestations include progressive MUSCLE SPASTICITY; hyperreflexia; MUSCLE RIGIDITY; DYSTONIA; DYSARTHRIA; and intellectual deterioration which progresses to severe dementia over several years. (From Adams et al., Principles of Neurology, 6th ed, p972; Davis & Robertson, Textbook of Neuropathology, 2nd ed, pp972-929)		02.0510
Carcinoma, Colloid
[description not available]		02.4420
Adenocarcinoma, Mucinous
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)		02.4420
Facies
The appearance of the face that is often characteristic of a disease or pathological condition, as the elfin facies of WILLIAMS SYNDROME or the mongoloid facies of DOWN SYNDROME. (Random House Unabridged Dictionary, 2d ed)		02.4420
Familial Turner Syndrome
[description not available]		02.4620
Noonan Syndrome
A genetically heterogeneous, multifaceted disorder characterized by short stature, webbed neck, ptosis, skeletal malformations, hypertelorism, hormonal imbalance, CRYPTORCHIDISM, multiple cardiac abnormalities (most commonly including PULMONARY VALVE STENOSIS), and some degree of INTELLECTUAL DISABILITY. The phenotype bears similarities to that of TURNER SYNDROME that occurs only in females and has its basis in a 45, X karyotype abnormality. Noonan syndrome occurs in both males and females with a normal karyotype (46,XX and 46,XY). Mutations in a several genes (PTPN11, KRAS, SOS1, NF1 and RAF1) have been associated the NS phenotype. Mutations in PTPN11 are the most common. LEOPARD SYNDROME, a disorder that has clinical features overlapping those of Noonan Syndrome, is also due to mutations in PTPN11. In addition, there is overlap with the syndrome called neurofibromatosis-Noonan syndrome due to mutations in NF1.		07.4620
Alcohol Problem
[description not available]		02.0510
Alcohol-Related Disorders
Disorders related to or resulting from abuse or misuse of alcohol.		02.0510
Apolipoprotein C-II Deficiency
[description not available]		04.1660
Hyperlipoproteinemia Type I
An inherited condition due to a deficiency of either LIPOPROTEIN LIPASE or APOLIPOPROTEIN C-II (a lipase-activating protein). The lack of lipase activities results in inability to remove CHYLOMICRONS and TRIGLYCERIDES from the blood which has a creamy top layer after standing.		04.1660
Dental Enamel Hypoplasia
An acquired or hereditary condition due to deficiency in the formation of tooth enamel (AMELOGENESIS). It is usually characterized by defective, thin, or malformed DENTAL ENAMEL. Risk factors for enamel hypoplasia include gene mutations, nutritional deficiencies, diseases, and environmental factors.		02.6930
ADPKD
[description not available]		02.4420
Polycystic Kidney, Autosomal Dominant
Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.		02.4420
Hydronephrosis
Abnormal enlargement or swelling of a KIDNEY due to dilation of the KIDNEY CALICES and the KIDNEY PELVIS. It is often associated with obstruction of the URETER or chronic kidney diseases that prevents normal drainage of urine into the URINARY BLADDER.		06.9210
Craniofacial Pain
[description not available]		02.0510
Facial Pain
Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.		02.0510
Bilirubinemia
[description not available]		02.3820
Distorted Hearing
[description not available]		02.0510
Kaposi Disease
[description not available]		02.9240
Xeroderma Pigmentosum
A rare, pigmentary, and atrophic autosomal recessive disease. It is manifested as an extreme photosensitivity to ULTRAVIOLET RAYS as the result of a deficiency in the enzyme that permits excisional repair of ultraviolet-damaged DNA.		02.9240
Complications, Parasitic Pregnancy
[description not available]		02.0510
Convulsions, Grand Mal
[description not available]		02.0510
Epilepsy, Tonic-Clonic
A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329)		02.0510
Cancer of the Vulva
[description not available]		02.0510
Vulvar Neoplasms
Tumors or cancer of the VULVA.		02.0510
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.940
Knee Dislocation
Slippage of the FEMUR off the TIBIA.		02.0510
Chorea Disorders
[description not available]		02.0510
Chorea
Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES.		02.0510
Left Ventricular Hypertrophy
[description not available]		07.9540
Hypertrophy, Left Ventricular
Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.		02.9540
MEA 2a
[description not available]		04.1960
Adrenal Cancer
[description not available]		04.5290
Pheochromocytoma, Extra-Adrenal
[description not available]		03.690
Pheochromocytoma
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)		08.690
Carcinoma, Medullary
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)		04.2160
Carcinoma, Thymic
[description not available]		02.0510
Cancer of the Thymus
[description not available]		02.9640
Thymoma
A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)		07.0510
Thymus Neoplasms
Tumors or cancer of the THYMUS GLAND.		02.9640
Androgen Insensitivity Syndrome
[description not available]		02.4620
Hemarthrosis
Bleeding into the joints. It may arise from trauma or spontaneously in patients with hemophilia.		02.0510
Anterior Circulation Transient Ischemic Attack
[description not available]		03.2560
Ischemic Attack, Transient
Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)		03.2560
Amyloid Neuropathies
Disorders of the peripheral nervous system associated with the deposition of AMYLOID in nerve tissue. Familial, primary (nonfamilial), and secondary forms have been described. Some familial subtypes demonstrate an autosomal dominant pattern of inheritance. Clinical manifestations include sensory loss, mild weakness, autonomic dysfunction, and CARPAL TUNNEL SYNDROME. (Adams et al., Principles of Neurology, 6th ed, p1349)		04.5390
Male Genitourinary Diseases
[description not available]		02.0610
Adenoma, beta-Cell
[description not available]		02.9340
Insulinoma
A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.		02.9340
Familial Hypokalemia-Hypomagnesemia
[description not available]		02.0510
Frontotemporal Lobar Degeneration
Heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Multiple subtypes or forms are recognized based on presence or absence of TAU PROTEIN inclusions. FTLD includes three clinical syndromes: FRONTOTEMPORAL DEMENTIA, semantic dementia, and PRIMARY PROGRESSIVE NONFLUENT APHASIA.		02.4620
Inguinal Hernia
[description not available]		02.0610
Hernia, Inguinal
An abdominal hernia with an external bulge in the GROIN region. It can be classified by the location of herniation. Indirect inguinal hernias occur through the internal inguinal ring. Direct inguinal hernias occur through defects in the ABDOMINAL WALL (transversalis fascia) in Hesselbach's triangle. The former type is commonly seen in children and young adults; the latter in adults.		02.0610
BH4 Deficiency
[description not available]		04.2670
Phenylketonurias
A group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme PHENYLALANINE HYDROXYLASE or less frequently by reduced activity of DIHYDROPTERIDINE REDUCTASE (i.e., atypical phenylketonuria). Classical phenylketonuria is caused by a severe deficiency of phenylalanine hydroxylase and presents in infancy with developmental delay; SEIZURES; skin HYPOPIGMENTATION; ECZEMA; and demyelination in the central nervous system. (From Adams et al., Principles of Neurology, 6th ed, p952).		04.2670
Hair Diseases
Diseases affecting the orderly growth and persistence of hair.		02.0610
Arrhythmogenic Right Ventricular Cardiomyopathy
[description not available]		02.0610
Arrhythmogenic Right Ventricular Dysplasia
A congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the RIGHT VENTRICLE wall and loss of myocardial cells. Primary injuries usually are at the free wall of right ventricular and right atria resulting in ventricular and supraventricular arrhythmias.		02.0610
Genetic Diseases, X-Chromosome Linked
[description not available]		02.7230
Acquired Vocal Cord Palsy
[description not available]		02.0510
Vocal Cord Paralysis
Congenital or acquired paralysis of one or both VOCAL CORDS. This condition is caused by defects in the CENTRAL NERVOUS SYSTEM, the VAGUS NERVE and branches of LARYNGEAL NERVES. Common symptoms are VOICE DISORDERS including HOARSENESS or APHONIA.		02.0510
Avian Flu
[description not available]		02.4620
Influenza in Birds
Infection of domestic and wild fowl and other BIRDS with INFLUENZA A VIRUS. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic POULTRY.		02.4620
Inferior Dislocation
[description not available]		02.0510
Temporomandibular Disorders
[description not available]		02.0510
Costen's Syndrome
[description not available]		02.0510
Temporomandibular Joint Disorders
A variety of conditions affecting the anatomic and functional characteristics of the temporomandibular joint. Factors contributing to the complexity of temporomandibular diseases are its relation to dentition and mastication and the symptomatic effects in other areas which account for referred pain to the joint and the difficulties in applying traditional diagnostic procedures to temporomandibular joint pathology where tissue is rarely obtained and x-rays are often inadequate or nonspecific. Common diseases are developmental abnormalities, trauma, subluxation, luxation, arthritis, and neoplasia. (From Thoma's Oral Pathology, 6th ed, pp577-600)		02.0510
Diseases in Twins
Disorders affecting TWINS, one or both, at any age.		02.6930
Cleidocranial Digital Dysostosis
[description not available]		02.0510
Molar, Fourth
[description not available]		02.0510
Leukemic Infiltration
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.		02.0510
Arteriovenous Malformations, Cerebral
[description not available]		02.0510
Intracranial Arteriovenous Malformations
Congenital vascular anomalies in the brain characterized by direct communication between an artery and a vein without passing through the CAPILLARIES. The locations and size of the shunts determine the symptoms including HEADACHES; SEIZURES; STROKE; INTRACRANIAL HEMORRHAGES; mass effect; and vascular steal effect.		02.0510
Hypophosphatemia
A condition of an abnormally low level of PHOSPHATES in the blood.		02.0610
Sicca Syndrome
[description not available]		02.4520
Sjogren's Syndrome
Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.		02.4520
Adenitis
[description not available]		02.0610
Tonsillitis
Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent.		02.420
Congenital Myasthenia
[description not available]		02.4420
Myasthenic Syndromes, Congenital
A heterogeneous group of disorders characterized by a congenital defect in neuromuscular transmission at the NEUROMUSCULAR JUNCTION. This includes presynaptic, synaptic, and postsynaptic disorders (that are not of autoimmune origin). The majority of these diseases are caused by mutations of various subunits of the nicotinic acetylcholine receptor (RECEPTORS, NICOTINIC) on the postsynaptic surface of the junction. (From Arch Neurol 1999 Feb;56(2):163-7)		02.4420
Anasarca
[description not available]		02.8940
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		07.8940
Rodent Diseases
Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).		02.0610
Infection, Postoperative Wound
[description not available]		02.0610
Choroid Neovascularization
[description not available]		02.0610
Polyps
Discrete abnormal tissue masses that protrude into the lumen of the DIGESTIVE TRACT or the RESPIRATORY TRACT. Polyps can be spheroidal, hemispheroidal, or irregular mound-shaped structures attached to the MUCOUS MEMBRANE of the lumen wall either by a stalk, pedunculus, or by a broad base.		02.4520
Retinal Pigment Epithelial Detachment
[description not available]		02.4520
Hemorrhage, Retinal
[description not available]		02.0610
Choroid Diseases
Disorders of the choroid including hereditary choroidal diseases, neoplasms, and other abnormalities of the vascular layer of the uvea.		02.0610
Retinal Detachment
Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).		02.4520
Vascular Diseases
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.		02.0610
Pulmonary Consumption
[description not available]		04.0150
Tuberculosis, Pulmonary
MYCOBACTERIUM infections of the lung.		04.0150
Cancer of Muscle
[description not available]		02.0610
Adult Neuronal Ceroid Lipofuscinosis
[description not available]		02.4220
Neuronal Ceroid-Lipofuscinoses
A group of severe neurodegenerative diseases characterized by intracellular accumulation of autofluorescent wax-like lipid materials (CEROID; LIPOFUSCIN) in neurons. There are several subtypes based on mutations of the various genes, time of disease onset, and severity of the neurological defects such as progressive DEMENTIA; SEIZURES; and visual failure.		02.4220
Basedow Disease
[description not available]		02.6930
Graves Disease
A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).		02.6930
Acquired-Immune Deficiency Syndrome Dementia Complex
[description not available]		02.0610
AIDS Dementia Complex
A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40)		02.0610
Cancer, Radiation-Induced
[description not available]		03.1350
Carotid Arteriopathies, Traumatic
[description not available]		02.7630
Infections, Klebsiella
[description not available]		02.6930
Klebsiella Infections
Infections with bacteria of the genus KLEBSIELLA.		02.6930
Coronary Heart Disease
[description not available]		04.8120
Coronary Disease
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.		04.8120
Hematologic Malignancies
[description not available]		03.3920
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		03.3920
Adamantiades-Behcet Disease
[description not available]		02.0610
Lichen Ruber Planus
[description not available]		02.0610
Angiogranuloma
[description not available]		02.0610
Behcet Syndrome
Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well.		02.0610
Lichen Planus
An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a saw-tooth pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.		02.0610
Epilepsy Progressive Myoclonic 2
[description not available]		02.0610
Morbid Obesity
[description not available]		02.0710
Obesity, Morbid
The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.		02.0710
Infections, Respiratory Syncytial Virus
[description not available]		02.0610
Respiratory Syncytial Virus Infections
Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.		02.0610
Asphyxia Neonatorum
Respiratory failure in the newborn. (Dorland, 27th ed)		02.0710
Infantile Respiratory Distress Syndrome
[description not available]		02.0710
Respiratory Distress Syndrome, Newborn
A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.		02.0710
Atheroma
[description not available]		02.0610
Adenosis of Breast
[description not available]		02.4320
Fibrocystic Breast Disease
A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.		02.4320
Hyperplasia
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.		03.150
Experimental Hepatoma
[description not available]		05.37230
Celiac Sprue
[description not available]		02.8740
Celiac Disease
A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.		02.8740
Adrenocortical Carcinoma
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.		02.0710
Carney Complex
Autosomal dominant syndrome characterized by cardiac and cutaneous MYXOMAS; LENTIGINOSIS (spotty pigmentation of the skin), and endocrinopathy and its associated endocrine tumors. The cardiac myxomas may lead to SUDDEN CARDIAC DEATH and other complications in Carney complex patients. The gene coding for the PRKAR1A protein is one of the causative genetic loci (type 1). A second locus is at chromosome 2p16 (type 2).		02.0710
Adrenal Cortex Cancer
[description not available]		02.730
Adrenal Cortex Neoplasms
Tumors or cancers of the ADRENAL CORTEX.		02.730
Adrenal Gland Diseases
Pathological processes of the ADRENAL GLANDS.		02.0710
Cancer of Pituitary
[description not available]		02.9240
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.		02.9240
Familial Combined Hyperlipidemia
[description not available]		02.4220
Hyperlipidemia, Familial Combined
A type of familial lipid metabolism disorder characterized by a variable pattern of elevated plasma CHOLESTEROL and/or TRIGLYCERIDES. Multiple genes on different chromosomes may be involved, such as the major late transcription factor (UPSTREAM STIMULATORY FACTORS) on CHROMOSOME 1.		02.4220
Fibrillary Chorea
[description not available]		02.0710
Acquired Neuromyotonia
[description not available]		02.0710
Angiohemophilia
[description not available]		02.9440
von Willebrand Diseases
Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion.		02.9440
Bilateral Wilms Tumor
[description not available]		02.4620
Wilms Tumor
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.		02.4620
Bladder, Overactive
[description not available]		02.0710
Urinary Bladder, Overactive
Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.		02.0710
Deficiency, Factor II
[description not available]		02.0710
Alcoholic Intoxication
An acute brain syndrome which results from the excessive ingestion of ETHANOL or ALCOHOLIC BEVERAGES.		08.2260
Heritable Pulmonary Arterial Hypertension
[description not available]		02.4820
Familial Primary Pulmonary Hypertension
Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.		02.4820
Infections, Lentivirus
[description not available]		02.0710
Deficiency, Protein C
[description not available]		02.6930
Deep Vein Thrombosis
[description not available]		02.4620
Venous Thrombosis
The formation or presence of a blood clot (THROMBUS) within a vein.		02.4620
Colitis, Granulomatous
[description not available]		03.6430
Crohn Disease
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.		03.6430
Follicular Thyroid Carcinoma
[description not available]		02.4420
Adenocarcinoma, Follicular
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)		02.4420
Hyperparathyroidism
A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.		02.9910
Neointima
The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.		02.4820
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		02.4420
Pneumonia
Infection of the lung often accompanied by inflammation.		02.4420
Hormone-Dependent Neoplasms
[description not available]		02.7230
Devic Disease
[description not available]		02.0710
Neuromyelitis Optica
A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.		02.0710
Obstructive Lung Diseases
[description not available]		02.0710
Complications, Pregnancy
[description not available]		02.6730
Bronchitis
Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.		02.6530
Lung Diseases, Obstructive
Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.		02.0710
Experimental Pneumococcal Meningitis
[description not available]		02.9910
Bacterial Endocarditides, Subacute
[description not available]		02.9910
Meningitis, Pneumococcal
An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)		02.9910
Pneumonia, Pneumococcal
A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.		02.9910
Choline Deficiency
A condition produced by a deficiency of CHOLINE in animals. Choline is known as a lipotropic agent because it has been shown to promote the transport of excess fat from the liver under certain conditions in laboratory animals. Combined deficiency of choline (included in the B vitamin complex) and all other methyl group donors causes liver cirrhosis in some animals. Unlike compounds normally considered as vitamins, choline does not serve as a cofactor in enzymatic reactions. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)		03.2260
Basophilic Leukemia, Acute
[description not available]		02.730
Leukemia, Basophilic, Acute
A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.		02.730
Carbon Tetrachloride Poisoning
Poisoning that results from ingestion, injection, inhalation, or skin absorption of CARBON TETRACHLORIDE.		02.420
Nephrotic Syndrome
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.		02.4520
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.		08.3570
Hypophosphatasia
A genetic metabolic disorder resulting from serum and bone alkaline phosphatase deficiency leading to hypercalcemia, ethanolamine phosphatemia, and ethanolamine phosphaturia. Clinical manifestations include severe skeletal defects resembling vitamin D-resistant rickets, failure of the calvarium to calcify, dyspnea, cyanosis, vomiting, constipation, renal calcinosis, failure to thrive, disorders of movement, beading of the costochondral junction, and rachitic bone changes. (From Dorland, 27th ed)		07.0710
Lordosis
The anterior concavity in the curvature of the lumbar and cervical spine as viewed from the side. The term usually refers to abnormally increased curvature (hollow back, saddle back, swayback). It does not include lordosis as normal mating posture in certain animals ( = POSTURE + SEX BEHAVIOR, ANIMAL).		02.0710
Central Nervous System Viral Diseases
Viral infections of the brain, spinal cord, meninges, or perimeningeal spaces.		02.0710
AIDS Seroconversion
[description not available]		02.0810
Bannayan-Riley-Ruvalcaba Syndrome
[description not available]		02.0810
Autosomal Chromosome Disorders
[description not available]		02.940
Hamartoma Syndrome, Multiple
A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.		02.0810
Cancer of Spleen
[description not available]		02.0710
Gestational Hypertension
[description not available]		02.0810
Hypertension, Pregnancy-Induced
A condition in pregnant women with elevated systolic (		02.0810
Basal Ganglia Diseases
Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.		02.730
Monkey Diseases
Diseases of Old World and New World monkeys. This term includes diseases of baboons but not of chimpanzees or gorillas (= APE DISEASES).		02.0810
Hearing Loss, High-Frequency
Hearing loss in frequencies above 1000 hertz.		02.0810
Encephalopathy, Hepatic
[description not available]		02.3820
Hepatic Encephalopathy
A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)		02.3820
Cancer of Duodenum
[description not available]		02.0110
AIDS Nephropathy
[description not available]		02.0110
AIDS-Associated Nephropathy
Renal syndrome in human immunodeficiency virus-infected patients characterized by nephrotic syndrome, severe proteinuria, focal and segmental glomerulosclerosis with distinctive tubular and interstitial changes, enlarged kidneys, and peculiar tubuloreticular structures. The syndrome is distinct from heroin-associated nephropathy as well as other forms of kidney disease seen in HIV-infected patients.		02.0110
Interstitial Cell Tumor
[description not available]		03.3220
Adjuvant Arthritis
[description not available]		02.9340
Heartwater Disease
A tick-borne septicemic disease of domestic and wild ruminants caused by EHRLICHIA RUMINANTIUM.		02.0110
Cushing's Syndrome
[description not available]		02.0110
Cushing Syndrome
A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.		02.0110
Hypokalemia
Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)		02.4220
Abdominal Cryptorchidism
[description not available]		02.0110
Bilateral Deafness
[description not available]		02.0110
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		04.67110
Anemia, Megaloblastic
A disorder characterized by the presence of ANEMIA, abnormally large red blood cells (megalocytes or macrocytes), and MEGALOBLASTS.		03.7940
CBS Deficiency
[description not available]		05.99170
Homocystinuria
Autosomal recessive inborn error of methionine metabolism usually caused by a deficiency of CYSTATHIONINE BETA-SYNTHASE and associated with elevations of homocysteine in plasma and urine. Clinical features include a tall slender habitus, SCOLIOSIS, arachnodactyly, MUSCLE WEAKNESS, genu varus, thin blond hair, malar flush, lens dislocations, an increased incidence of MENTAL RETARDATION, and a tendency to develop fibrosis of arteries, frequently complicated by CEREBROVASCULAR ACCIDENTS and MYOCARDIAL INFARCTION. (From Adams et al., Principles of Neurology, 6th ed, p979)		05.99170
Congenital Adrenal Hyperplasia
[description not available]		05.3370
Adrenal Hyperplasia, Congenital
A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.		05.3370
Adenomatous Polyposis Coli, Familial
[description not available]		02.4120
Adenomatous Polyposis Coli
A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.		02.4120
Bone Loss, Perimenopausal
[description not available]		02.730
Osteoporosis, Postmenopausal
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.		02.730
Adult Fanconi Syndrome
[description not available]		02.0110
Anaplastic Oligodendroglioma
[description not available]		02.0110
Oligodendroglioma
A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)		02.0110
Acidosis, Diabetic
[description not available]		02.3720
Diabetic Ketoacidosis
A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA.		02.3720
Congenital X-Linked Retinoschisis
[description not available]		02.0110
Asymmetric Septal Hypertrophy, Familial
[description not available]		02.9340
Encephalitis, Viral
Inflammation of brain parenchymal tissue as a result of viral infection. Encephalitis may occur as primary or secondary manifestation of TOGAVIRIDAE INFECTIONS; HERPESVIRIDAE INFECTIONS; ADENOVIRIDAE INFECTIONS; FLAVIVIRIDAE INFECTIONS; BUNYAVIRIDAE INFECTIONS; PICORNAVIRIDAE INFECTIONS; PARAMYXOVIRIDAE INFECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; RETROVIRIDAE INFECTIONS; and ARENAVIRIDAE INFECTIONS.		02.0110
Herpes Simplex Keratitis
[description not available]		02.0110
Keratitis, Herpetic
A superficial, epithelial Herpesvirus hominis infection of the cornea, characterized by the presence of small vesicles which may break down and coalesce to form dendritic ulcers (KERATITIS, DENDRITIC). (Dictionary of Visual Science, 3d ed)		02.0110
Central Hypothyroidism
[description not available]		02.8840
Hypothyroidism
A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.		02.8840
Night Blindness
Failure or imperfection of vision at night or in dim light, with good vision only on bright days. (Dorland, 27th ed)		02.0110
Pigmentary Retinopathy
[description not available]		03.68100
Retinitis Pigmentosa
Hereditary, progressive degeneration of the retina due to death of ROD PHOTORECEPTORS initially and subsequent death of CONE PHOTORECEPTORS. It is characterized by deposition of pigment in the retina.		03.68100
Alcohol Abuse, Nervous System
[description not available]		02.0110
Benign Hypothalamic Neoplasms
[description not available]		02.0110
Degenerative Disease, Nervous System, Hereditary
[description not available]		02.0110
Brain Vascular Disorders
[description not available]		02.0110
Central Nervous System Cysts
Congenital or acquired cysts of the brain, spinal cord, or meninges which may remain stable in size or undergo progressive enlargement.		02.4320
Cerebrovascular Disorders
A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.		02.0110
Amnesia, Pre-Ictal
[description not available]		02.3820
Anorexia Nervosa
An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)		02.0110
Cancer of Gallbladder
[description not available]		02.4320
Gallbladder Neoplasms
Tumors or cancer of the gallbladder.		02.4320
Enterocolitis
Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses.		02.0110
Carbohydrate Inducible Hyperlipemia
[description not available]		02.0110
Hyperlipoproteinemia Type IV
A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.		02.0110
Brain Atrophy, Circumscribed Lobar
[description not available]		02.9340
Pick Disease of the Brain
A rare form of DEMENTIA that is sometimes familial. Clinical features include APHASIA; APRAXIA; CONFUSION; ANOMIA; memory loss; and personality deterioration. This pattern is consistent with the pathologic findings of circumscribed atrophy of the poles of the FRONTAL LOBE and TEMPORAL LOBE. Neuronal loss is maximal in the HIPPOCAMPUS, entorhinal cortex, and AMYGDALA. Some ballooned cortical neurons contain argentophylic (Pick) bodies. (From Brain Pathol 1998 Apr;8(2):339-54; Adams et al., Principles of Neurology, 6th ed, pp1057-9)		02.9340
AIDS, Simian
[description not available]		02.0110
Mumps
An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)		01.9310
Poisoning, Mercury
[description not available]		02.3420
Mercury Poisoning
Poisoning that results from chronic or acute ingestion, injection, inhalation, or skin absorption of MERCURY or MERCURY COMPOUNDS.		02.3420
Food Poisoning
[description not available]		01.9310
EHS Tumor
[description not available]		03.3370
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		04.81340
Reticulum Cell-Like Sarcoma, Yoshida
[description not available]		03.7940
Deficiency, Ascorbic Acid
[description not available]		02.3420
Hypoascorbemia
[description not available]		01.9310
Ascorbic Acid Deficiency
A condition due to a dietary deficiency of ascorbic acid (vitamin C), characterized by malaise, lethargy, and weakness. As the disease progresses, joints, muscles, and subcutaneous tissues may become the sites of hemorrhage. Ascorbic acid deficiency frequently develops into SCURVY in young children fed unsupplemented cow's milk exclusively during their first year. It develops also commonly in chronic alcoholism. (Cecil Textbook of Medicine, 19th ed, p1177)		07.3420
Scurvy
An acquired blood vessel disorder caused by severe deficiency of vitamin C (ASCORBIC ACID) in the diet leading to defective collagen formation in small blood vessels. Scurvy is characterized by bleeding in any tissue, weakness, ANEMIA, spongy gums, and a brawny induration of the muscles of the calves and legs.		01.9310
Carcinoma 256, Walker
A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)		02.8540
Necrobiosis
[description not available]		06.9310
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.		03.81120
Teratogenesis
The formation of CONGENITAL ABNORMALITIES.		01.9310
Bleeding
[description not available]		04.1660
Hemorrhage
Bleeding or escape of blood from a vessel.		04.1660
Ornithosis
[description not available]		02.3620
Psittacosis
Infection with CHLAMYDOPHILA PSITTACI (formerly Chlamydia psittaci), transmitted to humans by inhalation of dust-borne contaminated nasal secretions or excreta of infected BIRDS. This infection results in a febrile illness characterized by PNEUMONITIS and systemic manifestations.		02.3620
Encephalomyelitis, Inflammatory
[description not available]		02.3420
Encephalomyelitis
A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature.		02.3420
Bilirubin Encephalopathy
[description not available]		01.9310
Kernicterus
A term used pathologically to describe BILIRUBIN staining of the BASAL GANGLIA; BRAIN STEM; and CEREBELLUM and clinically to describe a syndrome associated with HYPERBILIRUBINEMIA. Clinical features include athetosis, MUSCLE SPASTICITY or hypotonia, impaired vertical gaze, and DEAFNESS. Nonconjugated bilirubin enters the brain and acts as a neurotoxin, often in association with conditions that impair the BLOOD-BRAIN BARRIER (e.g., SEPSIS). This condition occurs primarily in neonates (INFANT, NEWBORN), but may rarely occur in adults. (Menkes, Textbook of Child Neurology, 5th ed, p613)		01.9310
Alcohol Abuse
[description not available]		05.31131
Alcoholic Cirrhosis
[description not available]		07.3520
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		05.31131
Liver Cirrhosis, Alcoholic
FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.		02.3520
Neoplasms, Plasma Cell
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.		01.9310
Anemia, Macrocytic
Anemia characterized by larger than normal erythrocytes, increased mean corpuscular volume (MCV) and increased mean corpuscular hemoglobin (MCH).		04.1160
Deficiency, Thiamine
[description not available]		03.4580
Thiamine Deficiency
A nutritional condition produced by a deficiency of THIAMINE in the diet, characterized by anorexia, irritability, and weight loss. Later, patients experience weakness, peripheral neuropathy, headache, and tachycardia. In addition to being caused by a poor diet, thiamine deficiency in the United States most commonly occurs as a result of alcoholism, since ethanol interferes with thiamine absorption. In countries relying on polished rice as a dietary staple, BERIBERI prevalence is very high. (From Cecil Textbook of Medicine, 19th ed, p1171)		03.4580
Infections, Nematomorpha
[description not available]		02.3420
Helminthiasis
Infestation with parasitic worms of the helminth class.		02.3420
Deficiency, Riboflavin
[description not available]		02.8640
Deficiency, Vitamin B
[description not available]		02.8640
Vitamin B Deficiency
A condition due to deficiency in any member of the VITAMIN B COMPLEX. These B vitamins are water-soluble and must be obtained from the diet because they are easily lost in the urine. Unlike the lipid-soluble vitamins, they cannot be stored in the body fat.		02.8640
Hypertension, Renal
Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.		02.3420
Calculosis
[description not available]		01.9310
Nephrolithiasis
Formation of stones in the KIDNEY.		01.9310
Silicosis
A form of pneumoconiosis resulting from inhalation of dust containing crystalline form of SILICON DIOXIDE, usually in the form of quartz. Amorphous silica is relatively nontoxic.		01.9410
Allergic Encephalomyelitis
[description not available]		03.3770
Hydrophobia
[description not available]		03.2620
Papilloma, Squamous Cell
[description not available]		03.5830
Fibroma, Shope
[description not available]		04.0530
Papilloma
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)		03.5830
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		02.6530
Necrotizing Pyelonephritis
[description not available]		02.6430
Hepatitis
INFLAMMATION of the LIVER.		02.8640
Pyelonephritis
Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.		02.6430
Aminoaciduria, Renal
[description not available]		03.82120
Deficiency, Vitamin D
[description not available]		02.3420
Vitamin D Deficiency
A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)		02.3420
Calculus, Dental
[description not available]		01.9410
Kwashiorkor
A syndrome produced by severe protein deficiency, characterized by retarded growth, changes in skin and hair pigment, edema, and pathologic changes in the liver, including fatty infiltration, necrosis, and fibrosis. The word is a local name in Gold Coast, Africa, meaning displaced child. Although first reported from Africa, kwashiorkor is now known throughout the world, but mainly in the tropics and subtropics. It is considered to be related to marasmus. (From Dorland, 27th ed)		04.2470
Dermatitis, Eczematous
[description not available]		01.9410
Hives
[description not available]		01.9410
Eczema
A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).		01.9410
Erythema Multiforme
A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic bull's-eye lesions usually occurring on the dorsal aspect of the hands and forearms.		01.9410
Urticaria
A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.		01.9410
Leukemia L 1210
[description not available]		03.9130
Bordetella pertussis Infection, Respiratory
[description not available]		01.9410
Whooping Cough
A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.		01.9410
Peripheral Nerve Injury
[description not available]		01.9410
Peripheral Nerve Injuries
Injuries to the PERIPHERAL NERVES.		01.9410
Rachitis
[description not available]		02.6330
Marfan Syndrome, Type I
[description not available]		02.3620
Marfan Syndrome
An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome (type 1) is associated with mutations in the gene encoding FIBRILLIN-1 (FBN1), a major element of extracellular microfibrils of connective tissue. Mutations in the gene encoding TYPE II TGF-BETA RECEPTOR (TGFBR2) are associated with Marfan syndrome type 2.		02.3620
Cardiac Death
[description not available]		01.9410
Angiomyxoma
[description not available]		01.9310
Vaccinia
The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.		06.9310
Adenocarcinoma, Papillary
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)		02.4120
Cardiac Output, Low
A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.		02.0110
Anovulation
Suspension or cessation of OVULATION in animals or humans with follicle-containing ovaries (OVARIAN FOLLICLE). Depending on the etiology, OVULATION may be induced with appropriate therapy.		02.0110
Histiocytosis, Non-Langerhans-Cell
Group of disorders which feature accumulations of active HISTIOCYTES and LYMPHOCYTES, but where the histiocytes are not LANGERHANS CELLS. The group includes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; SINUS HISTIOCYTOSIS; xanthogranuloma; reticulohistiocytoma; JUVENILE XANTHOGRANULOMA; xanthoma disseminatum; as well as the lipid storage diseases (SEA-BLUE HISTIOCYTE SYNDROME; and NIEMANN-PICK DISEASES).		02.4220
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		07.3920
Organophosphorus Poisoning
[description not available]		02.0110
Organophosphate Poisoning
Poisoning due to exposure to ORGANOPHOSPHORUS COMPOUNDS, such as ORGANOPHOSPHATES; ORGANOTHIOPHOSPHATES; and ORGANOTHIOPHOSPHONATES.		02.0110
Methemoglobinemia
The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed)		07.6930
Coronary Restenosis
Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.		02.4220
Anterior Choroidal Artery Infarction
[description not available]		02.940
Cerebral Infarction
The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).		02.940
Chronic Primary Open Angle Glaucoma
[description not available]		02.7230
Glaucoma, Open-Angle
Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.		02.7230
Neuroses
[description not available]		02.0210
Neurotic Disorders
Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.		02.0210
Acute Kidney Tubular Necrosis
[description not available]		03.3570
Kidney Tubular Necrosis, Acute
Acute kidney failure resulting from destruction of EPITHELIAL CELLS of the KIDNEY TUBULES. It is commonly attributed to exposure to toxic agents or renal ISCHEMIA following severe TRAUMA.		03.3570
Uremia
A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.		06.34151
Deficiency, Factor 10
[description not available]		02.9240
Factor X Deficiency
Blood coagulation disorder usually inherited as an autosomal recessive trait, though it can be acquired. It is characterized by defective activity in both the intrinsic and extrinsic pathways, impaired thromboplastin time, and impaired prothrombin consumption.		02.9240
Deficiency, Protein
[description not available]		05160
Infant, Small for Gestational Age
An infant having a birth weight lower than expected for its gestational age.		02.4320
Haim-Monk Syndrome
[description not available]		02.9310
Fish Diseases
Diseases of freshwater, marine, hatchery or aquarium fish. This term includes diseases of both teleosts (true fish) and elasmobranchs (sharks, rays and skates).		02.4120
Colon Cancer, Familial Nonpolyposis
[description not available]		02.9540
Cafe-au-Lait Spots with Pulmonic Stenosis
[description not available]		02.0210
Colorectal Neoplasms, Hereditary Nonpolyposis
A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.		02.9540
Neurofibromatosis 1
An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).		02.0210
EBS-DM
[description not available]		02.0210
Epidermolysis Bullosa Simplex
A form of epidermolysis bullosa characterized by serous bullae that heal without scarring. Mutations in the genes that encode KERATIN-5 and KERATIN-14 have been associated with several subtypes of epidermolysis bullosa simplex.		02.0210
Sinus Tachycardia
[description not available]		02.0210
Adult Sandhoff Disease
[description not available]		02.6930
Sandhoff Disease
An autosomal recessive neurodegenerative disorder characterized by an accumulation of G(M2) GANGLIOSIDE in neurons and other tissues. It is caused by mutation in the common beta subunit of HEXOSAMINIDASE A and HEXOSAMINIDASE B. Thus this disease is also known as the O variant since both hexosaminidase A and B are missing. Clinically, it is indistinguishable from TAY-SACHS DISEASE.		02.6930
Autosomal Dominant Hereditary Spastic Paraplegia
[description not available]		02.7230
Spastic Paraplegia, Hereditary
A group of inherited diseases that share similar phenotypes but are genetically diverse. Different genetic loci for autosomal recessive, autosomal dominant, and x-linked forms of hereditary spastic paraplegia have been identified. Clinically, patients present with slowly progressive distal limb weakness and lower extremity spasticity. Peripheral sensory neurons may be affected in the later stages of the disease. (J Neurol Neurosurg Psychiatry 1998 Jan;64(1):61-6; Curr Opin Neurol 1997 Aug;10(4):313-8)		02.7230
Gastroduodenal Ulcer
[description not available]		02.6730
Peptic Ulcer
Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.6730
Charcot-Marie-Tooth Disease, Demyelinating, Type 4f
[description not available]		02.730
Collagen Diseases
Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that collagen was equivalent to connective tissue, but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term collagen diseases now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)		02.420
Batten Turner Congenital Myopathy
[description not available]		02.0210
Fetal Death
Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.		02.4220
Acoustic Neurinoma, Bilateral
[description not available]		02.4220
Neurofibromatosis 2
An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.		02.4220
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		03.150
Erythrocytosis
[description not available]		03.9650
Neoplasms, Squamous Cell
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.		02.4220
Action Tremor
[description not available]		03.9750
Tremor
Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.		08.9750
Autosomal Dominant Myotubular Myopathy
[description not available]		02.4320
Bowen Disease
[description not available]		02.0210
Carcinoma, Basal Cell, Pigmented
[description not available]		02.4320
Keratoderma Blennorrhagicum
[description not available]		02.3720
Carcinoma, Basal Cell
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)		02.4320
Keratosis
Any horny growth such as a wart or callus.		02.3720
Respiratory Syndrome, Acute, Severe
[description not available]		02.7230
Severe Acute Respiratory Syndrome
A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.		02.7230
Nevi, Melanocytic
[description not available]		02.0210
Nevus, Pigmented
A nevus containing melanin. The term is usually restricted to nevocytic nevi (round or oval collections of melanin-containing nevus cells occurring at the dermoepidermal junction of the skin or in the dermis proper) or moles, but may be applied to other pigmented nevi.		02.0210
Nicotine Addiction
[description not available]		02.9310
Tobacco Use Disorder
Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.		02.9310
Bleb
[description not available]		02.0210
Pemphigoid
[description not available]		02.0210
Acquired Form of Epidermolysis Bullosa
[description not available]		02.0210
Pemphigoid, Bullous
A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis.		02.0210
Epidermolysis Bullosa Acquisita
Form of epidermolysis bullosa characterized by trauma-induced, subepidermal blistering with no family history of the disease. Direct immunofluorescence shows IMMUNOGLOBULIN G deposited at the dermo-epidermal junction.		02.0210
Hospital-Acquired Condition
[description not available]		02.0210
Aortitis Syndrome
[description not available]		02.0210
Takayasu Arteritis
A chronic inflammatory process that affects the AORTA and its primary branches, such as the brachiocephalic artery (BRACHIOCEPHALIC TRUNK) and CAROTID ARTERIES. It results in progressive arterial stenosis, occlusion, and aneurysm formation. The pulse in the arm is hard to detect. Patients with aortitis syndrome often exhibit retinopathy.		02.0210
Glycosuria
The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).		03.2360
Acquired Facial Neuropathy
[description not available]		02.0210
Diabetes Mellitus, Lipoatrophic
A type of diabetes mellitus that is characterized by severe INSULIN RESISTANCE and LIPODYSTROPHY. The latter may be generalized, partial, acquired, or congenital (LIPODYSTROPHY, CONGENITAL GENERALIZED).		02.420
Craniocerebral Injuries
[description not available]		02.4220
Craniocerebral Trauma
Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage.		02.4220
4 Hydroxyphenylpyruvate Dioxygenase Deficiency Disease
[description not available]		02.0210
Tyrosinemias
A group of disorders which have in common elevations of tyrosine in the blood and urine secondary to an enzyme deficiency. Type I tyrosinemia features episodic weakness, self-mutilation, hepatic necrosis, renal tubular injury, and seizures and is caused by a deficiency of the enzyme fumarylacetoacetase. Type II tyrosinemia features INTELLECTUAL DISABILITY, painful corneal ulcers, and keratoses of the palms and plantar surfaces and is caused by a deficiency of the enzyme TYROSINE TRANSAMINASE. Type III tyrosinemia features INTELLECTUAL DISABILITY and is caused by a deficiency of the enzyme 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE. (Menkes, Textbook of Child Neurology, 5th ed, pp42-3)		02.0210
Elevated Cholesterol
[description not available]		04.551
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		09.551
Deficiency, Factor 11
[description not available]		02.0210
Cervix Dysplasia
[description not available]		02.7230
Uterine Cervical Dysplasia
Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE.		02.7230
Joint Pain
[description not available]		02.0210
Arthralgia
Pain in the joint.		02.0210
Fibroadenoma
An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)		02.0210
Deficiency, Vitamin A
[description not available]		03.5830
Vitamin A Deficiency
A nutritional condition produced by a deficiency of VITAMIN A in the diet, characterized by NIGHT BLINDNESS and other ocular manifestations such as dryness of the conjunctiva and later of the cornea (XEROPHTHALMIA). Vitamin A deficiency is a very common problem worldwide, particularly in developing countries as a consequence of famine or shortages of vitamin A-rich foods. In the United States it is found among the urban poor, the elderly, alcoholics, and patients with malabsorption. (From Cecil Textbook of Medicine, 19th ed, p1179)		03.5830
Deficiency, Factor 7
[description not available]		02.0210
Factor VII Deficiency
An autosomal recessive characteristic or a coagulation disorder acquired in association with VITAMIN K DEFICIENCY. FACTOR VII is a Vitamin K dependent glycoprotein essential to the extrinsic pathway of coagulation.		02.0210
HbS Disease
[description not available]		04.1660
Anemia, Sickle Cell
A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.		04.1660
Potassium Deficiency
A condition due to decreased dietary intake of potassium, as in starvation or failure to administer in intravenous solutions, or to gastrointestinal loss in diarrhea, chronic laxative abuse, vomiting, gastric suction, or bowel diversion. Severe potassium deficiency may produce muscular weakness and lead to paralysis and respiratory failure. Muscular malfunction may result in hypoventilation, paralytic ileus, hypotension, muscle twitches, tetany, and rhabomyolysis. Nephropathy from potassium deficit impairs the concentrating mechanism, producing POLYURIA and decreased maximal urinary concentrating ability with secondary POLYDIPSIA. (Merck Manual, 16th ed)		02.6730
Di Guglielmo Disease
[description not available]		03.69100
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.		03.69100
Chronic Wasting Disease
[description not available]		02.0210
Adult Pelizaeus-Merzbacher Disease
[description not available]		02.0210
Genital Infantilism
[description not available]		02.9410
Anemia, Hypochromic
Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393)		03.2160
Cockayne-Touraine Disease
[description not available]		02.0210
Epidermolysis Bullosa Dystrophica
Form of epidermolysis bullosa characterized by atrophy of blistered areas, severe scarring, and nail changes. It is most often present at birth or in early infancy and occurs in both autosomal dominant and recessive forms. All forms of dystrophic epidermolysis bullosa result from mutations in COLLAGEN TYPE VII, a major component fibrils of BASEMENT MEMBRANE and EPIDERMIS.		02.0210
African Swine Fever
A sometimes fatal ASFIVIRUS infection of pigs, characterized by fever, cough, diarrhea, hemorrhagic lymph nodes, and edema of the gallbladder. It is transmitted between domestic swine by direct contact, ingestion of infected meat, or fomites, or mechanically by biting flies or soft ticks (genus Ornithodoros).		02.0210
Kaposi Sarcoma
[description not available]		02.7130
AIDS-Associated Lymphoma
[description not available]		02.0310
Sarcoma, Kaposi
A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.		02.7130
Lymphoma, AIDS-Related
B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.		02.0310
Abdominal Epilepsy
[description not available]		03.9850
Epilepsies, Partial
Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)		03.9850
Choriocarcinoma
A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).		02.3920
Autosomal Recessive Emery-Dreifuss Muscular Dystrophy
[description not available]		02.4220
Histomoniasis
[description not available]		02.9410
Rhabdomyolysis
Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.		02.0210
Acoustic Neuroma
[description not available]		02.4420
Biliary Cirrhosis
[description not available]		02.0210
Liver Cirrhosis, Biliary
FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.		02.0210
Dermatitis, Radiation-Induced
[description not available]		02.0310
Radiodermatitis
A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.		02.0310
Dysmyelopoietic Syndromes
[description not available]		02.0310
Myelodysplastic Syndromes
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.		02.0310
Autosomal Dominant Striatonigral Degeneration
[description not available]		02.0210
Machado-Joseph Disease
A dominantly-inherited ATAXIA first described in people of Azorean and Portuguese descent, and subsequently identified in Brazil, Japan, China, and Australia. This disorder is classified as one of the SPINOCEREBELLAR ATAXIAS (Type 3) and has been associated with a mutation of the MJD1 gene on chromosome 14. Clinical features include progressive ataxia, DYSARTHRIA, postural instability, nystagmus, eyelid retraction, and facial FASCICULATIONS. DYSTONIA is prominent in younger patients (referred to as Type I Machado-Joseph Disease). Type II features ataxia and ocular signs; Type III features MUSCULAR ATROPHY and a sensorimotor neuropathy; and Type IV features extrapyramidal signs combined with a sensorimotor neuropathy. (From Clin Neurosci 1995;3(1):17-22; Ann Neurol 1998 Mar;43(3):288-96)		02.0210
Chromosome Deletion
Actual loss of portion of a chromosome.		03.68100
Congenital Erythropoietic Porphyria
[description not available]		02.4120
Hibernation, Myocardial
[description not available]		02.0310
Amyloidosis, Hereditary
[description not available]		02.4420
Amyloidosis, Familial
Diseases in which there is a familial pattern of AMYLOIDOSIS.		02.4420
Acrocephaly
Premature closing of the lambdoid and coronal sutures.		03.2660
Craniofacial Dysarthrosis
[description not available]		02.4220
Craniosynostoses
Premature closure of one or more CRANIAL SUTURES. It often results in plagiocephaly. Craniosynostoses that involve multiple sutures are sometimes associated with congenital syndromes such as ACROCEPHALOSYNDACTYLIA; and CRANIOFACIAL DYSOSTOSIS.		03.2660
Lathyrism
A paralytic condition of the legs caused by ingestion of lathyrogens, especially BETA-AMINOPROPIONITRILE or beta-N-oxalyl amino-L-alanine, which are found in the seeds of plants of the genus LATHYRUS.		02.0310
Glycogenosis
[description not available]		02.0310
Glycogen Storage Disease
A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalized storage of glycogen occurs, sometimes with prominent cardiac involvement.		02.0310
Anoxia, Brain
[description not available]		03.0950
Hirsutism
A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.		02.0310
Encephalitis, JC Polyomavirus
[description not available]		02.0310
Leukoencephalopathy, Progressive Multifocal
An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7)		02.0310
Deficiency, Vitamin E
[description not available]		02.6730
Absence Seizure Disorder
[description not available]		02.0310
Epilepsy, Absence
A seizure disorder usually occurring in childhood characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures. (Menkes, Textbook of Child Neurology, 5th ed, p736)		02.0310
Tooth Loss
The failure to retain teeth as a result of disease or injury.		02.0310
Asystole
[description not available]		02.0310
Heart Arrest
Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.		02.0310
Autoimmune Thyroiditis
[description not available]		02.0310
Hematochezia
The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.		02.0310
Gastrointestinal Hemorrhage
Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.		02.0310
Absent Iris
[description not available]		02.4120
Aniridia
A congenital abnormality in which there is only a rudimentary iris. This is due to the failure of the optic cup to grow. Aniridia also occurs in a hereditary form, usually autosomal dominant.		02.4120
Brain Emboli
[description not available]		02.0310
ANS (Autonomic Nervous System) Diseases
[description not available]		04.1460
Hansen Disease
[description not available]		02.4420
Leprosy
A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.		07.4420
Corneal Diseases
Diseases of the cornea.		02.4420
Lens Dislocation
[description not available]		02.0310
Advanced Sleep Phase Syndrome
[description not available]		02.4220
Sleep Disorders, Circadian Rhythm
Dyssomnias associated with disruption of the normal 24 hour sleep wake cycle secondary to travel (e.g., JET LAG SYNDROME), shift work, or other causes.		02.4220
Erythermalgia
[description not available]		02.0310
Erythromelalgia
A peripheral arterial disease that is characterized by the triad of ERYTHEMA, burning PAIN, and increased SKIN TEMPERATURE of the extremities (or red, painful extremities). Erythromelalgia may be classified as primary or idiopathic, familial or non-familial. Secondary erythromelalgia is associated with other diseases, the most common being MYELOPROLIFERATIVE DISORDERS.		02.0310
Cancer Syndromes, Hereditary
[description not available]		02.0310
Neoplasms, Sebaceous Gland
[description not available]		02.0310
Multiple Primary Neoplasms
[description not available]		02.7130
Delusional Disorder
Disorder with presentation of a facade of coldness with characteristic pervasive mistrust and suspiciousness of others.		02.4220
Hebephrenic Schizophrenia
[description not available]		02.4220
Acid Alpha-Glucosidase Deficiency
[description not available]		02.0310
Glycogen Storage Disease Type II
An autosomal recessively inherited glycogen storage disease caused by GLUCAN 1,4-ALPHA-GLUCOSIDASE deficiency. Large amounts of GLYCOGEN accumulate in the LYSOSOMES of skeletal muscle (MUSCLE, SKELETAL); HEART; LIVER; SPINAL CORD; and BRAIN. Three forms have been described: infantile, childhood, and adult. The infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (CARDIOMYOPATHY, HYPERTROPHIC). The childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. The adult form consists of a slowly progressive proximal myopathy. (From Muscle Nerve 1995;3:S61-9; Menkes, Textbook of Child Neurology, 5th ed, pp73-4)		02.0310
Infections, Parvoviridae
[description not available]		02.0310
Cardiac Complex, Premature
[description not available]		02.0310
Cat Diseases
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.		02.0310
Glaucoma, Suspect
[description not available]		02.9410
Ocular Hypertension
A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.		02.9410
Complications, Hematologic Pregnancy
[description not available]		03.3420
Infections, Pneumococcal
[description not available]		02.4220
Pneumococcal Infections
Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.		02.4220
Blepharophimosis
The abnormal narrowness of the palpebral fissure in the horizontal direction caused by the lateral displacement of the medial canthi of the eyelids. (Dorland, 27th ed)		02.0310
Black Death
[description not available]		02.0310
Plague
An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.		02.0310
Bronchopulmonary Dysplasia
A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.		02.0310
Dissociation
[description not available]		02.0310
Granuloma, Hodgkin
[description not available]		02.0310
Lymphomatoid Papulosis
Clinically benign, histologically malignant, recurrent cutaneous T-cell lymphoproliferative disorder characterized by an infiltration of large atypical cells surrounded by inflammatory cells. The atypical cells resemble REED-STERNBERG CELLS of HODGKIN DISEASE or the malignant cells of CUTANEOUS T-CELL LYMPHOMA. In some cases, lymphomatoid papulosis progresses to lymphomatous conditions including MYCOSIS FUNGOIDES; HODGKIN DISEASE; CUTANEOUS T-CELL LYMPHOMA; or ANAPLASTIC LARGE-CELL LYMPHOMA.		02.0310
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.		02.0310
Deficiency Diseases
A condition produced by dietary or metabolic deficiency. The term includes all diseases caused by an insufficient supply of essential nutrients, i.e., protein (or amino acids), vitamins, and minerals. It also includes an inadequacy of calories. (From Dorland, 27th ed; Stedman, 25th ed)		04.9590
Amaurosis
[description not available]		02.4420
Blindness
The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.		02.4420
22q11.2 Deletion Syndrome
[description not available]		02.0310
DiGeorge Syndrome
Congenital syndrome characterized by a wide spectrum of characteristics including the absence of the THYMUS and PARATHYROID GLANDS resulting in T-cell immunodeficiency, HYPOCALCEMIA, defects in the outflow tract of the heart, and craniofacial anomalies.		02.0310
Brucella Infection
[description not available]		02.0310
Brucellosis
Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.		02.0310
Lead Poisoning, Nervous System
Injury to the nervous system secondary to exposure to lead compounds. Two distinct clinical patterns occur in children (LEAD POISONING, NERVOUS SYSTEM, CHILDHOOD) and adults (LEAD POISONING, NERVOUS SYSTEM, ADULT). In children, lead poisoning typically produces an encephalopathy. In adults, exposure to toxic levels of lead is associated with a peripheral neuropathy.		02.0310
HMN (Hereditary Motor Neuropathy) Proximal Type I
[description not available]		02.0310
Spinal Muscular Atrophies of Childhood
A group of recessive inherited diseases that feature progressive muscular atrophy and hypotonia. They are classified as type I (Werdnig-Hoffman disease), type II (intermediate form), and type III (Kugelberg-Welander disease). Type I is fatal in infancy, type II has a late infantile onset and is associated with survival into the second or third decade. Type III has its onset in childhood, and is slowly progressive. (J Med Genet 1996 Apr:33(4):281-3)		02.0310
Disease, Pulmonary
[description not available]		02.0310
Lung Diseases
Pathological processes involving any part of the LUNG.		02.0310
A-V Dissociation
[description not available]		02.3920
Thalassemias
[description not available]		02.8840
Thalassemia
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.		02.8840
Distal Muscular Dystrophies
[description not available]		02.0310
Distal Myopathies
A heterogeneous group of genetic disorders characterized by progressive MUSCULAR ATROPHY and MUSCLE WEAKNESS beginning in the hands, the legs, or the feet. Most are adult-onset autosomal dominant forms. Others are autosomal recessive.		02.0310
Desmoid
[description not available]		02.0310
Fibromatosis, Aggressive
A childhood counterpart of abdominal or extra-abdominal desmoid tumors, characterized by firm subcutaneous nodules that grow rapidly in any part of the body but do not metastasize. The adult form of abdominal fibromatosis is FIBROMATOSIS, ABDOMINAL. (Stedman, 25th ed)		02.0310
Age-Related Macular Degeneration
[description not available]		04.370
Macular Degeneration
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.		04.370
Afibrinogenemia, Congenital
[description not available]		02.0310
Afibrinogenemia
A deficiency or absence of FIBRINOGEN in the blood.		02.0310
Aneurysm, Aortic
[description not available]		02.4220
Aortic Aneurysm
An abnormal balloon- or sac-like dilatation in the wall of AORTA.		02.4220
Corneal Dystrophies
[description not available]		02.4420
CJD (Creutzfeldt-Jakob Disease)
[description not available]		02.0410
Creutzfeldt-Jakob Syndrome
A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))		02.0410
Aggression
Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.		02.6530
Abnormalities, Skin
[description not available]		02.0410
Skin Abnormalities
Congenital structural abnormalities of the skin.		02.0410
Gonadal Agenesis
The complete failure of gonadal development.		02.4220
Testicular Diseases
Pathological processes of the TESTIS.		02.0410
Frasier Syndrome
A syndrome characterized by CHRONIC KIDNEY FAILURE and GONADAL DYSGENESIS in phenotypic females with karyotype of 46,XY or female individual with a normal 46,XX karyotype. It is caused by donor splice-site mutations of Wilms tumor suppressor gene (GENES, WILMS TUMOR) on chromosome 11.		02.0410
Dysarthria, Pseudobulbar
[description not available]		02.0410
Botulism, Infantile
[description not available]		02.0410
Botulism
A disease caused by potent protein NEUROTOXINS produced by CLOSTRIDIUM BOTULINUM which interfere with the presynaptic release of ACETYLCHOLINE at the NEUROMUSCULAR JUNCTION. Clinical features include abdominal pain, vomiting, acute PARALYSIS (including respiratory paralysis), blurred vision, and DIPLOPIA. Botulism may be classified into several subtypes (e.g., food-borne, infant, wound, and others). (From Adams et al., Principles of Neurology, 6th ed, p1208)		02.0410
Acetyl-CoA:alpha-Glucosaminide N-Acetyltransferase Deficiency
[description not available]		02.0410
Mucopolysaccharidosis III
Mucopolysaccharidosis characterized by heparitin sulfate in the urine, progressive mental retardation, mild dwarfism, and other skeletal disorders. There are four clinically indistinguishable but biochemically distinct forms, each due to a deficiency of a different enzyme.		02.0410
Biliary Tract Cancer
[description not available]		02.0410
Biliary Tract Neoplasms
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.		02.0410
Anemia, Hemolytic, Hereditary
[description not available]		01.9410
Anemia, Hemolytic, Congenital
Hemolytic anemia due to various intrinsic defects of the erythrocyte.		01.9410
Porphyria
[description not available]		02.6530
Porphyrias
A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of HEME in the LIVER, the BONE MARROW, or both. They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues.		02.6530
Plasma Cell Tumor
[description not available]		03.4580
Plasmacytoma
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.		03.4580
Cystine Diathesis
[description not available]		03.2820
Cystinosis
A metabolic disease characterized by the defective transport of CYSTINE across the lysosomal membrane due to mutation of a membrane protein cystinosin. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. In the KIDNEY, nephropathic cystinosis is a common cause of RENAL FANCONI SYNDROME.		03.2820
Low Bone Density
[description not available]		01.9610
Bone Diseases, Metabolic
Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.		01.9610
Sarcoma 37
An experimental sarcoma of mice.		02.6430
Stunted Growth
[description not available]		03.5730
Adenomatoses, Bovine Pulmonary
[description not available]		02.8810
Growth Disorders
Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.		03.5730
Muscular Dystrophy, Animal
MUSCULAR DYSTROPHY that occurs in VERTEBRATE animals.		02.3620
Island Cell Tumor
[description not available]		02.3720
Adenoma, Islet Cell
A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM.		02.3720
Hypotension, Postural
[description not available]		08.35162
Hypotension, Orthostatic
A significant drop in BLOOD PRESSURE after assuming a standing position. Orthostatic hypotension is a finding, and defined as a 20-mm Hg decrease in systolic pressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the person has risen from supine to standing. Symptoms generally include DIZZINESS, blurred vision, and SYNCOPE.		08.35162
Anochlesia
[description not available]		02.6530
Dizzyness
[description not available]		02.8810
Dizziness
An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.		02.8810
Embryopathies
[description not available]		03.0650
Complication, Intraoperative
[description not available]		01.9610
Catatonic Rigidity
[description not available]		01.9610
Muscle Rigidity
Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73)		01.9610
Cerebellar Diseases
Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA.		02.3620
Nearsightedness
[description not available]		01.9510
Myopia
A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness.		01.9510
Calciphylaxes
[description not available]		01.9610
BCKD Deficiency
[description not available]		03.7940
Maple Syrup Urine Disease
An autosomal recessive inherited disorder with multiple forms of phenotypic expression, caused by a defect in the oxidative decarboxylation of branched-chain amino acids (AMINO ACIDS, BRANCHED-CHAIN). These metabolites accumulate in body fluids and render a maple syrup odor. The disease is divided into classic, intermediate, intermittent, and thiamine responsive subtypes. The classic form presents in the first week of life with ketoacidosis, hypoglycemia, emesis, neonatal seizures, and hypertonia. The intermediate and intermittent forms present in childhood or later with acute episodes of ataxia and vomiting. (From Adams et al., Principles of Neurology, 6th ed, p936)		03.7940
Coagulation Factor 12 Deficiency
[description not available]		01.9610
Granulomas
[description not available]		01.9610
Mucorales Infection
[description not available]		01.9610
Granuloma
A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.		01.9610
Mucormycosis
Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION.		01.9610
Acquired Metabolic Diseases, Brain
[description not available]		02.3620
Entrapment Neuropathies
[description not available]		01.9510
Hyperandrogenism
A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.		03.3120
Abscess, Amebic, Hepatic
[description not available]		02.6830
Atheroembolism
[description not available]		01.9810
Embolism, Cholesterol
Blocking of a blood vessel by CHOLESTEROL-rich atheromatous deposits, generally occurring in the flow from a large artery to small arterial branches. It is also called arterial-arterial embolization or atheroembolism which may be spontaneous or iatrogenic. Patients with spontaneous atheroembolism often have painful, cyanotic digits of acute onset.		01.9810
Ambiguous Genitalia
[description not available]		02.3920
Disorders of Sex Development
In gonochoristic organisms, congenital conditions in which development of chromosomal, gonadal, or anatomical sex is atypical. Effects from exposure to abnormal levels of GONADAL HORMONES in the maternal environment, or disruption of the function of those hormones by ENDOCRINE DISRUPTORS are included.		02.3920
Anesthesia Related Hyperthermia
[description not available]		02.3920
Aganglionic Megacolon
[description not available]		01.9810
Hirschsprung Disease
Congenital MEGACOLON resulting from the absence of ganglion cells (aganglionosis) in a distal segment of the LARGE INTESTINE. The aganglionic segment is permanently contracted thus causing dilatation proximal to it. In most cases, the aganglionic segment is within the RECTUM and SIGMOID COLON.		01.9810
Marchiafava-Micheli Syndrome
[description not available]		01.9810
Hemoglobinuria, Paroxysmal
A condition characterized by the recurrence of HEMOGLOBINURIA caused by intravascular HEMOLYSIS. In cases occurring upon cold exposure (paroxysmal cold hemoglobinuria), usually after infections, there is a circulating antibody which is also a cold hemolysin. In cases occurring during or after sleep (paroxysmal nocturnal hemoglobinuria), the clonal hematopoietic stem cells exhibit a global deficiency of cell membrane proteins.		01.9810
Bone Diseases, Developmental
Diseases resulting in abnormal GROWTH or abnormal MORPHOGENESIS of BONES.		02.3620
ATLL
[description not available]		02.3920
Leukemia-Lymphoma, Adult T-Cell
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.		02.3920
Anti-GBM Disease
[description not available]		02.910
Anti-Glomerular Basement Membrane Disease
An autoimmune disease of the KIDNEY and the LUNG. It is characterized by the presence of circulating autoantibodies targeting the epitopes in the non-collagenous domains of COLLAGEN TYPE IV in the basement membranes of kidney glomeruli (KIDNEY GLOMERULUS) and lung alveoli (PULMONARY ALVEOLI), and the subsequent destruction of these basement membranes. Clinical features include pulmonary alveolar hemorrhage and glomerulonephritis.		02.910
Cancer of Larynx
[description not available]		03.0550
Laryngeal Neoplasms
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.		03.0550
Adult Onset Nemaline Myopathy
[description not available]		01.9810
Myopathies, Nemaline
A group of inherited congenital myopathic conditions characterized clinically by weakness, hypotonia, and prominent hypoplasia of proximal muscles including the face. Muscle biopsy reveals large numbers of rod-shaped structures beneath the muscle fiber plasma membrane. This disorder is genetically heterogeneous and may occasionally present in adults. (Adams et al., Principles of Neurology, 6th ed, p1453)		01.9810
Generalized Resistance to Thyroid Hormone
[description not available]		04.2941
Biliary Fistula
Abnormal passage in any organ of the biliary tract or between biliary organs and other organs.		01.9810
Cholecystoduodenal Fistula
[description not available]		01.9810
Duodenal Diseases
Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).		01.9810
ARSA Deficiency
[description not available]		03.5730
Leukodystrophy, Metachromatic
An autosomal recessive metabolic disease caused by a deficiency of CEREBROSIDE-SULFATASE leading to intralysosomal accumulation of cerebroside sulfate (SULFOGLYCOSPHINGOLIPIDS) in the nervous system and other organs. Pathological features include diffuse demyelination, and metachromatically-staining granules in many cell types such as the GLIAL CELLS. There are several allelic and nonallelic forms with a variety of neurological symptoms.		03.5730
Alport Syndrome
[description not available]		07.3820
Nephritis, Hereditary
A group of inherited conditions characterized initially by HEMATURIA and slowly progressing to RENAL INSUFFICIENCY. The most common form is the Alport syndrome (hereditary nephritis with HEARING LOSS) which is caused by mutations in genes for TYPE IV COLLAGEN and defective GLOMERULAR BASEMENT MEMBRANE.		02.3820
Complication, Postoperative
[description not available]		02.3620
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		02.3620
Complex Partial Epilepsy
[description not available]		01.9810
Epilepsy, Complex Partial
A disorder characterized by recurrent partial seizures marked by impairment of cognition. During the seizure the individual may experience a wide variety of psychic phenomenon including formed hallucinations, illusions, deja vu, intense emotional feelings, confusion, and spatial disorientation. Focal motor activity, sensory alterations and AUTOMATISM may also occur. Complex partial seizures often originate from foci in one or both temporal lobes. The etiology may be idiopathic (cryptogenic partial complex epilepsy) or occur as a secondary manifestation of a focal cortical lesion (symptomatic partial complex epilepsy). (From Adams et al., Principles of Neurology, 6th ed, pp317-8)		01.9810
Breast Diseases
Pathological processes of the BREAST.		01.9810
Adenovirus Infections
[description not available]		01.9810
Adenoviridae Infections
Virus diseases caused by the ADENOVIRIDAE.		01.9810
Active Hyperemia
[description not available]		01.9810
Hyperemia
The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).		01.9810
Hereditary Optic Atrophy
[description not available]		02.3920
Achromatopsia
Severely deficient color perception, typically with monochromacy and reduced visual acuity. The atypical form can include normal visual acuity with pseudomonochromacy.		02.3920
Color Vision Defects
Defects of color vision are mainly hereditary traits but can be secondary to acquired or developmental abnormalities in the CONES (RETINA). Severity of hereditary defects of color vision depends on the degree of mutation of the ROD OPSINS genes (on X CHROMOSOME and CHROMOSOME 3) that code the photopigments for red, green and blue.		02.3920
Dejerine-Thomas Syndrome
[description not available]		02.3820
Amaurotic Familial Idiocy
An outdated term for Tay-Sachs disease.		01.9810
Tay-Sachs Disease
An autosomal recessive neurodegenerative disorder characterized by the onset in infancy of an exaggerated startle response, followed by paralysis, dementia, and blindness. It is caused by mutation in the alpha subunit of the HEXOSAMINIDASE A resulting in lipid-laden ganglion cells. It is also known as the B variant (with increased HEXOSAMINIDASE B but absence of hexosaminidase A) and is strongly associated with Ashkenazic Jewish ancestry.		01.9810
Conductive Hearing Loss
[description not available]		01.9810
Gastric Diseases
[description not available]		01.9810
Gastric Ulcer
[description not available]		02.3620
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.3620
Leprosy, Cutaneous
[description not available]		01.9810
Autoimmune Demyelinating Disease, Peripheral
[description not available]		01.9810
Teratocarcinoma
A malignant neoplasm consisting of elements of teratoma with those of embryonal carcinoma or choriocarcinoma, or both. It occurs most often in the testis. (Dorland, 27th ed)		01.9910
Arterial Obstructive Diseases
[description not available]		02.910
Arterial Occlusive Diseases
Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.		02.910
alpha-LCAT Deficiency
[description not available]		01.9810
Lecithin Cholesterol Acyltransferase Deficiency
An autosomal recessive disorder of lipoprotein metabolism caused by mutation of LECITHIN CHOLESTEROL ACYLTRANSFERASE gene. It is characterized by low HDL-cholesterol levels, and the triad of CORNEAL OPACITIES; HEMOLYTIC ANEMIA; and PROTEINURIA with renal failure.		01.9810
Angioma, Cavernous
A tumor-like mass with large vascular space that is filled with blood or lymph.		01.9910
Lysosomal Enzyme Disorders
[description not available]		02.3920
Alcaptonuria
[description not available]		02.420
Alkaptonuria
An inborn error of amino acid metabolism resulting from a defect in the enzyme HOMOGENTISATE 1,2-DIOXYGENASE, an enzyme involved in the breakdown of PHENYLALANINE and TYROSINE. It is characterized by accumulation of HOMOGENTISIC ACID in the urine, OCHRONOSIS in various tissues, and ARTHRITIS.		02.420
Hemorrhagic Diathesis
[description not available]		02.3920
Hemorrhagic Disorders
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).		02.3920
Hepatic Veno Occlusive Disease
[description not available]		01.9910
Hepatic Veno-Occlusive Disease
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.		01.9910
Deficiency of GP 2b 3a Complex
[description not available]		02.940
Deficiency, Protein S
[description not available]		01.9910
Congenital Hand Deformities
[description not available]		02.6930
Congenital Hypocupremia
[description not available]		01.9910
Menkes Kinky Hair Syndrome
An inherited disorder of copper metabolism transmitted as an X-linked trait and characterized by the infantile onset of HYPOTHERMIA, feeding difficulties, hypotonia, SEIZURES, bony deformities, pili torti (twisted hair), and severely impaired intellectual development. Defective copper transport across plasma and endoplasmic reticulum membranes results in copper being unavailable for the synthesis of several copper containing enzymes, including PROTEIN-LYSINE 6-OXIDASE; CERULOPLASMIN; and SUPEROXIDE DISMUTASE. Pathologic changes include defects in arterial elastin, neuronal loss, and gliosis. (From Menkes, Textbook of Child Neurology, 5th ed, p125)		01.9910
Apolipoprotein B-100, Familial Defective
[description not available]		01.9910
Hyperlipoproteinemia Type II
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).		01.9910
Human T-lymphotropic Virus 1 Infection
[description not available]		01.9910
HTLV-I Infections
Diseases caused by HUMAN T-LYMPHOTROPIC VIRUS 1.		01.9910
Chromosome Inversion
An aberration in which a chromosomal segment is deleted and reinserted in the same place but turned 180 degrees from its original orientation, so that the gene sequence for the segment is reversed with respect to that of the rest of the chromosome.		02.420
Beuren Syndrome
[description not available]		03.3220
Hyperthyroid
[description not available]		08.0650
Hyperthyroidism
Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.		08.0650
Alobar Holoprosencephaly
[description not available]		01.9910
Carcinoma, Embryonal
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)		01.9910
Acidosis, Renal Tubular, Type I
[description not available]		01.9910
Acidosis, Renal Tubular
A group of genetic disorders of the KIDNEY TUBULES characterized by the accumulation of metabolically produced acids with elevated plasma chloride, hyperchloremic metabolic ACIDOSIS. Defective renal acidification of URINE (proximal tubules) or low renal acid excretion (distal tubules) can lead to complications such as HYPOKALEMIA, hypercalcinuria with NEPHROLITHIASIS and NEPHROCALCINOSIS, and RICKETS.		01.9910
Polyomavirus Infections
Infections with POLYOMAVIRUS, which are often cultured from the urine of kidney transplant patients. Excretion of BK VIRUS is associated with ureteral strictures and CYSTITIS, and that of JC VIRUS with progressive multifocal leukoencephalopathy (LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL).		01.9910
Dental Deposit
[description not available]		02.8940
Paralysis, Legs
[description not available]		01.9910
Paraplegia
Severe or complete loss of motor function in the lower extremities and lower portions of the trunk. This condition is most often associated with SPINAL CORD DISEASES, although BRAIN DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; and MUSCULAR DISEASES may also cause bilateral leg weakness.		01.9910
Antithrombin 3 Deficiency
[description not available]		02.3920
Thromboembolism
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.		02.3720
Antithrombin III Deficiency
An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis.		02.3920
Infections, Hepadnaviridae
[description not available]		01.9910
Hepadnaviridae Infections
Virus diseases caused by the HEPADNAVIRIDAE.		01.9910
Fructose Metabolism, Inborn Errors
Inherited abnormalities of fructose metabolism, which include three known autosomal recessive types: hepatic fructokinase deficiency (essential fructosuria), hereditary fructose intolerance, and hereditary fructose-1,6-diphosphatase deficiency. Essential fructosuria is a benign asymptomatic metabolic disorder caused by deficiency in fructokinase, leading to decreased conversion of fructose to fructose-1-phosphate and alimentary hyperfructosemia, but with no clinical dysfunction; may produce a false-positive diabetes test.		02.9110
Bone Diseases
Diseases of BONES.		02.9110
Cytomegaloviral Retinitis
[description not available]		01.9910
AIDS-Related Opportunistic Infections
Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.		01.9910
Cytomegalovirus Retinitis
Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.		01.9910
Chronic Hepatitis C
[description not available]		01.9910
Hepatitis C, Chronic
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.		01.9910
Parasitemia
The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)		01.9910
Acute-Phase Reaction
An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma.		01.9910
Cachexia
General ill health, malnutrition, and weight loss, usually associated with chronic disease.		02.420
Genetic Diseases
[description not available]		02.3720
Myotonia
Prolonged failure of muscle relaxation after contraction. This may occur after voluntary contractions, muscle percussion, or electrical stimulation of the muscle. Myotonia is a characteristic feature of MYOTONIC DISORDERS.		01.9910
Genetic Diseases, Inborn
Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.		02.3720
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		01.9910
Hyperlipoproteinemia
[description not available]		01.9910
Hyperlipoproteinemias
Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.		01.9910
Cerebral Cholesterinosis
[description not available]		01.9910
Xanthomatosis, Cerebrotendinous
An autosomal recessive lipid storage disorder due to mutation of the gene CYP27A1 encoding a CHOLESTANETRIOL 26-MONOOXYGENASE. It is characterized by large deposits of CHOLESTEROL and CHOLESTANOL in various tissues resulting in xanthomatous swelling of tendons, early CATARACT, and progressive neurological symptoms.		01.9910
Coma
A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.		01.9910
Vestibular Diseases
Pathological processes of the VESTIBULAR LABYRINTH which contains part of the balancing apparatus. Patients with vestibular diseases show instability and are at risk of frequent falls.		0210
Acrania
[description not available]		0210
Neural Tube Defects
Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy generally occurring between days 18-29 of gestation. Ectodermal and mesodermal malformations (mainly involving the skull and vertebrae) may occur as a result of defects of neural tube closure. (From Joynt, Clinical Neurology, 1992, Ch55, pp31-41)		0210
Addison Disease and Cerebral Sclerosis
[description not available]		03.630
Adrenoleukodystrophy
An X-linked recessive disorder characterized by the accumulation of saturated very long chain fatty acids in the LYSOSOMES of ADRENAL CORTEX and the white matter of CENTRAL NERVOUS SYSTEM. This disease occurs almost exclusively in the males. Clinical features include the childhood onset of ATAXIA; NEUROBEHAVIORAL MANIFESTATIONS; HYPERPIGMENTATION; ADRENAL INSUFFICIENCY; SEIZURES; MUSCLE SPASTICITY; and DEMENTIA. The slowly progressive adult form is called adrenomyeloneuropathy. The defective gene ABCD1 is located at Xq28, and encodes the adrenoleukodystrophy protein (ATP-BINDING CASSETTE TRANSPORTERS).		03.630
Deficiency, Muscle Phosphorylase
[description not available]		0210
Glycogen Storage Disease Type V
Glycogenosis due to muscle phosphorylase deficiency. Characterized by painful cramps following sustained exercise.		0210
Appetite Disorders
[description not available]		0210
Binge Eating
[description not available]		0210
Feeding and Eating Disorders
A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.		0210
Bulimia
Eating an excess amount of food in a short period of time, as seen in the disorder of BULIMIA NERVOSA. It is caused by an abnormal craving for food, or insatiable hunger also known as ox hunger.		0210
Bacterial Infections, Gram-Positive
[description not available]		0210
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		0210
Nutritional Disorders
[description not available]		04.4790
Nutrition Disorders
Disorders caused by nutritional imbalance, either overnutrition or undernutrition.		04.4790
Klein Syndrome
[description not available]		0210
Birnaviridae Infections
Virus diseases caused by the BIRNAVIRIDAE.		0210
Diseases, Occupational
[description not available]		0210
Cocarcinogenesis
The combination of two or more different factors in the production of cancer.		0210
Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans
[description not available]		02.4120
Achondroplasia
An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, GENU VARUM, and trident hand. (Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim, MIM#100800, April 20, 2001)		02.4120
alpha-Galactosidase A Deficiency
[description not available]		02.3920
Fabry Disease
An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.		02.3920
Atopic Hypersensitivity
[description not available]		03.2920
Adenohypophyseal Hyposecretion
[description not available]		04.6721
Hypopituitarism
Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions.		04.6721
Cerebral Pseudosclerosis
[description not available]		02.6530
Hepatolenticular Degeneration
A rare autosomal recessive disease characterized by the deposition of copper in the BRAIN; LIVER; CORNEA; and other organs. It is caused by defects in the ATP7B gene encoding copper-transporting ATPase 2 (EC 3.6.3.4), also known as the Wilson disease protein. The overload of copper inevitably leads to progressive liver and neurological dysfunction such as LIVER CIRRHOSIS; TREMOR; ATAXIA and intellectual deterioration. Hepatic dysfunction may precede neurologic dysfunction by several years.		02.6530
Gelineau Syndrome
[description not available]		02.3620
Panic Attacks
[description not available]		0210
Narcolepsy
A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)		02.3620
Panic Disorder
A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.		0210
Fallot's Tetralogy
[description not available]		0210
Tetralogy of Fallot
A combination of congenital heart defects consisting of four key features including VENTRICULAR SEPTAL DEFECTS; PULMONARY STENOSIS; RIGHT VENTRICULAR HYPERTROPHY; and a dextro-positioned AORTA. In this condition, blood from both ventricles (oxygen-rich and oxygen-poor) is pumped into the body often causing CYANOSIS.		0210
Failure to Thrive
A condition of substandard growth or diminished capacity to maintain normal function.		0210
Developmental Coordination Disorder
[description not available]		0210
Common Variable Hypogammaglobulinemia
[description not available]		0210
Common Variable Immunodeficiency
Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.		0210
Adrenal Gland Hypofunction
[description not available]		0210
Adrenal Insufficiency
Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.		0210
Niemann-Pick Disease
[description not available]		02.3920
Niemann-Pick Diseases
A group of autosomal recessive disorders in which harmful quantities of lipids accumulate in the viscera and the central nervous system. They can be caused by deficiencies of enzyme activities (SPHINGOMYELIN PHOSPHODIESTERASE) or defects in intracellular transport, resulting in the accumulation of SPHINGOMYELINS and CHOLESTEROL. There are various subtypes based on their clinical and genetic differences.		02.3920
Clear Cell Sarcoma of Soft Tissue
[description not available]		0210
Sarcoma, Clear Cell
A sarcoma of young adults occurring in the lower extremities and acral regions. It is found intimately bound to tendons as a circumscribed but unencapsulated melanin-bearing tumor of neuroectodermal origin. Clear cell sarcoma is associated with a specific t(12;22)(q13;q12) translocation.		0210
Hamartoma
A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area.		0210
Keratosis, Oral
[description not available]		0210
Mouth Diseases
Diseases involving the MOUTH.		0210
Leukoplakia, Oral
A white patch seen on the oral mucosa. It is considered a premalignant condition and is often tobacco-induced. When evidence of Epstein-Barr virus is present, the condition is called hairy leukoplakia (LEUKOPLAKIA, HAIRY).		0210
Hypercoagulability
[description not available]		02.9210
Embolus
[description not available]		02.9210
Embolism
Blocking of a blood vessel by an embolus which can be a blood clot or other undissolved material in the blood stream.		02.9210
Thrombophilia
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.		02.9210
Hypocalcemia
Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)		02.3720
Encephalopathy, Mercury
[description not available]		0210
Cockayne Syndrome
A syndrome characterized by multiple system abnormalities including DWARFISM; PHOTOSENSITIVITY DISORDERS; PREMATURE AGING; and HEARING LOSS. It is caused by mutations of a number of autosomal recessive genes encoding proteins that involve transcriptional-coupled DNA REPAIR processes. Cockayne syndrome is classified by the severity and age of onset. Type I (classical; CSA) is early childhood onset in the second year of life; type II (congenital; CSB) is early onset at birth with severe symptoms; type III (xeroderma pigmentosum; XP) is late childhood onset with mild symptoms.		0210
Colonic Polyps
Discrete tissue masses that protrude into the lumen of the COLON. These POLYPS are connected to the wall of the colon either by a stalk, pedunculus, or by a broad base.		0210
Aberrant Tissue
[description not available]		0210
Myoclonic Jerk
[description not available]		02.3720
Coronary Artery Stenosis
[description not available]		0210
Coronary Stenosis
Narrowing or constriction of a coronary artery.		0210
7-Dehydrocholesterol Reductase Deficiency
[description not available]		02.0110
Smith-Lemli-Opitz Syndrome
An autosomal recessive disorder of CHOLESTEROL metabolism. It is caused by a deficiency of 7-dehydrocholesterol reductase, the enzyme that converts 7-dehydrocholesterol to cholesterol, leading to an abnormally low plasma cholesterol. This syndrome is characterized by multiple CONGENITAL ABNORMALITIES, growth deficiency, and INTELLECTUAL DISABILITY.		02.0110
B-Cell Leukemia
[description not available]		02.0110
Carbohydrate-Deficient Glycoprotein Syndrome
[description not available]		02.0110
Congenital Disorders of Glycosylation
A genetically heterogeneous group of heritable disorders resulting from defects in protein N-glycosylation.		02.0110
Allergy, Drug
[description not available]		02.0110
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		02.0110
Leprosy, Macular
[description not available]		02.0110
Cancer of the Urinary Tract
[description not available]		02.0110
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		02.0110
Cardiac Cancer
[description not available]		02.0110
Myelopathy
[description not available]		02.3620
Spinal Cord Diseases
Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.		02.3620
Muscle Spasm
[description not available]		01.9510
Spasm
An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.		01.9510
African Sleeping Sickness
[description not available]		01.9510
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		01.9510
Optic Atrophy
Atrophy of the optic disk which may be congenital or acquired. This condition indicates a deficiency in the number of nerve fibers which arise in the RETINA and converge to form the OPTIC DISK; OPTIC NERVE; OPTIC CHIASM; and optic tracts. GLAUCOMA; ISCHEMIA; inflammation, a chronic elevation of intracranial pressure, toxins, optic nerve compression, and inherited conditions (see OPTIC ATROPHIES, HEREDITARY) are relatively common causes of this condition.		01.9510
Delayed Hypersensitivity
[description not available]		02.3620
Tracheal Neoplasms
New abnormal growth of tissue in the TRACHEA.		01.9510
Addison's Anemia
[description not available]		04.1160
Lymphogranuloma Inguinale
[description not available]		01.9510
Parodontosis
[description not available]		01.9510
Periodontal Diseases
Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.		01.9510
Interstitial Nephritis
[description not available]		01.9510
Nephritis, Interstitial
Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.		01.9510
Choreoathetosis Self-Mutilation Hyperuricemia Syndrome
[description not available]		02.3520
Lesch-Nyhan Syndrome
An inherited disorder transmitted as a sex-linked trait and caused by a deficiency of an enzyme of purine metabolism; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE. Affected individuals are normal in the first year of life and then develop psychomotor retardation, extrapyramidal movement disorders, progressive spasticity, and seizures. Self-destructive behaviors such as biting of fingers and lips are seen frequently. Intellectual impairment may also occur but is typically not severe. Elevation of uric acid in the serum leads to the development of renal calculi and gouty arthritis. (Menkes, Textbook of Child Neurology, 5th ed, pp127)		02.3520
Remission, Spontaneous
A spontaneous diminution or abatement of a disease over time, without formal treatment.		02.3520
Friedreich Disease
[description not available]		01.9510
Friedreich Ataxia
An autosomal recessive disease, usually of childhood onset, characterized pathologically by degeneration of the spinocerebellar tracts, posterior columns, and to a lesser extent the corticospinal tracts. Clinical manifestations include GAIT ATAXIA, pes cavus, speech impairment, lateral curvature of spine, rhythmic head tremor, kyphoscoliosis, congestive heart failure (secondary to a cardiomyopathy), and lower extremity weakness. Most forms of this condition are associated with a mutation in a gene on chromosome 9, at band q13, which codes for the mitochondrial protein frataxin. (From Adams et al., Principles of Neurology, 6th ed, p1081; N Engl J Med 1996 Oct 17;335(16):1169-75) The severity of Friedreich ataxia associated with expansion of GAA repeats in the first intron of the frataxin gene correlates with the number of trinucleotide repeats. (From Durr et al, N Engl J Med 1996 Oct 17;335(16):1169-75)		01.9510
Foot Rot
A disease of the horny parts and of the adjacent soft structures of the feet of cattle, swine, and sheep. It is usually caused by Corynebacterium pyogenes or Bacteroides nodosus (see DICHELOBACTER NODOSUS). It is also known as interdigital necrobacillosis. (From Black's Veterinary Dictionary, 18th ed)		01.9510
Hepatitis, Infectious
[description not available]		01.9510
Hepatitis A
INFLAMMATION of the LIVER in humans caused by a member of the HEPATOVIRUS genus, HUMAN HEPATITIS A VIRUS. It can be transmitted through fecal contamination of food or water.		01.9510
Hyperoxaluria
Excretion of an excessive amount of OXALATES in the urine.		06.9810
Phlegmasia Alba Dolens
Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.		02.3820
Thrombophlebitis
Inflammation of a vein associated with a blood clot (THROMBUS).		02.3820
Acute Respiratory Distress Syndrome
[description not available]		02.8910
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		02.8910
Lactic Acidosis
[description not available]		01.9710
Ataxia with Lactic Acidosis
[description not available]		01.9710
Acidosis, Lactic
Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as DIABETES MELLITUS; LEUKEMIA; or LIVER FAILURE.		01.9710
Pyruvate Dehydrogenase Complex Deficiency Disease
An inherited metabolic disorder caused by deficient enzyme activity in the PYRUVATE DEHYDROGENASE COMPLEX, resulting in deficiency of acetyl CoA and reduced synthesis of acetylcholine. Two clinical forms are recognized: neonatal and juvenile. The neonatal form is a relatively common cause of lactic acidosis in the first weeks of life and may also feature an erythematous rash. The juvenile form presents with lactic acidosis, alopecia, intermittent ATAXIA; SEIZURES; and an erythematous rash. (From J Inherit Metab Dis 1996;19(4):452-62) Autosomal recessive and X-linked forms are caused by mutations in the genes for the three different enzyme components of this multisubunit pyruvate dehydrogenase complex. One of the mutations at Xp22.2-p22.1 in the gene for the E1 alpha component of the complex leads to LEIGH DISEASE.		01.9710
Cerebro-Hepato-Renal Syndrome
[description not available]		02.8910
Zellweger Syndrome
An autosomal recessive disorder due to defects in PEROXISOME biogenesis which involves more than 13 genes encoding peroxin proteins of the peroxisomal membrane and matrix. Zellweger syndrome is typically seen in the neonatal period with features such as dysmorphic skull; MUSCLE HYPOTONIA; SENSORINEURAL HEARING LOSS; visual compromise; SEIZURES; progressive degeneration of the KIDNEYS and the LIVER. Zellweger-like syndrome refers to phenotypes resembling the neonatal Zellweger syndrome but seen in children or adults with apparently intact peroxisome biogenesis.		02.8910
Ritter Disease
[description not available]		01.9710
Fistula
Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.		01.9710
Inner Ear Disease
[description not available]		01.9710
Labyrinth Diseases
Pathological processes of the inner ear (LABYRINTH) which contains the essential apparatus of hearing (COCHLEA) and balance (SEMICIRCULAR CANALS).		01.9710
Albinism
General term for a number of inherited defects of amino acid metabolism in which there is a deficiency or absence of pigment in the eyes, skin, or hair.		02.3820
Adenoma, Prostatic
[description not available]		01.9710
Prostatic Hyperplasia
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.		01.9710
Deficiency of Glucose-6-Phosphate Dehydrogenase
[description not available]		01.9710
Glucosephosphate Dehydrogenase Deficiency
A disease-producing enzyme deficiency subject to many variants, some of which cause a deficiency of GLUCOSE-6-PHOSPHATE DEHYDROGENASE activity in erythrocytes, leading to hemolytic anemia.		01.9710
Atypical Cluster Headache
[description not available]		01.9710
Cephalgia, Vascular
[description not available]		01.9710
Autonomic Failure, Progressive
[description not available]		03.9850
Drop Attack
[description not available]		01.9710
Syncope
A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)		01.9710
Enteric Fever
[description not available]		01.9710
Typhoid Fever
An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.		01.9710
Ganglioside Storage Diseases
[description not available]		01.9710
Gangliosidoses
A group of autosomal recessive lysosomal storage disorders marked by the accumulation of GANGLIOSIDES. They are caused by impaired enzymes or defective cofactors required for normal ganglioside degradation in the LYSOSOMES. Gangliosidoses are classified by the specific ganglioside accumulated in the defective degradation pathway.		06.9710
Bullous Dermatoses
[description not available]		01.9710
Marasmus
[description not available]		02.8740
Protein-Energy Malnutrition
The lack of sufficient energy or protein to meet the body's metabolic demands, as a result of either an inadequate dietary intake of protein, intake of poor quality dietary protein, increased demands due to disease, or increased nutrient losses.		02.8740
Viral Hepatitis, Human
[description not available]		01.9610
Hepatitis, Viral, Human
INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).		01.9610
Infections, Salmonella
[description not available]		01.9610
Altered Level of Consciousness
[description not available]		02.3720
Deficiency Disease, Ornithine Carbamoyltransferase
[description not available]		01.9610
Ornithine Carbamoyltransferase Deficiency Disease
An inherited urea cycle disorder associated with deficiency of the enzyme ORNITHINE CARBAMOYLTRANSFERASE, transmitted as an X-linked trait and featuring elevations of amino acids and ammonia in the serum. Clinical features, which are more prominent in males, include seizures, behavioral alterations, episodic vomiting, lethargy, and coma. (Menkes, Textbook of Child Neurology, 5th ed, pp49-50)		01.9610
Clerambault Syndrome
[description not available]		01.9710
Brain Damage, Chronic
A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.		01.9710
Avian Leukosis
A group of transmissible viral diseases of chickens and turkeys. Liver tumors are found in most forms, but tumors can be found elsewhere.		01.9710
Pachymeningitis
[description not available]		01.9710
Aseptic Meningitis
[description not available]		01.9710
Meningitis
Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)		01.9710
Meningitis, Aseptic
A syndrome characterized by headache, neck stiffness, low grade fever, and CSF lymphocytic pleocytosis in the absence of an acute bacterial pathogen. Viral meningitis is the most frequent cause although MYCOPLASMA INFECTIONS; RICKETTSIA INFECTIONS; diagnostic or therapeutic procedures; NEOPLASTIC PROCESSES; septic perimeningeal foci; and other conditions may result in this syndrome. (From Adams et al., Principles of Neurology, 6th ed, p745)		01.9710
Daytime Sleepiness
[description not available]		01.9710
Long Sleeper Syndrome
[description not available]		01.9710
Disorders of Excessive Somnolence
Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)		01.9710
Sleep Wake Disorders
Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.		01.9710
Alcohol Amnestic Disorder
A mental disorder associated with chronic ethanol abuse (ALCOHOLISM) and nutritional deficiencies characterized by short term memory loss, confabulations, and disturbances of attention. (Adams et al., Principles of Neurology, 6th ed, p1139)		03.3511
Decerebrate Posturing
[description not available]		02.3620
Extravasation of Contrast Media
[description not available]		01.9710
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		02.3620
Leukemia L5178
An experimental lymphocytic leukemia of mice.		01.9610
Childhood Schizophrenia
[description not available]		01.9610
Polyneuropathy, Acquired
[description not available]		02.8810
Polyneuropathies
Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.		02.8810
Leukemia, Lymphocytic
[description not available]		03.260
Leukemia, Lymphoid
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.		03.260
Schwartzman Phenomenon
[description not available]		01.9410
Anaphylactic Reaction
[description not available]		03.2720
Anaphylaxis
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.		03.2720
Anemia, Sideroblastic
Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.		01.9410
Blood Protein Disorders
Hematologic diseases caused by structural or functional defects of BLOOD PROTEINS.		02.3520
Lipodystrophy, Intestinal
[description not available]		01.9410
Malabsorption Syndromes
General term for a group of MALNUTRITION syndromes caused by failure of normal INTESTINAL ABSORPTION of nutrients.		03.9650
Infant Malnutrition
Malnutrition, occurring in infants ages 1 month to 24 months, which is due to insufficient intake of food, dietary nutrients, or a pathophysiologic condition which prevents the absorption and utilization of food. Growth and development are markedly affected.		02.6430
Eccentro-Osteochondrodysplasia
[description not available]		03.0450
Mucopolysaccharidosis IV
Genetic disorder of mucopolysaccharide metabolism characterized by skeletal abnormalities, joint instability, development of cervical myelopathy, and excessive urinary keratan sulfate. There are two biochemically distinct forms, each due to a deficiency of a different enzyme.		03.0450
alpha-L-Iduronidase Deficiency
[description not available]		02.3420
Mucopolysaccharidosis I
Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE) and characterized by progressive physical deterioration with urinary excretion of DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.		02.3420
Alpers Diffuse Degeneration of Cerebral Gray Matter with Hepatic Cirrhosis
[description not available]		03.7740
Mucopolysaccharidosis
[description not available]		02.6430
Mucopolysaccharidoses
Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency.		02.6430
Mast-Cell Sarcoma
A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.		02.8640
Bouillaud Disease
[description not available]		01.9410
Rheumatic Heart Disease
Cardiac manifestation of systemic rheumatological conditions, such as RHEUMATIC FEVER. Rheumatic heart disease can involve any part the heart, most often the HEART VALVES and the ENDOCARDIUM.		01.9410
Arthropathies
[description not available]		01.9410
Hypertrichosis
Excessive hair growth at inappropriate locations, such as on the extremities, the head, and the back. It is caused by genetic or acquired factors, and is an androgen-independent process. This concept does not include HIRSUTISM which is an androgen-dependent excess hair growth in WOMEN and CHILDREN.		01.9410
Joint Diseases
Diseases involving the JOINTS.		01.9410
Acne
[description not available]		06.9510
Acne Vulgaris
A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.		01.9510
Enteritis
Inflammation of any segment of the SMALL INTESTINE.		01.9410
Actinic Reticuloid Syndrome
[description not available]		01.9410
Muscle Tissue Neoplasms
[description not available]		01.9410
Teeth, Unerupted
[description not available]		01.9510
Contact Dermatitis
[description not available]		01.9510
Dermatitis, Contact
A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.		01.9510
Poisoning, Lead
[description not available]		01.9510
Lead Poisoning
Poisoning that results from chronic or acute ingestion, injection, inhalation, or skin absorption of LEAD or lead compounds.		01.9510
Eosinophilic Granuloma
The most benign and common form of Langerhans-cell histiocytosis which involves localized nodular lesions predominantly of the bones but also of the gastric mucosa, small intestine, lungs, or skin, with infiltration by EOSINOPHILS.		01.9510
Lymphatic Diseases
Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.		01.9510
Corpus Luteum Cyst
[description not available]		02.3520
Ovarian Cysts
General term for CYSTS and cystic diseases of the OVARY.		02.3520
Dental Fluoroses
[description not available]		01.9410
Fluorosis, Dental
A chronic endemic form of hypoplasia of the dental enamel caused by drinking water with a high fluorine content during the time of tooth formation, and characterized by defective calcification that gives a white chalky appearance to the enamel, which gradually undergoes brown discoloration. (Jablonski's Dictionary of Dentistry, 1992, p286)		01.9410
Gastric Fistula
Abnormal passage communicating with the STOMACH.		01.9510
Pancreatic Diseases
Pathological processes of the PANCREAS.		02.8610
Biliary Tract Diseases
Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.		02.8610
Carcinoma, Krebs 2
A transplantable neoplasm of mice.		01.9410
Intestinal Diseases
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.		01.9510
Amnesia-Memory Loss
[description not available]		01.9510
Amnesia
Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)		01.9510
Kidney Tubular Transport, Inborn Error
[description not available]		02.3520
Classic Globoid Cell Leukodystrophy
[description not available]		01.9510
Leukodystrophy, Globoid Cell
An autosomal recessive metabolic disorder caused by a deficiency of GALACTOSYLCERAMIDASE leading to intralysosomal accumulation of galactolipids such as GALACTOSYLCERAMIDES and PSYCHOSINE. It is characterized by demyelination associated with large multinucleated globoid cells, predominantly involving the white matter of the central nervous system. The loss of MYELIN disrupts normal conduction of nerve impulses.		01.9510
Bronchospasm
[description not available]		01.9410
Bronchial Spasm
Spasmodic contraction of the smooth muscle of the bronchi.		06.9410
Blood Diseases
[description not available]		02.8610
Hematologic Diseases
Disorders of the blood and blood forming tissues.		02.8610
Amino Acid Transport Disorder, Neutral
[description not available]		03.2620
Thyroiditis
Inflammatory diseases of the THYROID GLAND. Thyroiditis can be classified into acute (THYROIDITIS, SUPPURATIVE), subacute (granulomatous and lymphocytic), chronic fibrous (Riedel's), chronic lymphocytic (HASHIMOTO DISEASE), transient (POSTPARTUM THYROIDITIS), and other AUTOIMMUNE THYROIDITIS subtypes.		01.9410
Familial Waldenstrom's Macroglobulinaemia
[description not available]		01.9410
Waldenstrom Macroglobulinemia
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.		01.9410
Curling Ulcer
Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.		01.9410
Duodenal Ulcer
A PEPTIC ULCER located in the DUODENUM.		01.9410
Broad Thumb-Hallux Syndrome
[description not available]		01.9410
Rubinstein-Taybi Syndrome
A chromosomal disorder characterized by MENTAL RETARDATION, broad thumbs, webbing of fingers and toes, beaked nose, short upper lip, pouting lower lip, agenesis of corpus callosum, large foramen magnum, keloid formation, pulmonary stenosis, vertebral anomalies, chest wall anomalies, sleep apnea, and megacolon. The disease has an autosomal dominant pattern of inheritance and is associated with deletions of the short arm of chromosome 16 (16p13.3).		01.9410
Puerperal Disorders
Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.		01.9410
Encephalitis, Inclusion Body, Measles
[description not available]		01.9410
Central Nervous System Origin Vertigo
[description not available]		01.9410
Vertigo
An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)		01.9410
Athetoid Movements
[description not available]		01.9410
Apnea
A transient absence of spontaneous respiration.		01.9410
Aprosodia
[description not available]		01.9410
Nail Abnormalities
[description not available]		01.9410
Maxillary Neoplasms
Cancer or tumors of the MAXILLA or upper jaw.		01.9410
Pellagra
A disease due to deficiency of NIACIN, a B-complex vitamin, or its precursor TRYPTOPHAN. It is characterized by scaly DERMATITIS which is often associated with DIARRHEA and DEMENTIA (the three D's).		01.9410
Skin Manifestations
Dermatologic disorders attendant upon non-dermatologic disease or injury.		01.9410
Agranulocytosis
A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).		01.9410
Infant, Newborn, Diseases
Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.		01.9410
Cicatrization
The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.		06.9410
Cancer of Pharynx
[description not available]		01.9410
Cicatrix
The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.		01.9410
Pharyngeal Neoplasms
Tumors or cancer of the PHARYNX.		01.9410
Acidosis, Respiratory
Respiratory retention of carbon dioxide. It may be chronic or acute.		01.9410
Alkalosis
A pathological condition that removes acid or adds base to the body fluids.		01.9410
Purpura, Thrombopenic
[description not available]		01.9410
Purpura, Thrombocytopenic
Any form of purpura in which the PLATELET COUNT is decreased. Many forms are thought to be caused by immunological mechanisms.		01.9410
Inappropriate GH Secretion Syndrome (Acromegaly)
[description not available]		01.9410
Dwarfism, Growth Hormone Deficiency
[description not available]		01.9410
Acromegaly
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)		01.9410
Dwarfism, Pituitary
A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development.		01.9410
Encephalitis Lethargica Type Parkinsonism
[description not available]		01.9410
Parkinson Disease, Postencephalitic
Parkinsonism following encephalitis, historically seen as a sequella of encephalitis lethargica (Von Economo Encephalitis). The early age of onset, the rapid progression of symptoms followed by stabilization, and the presence of a variety of other neurological disorders (e.g., sociopathic behavior; TICS; MUSCLE SPASMS; oculogyric crises; hyperphagia; and bizarre movements) distinguish this condition from primary PARKINSON DISEASE. Pathologic features include neuronal loss and gliosis concentrated in the MESENCEPHALON; SUBTHALAMUS; and HYPOTHALAMUS. (From Adams et al., Principles of Neurology, 6th ed, p754)		01.9410
Encephalitis, Equine
[description not available]		01.9410
Abnormality, Torsion
[description not available]		01.9410
Cardiovascular Pregnancy Complications
[description not available]		01.9410
Bronchial Pneumonia
[description not available]		01.9410
Pyelitis
Inflammation of the KIDNEY PELVIS and KIDNEY CALICES where urine is collected before discharge, but does not involve the renal parenchyma (the NEPHRONS) where urine is processed.		01.9410
Pleural Effusion
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.		01.9410
Chicken Pox
[description not available]		01.9410
Rubeola
[description not available]		01.9410
Measles, German
[description not available]		01.9410
Chickenpox
A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed)		01.9410
Measles
A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.		01.9410
Scarlet Fever
Infection with group A streptococci that is characterized by tonsillitis and pharyngitis. An erythematous rash is commonly present.		01.9410
Infant, Premature, Diseases
Diseases that occur in PREMATURE INFANTS.		01.9410
Asthma, Cardiac
[description not available]		01.9410
Neoplasms, Bronchial
[description not available]		01.9410
Bronchial Neoplasms
Tumors or cancer of the BRONCHI.		01.9410
Nephrosis
Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.		01.9410
Glomerular Necrosis
[description not available]		01.9410
Ranula
A form of retention cyst of the floor of the mouth, usually due to obstruction of the ducts of the submaxillary or sublingual glands, presenting a slowly enlarging painless deep burrowing mucocele of one side of the mouth. It is also called sublingual cyst and sublingual ptyalocele.		01.9410